01135000000000457000450099100020000070000020000270600020000470100020000609100090
00081300032000171510016000490350010000654800035000750300017001109300004001271170
00800131085000500139935001000144031000300154032000200157036000600159042000200165
20000020016706500090016912200030017804800140018104800140019504800240020904900320
02330490032002650490024002970490032003210490029003530490029003820490027004110490
02100438049002200459043006600481043006500547043006500612#1#0#i#1#20110318#Jornal
 Brasileiro de Nefrologia#J. Bras. Nefrol#0101-2800#Sociedade Brasileira de Nefr
ologia#J. Bras. Nefrol.#JBN#vancouv#decs#0101-2800#33#1#20111#1#0#20110300#16#^l
es^hSumario#^lpt^hSumário#^len^hTable of Contents#^lpt^cJBN020^tArtigos Originai
s#^len^cJBN020^tOriginal Articles#^lpt^cJBN060^tEditorial#^lpt^cJBN110^tArtigo d
e Revisão#^len^cJBN110^tReview Article#^lpt^cJBN120^tRelato de Caso#^len^cJBN120
^tCase Reports#^lpt^cJBN150^tCartas#^len^cJBN150^tLetters#^les^tJ. Bras. Nefrol.
^vvol.33^nno.1^cSão Paulo^menero/mar.^a2011#^lpt^tJ. Bras. Nefrol.^vvol.33^nno.1
^cSão Paulo^mjan./mar.^a2011#^len^tJ. Bras. Nefrol.^vvol.33^nno.1^cSão Paulo^mJa
n./Mar.^a2011##
00271000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00400097#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#o#1#1#text#1#201
10411#092848#v33n1a01.htm#143##
01309000000000445000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000400086121000300090049000700093158000300100030001700103
03100030012003200020012306500090012501400070013403500100014112300020015101201070
01530120134002600100036003940100024004300100041004540700171004950700039006660700
13400705117000800839072000300847002001300850#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a01.htm#S#h#2#1#text#1#ed#pt#br1.1#1#4.0#TAB#01#JBN060#nd#J. Bras. Nef
rol.#33#1#20110300#^f1^l7#0101-2800#1#Dia Mundial do Rim 2011 albuminúria e crea
tinina: testes simples, baratos e essenciais no curso da DRC^lpt#World Kidney Da
y 2011 albuminuria and creatinine: simple, inexpensive and essential tests in th
e course of chronic kidney disease^len#^rND^1A01 A02^nMarcus Gomes^sBastos#^rND^
nAdagmar^sAndriolo#^rND^1A03^nGianna Mastroianni^sKirsztajn#da UFJF Fundação Ins
tituto Mineiro de Estudos e Pesquisa em Nefrologia^iA01^1Departamento de Epidemi
ologia e Prevenção de Doença Renal^2Sociedade Brasileira de Nefrologia#Universid
ade Federal de São Paulo^iA02#Universidade Federal de São Paulo^iA03^1Departamen
to de Epidemiologia e Prevenção de Doença Renal^2Sociedade Brasileira de Nefrolo
gia#vancouv#36#v33n1a01.htm##
01337000000000445000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000400086121000300090049000700093158000300100030001700103
03100030012003200020012306500090012501400070013403500100014112300020015101201210
01530120148002740100036004220100024004580100041004820700171005230700039006940700
13400733117000800867072000300875002001300878#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a01.htm#S#f#3#1#text#1#ed#pt#br1.1#1#4.0#TAB#01#JBN060#nd#J. Bras. Nef
rol.#33#1#20110300#^f1^l7#0101-2800#1#<b>Dia Mundial do Rim 2011 albuminúria e c
reatinina</b>: <b>testes simples, baratos e essenciais no curso da DRC</b>^lpt#<
b>World Kidney Day 2011 albuminuria and creatinine</b>: <b>simple, inexpensive a
nd essential tests in the course of chronic kidney disease</b>^len#^rND^1A01 A02
^nMarcus Gomes^sBastos#^rND^nAdagmar^sAndriolo#^rND^1A03^nGianna Mastroianni^sKi
rsztajn#da UFJF Fundação Instituto Mineiro de Estudos e Pesquisa em Nefrologia^i
A01^1Departamento de Epidemiologia e Prevenção de Doença Renal^2Sociedade Brasil
eira de Nefrologia#Universidade Federal de São Paulo^iA02#Universidade Federal d
e São Paulo^iA03^1Departamento de Epidemiologia e Prevenção de Doença Renal^2Soc
iedade Brasileira de Nefrologia#vancouv#36#v33n1a01.htm##
01445000000000469000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100038000400104121000300108049000700111158000300118
03000160012103100030013703200020014006500090014201400070015103500100015812300020
01680120107001700120134002770100036004110100024004470100041004710700173005120700
04100685070013600726117000800862072000300870002001300873008008900886#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#l#4#1#text#1#^mjan./mar.^a2011#ed#pt
#br1.1#1#4.0#tab#01#JBN060#nd#J. Bras. Nefrol#33#1#20110300#^f1^l7#0101-2800#1#D
ia Mundial do Rim 2011 albuminúria e creatinina: testes simples, baratos e essen
ciais no curso da DRC^lpt#World Kidney Day 2011 albuminuria and creatinine: simp
le, inexpensive and essential tests in the course of chronic kidney disease^len#
^rND^1A01 A02^nMarcus Gomes^sBastos#^rND^nAdagmar^sAndriolo#^rND^1A03^nGianna Ma
stroianni^sKirsztajn#^iA01^1da UFJF Fundação Instituto Mineiro de Estudos e Pesq
uisa em Nefrologia^2Departamento de Epidemiologia e Prevenção de Doença Renal^3S
ociedade Brasileira de Nefrologia#^iA02^1Universidade Federal de São Paulo#^iA03
^1Universidade Federal de São Paulo^2Departamento de Epidemiologia e Prevenção d
e Doença Renal^3Sociedade Brasileira de Nefrologia#vancouv#36#v33n1a01.htm#Inter
net^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100
001##
00353000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704012400070002001300194#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#5#1#text#103#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL </b>EDITORIAL <
/font></p>     ^cY#v33n1a01.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#6#2#text#103#<p>&nbsp;</p>     ^cY#v33
n1a01.htm##
00428000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704019900070002001300269#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#7#3#text#103#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Dia Mundial do Rim 2011 albumin&uacute;
ria e creatinina: testes simples, baratos e essenciais no curso da DRC</b></font
></p>     ^cY#v33n1a01.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#8#4#text#103#<p>&nbsp;</p>     ^cY#v33
n1a01.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#9#5#text#103#<p>&nbsp;</p>     ^cY#v33
n1a01.htm##
00426000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704019600071002001300267#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#10#6#text#103#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Marcus Gomes Bastos<sup>I</sup>; Adagm
ar Andriolo<sup>II</sup>; Gianna Mastroianni Kirsztajn<sup>III</sup></b></font><
/p>     ^cY#v33n1a01.htm##
00707000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704047700071002001300548#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#11#7#text#103#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Faculdade    de Medicina da U
niversidade Federal de Juiz de Fora - UFJF N&uacute;cleo Interdisciplinar    de 
Estudos, Pesquisas e Tratamento em Nefrologia da UFJF Funda&ccedil;&atilde;o    
Instituto Mineiro de Estudos e Pesquisa em Nefrologia Departamento de Epidemiolo
gia    e Prevenção de Doença Renal da Sociedade Brasileira de Nefrologia. Editor
-chefe    do Jornal Brasileiro de Nefrologia     ^cY#v33n1a01.htm##
00350000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704012000071002001300191#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#12#8#text#103#<br>   <sup>II</sup>Univ
ersidade Federal de São Paulo. Jornal Brasileiro de Patologia    e Medicina Labo
ratorial    ^cY#v33n1a01.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704024600071002001300317#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#13#9#text#103#<br>   <sup>III</sup>Uni
versidade Federal de S&atilde;o Paulo &#150; UNIFESP. Ambulat&oacute;rio    de G
lomerulopatias UNIFESP. Departamento de Epidemiologia e Prevenção de Doença    R
enal da Sociedade Brasileira de Nefrologia</font></p>     ^cY#v33n1a01.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#14#10#text#103#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#15#11#text#103#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
01360000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704112900072002001301201#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#16#12#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A doen&ccedil;a renal cr&ocirc;nica (DRC
), ao contr&aacute;rio do que se pensava h&aacute; pouco tempo, &eacute; uma doe
n&ccedil;a comum, a ponto de ser considerada, atualmente, um problema de sa&uacu
te;de p&uacute;blica. <sup>2</sup> Isso se deve &agrave; nova defini&ccedil;&ati
lde;o que facilitou o diagn&oacute;stico da DRC, principalmente nos seus est&aac
ute;gios mais iniciais, quando ela &eacute; frequentemente assintom&aacute;tica.
 Al&eacute;m disso, o diagn&oacute;stico precoce e o tratamento da DRC permitem 
implementar interven&ccedil;&otilde;es que reduzem a morbidade cardiovascular, a
 principal causa de morte em pacientes com DRC em todo mundo. De fato, &eacute; 
not&oacute;ria a interrela&ccedil;&atilde;o entre DRC e DCV, uma favorecendo o d
esenvolvimento e complicando a evolu&ccedil;&atilde;o da outra. <sup>2</sup> Em 
ambas as condi&ccedil;&otilde;es, a preven&ccedil;&atilde;o atrav&eacute;s de di
agn&oacute;stico precoce e de bons h&aacute;bitos de vida constitui-se na primei
ra interven&ccedil;&atilde;o a ser realizada. </font></p>     ^cY#v33n1a01.htm##
00875000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704064400072002001300716#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#17#13#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Em se tratando de DRC, os casos que se e
ncontram em est&aacute;gios mais precoces da doen&ccedil;a podem ser diagnostica
dos por meio de testes laboratoriais e o diagn&oacute;stico nessa etapa &eacute;
 importante, visto que o tratamento adequado &eacute; capaz de reduzir a velocid
ade de progress&atilde;o para insufici&ecirc;ncia renal cr&ocirc;nica (IRC) grav
e com necessidade de di&aacute;lise ou transplante, corrigir as complica&ccedil;
&otilde;es mais frequentes da doen&ccedil;a e prevenir a evolu&ccedil;&atilde;o 
precoce para o &oacute;bito. <sup>3</sup></font></p>     ^cY#v33n1a01.htm##
01436000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704120500072002001301277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#18#14#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A creatinina, frequentemente utilizada n
a estimativa da filtra&ccedil;&atilde;o glomerular (FGe), e a albumin&uacute;ria
 em quantidades "micro" ou "macro" (esta usualmente denominada protein&uacute;ri
a) s&atilde;o dois testes fundamentais no diagn&oacute;stico da DRC. De fato, em
 reuni&atilde;o de consenso da <i>National Kidney Foundation / Kidney Disease Ou
tcomes Quality Initiative </i>(NKF-KDOQI) e <i>Kidney Disease: Improving Global 
Outcomes</i> (KDIGO) realizada em 2009, em Londres, Reino Unido<sup>4</sup> fico
u estabelecido endossar a defini&ccedil;&atilde;o de DRC proposta pelo K/DOKI,<s
up>5</sup> na qual &eacute; portador de DRC todo indiv&iacute;duo que apresentar
 albumin&uacute;ria e/ou filtra&ccedil;&atilde;o glomerular estimada (FGe) &lt; 
60 mL/min/1,73m<sup>2</sup>, confirmadas em pelo menos duas medidas num per&iacu
te;odo superior a tr&ecirc;s meses. Essa defini&ccedil;&atilde;o &eacute; a base
 do atual sistema de estagiamento da DRC e foi respons&aacute;vel pela grande at
en&ccedil;&atilde;o recebida pela doen&ccedil;a a n&iacute;vel cl&iacute;nico, d
e pesquisa e sa&uacute;de p&uacute;blica. </font></p>     ^cY#v33n1a01.htm##
02016000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704178500072002001301857#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#19#15#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A creatinina medida no plasma ou no soro
 &eacute; considerada um bom marcador das altera&ccedil;&otilde;es da filtra&cce
dil;&atilde;o glomerular em um determinado paciente, contudo, a sua performance 
deixa a desejar para a medida da FG absoluta. <sup>4 </sup>Os principais problem
as da creatinina s&atilde;o a interfer&ecirc;ncia anal&iacute;tica de crom&oacut
e;genos n&atilde;o creatinina, a sua rela&ccedil;&atilde;o inversa com a FG e a 
depend&ecirc;ncia da massa muscular. &Eacute; importante lembrar que a creatinin
a s&eacute;rica aumenta com a ingest&atilde;o da carne cozida, independentemente
 de altera&ccedil;&atilde;o da fun&ccedil;&atilde;o renal, raz&atilde;o pela qua
l deveria ser dosada ap&oacute;s 12 horas de absten&ccedil;&atilde;o de carne. O
 c&aacute;lculo da FGe pelas equa&ccedil;&otilde;es do estudo MDRD<sup>7</sup> e
 CKD-EPI<sup>8</sup> &eacute; derivado da creatinina s&eacute;rica, idade, g&eci
rc;nero e ra&ccedil;a, os quais essencialmente corrigem para massa muscular. Se 
a massa muscular diferir acentuadamente da m&eacute;dia para a idade, ra&ccedil;
a e g&ecirc;nero, a FGe fornecer&aacute; resultados menos confi&aacute;veis, com
o, por exemplo, os observados nos pacientes amputados e nos desnutridos. <sup>5<
/sup> Nesses pacientes, a recomenda&ccedil;&atilde;o &eacute; determinar a depur
a&ccedil;&atilde;o da creatinina em amostra urin&aacute;ria colhida durante 24 h
oras. <sup>5</sup> A FGe tem sido validada em indiv&iacute;duos de diferentes ra
&ccedil;as, inclusive na popula&ccedil;&atilde;o brasileira. <sup>9 </sup>Desaco
nselha-se o uso da FGe em crian&ccedil;as, em gr&aacute;vidas, nos indiv&iacute;
duos muito idosos e em ambos os extremos de peso. <sup>5</sup></font></p>     ^c
Y#v33n1a01.htm##
01461000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704123000072002001301302#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#20#16#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A FGe com a equa&ccedil;&atilde;o do est
udo MDRD n&atilde;o &eacute; acurada o suficiente quando o seu valor est&aacute;
 acima de 60 mL/min/1,73m<sup>2</sup>; a recomenda&ccedil;&atilde;o atual &eacut
e; que os laborat&oacute;rios que j&aacute; adotam a pr&aacute;tica de estimar a
 fun&ccedil;&atilde;o renal quando da dosagem da creatinina s&eacute;rica n&atil
de;o mencionem resultados acima daquele valor. Nesta situa&ccedil;&atilde;o, a e
qua&ccedil;&atilde;o CKD-EPI tem sido recomendada. <sup>8</sup> &Eacute; importa
nte lembrar que a FGe reflete a filtra&ccedil;&atilde;o glomerular somente em es
tado de equil&iacute;brio, n&atilde;o sendo recomendada para estimar a fun&ccedi
l;&atilde;o renal de pacientes com insufici&ecirc;ncia renal aguda, situa&ccedil
;&atilde;o cl&iacute;nica em que se recomenda a depura&ccedil;&atilde;o da creat
inina. <sup>5</sup> A identifica&ccedil;&atilde;o de FGe reduzida imp&otilde;e a
 repeti&ccedil;&atilde;o do exame ap&oacute;s tr&ecirc;s meses, com o objetivo d
e confirmar ou n&atilde;o a cronicidade da altera&ccedil;&atilde;o funcional ren
al, ou seja, a exist&ecirc;ncia ou n&atilde;o de DRC. <sup>5</sup> </font></p>  
   ^cY#v33n1a01.htm##
01191000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704096000072002001301032#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#21#17#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A pesquisa de protein&uacute;ria &eacute
; v&aacute;lida tanto atrav&eacute;s da detec&ccedil;&atilde;o na urina da prese
n&ccedil;a de prote&iacute;na total quanto da fra&ccedil;&atilde;o albumina. As 
fitas reagentes, amplamente utilizadas na pesquisa de protein&uacute;ria, s&atil
de;o pr&aacute;ticas, mas sua <i>performance</i> depende do fluxo de urina. A cr
eatinina &eacute; excretada na urina a uma taxa relativamente constante e pode s
er utilizada na quantifica&ccedil;&atilde;o da protein&uacute;ria (rela&ccedil;&
atilde;o prote&iacute;na/creatinina ou RPC) ou albumin&uacute;ria (rela&ccedil;&
atilde;o albumina/creatinina ou RAC) em amostras urin&aacute;rias isoladas. Esse
s m&eacute;todos apresentam excelente correla&ccedil;&atilde;o com as determina&
ccedil;&otilde;es realizadas em urina obtida durante 24 horas, al&eacute;m de se
rem mais convenientes. <sup>10</sup> </font></p>     ^cY#v33n1a01.htm##
00718000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704048700072002001300559#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#22#18#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A RAC apresenta papel central na doen&cc
edil;a renal diab&eacute;tica e deveria ser utilizada, no m&iacute;nimo, anualme
nte, tanto no rastreio quanto no acompanhamento da les&atilde;o renal em diab&ea
cute;ticos. O papel da RAC ou RPC em pacientes n&atilde;o diab&eacute;ticos aind
a n&atilde;o est&aacute; estabelecido, devido a recomenda&ccedil;&otilde;es cont
roversas das diretrizes. <sup>5,11,12</sup> </font></p>     ^cY#v33n1a01.htm##
00949000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704071800072002001300790#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#23#19#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A maioria dos estudos sobre desfechos e 
interven&ccedil;&otilde;es baseia-se na determina&ccedil;&atilde;o da protein&ua
cute;ria total e, menos frequentemente, na albumin&uacute;ria, que &eacute; mais
 custosa. A descri&ccedil;&atilde;o recente do uso do corante Coomassie azul bri
lhante R-250 para detectar microalbumin&uacute;ria<sup>13</sup> revela um m&eacu
te;todo com excelente sensibilidade, que apresenta baixo custo (cada exame custa
 cerca de cinco centavos de Real), o que permitir&aacute; a sua utiliza&ccedil;&
atilde;o no diagn&oacute;stico precoce de les&atilde;o parenquimatosa renal em s
eus est&aacute;gios mais iniciais. </font></p>     ^cY#v33n1a01.htm##
00615000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704038400072002001300456#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#24#20#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">&Eacute; importante lembrar que a classi
fica&ccedil;&atilde;o da DRC em est&aacute;gios, atualmente adotada em todo o mu
ndo, baseia-se na FGe e na presen&ccedil;a ou n&atilde;o da albumin&uacute;ria (
protein&uacute;ria)<sup> 4,5,12</sup> (<a href="/img/revistas/jbn/v33n1/a01qd01m
.jpg">Quadro 1</a>). </font></p>     ^cY#v33n1a01.htm##
02310000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704207900072002001302151#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#25#21#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Contudo, as determina&ccedil;&otilde;es 
da FGe e albumin&uacute;ria, al&eacute;m de serem chaves no diagn&oacute;stico e
 estagiamento da DRC, s&atilde;o tamb&eacute;m importantes em prever desfechos (
<a href="/img/revistas/jbn/v33n1/a01qd02m.jpg">Quadro 2</a>). Os benef&iacute;ci
os de avaliar funcionalmente o rim pela FGe n&atilde;o se limitam somente &agrav
e; previs&atilde;o dos pacientes que, ao longo do curso da doen&ccedil;a, necess
itar&atilde;o de terapia renal substitutiva (TRS), mas tamb&eacute;m incluem a i
dentifica&ccedil;&atilde;o daqueles que apresentam risco aumentado de perda acel
erada da fun&ccedil;&atilde;o renal associada &agrave; morbimortalidade. Quanto 
menor a FG apresentada por um paciente maior &eacute; a probabilidade de ele vir
 a precisar de di&aacute;lise ou transplante renal. Estudos epidemiol&oacute;gic
os evidenciam que o risco de um paciente no est&aacute;gio 1 ou 2 da DRC necessi
tar de TRS &eacute; menor do que o de um paciente no est&aacute;gio 3 ou 4 da do
en&ccedil;a, posto que o tempo necess&aacute;rio para exaurir a sua reserva func
ional renal &eacute; maior. Essas observa&ccedil;&otilde;es, contudo, n&atilde;o
 s&atilde;o absolutas, pois a velocidade de progress&atilde;o das doen&ccedil;as
 renais depende de v&aacute;rios determinantes, entre eles a idade do paciente, 
a etiologia da DRC, a presen&ccedil;a de fatores de risco para a progress&atilde
;o da doen&ccedil;a e comorbidades, particularmente as cardiovasculares. Natural
mente, quanto maior o n&uacute;mero de dados sobre FGe dispon&iacute;vel e mais 
longo o estudo, mais confi&aacute;vel ser&aacute; o c&aacute;lculo da queda da F
Ge. <sup>10,14,15</sup> Infelizmente, at&eacute; o momento, poucos s&atilde;o os
 estudos que investigaram os fatores de risco determinantes de perda acelerada d
a fun&ccedil;&atilde;o renal. Estudos dessa natureza, idealmente, deveriam ofere
cer dados de acompanhamento sequencial para o c&aacute;lculo das altera&ccedil;&
otilde;es da FGe ao longo do tempo. </font></p>     ^cY#v33n1a01.htm##
02082000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704185100072002001301923#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#26#22#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">At&eacute; o momento, ainda n&atilde;o e
st&aacute; claro se &eacute; a gravidade da perda da capacidade de filtra&ccedil
;&atilde;o (expressa como FGe) ou a presen&ccedil;a de sinais de les&atilde;o pa
renquimatosa renal (expressa pela albumin&uacute;ria) o melhor preditor de DRC p
rogressiva. De maneira geral, a incid&ecirc;ncia de IRC aumenta com a piora da F
Ge basal. <sup>16 </sup>No entanto, o curso da DRC pode ser diferente, dependend
o da presen&ccedil;a ou n&atilde;o de alguma evid&ecirc;ncia de les&atilde;o do 
par&ecirc;nquima renal. De fato, a incid&ecirc;ncia de IRC &eacute; cerca de cem
 vezes maior no paciente que apresenta protein&uacute;ria, quando comparada a ou
tro com a mesma FGe, mas sem protein&uacute;ria. Em estudo populacional realizad
o no Jap&atilde;o, os autores observaram que um paciente no est&aacute;gio 1 ou 
2 da DRC e com protein&uacute;ria detectada com fitas reagentes apresentava maio
r risco de vir a necessitar de TRS do que pacientes no est&aacute;gio 3 e at&eac
ute; mesmo 4 da doen&ccedil;a, por&eacute;m com fitas reagentes negativas para p
rotein&uacute;ria. <sup>17</sup> Dados mais recentes originados do estudo <i>Mul
tiple Risk Factor Intervention Trial</i> (MRFIT) confirmam essas observa&ccedil;
&otilde;es. O risco de necessidade de TRS para um paciente no est&aacute;gio 3 d
a DRC e sem protein&uacute;ria aumenta apenas 2,4 vezes comparado ao da popula&c
cedil;&atilde;o sem DRC, mas aumenta 33 vezes se o mesmo paciente apresenta prot
ein&uacute;ria. &Eacute; importante destacar que o risco de progredir para IRC &
eacute; de cerca de 12 vezes para um paciente com DRC est&aacute;gio 1 ou 2 com 
protein&uacute;ria, ou seja, maior do que o observado em paciente no est&aacute;
gio 3, mas sem protein&uacute;ria. <sup>18</sup></font></p>     ^cY#v33n1a01.htm
##
01222000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704099100072002001301063#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#27#23#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">No estudo <i>Prevention of Renal and Vas
cular Endstage Disease</i> (PREVEND), realizado prospectivamente na popula&ccedi
l;&atilde;o Holandesa, no qual os participantes foram avaliados sequencialmente 
a cada tr&ecirc;s ou quatro anos ao longo de 6,2 anos, foi observado, numa coort
e de 6.879 integrantes, que a FGe diminuiu numa velocidade de 0,45 ± 1,60 mL/min
/1,73m<sup>2</sup>/ano. <sup>20</sup> Se ajustado para idade e g&ecirc;nero, o d
ecl&iacute;nio da FGe se acentuou gradualmente com o aumento da protein&uacute;r
ia. <sup>19</sup> Em qualquer est&aacute;gio da DRC, a velocidade de queda da FG
e foi maior nos pacientes protein&uacute;ricos quando comparados aos n&atilde;o 
protein&uacute;ricos. O estudo tamb&eacute;m permitiu identificar a hipertens&at
ilde;o arterial, a glicemia e a albumin&uacute;ria como fatores de risco indepen
dentes de progress&atilde;o da DRC em ambos os sexos. <sup>20 </sup></font></p> 
    ^cY#v33n1a01.htm##
01618000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704138700072002001301459#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#28#24#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">No final do s&eacute;culo passado, estav
a evidente que ser portador de DRC em tratamento dial&iacute;tico era um fator p
redisponente a maior probabilidade de morte cardiovascular. Por exemplo, a chanc
e de &oacute;bito de um jovem de 20 anos em TRS &eacute; 500 vezes maior do que 
a de um indiv&iacute;duo saud&aacute;vel da mesma idade e &eacute; a mesma que a
 de um idoso de 80 anos. <sup>21 </sup>Contudo, esta associa&ccedil;&atilde;o de
 DRC com mortalidade cardiovascular n&atilde;o se restringe aos pacientes em di&
aacute;lise e pode ser observada nos pacientes ainda nos est&aacute;gios pr&eacu
te;-dial&iacute;ticos da doen&ccedil;a. &Eacute; extremamente inquietante saber 
que a queda da FGe se associa gradualmente com maior mortalidade (principalmente
 por DCV) e que um paciente com DRC est&aacute;gio 4 apresenta duas vezes mais c
hances de &oacute;bito do que de evoluir para di&aacute;lise. <sup>18 </sup>Cont
udo, n&atilde;o &eacute; s&oacute; a queda da FGe que se associa com maior morta
lidade na DRC. Assim, um paciente no est&aacute;gio 1 ou 2 da DRC (FGe &gt; 60 m
L/min/1,73m<sup>2</sup>) e com albumin&uacute;ria apresenta taxa de mortalidade 
ajustada duas vezes maior do que um outro no est&aacute;gio 3 (FGe de 45-59 mL/m
in/1,73m<sup>2</sup>), mas sem albumin&uacute;ria. <sup>23</sup></font></p>     
^cY#v33n1a01.htm##
01422000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704119100072002001301263#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#29#25#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Atualmente, aceita-se que n&iacute;veis 
aumentados de albumin&uacute;ria<sup>24 </sup>e diminu&iacute;dos de FGe<sup>25 
</sup>s&atilde;o fatores de risco independentes dos chamados fatores "tradiciona
is" para mortalidade cardiovascular. Contudo, a confiabilidade desses dois marca
dores em predizer os eventos cardiovasculares ainda &eacute; question&aacute;vel
. Por exemplo, estudos realizados na Holanda<sup>26 </sup>e nos Estados Unidos<s
up>27 </sup>descreveram um aumento significativo da ocorr&ecirc;ncia de eventos 
cardiovasculares em pacientes com DRC est&aacute;gio 3B (ou FGe &lt; 45 mL/min/1
,73m<sup>2</sup>) e sem protein&uacute;ria. Por outro lado, numa avalia&ccedil;&
atilde;o de pacientes ap&oacute;s infarto do mioc&aacute;rdio<sup>28 </sup>e em 
dois outros estudos populacionais,<sup>29,30</sup> o risco de eventos cardiovasc
ulares ajustado para idade e g&ecirc;nero n&atilde;o foi estatisticamente elevad
o em pacientes com DRC est&aacute;gio 3 sem protein&uacute;ria, embora tenha sid
o evidentemente aumentado em pacientes no mesmo est&aacute;gio da DRC, por&eacut
e;m com protein&uacute;ria. </font></p>     ^cY#v33n1a01.htm##
00980000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704074900072002001300821#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#30#26#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">No nosso estudo com pacientes ambulatori
ais com insufici&ecirc;ncia card&iacute;aca (IC) est&aacute;gios B e C, acompanh
ados por 12 meses, a DRC est&aacute;gios 3 a 5 foi diagnosticada em 50% dos caso
s e a sua ocorr&ecirc;ncia se associou a &oacute;bito ou hospitaliza&ccedil;&ati
lde;o por descompensa&ccedil;&atilde;o card&iacute;aca em 100% e 65% dos pacient
es com IC est&aacute;gios B e C, respectivamente. <sup>31</sup> Ap&oacute;s os a
justes para os outros fatores progn&oacute;sticos para IC no per&iacute;odo basa
l, foi observado que a ocorr&ecirc;ncia de DRC, de maneira independente, aumento
u em 3,6 vezes a possibilidade de desfechos desfavor&aacute;veis. </font></p>   
  ^cY#v33n1a01.htm##
01036000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704080500072002001300877#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#31#27#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">&Eacute; interessante observar que os re
sultados dos estudos citados acima referentes &agrave; ocorr&ecirc;ncia de risco
 aumentado de DCV nos pacientes com DRC est&aacute;gios 1 ou 2 comparativamente 
aos indiv&iacute;duos sem doen&ccedil;a renal em muito se assemelham &agrave; re
la&ccedil;&atilde;o da DRC com evolu&ccedil;&atilde;o para TRS. O paralelo entre
 o impacto da albumin&uacute;ria como preditor independente de risco CV e renal 
&eacute; impressionante. At&eacute; recentemente, admitia-se que a macroalbumin&
uacute;ria era um sinal de les&atilde;o glomerular, enquanto a microalbumin&uacu
te;ria sinalizava para ocorr&ecirc;ncia de les&atilde;o vascular e nem sempre es
tava relacionada a comprometimento renal. </font></p>     ^cY#v33n1a01.htm##
00939000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704070800072002001300780#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#32#28#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Devido a isso, durante muito tempo, a ma
croalbumin&uacute;ria foi considerada preditor da IRC, enquanto a microalbumin&u
acute;ria foi utilizada como fator de risco para eventos cardiovasculares. No en
tanto, atualmente, est&aacute; evidente que a macroalbumin&uacute;ria tamb&eacut
e;m se associa com os eventos cardiovasculares<sup>32,33</sup> e a microalbumin&
uacute;ria, por sua vez, identifica os pacientes com DRC de car&aacute;ter progr
essivo e que evoluir&atilde;o para TRS, seja no paciente com diabetes,<sup>34,35
</sup> hipertens&atilde;o arterial<sup>36 </sup>ou na popula&ccedil;&atilde;o ge
ral. <sup>19,20,29</sup> </font></p>     ^cY#v33n1a01.htm##
01148000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704091700072002001300989#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#33#29#text#103#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Em suma, a estimativa da FG a partir da 
creatinina plasm&aacute;tica e a determina&ccedil;&atilde;o da quantidade de alb
umina excretada na urina s&atilde;o testes simples, amplamente dispon&iacute;vei
s e de alt&iacute;ssima relev&acirc;ncia cl&iacute;nica. Deveriam ser realizados
 regularmente naqueles pacientes com maior probabilidade de desenvolvimento de D
RC (diab&eacute;ticos, hipertensos, idosos, familiares de pacientes em TRS), par
ticularmente nos est&aacute;gios pr&eacute;-cl&iacute;nicos da doen&ccedil;a (qu
ando a FGe &eacute; maior que 60 mL/min/1,73m<sup>2</sup>), assim como nos pacie
ntes com DCV. S&atilde;o testes interativos e quando utilizados em conjunto, con
stituem poderoso instrumento proped&ecirc;utico no diagn&oacute;stico e progn&oa
cute;stico da DRC e preditores de desfechos adversos incluindo mortalidade</font
></p>     ^cY#v33n1a01.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#34#30#text#103#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010700072002001300179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#35#31#text#103#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     
^cY#v33n1a01.htm##
00450000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704020500074002001300279#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#36#32#text#103#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Eknoyan G, Lameire N, B
arsoum R <i>et al. </i> The burden of kidney disease: improving global outcomes.
 Kidney Int 2004; 66:1310-4.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#37#33#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00425000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704018000074002001300254#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#38#34#text#103#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Mastroianni Kirsztajn G
. Renal function markers as prevention tools. J Bras Nefrol 2006; 28(Supl.2):48-
52.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#39#35#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704022100074002001300295#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#40#36#text#103#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Middleton JP, Pun PH. H
ypertension, chronic kidney disease, and the development of cardiovascular risk:
 a joint primacy. Kidney Int 2010; 77:753-5.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#41#37#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00522000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704027700074002001300351#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#42#38#text#103#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Eckardt KU, Berns JS, R
occo MV <i>et al</i>. Definition and classification of CKD: the debate should be
 about patient prognosis-a position statement from KDOQI and KDIGO. Am J Kidney 
Dis 2009; 53:915-20.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#43#39#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704022700074002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#44#40#text#103#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. K/DOQI clinical practic
e guidelines for chronic kidney disease: evaluation, classification and stratifi
cation. Am J Kidney Dis 2002; 39(Suppl 2):S1-S246.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#45#41#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704027500074002001300349#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#46#42#text#103#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Lamb EJ, Tomson CR, Rod
erick PJ. Clinical Sciences Reviews Committee of the Association for Clinical Bi
ochemistry. Estimating kidney function in adults using formulae. Ann Clin Bioche
m 2005; 42:321-45.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#47#43#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00492000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704024700074002001300321#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#48#44#text#103#7#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Levey AS, Greene T, Kus
ek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from
 serum creatinine &#91;Abstract&#93;. J Am Soc Nephrol. 2000;11:A0828.    ^cY#v3
3n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#49#45#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00454000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704020900074002001300283#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#50#46#text#103#8#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Levey AS, Stevens LA, S
chmid CH, <i>et al. </i> A new equation to estimate glomerular filtration rate. 
Ann Intern Med. 2009;150:604-12.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#51#47#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00597000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704035200074002001300426#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#52#48#text#103#9#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Polito MG, Gabriel IC, 
Silva MS, Nishida SK, Moreira SR, Mastroianni Kirsztajn G. Clearance de iohexol,
 cistatina C e creatinina s&eacute;ricas como marcadores de fun&ccedil;&atilde;o
 renal em indiv&iacute;duos normais e pacientes com glomerulopatias. J Bras Nefr
ol 2006; 28:41.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#53#49#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00414000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704016800075002001300243#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#54#50#text#103#10#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">10. McIntyre NJ, Taal MW.
 How to measure proteinuria? Curr Opin Nephrol Hypertens 2008; 17:600-3.    ^cY#
v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#55#51#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00641000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704039500075002001300470#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#56#52#text#103#11#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Scottish Intercollegi
ate Guideline Network. Diagnosis and management of chronic kidney disease. A nat
ional clinical guideline. SIGN Guideline 103. Edinburgh: SIGN, 2008. Available a
t <a href="http://www.sign.ac.uk/guidelines/fulltext/103/index.html" target="_bl
ank">www.sign.ac.uk/guidelines/fulltext/103/index.html</a>.    ^cY#v33n1a01.htm#
#
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#57#53#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00658000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704041200075002001300487#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#58#54#text#103#12#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">12. National Institute fo
r Health and Clinical Excellence. Chronic kidney disease. Early identification a
nd management of chronic kidney disease in adults in primary and secondary care.
 Clinical guideline CG73. London: NICE, 2008. Available at <a href="http://www.n
ice.org.uk/Guidance/CG73" target="_blank">www.nice.org.uk/Guidance/CG73</a>.    
^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#59#55#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704022100075002001300296#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#60#56#text#103#13#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Tugirimana PL and Del
anghe JR. Development of an affordable dye-stained microalbuminuria screening te
st. Nephrol Dial Transplant 2009; 24:1485-90.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#61#57#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00813000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704056700075002001300642#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#62#58#text#103#14#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Sarnak MJ, Levey AS, 
Schoolwerth AC<i> et al. </i>, American Heart Association Councils on Kidney in 
Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and E
pidemiology and Prevention. Kidney disease as a risk factor for development of c
ardiovascular disease: A statement from the American Heart Association Councils 
on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Card
iology, and Epidemiology and Prevention. Circulation 2003; 108:2154-69.    ^cY#v
33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#63#59#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00632000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704038600075002001300461#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#64#60#text#103#15#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Canadian Diabetes Ass
ociation: 2008 clinical practice guidelines for the prevention and management of
 diabetes in Canada. Can J Diabetes 2008; 32 (Suppl 1):S126-S133. Available at: 
<a href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank">http
://www.diabetes.ca/files/cpg2008/cpg-2008.pdf</a>.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#65#61#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00623000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704037700075002001300452#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#66#62#text#103#16#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Levey AS, Schoolwerth
 AC, Burrows NR, Williams DE, Stith KR, McClellan W. Comprehensive Public Health
 Strategies for Preventing the Development, Progression, and Complications of CK
D: report of an expert panel convened by the centers for disease control and pre
vention. Am J Kidney Dis 2009; 53:522-35.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#67#63#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704026600075002001300341#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#68#64#text#103#17#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Iseki K, Kinjo K, Ise
ki C, Takishita S. Relationship between predicted creatinine clearance and prote
inuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004; 
44:806-14.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#69#65#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00636000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704039000075002001300465#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#70#66#text#103#18#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Ishani A, Grandits GA
, Grimm RH<i> et al. </i>, MRFIT Research group. Association of single measureme
nts of dipstick proteinuria, estimated glomerular filtration rate, and hematocri
t with 25-year incidence of end-stage renal disease in the Multiple Risk Factor 
Intervention Trial. J Am Soc Nephrol 2006; 17:1444-52.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#71#67#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704023400075002001300309#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#72#68#text#103#19#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">19. van der Velde M, Halb
esma N, de Charro FT<i> et al. </i> Screening for albuminuria identify subjects 
at increased renal risk. J Am Soc Nephrol 2009; 20:852-62.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#73#69#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704026800075002001300343#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#74#70#text#103#20#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Halbesma N, Brantsma 
AH, Bakker SJL<i> et al. </i>, PREVEND study group. Gender differences in predic
tors of the decline of renal function in the general population. Kidney Int 2008
; 74:505-12.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#75#71#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704022600075002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#76#72#text#103#21#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Foley RN, Parfrey PS,
 Sarnak MJ. Clinical Epidemiology of Cardiovascular Disease in Chronic Renal Dis
ease. Am J Kidney Dis 1988; 32(Suppl 3):S112-S119.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#77#73#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00529000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704028300075002001300358#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#78#74#text#103#22#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Keith DS, Nichols GA,
 Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a pop
ulation with chronic kidney disease in a large managed care organization. Arch I
ntern Med 2004; 164:659-63.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#79#75#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00458000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704021200075002001300287#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#80#76#text#103#23#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Hemmelgarn BR, Manns 
BJ, Lloyd A<i> et al</i>. Relation Between Kidney Function, Proteinuria, and Adv
erse Outcomes. JAMA 2010; 303:423-9.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#81#77#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00525000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704027900075002001300354#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#82#78#text#103#24#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Hillege HL, Fidler V,
 Diercks GF<i> et al. </i> Prevend study group. Urinary albumin excretion predic
ts cardiovascular and noncardiovascular mortality in general population. Circula
tion 2010; 106:1777-82.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#83#79#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00493000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704024700075002001300322#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#84#80#text#103#25#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Go AS, Chertow GM, Fa
n D, Mc Culloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardi
ovascular events, and hospitalization. N Engl J Med 2004; 351:1296-305.    ^cY#v
33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#85#81#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704029400075002001300369#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#86#82#text#103#26#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Hallan S, Astor B, Ro
mundstad S, Aasarod K, Kvenild K, Coresh J. Association of kidney function and a
lbuminuria with cardiovascular mortality in older <i>versus</i> younger individu
als. Arch Intern Med 2007; 167:2490-6.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#87#83#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704027700075002001300352#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#88#84#text#103#27#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Astor BC, Hallan SI, 
Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and r
isk of cardiovascular and all-cause mortality in the US population. Am J Epidemi
ol 2008; 167:1226-34.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#89#85#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00577000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704033100075002001300406#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#90#86#text#103#28#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Tonelli M, Jose P, Cu
rhan G, Sacks F, Braunwald E, Pfeffer M, CARE trial investigators. Proteinuria, 
impaired kidney function, and adverse outcomes in people with coronary disease: 
analysis of a previously conducted randomized trial. BMJ 2006; 332:1426-31.    ^
cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#91#87#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704032700075002001300402#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#92#88#text#103#29#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Brantsma AH, Bakker S
JL, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Cardiovascular and renal 
outcome in subjects with KDOQI stages 1-3 chronic kidney disease: the importance
 of urinary albumin excretion. Nephrol Dial Transplant 2008; 23:3851-8.    ^cY#v
33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#93#89#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704023600075002001300311#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#94#90#text#103#30#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Foster MC, Hwang S-J,
 Larson MG<i> et al. </i>Cross-classification of microalbuminuria and reduced gl
omerular filtration rate. Arch Intern Med 2007; 167:1386-92.    ^cY#v33n1a01.htm
##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#95#91#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704026600075002001300341#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#96#92#text#103#31#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Galil, AGS, Pinheiro 
HS, Chaoubah A, Costa DMN, Bastos MG. Chronic kidney disease increases cardiovas
cular unfavourable outcomes in outpatients with heart failure. BMC Nephrology 20
09; 10:31.    ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#97#93#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704023600075002001300311#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#98#94#text#103#32#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Ordonnez JD, Hiatt RA
, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associa
ted with the nephrotic syndrome. Kidney Int 1993; 44:638-42.    ^cY#v33n1a01.htm
##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#99#95#text#103# </font></p>     ^cY#v3
3n1a01.htm##
00525000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069888000300073704027800076002001300354#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#100#96#text#103#33#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Gerstein HC, Mann JF
, Yi Q<i> et al. </i>, HOPE Study Investigators. Albuminuria and risk of cardiov
ascular events, death, and heart failure in diabetic and nondiabetic individuals
. JAMA 2001; 286:421-6.    ^cY#v33n1a01.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704002100073002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#101#97#text#103# </font></p>     ^cY#v
33n1a01.htm##
00494000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069888000300073704024700076002001300323#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#102#98#text#103#34#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Parving H-H, Oxenbol
l B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at r
isk of developing diabetic nephropathy. Acta Endocrinol 1982; 100:550-5.    ^cY#
v33n1a01.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704002100073002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#103#99#text#103# </font></p>     ^cY#v
33n1a01.htm##
00443000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704019500077002001300272#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#104#100#text#103#35#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Mogensen CE, Christ
ensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl 
J Med1984; 311:89-93.    ^cY#v33n1a01.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#105#101#text#103# </font></p>     ^cY#
v33n1a01.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704026200077002001300339#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#106#102#text#103#36#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Bigazzi R, Bianchi 
S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and re
nal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:
1325-33.    ^cY#v33n1a01.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002000074002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a01.htm#S#p#107#103#text#103#</font></p>     ^cY#v
33n1a01.htm##
00551000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100017000730100017000900110
01600107012006000123030001100183065000900194064000500203031000300208014000700211
865000900218002001300227035001000240801001100250#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a01.htm#S#c#108#1#text#36#1#^rND^sEknoyan^nG#^rND^sLameire^nN#Bars
oum R et al#The burden of kidney disease: improving global outcomes^len#Kidney I
nt#20040000#2004#66#1310-4#20110300#v33n1a01.htm#0085-2538#Kidney int##
00516000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100031000730120047001040300
01400151065000900165064000500174031000300179032000400182014000600186865000900192
002001300201035001000214801001400224#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a01.htm#S#c#109#2#text#36#2#^rND^sMastroianni Kirsztajn^nG#Renal function mark
ers as prevention tools^len#J Bras Nefrol#20060000#2006#28#^s2#48-52#20110300#v3
3n1a01.htm#0101-2800#J Bras Nefrol##
00564000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100020000730100014000930120
10200107030001100209065000900220064000500229031000300234014000600237865000900243
002001300252035001000265801001100275#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a01.htm#S#c#110#3#text#36#3#^rND^sMiddleton^nJP#^rND^sPun^nPH#Hypertension, ch
ronic kidney disease, and the development of cardiovascular risk: a joint primac
y^len#Kidney Int#20100000#2010#77#753-5#20110300#v33n1a01.htm#0085-2538#Kidney i
nt##
00648000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100018000730100016000910100
01600107810000600123012012900129030001600258065000900274064000500283031000300288
014000700291865000900298002001300307035001000320801001600330#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#111#4#text#36#4#^rND^sEckardt^nKU#^rND^sBe
rns^nJS#^rND^sRocco^nMV#et al#Definition and classification of CKD: the debate s
hould be about patient prognosis-a position statement from KDOQI and KDIGO^len#A
m J Kidney Dis#20090000#2009#53#915-20#20110300#v33n1a01.htm#0272-6386#Am J Kidn
ey Dis##
00546000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710120114000730300016001870650
00900203064000500212031000300217032000400220014000800224865000900232002001300241
035001000254801001600264#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#
c#112#5#text#36#5#K/DOQI clinical practice guidelines for chronic kidney disease
: evaluation, classification and stratification^len#Am J Kidney Dis#20020000#200
2#39#^s2#S1-S246#20110300#v33n1a01.htm#0272-6386#Am J Kidney Dis##
00642000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100015000730100017000880100
01900105012013800124030001700262065000900279064000500288031000300293014000700296
865000900303002001300312035001000325801001700335#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a01.htm#S#c#113#6#text#36#6#^rND^sLamb^nEJ#^rND^sTomson^nCR#^rND^s
Roderick^nPJ#Clinical Sciences Reviews Committee of the Association for Clinical
 Biochemistry: Estimating kidney function in adults using formulae^len#Ann Clin 
Biochem#20050000#2005#42#321-45#20110300#v33n1a01.htm#0004-5632#Ann Clin Biochem
##
00596000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100016000730100016000890100
01600105010001500121012011500136030000800251710000200259065000900261064000500270
031000300275014000600278865000900284002001300293#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a01.htm#S#c#114#7#text#36#7#^rND^sLevey^nAS#^rND^sGreene^nT#^rND^s
Kusek^nJW#^rND^sBeck^nGJ#A simplified equation to predict glomerular filtration 
rate from serum creatinine &#91;Abstract&#93;: J Am Soc^len#Nephrol#2#20000000#2
000#11#A0828#20110300#v33n1a01.htm##
00577000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100016000730100018000890100
01700107810000600124012005800130030001500188065000900203064000500212031000400217
014000700221865000900228002001300237035001000250801001500260#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#115#8#text#36#8#^rND^sLevey^nAS#^rND^sStev
ens^nLA#^rND^sSchmid^nCH#et al#A new equation to estimate glomerular filtration 
rate^len#Ann Intern Med#20090000#2009#150#604-12#20110300#v33n1a01.htm#0003-4819
#Ann Intern Med##
00742000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100017000730100018000900100
01600108010001800124010001800142010003100160012014500191030001400336065000900350
06400050035903100030036401400030036786500090037000200130037903500100039280100140
0402#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#116#9#text#36#9#^r
ND^sPolito^nMG#^rND^sGabriel^nIC#^rND^sSilva^nMS#^rND^sNishida^nSK#^rND^sMoreira
^nSR#^rND^sMastroianni Kirsztajn^nG#Clearance de iohexol, cistatina C e creatini
na séricas como marcadores de função renal em indivíduos normais e pacientes com
 glomerulopatias^lpt#J Bras Nefrol#20060000#2006#28#41#20110300#v33n1a01.htm#010
1-2800#J Bras Nefrol##
00529000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100019000750100015000940120
03100109030002800140065000900168064000500177031000300182014000600185865000900191
002001300200035001000213801002800223#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a01.htm#S#c#117#10#text#36#10#^rND^sMcIntyre^nNJ#^rND^sTaal^nMW#How to measure
 proteinuria^len#Curr Opin Nephrol Hypertens#20080000#2008#17#600-3#20110300#v33
n1a01.htm#1062-4821#Curr Opin Nephrol Hypertens##
00567000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720170043000750180106001180660
01000224062000500234065000900239064000500248037005000253865000900303002001300312
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#118#11#text#36#11#Scot
tish Intercollegiate Guideline Network#Diagnosis and management of chronic kidne
y disease: A national clinical guideline. SIGN Guideline 103^len#Edinburgh#SIGN#
20080000#2008#www.sign.ac.uk/guidelines/fulltext/103/index.html#20110300#v33n1a0
1.htm##
00604000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720170054000750180155001290660
00700284062000500291065000900296064000500305037003000310865000900340002001300349
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#119#12#text#36#12#Nati
onal Institute for Health and Clinical Excellence#Chronic kidney disease: Early 
identification and management of chronic kidney disease in adults in primary and
 secondary care. Clinical guideline CG73^len#London#NICE#20080000#2008#www.nice.
org.uk/Guidance/CG73#20110300#v33n1a01.htm##
00575000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100019000960120
07700115030002400192065000900216064000500225031000300230014000800233865000900241
002001300250035001000263801002400273#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a01.htm#S#c#120#13#text#36#13#^rND^sTugirimana^nPL#^rND^sDelanghe^nJR#Developm
ent of an affordable dye-stained microalbuminuria screening test^len#Nephrol Dia
l Transplant#20090000#2009#24#1485-90#20110300#v33n1a01.htm#0931-0509#Nephrol Di
al Transplant##
00776000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100017000750100016000920100
02200108810000600130012025600136030001200392065000900404064000500413031000400418
014000800422865000900430002001300439035001000452801001200462#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#121#14#text#36#14#^rND^sSarnak^nMJ#^rND^sL
evey^nAS#^rND^sSchoolwerth^nAC#et al#Kidney disease as a risk factor for develop
ment of cardiovascular disease: A statement from the American Heart Association 
Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clin
ical Cardiology, and Epidemiology and Prevention^len#Circulation#20030000#2003#1
08#2154-69#20110300#v33n1a01.htm#0009-7322#Circulation##
00597000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720110030000750120094001050300
01500199710000200214065000900216064000500225031000300230032000400233014001000237
037005000247865000900297002001300306#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a01.htm#S#c#122#15#text#36#15#Canadian Diabetes Association#2008 clinical prac
tice guidelines for the prevention and management of diabetes in Canada^len#Can 
J Diabetes#2#20080000#2008#32#^s1#S126-S133#http://www.diabetes.ca/files/cpg2008
/cpg-2008.pdf#20110300#v33n1a01.htm##
00798000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100022000910100
01800113010001900131010001600150010001900166012019900185030001600384065000900400
06400050040903100030041401400070041786500090042400200130043303500100044680100160
0456#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#123#16#text#36#16#
^rND^sLevey^nAS#^rND^sSchoolwerth^nAC#^rND^sBurrows^nNR#^rND^sWilliams^nDE#^rND^
sStith^nKR#^rND^sMcClellan^nW#Comprehensive Public Health Strategies for Prevent
ing the Development, Progression, and Complications of CKD: report of an expert 
panel convened by the centers for disease control and prevention^len#Am J Kidney
 Dis#20090000#2009#53#522-35#20110300#v33n1a01.htm#0272-6386#Am J Kidney Dis##
00651000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100015000750100015000900100
01500105010001900120012012200139030001600261065000900277064000500286031000300291
014000700294865000900301002001300310035001000323801001600333#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#124#17#text#36#17#^rND^sIseki^nK#^rND^sKin
jo^nK#^rND^sIseki^nC#^rND^sTakishita^nS#Relationship between predicted creatinin
e clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan^le
n#Am J Kidney Dis#20040000#2004#44#806-14#20110300#v33n1a01.htm#0272-6386#Am J K
idney Dis##
00739000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100019000910100
01600110810000600126012021400132030001700346065000900363064000500372031000300377
014000800380865000900388002001300397035001000410801001700420#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#125#18#text#36#18#^rND^sIshani^nA#^rND^sGr
andits^nGA#^rND^sGrimm^nRH#et al#Association of single measurements of dipstick 
proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year i
ncidence of end-stage renal disease in the Multiple Risk Factor Intervention Tri
al^len#J Am Soc Nephrol#20060000#2006#17#1444-52#20110300#v33n1a01.htm#1046-6673
#J Am Soc Nephrol##
00549000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720110046000750120072001210300
01700193065000900210064000500219031000300224014000700227865000900234002001300243
035001000256801001700266#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#
c#126#19#text#36#19#van der Velde M.Halbesma N.de Charro FT et al#Screening for 
albuminuria identify subjects at increased renal risk^len#J Am Soc Nephrol#20090
000#2009#20#852-62#20110300#v33n1a01.htm#1046-6673#J Am Soc Nephrol##
00612000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750100019000930100
01800112810000600130012009600136030001100232065000900243064000500252031000300257
014000700260865000900267002001300276035001000289801001100299#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#127#20#text#36#20#^rND^sHalbesma^nN#^rND^s
Brantsma^nAH#^rND^sBakker^nSJL#et al#Gender differences in predictors of the dec
line of renal function in the general population^len#Kidney Int#20080000#2008#74
#505-12#20110300#v33n1a01.htm#0085-2538#Kidney int##
00600000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100018000910100
01700109012007700126030001600203065000900219064000500228031000300233032000400236
014001000240865000900250002001300259035001000272801001600282#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#128#21#text#36#21#^rND^sFoley^nRN#^rND^sPa
rfrey^nPS#^rND^sSarnak^nMJ#Clinical Epidemiology of Cardiovascular Disease in Ch
ronic Renal Disease^len#Am J Kidney Dis#19880000#1988#32#^s3#S112-S119#20110300#
v33n1a01.htm#0272-6386#Am J Kidney Dis##
00686000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100018000910100
01800109010001600127010001600143012012400159030001600283065000900299064000500308
031000400313014000700317865000900324002001300333035001000346801001600356#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#129#22#text#36#22#^rND^sKeith^
nDS#^rND^sNichols^nGA#^rND^sGullion^nCM#^rND^sBrown^nJB#^rND^sSmith^nDH#Longitud
inal follow-up and outcomes among a population with chronic kidney disease in a 
large managed care organization^len#Arch Intern Med#20040000#2004#164#659-63#201
10300#v33n1a01.htm#0003-9926#Arch Intern Med##
00573000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100016000960100
01500112810000600127012007200133030000500205065000900210064000500219031000400224
014000600228865000900234002001300243035001000256801000500266#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#130#23#text#36#23#^rND^sHemmelgarn^nBR#^rN
D^sManns^nBJ#^rND^sLloyd^nA#et al#Relation Between Kidney Function, Proteinuria,
 and Adverse Outcomes^len#JAMA#20100000#2010#303#423-9#20110300#v33n1a01.htm#009
8-7484#JAMA##
00627000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750100016000930110
01700109012012900126030001200255065000900267064000500276031000400281014000800285
865000900293002001300302035001000315801001200325#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a01.htm#S#c#131#24#text#36#24#^rND^sHillege^nHL#^rND^sFidler^nV#Di
ercks GF et al#Prevend study group: Urinary albumin excretion predicts cardiovas
cular and noncardiovascular mortality in general population^len#Circulation#2010
0000#2010#106#1777-82#20110300#v33n1a01.htm#0009-7322#Circulation##
00647000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100013000750100018000880100
01300106010002100119010001400140012009400154030001300248065000900261064000500270
031000400275014000900279865000900288002001300297035001000310801001300320#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#132#25#text#36#25#^rND^sGo^nAS
#^rND^sChertow^nGM#^rND^sFan^nD#^rND^sMc Culloch^nCE#^rND^sHsu^nCY#Chronic kidne
y disease and the risks of death, cardiovascular events, and hospitalization^len
#N Engl J Med#20040000#2004#351#1296-305#20110300#v33n1a01.htm#0028-4793#N Engl 
J Med##
00708000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100015000910100
02000106010001700126010001700143010001600160012011700176030001600293065000900309
06400050031803100040032301400070032786500090033400200130034303500100035680100160
0366#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#133#26#text#36#26#
^rND^sHallan^nS#^rND^sAstor^nB#^rND^sRomundstad^nS#^rND^sAasarod^nK#^rND^sKvenil
d^nK#^rND^sCoresh^nJ#Association of kidney function and albuminuria with cardiov
ascular mortality in older versus younger individuals^len#Arch Intern Med#200700
00#2007#167#2490-6#20110300#v33n1a01.htm#0003-9926#Arch Intern Med##
00679000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100017000910100
02100108010001500129010001600144012011700160030001500277065000900292064000500301
031000400306014000800310865000900318002001300327035001000340801001500350#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#134#27#text#36#27#^rND^sAstor^
nBC#^rND^sHallan^nSI#^rND^sMiller 3rd^nER#^rND^sYeung^nE#^rND^sCoresh^nJ#Glomeru
lar filtration rate, albuminuria, and risk of cardiovascular and all-cause morta
lity in the US population^len#Am J Epidemiol#20080000#2008#167#1226-34#20110300#
v33n1a01.htm#0002-9262#Am J Epidemiol##
00751000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100017000750100014000920100
01600106010001500122010001900137010001700156011002500173012014900198030000400347
06500090035106400050036003100040036501400080036986500090037700200130038603500100
0399801000400409#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#135#28
#text#36#28#^rND^sTonelli^nM#^rND^sJose^nP#^rND^sCurhan^nG#^rND^sSacks^nF#^rND^s
Braunwald^nE#^rND^sPfeffer^nM#CARE trial investigators#Proteinuria, impaired kid
ney function, and adverse outcomes in people with coronary disease: analysis of 
a previously conducted randomized trial^len#BMJ#20060000#2006#332#1426-31#201103
00#v33n1a01.htm#0959-8138#BMJ##
00756000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100019000750100018000940100
01800112010001800130010001800148010002100166012013900187030002400326065000900350
06400050035903100030036401400070036786500090037400200130038303500100039680100240
0406#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#136#29#text#36#29#
^rND^sBrantsma^nAH#^rND^sBakker^nSJL#^rND^sHillege^nHL#^rND^sde Zeeuw^nD#^rND^sd
e Jong^nPE#^rND^sGansevoort^nRT#Cardiovascular and renal outcome in subjects wit
h KDOQI stages 1-3 chronic kidney disease: the importance of urinary albumin exc
retion^len#Nephrol Dial Transplant#20080000#2008#23#3851-8#20110300#v33n1a01.htm
#0931-0509#Nephrol Dial Transplant##
00588000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100017000750100016000920110
01600108012008400124030001600208065000900224064000500233031000400238014000800242
865000900250002001300259035001000272801001600282#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a01.htm#S#c#137#30#text#36#30#^rND^sFoster^nMC#^rND^sHwang S-J#Lar
son MG et al#Cross-classification of microalbuminuria and reduced glomerular fil
tration rate^len#Arch Intern Med#20070000#2007#167#1386-92#20110300#v33n1a01.htm
#0003-9926#Arch Intern Med##
00649000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100012000750100010000870100
01900097010001800116010001700134010001700151012010800168030001500276710000200291
065000900293064000500302031000300307014000300310865000900313002001300322#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#138#31#text#36#31#^rND^sGalil#
^rND^sAGS#^rND^sPinheiro^nHS#^rND^sChaoubah^nA#^rND^sCosta^nDMN#^rND^sBastos^nMG
#Chronic kidney disease increases cardiovascular unfavourable outcomes in outpat
ients with heart failure^len#BMC Nephrology#2#20090000#2009#10#31#20110300#v33n1
a01.htm##
00616000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100019000750100016000940100
02000110010001800130012008800148030001100236065000900247064000500256031000300261
014000700264865000900271002001300280035001000293801001100303#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#139#32#text#36#32#^rND^sOrdonnez^nJD#^rND^
sHiatt^nRA#^rND^sKillebrew^nEJ#^rND^sFireman^nBH#The increased risk of coronary 
heart disease associated with the nephrotic syndrome^len#Kidney Int#19930000#199
3#44#638-42#20110300#v33n1a01.htm#0085-2538#Kidney int##
00617000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100019000750100015000940110
03600109012011600145030000500261065000900266064000500275031000400280014000600284
865000900290002001300299035001000312801000500322#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a01.htm#S#c#140#33#text#36#33#^rND^sGerstein^nHC#^rND^sMann^nJF#Yi
 Q et al.HOPE Study Investigators#Albuminuria and risk of cardiovascular events,
 death, and heart failure in diabetic and nondiabetic individuals^len#JAMA#20010
000#2001#286#421-6#20110300#v33n1a01.htm#0098-7484#JAMA##
00649000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750100018000930100
01900111010002300130010001900153012007500172030001600247065000900263064000500272
031000400277014000600281865000900287002001300296035001000309801001600319#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#141#34#text#36#34#^rND^sParvin
g H-H#^rND^sOxenboll^nB#^rND^sSvendsen^nPA#^rND^sChristiansen^nJS#^rND^sAndersen
^nAR#Early detection of patients at risk of developing diabetic nephropathy^len#
Acta Endocrinol#19820000#1982#100#550-5#20110300#v33n1a01.htm#0001-5598#Acta end
ocrinol##
00467000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100019000750100022000940120
06600116030000900182710000200191031000400193014000600197865000900203002001300212
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a01.htm#S#c#142#35#text#36#35#^rND
^sMogensen^nCE#^rND^sChristensen^nCK#Predicting diabetic nephropathy in insulin-
dependent patients^len#N Engl J#2#311#89-93#20110300#v33n1a01.htm##
00643000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100017000750100017000920100
01700109010001800126012011600144030001200260065000900272064000500281031000300286
014000800289865000900297002001300306035001000319801001200329#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a01.htm#S#c#143#36#text#36#36#^rND^sBigazzi^nR#^rND^sB
ianchi^nS#^rND^sBaldari^nD#^rND^sCampese^nVM#Microalbuminuria predicts cardiovas
cular events and renal insufficiency in patients with essential hypertension^len
#J Hypertens#19980000#1998#16#1325-33#20110300#v33n1a01.htm#0263-6352#J Hyperten
s##
00271000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00400097#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#o#1#1#text#1#201
10411#092856#v33n1a02.htm#162##
00897000000000421000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001700102
03100030011903200020012206500090012401400090013303500100014212300020015201200660
01540120065002200100029002850100028003140700043003420700066003851170008004510720
00300459002001300462#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#h#2#
1#text#1#ed#pt#br1.1#1#4.0#ND#02#JBN060#nd#J. Bras. Nefrol.#33#1#20110300#^f15^l
20#0101-2800#1#Dia Mundial do Rim 2011: proteja seus rins, salve seu coração^lpt
#World Kidney Day 2011: protect your kidneys, save your heart^len#^rND^1A01^nWil
liam G^sCouser#^rND^1A02^nMiguel C^sRiella#Sociedade Internacional de Nefrologia
^iA01#Federação Internacional de Fundações do Rim^iA02^1Comitê Diretivo#vancouv#
40#v33n1a02.htm##
00925000000000421000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001700102
03100030011903200020012206500090012401400090013303500100014212300020015201200800
01540120079002340100029003130100028003420700043003700700066004131170008004790720
00300487002001300490#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#f#3#
1#text#1#ed#pt#br1.1#1#4.0#ND#02#JBN060#nd#J. Bras. Nefrol.#33#1#20110300#^f15^l
20#0101-2800#1#<b>Dia Mundial do Rim 2011</b>: <b>proteja seus rins, salve seu c
oração</b>^lpt#<b>World Kidney Day 2011</b>: <b>protect your kidneys, save your 
heart</b>^len#^rND^1A01^nWilliam G^sCouser#^rND^1A02^nMiguel C^sRiella#Sociedade
 Internacional de Nefrologia^iA01#Federação Internacional de Fundações do Rim^iA
02^1Comitê Diretivo#vancouv#40#v33n1a02.htm##
01016000000000433000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030001600117
03100030013303200020013606500090013801400090014703500100015612300020016601200660
01680120065002340100029002990100028003280700045003560700068004011170008004690720
00300477002001300480008008900493#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a0
2.htm#S#l#4#1#text#1#^mjan./mar.^a2011#ed#pt#br1.1#1#4.0#02#JBN060#nd#J. Bras. N
efrol#33#1#20110300#^f15^l20#0101-2800#1#Dia Mundial do Rim 2011: proteja seus r
ins, salve seu coração^lpt#World Kidney Day 2011: protect your kidneys, save you
r heart^len#^rND^1A01^nWilliam G^sCouser#^rND^1A02^nMiguel C^sRiella#^iA01^1Soci
edade Internacional de Nefrologia#^iA02^1Federação Internacional de Fundações do
 Rim^2Comitê Diretivo#vancouv#40#v33n1a02.htm#Internet^ihttp://www.scielo.br/sci
elo.php?script=sci_arttext&pid=S0101-28002011000100002##
00353000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704012400070002001300194#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#5#1#text#117#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL </b>EDITORIAL <
/font></p>     ^cY#v33n1a02.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#6#2#text#117#<p>&nbsp;</p>     ^cY#v33
n1a02.htm##
00395000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704016600070002001300236#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#7#3#text#117#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Dia Mundial do Rim 2011: proteja seus r
ins, salve seu cora&ccedil;&atilde;o </b></font></p>     ^cY#v33n1a02.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#8#4#text#117#<p>&nbsp;</p>     ^cY#v33
n1a02.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#9#5#text#117#<p>&nbsp;</p>     ^cY#v33
n1a02.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704015500071002001300226#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#10#6#text#117#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>William G Couser MD<sup>I</sup>; Migue
l C Riella, MD<sup>II</sup></b></font></p>     ^cY#v33n1a02.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704012100071002001300192#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#11#7#text#117#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Sociedade Internacional de Ne
frologia     ^cY#v33n1a02.htm##
00542000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704031200071002001300383#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#12#8#text#117#<br>   <sup>II</sup>Fede
ra&ccedil;&atilde;o Internacional de Funda&ccedil;&otilde;es do Rim e  Comit&eci
rc; Diretivo do Dia Mundial do Rim 2011 (Georgi Abraham, Paul Berkens, John Feeh
ally,  Guillermo Garcia Garcia, Jan Lantik, Dan Larsen,  Philip Li,  Mark Murphy
, Bernardo Rodriguez-Iturbe)</font></p>     ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#13#9#text#117#<p>&nbsp;</p>     ^cY#v3
3n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#14#10#text#117#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00372000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014100072002001300213#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#15#11#text#117#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O AO DIA MUNDI
AL DO RIM 2011</b></font></p>     ^cY#v33n1a02.htm##
01041000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704081000072002001300882#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#16#12#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">O dia 10 de mar&ccedil;o de 2011 marcar&
aacute; a comemora&ccedil;&atilde;o do 6º Dia Mundial do Rim (DMR), um evento an
ual patrocinado pela Sociedade Internacional de Nefrologia e pela Federa&ccedil;
&atilde;o Internacional de Funda&ccedil;&otilde;es do Rim. Desde a sua origem em
 2006, o DMR vem adquirindo cada vez mais import&acirc;ncia, tendo se tornado o 
mais comemorado evento mundial associado &agrave; doen&ccedil;a renal e o mais b
em-sucedido esfor&ccedil;o de conscientiza&ccedil;&atilde;o tanto do p&uacute;bl
ico em geral quanto das autoridades governamentais ligadas &agrave; sa&uacute;de
 com rela&ccedil;&atilde;o aos perigos da doen&ccedil;a renal, em particular &ag
rave; doen&ccedil;a renal cr&ocirc;nica (DRC). </font></p>     ^cY#v33n1a02.htm#
#
00575000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704034400072002001300416#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#17#13#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Em 2011, o DMR enfatizar&aacute; o signi
ficativo, embora frequentemente subestimado, papel desempenhado pela disfun&cced
il;&atilde;o renal no aumento da doen&ccedil;a cardiovascular (DCV) prematura, a
 causa mais comum de morbimortalidade no mundo. <sup>1</sup> </font></p>     ^cY
#v33n1a02.htm##
00936000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704070500072002001300777#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#18#14#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Ser&aacute; que o foco na detec&ccedil;&
atilde;o precoce e preven&ccedil;&atilde;o da doen&ccedil;a renal pode realmente
 melhorar a sa&uacute;de cardiovascular (CV) a longo prazo? Neste editorial, esp
eramos veicular a mensagem de que uma maior aten&ccedil;&atilde;o aos rins pode 
realmente melhorar os desfechos de sa&uacute;de a longo prazo ao reduzir tanto a
 doen&ccedil;a renal quanto a cardiovascular, devendo, portanto, ser um componen
te central de qualquer estrat&eacute;gia global de sa&uacute;de que vise a reduz
ir o enorme e crescente peso das doen&ccedil;as n&atilde;o comunic&aacute;veis (
DNCs) cr&ocirc;nicas. </font></p>     ^cY#v33n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#19#15#text#117#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013100072002001300203#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#20#16#text#117#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b> A DOEN&Ccedil;A CARDIOVASCULAR E OS 
RINS</b></font></p>     ^cY#v33n1a02.htm##
00900000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704066900072002001300741#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#21#17#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A DCV &eacute; a mais comum das DNCs cr&
ocirc;nicas que t&ecirc;m impacto na mortalidade global. A DCV sozinha &eacute; 
respons&aacute;vel por cerca de 30% de todas as mortes no mundo e 10% de toda a 
vida saud&aacute;vel perdida por doen&ccedil;a. <sup>1</sup> Embora tenha havido
 uma certa redu&ccedil;&atilde;o na mortalidade por DCV nos pa&iacute;ses desenv
olvidos, tal redu&ccedil;&atilde;o n&atilde;o foi relatada nos pa&iacute;ses em 
desenvolvimento, nas minorias populacionais em desvantagem &eacute;tnica e socia
l, e nem em indiv&iacute;duos com DRC concomitante. <sup>2,3</sup></font></p>   
  ^cY#v33n1a02.htm##
00877000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704064600072002001300718#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#22#18#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A presen&ccedil;a de DRC aumenta signifi
cativamente o risco de um evento CV tanto em diabetes quanto em hipertens&atilde
;o. <sup>4,5</sup> No entanto, ainda &eacute; pouco o fato de que a DRC sozinha 
&eacute; um forte fator de risco para DCV, a despeito da exist&ecirc;ncia de dia
betes, hipertens&atilde;o ou qualquer outro fator de risco convencional para DCV
. <sup>6,7</sup> Isso &eacute; particularmente verdadeiro na presen&ccedil;a de 
um aumento na protein&uacute;ria, um importante alvo de qualquer programa de det
ec&ccedil;&atilde;o de DRC. <sup>6-9</sup> </font></p>     ^cY#v33n1a02.htm##
00818000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704058700072002001300659#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#23#19#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">H&aacute; muito j&aacute; se conhece o a
umento de 20 a 30 vezes de DCV em pacientes com doen&ccedil;a renal avan&ccedil;
ada, mas o aumento do risco de DCV associado a menores graus de comprometimento 
da fun&ccedil;&atilde;o renal s&oacute; foi definitivamente demonstrado em 2004.
 Go <i>et al. </i> relataram uma associa&ccedil;&atilde;o independente e gradual
 da TFG com risco de morte, eventos CV e hospitaliza&ccedil;&otilde;es em um est
udo populacional com mais de mil indiv&iacute;duos. <sup>6</sup></font></p>     
^cY#v33n1a02.htm##
01576000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704134500072002001301417#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#24#20#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Esse dram&aacute;tico aumento no risco d
e DCV associado &agrave; DRC deve-se realmente &agrave; DRC ou apenas reflete a 
coexist&ecirc;ncia de diabetes ou hipertens&atilde;o na maioria desses pacientes
? O efeito independente da DRC isolada j&aacute; foi bem documentado em v&aacute
;rios estudos. <sup>7</sup> O risco de morte card&iacute;aca est&aacute; aumenta
do em 46% em indiv&iacute;duos com TFG entre 30 e 60 ml/min (DRC est&aacute;gio 
III) independentemente da presen&ccedil;a dos tradicionais fatores de risco CV, 
incluindo diabetes e hipertens&atilde;o. <sup>10</sup> O risco aumentado de even
tos e mortalidade CV em indiv&iacute;duos acima de 55 anos apenas com DRC &eacut
e; equivalente a, ou at&eacute; maior do que, aquele observado em pacientes com 
diabetes ou infartos mioc&aacute;rdicos pr&eacute;vios. <sup>11</sup> Tanto a po
pula&ccedil;&atilde;o geral<sup>6,12</sup> quanto a de alto risco<sup>13,14</sup
> exibem um aumento no risco de DCV na presen&ccedil;a de DRC. Tal eleva&ccedil;
&atilde;o de risco para DCV n&atilde;o se limita aos idosos - em volunt&aacute;r
ios com idade m&eacute;dia de 45 anos, o risco de infarto mioc&aacute;rdico, aci
dente vascular cerebral e mortalidade devida a todas as causas dobrou naqueles c
om DRC. <sup>14</sup> </font></p>     ^cY#v33n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#25#21#text#117#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012000072002001300192#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#26#22#text#117#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>PROTEIN&Uacute;RIA E RISCO CV </b></f
ont></p>     ^cY#v33n1a02.htm##
00839000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704060800072002001300680#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#27#23#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Ao se considerar a import&acirc;ncia da 
recomenda&ccedil;&atilde;o de triagem para DRC juntamente com os fatores de risc
o convencionais para DCV em indiv&iacute;duos selecionados, os dados mostram que
 o risco de DCV acha-se melhor correlacionado com protein&uacute;ria (albumin&ua
cute;ria) do que apenas com a TFG. Isso &eacute; de particular import&acirc;ncia
, uma vez que a protein&uacute;ria &eacute; quase sempre um marcador de doen&cce
dil;a renal e n&atilde;o um fator de risco convencional para DCV. <sup>6,8,9,15<
/sup></font></p>     ^cY#v33n1a02.htm##
00785000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704055400072002001300626#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#28#24#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o &agrave; prote
in&uacute;ria como preditor de DCV tardia, o estudo PREVEND mostrou uma rela&cce
dil;&atilde;o linear direta entre albumin&uacute;ria e risco de morte CV na popu
la&ccedil;&atilde;o em geral, mesmo em n&iacute;veis de excre&ccedil;&atilde;o d
e albumina geralmente considerados dentro da "normalidade" (15-29 mg/dia), e tal
 risco aumentou mais de seis vezes quando a excre&ccedil;&atilde;o de albumina e
xcedeu 300 mg/dia. <sup>8</sup></font></p>     ^cY#v33n1a02.htm##
01179000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704094800072002001301020#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#29#25#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Informa&ccedil;&otilde;es recentes da ba
se de dados NHANES norte-americana e do Jap&atilde;o tamb&eacute;m mostram um ef
eito independente da albumin&uacute;ria sobre o risco tanto de DCV quanto de mor
talidade devida a todas as causas em todos os n&iacute;veis de TFG. <sup>15,16</
sup> Em pacientes com insufici&ecirc;ncia card&iacute;aca congestiva, mas sem di
abetes, hipertens&atilde;o ou redu&ccedil;&atilde;o da TFG, a eleva&ccedil;&atil
de;o da albumina urin&aacute;ria prediz mortalidade tanto CV quanto devida a tod
as as causas. <sup>17</sup> Resultados semelhantes s&atilde;o obtidos quando se 
estudam pacientes com doen&ccedil;a coron&aacute;ria ou infartos mioc&aacute;rdi
cos pr&eacute;vios, nos quais a protein&uacute;ria conferiu maior risco de morta
lidade do que a TFG reduzida, embora ambos exer&ccedil;am um impacto adverso nos
 desfechos. <sup>18</sup></font></p>     ^cY#v33n1a02.htm##
01835000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704160400072002001301676#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#30#26#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">&Eacute; importante ressaltar que a poss
ibilidade de um evento CV &eacute; significativamente aumentada, assim como o te
mpo necess&aacute;rio para o seu desenvolvimento &eacute; significativamente ace
lerado pela presen&ccedil;a de protein&uacute;ria em todos os n&iacute;veis de T
FG. <sup>19</sup> Em indiv&iacute;duos n&atilde;o diab&eacute;ticos com n&iacute
;veis normais de creatinina s&eacute;rica submetidos a interven&ccedil;&otilde;e
s coronarianas percut&acirc;neas, cerca de 78% t&ecirc;m DRC demonstr&aacute;vel
 quando examinados de maneira mais r&iacute;gida para fun&ccedil;&atilde;o renal
 (TFGe, prote&iacute;na urin&aacute;ria). <sup>20</sup> A presen&ccedil;a de DRC
 n&atilde;o &eacute; apenas um potencial fator de acelera&ccedil;&atilde;o do de
senvolvimento de doen&ccedil;a coron&aacute;ria nesses pacientes, mas tamb&eacut
e;m foi associada ao aumento de outros riscos, incluindo complica&ccedil;&otilde
;es hemorr&aacute;gicas, nefropatia por contraste, re-estenose e morte. <sup>10<
/sup> Hoje, v&aacute;rios estudos confirmam que a protein&uacute;ria &eacute; um
 fator de risco gradativo para DCV independente de TFG, hipertens&atilde;o e dia
betes, e que tal risco se estende a espectros de excre&ccedil;&atilde;o de album
ina geralmente considerados "normais". <sup>21,22</sup> Al&eacute;m disso, esse 
elevado risco CV foi bem demonstrado em v&aacute;rios estudos, nos quais apenas 
fitas reagentes foram utilizadas para investigar aumento da excre&ccedil;&atilde
;o de prote&iacute;na. <sup>6,18,23</sup></font></p>     ^cY#v33n1a02.htm##
00897000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704066600072002001300738#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#31#27#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A despeito da preocupa&ccedil;&atilde;o 
de que a DRC diagnosticada atrav&eacute;s apenas de redu&ccedil;&atilde;o da TFG
 identifique predominantemente adultos mais idosos com risco aumentado devido ap
enas &agrave; idade,<sup>24</sup> a liga&ccedil;&atilde;o com protein&uacute;ria
 como um fator de risco independente para mortalidade CV foi confirmada por meta
-an&aacute;lise de 22 estudos de coorte, com popula&ccedil;&atilde;o geral, sepa
rados, e tanto para indiv&iacute;duos mais idosos (&gt; 65) quanto mais jovens d
e v&aacute;rias nacionalidades e grupos raciais. <sup>23</sup> </font></p>     ^
cY#v33n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#32#28#text#117#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012700072002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#33#29#text#117#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>O TRATAMENTO DE DRC PODE REDUZIR DCV?
</b></font></p>     ^cY#v33n1a02.htm##
03334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704310300072002001303175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#34#30#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Por fim, e mais importante, a partir de 
uma perspectiva cl&iacute;nica, h&aacute; dados sugestivos de que interven&ccedi
l;&otilde;es que tenham o rim como alvo e que s&atilde;o destinadas a reduzir a 
protein&uacute;ria e a retardar a progress&atilde;o de DRC possam tamb&eacute;m 
reduzir o risco de DCV. O benef&iacute;cio dos IECAs e/ou BRAs para frear a prog
ress&atilde;o de DRC diab&eacute;tica e n&atilde;o diab&eacute;tica estabelecida
 j&aacute; foi bem documentado. <sup>25-29</sup> Com rela&ccedil;&atilde;o &agra
ve; diminui&ccedil;&atilde;o da progress&atilde;o, a incid&ecirc;ncia de DCV em 
DRC &eacute; bastante maior com perda mais r&aacute;pida da TFG independentement
e de outros fatores de risco, sugerindo que as interven&ccedil;&otilde;es que re
tardam a progress&atilde;o tamb&eacute;m podem reduzir a DCV. <sup>19</sup> H&aa
cute; relato de redu&ccedil;&atilde;o de 44% na mortalidade CV ao longo de quatr
o anos em pacientes investigados de uma popula&ccedil;&atilde;o geral sem fatore
s de risco, exceto o aumento de albumina na urina, e tratados com IECA tendo o r
im por alvo. <sup>30</sup> Tal efeito foi primariamente observado em indiv&iacut
e;duos com taxas de excre&ccedil;&atilde;o de albumina &gt; 50 mg/dia em um estu
do piloto, e a interven&ccedil;&atilde;o mostrou-se custo-efetiva naquela popula
&ccedil;&atilde;o. <sup>31</sup> Os desfechos CV foram significativamente reduzi
dos na propor&ccedil;&atilde;o direta da redu&ccedil;&atilde;o da albumin&uacute
;ria com IECA, e a albumin&uacute;ria provou ser o &uacute;nico preditor de desf
echo CV. <sup>32</sup> Outros estudos tamb&eacute;m demonstraram que altera&cced
il;&otilde;es na protein&uacute;ria (em diab&eacute;ticos) s&atilde;o melhores p
reditores de desfecho do que as altera&ccedil;&otilde;es na press&atilde;o arter
ial (PA) obtidas com os IECAs. <sup>33</sup> O benef&iacute;cio potencial de ter
apias tendo o rim por alvo foi recentemente enfatizado por observa&ccedil;&otild
e;es de que doses maiores do que as necess&aacute;rias de bloqueadores do sistem
a renina-angiotensina (SRA) para apenas controlar a PA podem reduzir a protein&u
acute;ria independentemente dos efeitos na PA ou TFG, e que a adi&ccedil;&atilde
;o de diur&eacute;ticos ou restri&ccedil;&atilde;o de sal, duas interven&ccedil;
&otilde;es de baixo custo, podem aumentar ainda mais o efeito redutor de protein
&uacute;ria do bloqueio do SRA. <sup>34,35</sup> N&atilde;o h&aacute; ainda dado
s dispon&iacute;veis que permitam afirmar que a investiga&ccedil;&atilde;o para 
DRC e subsequentes interven&ccedil;&otilde;es reduzam a mortalidade CV e sejam c
usto-efetivas em indiv&iacute;duos mais jovens (&lt; 55). <sup>36</sup> Entretan
to, sabe-se hoje que: a albumin&uacute;ria &eacute; um melhor preditor de evento
s renais e cardiovasculares do que apenas a PA isolada; a redu&ccedil;&atilde;o 
da protein&uacute;ria tem um efeito reno e cardioprotetor maior do que a redu&cc
edil;&atilde;o da PA isolada; e a identifica&ccedil;&atilde;o de DRC pode melhor
ar os desfechos CV. </font></p>     ^cY#v33n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#35#31#text#117#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010600072002001300178#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#36#32#text#117#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>     ^
cY#v33n1a02.htm##
03543000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704331200072002001303384#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#37#33#text#117#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Com a proximidade das comemora&ccedil;&o
tilde;es do 6º Dia Mundial do Rim em 10 de mar&ccedil;o de 2011, vale a pena obs
ervar que, at&eacute; a &uacute;ltima d&eacute;cada, a doen&ccedil;a renal era v
ista pela maioria das autoridades governamentais e de sa&uacute;de p&uacute;blic
a como confinada aos pacientes com doen&ccedil;a renal avan&ccedil;ada, felizmen
te uma condi&ccedil;&atilde;o rara, j&aacute; que o enorme custo da terapia rena
l substitutiva consome de modo desproporcional os escassos recursos da sa&uacute
;de, estando muito aqu&eacute;m das possibilidades de pa&iacute;ses habitados po
r mais de 80% da popula&ccedil;&atilde;o mundial (37,38). A mudan&ccedil;a foi g
rande. Hoje sabemos que a doen&ccedil;a renal n&atilde;o &eacute; rara - 10% da 
popula&ccedil;&atilde;o apresenta evid&ecirc;ncia de disfun&ccedil;&atilde;o ren
al. E sabemos que tais indiv&iacute;duos merecem aten&ccedil;&atilde;o, n&atilde
;o apenas porque alguns evoluir&atilde;o para doen&ccedil;a renal avan&ccedil;ad
a, mas porque apresentam um risco bastante aumentado de morte prematura devido a
 DCV, a maior e mais dispendiosa amea&ccedil;a &agrave; assist&ecirc;ncia &agrav
e; sa&uacute;de enfrentada em n&iacute;vel global. <sup>1</sup> Ao mesmo tempo e
m que progredimos no tratamento da maioria dos fatores de risco CV tradicionais,
 a DRC surge como mais um causador de substancial toxicidade vascular independen
te. Felizmente, tamb&eacute;m h&aacute; boas not&iacute;cias. Os biomarcadores d
e DRC (protein&uacute;ria, TFGe) s&atilde;o de detec&ccedil;&atilde;o f&aacute;c
il e de baixo custo, e um deles, a protein&uacute;ria, aparece cedo na evolu&cce
dil;&atilde;o de doen&ccedil;a vascular generalizada. Assim, programas de detec&
ccedil;&atilde;o e preven&ccedil;&atilde;o tendo o rim como alvo parecem oferece
r uma valiosa oportunidade para a institui&ccedil;&atilde;o de medidas preventiv
as precoces que v&atilde;o al&eacute;m das tradicionais abordagens cardioproteto
ras. Hoje existe prova irrefut&aacute;vel de que a inclus&atilde;o de triagem se
letiva para DRC em programas de sa&uacute;de global destinados primariamente &ag
rave; redu&ccedil;&atilde;o de DCV vai melhorar de maneira significativa os desf
echos n&atilde;o apenas da doen&ccedil;a renal, mas, sobretudo, de DNCs, como di
abetes e DCV, que dominam as futuras estrat&eacute;gias de assist&ecirc;ncia &ag
rave; sa&uacute;de. Os caminhos para que isso seja alcan&ccedil;ado j&aacute; fo
ram apresentados tanto para pa&iacute;ses desenvolvidos<sup>39,40</sup> quanto p
ara pa&iacute;ses em desenvolvimento. <sup>1,41</sup> No entanto, a efetiva impl
ementa&ccedil;&atilde;o de tais estrat&eacute;gias s&oacute; vai ocorrer quando 
o p&uacute;blico em geral e a comunidade renal trabalharem em conjunto para conv
encer as autoridades de sa&uacute;de de que isso se trata de interesse p&uacute;
blico. Temos esperan&ccedil;a de que a comemora&ccedil;&atilde;o em todo o mundo
 do Dia Mundial do Rim 2011 seja uma oportunidade para refor&ccedil;ar a mensage
m de que a doen&ccedil;a renal &eacute; de fato comum, nociva, mas trat&aacute;v
el, e que a prote&ccedil;&atilde;o de seus rins &eacute; uma importante estrat&e
acute;gia de sa&uacute;de que pode salvar seu cora&ccedil;&atilde;o. </font></p>
     ^cY#v33n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#38#34#text#117#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010700072002001300179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#39#35#text#117#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     
^cY#v33n1a02.htm##
00647000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704040200074002001300476#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#40#36#text#117#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. World Health Organizati
on. Preventing Chronic Diseases: A Vital Investment: WHO Global Report. 2005. 20
08-2013 action plan for the global strategy for the prevention and control of no
ncommunicable diseases: prevent and control cardiovascular diseases, cancers, ch
ronic respiratory diseases and diabetes. WHO Global Report, 2005.    ^cY#v33n1a0
2.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#41#37#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00451000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704020600074002001300280#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#42#38#text#117#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Anderson GF, Chu E. Exp
anding priorities - Confronting chronic disease in countries with low income. N 
Engl J Med 2007 356: 209-211.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#43#39#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00431000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704018600074002001300260#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#44#40#text#117#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Narayan KM, Ali MK, Kop
lan JP. Global noncommunicable diseases-where worlds meet. N Engl J Med 2010; 36
3:1196-8.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#45#41#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00459000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704021400074002001300288#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#46#42#text#117#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Ritz E, Bakris G, World
 Kidney Day Organising Committee. World Kidney Day: hypertension and chronic kid
ney disease. Lancet 2009; 373:1157-8.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#47#43#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704021800074002001300292#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#48#44#text#117#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Atkins RC, Zimmet P, IS
N-IFKF World Kidney Day Steering Committee. Diabetic kidney disease: act now or 
pay later. Nat Rev Nephrol 2010; 6:134-6.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#49#45#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704024500074002001300319#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#50#46#text#117#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Go AS, Chertow GM, Fan 
D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiova
scular events, and hospitalization. N Engl J Med 2004; 351:1296-305.    ^cY#v33n
1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#51#47#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00462000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704021700074002001300291#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#52#48#text#117#7#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Tonelli M, Wiebe N, Cul
leton B<i> et al. </i>Chronic kidney disease and mortality risk: a systematic re
view. J Am Soc Nephrol 2006; 17:2034-47.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#53#49#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704028800074002001300362#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#54#50#text#117#8#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Hillege HL, Fidler V, D
iercks GFH<i> et al. ,</i> for the PREVEND study group. Urinary albumin excretio
n predicts cardiovascular and noncardiovascular mortality in general population.
 Circulation 2002; 106:1777-82.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#55#51#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00568000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000200072704032300074002001300397#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#56#52#text#117#9#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Klausen K, Borch-Johnse
n K, Feldt-Rasmussen B <i>et al</i>. Very low levels of microalbuminuria are ass
ociated with increased risk of coronary heart disease and death independently of
 renal function, hypertension, and diabetes. Circ 2004; 110:32-35.    ^cY#v33n1a
02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#57#53#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00522000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704027600075002001300351#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#58#54#text#117#10#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">10. van Domburg RT, Hoeks
 SE, Welten GMJM, Chonchol M, Elhendy A, Poldermans D. Renal insufficiency and m
ortality in patients with known or suspected coronary artery disease. J Am Soc N
eph 2008; 19:158-63.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#59#55#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00570000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704032400075002001300399#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#60#56#text#117#11#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Rashidi A, Sehgal AR,
 Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, 
and myocardial infarction being equivalent risk factors for cardiovascular morta
lity in patients older than 65 years. Am J Cardiol 2008; 102:1668-7.    ^cY#v33n
1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#61#57#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00663000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704041700075002001300492#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#62#58#text#117#12#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">12. McCullough PA, Li S, 
Jurkovitz CT <i>et al. ,</i> for the Kidney Early Evaluation Program Investigato
rs. CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General P
opulations: The Kidney Early Evaluation Program (KEEP) and National Health and N
utrition Examination Survey (NHANES) 1999-2004. Am J Kidney Ds 2008; 51, S38-S45
.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#63#59#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00576000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704033000075002001300405#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#64#60#text#117#13#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">13. McCullough PA, Jurkov
itz CT, Pergola PE<i> et al. </i>; for the KEEP Investigators. Independent compo
nents of chronic kidney disease as a cardiovascular risk state: results from the
 Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167:1122-9.    ^c
Y#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#65#61#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704029400075002001300369#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#66#62#text#117#14#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">14. McCullough PA, Li S, 
Jurkovitz CT<i> et al. </i>; for the KEEP Investigators. Chronic kidney disease:
 prevalence of premature cardiovascular disease and relationship to short-term m
ortality. Am Heart J 2008; 156:277-83.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#67#63#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704027700075002001300352#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#68#64#text#117#15#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Astor BC, Hallan SI, 
Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and r
isk of cardiovascular and all-cause mortality in the US population. Am J Epidemi
ol 2008; 167:1226-33.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#69#65#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704029400075002001300369#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#70#66#text#117#16#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Irie F, Iso H, Sairen
chi T <i>et al. </i> The relationships of proteinuria, serum creatinine, glomeru
lar filtration rate with cardiovascular disease mortality in Japanese general po
pulation. Kidney Int 2006; 69:1264-71.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#71#67#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704023400075002001300309#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#72#68#text#117#17#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Granger CB, Swedberg 
K, Pfeffer MA, Yusuf S, McMurray JJ; for the CHARM Investigators Individuals at 
Increased renal risk. J Amer Soc Nephrol 2009; 20:852-862.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#73#69#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00609000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704036300075002001300438#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#74#70#text#117#18#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Tonelli M, Jose P, Cu
rhan G, Sacks F, Braunwald E, Pfeffer M; Cholesterol and Recurrent Events (CARE)
 Trial Investigators. Proteinuria, impaired kidney function, and adverse outcome
s in people with coronary disease: analysis of a previously conducted randomised
 trial. BMJ 2006; 332:1426.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#75#71#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704025600075002001300331#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#76#72#text#117#19#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Matsushita K, Selvin 
E, Bash LD, Franceschini N, Astor BC, Coresh J. Change in estimated GFR associat
es with coronary heart disease and mortality. J Am Soc Nephrol 2009; 20:2617-24.
    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#77#73#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00549000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704030300075002001300378#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#78#74#text#117#20#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Malyszko J, Bachorzew
ska-Gajewska H, Malyszko JS<i> et al. </i> Prevalence of chronic kidney disease 
in elderly patients with normal serum creatinine levels undergoing percutaneous 
coronary interventions. Gerontol 2010; 56:51-4.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#79#75#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00492000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704024600075002001300321#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#80#76#text#117#21#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Hemmelgarn BR, Manns 
BJ, Lloyd A<i> et al. </i>; Alberta Kidney Disease Network. Relation between kid
ney function, proteinuria, and adverse outcomes. JAMA 2010; 303:423-9.    ^cY#v3
3n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#81#77#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704020300075002001300278#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#82#78#text#117#22#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Gansevoort RT, de Jon
g PE. The case for using albuminuria in staging chronic kidney disease. J Amer S
oc Nephrol 2009; 20:465-68.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#83#79#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00565000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704031900075002001300394#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#84#80#text#117#23#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Chronic Kidney Diseas
e Prognosis Consortium. Association of estimated glomerular filtration rate and 
albuminuria with all-cause and cardiovascular mortality in general population co
horts: a collaborative meta-analysis. Lancet 2010; 375:2073-81.    ^cY#v33n1a02.
htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#85#81#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704022600075002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#86#82#text#117#24#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Abdelhafiz AH, Brown 
SH, Bello A, El Nahas M Chronic kidney disease in older people: physiology, path
ology or both? Nephron Clin Pract 2010; 116:19-24.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#87#83#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00506000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704026000075002001300335#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#88#84#text#117#25#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Brenner BM, Cooper ME
, de Zeeuw D<i> et al. </i> Effects of losartan on renal and cardiovascular outc
omes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:86
1-9.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#89#85#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704025300075002001300328#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#90#86#text#117#26#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Ruggenenti P, Perna A
, Gherardi G<i> et al</i>. Renoprotective properties of ACE-inhibition in non-di
abetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359-64.   
 ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#91#87#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00630000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704038400075002001300459#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#92#88#text#117#27#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Ruggenenti P, Perna A
, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for
 dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up 
trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril E
fficacy in Nephropathy. Lancet 1998; 352:1252-6.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#93#89#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00595000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704034900075002001300424#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#94#90#text#117#28#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">27. The GISEN Group (Grup
po Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlle
d trial of effect of ramipril on decline in glomerular filtration rate and risk 
of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;
 349:1857-63.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#95#91#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00454000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704020800075002001300283#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#96#92#text#117#29#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">28. The ESCAPE trial grou
p: Strict blood pressure control and progression of renal failure in children. N
ew Engl J Med 2009; 361:1639-50.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#97#93#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00609000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068888000300072704036300075002001300438#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#98#94#text#117#30#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Asselbergs FW, Dierck
s GF, Hillege HL<i> et al. </i>, for the Prevention of Renal and Vascular Endsta
ge Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril 
and pravastatin on cardiovascular events in subjects with microalbuminuria. Circ
ulation 2004; 110 :2809-16.    ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704002100072002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#99#95#text#117# </font></p>     ^cY#v3
3n1a02.htm##
00744000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069888000300073704049700076002001300573#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#100#96#text#117#31#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Atthobari J, Asselbe
rgs FW, Boersma C<i> et al. </i>; PREVEND IT Study Group. Cost-effectiveness of 
screening for albuminuria with subsequent fosinopril treatment to prevent cardio
vascular events: A pharmacoeconomic analysis linked to the prevention of renal a
nd vascular endstage disease (PREVEND) study and the prevention of renal and vas
cular endstage disease intervention trial (PREVEND IT). Clin Ther 2006; 28:432-4
4.    ^cY#v33n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704002100073002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#101#97#text#117# </font></p>     ^cY#v
33n1a02.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069888000300073704024900076002001300325#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#102#98#text#117#32#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">31. de Zeeuw D, Remuzzi 
G, Parving HH<i> et al. </i> Albuminuria: a therapeutic target for cardiovascula
r protection in type 2 diabetic nephropathy. Circulation 2004; 110 :921-7.    ^c
Y#v33n1a02.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704002100073002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#103#99#text#117# </font></p>     ^cY#v
33n1a02.htm##
00654000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704040600077002001300483#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#104#100#text#117#33#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Eijkelkamp WB, Zhan
g Z, Remuzzi G <i>et al</i>. Albuminuria is a target for renoprotective therapy 
independent from blood pressure in type II diabetic patients with nephropathy. P
ost hoc analysis from the Reduction in End Points in NIDDM with the Angiotensin 
II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18:1540-6.    ^cY#
v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#105#101#text#117# </font></p>     ^cY#
v33n1a02.htm##
00535000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704028700077002001300364#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#106#102#text#117#34#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Muirhead N, Rene de
 Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial)
 Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J
 Am Soc Nephrol 2009; 20:893-900.    ^cY#v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#107#103#text#117# </font></p>     ^cY#
v33n1a02.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704025700077002001300334#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#108#104#text#117#35#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Vogt L, Waanders F,
 Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazi
de on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999-10
07.    ^cY#v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#109#105#text#117# </font></p>     ^cY#
v33n1a02.htm##
00434000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704018600077002001300263#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#110#106#text#117#36#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Fried L. Are we rea
dy to screen the general population for microalbuminuria? J Am Soc Nephrol 2009;
 20:686-688.    ^cY#v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#111#107#text#117# </font></p>     ^cY#
v33n1a02.htm##
00430000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704018200077002001300259#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#112#108#text#117#37#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">36. El Nahas M. the glo
bal challenge of chronic kidney disease. (Nephrology Forum) Kidney Int 2005; 68:
2918-29.    ^cY#v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#113#109#text#117# </font></p>     ^cY#
v33n1a02.htm##
00414000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704016600077002001300243#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#114#110#text#117#38#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Barsoum RS. Chronic
 Kidney disease in the developing world. New Engl J Med 2006; 354:997-9.    ^cY#
v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#115#111#text#117# </font></p>     ^cY#
v33n1a02.htm##
00682000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704043400077002001300511#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#116#112#text#117#39#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Levey AS, Schoolwer
th AC, Burrows NR, Williams DE, Stith KR, McClellan W; Centers for Disease Contr
ol and Prevention Expert Panel. Comprehensive public health strategies for preve
nting the development, progression, and complications of CKD: report of an exper
t panel convened by the Centers for Disease Control and Prevention. Am J Kidney 
Dis 2009; 53:522-35.    ^cY#v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#117#113#text#117# </font></p>     ^cY#
v33n1a02.htm##
00428000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704018000077002001300257#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#118#114#text#117#40#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">39. James MT, Hemmelgar
n, BR, Tonelli, M. Early recognition and prevention of CKD. Lancet 2010; 379:129
6-309.    ^cY#v33n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#119#115#text#117# </font></p>     ^cY#
v33n1a02.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070888000300074704024300077002001300320#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#120#116#text#117#41#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Perico N, Bravo RF,
 De Leon FR, Remuzzi G. Screening for chronic kidney disease in emerging countri
es: feasibility and hurdles. Nephrol Dial Transplant 2009; 24:1355-8.    ^cY#v33
n1a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a02.htm#S#p#121#117#text#117# </font></p>     ^cY#
v33n1a02.htm##
00621000000000205000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710170026000730180280000990650
00900379064000500388865000900393002001300402#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a02.htm#S#c#122#1#text#41#1#World Health Organization#Preventing Chron
ic Diseases: A Vital Investment: WHO Global Report. 2005. 2008-2013 action plan 
for the global strategy for the prevention and control of noncommunicable diseas
es: prevent and control cardiovascular diseases, cancers, chronic respiratory di
seases and diabetes^len#20050000#2005#20110300#v33n1a02.htm##
00550000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100019000730100013000920120
08300105030001300188065000900201064000500210031000400215014000800219865000900227
002001300236035001000249801001300259#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a02.htm#S#c#123#2#text#41#2#^rND^sAnderson^nGF#^rND^sChu^nE#Expanding prioriti
es: Confronting chronic disease in countries with low income^len#N Engl J Med#20
070000#2007#356#209-211#20110300#v33n1a02.htm#0028-4793#N Engl J Med##
00549000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100018000730100014000910100
01700105012005400122030001300176065000900189064000500198031000400203014000700207
865000900214002001300223035001000236801001300246#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#124#3#text#41#3#^rND^sNarayan^nKM#^rND^sAli^nMK#^rND^s
Koplan^nJP#Global noncommunicable diseases-where worlds meet^len#N Engl J Med#20
100000#2010#363#1196-8#20110300#v33n1a02.htm#0028-4793#N Engl J Med##
00564000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100014000730100016000870110
03800103012006200141030000700203065000900210064000500219031000400224014000700228
865000900235002001300244035001000257801000700267#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#125#4#text#41#4#^rND^sRitz^nE#^rND^sBakris^nG#World Ki
dney Day Organising Committee#World Kidney Day: hypertension and chronic kidney 
disease^len#Lancet#20090000#2009#373#1157-8#20110300#v33n1a02.htm#0099-5355#Lanc
et##
00541000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100017000730100016000900110
04500106012005000151030001600201710000200217065000900219064000500228031000200233
014000600235865000900241002001300250#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a02.htm#S#c#126#5#text#41#5#^rND^sAtkins^nRC#^rND^sZimmet^nP#ISN-IFKF World Ki
dney Day Steering Committee#Diabetic kidney disease: act now or pay later^len#Na
t Rev Nephrol#2#20100000#2010#6#134-6#20110300#v33n1a02.htm##
00644000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100013000730100018000860100
01300104010002000117010001400137012009400151030001300245065000900258064000500267
031000400272014000900276865000900285002001300294035001000307801001300317#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#127#6#text#41#6#^rND^sGo^nAS#^
rND^sChertow^nGM#^rND^sFan^nD#^rND^sMcCulloch^nCE#^rND^sHsu^nCY#Chronic kidney d
isease and the risks of death, cardiovascular events, and hospitalization^len#N 
Engl J Med#20040000#2004#351#1296-305#20110300#v33n1a02.htm#0028-4793#N Engl J M
ed##
00570000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100017000730100015000900110
01700105012006700122030001700189065000900206064000500215031000300220014000800223
865000900231002001300240035001000253801001700263#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#128#7#text#41#7#^rND^sTonelli^nM#^rND^sWiebe^nN#Cullet
on B et al#Chronic kidney disease and mortality risk: a systematic review^len#J 
Am Soc Nephrol#20060000#2006#17#2034-47#20110300#v33n1a02.htm#1046-6673#J Am Soc
 Nephrol##
00633000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100018000730100016000910110
04600107012010800153030001200261065000900273064000500282031000400287014000800291
865000900299002001300308035001000321801001200331#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#129#8#text#41#8#^rND^sHillege^nHL#^rND^sFidler^nV#Dier
cks GFH et al.for the PREVEND study group#Urinary albumin excretion predicts car
diovascular and noncardiovascular mortality in general population^len#Circulatio
n#20020000#2002#106#1777-82#20110300#v33n1a02.htm#0009-7322#Circulation##
00639000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100017000730100023000900110
02400113012017100137030000500308710000200313065000900315064000500324031000400329
014000600333865000900339002001300348#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a02.htm#S#c#130#9#text#41#9#^rND^sKlausen^nK#^rND^sBorch-Johnsen^nK#Feldt-Rasm
ussen B et al#Very low levels of microalbuminuria are associated with increased 
risk of coronary heart disease and death independently of renal function, hypert
ension, and diabetes^len#Circ#2#20040000#2004#110#32-35#20110300#v33n1a02.htm##
00661000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100022000750100016000970100
01900113010001800132010001700150010002000167012009800187030001400285710000200299
065000900301064000500310031000300315014000700318865000900325002001300334#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#131#10#text#41#10#^rND^svan Do
mburg^nRT#^rND^sHoeks^nSE#^rND^sWelten^nGMJM#^rND^sChonchol^nM#^rND^sElhendy^nA#
^rND^sPoldermans^nD#Renal insufficiency and mortality in patients with known or 
suspected coronary artery disease^len#J Am Soc Neph#2#20080000#2008#19#158-63#20
110300#v33n1a02.htm##
00705000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100017000750100017000920100
01600109010001800125012017700143030001300320065000900333064000500342031000400347
014000700351865000900358002001300367035001000380801001300390#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#132#11#text#41#11#^rND^sRashidi^nA#^rND^sS
ehgal^nAR#^rND^sRahman^nM#^rND^sO'Connor AS#The case for chronic kidney disease,
 diabetes mellitus, and myocardial infarction being equivalent risk factors for 
cardiovascular mortality in patients older than 65 years^len#Am J Cardiol#200800
00#2008#102#1668-7#20110300#v33n1a02.htm#0002-9149#Am J Cardiol##
00750000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100012000960100
02000108810000600128012026200134030001500396710000200411065000900413064000500422
031000300427014000800430865000900438002001300447#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#133#12#text#41#12#^rND^sMcCullough^nPA#^rND^sLi^nS#^rN
D^sJurkovitz^nCT#et al#for the Kidney Early Evaluation Program Investigators: CK
D and Cardiovascular Disease in Screened High-Risk Volunteer and General Populat
ions: The Kidney Early Evaluation Program (KEEP) and National Health and Nutriti
on Examination Survey (NHANES) 1999-2004^len#Am J Kidney Ds#2#20080000#2008#51#S
38-S45#20110300#v33n1a02.htm##
00679000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100020000960110
04300116012014100159030001600300065000900316064000500325031000400330014000700334
865000900341002001300350035001000363801001600373#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#134#13#text#41#13#^rND^sMcCullough^nPA#^rND^sJurkovitz
^nCT#Pergola PE et alfor the KEEP Investigators#Independent components of chroni
c kidney disease as a cardiovascular risk state: results from the Kidney Early E
valuation Program (KEEP)^len#Arch Intern Med#20070000#2007#167#1122-9#20110300#v
33n1a02.htm#0003-9926#Arch Intern Med##
00638000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100012000960110
04500108012011600153030001100269065000900280064000500289031000400294014000700298
865000900305002001300314035001000327801001100337#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#135#14#text#41#14#^rND^sMcCullough^nPA#^rND^sLi^nS#Jur
kovitz CT et alfor the KEEP Investigators#Chronic kidney disease: prevalence of 
premature cardiovascular disease and relationship to short-term mortality^len#Am
 Heart J#20080000#2008#156#277-83#20110300#v33n1a02.htm#0002-8703#Am Heart J##
00679000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100017000910100
02100108010001500129010001600144012011700160030001500277065000900292064000500301
031000400306014000800310865000900318002001300327035001000340801001500350#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#136#15#text#41#15#^rND^sAstor^
nBC#^rND^sHallan^nSI#^rND^sMiller 3rd^nER#^rND^sYeung^nE#^rND^sCoresh^nJ#Glomeru
lar filtration rate, albuminuria, and risk of cardiovascular and all-cause morta
lity in the US population^len#Am J Epidemiol#20080000#2008#167#1226-33#20110300#
v33n1a02.htm#0002-9262#Am J Epidemiol##
00641000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100014000750100013000890110
01800102012015200120030001100272065000900283064000500292031000300297014000800300
865000900308002001300317035001000330801001100340#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#137#16#text#41#16#^rND^sIrie^nF#^rND^sIso^nH#Sairenchi
 T et al#The relationships of proteinuria, serum creatinine, glomerular filtrati
on rate with cardiovascular disease mortality in Japanese general population^len
#Kidney Int#20060000#2006#69#1264-71#20110300#v33n1a02.htm#0085-2538#Kidney int#
#
00601000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750100018000930100
01800111010001500129010001900144012006800163030001900231710000200250065000900252
064000500261031000300266014000800269865000900277002001300286#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#138#17#text#41#17#^rND^sGranger^nCB#^rND^s
Swedberg^nK#^rND^sPfeffer^nMA#^rND^sYusuf^nS#^rND^sMcMurray^nJJ#for the CHARM In
vestigators Individuals at Increased renal risk^len#J Amer Soc Nephrol#2#2009000
0#2009#20#852-862#20110300#v33n1a02.htm##
00776000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100017000750100014000920100
01600106010001500122010001900137010001700156011005300173012014900226030000400375
06500090037906400050038803100040039301400050039786500090040200200130041103500100
0424801000400434#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#139#18
#text#41#18#^rND^sTonelli^nM#^rND^sJose^nP#^rND^sCurhan^nG#^rND^sSacks^nF#^rND^s
Braunwald^nE#^rND^sPfeffer^nM#Cholesterol and Recurrent Events Trial Investigato
rs#Proteinuria, impaired kidney function, and adverse outcomes in people with co
ronary disease: analysis of a previously conducted randomised trial^len#BMJ#2006
0000#2006#332#1426#20110300#v33n1a02.htm#0959-8138#BMJ##
00678000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100020000750100016000950100
01500111010002200126010001600148010001600164012008100180030001700261065000900278
06400050028703100030029201400080029586500090030300200130031203500100032580100170
0335#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#140#19#text#41#19#
^rND^sMatsushita^nK#^rND^sSelvin^nE#^rND^sBash^nLD#^rND^sFranceschini^nN#^rND^sA
stor^nBC#^rND^sCoresh^nJ#Change in estimated GFR associates with coronary heart 
disease and mortality^len#J Am Soc Nephrol#20090000#2009#20#2617-24#20110300#v33
n1a02.htm#1046-6673#J Am Soc Nephrol##
00638000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750100031000930100
01900124810000600143012014400149030000900293710000200302065000900304064000500313
031000300318014000500321865000900326002001300335#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#141#20#text#41#20#^rND^sMalyszko^nJ#^rND^sBachorzewska
-Gajewska^nH#^rND^sMalyszko^nJS#et al#Prevalence of chronic kidney disease in el
derly patients with normal serum creatinine levels undergoing percutaneous coron
ary interventions^len#Gerontol#2#20100000#2010#56#51-4#20110300#v33n1a02.htm##
00573000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100016000960100
01500112810000600127012007200133030000500205065000900210064000500219031000400224
014000600228865000900234002001300243035001000256801000500266#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#142#21#text#41#21#^rND^sHemmelgarn^nBR#^rN
D^sManns^nBJ#^rND^sLloyd^nA#et al#Relation between kidney function, proteinuria,
 and adverse outcomes^len#JAMA#20100000#2010#303#423-9#20110300#v33n1a02.htm#009
8-7484#JAMA##
00516000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100018000960120
06900114030001900183710000200202065000900204064000500213031000300218014000700221
865000900228002001300237#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#
c#143#22#text#41#22#^rND^sGansevoort^nRT#^rND^sde Jong^nPE#The case for using al
buminuria in staging chronic kidney disease^len#J Amer Soc Nephrol#2#20090000#20
09#20#465-68#20110300#v33n1a02.htm##
00634000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720110044000750120177001190300
00700296065000900303064000500312031000400317014000800321865000900329002001300338
035001000351801000700361#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#
c#144#23#text#41#23#Chronic Kidney Disease Prognosis Consortium#Association of e
stimated glomerular filtration rate and albuminuria with all-cause and cardiovas
cular mortality in general population cohorts: a collaborative meta-analysis^len
#Lancet#20100000#2010#375#2073-81#20110300#v33n1a02.htm#0099-5355#Lancet##
00577000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100016000960100
01500112010001800127012007500145030001900220710000200239065000900241064000500250
031000400255014000600259865000900265002001300274#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#145#24#text#41#24#^rND^sAbdelhafiz^nAH#^rND^sBrown^nSH
#^rND^sBello^nA#^rND^sEl Nahas^nM#Chronic kidney disease in older people: physio
logy, pathology or both?^len#Nephron Clin Pract#2#20100000#2010#116#19-24#201103
00#v33n1a02.htm##
00628000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750100017000930100
01800110810000600128012011000134030001300244065000900257064000500266031000400271
014000600275865000900281002001300290035001000303801001300313#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#146#25#text#41#25#^rND^sBrenner^nBM#^rND^s
Cooper^nME#^rND^sde Zeeuw^nD#et al#Effects of losartan on renal and cardiovascul
ar outcomes in patients with type 2 diabetes and nephropathy^len#N Engl J Med#20
010000#2001#345#861-9#20110300#v33n1a02.htm#0028-4793#N Engl J Med##
00616000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100020000750100015000950100
01800110810000600128012010900134030000700243065000900250064000500259031000400264
014000700268865000900275002001300284035001000297801000700307#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#147#26#text#41#25#^rND^sRuggenenti^nP#^rND
^sPerna^nA#^rND^sGherardi^nG#et al#Renoprotective properties of ACE-inhibition i
n non-diabetic nephropathies with non-nephrotic proteinuria^len#Lancet#19990000#
1999#354#359-64#20110300#v33n1a02.htm#0099-5355#Lancet##
00796000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100020000750100015000950100
01800110010001700128010001600145010001700161012022100178030000700399065000900406
06400050041503100040042001400070042486500090043100200130044003500100045380100070
0463#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#148#27#text#41#26#
^rND^sRuggenenti^nP#^rND^sPerna^nA#^rND^sGherardi^nG#^rND^sGaspari^nF#^rND^sBeni
ni^nR#^rND^sRemuzzi^nG#Renal function and requirement for dialysis in chronic ne
phropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano 
di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy^
len#Lancet#19980000#1998#352#1252-6#20110300#v33n1a02.htm#0099-5355#Lancet##
00615000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100023000750120179000980300
00700277065000900284064000500293031000400298014000800302865000900310002001300319
035001000332801000700342#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#
c#149#28#text#41#27#^rND^sThe Group^nGISEN#Randomised placebo-controlled trial o
f effect of ramipril on decline in glomerular filtration rate and risk of termin
al renal failure in proteinuric, non-diabetic nephropathy^len#Lancet#19970000#19
97#349#1857-63#20110300#v33n1a02.htm#0099-5355#Lancet##
00485000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720120103000750300015001787100
00200193065000900195064000500204031000400209014000800213865000900221002001300230
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#150#29#text#41#28#The 
ESCAPE trial group: Strict blood pressure control and progression of renal failu
re in children^len#New Engl J Med#2#20090000#2009#361#1639-50#20110300#v33n1a02.
htm##
00715000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100018000960100
01800114810000600132012019300138030001200331065000900343064000500352031000400357
014000800361865000900369002001300378035001000391801001200401#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#151#30#text#41#29#^rND^sAsselbergs^nFW#^rN
D^sDiercks^nGF#^rND^sHillege^nHL#et al#for the Prevention of Renal and Vascular 
Endstage Disease Intervention Trial Investigators: Effects of fosinopril and pra
vastatin on cardiovascular events in subjects with microalbuminuria^len#Circulat
ion#20040000#2004#110#2809-16#20110300#v33n1a02.htm#0009-7322#Circulation##
00837000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100019000750100021000940100
01700115810000600132012032100138030001000459065000900469064000500478031000300483
014000700486865000900493002001300502035001000515801001000525#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#152#31#text#41#30#^rND^sAtthobari^nJ#^rND^
sAsselbergs^nFW#^rND^sBoersma^nC#et al#Cost-effectiveness of screening for album
inuria with subsequent fosinopril treatment to prevent cardiovascular events: A 
pharmacoeconomic analysis linked to the prevention of renal and vascular endstag
e disease (PREVEND) study and the prevention of renal and vascular endstage dise
ase intervention trial (PREVEND IT)^len#Clin Ther#20060000#2006#28#432-44#201103
00#v33n1a02.htm#0149-2918#Clin Ther##
00615000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750100017000930100
01800110810000600128012009900134030001200233065000900245064000500254031000400259
014000600263865000900269002001300278035001000291801001200301#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#153#32#text#41#31#^rND^sde Zeeuw^nD#^rND^s
Remuzzi^nG#^rND^sParving^nHH#et al#Albuminuria: a therapeutic target for cardiov
ascular protection in type 2 diabetic nephropathy^len#Circulation#20040000#2004#
110#921-7#20110300#v33n1a02.htm#0009-7322#Circulation##
00779000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100021000750100015000960100
01700111810000600128012025300134030001700387065000900404064000500413031000300418
014000700421865000900428002001300437035001000450801001700460#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#154#33#text#41#32#^rND^sEijkelkamp^nWB#^rN
D^sZhang^nZ#^rND^sRemuzzi^nG#et al#Albuminuria is a target for renoprotective th
erapy independent from blood pressure in type II diabetic patients with nephropa
thy: Post hoc analysis from the Reduction in End Points in NIDDM with the Angiot
ensin II Antagonist Losartan (RENAAL) trial^len#J Am Soc Nephrol#20070000#2007#1
8#1540-6#20110300#v33n1a02.htm#1046-6673#J Am Soc Nephrol##
00589000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750110061000930120
06600154030001700220065000900237064000500246031000300251014000800254865000900262
002001300271035001000284801001700294#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a02.htm#S#c#155#34#text#41#33#^rND^sMuirhead^nN#Rene de Cotret P.Chiu A.Pichet
te V.Tobe SSMART Investigators#Supramaximal dose of candesartan in proteinuric r
enal disease^len#J Am Soc Nephrol#20090000#2009#20#893-900#20110300#v33n1a02.htm
#1046-6673#J Am Soc Nephrol##
00661000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100014000750100018000890100
01700107010001800124010001500142012009800157030001700255065000900272064000500281
031000300286014000900289865000900298002001300307035001000320801001700330#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#156#35#text#41#34#^rND^sVogt^n
L#^rND^sWaanders^nF#^rND^sBoomsma^nF#^rND^sde Zeeuw^nD#^rND^sNavis^nG#Effects of
 dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losar
tan^len#J Am Soc Nephrol#20080000#2008#19#999-1007#20110300#v33n1a02.htm#1046-66
73#J Am Soc Nephrol##
00518000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100015000750120071000900300
01700161065000900178064000500187031000300192014000800195865000900203002001300212
035001000225801001700235#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#
c#157#36#text#41#35#^rND^sFried^nL#Are we ready to screen the general population
 for microalbuminuria^len#J Am Soc Nephrol#20090000#2009#20#686-688#20110300#v33
n1a02.htm#1046-6673#J Am Soc Nephrol##
00477000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750120051000930300
03000144710000200174065000900176064000500185031000300190014000800193865000900201
002001300210#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#158#37#tex
t#41#36#^rND^sEl Nahas^nM#the global challenge of chronic kidney disease^len#(Ne
phrology Forum) Kidney Int#2#20050000#2005#68#2918-29#20110300#v33n1a02.htm##
00461000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100018000750120051000930300
01500144710000200159065000900161064000500170031000400175014000600179865000900185
002001300194#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#159#38#tex
t#41#37#^rND^sBarsoum^nRS#Chronic Kidney disease in the developing world^len#New
 Engl J Med#2#20060000#2006#354#997-9#20110300#v33n1a02.htm##
00866000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100022000910100
01800113010001900131010001600150010001900166011005600185012019900241030001600440
06500090045606400050046503100030047001400070047386500090048000200130048903500100
0502801001600512#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a02.htm#S#c#160#39
#text#41#38#^rND^sLevey^nAS#^rND^sSchoolwerth^nAC#^rND^sBurrows^nNR#^rND^sWillia
ms^nDE#^rND^sStith^nKR#^rND^sMcClellan^nW#Centers for Disease Control and Preven
tion Expert Panel#Comprehensive public health strategies for preventing the deve
lopment, progression, and complications of CKD: report of an expert panel conven
ed by the Centers for Disease Control and Prevention^len#Am J Kidney Dis#2009000
0#2009#53#522-35#20110300#v33n1a02.htm#0272-6386#Am J Kidney Dis##
00536000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100021000910100
01700112012004400129030000700173065000900180064000500189031000400194014000900198
865000900207002001300216035001000229801000700239#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a02.htm#S#c#161#40#text#41#39#^rND^sJames^nMT#^rND^sHemmelgarn^nBR
#^rND^sTonelli^nM#Early recognition and prevention of CKD^len#Lancet#20100000#20
10#379#1296-309#20110300#v33n1a02.htm#0099-5355#Lancet##
00636000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100016000750100016000910100
01800107010001700125012008800142030002400230065000900254064000500263031000300268
014000700271865000900278002001300287035001000300801002400310#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a02.htm#S#c#162#41#text#41#40#^rND^sPerico^nN#^rND^sBr
avo^nRF#^rND^sDe Leon^nFR#^rND^sRemuzzi^nG#Screening for chronic kidney disease 
in emerging countries: feasibility and hurdles^len#Nephrol Dial Transplant#20090
000#2009#24#1355-8#20110300#v33n1a02.htm#0931-0509#Nephrol Dial Transplant##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#o#1#1#article#1#
20110411#092901#v33n1a03.htm#105##
03989000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030001700106
03100030012303200020012606500090012801400090013703500100014601201500015601201370
03060100041004430100041004840100036005250100040005610100043006010100032006440700
05800676083114500734085001001879085002101889085004201910085004001952085002601992
08311300201808500100314808500220315808500460318008500350322608500270326111700080
3288072000203296112000903298111001103307114000903318113001103327002001303338#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#h#2#1#article#1#oa#pt#br1.1#
1#4.0#TAB#03#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f27^l30#0101-2800#Compara
ção da capacidade cognitiva de pacientes em programa de hemodiálise crônica entr
e os que realizam atividade física assistida e os inativos^lpt#Comparison of cog
nitive function between patients on chronic hemodialysis who carry out assisted 
physical activity and inactive ones^len#^rND^1A01^nCarmen Tzanno Branco^sMartins
#^rND^1A01^nGeison Stein Meirelles^sRamos#^rND^1A01^nSimone Adriana^sGuaraldo#^r
ND^1A01^nClarissa Baia Bargas^sUezima#^rND^1A01^nJoão Paulo Lian Branco^sMartins
#^rND^1A01^nElzo^sRibeiro Junior#Home Dialysis Center^iA01^1Centro Integrado de 
Nefrologia#^lpt^aA inatividade física é um dos determinantes de agravos clínicos
 e problemas psíquicos em pacientes renais. Em duas clínicas-satélite, foi ofere
cido um programa de atividade física (AF) para 86 pacientes em hemodiálise. Dest
es, 49 pacientes iniciaram AF de forma espontânea e 37 permaneceram inativos. Ap
ós 6 meses, foi aplicado um questionário de satisfação autorreferido e o teste M
iniexame do Estado Mental Modificado (3MS) para avaliação de capacidade cognitiv
a. A cognição dos pacientes inativos foi comparada com a daqueles que participar
am do programa de AF por, no mínimo, três meses. Os pacientes, independentemente
 da idade e do tempo de tratamento dialítico, apresentaram déficit cognitivo aci
ma do esperado. No grupo geral, os pacientes ativos obtiveram melhor desempenho 
cognitivo em comparação aos inativos (p < 0,05). Quando separados por grupos etá
rios, os pacientes ativos acima de 60 anos apresentaram melhores resultados do q
ue os inativos (p < 0,05). Concluímos que pacientes com respostas cognitivas mel
hores são mais ativos fisicamente e/ou a atividade física contribui para a melho
r capacidade cognitiva nesse grupo.#^ddecs^i1#^tm^lpt^kcognição^i1#^tm^lpt^keduc
ação física e treinamento^i1#^tm^lpt^kinsuficiência renal crônica^i1#^tm^lpt^kdi
álise renal^i1#^len^aPhysical inactivity is a determinant of clinical disorders 
and psychological problems in patients with chronic kidney disease patients. In 
two satellite clinics, a program of physical activity (PA) was offered to 86 pat
ients undergoing hemodialysis. Of those, 49 patients entered the PA program spon
taneously and 37 remained inactive. After six months, a satisfaction self-report
ed questionnaire and the Modified Mini-Mental State (3MS) Examination for assess
ment of cognitive function were applied. Cognition was compared between inactive
 patients and those participating in the PA program for at least three months. R
egardless of age and duration of dialysis, patients showed a cognitive deficit g
reater than expected. In the general group, better cognitive function was observ
ed in active patients as compared to the inactive ones (p < 0.05). When separate
d by age groups, active patients over the age of 60 years had better results tha
n the inactive ones (p < 0.05). We concluded that patients with better cognitive
 responses are more physically active and/or physical activity contributes to be
tter cognitive function.#^ddecs^i2#^tm^len^kcognition^i2#^tm^len^kphysical educa
tional and training^i2#^tm^len^kchronic kidney failure^i2#^tm^len^krenal dialysi
s^i2#vancouv#9#20100127#27/01/2010#20100928#28/09/2010#v33n1a03.htm##
04015000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030001700106
03100030012303200020012606500090012801400090013703500100014601201570015601201440
03130100041004570100041004980100036005390100040005750100043006150100032006580700
05800690083115100748085001001899085002101909085004201930085004001972085002602012
08311360203808500100317408500220318408500460320608500350325208500270328711700080
3314072000203322112000903324111001103333114000903344113001103353002001303364#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#f#3#1#article#1#oa#pt#br1.1#
1#4.0#TAB#03#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f27^l30#0101-2800#<b>Comp
aração da capacidade cognitiva de pacientes em programa de hemodiálise crônica e
ntre os que realizam atividade física assistida e os inativos</b>^lpt#<b>Compari
son of cognitive function between patients on chronic hemodialysis who carry out
 assisted physical activity and inactive ones</b>^len#^rND^1A01^nCarmen Tzanno B
ranco^sMartins#^rND^1A01^nGeison Stein Meirelles^sRamos#^rND^1A01^nSimone Adrian
a^sGuaraldo#^rND^1A01^nClarissa Baia Bargas^sUezima#^rND^1A01^nJoão Paulo Lian B
ranco^sMartins#^rND^1A01^nElzo^sRibeiro Junior#Home Dialysis Center^iA01^1Centro
 Integrado de Nefrologia#^lpt^aA inatividade física é um dos determinantes de ag
ravos clínicos e problemas psíquicos em pacientes renais. Em duas clínicas-satél
ite, foi oferecido um programa de atividade física (AF) para 86 pacientes em hem
odiálise. Destes, 49 pacientes iniciaram AF de forma espontânea e 37 permanecera
m inativos. Após 6 meses, foi aplicado um questionário de satisfação autorreferi
do e o teste Miniexame do Estado Mental Modificado (3MS) para avaliação de capac
idade cognitiva. A cognição dos pacientes inativos foi comparada com a daqueles 
que participaram do programa de AF por, no mínimo, três meses. Os pacientes, ind
ependentemente da idade e do tempo de tratamento dialítico, apresentaram déficit
 cognitivo acima do esperado. No grupo geral, os pacientes ativos obtiveram melh
or desempenho cognitivo em comparação aos inativos (p &lt; 0,05). Quando separad
os por grupos etários, os pacientes ativos acima de 60 anos apresentaram melhore
s resultados do que os inativos (p &lt; 0,05). Concluímos que pacientes com resp
ostas cognitivas melhores são mais ativos fisicamente e/ou a atividade física co
ntribui para a melhor capacidade cognitiva nesse grupo.#^ddecs^i1#^tm^lpt^kcogni
ção^i1#^tm^lpt^keducação física e treinamento^i1#^tm^lpt^kinsuficiência renal cr
ônica^i1#^tm^lpt^kdiálise renal^i1#^len^aPhysical inactivity is a determinant of
 clinical disorders and psychological problems in patients with chronic kidney d
isease patients. In two satellite clinics, a program of physical activity (PA) w
as offered to 86 patients undergoing hemodialysis. Of those, 49 patients entered
 the PA program spontaneously and 37 remained inactive. After six months, a sati
sfaction self-reported questionnaire and the Modified Mini-Mental State (3MS) Ex
amination for assessment of cognitive function were applied. Cognition was compa
red between inactive patients and those participating in the PA program for at l
east three months. Regardless of age and duration of dialysis, patients showed a
 cognitive deficit greater than expected. In the general group, better cognitive
 function was observed in active patients as compared to the inactive ones (p &l
t; 0.05). When separated by age groups, active patients over the age of 60 years
 had better results than the inactive ones (p &lt; 0.05). We concluded that pati
ents with better cognitive responses are more physically active and/or physical 
activity contributes to better cognitive function.#^ddecs^i2#^tm^len^kcognition^
i2#^tm^len^kphysical educational and training^i2#^tm^len^kchronic kidney failure
^i2#^tm^len^krenal dialysis^i2#vancouv#9#20100127#27/01/2010#20100928#28/09/2010
#v33n1a03.htm##
04121000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000400107121000300111049000700114158000300121
03000160012403100030014003200020014306500090014501400090015403500100016301201500
01730120137003230100041004600100041005010100036005420100040005780100043006180100
03200661070006000693083114500753085001001898085002101908085004201929085004001971
08500260201108311300203708500100316708500220317708500460319908500350324508500270
32801170008033070720002033151120009033171110011033261140009033371130011033460020
01303357008008903370#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#l#4#
1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#tab#03#JBN020#nd#J. Bras. Nefrol
#33#1#20110300#^f27^l30#0101-2800#Comparação da capacidade cognitiva de paciente
s em programa de hemodiálise crônica entre os que realizam atividade física assi
stida e os inativos^lpt#Comparison of cognitive function between patients on chr
onic hemodialysis who carry out assisted physical activity and inactive ones^len
#^rND^1A01^nCarmen Tzanno Branco^sMartins#^rND^1A01^nGeison Stein Meirelles^sRam
os#^rND^1A01^nSimone Adriana^sGuaraldo#^rND^1A01^nClarissa Baia Bargas^sUezima#^
rND^1A01^nJoão Paulo Lian Branco^sMartins#^rND^1A01^nElzo^sRibeiro Junior#^iA01^
1Home Dialysis Center^2Centro Integrado de Nefrologia#^lpt^aA inatividade física
 é um dos determinantes de agravos clínicos e problemas psíquicos em pacientes r
enais. Em duas clínicas-satélite, foi oferecido um programa de atividade física 
(AF) para 86 pacientes em hemodiálise. Destes, 49 pacientes iniciaram AF de form
a espontânea e 37 permaneceram inativos. Após 6 meses, foi aplicado um questioná
rio de satisfação autorreferido e o teste Miniexame do Estado Mental Modificado 
(3MS) para avaliação de capacidade cognitiva. A cognição dos pacientes inativos 
foi comparada com a daqueles que participaram do programa de AF por, no mínimo, 
três meses. Os pacientes, independentemente da idade e do tempo de tratamento di
alítico, apresentaram déficit cognitivo acima do esperado. No grupo geral, os pa
cientes ativos obtiveram melhor desempenho cognitivo em comparação aos inativos 
(p < 0,05). Quando separados por grupos etários, os pacientes ativos acima de 60
 anos apresentaram melhores resultados do que os inativos (p < 0,05). Concluímos
 que pacientes com respostas cognitivas melhores são mais ativos fisicamente e/o
u a atividade física contribui para a melhor capacidade cognitiva nesse grupo.#^
ddecs^i1#^tm^lpt^kcognição^i1#^tm^lpt^keducação física e treinamento^i1#^tm^lpt^
kinsuficiência renal crônica^i1#^tm^lpt^kdiálise renal^i1#^len^aPhysical inactiv
ity is a determinant of clinical disorders and psychological problems in patient
s with chronic kidney disease patients. In two satellite clinics, a program of p
hysical activity (PA) was offered to 86 patients undergoing hemodialysis. Of tho
se, 49 patients entered the PA program spontaneously and 37 remained inactive. A
fter six months, a satisfaction self-reported questionnaire and the Modified Min
i-Mental State (3MS) Examination for assessment of cognitive function were appli
ed. Cognition was compared between inactive patients and those participating in 
the PA program for at least three months. Regardless of age and duration of dial
ysis, patients showed a cognitive deficit greater than expected. In the general 
group, better cognitive function was observed in active patients as compared to 
the inactive ones (p < 0.05). When separated by age groups, active patients over
 the age of 60 years had better results than the inactive ones (p < 0.05). We co
ncluded that patients with better cognitive responses are more physically active
 and/or physical activity contributes to better cognitive function.#^ddecs^i2#^t
m^len^kcognition^i2#^tm^len^kphysical educational and training^i2#^tm^len^kchron
ic kidney failure^i2#^tm^len^krenal dialysis^i2#vancouv#9#20100127#27/01/2010#20
100928#28/09/2010#v33n1a03.htm#Internet^ihttp://www.scielo.br/scielo.php?script=
sci_arttext&pid=S0101-28002011000100003##
00367000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704013600072002001300208#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#5#1#article#92#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> ORI
GINAL ARTICLE</font></p>     ^cY#v33n1a03.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#6#2#article#92#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00519000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704028800072002001300360#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#7#3#article#92#<p><a name="enda"></a><
font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Compara&ccedil;&at
ilde;o da capacidade cognitiva de pacientes em programa de hemodi&aacute;lise cr
&ocirc;nica entre os que realizam atividade f&iacute;sica assistida e os inativo
s</b></font></p>     ^cY#v33n1a03.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#8#4#article#92#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#9#5#article#92#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00495000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704026300073002001300336#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#10#6#article#92#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>Carmen Tzanno Branco Martins; Geison
 Stein Meirelles Ramos; Simone Adriana  Guaraldo; Clarissa Baia Bargas Uezima; J
o&atilde;o Paulo Lian Branco Martins; Elzo Ribeiro Junior</b></font></p>     ^cY
#v33n1a03.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704014200073002001300215#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#11#7#article#92#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Centro Integrado de Nefrologia - CINE; 
Home Dialysis Center</font></p>     ^cY#v33n1a03.htm##
00356000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704012400073002001300197#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#12#8#article#92#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia</
a></font></p>     ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#13#9#article#92#<p>&nbsp;</p>     ^cY#
v33n1a03.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704004400074002001300118#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#14#10#article#92#<p>&nbsp;</p> <hr siz
e="1" noshade>     ^cY#v33n1a03.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009600074002001300170#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#15#11#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n1
a03.htm##
01650000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704141700074002001301491#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#16#12#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A inatividade f&iacute;sica &eacute; u
m dos determinantes de agravos cl&iacute;nicos e problemas ps&iacute;quicos em p
acientes renais. Em duas cl&iacute;nicas-sat&eacute;lite, foi oferecido um progr
ama de atividade f&iacute;sica (AF) para 86 pacientes em hemodi&aacute;lise. Des
tes, 49 pacientes iniciaram AF de forma espont&acirc;nea e 37 permaneceram inati
vos. Ap&oacute;s 6 meses, foi aplicado  um question&aacute;rio de satisfa&ccedil
;&atilde;o autorreferido e o teste Miniexame do Estado Mental Modificado (3MS) p
ara avalia&ccedil;&atilde;o de capacidade cognitiva. A cogni&ccedil;&atilde;o do
s pacientes inativos foi comparada com a daqueles que participaram do programa d
e AF por, no m&iacute;nimo, tr&ecirc;s meses. Os pacientes, independentemente da
 idade e do tempo de tratamento dial&iacute;tico, apresentaram d&eacute;ficit co
gnitivo acima do esperado. No grupo geral, os pacientes ativos obtiveram melhor 
desempenho cognitivo em compara&ccedil;&atilde;o aos inativos  (p &lt; 0,05). Qu
ando separados por grupos et&aacute;rios, os pacientes ativos acima de 60 anos a
presentaram melhores resultados do que os inativos (p &lt; 0,05). Conclu&iacute;
mos que pacientes com respostas cognitivas melhores s&atilde;o mais ativos fisic
amente e/ou a atividade f&iacute;sica contribui para a melhor capacidade cogniti
va nesse grupo. </font></p>     ^cY#v33n1a03.htm##
00500000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704026700074002001300341#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#17#13#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> cogni&ccedil;&a
tilde;o, educa&ccedil;&atilde;o f&iacute;sica e treinamento, insufici&ecirc;ncia
 renal cr&ocirc;nica, di&aacute;lise renal. </font></p> <hr size="1" noshade>   
  ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#18#14#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#19#15#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00347000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704011400074002001300188#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#20#16#article#92#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font>
</p>     ^cY#v33n1a03.htm##
01030000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704079700074002001300871#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#21#17#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A inatividade f&iacute;sica &eacute; u
m dos fatores de aumento das intercorr&ecirc;ncias m&eacute;dicas em paciente re
nais<sup>1</sup> bem como de problemas ps&iacute;quicos. <sup>2</sup> Com o intu
ito de conscientizar os pacientes da import&acirc;ncia e do benef&iacute;cio da 
pr&aacute;tica de atividade f&iacute;sica, foi implementado o trabalho conjunto,
 entre psic&oacute;logo e educador f&iacute;sico, nas cl&iacute;nicas-sat&eacute
;lite CINE - Centro Integrado de Nefrologia (Guarulhos - SP) e Home Dialysis Cen
ter (Penha, S&atilde;o Paulo - SP). Elaboramos um programa de atividade f&iacute
;sica (AF) para os pacientes em tratamento de hemodi&aacute;lise (HD), com plano
 de ades&atilde;o espont&acirc;nea. </font></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#22#18#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704011500074002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#23#19#article#92#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODO</b></font
></p>     ^cY#v33n1a03.htm##
00749000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704051600074002001300590#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#24#20#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O programa consiste em duas sess&otild
e;es semanais, sempre antes do in&iacute;cio das sess&otilde;es de HD, com dura&
ccedil;&atilde;o de 20 a 30 minutos de exerc&iacute;cios de fortalecimento, resi
st&ecirc;ncia muscular perif&eacute;rica e alongamento. O objetivo &eacute; melh
orar a for&ccedil;a e o alongamento para facilitar as atividades da vida di&aacu
te;ria. A ades&atilde;o &eacute; espont&acirc;nea por parte dos pacientes. </fon
t></p>     ^cY#v33n1a03.htm##
00650000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704041700074002001300491#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#25#21#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O programa de AF    foi oferecido a 86
 pacientes com no m&iacute;nimo 6 (seis) meses de programa    de HD. Destes, 49 
pacientes aderiram e 37 se mantiveram inativos. Para serem    considerados ativo
s, os pacientes tiveram de participar da AF supervisionada    por, no m&iacute;n
imo, 3 (tr&ecirc;s) meses com 100% de frequ&ecirc;ncia. </font></p>     ^cY#v33n
1a03.htm##
01445000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704121200074002001301286#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#26#22#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s 6 (seis) meses, aplicamos 
o teste do Miniexame do Estado Mental Modificado (3MS)<sup>3</sup> com o intuito
 de verificar se os fisicamente ativos apresentavam melhor capacidade cognitiva.
 Comparamos a cogni&ccedil;&atilde;o de inativos com a daqueles que participaram
 do programa de AF por, no m&iacute;nimo, 3 (tr&ecirc;s) meses. O teste foi apli
cado durante a sess&atilde;o de hemodi&aacute;lise (HD) at&eacute; uma hora depo
is de seu in&iacute;cio. Comparamos os resultados obtidos da fun&ccedil;&atilde;
o cognitiva (abaixo da m&eacute;dia ou acima da m&eacute;dia e na m&eacute;dia) 
entre os pacientes ativos e inativos no grupo geral (n = 86) e por faixa et&aacu
te;ria. Classificamos o grupo por faixa et&aacute;ria, sendo o Grupo I referente
 aos pacientes com menos de 35 anos (n = 11), Grupo II pacientes de 35 a 60 anos
  (n = 47) e Grupo III acima de 60 anos (n = 28) para avaliar se o benef&iacute;
cio seria maior no grupo idoso. Como havia 2 (duas) vari&aacute;veis categ&oacut
e;ricas (atividade f&iacute;sica e resultado do 3MS), realizamos tamb&eacute;m o
 teste de Qui-quadrado e o teste exato de Fischer. </font></p>     ^cY#v33n1a03.
htm##
00687000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704045400074002001300528#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#27#23#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Quando comparamos a pontua&ccedil;&ati
lde;o obtida no 3MS (dados num&eacute;ricos), verificamos que os indiv&iacute;du
os inativos apresentaram pontua&ccedil;&otilde;es mais baixas do que os ativos n
o grupo geral e no Grupo III (&gt; 60 anos). N&atilde;o observamos diferen&ccedi
l;as nos demais grupos. Foi utilizado o teste n&atilde;o param&eacute;trico de M
ann-Whitney. </font></p>     ^cY#v33n1a03.htm##
00712000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704047900074002001300553#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#28#24#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s 6 meses de interven&ccedil
;&atilde;o de AF, a fim de avaliarmos nosso programa, aplicamos um question&aacu
te;rio de satisfa&ccedil;&atilde;o autorreferido, com seis quest&otilde;es de m&
uacute;ltipla escolha e uma aberta, relacionadas a dores no corpo, mudan&ccedil;
as f&iacute;sicas e ps&iacute;quicas e objetivo da participa&ccedil;&atilde;o. A
s quest&otilde;es foram as seguintes: </font></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#29#25#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00311000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007800074002001300152#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#30#26#article#92#<p align="center"><im
g src="/img/revistas/jbn/v33n1/a03qd01.jpg"></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#31#27#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010000074002001300174#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#32#28#article#92#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#v
33n1a03.htm##
00458000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704022500074002001300299#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#33#29#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A distribui&ccedil;&atilde;o de sexo f
oi semelhante nos tr&ecirc;s grupos analisados (<a href="#tab1">Tabelas 1</a> e 
<a href="#tab2">2</a>). </font></p>     ^cY#v33n1a03.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003500074002001300109#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#34#30#article#92#<p><a name="tab1"></a
></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#35#31#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#36#32#article#92#<p align="center"><im
g src="/img/revistas/jbn/v33n1/a03tab01.jpg"></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#37#33#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003500074002001300109#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#38#34#article#92#<p><a name="tab2"></a
></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#39#35#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#40#36#article#92#<p align="center"><im
g src="/img/revistas/jbn/v33n1/a03tab02.jpg"></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#41#37#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00801000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704056800074002001300642#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#42#38#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Observamos d&eacute;ficit progressivo 
de capacidade cognitiva em fun&ccedil;&atilde;o da idade (<a href="#tab3">Tabela
 3</a>). Quando comparamos a capacidade cognitiva com a atividade f&iacute;sica 
como vari&aacute;veis categ&oacute;ricas, verificamos a tend&ecirc;ncia de pacie
ntes com resultados na m&eacute;dia ou acima da m&eacute;dia serem os mais ativo
s fisicamente. O resultado sugere que devemos aumentar o n&uacute;mero de pacien
tes analisados (<a href="#tab4">Tabela 4</a>). </font></p>     ^cY#v33n1a03.htm#
#
00268000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003500074002001300109#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#43#39#article#92#<p><a name="tab3"></a
></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#44#40#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#45#41#article#92#<p align="center"><im
g src="/img/revistas/jbn/v33n1/a03tab03.jpg"></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#46#42#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003500074002001300109#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#47#43#article#92#<p><a name="tab4"></a
></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#48#44#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#49#45#article#92#<p align="center"><im
g src="/img/revistas/jbn/v33n1/a03tab04.jpg"></p>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#50#46#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00862000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704062900074002001300703#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#51#47#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Comparamos as pontua&ccedil;&otilde;es
 obtidas pelos pacientes no grupo geral (n = 86) e conforme a faixa et&aacute;ri
a. Verificamos uma diferen&ccedil;a significativa no grupo acima de 60 anos. Os 
pacientes ativos fisicamente alcan&ccedil;aram maior pontua&ccedil;&atilde;o no 
3MS. Observa-se uma redu&ccedil;&atilde;o da pontua&ccedil;&atilde;o com o avan&
ccedil;ar da idade em ambos os grupos. Entretanto, nos inativos fisicamente, a p
erda foi maior (80 ± 13, 75 ± 19 e 62 ± 15) (<a href="/img/revistas/jbn/v33n1/a0
3tab05m.jpg">Tabela 5</a>). </font></p>     ^cY#v33n1a03.htm##
00660000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704042700074002001300501#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#52#48#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A pr&aacute;tica de AF nesta popula&cc
edil;&atilde;o resultou em respostas autorreferidas positivas. No grupo de pacie
ntes ativos fisicamente, obtivemos uma diminui&ccedil;&atilde;o de queixas de do
r (52% das respostas) e 25% de respostas positivas quanto ao aumento do bem-esta
r, expressas como melhora da disposi&ccedil;&atilde;o e do humor. </font></p>   
  ^cY#v33n1a03.htm##
00422000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704018900074002001300263#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#53#49#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Os resultados foram interpretados como
 satisfat&oacute;rios e o programa de AF foi mantido e incentivado. </font></p> 
    ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#54#50#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010600074002001300180#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#55#51#article#92#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>    
 ^cY#v33n1a03.htm##
01256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704102300074002001301097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#56#52#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Na m&eacute;dia geral da popula&ccedil
;&atilde;o brasileira com 60 anos ou mais, observa-se uma preval&ecirc;ncia de d
&eacute;ficit cognitivo entre 5,9 a 29,7%. <sup>4,5</sup> Em metan&aacute;lise d
a literatura especializada, em que foram avaliados 27 estudos, Jorm <i>et al. </
i><sup>6</sup> constataram que a preval&ecirc;ncia de dem&ecirc;ncia dobra a cad
a 5,1 anos, a partir dos 60 anos de idade. Na amostra estudada, verificamos que 
os pacientes com doen&ccedil;a renal cr&ocirc;nica em programa de hemodi&aacute;
lise, independentemente do sexo e do tempo de tratamento dial&iacute;tico, exibi
ram d&eacute;ficit cognitivo acima do esperado para a respectiva faixa et&aacute
;ria (26%, 47% e 71%). Estes achados s&atilde;o corroborados pelo estudo de Yaff
e K <i>et al</i>. <sup>7</sup> que demonstrou uma redu&ccedil;&atilde;o da respo
sta cognitiva em pacientes com doen&ccedil;a renal cr&ocirc;nica em fase pr&eacu
te;-dial&iacute;tica. </font></p>     ^cY#v33n1a03.htm##
00481000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704024800074002001300322#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#57#53#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A cogni&ccedil;&atilde;o &eacute; um f
ator importante para a determina&ccedil;&atilde;o da abordagem terap&ecirc;utica
 e para avaliar a ades&atilde;o ao tratamento. </font></p>     ^cY#v33n1a03.htm#
#
01134000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704090100074002001300975#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#58#54#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Recentemente, um estudo realizado pelo
 Grupo de Neurologia Cognitiva e do Comportamento da Cl&iacute;nica Neurol&oacut
e;gica do Hospital das Cl&iacute;nicas da Faculdade de Medicina da Universidade 
de S&atilde;o Paulo revelou que mais da metade da popula&ccedil;&atilde;o tem di
ficuldade em entender informa&ccedil;&otilde;es referentes &agrave; administra&c
cedil;&atilde;o de medicamentos, resultados de exames e agendamento de consultas
. Foram analisadas 312 pessoas, das quais 32,4% mostraram dificuldades de compre
ens&atilde;o de frases e textos simples. Entre idosos esta taxa atingiu 51,6%. E
mbora o estudo tenha focado o analfabetismo funcional, n&atilde;o podemos exclui
r os d&eacute;ficits cognitivos na popula&ccedil;&atilde;o idosa como fatores li
mitantes &agrave; ades&atilde;o ao tratamento. <sup>8</sup> </font></p>     ^cY#
v33n1a03.htm##
00741000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704050800074002001300582#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#59#55#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Considerando que 39% dos pacientes em 
programa de HD cr&ocirc;nica no Brasil<sup>9</sup> t&ecirc;m mais de 60 anos, e 
que na amostra estudada 71% dos pacientes apresentaram d&eacute;ficit cognitivo 
nessa faixa et&aacute;ria, acreditamos que se devam direcionar as a&ccedil;&otil
de;es da equipe multiprofissional para abordagens mais simples e diretas e, muit
as vezes, incluir o cuidador durante as orienta&ccedil;&otilde;es. </font></p>  
   ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#60#56#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010600074002001300180#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#61#57#article#92#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>    
 ^cY#v33n1a03.htm##
00504000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704027100074002001300345#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#62#58#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Podemos inferir que pacientes com melh
ores respostas cognitivas s&atilde;o mais ativos fisicamente e/ou a atividade f&
iacute;sica contribui para a melhor capacidade cognitiva neste grupo. </font></p
>     ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#63#59#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010700074002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#64#60#article#92#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>   
  ^cY#v33n1a03.htm##
00455000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704020800076002001300284#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#65#61#article#92#1#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Medeiros RH, Pinent C
EC. Aptid&atilde;o f&iacute;sica do individuo com doen&ccedil;a renal cr&ocirc;n
ica. J Bras Nefrol 2002; 24:81-7.    ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#66#62#article#92# </font></p>     ^cY#
v33n1a03.htm##
00455000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704020800076002001300284#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#67#63#article#92#2#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Velloso RLM. Efeitos 
da hemodi&aacute;lise no campo subjetivo dos pacientes renais cr&ocirc;nicos.Cog
ito &#91;Epub&#93; 2001; 3:73-82.    ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#68#64#article#92# </font></p>     ^cY#
v33n1a03.htm##
00563000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704031600076002001300392#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#69#65#article#92#3#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Moura SM. Contribui&c
cedil;&otilde;es de quatro instrumentos de triagem para o diagn&oacute;stico de 
d&eacute;ficits cognitivos no envelhecimento no Brasil: validade de crit&eacute;
rio e normas de desempenho, FAFICH-UFMG, Belo Horizonte 2008.    ^cY#v33n1a03.ht
m##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#70#66#article#92# </font></p>     ^cY#
v33n1a03.htm##
00525000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704027800076002001300354#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#71#67#article#92#4#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Almeida Filho N, Sant
ana VS, Pinho AR. Estudo epidemiol&oacute;gico dos transtornos mentais em uma po
pula&ccedil;&atilde;o de idosos: &aacute;rea urbana de Salvador - BA. J Bras Psi
quiatr 1984; 33:114-20.    ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#72#68#article#92# </font></p>     ^cY#
v33n1a03.htm##
00553000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704030600076002001300382#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#73#69#article#92#5#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Veras RP, Coutinho E.
 Preval&ecirc;ncia da s&iacute;ndrome cerebral org&acirc;nica em popula&ccedil;&
atilde;o de idosos de &aacute;rea metropolitana da regi&atilde;o sudeste do Bras
il. Rev Sa&uacute;de P&uacute;blica1994; 28: 26-37.    ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#74#70#article#92# </font></p>     ^cY#
v33n1a03.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704021900076002001300295#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#75#71#article#92#6#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Jorm AF, Korten AE, H
enderson AS. The prevalence of dementia: A quantitative integration of the liter
ature. Acta Psychiatr Scand 1987; 76:465-79.    ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#76#72#article#92# </font></p>     ^cY#
v33n1a03.htm##
00550000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704030300076002001300379#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#77#73#article#92#7#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Yaffe K, Ackerson L, 
Tamura MK <i>et al. </i> Chronic Kidney Disease and Cognitive Function in Older 
Adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study. J 
Am Geriatric Soc &#91;Epub&#93; 2010; 58:338-45.    ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#78#74#article#92# </font></p>     ^cY#
v33n1a03.htm##
00539000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704029200076002001300368#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#79#75#article#92#8#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Carthery-Goulart MT, 
Anghinah R, Areza-Fegyveres R <i>et al. </i>Performance of a Brazilian populatio
n on the test of functional health literacy in adults. Rev Sa&uacute;de P&uacute
;blica &#91;Epub&#93; 2009; 43:631-8.    ^cY#v33n1a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#80#76#article#92# </font></p>     ^cY#
v33n1a03.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704028900076002001300365#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#81#77#article#92#9#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Sociedade Brasileira 
de Nefrologia. Censo SBN 2009. Dispon&iacute;vel em: &#91;<a href="http://www.sb
n.org.br/pdf/censo_SBN_2009_final.pdf" target="_blank">http://www.sbn.org.br/pdf
/censo_SBN_2009_final.pdf</a>&#93;    ^cY#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#82#78#article#92#. </font></p>     ^cY
#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#83#79#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#84#80#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00434000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704020100074002001300275#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#85#81#article#92#<p><a name="endb"></a
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda"><im
g src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b>  Correspond&ecirc;nc
ia para:</b>    ^cY#v33n1a03.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704004100074002001300115#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#86#82#article#92#<br> Carmen Tzanno Br
anco Martins    ^cY#v33n1a03.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704006100074002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#87#83#article#92#<br> Rua Poeta Castro
 Alves, 173, Vila das Palmeiras     ^cY#v33n1a03.htm##
00285000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704005200074002001300126#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#88#84#article#92#<br> Guarulhos - SP -
 Brasil CEP: 07013-150     ^cY#v33n1a03.htm##
00263000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003000074002001300104#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#89#85#article#92#<br> Tel: 11 2358-206
7    ^cY#v33n1a03.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704011200074002001300186#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#90#86#article#92#<br> E-mail:  <a href
="mailto:psicologia@hdcdialise.com.br">psicologia@hdcdialise.com.br</a></font></
p>     ^cY#v33n1a03.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010700074002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#91#87#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 27/01/2010  
  ^cY#v33n1a03.htm##
00289000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704005600074002001300130#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#92#88#article#92#<br> Data de aprova&c
cedil;&atilde;o: 28/09/2010    ^cY#v33n1a03.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009300074002001300167#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#93#89#article#92#<br> Os autores decla
ram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33n1a03
.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#94#90#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#95#91#article#92#<p>&nbsp;</p>     ^cY
#v33n1a03.htm##
00413000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704018000074002001300254#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a03.htm#S#p#96#92#article#92#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado no Cen
tro Integrado de Nefrologia (CINE) e Home Dialysis Center. </font></p>     ^cY#v
33n1a03.htm##
00528000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100019000740100018000930120
05700111030001400168065000900182064000500191031000300196014000500199865000900204
002001300213035001000226801001400236#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a03.htm#S#c#97#1#article#9#1#^rND^sMedeiros^nRH#^rND^sPinent^nCEC#Aptidão físi
ca do individuo com doença renal crônica^lpt#J Bras Nefrol#20020000#2002#24#81-7
#20110300#v33n1a03.htm#0101-2800#J Bras Nefrol##
00481000000000253000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100019000740120076000930300
01200169710000200181065000900183064000500192031000200197014000600199865000900205
002001300214#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#c#98#2#artic
le#9#2#^rND^sVelloso^nRLM#Efeitos da hemodiálise no campo subjetivo dos paciente
s renais crônicos^lpt#Cogito Epub#2#20010000#2001#3#73-82#20110300#v33n1a03.htm#
#
00550000000000229000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720160016000740180167000900620
01200257066001500269065000900284064000500293865000900298002001300307#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#c#99#3#article#9#3#^rND^sMoura^nSM#C
ontribuições de quatro instrumentos de triagem para o diagnóstico de déficits co
gnitivos no envelhecimento no Brasil: validade de critério e normas de desempenh
o^lpt#FAFICH-UFMG#Belo Horizonte#20080000#2008#20110300#v33n1a03.htm##
00619000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080002000711180002000730100023000750100018000980100
01600116012010700132030001700239065000900256064000500265031000300270014000700273
865000900280002001300289035001000302801001700312#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a03.htm#S#c#100#4#article#9#4#^rND^sAlmeida Filho^nN#^rND^sSantana
^nVS#^rND^sPinho^nAR#Estudo epidemiológico dos transtornos mentais em uma popula
ção de idosos: área urbana de Salvador - BA^lpt#J Bras Psiquiatr#19840000#1984#3
3#114-20#20110300#v33n1a03.htm#0047-2085#J Bras Psiquiatr##
00559000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080002000711180002000730100016000750100018000910120
11900109030001800228710000200246065000900248064000500257031000300262014000600265
865000900271002001300280#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a03.htm#S#
c#101#5#article#9#5#^rND^sVeras^nRP#^rND^sCoutinho^nE#Prevalência da síndrome ce
rebral orgânica em população de idosos de área metropolitana da região sudeste d
o Brasil^lpt#Rev Saúde Pública#2#19940000#1994#28#26-37#20110300#v33n1a03.htm##
00592000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080002000711180002000730100015000750100017000900100
02000107012007700127030002100204065000900225064000500234031000300239014000700242
865000900249002001300258035001000271801002100281#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a03.htm#S#c#102#6#article#9#6#^rND^sJorm^nAF#^rND^sKorten^nAE#^rND
^sHenderson^nAS#The prevalence of dementia: A quantitative integration of the li
terature^len#Acta Psychiatr Scand#19870000#1987#76#465-79#20110300#v33n1a03.htm#
0001-690X#Acta Psychiatr Scand##
00612000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080002000711180002000730100015000750100018000900110
01600108012013600124030002600260710000200286065000900288064000500297031000300302
014000700305865000900312002001300321#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a03.htm#S#c#103#7#article#9#7#^rND^sYaffe^nK#^rND^sAckerson^nL#Tamura MK et al
#Chronic Kidney Disease and Cognitive Function in Older Adults: Findings from th
e Chronic Renal Insufficiency Cohort Cognitive Study^len#J Am Geriatric Soc [Epu
b]#2#20100000#2010#58#338-45#20110300#v33n1a03.htm##
00607000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080002000711180002000730100027000750100018001020100
02500120810000600145012009400151030002500245710000200270065000900272064000500281
031000300286014000600289865000900295002001300304#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a03.htm#S#c#104#8#article#9#8#^rND^sCarthery-Goulart^nMT#^rND^sAng
hinah^nR#^rND^sAreza-Fegyveres^nR#et al#Performance of a Brazilian population on
 the test of functional health literacy in adults^len#Rev Saúde Pública [Epub]#2
#20090000#2009#43#631-8#20110300#v33n1a03.htm##
00396000000000193000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080002000711180002000730170035000750180019001100370
05100129865000900180002001300189#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a0
3.htm#S#c#105#9#article#9#9#Sociedade Brasileira de Nefrologia#Censo SBN 2009^lp
t#http://www.sbn.org.br/pdf/censo_SBN_2009_final.pdf#20110300#v33n1a03.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#o#1#1#article#1#
20110411#092905#v33n1a04.htm#134##
05343000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101200940
01610120084002550100032003390100034003710100030004050100037004350100034004720100
02900506010003300535070010300568070005100671070009200722083169800814085001002512
08500470252208500230256908500300259208317470262208500100436908500450437908500230
44240850028044471170008044750720003044831120009044861110011044951140009045061130
01104515058006204526058005604588002001304644#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a04.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#04#JBN020#nd#J. B
ras. Nefrol.#33#1#20110300#^f31^l37#0101-2800#Perfil e produção científica dos p
esquisadores do CNPq nas áreas de Nefrologia e Urologia^lpt#Profile and scientif
ic production of CNPq researchers in Nephrology and Urology^len#^rND^1A01^nEduar
do A.^sOliveira#^rND^1A02^nRoberto^sPécoits-Filho#^rND^1A01^nIsabel G.^sQuirino#
^rND^1A01^nMaria Christina^sOliveira#^rND^1A03^nDaniela Reis^sMartelli#^rND^1A03
^nLeonardo S.^sLima#^rND^1A03^nHercílio^sMartelli Jr#Universidade Federal de Min
as Gerais^iA01^1Departamento de Pediatria^2Unidade de Nefrologia Pediátrica#Pont
ífica Universidade Católica^iA02^sPR^cCuritiba#Universidade Estadual de Montes C
laros^iA03^1Programa de Pós-Graduação em Ciências da Saúde#^lpt^aOBJETIVO: O obj
etivo deste estudo foi avaliar o perfil e a produção científica de pesquisadores
 de Nefrologia e Urologia, cadastrados como bolsistas de produtividade no Consel
ho Nacional de Desenvolvimento Científico e Tecnológico. MÉTODOS: Os currículos 
Lattes de 39 pesquisadores com bolsas ativas no triênio 2006 a 2008 foram incluí
dos na análise. As variáveis de interesse foram: sexo, instituição, tempo de dou
toramento, artigos publicados, e orientação de alunos de graduação, mestres e do
utores. RESULTADOS: Houve uma predominância do gênero masculino (74,4%) e de bol
sistas na categoria 2 (56,4%). Três estados da federação são responsáveis por 90
% dos pesquisadores: SP (28; 71,8%), RS (4; 10,3%) e MG (3; 7,7%). Quatro instit
uições são responsáveis por 70% dos pesquisadores: UNIFESP (14; 36%), USP (8; 20
,5%), UFMG (3, 7,7%) e UNICAMP (3; 7,7%). No total da carreira acadêmica, os pes
quisadores em Nefrourologia publicaram 3.195 artigos em periódicos, sendo a medi
ana de 75 artigos por pesquisador (IQ = 52 - 100). Os pesquisadores receberam um
 total de 25.923 citações na base de dados Web of Science®, sendo a mediana por 
pesquisador de 452 citações (IQ = 161 - 927). A média de citações por artigo foi
 de 13,8 citações (DP = 11,6). CONCLUSÕES: Há uma concentração dos pesquisadores
 na região Sudeste. Neste estudo, pode ser observado um aumento da produção cien
tífica entre a maioria dos pesquisadores nos últimos cinco anos. Através do conh
ecimento do perfil dos pesquisadores das áreas de Nefrologia e Urologia podem se
r definidas, de maneira mais eficaz, estratégias para incentivar a produção cien
tífica e a demanda de recursos para o financiamento de projetos de pesquisa.#^dd
ecs^i1#^tm^lpt^kindicadores de produção científica^i1#^tm^lpt^kNefrologia^i1#^tm
^lpt^kCiências da Saúde^i1#^len^aOBJECTIVE: This study aimed at evaluating the p
rofile and scientific production of researchers in Nephrology and Urology, recei
ving grants in the area of Clinical Medicine from the Brazilian National Researc
h Council. METHODS: The standardized online curriculum vitae (Curriculum Lattes)
 of 39 researchers in Medicine receiving grants in the 2006-2008 triennium were 
included in the analysis. The variables analyzed were: gender, affiliation, time
 from completion of the PhD program, scientific production, and supervision of u
ndergraduate students, and master's and PhD programs. RESULTS: Males (74.4%) and
 category 2 grants (56.4%) predominated. The following three Brazilian states ar
e responsible for 90% of the researchers: São Paulo (28; 71.8%); Rio Grande do S
ul (4; 10.3%); and Minas Gerais (3; 7.7%). Four institutions are responsible for
 70% of the researchers: UNIFESP (14; 36%); USP (8; 20.5%); UFMG (3, 7.7%); and 
UNICAMP (3; 7.7%). Considering the academic career, the assessed researchers pub
lished 3,195 articles in medical journals, with a median of 75 articles per rese
archer (QI = 52-100). The researchers received a total of 25,923 citations at th
e database Web of Science®, with a median of 452 citations per researcher (QI = 
161-927). The average number of citations per article was 13.8 citations (SD = 1
1.6). CONCLUSIONS: The Southeastern region of Brazil concentrates researchers in
 Nephrology and Urology. Our study has shown an increase in the scientific produ
ction of most researchers in the last five years. By knowing the profile of rese
archers in Nephrology and Urology, more effective strategies to encourage the sc
ientific production and the demand for resources to finance research projects ca
n be defined.#^ddecs^i2#^tm^len^kscientific production indicators^i2#^tm^len^kNe
phrology^i2#^tm^len^kHealth Sciences^i2#vancouv#13#20100907#07/09/2010#20100930#
30/09/2010#Conselho Nacional de Desenvolvimento Científico e Tecnológico#Fundaçã
o de Amparo à Pesquisa do Estado de Minas Gerais#v33n1a04.htm##
05456000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201010
01610120091002620100032003530100034003850100030004190100037004490100034004860100
02900520010003300549070010300582070005100685070009200736083174400828085001002572
08500470258208500230262908500300265208318000268208500100448208500450449208500230
45370850028045601170008045880720003045961120009045991110011046081140009046191130
01104628058006204639058005604701002001304757#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a04.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#04#JBN020#nd#J. B
ras. Nefrol.#33#1#20110300#^f31^l37#0101-2800#<b>Perfil e produção científica do
s pesquisadores do CNPq nas áreas de Nefrologia e Urologia</b>^lpt#<b>Profile an
d scientific production of CNPq researchers in Nephrology and Urology</b>^len#^r
ND^1A01^nEduardo A.^sOliveira#^rND^1A02^nRoberto^sPécoits-Filho#^rND^1A01^nIsabe
l G.^sQuirino#^rND^1A01^nMaria Christina^sOliveira#^rND^1A03^nDaniela Reis^sMart
elli#^rND^1A03^nLeonardo S.^sLima#^rND^1A03^nHercílio^sMartelli Jr#Universidade 
Federal de Minas Gerais^iA01^1Departamento de Pediatria^2Unidade de Nefrologia P
ediátrica#Pontífica Universidade Católica^iA02^sPR^cCuritiba#Universidade Estadu
al de Montes Claros^iA03^1Programa de Pós-Graduação em Ciências da Saúde#^lpt^a<
b>OBJETIVO: </b>O objetivo deste estudo foi avaliar o perfil e a produção cientí
fica de pesquisadores de Nefrologia e Urologia, cadastrados como bolsistas de pr
odutividade no Conselho Nacional de Desenvolvimento Científico e Tecnológico. <b
>MÉTODOS:</b> Os currículos Lattes de 39 pesquisadores com bolsas ativas no triê
nio 2006 a 2008 foram incluídos na análise. As variáveis de interesse foram: sex
o, instituição, tempo de doutoramento, artigos publicados, e orientação de aluno
s de graduação, mestres e doutores. <b>RESULTADOS:</b> Houve uma predominância d
o gênero masculino (74,4%) e de bolsistas na categoria 2 (56,4%). Três estados d
a federação são responsáveis por 90% dos pesquisadores: SP (28; 71,8%), RS (4; 1
0,3%) e MG (3; 7,7%). Quatro instituições são responsáveis por 70% dos pesquisad
ores: UNIFESP (14; 36%), USP (8; 20,5%), UFMG (3, 7,7%) e UNICAMP (3; 7,7%). No 
total da carreira acadêmica, os pesquisadores em Nefrourologia publicaram 3.195 
artigos em periódicos, sendo a mediana de 75 artigos por pesquisador (IQ = 52 - 
100). Os pesquisadores receberam um total de 25.923 citações na base de dados <i
>Web of Science<sup>®</sup></i>, sendo a mediana por pesquisador de 452 citações
 (IQ = 161 - 927). A média de citações por artigo foi de 13,8 citações (DP = 11,
6). <b>CONCLUSÕES:</b> Há uma concentração dos pesquisadores na região Sudeste. 
Neste estudo, pode ser observado um aumento da produção científica entre a maior
ia dos pesquisadores nos últimos cinco anos. Através do conhecimento do perfil d
os pesquisadores das áreas de Nefrologia e Urologia podem ser definidas, de mane
ira mais eficaz, estratégias para incentivar a produção científica e a demanda d
e recursos para o financiamento de projetos de pesquisa.#^ddecs^i1#^tm^lpt^kindi
cadores de produção científica^i1#^tm^lpt^kNefrologia^i1#^tm^lpt^kCiências da Sa
úde^i1#^len^a<b>OBJECTIVE:</b> This study aimed at evaluating the profile and sc
ientific production of researchers in Nephrology and Urology, receiving grants i
n the area of Clinical Medicine from the Brazilian National Research Council. <b
>METHODS:</b> The standardized online curriculum vitae (<i>Curriculum Lattes</i>
) of 39 researchers in Medicine receiving grants in the 2006-2008 triennium were
 included in the analysis. The variables analyzed were: gender, affiliation, tim
e from completion of the PhD program, scientific production, and supervision of 
undergraduate students, and master's and PhD programs. <b>RESULTS:</b> Males (74
.4%) and category 2 grants (56.4%) predominated. The following three Brazilian s
tates are responsible for 90% of the researchers: São Paulo (28; 71.8%); Rio Gra
nde do Sul (4; 10.3%); and Minas Gerais (3; 7.7%). Four institutions are respons
ible for 70% of the researchers: UNIFESP (14; 36%); USP (8; 20.5%); UFMG (3, 7.7
%); and UNICAMP (3; 7.7%). Considering the academic career, the assessed researc
hers published 3,195 articles in medical journals, with a median of 75 articles 
per researcher (QI = 52-100). The researchers received a total of 25,923 citatio
ns at the database <i>Web of Science<sup>®</sup></i>, with a median of 452 citat
ions per researcher (QI = 161-927). The average number of citations per article 
was 13.8 citations (SD = 11.6). <b>CONCLUSIONS:</b> The Southeastern region of B
razil concentrates researchers in Nephrology and Urology. Our study has shown an
 increase in the scientific production of most researchers in the last five year
s. By knowing the profile of researchers in Nephrology and Urology, more effecti
ve strategies to encourage the scientific production and the demand for resource
s to finance research projects can be defined.#^ddecs^i2#^tm^len^kscientific pro
duction indicators^i2#^tm^len^kNephrology^i2#^tm^len^kHealth Sciences^i2#vancouv
#13#20100907#07/09/2010#20100930#30/09/2010#Conselho Nacional de Desenvolvimento
 Científico e Tecnológico#Fundação de Amparo à Pesquisa do Estado de Minas Gerai
s#v33n1a04.htm##
05656000000000709000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400090015903500100
01680120094001780120084002720100031003560100034003870100029004210100037004500100
03400487010002800521010003700549070010500586070005300691070009400744083179700838
08500100263508500470264508500230269208500300271508318240274508500100456908500450
45790850023046240850028046471170008046750720003046831120009046861110011046951140
00904706113001104715058006204726058005604788002001304844008008904857#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa
#pt#br1.1#1#4.0#ilus#tab#04#JBN020#nd#J. Bras. Nefrol#33#1#20110300#^f31^l37#010
1-2800#Perfil e produção científica dos pesquisadores do CNPq nas áreas de Nefro
logia e Urologia^lpt#Profile and scientific production of CNPq researchers in Ne
phrology and Urology^len#^rND^1A01^nEduardo A^sOliveira#^rND^1A02^nRoberto^sPéco
its-Filho#^rND^1A01^nIsabel G^sQuirino#^rND^1A01^nMaria Christina^sOliveira#^rND
^1A03^nDaniela Reis^sMartelli#^rND^1A03^nLeonardo S^sLima#^rND^1A03^nHercílio^sM
artelli Júnior#^iA01^1Universidade Federal de Minas Gerais^2Departamento de Pedi
atria^3Unidade de Nefrologia Pediátrica#^iA02^1Pontífica Universidade Católica^s
PR^cCuritiba#^iA03^1Universidade Estadual de Montes Claros^2Programa de Pós-Grad
uação em Ciências da Saúde#^lpt^aOBJETIVO: O objetivo deste estudo foi avaliar o
 perfil e a produção científica de pesquisadores de Nefrologia e Urologia, cadas
trados como bolsistas de produtividade no Conselho Nacional de Desenvolvimento C
ientífico e Tecnológico. MÉTODOS: Os currículos Lattes de 39 pesquisadores com b
olsas ativas no triênio 2006 a 2008 foram incluídos na análise. As variáveis de 
interesse foram: sexo, instituição, tempo de doutoramento, artigos publicados, e
 orientação de alunos de graduação, mestres e doutores. RESULTADOS: Houve uma pr
edominância do gênero masculino (74,4 por cento) e de bolsistas na categoria 2 (
56,4 por cento). Três estados da federação são responsáveis por 90 por cento dos
 pesquisadores: SP (28; 71,8 por cento), RS (4; 10,3 por cento) e MG (3; 7,7 por
 cento). Quatro instituições são responsáveis por 70 por cento dos pesquisadores
: UNIFESP (14; 36 por cento), USP (8; 20,5 por cento), UFMG (3, 7,7 por cento) e
 UNICAMP (3; 7,7 por cento). No total da carreira acadêmica, os pesquisadores em
 Nefrourologia publicaram 3.195 artigos em periódicos, sendo a mediana de 75 art
igos por pesquisador (IQ = 52 - 100). Os pesquisadores receberam um total de 25.
923 citações na base de dados Web of Science®, sendo a mediana por pesquisador d
e 452 citações (IQ = 161 - 927). A média de citações por artigo foi de 13,8 cita
ções (DP = 11,6). CONCLUSÕES: Há uma concentração dos pesquisadores na região Su
deste. Neste estudo, pode ser observado um aumento da produção científica entre 
a maioria dos pesquisadores nos últimos cinco anos. Através do conhecimento do p
erfil dos pesquisadores das áreas de Nefrologia e Urologia podem ser definidas, 
de maneira mais eficaz, estratégias para incentivar a produção científica e a de
manda de recursos para o financiamento de projetos de pesquisa.#^ddecs^i1#^tm^lp
t^kindicadores de produção científica^i1#^tm^lpt^kNefrologia^i1#^tm^lpt^kCiência
s da Saúde^i1#^len^aOBJECTIVE: This study aimed at evaluating the profile and sc
ientific production of researchers in Nephrology and Urology, receiving grants i
n the area of Clinical Medicine from the Brazilian National Research Council. ME
THODS: The standardized online curriculum vitae (Curriculum Lattes) of 39 resear
chers in Medicine receiving grants in the 2006-2008 triennium were included in t
he analysis. The variables analyzed were: gender, affiliation, time from complet
ion of the PhD program, scientific production, and supervision of undergraduate 
students, and master's and PhD programs. RESULTS: Males (74.4 percent) and categ
ory 2 grants (56.4 percent) predominated. The following three Brazilian states a
re responsible for 90 percent of the researchers: São Paulo (28; 71.8 percent); 
Rio Grande do Sul (4; 10.3 percent); and Minas Gerais (3; 7.7 percent). Four ins
titutions are responsible for 70 percent of the researchers: UNIFESP (14; 36 per
cent); USP (8; 20.5 percent); UFMG (3, 7.7 percent); and UNICAMP (3; 7.7 percent
). Considering the academic career, the assessed researchers published 3,195 art
icles in medical journals, with a median of 75 articles per researcher (QI = 52-
100). The researchers received a total of 25,923 citations at the database Web o
f Science®, with a median of 452 citations per researcher (QI = 161-927). The av
erage number of citations per article was 13.8 citations (SD = 11.6). CONCLUSION
S: The Southeastern region of Brazil concentrates researchers in Nephrology and 
Urology. Our study has shown an increase in the scientific production of most re
searchers in the last five years. By knowing the profile of researchers in Nephr
ology and Urology, more effective strategies to encourage the scientific product
ion and the demand for resources to finance research projects can be defined.#^d
decs^i2#^tm^len^kscientific production indicators^i2#^tm^len^kNephrology^i2#^tm^
len^kHealth Sciences^i2#vancouv#13#20100907#07/09/2010#20100930#30/09/2010#Conse
lho Nacional de Desenvolvimento Científico e Tecnológico#Fundação de Amparo à Pe
squisa do Estado de Minas Gerais#v33n1a04.htm#Internet^ihttp://www.scielo.br/sci
elo.php?script=sci_arttext&pid=S0101-28002011000100004##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#5#1#article#117#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a04.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#6#2#article#117#<p>&nbsp;</p>     ^cY#
v33n1a04.htm##
00458000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704022600073002001300299#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#7#3#article#117#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Perfil e produ&cc
edil;&atilde;o cient&iacute;fica dos pesquisadores do CNPq nas &aacute;reas de N
efrologia e Urologia</b></font></p>     ^cY#v33n1a04.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#8#4#article#117#<p>&nbsp;</p>     ^cY#
v33n1a04.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#9#5#article#117#<p>&nbsp;</p>     ^cY#
v33n1a04.htm##
00578000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704034500074002001300419#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#10#6#article#117#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Eduardo A. Oliveira<sup>I</sup>; Ro
berto P&eacute;coits-Filho<sup>II</sup>; Isabel G. Quirino<sup>I</sup>; Maria Ch
ristina Oliveira<sup>I</sup>; Daniela Reis Martelli<sup>III</sup>; Leonardo S. L
ima<sup>III</sup>; Herc&iacute;lio Martelli Jr<sup>III</sup></b></font></p>     
^cY#v33n1a04.htm##
00428000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704019500074002001300269#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#11#7#article#117#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Unidade de Nefrologia Pedi
&aacute;trica - Departamento de Pediatria, Universidade Federal de Minas Gerais 
- UFMG    ^cY#v33n1a04.htm##
00325000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704009200074002001300166#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#12#8#article#117#<br>   <sup>II</sup>P
ont&iacute;fica Universidade Cat&oacute;lica - PUC PR, Curitiba    ^cY#v33n1a04.
htm##
00408000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704017500074002001300249#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#13#9#article#117#<br>   <sup>III</sup>
Programa de P&oacute;s-Gradua&ccedil;&atilde;o em Ci&ecirc;ncias da Sa&uacute;de
 da Universidade Estadual de Montes Claros - UNIMONTES</font></p>     ^cY#v33n1a
04.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#14#10#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia
</a></font></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#15#11#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#16#12#article#117#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a04.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#17#13#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a04.htm##
00580000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034600075002001300421#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#18#14#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJETIVO: </b> O objetivo deste es
tudo foi avaliar o perfil e a produ&ccedil;&atilde;o cient&iacute;fica de pesqui
sadores de Nefrologia e Urologia, cadastrados como bolsistas de produtividade no
 Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico.   
  ^cY#v33n1a04.htm##
00610000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037600075002001300451#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#19#15#article#117#<br>   <b>M&Eacute;T
ODOS:</b> Os curr&iacute;culos Lattes de 39 pesquisadores com bolsas ativas no t
ri&ecirc;nio 2006 a 2008 foram inclu&iacute;dos na an&aacute;lise. As vari&aacut
e;veis de interesse foram: sexo, institui&ccedil;&atilde;o, tempo de doutorament
o, artigos publicados, e orienta&ccedil;&atilde;o de alunos de gradua&ccedil;&at
ilde;o, mestres e doutores.     ^cY#v33n1a04.htm##
01178000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094400075002001301019#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#20#16#article#117#<br>   <b>RESULTADOS
:</b> Houve uma predomin&acirc;ncia do g&ecirc;nero masculino (74,4%) e de bolsi
stas na categoria 2 (56,4%). Tr&ecirc;s estados da federa&ccedil;&atilde;o s&ati
lde;o respons&aacute;veis por 90% dos pesquisadores: SP (28; 71,8%), RS (4; 10,3
%) e MG (3; 7,7%). Quatro institui&ccedil;&otilde;es s&atilde;o respons&aacute;v
eis por 70% dos pesquisadores: UNIFESP (14; 36%), USP (8; 20,5%), UFMG (3, 7,7%)
 e UNICAMP (3; 7,7%). No total da carreira acad&ecirc;mica, os pesquisadores em 
Nefrourologia publicaram 3.195 artigos em peri&oacute;dicos, sendo a mediana de 
75 artigos por pesquisador (IQ = 52 - 100). Os pesquisadores receberam um total 
de 25.923 cita&ccedil;&otilde;es na base de dados <i>Web of Science</i><sup><i>&
reg;</i></sup>, sendo a mediana por pesquisador de 452 cita&ccedil;&otilde;es (I
Q = 161 - 927). A m&eacute;dia de cita&ccedil;&otilde;es por artigo foi de 13,8 
cita&ccedil;&otilde;es (DP = 11,6).     ^cY#v33n1a04.htm##
00820000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058600075002001300661#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#21#17#article#117#<br>   <b>CONCLUS&Ot
ilde;ES:</b> H&aacute; uma concentra&ccedil;&atilde;o dos pesquisadores na regi&
atilde;o Sudeste. Neste estudo, pode ser observado um aumento da produ&ccedil;&a
tilde;o cient&iacute;fica entre a  maioria dos pesquisadores nos &uacute;ltimos 
cinco anos. Atrav&eacute;s do conhecimento do perfil dos pesquisadores das &aacu
te;reas de Nefrologia e Urologia podem ser definidas, de maneira mais eficaz, es
trat&eacute;gias para incentivar a produ&ccedil;&atilde;o cient&iacute;fica e a 
demanda de recursos para o financiamento de projetos de pesquisa. </font></p>   
  ^cY#v33n1a04.htm##
00463000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022900075002001300304#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#22#18#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b>indicadores de
 produ&ccedil;&atilde;o cient&iacute;fica, Nefrologia, Ci&ecirc;ncias da Sa&uacu
te;de. </font></p> <hr size="1" noshade>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#23#19#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#24#20#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#25#21#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a04.htm##
01698000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704146400075002001301539#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#26#22#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As atividades de produ&ccedil;&atilde
;o de indicadores quantitativos em ci&ecirc;ncia, tecnologia e inova&ccedil;&ati
lde;o v&ecirc;m se fortalecendo no pa&iacute;s na &uacute;ltima d&eacute;cada, c
om o reconhecimento da necessidade, por parte do governo federal e governos esta
duais, e da comunidade cient&iacute;fica nacional, de dispor de instrumentos par
a defini&ccedil;&atilde;o de diretrizes, aloca&ccedil;&atilde;o de investimentos
 e recursos, formula&ccedil;&atilde;o de programas e avalia&ccedil;&atilde;o de 
atividades relacionadas ao desenvolvimento cient&iacute;fico e tecnol&oacute;gic
o no pa&iacute;s. <sup>1</sup> Em recente artigo de opini&atilde;o no peri&oacut
e;dico <i>Nature</i>, a diretora do National Science Foundation, Julia Lane, fez
 um contundente apelo para o desenvolvimento de sistemas m&eacute;tricos que ava
liem permanentemente pesquisadores e universidades. <sup>2</sup> De interesse pa
ra o contexto brasileiro, essa autora faz men&ccedil;&atilde;o elogiosa &agrave;
 plataforma Lattes (<a href="http://lattes.cnpq.br/" target="_blank">http://latt
es.cnpq.br/</a>), pontuando que a experi&ecirc;ncia brasileira com esse instrume
nto &eacute; um poderoso exemplo de boa pr&aacute;tica, provendo dados de alta q
ualidade sobre aproximadamente 1,6 milh&otilde;es de pesquisadores e 4.000 insti
tui&ccedil;&otilde;es no pa&iacute;s e no exterior. <sup>2</sup></font></p>     
^cY#v33n1a04.htm##
01245000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704101100075002001301086#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#27#23#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nos &uacute;ltimos anos, diversos est
udos t&ecirc;m analisado o perfil e a produ&ccedil;&atilde;o cient&iacute;fica d
os pesquisadores do Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tec
nol&oacute;gico (CNPq), em diversas &aacute;reas do conhecimento. <sup>3-7</sup>
 Recentemente, avaliamos o perfil dos bolsistas de produtividade cient&iacute;fi
ca da &aacute;rea de Medicina, comparando as diversas &aacute;reas de atua&ccedi
l;&atilde;o. <sup>5, 8 </sup>Entretanto, no escopo das &aacute;reas de Nefrologi
a e Urologia, os dados s&atilde;o escassos, desatualizados e limitados &agrave; 
America Latina como um todo. <sup>9</sup> O presente estudo transversal tem como
 objetivo descrever as caracter&iacute;sticas demogr&aacute;ficas e a produ&cced
il;&atilde;o acad&ecirc;mica dos pesquisadores bolsistas em Medicina do CNPq, cu
ja principal &aacute;rea de atua&ccedil;&atilde;o seja centrada em Nefrologia ou
 Urologia. </font></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#28#24#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#29#25#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>     
^cY#v33n1a04.htm##
00361000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012700075002001300202#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#30#26#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Desenho do estudo. Estudo transver
sal</b></font></p>     ^cY#v33n1a04.htm##
00912000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067800075002001300753#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#31#27#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Participantes. Foi inicialmente inclu
&iacute;do no banco de dados um total de 411 pesquisadores registrados como bols
istas de produtividade cient&iacute;fica do CNPq, de acordo com a lista fornecid
a pela ag&ecirc;ncia federal de fomento &agrave; pesquisa em fevereiro de 2009. 
Foram exclu&iacute;dos do presente estudo pesquisadores que se encontravam com b
olsas suspensas, como nos casos de realiza&ccedil;&atilde;o de p&oacute;s-doutor
ado no exterior. Foram tamb&eacute;m exclu&iacute;dos tr&ecirc;s pesquisadores s
eniores e um pesquisador falecido quando do in&iacute;cio da coleta de dados. </
font></p>     ^cY#v33n1a04.htm##
01176000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094200075002001301017#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#32#28#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">&Aacute;rea de atua&ccedil;&atilde;o.
 Para essa vari&aacute;vel foi considerada a &aacute;rea especificamente atribu&
iacute;da pelo pesquisador no curr&iacute;culo Lattes. Quando essa informa&ccedi
l;&atilde;o era omissa, foi analisada pelos autores do estudo a produ&ccedil;&at
ilde;o cient&iacute;fica nos &uacute;ltimos cinco anos e atribu&iacute;da uma &a
acute;rea na qual havia predomin&acirc;ncia dos temas publicados e/ou orientados
. Em casos espec&iacute;ficos de atua&ccedil;&atilde;o em sub&aacute;reas bem de
finidas, como por exemplo, Nefrologia Pedi&aacute;trica, o pesquisador foi inser
ido na &aacute;rea de Nefrologia e a sub&aacute;rea de atua&ccedil;&atilde;o foi
 considerada em uma vari&aacute;vel &agrave; parte. Seguindo essa metodologia, i
dentificamos 39 pesquisadores com atua&ccedil;&atilde;o nas &aacute;reas de Nefr
ologia e de Urologia. </font></p>     ^cY#v33n1a04.htm##
01905000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704167100075002001301746#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#33#29#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Protocolo de coleta dos dados. Para e
ssa investiga&ccedil;&atilde;o cient&iacute;fica foi utilizada a rela&ccedil;&at
ilde;o dos bolsistas de produtividade em pesquisa do CNPq (PQ), na &aacute;rea d
e medicina, com bolsas ativas no tri&ecirc;nio de 2006 a 2008. Como crit&eacute;
rio de inclus&atilde;o, o pesquisador deveria ter sido contemplado com a bolsa d
e produtividade cient&iacute;fica do CNPq e a mesma se encontrar em vig&ecirc;nc
ia. A partir da identifica&ccedil;&atilde;o dos bolsistas, foram consultados os 
curr&iacute;culos Lattes de todos os pesquisadores para cada uma das categorias 
existentes no CNPq: 1 A, 1 B, 1 C, 1 D e categoria 2. A partir dos curr&iacute;c
ulos Lattes disponibilizados publicamente na plataforma Lattes (CNPq) foi constr
u&iacute;do um banco de dados, com informa&ccedil;&otilde;es relativas &agrave; 
distribui&ccedil;&atilde;o dos PQ por categoria (2, 1 A, 1 B, 1 C, 1 D e s&ecirc
;nior), distribui&ccedil;&atilde;o geogr&aacute;fica e institucional, tempo de c
onclus&atilde;o do curso de doutorado, produ&ccedil;&atilde;o cient&iacute;fica 
(artigos cient&iacute;ficos) e forma&ccedil;&atilde;o de recursos humanos (orien
ta&ccedil;&atilde;o de inicia&ccedil;&atilde;o cient&iacute;fica, mestrado e dou
torado). Para an&aacute;lise da produ&ccedil;&atilde;o cient&iacute;fica, consid
eraram-se todas as publica&ccedil;&otilde;es e orienta&ccedil;&otilde;es durante
 a carreira do pesquisador. Foram tamb&eacute;m analisadas as publica&ccedil;&ot
ilde;es e orienta&ccedil;&otilde;es dos &uacute;ltimos cincos anos, considerando
 o quinqu&ecirc;nio 2004-2008. </font></p>     ^cY#v33n1a04.htm##
02052000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704181800075002001301893#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#34#30#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Vari&aacute;veis de interesse. As seg
uintes vari&aacute;veis foram analisadas: g&ecirc;nero, institui&ccedil;&atilde;
o do pesquisador, tempo de doutoramento, institui&ccedil;&atilde;o de doutoramen
to, categoria da bolsa, orienta&ccedil;&otilde;es de bolsistas de inicia&ccedil;
&atilde;o cient&iacute;fica (BIC), disserta&ccedil;&atilde;o de mestrado e teses
 de doutorado, e publica&ccedil;&otilde;es em peri&oacute;dicos. Em rela&ccedil;
&atilde;o &agrave;s orienta&ccedil;&otilde;es e publica&ccedil;&otilde;es foram 
avaliados os valores absolutos de toda a carreira cient&iacute;fica e os valores
 referentes ao ultimo quinqu&ecirc;nio descritas no curr&iacute;culo Lattes. Al&
eacute;m disso, foram computadas as orienta&ccedil;&otilde;es e publica&ccedil;&
otilde;es ajustadas pelo tempo de doutoramento do pesquisador. Foram tamb&eacute
;m pesquisadas as bases de dados Web of Science Thomson - ISI<sup>&reg;</sup> - 
Institute for Scientific Information - (<a href="http://apps.isiknowledge.com/" 
target="_blank">http://apps.isiknowledge.com/</a>) e Scopus<sup>&reg;</sup> (<a 
href="http://www.scopus.com/home.url" target="_blank">http://www.scopus.com/home
.url</a>). Ambas foram consultadas atrav&eacute;s do s&iacute;tio eletr&ocirc;ni
co da CAPES (<a href="http://novo.periodicos.capes.gov.br/" target="_blank">http
://novo.periodicos.capes.gov.br/</a>). Nestas bases de dados foram pesquisados o
s artigos cient&iacute;ficos publicados pelos pesquisadores listados na base do 
CNPq. O nome cient&iacute;fico do pesquisador utilizado nessa investiga&ccedil;&
atilde;o foi aquele fornecido no curr&iacute;culo Lattes. Al&eacute;m disso, hou
ve uma pesquisa intensa das poss&iacute;veis varia&ccedil;&otilde;es dos nomes d
os pesquisadores. </font></p>     ^cY#v33n1a04.htm##
00910000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067600075002001300751#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#35#31#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">An&aacute;lise estat&iacute;stica. Ap
&oacute;s a constru&ccedil;&atilde;o do banco de dados por meio do programa esta
t&iacute;stico SPSS vers&atilde;o 18.0 para Windows, realizou-se a an&aacute;lis
e estat&iacute;stica descritiva e univariada dos dados obtidos. Dados cont&iacut
e;nuos foram reportados utilizando-se a mediana e os intervalos interquartis ent
re os percentis 25 e 75. O teste n&atilde;o param&eacute;trico de Mann-Whitney f
oi usado para compara&ccedil;&atilde;o dessas vari&aacute;veis. Vari&aacute;veis
 dicot&ocirc;micas ou nominais foram comparadas pelo teste do Qui-quadrado. </fo
nt></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#36#32#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#37#33#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADO</b></font></p>     ^cY#v
33n1a04.htm##
02866000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704263200075002001302707#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#38#34#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De um total de 411 pesquisadores em M
edicina, 39 (9.5%) foram identificados como da &aacute;rea da Nefrourologia. Des
tes, apenas 3 (0,73%) foram identificados como pesquisadores na &aacute;rea de U
rologia. Dentre as 30 &aacute;reas de atua&ccedil;&atilde;o identificadas, a Nef
rourologia foi respons&aacute;vel pelo maior percentual, seguida pelas &aacute;r
eas de Neuroci&ecirc;ncias e Endocrinologia (<a href="#fig1">Figura 1</a>). A di
stribui&ccedil;&atilde;o dos 39 pesquisadores por g&ecirc;nero e a categoria da 
bolsa est&atilde;o sumarizadas na <a href="#tab1">Tabela 1</a>. Houve uma predom
in&acirc;ncia do g&ecirc;nero masculino (74,4%) e de bolsistas na categoria 2 (5
6,4%). N&atilde;o houve diferen&ccedil;a significativa na distribui&ccedil;&atil
de;o de categorias entre os g&ecirc;neros (p = 0,52). Tr&ecirc;s estados da fede
ra&ccedil;&atilde;o s&atilde;o respons&aacute;veis por aproximadamente 90% dos p
esquisadores: S&atilde;o Paulo (28; 71,8%), Rio Grande do Sul (4; 10,3%), e Mina
s Gerais (3; 7,7%). Outros estados foram contemplados cada um com um bolsista: P
aran&aacute;, Distrito Federal, Bahia e Cear&aacute;. Em rela&ccedil;&atilde;o &
agrave; institui&ccedil;&atilde;o de origem, os pesquisadores da Nefrourologia s
e distribuem por 13 diferentes institui&ccedil;&otilde;es no pa&iacute;s. Contud
o, quatro institui&ccedil;&otilde;es s&atilde;o respons&aacute;veis por aproxima
damente 70% dos pesquisadores: UNIFESP (14; 36%), USP (8; 20,5%), UFMG (3; 7,7%)
 e UNICAMP (3; 7,7%). As outras institui&ccedil;&otilde;es contempladas s&atilde
;o: UFRGS, UNESP, FAMERP, PUC-PR, PUC-RS, UCS, UFBA e UFC. A mediana de tempo de
 doutoramento dos 39 pesquisadores foi de 15 anos (intervalo interquartil = 10 -
 20 anos). Em rela&ccedil;&atilde;o &agrave; institui&ccedil;&atilde;o de doutor
amento, 34 pesquisadores obtiveram o t&iacute;tulo no Brasil e cinco em institui
&ccedil;&otilde;es no exterior (dois no Reino Unido, e os demais nos Estados Uni
dos, Holanda e Alemanha). Em rela&ccedil;&atilde;o &agrave;s institui&ccedil;&ot
ilde;es brasileiras, predominaram a UNIFESP com 17 e a USP com 11 pesquisadores.
 As outras institui&ccedil;&otilde;es nas quais foram obtidos os t&iacute;tulos 
de doutorado foram: UFMG (3), UNICAMP (1), UNESP (1) e UFRS (1). A maioria dos p
esquisadores (77%) tem p&oacute;s-doutorado, sendo que 26 em institui&ccedil;&ot
ilde;es no exterior e quatro no Brasil. No exterior, predominaram as institui&cc
edil;&otilde;es nos Estados Unidos (21), seguido pela Fran&ccedil;a (2), Su&eacu
te;cia, Alemanha e Reino Unido. </font></p>     ^cY#v33n1a04.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#39#35#article#117#<p><a name="fig1"></
a></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#40#36#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#41#37#article#117#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a04fig01.jpg"></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#42#38#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#43#39#article#117#<p><a name="tab1"></
a></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#44#40#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#45#41#article#117#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a04tab01.jpg"></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#46#42#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#47#43#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ORIENTA&Ccedil;&Otilde;ES</b></fon
t></p>     ^cY#v33n1a04.htm##
00826000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059200075002001300667#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#48#44#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No total da carreira acad&ecirc;mica,
 os pesquisadores da Nefrourologia orientaram 394 bolsistas de inicia&ccedil;&at
ilde;o cient&iacute;fica (BIC), sendo a mediana de 7 (IQ = 2 - 14) por pesquisad
or, 353 disserta&ccedil;&otilde;es de mestrado (mediana de 7, IQ = 4 - 11) e 212
 teses de doutorado (mediana de 3, IQ = 2 - 8). Em rela&ccedil;&atilde;o aos val
ores ajustados pelo tempo de doutoramento, os pesquisadores orientaram em m&eacu
te;dia 0,72 BIC, 0,56 alunos de mestrado e 0,32 doutorandos anualmente. </font><
/p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#49#45#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00368000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013400075002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#50#46#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PUBLICA&Ccedil;&Otilde;ES/ PERI&Oa
cute;DICOS</b></font></p>     ^cY#v33n1a04.htm##
01812000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704157800075002001301653#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#51#47#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No total da carreira acad&ecirc;mica,
 os pesquisadores em Nefrourologia publicaram 3.195 artigos em peri&oacute;dicos
, sendo a mediana de 75 artigos por pesquisador (IQ = 52 - 100). No total foram 
1.763 artigos indexados na base de dados Web of Science<sup>&reg;</sup>, aproxim
adamente 55% do total de artigos publicados (mediana por pesquisador de 43, IQ, 
26 - 59). Na base de dados Scopus foram 2.219 artigos indexados (mediana de 54, 
IQ 31 - 71), equivalente a 69% da produ&ccedil;&atilde;o acad&ecirc;mica. Consid
erando-se o n&uacute;mero de artigos ajustado pelo tempo de carreira, a m&eacute
;dia de publica&ccedil;&otilde;es foi de quatro artigos/ano (DP = 1,98). A m&eac
ute;dia ajustada de artigos publicados na base de dados Web of Science<sup>&reg;
</sup> foi de 2,4/ano (DP = 1,7) e na base de dados Scopus<sup>&reg;</sup> foi d
e 2,90/ano (DP = 1,8). A maioria dos pesquisadores (38; 97.5%) aumentou a produ&
ccedil;&atilde;o cient&iacute;fica nos &uacute;ltimos cinco anos, considerando a
 m&eacute;dia de artigos publicados por ano. Esse incremento variou de 2,8% a 20
6%, com m&eacute;dia de 78% (DP = 55) de aumento na produ&ccedil;&atilde;o cient
&iacute;fica. A <a href="/img/revistas/jbn/v33n1/a04fig02m.jpg">Figura 2</a> ilu
stra a m&eacute;dia de produ&ccedil;&atilde;o anual de artigos cient&iacute;fico
s, comparando a carreira cient&iacute;fica do pesquisador em rela&ccedil;&atilde
;o &agrave; produ&ccedil;&atilde;o cient&iacute;fica nos &uacute;ltimos cinco an
os (2004 / 2008). </font></p>     ^cY#v33n1a04.htm##
00905000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067100075002001300746#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#52#48#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na carreira acad&ecirc;mica, os pesqu
isadores em Nefrourologia publicaram em 602 diferentes peri&oacute;dicos. Deste 
total, identificou-se o Fator de Impacto (FI) de 350 peri&oacute;dicos na base d
e dados JCR. A mediana do FI foi de 2,45 (IQ = 1,67 - 3,77) variando nos extremo
s de 0,168 a 50,01. No tocante ainda aos peri&oacute;dicos cient&iacute;ficos, a
s <a href="#tab2">Tabelas 2</a> e <a href="#tab3">3</a> apresentam, respectivame
nte, os dez peri&oacute;dicos cient&iacute;ficos indexados e n&atilde;o indexado
s mais utilizados pelos bolsistas para suas publica&ccedil;&otilde;es. </font></
p>     ^cY#v33n1a04.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#53#49#article#117#<p><a name="tab2"></
a></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#54#50#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#55#51#article#117#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a04tab02.jpg"></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#56#52#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#57#53#article#117#<p><a name="tab3"></
a></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#58#54#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#59#55#article#117#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a04tab03.jpg"></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#60#56#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009700075002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#61#57#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>IMPACTO</b></font></p>     ^cY#v33
n1a04.htm##
01091000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704085700075002001300932#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#62#58#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na carreira acad&ecirc;mica, os pesqu
isadores em Nefrourologia receberam um total de 25.923 cita&ccedil;&otilde;es na
 base de dados Web of Science<sup>&reg;</sup>, sendo a mediana por pesquisador d
e 452 cita&ccedil;&otilde;es (IQ = 161 - 927, variando de 68 a 3.632 cita&ccedil
;&otilde;es). A m&eacute;dia por artigo foi de 13,8 cita&ccedil;&otilde;es (DP =
 11,6). Na base de dados Scopus<sup>&reg;</sup> foram identificadas 26.626 cita&
ccedil;&otilde;es aos pesquisadores da Nefrourologia, com uma mediana de 496 cit
a&ccedil;&otilde;es por pesquisador (IQ = 172 - 1.017, variando de um m&iacute;n
imo de 58 a um m&aacute;ximo de 2.974 cita&ccedil;&otilde;es). A m&eacute;dia de
 cita&ccedil;&otilde;es por artigo na base de dados Scopus<sup>&reg;</sup> foi 1
2,8 (DP = 10,7). </font></p>     ^cY#v33n1a04.htm##
01457000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704122300075002001301298#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#63#59#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A mediana do &iacute;ndice H na base 
de dados Web of Science<sup>&reg;</sup> de 10 (IQ = 7 - 16), variando de um m&ia
cute;nimo de quatro a um m&aacute;ximo de 23. O valor correspondente para o &iac
ute;ndice H na base Scopus, foi uma mediana de 11 (IQ = 7 - 17), variando de um 
m&iacute;nimo de tr&ecirc;s a um m&aacute;ximo de 25. Houve diferen&ccedil;a sig
nificativa na compara&ccedil;&atilde;o da mediana dos &iacute;ndices H de ambas 
as bases de dados: Web of Science<sup>&reg;</sup> (p &lt; 0,013) e Scopus<sup>&r
eg;</sup> (p &lt; 0,005). A <a href="#fig3">Figura 3</a> ilustra a distribui&cce
dil;&atilde;o dos &iacute;ndices H em ambas as bases de dados, de acordo com a c
ategoria da bolsa do pesquisador. Contudo, essa diferen&ccedil;a n&atilde;o foi 
significativa para o &iacute;ndice M, ou seja, o &iacute;ndice H corrigido pelo 
tempo de carreira acad&ecirc;mica do pesquisador: Web of Science<sup>&reg;</sup>
 (p &lt; 0,29) e Scopus<sup>&reg;</sup> (p &lt; 0,22). A <a href="#fig4">Figura 
4</a> ilustra a distribui&ccedil;&atilde;o dos &iacute;ndices M em ambas as base
s de dados, de acordo com a categoria da bolsa do pesquisador. </font></p>     ^
cY#v33n1a04.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#64#60#article#117#<p><a name="fig3"></
a></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#65#61#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#66#62#article#117#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a04fig03.jpg"></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#67#63#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#68#64#article#117#<p><a name="fig4"></
a></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#69#65#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#70#66#article#117#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a04fig04.jpg"></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#71#67#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#72#68#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v33n1a04.htm##
01034000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080000075002001300875#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#73#69#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O presente estudo transversal tendo c
omo foco os pesquisadores do CNPq nas &aacute;reas de Nefrologia e Urologia most
rou que h&aacute; uma grande concentra&ccedil;&atilde;o da pesquisa nessas &aacu
te;reas do conhecimento. Apenas tr&ecirc;s estados da federa&ccedil;&atilde;o, s
endo dois da regi&atilde;o Sudeste, respondem pela grande maioria (90%) dos pesq
uisadores. Os achados desse estudo mostram tamb&eacute;m que duas institui&ccedi
l;&otilde;es paulistas (UNIFESP e USP) s&atilde;o fortes centros formadores e pr
odutores de conhecimento cient&iacute;fico em Nefrologia em nosso pa&iacute;s. N
ada menos que 28 (72%) pesquisadores nessa &aacute;rea obtiveram o doutoramento 
nessas duas institui&ccedil;&otilde;es. </font></p>     ^cY#v33n1a04.htm##
00800000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056600075002001300641#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#74#70#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Esta concentra&ccedil;&atilde;o da pe
squisa m&eacute;dica observada aqui &eacute; tamb&eacute;m reconhecida por outro
s autores que avaliaram outras &aacute;reas do conhecimento. <sup>6</sup> Em nos
so estudo pr&eacute;vio, incluindo todos os 441 pesquisadores da Medicina, foi p
oss&iacute;vel observar uma concentra&ccedil;&atilde;o tamb&eacute;m pronunciada
; sendo 79% dos pesquisadores situados na regi&atilde;o Sudeste e 60% provenient
es do estado de S&atilde;o Paulo. <sup>8</sup></font></p>     ^cY#v33n1a04.htm##
01358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704112400075002001301199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#75#71#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outra caracter&iacute;stica important
e da atividade cient&iacute;fica se refere &agrave; forma&ccedil;&atilde;o de re
cursos humanos qualificados, destacando-se a orienta&ccedil;&atilde;o em n&iacut
e;vel de gradua&ccedil;&atilde;o (BIC) e em n&iacute;vel de p&oacute;s-gradua&cc
edil;&atilde;o (mestrado e doutorado). A presente an&aacute;lise verificou uma i
mportante participa&ccedil;&atilde;o dos pesquisadores na forma&ccedil;&atilde;o
 de novos pesquisadores. As medianas de orienta&ccedil;&otilde;es ajustadas pelo
 tempo de doutoramento de pesquisador foram de 0,56 para mestres e 0,32 para dou
tores por ano. Esses valores s&atilde;o bastante similares aos 411 pesquisadores
 de Medicina de maneira geral, levando-se em conta todas as especialidades (0,50
 e 0,30 para mestres e doutores, respectivamente). <sup>8</sup> Tamb&eacute;m s&
atilde;o compar&aacute;veis aos pesquisadores mais produtivos na &aacute;rea de 
sa&uacute;de p&uacute;blica, compilados por Barata e Goldbaum, em uma an&aacute;
lise dos pesquisadores do CNPq. <sup>3</sup></font></p>     ^cY#v33n1a04.htm##
01485000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704125100075002001301326#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#76#72#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise da produ&ccedil;&ati
lde;o cient&iacute;fica dos pesquisadores em Nefrourologia mostrou uma vigorosa 
produ&ccedil;&atilde;o com um expressivo n&uacute;mero de publica&ccedil;&atilde
;o de artigos cient&iacute;ficos em peri&oacute;dicos de m&eacute;dio a alto fat
or de impacto. Durante a carreira acad&ecirc;mica, a mediana por pesquisador foi
 de 75 artigos enquanto a mediana dos 411 pesquisadores da Medicina foi de 87 ar
tigos por pesquisador. <sup>8</sup> No entanto, considerando-se o n&uacute;mero 
de artigos ajustado pelo tempo de carreira, nossa an&aacute;lise mostrou que a m
&eacute;dia de publica&ccedil;&otilde;es foi de quatro artigos/ano, sendo 2,4/an
o na base de dados Web of Science<sup>&reg;</sup> e 2,90/ano na base de dados Sc
opus<sup>&reg;</sup>. Os respectivos valores para os 411 pesquisadores da medici
na foram: 4,13 artigos/ano, sendo 2,23/ano na base de dados Web of Science<sup>&
reg;</sup> e 2,90/ano na base de dados Scopus<sup>&reg;</sup>. <sup>8</sup> Esse
s dados sugerem que os pesquisadores nas &aacute;reas de Nefrologia e Urologia s
&atilde;o mais jovens quando comparados com os pesquisadores da Medicina de mane
ira geral. </font></p>     ^cY#v33n1a04.htm##
01588000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704135400075002001301429#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#77#73#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outro dado importante ressaltado em n
ossa an&aacute;lise &eacute; o expressivo aumento na produ&ccedil;&atilde;o cien
t&iacute;fica, fato este tamb&eacute;m observado em outras &aacute;reas como Odo
ntologia, Sa&uacute;de P&uacute;blica e Fisioterapia. <sup>3, 4, 6, 7</sup> Esse
 incremento quantitativo na produ&ccedil;&atilde;o cient&iacute;fica na medicina
 se correlaciona com o aumento geral da produ&ccedil;&atilde;o cient&iacute;fica
 brasileira e possivelmente reflete os v&aacute;rios mecanismos indutores estabe
lecidos pelas diversas ag&ecirc;ncias de fomento brasileiras. Entre esses pode s
er inclu&iacute;do o aperfei&ccedil;oamento do sistema de avalia&ccedil;&atilde;
o da p&oacute;s-gradua&ccedil;&atilde;o, que, por interm&eacute;dio da Coordena&
ccedil;&atilde;o de Aperfei&ccedil;oamento de Pessoal de N&iacute;vel Superior (
CAPES), prioriza o n&uacute;mero e a qualidade dos artigos publicados para conce
ituar os programas nacionais. <sup>10</sup> Outro mecanismo indutor que pode ser
 considerado &eacute; a pr&oacute;pria bolsa de produtividade em pesquisa que pr
omove uma competi&ccedil;&atilde;o entre os pares, incentivando tanto a forma&cc
edil;&atilde;o de novos pesquisadores como a publica&ccedil;&atilde;o de artigos
 em peri&oacute;dicos de impacto. </font></p>     ^cY#v33n1a04.htm##
01575000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704134100075002001301416#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#78#74#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outro aspecto importante a ser consid
erado &eacute; n&atilde;o somente um incremento quantitativo na produ&ccedil;&at
ilde;o cient&iacute;fica, mas uma melhora qualitativa com maior inser&ccedil;&at
ilde;o internacional dessa produ&ccedil;&atilde;o. No entanto, neste aspecto as 
&aacute;reas de Nefrologia e Urologia est&atilde;o aqu&eacute;m de outras &aacut
e;reas como Neuroci&ecirc;ncias e Psiquiatria, as quais apresentam um expressivo
 esfor&ccedil;o nesta busca de qualidade, com aproximadamente 70% dos artigos pu
blicados indexados na seletiva base de dados da Web of Science<sup>&reg;</sup>. 
Nesse aspecto, salienta-se outro ponto relevante, 9% dos artigos dos principais 
pesquisadores na &aacute;rea de Nefrologia foram publicados no <i>Jornal Brasile
iro de Nefrologia</i>, &oacute;rg&atilde;o oficial da Sociedade Brasileira de Ne
frologia. Dessa maneira, deve ser ressaltado o esfor&ccedil;o recente para index
ar esse peri&oacute;dico em base de dados qualificada, como a Scielo. <sup>11</s
up> Al&eacute;m disso, deve-se incentivar que ele possa ser indexado em outras b
ases de dados como o PubMed, JCR e Scopus<sup>&reg;</sup>, assim como em outros 
importantes peri&oacute;dicos de outras especialidades como Cardiologia, Pediatr
ia e Endocrinologia. </font></p>     ^cY#v33n1a04.htm##
01775000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704154100075002001301616#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#79#75#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outro ponto importante &eacute; a val
oriza&ccedil;&atilde;o dos peri&oacute;dicos brasileiros, fator essencial para o
 crescimento e desenvolvimento cient&iacute;fico nacional, como ressalta recente
 editorial assinado pelos mais eminentes editores dos principais peri&oacute;dic
os nacionais. <sup>12</sup> Incidentalmente, embora nosso estudo n&atilde;o tenh
a sido desenhado para responder a essa quest&atilde;o, nossos achados em rela&cc
edil;&atilde;o ao FI dos peri&oacute;dicos nos quais publicam os mais produtivos
 pesquisadores na &aacute;rea de Nefrologia refor&ccedil;am a contundente cr&iac
ute;tica sobre o novo QUALIS da CAPES. <sup>13</sup> Em nosso estudo, a mediana 
do FI foi de 2,45 e o percentil 75 foi de 3,77. Segundo os documentos da CAPES r
eferente &agrave; Medicina I, na qual se enquadra a Nefrologia, o ponto de corte
 para peri&oacute;dico A1 seria de 3,8 e para peri&oacute;dico A2 seria 2,5. Des
sa maneira, n&atilde;o nos parece razo&aacute;vel uma classifica&ccedil;&atilde;
o que subestima mais da metade da produ&ccedil;&atilde;o dos principais pesquisa
dores na &aacute;rea de Nefrologia, apenas por enquadr&aacute;-la junto a outras
 especialidades com FI muito diferentes. Na base de dados Web of Science<sup>&re
g;</sup>, referente a JCR 2009, recentemente liberado (junho de 2010) mostra que
 dos 63 peri&oacute;dicos nas &aacute;reas de Nefrologia e Urologia, apenas 9 (1
4%) possuem FI maior que 3,8 e apenas 22 (35%) acima de 2,5. </font></p>     ^cY
#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#80#76#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#81#77#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>   
  ^cY#v33n1a04.htm##
00832000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059800075002001300673#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#82#78#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na presente investiga&ccedil;&atilde;
o cient&iacute;fica, observou-se que h&aacute; uma grande concentra&ccedil;&atil
de;o dos pesquisadores da &aacute;rea de Nefrologia em poucas institui&ccedil;&o
tilde;es brasileiras. Atrav&eacute;s do conhecimento do perfil dos pesquisadores
 da &aacute;rea de Nefrologia m&eacute;dica, podem ser definidas, de maneira mai
s eficaz, estrat&eacute;gias para incentivar a produ&ccedil;&atilde;o cient&iacu
te;fica e a demanda de recursos para o financiamento de projetos de pesquisa. </
font></p>     ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#83#79#article#117#<p>&nbsp;</p>     ^c
Y#v33n1a04.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#84#80#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a04.htm##
00515000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026700077002001300344#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#85#81#article#117#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Mugnaini R, Jannuzzi
 PM, Quoniam L. Indicadores bibliom&eacute;tricos da produ&ccedil;&atilde;o cien
t&iacute;fica brasileira: uma an&aacute;lise a partir da base Pascal. Ci Inf 200
4; 33:123-31.    ^cY#v33n1a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#86#82#article#117# </font></p>     ^cY
#v33n1a04.htm##
00396000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704014800077002001300225#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#87#83#article#117#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Lane J. Lets make sc
ience metrics more scientific. Nature 2010; 464:488-9.    ^cY#v33n1a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#88#84#article#117# </font></p>     ^cY
#v33n1a04.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026600077002001300343#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#89#85#article#117#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Barata RB, Goldbaum 
M. A profile of researchers in public health with productivity grants from the B
razilian National Research Council (CNPq). Cad Sa&uacute;de P&uacute;blica 2003;
 19:1863-76.    ^cY#v33n1a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#90#86#article#117# </font></p>     ^cY
#v33n1a04.htm##
00570000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704032200077002001300399#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#91#87#article#117#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Cavalcante RA, Barbo
sa DR, Bonan PRF, Pires MBO, Martelli-Junior H. Perfil dos pesquisadores da &aac
ute;rea de odontologia no Conselho Nacional de Desenvolvimento Cient&iacute;fico
 e Tecnol&oacute;gico (CNPq). Rev Bras de Epidemiol 2008 ;11:106-13.    ^cY#v33n
1a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#92#88#article#117# </font></p>     ^cY
#v33n1a04.htm##
00527000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027900077002001300356#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#93#89#article#117#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Mendes PHC, Martelli
 DR, Souza WP, Filho SQ, Martelli Junior H. Perfil dos pesquisadores bolsistas d
e produtividade cient&iacute;fica na medicina no CNPq, Brasil. Rev Bras Educ Med
 &#91;in press&#93; 2010.    ^cY#v33n1a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#94#90#article#117# </font></p>     ^cY
#v33n1a04.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024100077002001300318#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#95#91#article#117#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Santos NCF, Candido 
LFO, Kuppens CL. Produtividade em pesquisa do CNPq: an&aacute;lise do perfil dos
 pesquisadores da qu&iacute;mica. Qu&iacute;m Nova 2010; 33:489-95.    ^cY#v33n1
a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#96#92#article#117# </font></p>     ^cY
#v33n1a04.htm##
00529000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704028100077002001300358#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#97#93#article#117#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Santos SMC, Lima LS,
 Martelli DRB, Martelli Junior H. Perfil dos pesquisadores da Sa&uacute;de Colet
iva no Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gi
co. Physis 2009; 19:761-75.    ^cY#v33n1a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#98#94#article#117# </font></p>     ^cY
#v33n1a04.htm##
00555000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704030700077002001300384#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#99#95#article#117#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Martelli Junior H, M
artelli DR, Quirino IG, Oliveira MCL, Lima LS, Oliveira EA. Pesquisadores do CNP
q na &aacute;rea de Medicina: compara&ccedil;&atilde;o das &aacute;reas de atua&
ccedil;&atilde;o. Rev Assoc Med Bras 2010; 56:478-83.    ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#100#96#article#117# </font></p>     ^c
Y#v33n1a04.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704021400078002001300292#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#101#97#article#117#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Weisinger JR, Bello
rin-Font E. Latin American nephrology: scientific production and impact of the p
ublications. Kidney Int 1999; 56:1584-90.    ^cY#v33n1a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#102#98#article#117# </font></p>     ^c
Y#v33n1a04.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704025000079002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#103#99#article#117#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Deheinzelin D, Ca
ramelli B. Scientific production, post-graduate education and Revista da Associa
&ccedil;&atilde;o M&eacute;dica Brasileira. Rev Assoc Med Bras 2007; 53:471-2.  
  ^cY#v33n1a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#104#100#article#117# </font></p>     ^
cY#v33n1a04.htm##
00375000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704012400080002001300204#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#105#101#article#117#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Bastos MG. Edito
rial. J Bras Nefrol 2010; 31:243.    ^cY#v33n1a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#106#102#article#117# </font></p>     ^
cY#v33n1a04.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024800080002001300328#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#107#103#article#117#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Editorial. Class
ifica&ccedil;&atilde;o dos peri&oacute;dicos no Sistema QUALIS da CAPES - a muda
n&ccedil;a dos crit&eacute;rios &eacute; URGENTE! J Bras Nefrol 2010; 32:1-3.   
 ^cY#v33n1a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#108#104#article#117# </font></p>     ^
cY#v33n1a04.htm##
00479000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022800080002001300308#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#109#105#article#117#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Rocha-e-Silva M.
 O novo QUALIS, que n&atilde;o tem nada a ver com a ci&ecirc;ncia do Brasil. Car
ta aberta ao presidente da CAPES. Clinics 2009; 68:721-4.    ^cY#v33n1a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#110#106#article#117# </font></p>     ^
cY#v33n1a04.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#111#107#article#117#<p>&nbsp;</p>     
^cY#v33n1a04.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#112#108#article#117#<p>&nbsp;</p>     
^cY#v33n1a04.htm##
00438000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020200077002001300279#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#113#109#article#117#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b>  Correspond&ecirc
;ncia para:</b>     ^cY#v33n1a04.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003500077002001300112#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#114#110#article#117#<br>   Eduardo A. 
Oliveira     ^cY#v33n1a04.htm##
00287000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005100077002001300128#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#115#111#article#117#<br>   Rua Engenhe
iro Amaro Lanari 389/501     ^cY#v33n1a04.htm##
00295000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005900077002001300136#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#116#112#article#117#<br>   Belo Horizo
nte - MG - Brasil CEP: 30310-580     ^cY#v33n1a04.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010900077002001300186#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#117#113#article#117#<br>   E - mail: <
a href="mailto:eduolive@medicina.ufmg.br">eduolive@medicina.ufmg.br</a></font></
p>     ^cY#v33n1a04.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010800077002001300185#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#118#114#article#117#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 07/09/201
0     ^cY#v33n1a04.htm##
00298000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006200077002001300139#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#119#115#article#117#<br>   Data de apr
ova&ccedil;&atilde;o: 30/09/2010 <b>    ^cY#v33n1a04.htm##
00495000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025900077002001300336#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#120#116#article#117#<br>   Suporte Fin
anceiro:</b> Esse estudo foi parcialmente apoiado pelo CNPq (Conselho Nacional d
e Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico) e pela FAPEMIG (Funda&
ccedil;&atilde;o de Amparo &agrave; Pesquisa do Estado de Minas Gerais).     ^cY
#v33n1a04.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a04.htm#S#p#121#117#article#117#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a04.htm##
00565000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100019000940100
01700113012010200130030000700232710000200239065000900241064000500250031000300255
014000700258865000900265002001300274#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a04.htm#S#c#122#1#article#13#1#^rND^sMugnaini^nR#^rND^sJannuzzi^nPM#^rND^sQuon
iam^nL#Indicadores bibliométricos da produção científica brasileira: uma análise
 a partir da base Pascal^lpt#Ci Inf#2#20040000#2004#33#123-31#20110300#v33n1a04.
htm##
00472000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760120046000900300
00700136065000900143064000500152031000400157014000600161865000900167002001300176
035001000189801000700199#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#
c#123#2#article#13#2#^rND^sLane^nJ#Lets make science metrics more scientific^len
#Nature#20100000#2010#464#488-9#20110300#v33n1a04.htm#0028-0836#Nature##
00567000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100018000930120
12300111030001800234710000200252065000900254064000500263031000300268014000800271
865000900279002001300288#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#
c#124#3#article#13#3#^rND^sBarata^nRB#^rND^sGoldbaum^nM#A profile of researchers
 in public health with productivity grants from the Brazilian National Research 
Council (CNPq)^len#Cad Saúde Pública#2#20030000#2003#19#1863-76#20110300#v33n1a0
4.htm##
00670000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760100018000970100
01700115010001700132010002500149012012400174030002200298710000200320065000900322
064000500331031000300336014000700339865000900346002001300355#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a04.htm#S#c#125#4#article#13#4#^rND^sCavalcante^nRA#^r
ND^sBarbosa^nDR#^rND^sBonan^nPRF#^rND^sPires^nMBO#^rND^sMartelli-Junior^nH#Perfi
l dos pesquisadores da área de odontologia no Conselho Nacional de Desenvolvimen
to Científico e Tecnológico (CNPq)^lpt#Rev Bras de Epidemiol#2#20080000#2008#11#
106-13#20110300#v33n1a04.htm##
00637000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100019000940100
01600113010001600129010002500145012009500170030001800265065000900283064000500292
865000900297002001300306035001000319801001800329#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a04.htm#S#c#126#5#article#13#5#^rND^sMendes^nPHC#^rND^sMartelli^nD
R#^rND^sSouza^nWP#^rND^sFilho^nSQ#^rND^sMartelli Junior^nH#Perfil dos pesquisado
res bolsistas de produtividade científica na medicina no CNPq, Brasil^lpt#Rev Br
as Educ Med#20100000#2010#20110300#v33n1a04.htm#0100-5502#Rev Bras Educ Med##
00553000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100019000940100
01800113012008600131030001000217710000200227065000900229064000500238031000300243
014000700246865000900253002001300262#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a04.htm#S#c#127#6#article#13#6#^rND^sSantos^nNCF#^rND^sCandido^nLFO#^rND^sKupp
ens^nCL#Produtividade em pesquisa do CNPq: análise do perfil dos pesquisadores d
a química^lpt#Quím Nova#2#20100000#2010#33#489-95#20110300#v33n1a04.htm##
00638000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100015000940100
02000109010002500129012011200154030000700266065000900273064000500282031000300287
014000700290865000900297002001300306035001000319801000700329#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a04.htm#S#c#128#7#article#13#7#^rND^sSantos^nSMC#^rND^
sLima^nLS#^rND^sMartelli^nDRB#^rND^sMartelli Junior^nH#Perfil dos pesquisadores 
da Saúde Coletiva no Conselho Nacional de Desenvolvimento Científico e Tecnológi
co^lpt#Physis#20090000#2009#19#761-75#20110300#v33n1a04.htm#0103-7331#PHYSIS##
00691000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100025000760100019001010100
01800120010002000138010001500158010001900173012007900192030001900271065000900290
06400050029903100030030401400070030786500090031400200130032303500100033680100190
0346#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#c#129#8#article#13#8
#^rND^sMartelli Junior^nH#^rND^sMartelli^nDR#^rND^sQuirino^nIG#^rND^sOliveira^nM
CL#^rND^sLima^nLS#^rND^sOliveira^nEA#Pesquisadores do CNPq na área de Medicina: 
comparação das áreas de atuação^lpt#Rev Assoc Med Bras#20100000#2010#56#478-83#2
0110300#v33n1a04.htm#0004-5241#Rev Assoc Med Bras##
00560000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100023000960120
08400119030001100203065000900214064000500223031000300228014000800231865000900239
002001300248035001000261801001100271#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a04.htm#S#c#130#9#article#13#9#^rND^sWeisinger^nJR#^rND^sBellorin-Font^nE#Lati
n American nephrology: scientific production and impact of the publications^len#
Kidney Int#19990000#1999#56#1584-90#20110300#v33n1a04.htm#0085-2538#Kidney int##
00584000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100019000990120
09500118030001900213065000900232064000500241031000300246014000600249865000900255
002001300264035001000277801001900287#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a04.htm#S#c#131#10#article#13#10#^rND^sDeheinzelin^nD#^rND^sCaramelli^nB#Scien
tific production, post-graduate education and Revista da Associação Médica Brasi
leira^len#Rev Assoc Med Bras#20070000#2007#53#471-2#20110300#v33n1a04.htm#0004-5
241#Rev Assoc Med Bras##
00456000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780120014000950300
01400109065000900123064000500132031000300137014000400140865000900144002001300153
035001000166801001400176#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#
c#132#11#article#13#11#^rND^sBastos^nMG#Editorial^lpt#J Bras Nefrol#20100000#201
0#31#243#20110300#v33n1a04.htm#0101-2800#J Bras Nefrol##
00536000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120095000940300
01400189065000900203064000500212031000300217014000400220865000900224002001300233
035001000246801001400256#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#
c#133#12#article#13#12#^rND^sEditorial#Classificação dos periódicos no Sistema Q
UALIS da CAPES: a mudança dos critérios é URGENTE^lpt#J Bras Nefrol#20100000#201
0#32#1-3#20110300#v33n1a04.htm#0101-2800#J Bras Nefrol##
00541000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780120103001010300
00800204065000900212064000500221031000300226014000600229865000900235002001300244
035001000257801000800267#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a04.htm#S#
c#134#13#article#13#13#^rND^sRocha-e-Silva^nM#O novo QUALIS, que não tem nada a 
ver com a ciência do Brasil: Carta aberta ao presidente da CAPES^lpt#Clinics#200
90000#2009#68#721-4#20110300#v33n1a04.htm#1807-5932#Clinics##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#o#1#1#article#1#
20110411#092910#v33n1a05.htm#180##
05187000000000745000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201080
01610120094002690100052003630100034004150100029004490100027004780100033005050100
03400538010003900572010003200611070010400643070007500747070003600822070003900858
07000670089707000540096407000910101808316470110908500100275608500310276608500300
27970850018028270850022028450831400028670850010042670850032042770850028043090850
01804337085002204355117000804377072000304385112000904388111001104397114000904408
113001104417002001304428#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#
h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#05#JBN020#nd#J. Bras. Nefrol.#33#1#20
110300#^f38^l44#0101-2800#Fatores associados à qualidade de vida de pacientes in
cidentes em diálise peritoneal no Brasil (BRAZPD)^lpt#Factors associated with th
e quality of life of incident patients on PD in Brazil (BRAZPD)^len#^rND^1A01 A0
2^nFabiane Rossi dos Santos^sGrincenkov#^rND^1A01 A02^nNatália^sFernandes#^rND^1
A04^nAlfredo^sChaoubah#^rND^1A05^nKleyton^sBastos#^rND^1A06^nAbdul Rashid^sQures
hi#^rND^1A07^nRoberto^sPécoits-Filho#^rND^1A07^nJosé Carolino^sDivino Filho#^rND
^1A03^nMarcus Gomes^sBastos#Universidade Federal de Juiz de Fora^iA01^1Núcleo In
terdisciplinar de Estudos e Pesquisas em Nefrologia#Centro de Ensino Superior de
 Juiz de Fora^iA02^1Departamento de Psicologia#UFJF^iA03^1Departamento de Medici
na#UFJF^iA04^1Departamento de Estatística#Universidade Federal de Sergipe^iA05^1
Departamento de Medicina^sSE#Karolinska Institute^iA06^1CLINTEC^cStockholm^pSwed
en#Pontifícia Universidade Católica do Paraná^iA07^1Centro de Saúde e CiÍncias B
iológicas^sPR#^lpt^aINTRODUÇÃO: O número de pacientes em diálise peritoneal (DP)
 no Brasil é significativo, havendo maior prevalência de diabéticos e idosos nes
te grupo do que no grupo em hemodiálise. Esses dados apontam para um viés de sel
eção nessa população. Objetivo: Avaliar a qualidade de vida (QdV) na admissão de
 pacientes em diálise peritoneal no Brasil. MÉTODOS: Avaliados 6.198 pacientes p
articipantes de um estudo de coorte prospectivo multicêntrico, utilizando-se os 
dados do BRAZPD. A avaliação da QdV foi realizada segundo o índice de Karnofsky 
(avaliação da QdV pelo profissional de saúde) e segundo o SF-36 (autoavaliação p
elo paciente) em 1.624 pacientes incidentes. RESULTADOS: Entre os pacientes anal
isados, 40% eram diabéticos e 47% eram idosos (acima de 60 anos). Os pacientes a
presentaram baixos escores de QdV em todos os aspectos do SF-36, sendo o domínio
 "aspectos físicos" o mais prejudicado. O domínio que apresentou melhor escore f
oi "aspecto social". Por outro lado, segundo o índice de Karnofsky, a maior part
e dos pacientes possuía altos escores de QdV. Idosos e diabéticos apresentaram q
ualidade de vida inferior quando comparados aos não idosos e não diabéticos atra
vés da avaliação pelo SF-36 e pelo Karnofsky. CONCLUSÃO: Na avaliação geral pelo
 SF-36 observou-se redução da qualidade de vida. A avaliação pelo Karnofsky apre
sentou melhor performance comparado ao SF-36 na avaliação geral da qualidade de 
vida, sendo encontrados resultados semelhantes entre os dois instrumentos no que
 diz respeitos aos subgrupos avaliados, onde os grupos que apresentaram pior QdV
 foram pacientes diabéticos e idosos em ambas as avaliações.#^ddecs^i1#^tm^lpt^k
diálise peritoneal^i1#^tm^lpt^kqualidade de vida^i1#^tm^lpt^kSF-36^i1#^tm^lpt^kK
arnofsky^i1#^len^aINTRODUCTION: The number of patients on peritoneal dialysis (P
D) in Brazil is significant, with a higher prevalence of diabetic and elderly in
dividuals on PD than on hemodialysis. These data point to a selection bias in th
at population. OBJECTIVE: To assess the quality of life (QOL) of patients starti
ng PD in Brazil. METHODS: The study assessed 6,198 patients participating in a m
ulticenter prospective cohort study, using data from BRAZPD. The QOL was assesse
d by use of the Karnofsky index (QOL assessment by health professionals) and the
 SF-36 (patient's self-assessment) in 1,624 incident patients. RESULTS: Of the p
atients analyzed, 40% were diabetic and 47% were elderly (over the age of 60 yea
rs). Patients had low QOL scores in all the SF-36 domains, the "physical role" d
omain being the most affected and the "social functioning" domain having the bes
t score. On the other hand, according to the Karnofsky index, most patients had 
high QOL scores. Elderly and diabetic patients had lower QOL as compared with no
n-elderly and non-diabetic by using both the SF-36 and Karnofsky index. CONCLUSI
ON: The overall evaluation by use of the SF-36 showed a reduction in the QOL. Th
e Karnofsky index showed a better QOL as compared with the SF-36 assessment, but
 similar results were found in the subgroups evaluated: the ederly and the diabe
tic patients had the worst QOL in both assessments.#^ddecs^i2#^tm^len^kperitonea
l dialysis^i2#^tm^len^kquality of life^i2#^tm^len^kSF-36^i2#^tm^len^kKarnofsky^i
2#vancouv#19#20100917#17/09/2010#20101103#03/11/2010#v33n1a05.htm##
05264000000000745000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201150
01610120101002760100052003770100034004290100029004630100027004920100033005190100
03400552010003900586010003200625070010400657070007500761070003600836070003900872
07000670091107000540097807000910103208316750112308500100279808500310280808500300
28390850018028690850022028870831435029090850010043440850032043540850028043860850
01804414085002204432117000804454072000304462112000904465111001104474114000904485
113001104494002001304505#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#
f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#05#JBN020#nd#J. Bras. Nefrol.#33#1#20
110300#^f38^l44#0101-2800#<b>Fatores associados à qualidade de vida de pacientes
 incidentes em diálise peritoneal no Brasil (BRAZPD)</b>^lpt#<b>Factors associat
ed with the quality of life of incident patients on PD in Brazil (BRAZPD)</b>^le
n#^rND^1A01 A02^nFabiane Rossi dos Santos^sGrincenkov#^rND^1A01 A02^nNatália^sFe
rnandes#^rND^1A04^nAlfredo^sChaoubah#^rND^1A05^nKleyton^sBastos#^rND^1A06^nAbdul
 Rashid^sQureshi#^rND^1A07^nRoberto^sPécoits-Filho#^rND^1A07^nJosé Carolino^sDiv
ino Filho#^rND^1A03^nMarcus Gomes^sBastos#Universidade Federal de Juiz de Fora^i
A01^1Núcleo Interdisciplinar de Estudos e Pesquisas em Nefrologia#Centro de Ensi
no Superior de Juiz de Fora^iA02^1Departamento de Psicologia#UFJF^iA03^1Departam
ento de Medicina#UFJF^iA04^1Departamento de Estatística#Universidade Federal de 
Sergipe^iA05^1Departamento de Medicina^sSE#Karolinska Institute^iA06^1CLINTEC^cS
tockholm^pSweden#Pontifícia Universidade Católica do Paraná^iA07^1Centro de Saúd
e e CiÍncias Biológicas^sPR#^lpt^a<b>INTRODUÇÃO: </b>O número de pacientes em di
álise peritoneal (DP) no Brasil é significativo, havendo maior prevalência de di
abéticos e idosos neste grupo do que no grupo em hemodiálise. Esses dados aponta
m para um viés de seleção nessa população. Objetivo: Avaliar a qualidade de vida
 (QdV) na admissão de pacientes em diálise peritoneal no Brasil. <b>MÉTODOS:</b>
 Avaliados 6.198 pacientes participantes de um estudo de coorte prospectivo mult
icêntrico, utilizando-se os dados do BRAZPD. A avaliação da QdV foi realizada se
gundo o índice de Karnofsky (avaliação da QdV pelo profissional de saúde) e segu
ndo o SF-36 (autoavaliação pelo paciente) em 1.624 pacientes incidentes. <b>RESU
LTADOS:</b> Entre os pacientes analisados, 40% eram diabéticos e 47% eram idosos
 (acima de 60 anos). Os pacientes apresentaram baixos escores de QdV em todos os
 aspectos do SF-36, sendo o domínio "aspectos físicos" o mais prejudicado. O dom
ínio que apresentou melhor escore foi "aspecto social". Por outro lado, segundo 
o índice de Karnofsky, a maior parte dos pacientes possuía altos escores de QdV.
 Idosos e diabéticos apresentaram qualidade de vida inferior quando comparados a
os não idosos e não diabéticos através da avaliação pelo SF-36 e pelo Karnofsky.
 <b>CONCLUSÃO: </b>Na avaliação geral pelo SF-36 observou-se redução da qualidad
e de vida. A avaliação pelo Karnofsky apresentou melhor performance comparado ao
 SF-36 na avaliação geral da qualidade de vida, sendo encontrados resultados sem
elhantes entre os dois instrumentos no que diz respeitos aos subgrupos avaliados
, onde os grupos que apresentaram pior QdV foram pacientes diabéticos e idosos e
m ambas as avaliações.#^ddecs^i1#^tm^lpt^kdiálise peritoneal^i1#^tm^lpt^kqualida
de de vida^i1#^tm^lpt^kSF-36^i1#^tm^lpt^kKarnofsky^i1#^len^a<b>INTRODUCTION:</b>
 The number of patients on peritoneal dialysis (PD) in Brazil is significant, wi
th a higher prevalence of diabetic and elderly individuals on PD than on hemodia
lysis. These data point to a selection bias in that population. <b>OBJECTIVE:</b
> To assess the quality of life (QOL) of patients starting PD in Brazil. <b>METH
ODS:</b> The study assessed 6,198 patients participating in a multicenter prospe
ctive cohort study, using data from BRAZPD. The QOL was assessed by use of the K
arnofsky index (QOL assessment by health professionals) and the SF-36 (patient's
 self-assessment) in 1,624 incident patients. <b>RESULTS:</b> Of the patients an
alyzed, 40% were diabetic and 47% were elderly (over the age of 60 years). Patie
nts had low QOL scores in all the SF-36 domains, the "physical role" domain bein
g the most affected and the "social functioning" domain having the best score. O
n the other hand, according to the Karnofsky index, most patients had high QOL s
cores. Elderly and diabetic patients had lower QOL as compared with non-elderly 
and non-diabetic by using both the SF-36 and Karnofsky index. <b>CONCLUSION:</b>
 The overall evaluation by use of the SF-36 showed a reduction in the QOL. The K
arnofsky index showed a better QOL as compared with the SF-36 assessment, but si
milar results were found in the subgroups evaluated: the ederly and the diabetic
 patients had the worst QOL in both assessments.#^ddecs^i2#^tm^len^kperitoneal d
ialysis^i2#^tm^len^kquality of life^i2#^tm^len^kSF-36^i2#^tm^len^kKarnofsky^i2#v
ancouv#19#20100917#17/09/2010#20101103#03/11/2010#v33n1a05.htm##
05363000000000769000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400090015903500100
01680120108001780120094002860100052003800100034004320100029004660100027004950100
03300522010003400555010003900589010003200628070010600660070007700766070003800843
07000410088107000690092207000560099107000930104708316650114008500100280508500310
28150850030028460850018028760850022028940831414029160850010043300850032043400850
02804372085001804400085002204418117000804440072000304448112000904451111001104460
114000904471113001104480002001304491008008904504#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a05.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus
#tab#05#JBN020#nd#J. Bras. Nefrol#33#1#20110300#^f38^l44#0101-2800#Fatores assoc
iados à qualidade de vida de pacientes incidentes em diálise peritoneal no Brasi
l (BRAZPD)^lpt#Factors associated with the quality of life of incident patients 
on PD in Brazil (BRAZPD)^len#^rND^1A01 A02^nFabiane Rossi dos Santos^sGrincenkov
#^rND^1A01 A02^nNatália^sFernandes#^rND^1A04^nAlfredo^sChaoubah#^rND^1A05^nKleyt
on^sBastos#^rND^1A06^nAbdul Rashid^sQureshi#^rND^1A07^nRoberto^sPécoits-Filho#^r
ND^1A07^nJosé Carolino^sDivino Filho#^rND^1A03^nMarcus Gomes^sBastos#^iA01^1Univ
ersidade Federal de Juiz de Fora^2Núcleo Interdisciplinar de Estudos e Pesquisas
 em Nefrologia#^iA02^1Centro de Ensino Superior de Juiz de Fora^2Departamento de
 Psicologia#^iA03^1UFJF^2Departamento de Medicina#^iA04^1UFJF^2Departamento de E
statística#^iA05^1Universidade Federal de Sergipe^2Departamento de Medicina^sSE#
^iA06^1Karolinska Institute^2CLINTEC^cStockholm^pSweden#^iA07^1Pontifícia Univer
sidade Católica do Paraná^2Centro de Saúde e CiÍncias Biológicas^sPR#^lpt^aINTRO
DUÇÃO: O número de pacientes em diálise peritoneal (DP) no Brasil é significativ
o, havendo maior prevalência de diabéticos e idosos neste grupo do que no grupo 
em hemodiálise. Esses dados apontam para um viés de seleção nessa população. Obj
etivo: Avaliar a qualidade de vida (QdV) na admissão de pacientes em diálise per
itoneal no Brasil. MÉTODOS: Avaliados 6.198 pacientes participantes de um estudo
 de coorte prospectivo multicêntrico, utilizando-se os dados do BRAZPD. A avalia
ção da QdV foi realizada segundo o índice de Karnofsky (avaliação da QdV pelo pr
ofissional de saúde) e segundo o SF-36 (autoavaliação pelo paciente) em 1.624 pa
cientes incidentes. RESULTADOS: Entre os pacientes analisados, 40 por cento eram
 diabéticos e 47 por cento eram idosos (acima de 60 anos). Os pacientes apresent
aram baixos escores de QdV em todos os aspectos do SF-36, sendo o domínio "aspec
tos físicos" o mais prejudicado. O domínio que apresentou melhor escore foi "asp
ecto social". Por outro lado, segundo o índice de Karnofsky, a maior parte dos p
acientes possuía altos escores de QdV. Idosos e diabéticos apresentaram qualidad
e de vida inferior quando comparados aos não idosos e não diabéticos através da 
avaliação pelo SF-36 e pelo Karnofsky. CONCLUSÃO: Na avaliação geral pelo SF-36 
observou-se redução da qualidade de vida. A avaliação pelo Karnofsky apresentou 
melhor performance comparado ao SF-36 na avaliação geral da qualidade de vida, s
endo encontrados resultados semelhantes entre os dois instrumentos no que diz re
speitos aos subgrupos avaliados, onde os grupos que apresentaram pior QdV foram 
pacientes diabéticos e idosos em ambas as avaliações.#^ddecs^i1#^tm^lpt^kdiálise
 peritoneal^i1#^tm^lpt^kqualidade de vida^i1#^tm^lpt^kSF-36^i1#^tm^lpt^kKarnofsk
y^i1#^len^aINTRODUCTION: The number of patients on peritoneal dialysis (PD) in B
razil is significant, with a higher prevalence of diabetic and elderly individua
ls on PD than on hemodialysis. These data point to a selection bias in that popu
lation. OBJECTIVE: To assess the quality of life (QOL) of patients starting PD i
n Brazil. METHODS: The study assessed 6,198 patients participating in a multicen
ter prospective cohort study, using data from BRAZPD. The QOL was assessed by us
e of the Karnofsky index (QOL assessment by health professionals) and the SF-36 
(patient's self-assessment) in 1,624 incident patients. RESULTS: Of the patients
 analyzed, 40 percent were diabetic and 47 percent were elderly (over the age of
 60 years). Patients had low QOL scores in all the SF-36 domains, the "physical 
role" domain being the most affected and the "social functioning" domain having 
the best score. On the other hand, according to the Karnofsky index, most patien
ts had high QOL scores. Elderly and diabetic patients had lower QOL as compared 
with non-elderly and non-diabetic by using both the SF-36 and Karnofsky index. C
ONCLUSION: The overall evaluation by use of the SF-36 showed a reduction in the 
QOL. The Karnofsky index showed a better QOL as compared with the SF-36 assessme
nt, but similar results were found in the subgroups evaluated: the ederly and th
e diabetic patients had the worst QOL in both assessments.#^ddecs^i2#^tm^len^kpe
ritoneal dialysis^i2#^tm^len^kquality of life^i2#^tm^len^kSF-36^i2#^tm^len^kKarn
ofsky^i2#vancouv#19#20100917#17/09/2010#20101103#03/11/2010#v33n1a05.htm#Interne
t^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-2800201100010000
5##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#5#1#article#157#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a05.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#6#2#article#157#<p>&nbsp;</p>     ^cY#
v33n1a05.htm##
00458000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704022600073002001300299#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#7#3#article#157#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Fatores associado
s &agrave; qualidade de vida de pacientes incidentes em di&aacute;lise peritonea
l no Brasil (BRAZPD)</b></font></p>     ^cY#v33n1a05.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#8#4#article#157#<p>&nbsp;</p>     ^cY#
v33n1a05.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#9#5#article#157#<p>&nbsp;</p>     ^cY#
v33n1a05.htm##
00637000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704040400074002001300478#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#10#6#article#157#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Fabiane Rossi dos Santos Grincenkov
<sup>I,II</sup>; Nat&aacute;lia Fernandes<sup>I,II</sup>; Alfredo Chaoubah<sup>I
V</sup>; Kleyton Bastos<sup>V</sup>; Abdul Rashid Qureshi<sup>VI</sup>; Roberto 
P&eacute;coits-Filho<sup>VII</sup>; Jos&eacute; Carolino Divino  Filho<sup>VII</
sup>; Marcus Gomes Bastos<sup>III</sup></b></font></p>     ^cY#v33n1a05.htm##
00428000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704019500074002001300269#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#11#7#article#157#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>N&uacute;cleo Interdiscipl
inar de Estudos e Pesquisas em Nefrologia; Universidade Federal de Juiz de Fora 
- UFJF    ^cY#v33n1a05.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704009700074002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#12#8#article#157#<br>   <sup>II</sup>D
epartamento de Psicologia; Centro de Ensino Superior de Juiz de Fora    ^cY#v33n
1a05.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704006100074002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#13#9#article#157#<br>   <sup>III</sup>
Departamento de Medicina - UFJF     ^cY#v33n1a05.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#14#10#article#157#<br>   <sup>IV</sup>
Departamento de Estat&iacute;stica - UFJF    ^cY#v33n1a05.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008900075002001300164#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#15#11#article#157#<br>   <sup>V</sup>D
epartamento de Medicina- Universidade Federal de Sergipe - SE    ^cY#v33n1a05.ht
m##
00343000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010900075002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#16#12#article#157#<br>   <sup>VI</sup>
Baxter Novum and Renal Medicine, CLINTEC, Karolinska Institute, Stockholm, Swede
n    ^cY#v33n1a05.htm##
00407000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017300075002001300248#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#17#13#article#157#<br>   <sup>VII</sup
>Centro de Sa&uacute;de e Ci&Iacute;ncias Biol&oacute;gicas; Pontif&iacute;cia U
niversidade Cat&oacute;lica do Paran&aacute; - PUC PR</font></p>     ^cY#v33n1a0
5.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#18#14#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia
</a></font></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#19#15#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#20#16#article#157#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a05.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#21#17#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a05.htm##
00760000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052600075002001300601#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#22#18#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O: </b>O n&
uacute;mero de pacientes em di&aacute;lise peritoneal (DP) no Brasil &eacute; si
gnificativo, havendo maior preval&ecirc;ncia de diab&eacute;ticos e idosos neste
 grupo do que no grupo em hemodi&aacute;lise. Esses dados apontam para um vi&eac
ute;s de sele&ccedil;&atilde;o nessa popula&ccedil;&atilde;o. Objetivo: Avaliar 
a qualidade de vida (QdV) na admiss&atilde;o de pacientes em di&aacute;lise peri
toneal no Brasil.     ^cY#v33n1a05.htm##
00646000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041200075002001300487#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#23#19#article#157#<br>   <b>M&Eacute;T
ODOS:</b> Avaliados 6.198 pacientes participantes de um estudo de coorte prospec
tivo multic&ecirc;ntrico, utilizando-se os dados do BRAZPD. A avalia&ccedil;&ati
lde;o da QdV foi realizada segundo o &iacute;ndice de Karnofsky (avalia&ccedil;&
atilde;o da QdV pelo profissional de sa&uacute;de) e segundo o SF-36 (autoavalia
&ccedil;&atilde;o pelo paciente) em 1.624 pacientes incidentes.     ^cY#v33n1a05
.htm##
00908000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067400075002001300749#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#24#20#article#157#<br>   <b>RESULTADOS
:</b> Entre os pacientes analisados, 40% eram diab&eacute;ticos e 47% eram idoso
s (acima de 60 anos). Os pacientes apresentaram baixos escores de QdV em todos o
s aspectos do SF-36, sendo o dom&iacute;nio "aspectos f&iacute;sicos" o mais pre
judicado. O dom&iacute;nio que apresentou melhor escore foi "aspecto social". Po
r outro lado, segundo o &iacute;ndice de Karnofsky, a maior parte dos pacientes 
possu&iacute;a altos escores de QdV. Idosos e diab&eacute;ticos apresentaram qua
lidade de vida inferior quando comparados aos n&atilde;o idosos e n&atilde;o dia
b&eacute;ticos atrav&eacute;s da avalia&ccedil;&atilde;o pelo SF-36 e pelo Karno
fsky.     ^cY#v33n1a05.htm##
00767000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053300075002001300608#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#25#21#article#157#<br>   <b>CONCLUS&At
ilde;O: </b>Na avalia&ccedil;&atilde;o geral pelo SF-36 observou-se redu&ccedil;
&atilde;o da qualidade de vida. A avalia&ccedil;&atilde;o pelo Karnofsky apresen
tou melhor performance comparado ao SF-36 na avalia&ccedil;&atilde;o geral da qu
alidade de vida, sendo encontrados resultados semelhantes entre os dois instrume
ntos no que diz respeitos aos subgrupos avaliados, onde os grupos que apresentar
am pior QdV foram pacientes diab&eacute;ticos e idosos em ambas as avalia&ccedil
;&otilde;es. </font></p>     ^cY#v33n1a05.htm##
00426000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019200075002001300267#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#26#22#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> di&aacute;lise
 peritoneal, qualidade de vida, SF-36, Karnofsky. </font></p> <hr size="1" nosha
de>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#27#23#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#28#24#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#29#25#article#157#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a05.htm##
00944000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071000075002001300785#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#30#26#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Pacientes com doen&ccedil;a renal cr&
ocirc;nica (DRC), em geral, tendem a apresentar redu&ccedil;&atilde;o da qualida
de de vida (QdV) em fun&ccedil;&atilde;o das diversas restri&ccedil;&otilde;es a
carretadas pelo tratamento. Em alguns estudos n&atilde;o s&atilde;o observadas d
iferen&ccedil;as na QdV entre pacientes submetidos &agrave; hemodi&aacute;lise (
HD) e di&aacute;lise peritoneal (DP), uma vez que ambos os grupos apresentaram r
edu&ccedil;&atilde;o de escores. <sup>1</sup> No entanto, alguns autores como Zh
ang <i>et al</i>. <sup>2</sup> referem melhor QdV em pacientes submetidos &agrav
e; di&aacute;lise peritoneal. </font></p>     ^cY#v33n1a05.htm##
00980000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074600075002001300821#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#31#27#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A presen&ccedil;a de diabetes &eacute
; um fator que pode influenciar na QdV desses pacientes. Observa-se que paciente
s diab&eacute;ticos, comparativamente aos n&atilde;o diab&eacute;ticos, usam mai
s medicamentos, t&ecirc;m maiores &iacute;ndices de press&atilde;o arterial, apr
esentam maiores complica&ccedil;&otilde;es cardiovasculares e menores pontua&cce
dil;&otilde;es nas escalas f&iacute;sicas do instrumento SF-36, al&eacute;m de a
presentarem pior autopercep&ccedil;&atilde;o da QdV, capacidade funcional mais b
aixa e maior mortalidade. <sup>3 </sup>A presen&ccedil;a de comorbidades pode, p
ortanto, estar relacionada &agrave; redu&ccedil;&atilde;o da QdV. </font></p>   
  ^cY#v33n1a05.htm##
00576000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034200075002001300417#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#32#28#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A predomin&acirc;ncia de pacientes id
osos e diab&eacute;ticos na popula&ccedil;&atilde;o em tratamento hemodial&iacut
e;tico pode influenciar negativamente em determinados dom&iacute;nios de QdV, co
mparativamente aos outros subgrupos de pacientes. <sup>4</sup></font></p>     ^c
Y#v33n1a05.htm##
00794000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056000075002001300635#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#33#29#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O impacto da doen&ccedil;a renal na Q
dV foi observado em pacientes australianos revelando um d&eacute;ficit significa
nte em todas as escalas do SF-36, exceto em vitalidade e sa&uacute;de mental. Pa
cientes que apresentavam outras comorbidades obtiveram escores mais baixos em ci
nco dos oito dom&iacute;nios de QdV. Al&eacute;m disso, a sa&uacute;de mental fo
i particularmente prejudicada no grupo mais jovem e os aspectos f&iacute;sicos n
o grupo mais idoso com DRC. <sup>5</sup></font></p>     ^cY#v33n1a05.htm##
00712000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047800075002001300553#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#34#30#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Fatores como idade e presen&ccedil;a 
de diabetes podem, portanto, ter influ&ecirc;ncia significativa na QdV de pacien
tes com doen&ccedil;a renal cr&ocirc;nica. S&atilde;o fundamentais interven&cced
il;&otilde;es que melhorem as condi&ccedil;&otilde;es cl&iacute;nicas e a QdV de
sses pacientes, uma vez que esta pode estar diretamente associada &agrave; morta
lidade dessa popula&ccedil;&atilde;o. </font></p>     ^cY#v33n1a05.htm##
00559000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032500075002001300400#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#35#31#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A associa&ccedil;&atilde;o entre a re
du&ccedil;&atilde;o da QdV e fatores preven&iacute;veis e control&aacute;veis ap
ontam para a import&acirc;ncia de interven&ccedil;&otilde;es psicossociais junto
 a essa popula&ccedil;&atilde;o. <sup>6</sup></font></p>     ^cY#v33n1a05.htm##
00453000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021900075002001300294#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#36#32#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo foi avaliar a
 QdV dos pacientes com DRC no in&iacute;cio do tratamento por di&aacute;lise per
itoneal no Brasil. </font></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#37#33#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#38#34#article#157#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODO</b></fon
t></p>     ^cY#v33n1a05.htm##
00878000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064400075002001300719#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#39#35#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram avaliados 6.198 pacientes parti
cipantes de um estudo de coorte prospectivo multic&ecirc;ntrico, utilizando- se 
os dados do BRAZPD (Estudo Cl&iacute;nico Multic&ecirc;ntrico em Di&aacute;lise 
Peritoneal). Nesse estudo foram inclu&iacute;dos 114 centros de terapia renal su
bstitutiva (TRS) com mais de 10 pacientes em di&aacute;lise peritoneal e que usa
vam sistemas Baxter. Em todos os centros, um m&eacute;dico e um enfermeiro foram
 treinados para o preenchimento dos dados dos pacientes no <i>software PDnet</i>
, especialmente desenvolvido para o estudo. </font></p>     ^cY#v33n1a05.htm##
00638000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040400075002001300479#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#40#36#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A <a href="#fig1">Figura 1</a> mostra
 que entre a popula&ccedil;&atilde;o de 6.198 pacientes, 2.039 eram incidentes. 
Quatrocentos e quinze pacientes n&atilde;o apresentavam dados completos de QdV p
ara an&aacute;lise, restando assim 1.624 pacientes. Houve 517 sa&iacute;das (271
 por &oacute;bito e 246 por outras causas). </font></p>     ^cY#v33n1a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#41#37#article#157#<p><a name="fig1"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#42#38#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#43#39#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05fig01.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#44#40#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00729000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049500075002001300570#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#45#41#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o da QdV foi 
realizada atrav&eacute;s de dois instrumentos: o &iacute;ndice de performance f&
iacute;sica Karnofsky<sup>7</sup> e o SF-36. <sup>8</sup> A avalia&ccedil;&atild
e;o segundo o &iacute;ndice de Karnofsky, cuja pontua&ccedil;&atilde;o m&aacute;
xima de 100 pontos corresponde a melhor QdV, foi realizada mensalmente por profi
ssionais de sa&uacute;de da &aacute;rea de enfermagem. </font></p>     ^cY#v33n1
a05.htm##
00949000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071500075002001300790#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#46#42#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As avalia&ccedil;&otilde;es pelo SF-3
6 foram realizadas em 3.642 pacientes. O SF-36 caracteriza-se pela autoavalia&cc
edil;&atilde;o pelo paciente, sendo uma vers&atilde;o reduzida do question&aacut
e;rio da <i>Medical Outcomes Trust</i> traduzida e validada para o portugu&ecirc
;s. Nela s&atilde;o analisados os dom&iacute;nios: capacidade funcional, aspecto
s f&iacute;sicos, dor, estado geral de sa&uacute;de, vitalidade, aspectos sociai
s, aspectos emocionais e sa&uacute;de mental. A cada dom&iacute;nio avaliado s&a
tilde;o atribu&iacute;dos escores que variam de zero a cem, correspondentes a pi
or ou melhor QdV, respectivamente. </font></p>     ^cY#v33n1a05.htm##
00662000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042800075002001300503#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#47#43#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados do SF-36 no BRAZPD incluem a
 aplica&ccedil;&atilde;o do instrumento de qualidade de vida em momentos diferen
ciados: 1) aplica&ccedil;&atilde;o aos seis meses de entrada em di&aacute;lise p
eritoneal para os pacientes incidentes; 2) aplica&ccedil;&atilde;o ap&oacute;s t
r&ecirc;s meses de entrada no estudo para os pacientes prevalentes. </font></p> 
    ^cY#v33n1a05.htm##
00569000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033500075002001300410#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#48#44#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No presente estudo foram analisados o
s dom&iacute;nios de qualidade de vida mais afetados no per&iacute;odo de entrad
a em di&aacute;lise dos pacientes incidentes, atrav&eacute;s da avalia&ccedil;&a
tilde;o de dois subgrupos: idosos e diab&eacute;ticos. </font></p>     ^cY#v33n1
a05.htm##
01607000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704137300075002001301448#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#49#45#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">M&eacute;dicos e enfermeiros preenche
ram os dados gerais deste estudo cl&iacute;nico. Os dados preenchidos pela enfer
magem incluem: idade, ra&ccedil;a, grau de instru&ccedil;&atilde;o, rendimento m
&eacute;dio mensal em classes de sal&aacute;rios m&iacute;nimos (segundo o Insti
tuto Brasileiro de Geografia e Estat&iacute;stica),<sup>9</sup> dist&acirc;ncia 
entre a resid&ecirc;ncia do paciente e o centro de di&aacute;lise (em quil&ocirc
;metros). <sup>10 </sup>J&aacute; os dados preenchidos pelo m&eacute;dico s&atil
de;o os seguites: I- etiologia da DRC (elaborada com base na codifica&ccedil;&at
ilde;o da European Dialysis and Transplant Association<i> - EDTA</i>); II - cuid
ados pr&eacute;-dial&iacute;ticos (se houve acompanhamento - tempo em anos e mes
es); III - se o paciente recebeu orienta&ccedil;&otilde;es sobre as modalidades 
de terapia renal substitutiva (TRS); IV - indica&ccedil;&atilde;o de DP (op&cced
il;&atilde;o do paciente, indica&ccedil;&atilde;o m&eacute;dica, &uacute;nica te
rapia poss&iacute;vel); V - especialidade do profissional que encaminhou o pacie
nte; VI - se possui acesso vascular e tipo; VII - hist&oacute;ria dial&iacute;ti
ca indicando o registro da TRS atual e das anteriores, assim como o tempo em que
 o paciente permaneceu em cada terapia. <sup>10</sup></font></p>     ^cY#v33n1a0
5.htm##
00693000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045900075002001300534#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#50#46#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o das comorbi
dades foi baseada no crit&eacute;rio de pontua&ccedil;&atilde;o utilizado por DA
VIES <i>et al</i>. <sup>11 </sup>Os dados pregressos de infec&ccedil;&atilde;o i
nclu&iacute;ram todas as infec&ccedil;&otilde;es (peritonite, local de sa&iacute
;da do cateter e t&uacute;nel subcut&acirc;neo) ocorridas antes do ingresso do p
aciente no estudo. </font></p>     ^cY#v33n1a05.htm##
00531000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029700075002001300372#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#51#47#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O projeto foi aprovado no Comit&ecirc
; de &Eacute;tica Nacional em Pesquisa Humana e aprovado sob o n&uacute;mero 448
. Os pacientes que aceitaram participar do estudo assinaram o consentimento livr
e e esclarecido. </font></p>     ^cY#v33n1a05.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012300075002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#52#48#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>AN&Aacute;LISE ESTAT&Iacute;STICA<
/b></font></p>     ^cY#v33n1a05.htm##
00719000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048500075002001300560#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#53#49#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foi realizada estat&iacute;stica desc
ritiva e a seguir foram comparadas as popula&ccedil;&otilde;es de idosos <i>vs <
/i>n&atilde;o idosos e diab&eacute;ticos <i>vs</i> n&atilde;o diab&eacute;ticos 
nos oito dom&iacute;nios do SF-36 e no Karnofsky. Para essa an&aacute;lise foi u
tilizado Teste T de Student para amostras independentes ou Mann Whitney conforme
 a caracter&iacute;stica da vari&aacute;vel. </font></p>     ^cY#v33n1a05.htm##
00440000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020600075002001300281#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#54#50#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Considerado significante um p <u>&lt;
</u> 0,05. Para a an&aacute;lise dos dados foi utilizado o <i>software SPSS </i>
13.0. </font></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#55#51#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#56#52#article#157#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v33n1a05.htm##
00515000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028100075002001300356#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#57#53#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A popula&ccedil;&atilde;o total foi d
e 6.198 pacientes, sendo avaliados 1.624 pacientes incidentes (mais de 3 meses e
m di&aacute;lise peritoneal) que apresentavam todos os dados necess&aacute;rios.
 </font></p>     ^cY#v33n1a05.htm##
00735000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050100075002001300576#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#58#54#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A <a href="#tab1">Tabela 1</a> aprese
nta os dados s&oacute;ciodemogr&aacute;ficos da popula&ccedil;&atilde;o avaliada
. A idade m&eacute;dia foi de 57,8 ± 15,3 anos, 47% dos pacientes eram idosos (m
ais de 60 anos), 55,2% eram do sexo feminino e 60% eram brancos. Com rela&ccedil
;&atilde;o &agrave; escolaridade, 10,3% eram analfabetos, 56,4% tinham ensino fu
ndamental, 25,5% ensino m&eacute;dio e 7,8% ensino superior. </font></p>     ^cY
#v33n1a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#59#55#article#157#<p><a name="tab1"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#60#56#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#61#57#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05tab01.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#62#58#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00714000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048000075002001300555#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#63#59#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com respeito &agrave; renda, 36,9% do
s pacientes recebiam at&eacute; dois sal&aacute;rios m&iacute;nimos, 41,7% de do
is  a  cinco sal&aacute;rios, 17% de  cinco  a  dez sal&aacute;rios, 3,8% de  de
z  a 20 sal&aacute;rios e 0,7% possu&iacute;a renda maior do que 20 sal&aacute;r
ios m&iacute;nimos. A maioria dos participantes do estudo (58,2%) residia at&eac
ute; 25 km do centro de di&aacute;lise. </font></p>     ^cY#v33n1a05.htm##
00653000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041900075002001300494#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#64#60#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na <a href="#tab2">Tabela 2</a> s&ati
lde;o apresentadas as caracter&iacute;sticas cl&iacute;nicas da amostra. Com rel
a&ccedil;&atilde;o &agrave; etiologia da doen&ccedil;a, 36,9% apresentavam nefro
patia diab&eacute;tica, 22,7% nefroesclerose hipertensiva, 11% glomerulonefrite 
cr&ocirc;nica, 14% etiologia indeterminada e 15,4% outras. </font></p>     ^cY#v
33n1a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#65#61#article#157#<p><a name="tab2"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#66#62#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#67#63#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05tab02.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#68#64#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00398000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016400075002001300239#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#69#65#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Entre os pacientes avaliados, 55,7% t
iveram acompanhamento pr&eacute;-dialitico. </font></p>     ^cY#v33n1a05.htm##
00686000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045200075002001300527#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#70#66#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o &agrave;s c
omorbidades, 90,3% apresentavam hipertens&atilde;o arterial sist&ecirc;mica, 44%
 HVE (hipertrofia do ventr&iacute;culo esquerdo), 40% eram diab&eacute;ticos, 25
,6% doen&ccedil;a vascular perif&eacute;rica, 25% insufici&ecirc;ncia card&iacut
e;aca, 2,6% neoplasias e 2,4% colagenose. Apenas 2,2% n&atilde;o apresentavam co
morbidades. </font></p>     ^cY#v33n1a05.htm##
00649000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041500075002001300490#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#71#67#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados gerais de qualidade de vida 
avaliados pelo &iacute;ndice de Karnofsky s&atilde;o apresentados em percentis n
a <a href="#fig2">Figura 2</a>. A maior parte dos pacientes possu&iacute;a altos
 escores de QdV: 75% apresentaram escores de qualidade maiores que 90, e 50% apr
esentaram escores maiores que 80 e 25% maiores que 70. </font></p>     ^cY#v33n1
a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#72#68#article#157#<p><a name="fig2"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#73#69#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#74#70#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05fig02.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#75#71#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00616000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038200075002001300457#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#76#72#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o de QdV pelo
 SF-36 evidenciou baixos escores de qualidade de vida em todos os dom&iacute;nio
s, sendo  "aspectos f&iacute;sicos" e  "sa&uacute;de mental" os mais prejudicado
s. O dom&iacute;nio que apresentou melhor escore foi "aspecto social" (<a href="
#fig3">Figura 3</a>). </font></p>     ^cY#v33n1a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#77#73#article#157#<p><a name="fig3"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#78#74#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#79#75#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05fig03.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#80#76#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00621000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038700075002001300462#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#81#77#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Comparando-se os subgrupos, observa-s
e que os pacientes idosos e diab&eacute;ticos apresentam escores inferiores aos 
dos n&atilde;o idosos e n&atilde;o diab&eacute;ticos pelo &iacute;ndice de Karno
sfsky (<a href="#tab3">Tabela 3</a>) e pelo SF-36 (<a href="#tab4">Tabelas 4</a>
 e <a href="#tab5">5</a>). </font></p>     ^cY#v33n1a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#82#78#article#157#<p><a name="tab3"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#83#79#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#84#80#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05tab03.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#85#81#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#86#82#article#157#<p><a name="tab4"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#87#83#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#88#84#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05tab04.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#89#85#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#90#86#article#157#<p><a name="tab5"></
a></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#91#87#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#92#88#article#157#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a05tab05.jpg"></p>     ^cY#v33n1a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#93#89#article#157#<p>&nbsp;</p>     ^c
Y#v33n1a05.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#94#90#article#157#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v33n1a05.htm##
00788000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055400075002001300629#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#95#91#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pacientes com DRC apresentam consi
der&aacute;vel diminui&ccedil;&atilde;o da QdV quando comparados &agrave; popula
&ccedil;&atilde;o geral havendo uma associa&ccedil;&atilde;o entre a fun&ccedil;
&atilde;o renal e os escores das escalas que avaliam bem-estar e QdV. <sup>12</s
up> Um dos fatores que poderia contribuir de modo efetivo para melhorar a QdV do
s pacientes com DRC seria uma poss&iacute;vel redu&ccedil;&atilde;o do n&uacute;
mero de comorbidades. <sup>2</sup></font></p>     ^cY#v33n1a05.htm##
00577000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034300075002001300418#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#96#92#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No presente estudo, nos interessou ob
servar o perfil da QdV dos pacientes em di&aacute;lise peritoneal  em que preval
ecem os pacientes idosos e diab&eacute;ticos. Geralmente, eles apresentam maiore
s comprometimentos f&iacute;sicos, ps&iacute;quicos e sociais. </font></p>     ^
cY#v33n1a05.htm##
02200000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704196600075002001302041#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#97#93#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na avalia&ccedil;&atilde;o geral de Q
dV, foi observada diferen&ccedil;a entre os &iacute;ndices de qualidade de vida 
avaliados pelos dois instrumentos. Pelo &iacute;ndice de Karnofsky, no qual a av
alia&ccedil;&atilde;o &eacute; feita por  profissional de sa&uacute;de, os pacie
ntes mostraram ter QdV satisfat&oacute;ria. Por outro lado, pela autoavalia&cced
il;&atilde;o dos pacientes (SF-36), os escores de QdV mostraram-se reduzidos, es
pecialmente os dom&iacute;nios "aspectos f&iacute;sicos" e "aspectos emocionais"
. Esses dados apontam para a possibilidade da vis&atilde;o das equipes a respeit
o dos seus pacientes ser diferente da percep&ccedil;&atilde;o que estes t&ecirc;
m sobre seu pr&oacute;prio estado de sa&uacute;de. No entanto, nas avalia&ccedil
;&otilde;es dos subgrupos de idosos e diab&eacute;ticos n&atilde;o foi observada
 diferen&ccedil;a entre os resultados obtidos pelos dois  instrumentos. Manteve-
se a pior performance entre idosos e diab&eacute;ticos, por&eacute;m com o vi&ea
cute;s do &iacute;ndice de Karnofsky apresentando melhores escores. Esses result
ados nos levam a destacar a import&acirc;ncia de se ouvir o paciente a respeito 
de seu processo de tratamento, suas limita&ccedil;&otilde;es e possibilidades. O
utro ponto a ser destacado &eacute; o fato do &iacute;ndice de Karnofsky, embora
 possa ser considerado um instrumento de qualidade de vida,<sup>13</sup> seja ap
enas uma avalia&ccedil;&atilde;o da performance f&iacute;sica. O conceito de qua
lidade de vida envolve n&atilde;o somente o bem-estar f&iacute;sico, mas tamb&ea
cute;m o social, ps&iacute;quico e espiritual. <sup>14 </sup>Esta &eacute; uma d
as limita&ccedil;&otilde;es do presente estudo pois foi utilizado como par&acirc
;metro de qualidade de vida um instrumento que avalia apenas o desempenho f&iacu
te;sico, n&atilde;o levando em conta os demais par&acirc;metros avaliados pelo S
F-36. </font></p>     ^cY#v33n1a05.htm##
00908000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067400075002001300749#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#98#94#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O conceito de QdV &eacute; definido c
omo a percep&ccedil;&atilde;o de um  indiv&iacute;duo sobre sua posi&ccedil;&ati
lde;o na vida no contexto cultural  e sistema de valores nos quais  vive e em re
la&ccedil;&atilde;o aos seus objetivos, expectativas, padr&otilde;es e preocupa&
ccedil;&otilde;es. Este conceito envolve  aspectos como subjetividade, multidime
nsionalidade, presen&ccedil;a de dimens&otilde;es positivas e negativas. <sup>14
</sup> Seria, desta forma, um conceito multifatorial e subjetivo e, portanto, &e
acute; importante que seja avaliado pelo pr&oacute;prio indiv&iacute;duo. </font
></p>     ^cY#v33n1a05.htm##
01115000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704088100075002001300956#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#99#95#article#157#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Atrav&eacute;s da avalia&ccedil;&atil
de;o pelo SF-36, os dom&iacute;nios "aspectos f&iacute;sicos" e "sa&uacute;de me
ntal" foram os mais prejudicados. As avalia&ccedil;&otilde;es num&eacute;ricas p
odem, muitas vezes, mensurar aspectos subjetivos tais como o impacto que a doen&
ccedil;a e o tratamento podem acarretar. Tais mensura&ccedil;&otilde;es nos perm
itiram perceber o efeito que o tratamento dial&iacute;tico pode ter no psiquismo
 e nas condi&ccedil;&otilde;es f&iacute;sicas de pacientes com DRC. A cronicidad
e da doen&ccedil;a associada &agrave;s comorbidades e &agrave; idade avan&ccedil
;ada s&atilde;o fatores que podem impactar de forma significativa na redu&ccedil
;&atilde;o das atividades  di&aacute;rias, nas rela&ccedil;&otilde;es sociais e 
na sa&uacute;de mental desses pacientes. </font></p>     ^cY#v33n1a05.htm##
01678000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704144300076002001301519#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#100#96#article#157#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As avalia&ccedil;&otilde;es de QdV n
o grupo de idosos mostraram que estes apresentavam QdV reduzida quando comparado
s aos n&atilde;o idosos. Esses dados s&atilde;o semelhantes aos encontrados na l
iteratura, pois a idade &eacute; um fator que pode ter um impacto negativo nos &
iacute;ndices de Qdv. Kusztal <i>et al</i>. <sup>15 </sup>avaliaram pacientes re
nais cr&ocirc;nicos e observaram que o impacto do envelhecimento foi mais eviden
te nas escalas f&iacute;sicas do SF-36. Resultados semelhantes foram encontrados
 em um estudo que avaliou pacientes em hemodi&aacute;lise revelando uma correla&
ccedil;&atilde;o negativa entre a idade e as dimens&otilde;es de Qdv como capaci
dade funcional, limita&ccedil;&atilde;o por aspectos f&iacute;sicos, dor, estado
 geral de sa&uacute;de, vitalidade e aspectos sociais. <sup>16 </sup>Castro <i>e
t al</i>. <sup>17 </sup>tamb&eacute;m observaram uma correla&ccedil;&atilde;o ne
gativa entre idade e os &iacute;ndices de capacidade funcional, aspectos f&iacut
e;sicos, dor e vitalidade do SF-36 de pacientes em hemodi&aacute;lise. Os autore
s destacam que a presen&ccedil;a de doen&ccedil;a cr&ocirc;nica, a necessidade d
e tratamento cont&iacute;nuo por um longo per&iacute;odo, idade avan&ccedil;ada,
 assim como a presen&ccedil;a de comorbidades s&atilde;o fatores que podem inter
ferir na Qdv dessa popula&ccedil;&atilde;o. </font></p>     ^cY#v33n1a05.htm##
01311000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704107600076002001301152#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#101#97#article#157#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em nosso estudo, pacientes diab&eacu
te;ticos tamb&eacute;m apresentaram QdV inferior aos n&atilde;o diab&eacute;tico
s. Atrav&eacute;s da avalia&ccedil;&atilde;o pelo SF-36, o dom&iacute;nio "aspec
tos f&iacute;sicos" entre os diab&eacute;ticos e idosos foi o mais prejudicado. 
Semelhante a esses resultados, Mingardi <i>et al</i>. <sup>18 </sup>observaram q
ue, entre os pacientes em di&aacute;lise analisados pelo SF-36, os diab&eacute;t
icos tamb&eacute;m apresentaram escores significativamente inferiores nos aspect
os f&iacute;sicos. E o impacto do envelhecimento foi mais evidente nas escalas f
&iacute;sicas. Em estudo realizado por Barbosa <i>et al</i>. <sup> 19</sup> em p
acientes em hemodi&aacute;lise, os autores observaram que a presen&ccedil;a de c
omorbidades como diabetes e doen&ccedil;a vascular perif&eacute;rica, al&eacute;
m da idade mais avan&ccedil;ada, estiveram significativamente associadas a menor
es pontua&ccedil;&otilde;es em pelo menos uma das dimens&otilde;es do SF-36. </f
ont></p>     ^cY#v33n1a05.htm##
00554000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704031900076002001300395#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#102#98#article#157#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Os resultados obtidos no presente es
tudo ressaltam a influ&ecirc;ncia de fatores como idade avan&ccedil;ada e a pres
en&ccedil;a de diabetes na redu&ccedil;&atilde;o dos par&acirc;metros de QdV de 
pacientes em di&aacute;lise peritoneal. </font></p>     ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#103#99#article#157#<p>&nbsp;</p>     ^
cY#v33n1a05.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#104#100#article#157#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O </b></font></p>
     ^cY#v33n1a05.htm##
00595000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704035900077002001300436#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#105#101#article#157#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Neste estudo de coorte prospectivo 
multic&ecirc;ntrico, utilizando-se os dados do BRAZPD, h&aacute; predomin&acirc;
ncia de  pacientes idosos e diab&eacute;ticos, sugerindo um vi&eacute;s de sele&
ccedil;&atilde;o negativa para a di&aacute;lise peritoneal em nosso pa&iacute;s.
 </font></p>     ^cY#v33n1a05.htm##
00953000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704071700077002001300794#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#106#102#article#157#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Na autoavalia&ccedil;&atilde;o pelo
 SF-36, os pacientes apresentaram baixa qualidade de vida, sendo o dom&iacute;ni
o "aspectos f&iacute;sicos" o mais afetado. Os grupos que apresentaram pior qual
idade de vida foram os grupos de pacientes diab&eacute;ticos e idosos, o que ref
or&ccedil;a a import&acirc;ncia de se dar aten&ccedil;&atilde;o especial a esses
 grupos. O Karnofsky n&atilde;o apresentou boa compatibilidade com os resultados
 do SF-36 na an&aacute;lise geral da qualidade de vida. Esses dados revelam a im
port&acirc;ncia de se valorizar a percep&ccedil;&atilde;o do pr&oacute;prio paci
ente sobre seu estado de sa&uacute;de. </font></p>     ^cY#v33n1a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#107#103#article#157#<p>&nbsp;</p>     
^cY#v33n1a05.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#108#104#article#157#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>
     ^cY#v33n1a05.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704026000079002001300339#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#109#105#article#157#1#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Wasserfallen JB, H
alabi G, Saudan P <i>et al</i>. Quality of life on chronic dialysis: comparison 
between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004; 19:
1594-99.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#110#106#article#157# </font></p>     ^
cY#v33n1a05.htm##
00525000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704027500079002001300354#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#111#107#article#157#2#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Zhang AH, Cheng LT
, Zhu N <i>et al</i>. Comparison of quality of life and causes of hospitalizatio
n between hemodialysis and peritoneal dialysis patients in China. Health Qual Li
fe Outcomes 2007; 5:49.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#112#108#article#157# </font></p>     ^
cY#v33n1a05.htm##
00529000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704027900079002001300358#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#113#109#article#157#3#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Martinez-Casteano 
A, Gorriz JL, Garcia-Lopez F <i>et al</i>. Perceived health-related quality of l
ife and comorbidity in diabetic patients starting dialysis (CALVIDIA study). J N
ephrol 2004; 17 (4):544-51.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#114#110#article#157# </font></p>     ^
cY#v33n1a05.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704025000079002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#115#111#article#157#4#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Vasquez I, Valderr
abano F, Jofr&eacute; R <i>et al</i>. Psychosocial factors and quality of life i
n young hemodialysis patients with low comorbidity. J Nephrol 2003; 16:886-94.  
  ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#116#112#article#157# </font></p>     ^
cY#v33n1a05.htm##
00506000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704025600079002001300335#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#117#113#article#157#5#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Chow FYF, Briganti
 EM, Kerr PG <i>et al</i>. Health-related quality of life in Australian adults w
ith renal insufficiency: a population-based study. Am J Kidney Dis 2003; 41:596-
604.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#118#114#article#157# </font></p>     ^
cY#v33n1a05.htm##
00506000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704025600079002001300335#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#119#115#article#157#6#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Lopes AA, Bragg-Gr
esham JL, Goodkin DA <i>et al</i>. Factors associated with health-related qualit
y of life among hemodialysis patients in the DOPPS. Qual Life Res 2007; 16(4):54
5-7.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#120#116#article#157# </font></p>     ^
cY#v33n1a05.htm##
00528000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704027800079002001300357#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#121#117#article#157#7#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Karnofsky DA, Burc
henal JH. The clinical evaluation of chemotherapyc agents in cancer. <i>In</i>: 
Evaluation of Chemoterapic Agents. Edited by Mc Leod CM. New York: Columbia Univ
ersity Press 1949,191-205.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#122#118#article#157# </font></p>     ^
cY#v33n1a05.htm##
00689000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704043900079002001300518#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#123#119#article#157#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Cicconelli, R. M. 
Tradu&ccedil;&atilde;o para o portugu&ecirc;s e valida&ccedil;&atilde;o do quest
ion&aacute;rio gen&eacute;rico de avalia&ccedil;&atilde;o de qualidade de vida "
Medical Outcomes Study 36-item-short-form health survey (SF-36)". &#91;Tese de D
outorado&#93; S&atilde;o Paulo: Escola Paulista de Medicina, Universidade Federa
l de S&atilde;o Paulo 1997.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#124#120#article#157# </font></p>     ^
cY#v33n1a05.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704024500079002001300324#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#125#121#article#157#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Instituto Brasilei
ro de Geografia e Estat&iacute;stica. <i>In</i>: <a href="http://www.ibge.gov.br
" target="_blank">http://www.ibge.gov.br</a>. Acessado em: abril de 2007.    ^cY
#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#126#122#article#157# </font></p>     ^
cY#v33n1a05.htm##
00587000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033600080002001300416#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#127#123#article#157#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Fernandes N, Bas
tos MG, Cassi HV <i>et al</i>. On behalf of the Brazilian Peritoneal Dialysis Mu
lticentric Study (BRAZPD) Group. The Brazilian Peritoneal Dialysis Multicentric 
Study (BRAZPD): Characterization of the Cohort. Kidney International 2008; 73:14
5-51.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#128#124#article#157# </font></p>     ^
cY#v33n1a05.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028200080002001300362#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#129#125#article#157#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Davies Sj, Phill
ips L, Naish Pf, Russel GI. Quantifying comorbidity in peritoneal dialysis patie
nts and its relationship to other predictors of survival. Nephrology Dialysis Tr
ansplantation 2002; 17:1085-92.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#130#126#article#157# </font></p>     ^
cY#v33n1a05.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023900080002001300319#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#131#127#article#157#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Gorodetskaya I, 
Zenios F, Mcculloch CF <i>et al</i>. Health-related quality of life and estimate
s of utility in chronic kidney disease. Kidney Int 2005; 68:2801-08.    ^cY#v33n
1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#132#128#article#157# </font></p>     ^
cY#v33n1a05.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026200080002001300342#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#133#129#article#157#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Danquah NFV, Was
serman J, Meininger J, Bergstrom N. Quality of Life Measures for Patients On Hem
odialysis: A Review of Psychometric Properties. Nephrology Nursing Journal 2010;
 37:255-69.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#134#130#article#157# </font></p>     ^
cY#v33n1a05.htm##
00545000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029400080002001300374#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#135#131#article#157#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Fleck MPA, Louza
da S, Xavier M <i>et al</i>. Aplica&ccedil;&atilde;o da vers&atilde;o em portugu
&ecirc;s do instrumento abreviado de qualidade de vida - WHOQOL-bref 2000. Rev S
a&uacute;de P&uacute;blica 2000; 34:178-83.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#136#132#article#157# </font></p>     ^
cY#v33n1a05.htm##
00532000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028100080002001300361#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#137#133#article#157#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Kusztal M, Nowak
 K, Magott-Procelewska M, Weyde W, Penar J. Evaluation of health-related quality
 of life in dialysis patients. Personal experience using questionary SF-36. Pol 
Merkuriusz Lek 2003; 14:113-7.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#138#134#article#157# </font></p>     ^
cY#v33n1a05.htm##
00530000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027900080002001300359#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#139#135#article#157#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Santos PR. Rela&
ccedil;&atilde;o do sexo e da idade com n&iacute;vel de qualidade de vida em ren
ais cr&ocirc;nicos hemodialisados. Revista Associa&ccedil;&atilde;o M&eacute;dic
a Brasileira 2006; 52:356-9.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#140#136#article#157# </font></p>     ^
cY#v33n1a05.htm##
00605000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704035400080002001300434#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#141#137#article#157#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Castro M, Caiuby
 AVS, Draibe AS, Canziani MEF. Qualidade de vida de pacientes com insufici&ecirc
;ncia renal cr&ocirc;nica em hemodi&aacute;lise avaliada atrav&eacute;s do instr
umento gen&eacute;rico SF-36. Revista Associa&ccedil;&atilde;o M&eacute;dica Bra
sileira 2003; 49:245-9.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#142#138#article#157# </font></p>     ^
cY#v33n1a05.htm##
00544000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029300080002001300373#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#143#139#article#157#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Miningardi G, Co
rnalba L, Cortinovis E, Mosconi P, Apolone G. Health-related quality of life in 
dialysis patients. A report from an Italian study using the SF-36 Health Survey.
 Nephrol Dial Transplant 1999; 14:1503-10.    ^cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#144#140#article#157# </font></p>     ^
cY#v33n1a05.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024600080002001300326#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#145#141#article#157#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Barbosa LMM, Jun
ior MPA, Bastos KA. Preditores de qualidade de vida em pacientes com doen&ccedil
;a renal cr&ocirc;nica em hemodi&aacute;lise. J Bras Nefrol 2007; 2: 222-8.    ^
cY#v33n1a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#146#142#article#157# </font></p>     ^
cY#v33n1a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#147#143#article#157#<p>&nbsp;</p>     
^cY#v33n1a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#148#144#article#157#<p>&nbsp;</p>     
^cY#v33n1a05.htm##
00437000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020100077002001300278#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#149#145#article#157#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b>  Correspond&ecirc
;ncia para:</b>    ^cY#v33n1a05.htm##
00286000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005000077002001300127#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#150#146#article#157#<br>   Fabiane Ros
si dos Santos Grincenkov    ^cY#v33n1a05.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004400077002001300121#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#151#147#article#157#<br>   Funda&ccedi
l;&atilde;o IMEPEN    ^cY#v33n1a05.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006800077002001300145#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#152#148#article#157#<br>   Rua Jos&eac
ute; Louren&ccedil;o Kelmer, 1.300/208-222    ^cY#v33n1a05.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#153#149#article#157#<br>   S&atilde;o 
Pedro Juiz de Fora - MG - Brasil    ^cY#v33n1a05.htm##
00264000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002800077002001300105#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#154#150#article#157#<br>   CEP: 360363
30    ^cY#v33n1a05.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009800077002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#155#151#article#157#<br>   E-mail:  <a
 href="mailto:fabpsic@yahoo.com.br">fabpsic@yahoo.com.br</a></font></p>     ^cY#
v33n1a05.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#156#152#article#157#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 17/09/201
0    ^cY#v33n1a05.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#157#153#article#157#<br>   Data de apr
ova&ccedil;&atilde;o: 03/11/2010    ^cY#v33n1a05.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#158#154#article#157#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#159#155#article#157#<p>&nbsp;</p>     
^cY#v33n1a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#160#156#article#157#<p>&nbsp;</p>     
^cY#v33n1a05.htm##
00429000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704019300077002001300270#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a05.htm#S#p#161#157#article#157#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado no 
N&uacute;cleo Interdisciplinar de Estudos e Pesquisas em Nefrologia; UFJF. </fon
t></p>     ^cY#v33n1a05.htm##
00642000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100023000760100016000990100
01600115810000600131012009800137030002400235065000900259064000500268031000300273
014000800276865000900284002001300293035001000306801002400316#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a05.htm#S#c#162#1#article#19#1#^rND^sWasserfallen^nJB#
^rND^sHalabi^nG#^rND^sSaudan^nP#et al#Quality of life on chronic dialysis: compa
rison between haemodialysis and peritoneal dialysis^len#Nephrol Dial Transplant#
20040000#2004#19#1594-99#20110300#v33n1a05.htm#0931-0509#Nephrol Dial Transplant
##
00613000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100016000920100
01300108810000600121012012700127030002600254710000200280065000900282064000500291
031000200296014000300298865000900301002001300310#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a05.htm#S#c#163#2#article#19#2#^rND^sZhang^nAH#^rND^sCheng^nLT#^rN
D^sZhu^nN#et al#Comparison of quality of life and causes of hospitalization betw
een hemodialysis and peritoneal dialysis patients in China^len#Health Qual Life 
Outcomes#2#20070000#2007#5#49#20110300#v33n1a05.htm##
00657000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100027000760100017001030100
02200120810000600142012011700148030001000265065000900275064000500284031000300289
032000200292014000700294865000900301002001300310035001000323801001000333#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#c#164#3#article#19#3#^rND^sMarti
nez-Casteano^nA#^rND^sGorriz^nJL#^rND^sGarcia-Lopez^nF#et al#Perceived health-re
lated quality of life and comorbidity in diabetic patients starting dialysis (CA
LVIDIA study)^len#J Nephrol#20040000#2004#17#4#544-51#20110300#v33n1a05.htm#1120
-3625#J Nephrol##
00611000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100022000930100
01500115810000600130012009700136030001000233065000900243064000500252031000300257
014000700260865000900267002001300276035001000289801001000299#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a05.htm#S#c#165#4#article#19#4#^rND^sVasquez^nI#^rND^s
Valderrabano^nF#^rND^sJofré^nR#et al#Psychosocial factors and quality of life in
 young hemodialysis patients with low comorbidity^len#J Nephrol#20030000#2003#16
#886-94#20110300#v33n1a05.htm#1120-3625#J Nephrol##
00630000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100019000920100
01500111810000600126012010700132030001600239065000900255064000500264031000300269
014000800272865000900280002001300289035001000302801001600312#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a05.htm#S#c#166#5#article#19#5#^rND^sChow^nFYF#^rND^sB
riganti^nEM#^rND^sKerr^nPG#et al#Health-related quality of life in Australian ad
ults with renal insufficiency: a population-based study^len#Am J Kidney Dis#2003
0000#2003#41#596-604#20110300#v33n1a05.htm#0272-6386#Am J Kidney Dis##
00639000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100024000920100
01800116810000600134012010000140030001400240065000900254064000500263031000300268
032000200271014000600273865000900279002001300288035001000301801001400311#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#c#167#6#article#19#6#^rND^sLopes
^nAA#^rND^sBragg-Gresham^nJL#^rND^sGoodkin^nDA#et al#Factors associated with hea
lth-related quality of life among hemodialysis patients in the DOPPS^len#Qual Li
fe Res#20070000#2007#16#4#545-7#20110300#v33n1a05.htm#0962-9343#Qual Life Res##
00561000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100020000960120
06200116018003800178066000900216062002600225065000900251064000500260014000800265
865000900273002001300282#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#
c#168#7#article#19#7#^rND^sKarnofsky^nDA#^rND^sBurchenal^nJH#The clinical evalua
tion of chemotherapyc agents in cancer^len#Evaluation of Chemoterapic Agents^len
#New York#Columbia University Press#19490000#1949#191-205#20110300#v33n1a05.htm#
#
00561000000000241000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740160023000760180101000990510
01000200046001000210050006300220045000900283044000500292865000900297002001300306
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#c#169#8#article#19#8#^rN
D^sCicconelli^nR. M#Tradução para o português e validação do questionário genéri
co de avaliação de qualidade de vida^lpt#Doutorado#São Paulo#Universidade Federa
l de São Paulo^dEscola Paulista de Medicina#19970000#1997#20110300#v33n1a05.htm#
#
00398000000000205000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740170048000760370023001241100
00900147109001400156865000900170002001300179#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a05.htm#S#c#170#9#article#19#9#Instituto Brasileiro de Geografia e Est
atística#http://www.ibge.gov.br#20070400#abril de 2007#20110300#v33n1a05.htm##
00716000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970100
01600114810000600130012018000136030002100316065000900337064000500346031000300351
014000700354865000900361002001300370035001000383801002100393#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a05.htm#S#c#171#10#article#19#10#^rND^sFernandes^nN#^r
ND^sBastos^nMG#^rND^sCassi^nHV#et al#On behalf of the Brazilian Peritoneal Dialy
sis Multicentric Study (BRAZPD) Group: The Brazilian Peritoneal Dialysis Multice
ntric Study (BRAZPD): Characterization of the Cohort^len#Kidney International#20
080000#2008#73#145-51#20110300#v33n1a05.htm#0085-2538#Kidney International##
00688000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01500112010001700127012011300144030003600257065000900293064000500302031000300307
014000800310865000900318002001300327035001000340801003600350#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a05.htm#S#c#172#11#article#19#11#^rND^sDavies Sj#^rND^
sPhillips^nL#^rND^sNaish Pf#^rND^sRussel^nGI#Quantifying comorbidity in peritone
al dialysis patients and its relationship to other predictors of survival^len#Ne
phrology Dialysis Transplantation#20020000#2002#17#1085-92#20110300#v33n1a05.htm
#0931-0509#Nephrology Dialysis Transplantation##
00609000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100016001000100
02000116810000600136012008600142030001100228065000900239064000500248031000300253
014000800256865000900264002001300273035001000286801001100296#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a05.htm#S#c#173#12#article#19#12#^rND^sGorodetskaya^nI
#^rND^sZenios^nF#^rND^sMcculloch^nCF#et al#Health-related quality of life and es
timates of utility in chronic kidney disease^len#Kidney Int#20050000#2005#68#280
1-08#20110300#v33n1a05.htm#0085-2538#Kidney int##
00614000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100019000970100
01900116010001900135012009500154030002700249710000200276065000900278064000500287
031000300292014000700295865000900302002001300311#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a05.htm#S#c#174#13#article#19#13#^rND^sDanquah^nNFV#^rND^sWasserma
n^nJ#^rND^sMeininger^nJ#^rND^sBergstrom^nN#Quality of Life Measures for Patients
 On Hemodialysis: A Review of Psychometric Properties^len#Nephrology Nursing Jou
rnal#2#20100000#2010#37#255-69#20110300#v33n1a05.htm##
00592000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01600112810000600128012010200134030001800236710000200254065000900256064000500265
031000300270014000700273865000900280002001300289#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a05.htm#S#c#175#14#article#19#14#^rND^sFleck^nMPA#^rND^sLouzada^nS
#^rND^sXavier^nM#et al#Aplicação da versão em português do instrumento abreviado
 de qualidade de vida - WHOQOL-bref 2000^lpt#Rev Saúde Pública#2#20000000#2000#3
4#178-83#20110300#v33n1a05.htm##
00690000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
02800110010001500138010001500153012011500168030001900283065000900302064000500311
031000300316014000600319865000900325002001300334035001000347801001900357#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#c#176#15#article#19#15#^rND^sKus
ztal^nM#^rND^sNowak^nK#^rND^sMagott-Procelewska^nM#^rND^sWeyde^nW#^rND^sPenar^nJ
#Evaluation of health-related quality of life in dialysis patients: Personal exp
erience using questionary SF-36^len#Pol Merkuriusz Lek#20030000#2003#14#113-7#20
110300#v33n1a05.htm#1426-9686#Pol Merkuriusz Lek##
00529000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780120096000950300
03700191710000200228065000900230064000500239031000300244014000600247865000900253
002001300262#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#c#177#16#art
icle#19#16#^rND^sSantos^nPR#Relação do sexo e da idade com nível de qualidade de
 vida em renais crônicos hemodialisados^lpt#Revista Associação Médica Brasileira
#2#20060000#2006#52#356-9#20110300#v33n1a05.htm##
00652000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01700112010002000129012012900149030003700278710000200315065000900317064000500326
031000300331014000600334865000900340002001300349#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a05.htm#S#c#178#17#article#19#17#^rND^sCastro^nM#^rND^sCaiuby^nAVS
#^rND^sDraibe^nAS#^rND^sCanziani^nMEF#Qualidade de vida de pacientes com insufic
iência renal crônica em hemodiálise avaliada através do instrumento genérico SF-
36^lpt#Revista Associação Médica Brasileira#2#20030000#2003#49#245-9#20110300#v3
3n1a05.htm##
00707000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100018000980100
02000116010001700136010001700153012011800170030002400288065000900312064000500321
031000300326014000800329865000900337002001300346035001000359801002400369#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a05.htm#S#c#179#18#article#19#18#^rND^sMin
ingardi^nG#^rND^sCornalba^nL#^rND^sCortinovis^nE#^rND^sMosconi^nP#^rND^sApolone^
nG#Health-related quality of life in dialysis patients: A report from an Italian
 study using the SF-36 Health Survey^len#Nephrol Dial Transplant#19990000#1999#1
4#1503-10#20110300#v33n1a05.htm#0931-0509#Nephrol Dial Transplant##
00593000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100018000970100
01700115012008900132030001400221065000900235064000500244031000200249014000600251
865000900257002001300266035001000279801001400289#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a05.htm#S#c#180#19#article#19#19#^rND^sBarbosa^nLMM#^rND^sJunior^n
MPA#^rND^sBastos^nKA#Preditores de qualidade de vida em pacientes com doença ren
al crônica em hemodiálise^lpt#J Bras Nefrol#20070000#2007#2#222-8#20110300#v33n1
a05.htm#0101-2800#J Bras Nefrol##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#o#1#1#article#1#
20110411#092916#v33n1a06.htm#126##
04818000000000625000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201020
01610120090002630100031003530100040003840100046004240100036004700100040005060700
08200546083166700628085001002295085004002305085002302345085002302368083163802391
08500100402908500240403908500250406308500350408805800050412311700080412807200030
4136112000904139111001104148114000904159113001104168002001304179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#T
AB#06#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f45^l49#0101-2800#Baixa resposta
 da vacinação intradérmica contra hepatite B em pacientes incidentes em hemodiál
ise^lpt#Low response to intradermal hepatitis B vaccination in incident hemodial
ysis patients^len#^rND^1A01^nRegina H.^sMedeiros#^rND^1A01^nAna Elizabeth PL^sFi
gueiredo#^rND^1A01^nCarlos Eduardo^sPoli-de-Figueiredo#^rND^1A01^nDomingos Otávi
o^sd'Avila#^rND^1A01^nCarlos Abaeté^sde los Santos#Pontifícia Universidade Catól
ica do Rio Grande do Sul^iA01^1Faculdade de Medicina#^lpt^aINTRODUÇÃO: A hepatit
e B pode evoluir para cirrose e hepatocarcinoma. Sua prevalência estimada é de 3
,2% em pacientes em hemodiálise (HD). A vacina para hepatite B (HB), quando apli
cada por via intramuscular (IM) em pacientes com insuficiência renal crônica fas
e V, frequentemente não induz produção adequada de anticorpos. A injeção intradé
rmica (ID) foi sugerida como sendo o método de inoculação mais eficiente. OBJETI
VO: Comparar a resposta imune à injeção IM ou ID da vacina em indivíduos em HD. 
PACIENTES E MÉTODOS: Trinta e um pacientes incidentes em HD foram randomizados a
lternativamente para vacinação contra HB via IM ou ID. Dezesseis foram designado
s aleatoriamente para receber vacina IM (40 mg/dose) e 15 ID (4mg /dose). Os nív
eis de anticorpos de superfície do vírus da hepatite B, parâmetros hematimétrico
s, ureia sérica, e Kt/V foram avaliados mensalmente. Proteína-C reativa, parator
mônio, ferritina, aminotransferases e albumina foram avaliados antes da inoculaç
ão inicial e seis meses após a mesma. RESULTADOS: Os níveis de uréia foram maior
es no grupo ID (P(1) = 0,031); os níveis de ferritina foram mais elevados no IM 
(P(2) = 0,037). Houve tendência a aumento nos níveis de proteína C reativa no gr
upo ID. A avaliação do Comitê de Monitoramento de Segurança dos indivíduos expos
tos recomendou a suspensão do estudo já que a inoculação por via IM converteu 62
,5% e a ID converteu apenas 13,3% dos pacientes expostos. CONCLUSÃO: Com a metod
ologia utilizada, os resultados da vacina contra HB aplicada por via ID foi infe
rior à inoculação IM. Tais resultados podem ser decorrentes das doses inoculadas
 ou de outros fatores, como inflamação.#^ddecs^i1#^tm^lpt^kinsuficiência renal c
rônica^i1#^tm^lpt^khepatite B^i1#^tm^lpt^kimunização^i1#^len^aINTRODUCTION: Hepa
titis B (HB) may progress to cirrhosis and liver carcinoma. Its prevalence is es
timated at 3.2 % in hemodialysis (HD) patients. HB vaccine when applied intramus
cularly (IM) in end-stage renal disease patients often does not induce appropria
te antibody titers. However, there has been suggestion for intradermal (ID) to b
e a more effective inoculation method. OBJECTIVE: To compare the immune response
 to IM or ID vaccine administration on HD patients. PATIENTS AND METHODS: Thirty
 one incident HD patients were randomly assigned alternately to IM or ID vaccine
 inoculation. Vaccine doses were applied at three monthly intervals, with patien
ts being followed-up for six months. Sixteen patients were assigned to IM (40 mg
/dose) and 15 to ID (4 mg/dose) vaccine administration. HB-virus surface antibod
y titer, hematimetric parameters, serum urea level and Kt/V were monthly evaluat
ed. C-reactive protein, parathormone, ferritin, aminotransferases and albumin se
rum levels were evaluated before and at the sixth month of the initial inoculati
on. RESULTS: Urea levels were significantly higher in the ID group (P(1) = 0.031
); ferritin levels were higher in the IM (P(2) = 0.037) and C-reactive protein l
evels tended to be higher in the ID group. An interim evaluation by the Safety M
onitoring Committee recommended discontinuing the study as IM vaccination had co
nverted 62.5% of the exposed subjects, while ID inoculation converted only 13.3%
. CONCLUSION: As performed, ID applied vaccine was inferior to the IM inoculatio
n. Such result may depend on the inoculated doses or some other factor, such as 
inflammation.#^ddecs^i2#^tm^len^khepatitis B^i2#^tm^len^kimmunization^i2#^tm^len
^kchronic kidney failure^i2#CNPq#vancouv#20#20100515#15/05/2010#20100711#11/07/2
010#v33n1a06.htm##
04902000000000625000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201090
01610120097002700100031003670100040003980100046004380100036004840100040005200700
08200560083170200642085001002344085004002354085002302394085002302417083167302440
08500100411308500240412308500250414708500350417205800050420711700080421207200030
4220112000904223111001104232114000904243113001104252002001304263#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#T
AB#06#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f45^l49#0101-2800#<b>Baixa respo
sta da vacinação intradérmica contra hepatite B em pacientes incidentes em hemod
iálise</b>^lpt#<b>Low response to intradermal hepatitis B vaccination in inciden
t hemodialysis patients</b>^len#^rND^1A01^nRegina H.^sMedeiros#^rND^1A01^nAna El
izabeth PL^sFigueiredo#^rND^1A01^nCarlos Eduardo^sPoli-de-Figueiredo#^rND^1A01^n
Domingos Otávio^sd'Avila#^rND^1A01^nCarlos Abaeté^sde los Santos#Pontifícia Univ
ersidade Católica do Rio Grande do Sul^iA01^1Faculdade de Medicina#^lpt^a<b>INTR
ODUÇÃO:</b> A hepatite B pode evoluir para cirrose e hepatocarcinoma. Sua preval
ência estimada é de 3,2% em pacientes em hemodiálise (HD). A vacina para hepatit
e B (HB), quando aplicada por via intramuscular (IM) em pacientes com insuficiên
cia renal crônica fase V, frequentemente não induz produção adequada de anticorp
os. A injeção intradérmica (ID) foi sugerida como sendo o método de inoculação m
ais eficiente. <b>OBJETIVO: </b>Comparar a resposta imune à injeção IM ou ID da 
vacina em indivíduos em HD. <b>PACIENTES E MÉTODOS:</b> Trinta e um pacientes in
cidentes em HD foram randomizados alternativamente para vacinação contra HB via 
IM ou ID. Dezesseis foram designados aleatoriamente para receber vacina IM (40 m
g/dose) e 15 ID (4mg /dose). Os níveis de anticorpos de superfície do vírus da h
epatite B, parâmetros hematimétricos, ureia sérica, e Kt/V foram avaliados mensa
lmente. Proteína-C reativa, paratormônio, ferritina, aminotransferases e albumin
a foram avaliados antes da inoculação inicial e seis meses após a mesma. <b>RESU
LTADOS:</b> Os níveis de uréia foram maiores no grupo ID (P(1) = 0,031); os níve
is de ferritina foram mais elevados no IM (P(2) = 0,037). Houve tendência a aume
nto nos níveis de proteína C reativa no grupo ID. A avaliação do Comitê de Monit
oramento de Segurança dos indivíduos expostos recomendou a suspensão do estudo j
á que a inoculação por via IM converteu 62,5% e a ID converteu apenas 13,3% dos 
pacientes expostos. <b>CONCLUSÃO: </b>Com a metodologia utilizada, os resultados
 da vacina contra HB aplicada por via ID foi inferior à inoculação IM. Tais resu
ltados podem ser decorrentes das doses inoculadas ou de outros fatores, como inf
lamação.#^ddecs^i1#^tm^lpt^kinsuficiência renal crônica^i1#^tm^lpt^khepatite B^i
1#^tm^lpt^kimunização^i1#^len^a<b>INTRODUCTION:</b> Hepatitis B (HB) may progres
s to cirrhosis and liver carcinoma. Its prevalence is estimated at 3.2 % in hemo
dialysis (HD) patients. HB vaccine when applied intramuscularly (IM) in end-stag
e renal disease patients often does not induce appropriate antibody titers. Howe
ver, there has been suggestion for intradermal (ID) to be a more effective inocu
lation method. <b>OBJECTIVE:</b> To compare the immune response to IM or ID vacc
ine administration on HD patients. <b>PATIENTS AND METHODS:</b> Thirty one incid
ent HD patients were randomly assigned alternately to IM or ID vaccine inoculati
on. Vaccine doses were applied at three monthly intervals, with patients being f
ollowed-up for six months. Sixteen patients were assigned to IM (40 mg/dose) and
 15 to ID (4 mg/dose) vaccine administration. HB-virus surface antibody titer, h
ematimetric parameters, serum urea level and Kt/V were monthly evaluated. C-reac
tive protein, parathormone, ferritin, aminotransferases and albumin serum levels
 were evaluated before and at the sixth month of the initial inoculation. <b>RES
ULTS:</b> Urea levels were significantly higher in the ID group (P(1) = 0.031); 
ferritin levels were higher in the IM (P(2) = 0.037) and C-reactive protein leve
ls tended to be higher in the ID group. An interim evaluation by the Safety Moni
toring Committee recommended discontinuing the study as IM vaccination had conve
rted 62.5% of the exposed subjects, while ID inoculation converted only 13.3%. <
b>CONCLUSION:</b> As performed, ID applied vaccine was inferior to the IM inocul
ation. Such result may depend on the inoculated doses or some other factor, such
 as inflammation.#^ddecs^i2#^tm^len^khepatitis B^i2#^tm^len^kimmunization^i2#^tm
^len^kchronic kidney failure^i2#CNPq#vancouv#20#20100515#15/05/2010#20100711#11/
07/2010#v33n1a06.htm##
04997000000000649000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400090015903500100
01680120102001780120090002800100030003700100040004000100046004400100036004860100
04000522070008400562083169400646085001002340085004002350085002302390085002302413
08316590243608500100409508500240410508500250412908500350415405800050418911700080
41940720003042021120009042051110011042141140009042251130011042340020013042450080
08904258#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#l#4#1#article#1#
^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab#06#JBN020#nd#J. Bras. Nefrol#33#1#2
0110300#^f45^l49#0101-2800#Baixa resposta da vacinação intradérmica contra hepat
ite B em pacientes incidentes em hemodiálise^lpt#Low response to intradermal hep
atitis B vaccination in incident hemodialysis patients^len#^rND^1A01^nRegina H^s
Medeiros#^rND^1A01^nAna Elizabeth PL^sFigueiredo#^rND^1A01^nCarlos Eduardo^sPoli
-de-Figueiredo#^rND^1A01^nDomingos Otávio^sd'Avila#^rND^1A01^nCarlos Abaeté^sde 
los Santos#^iA01^1Pontifícia Universidade Católica do Rio Grande do Sul^2Faculda
de de Medicina#^lpt^aINTRODUÇÃO: A hepatite B pode evoluir para cirrose e hepato
carcinoma. Sua prevalência estimada é de 3,2 por cento em pacientes em hemodiáli
se (HD). A vacina para hepatite B (HB), quando aplicada por via intramuscular (I
M) em pacientes com insuficiência renal crônica fase V, frequentemente não induz
 produção adequada de anticorpos. A injeção intradérmica (ID) foi sugerida como 
sendo o método de inoculação mais eficiente. OBJETIVO: Comparar a resposta imune
 à injeção IM ou ID da vacina em indivíduos em HD. PACIENTES E MÉTODOS: Trinta e
 um pacientes incidentes em HD foram randomizados alternativamente para vacinaçã
o contra HB via IM ou ID. Dezesseis foram designados aleatoriamente para receber
 vacina IM (40 mg/dose) e 15 ID (4mg /dose). Os níveis de anticorpos de superfíc
ie do vírus da hepatite B, parâmetros hematimétricos, ureia sérica, e Kt/V foram
 avaliados mensalmente. Proteína-C reativa, paratormônio, ferritina, aminotransf
erases e albumina foram avaliados antes da inoculação inicial e seis meses após 
a mesma. RESULTADOS: Os níveis de uréia foram maiores no grupo ID (P(1) = 0,031)
; os níveis de ferritina foram mais elevados no IM (P(2) = 0,037). Houve tendênc
ia a aumento nos níveis de proteína C reativa no grupo ID. A avaliação do Comitê
 de Monitoramento de Segurança dos indivíduos expostos recomendou a suspensão do
 estudo já que a inoculação por via IM converteu 62,5 por cento e a ID converteu
 apenas 13,3 por cento dos pacientes expostos. CONCLUSÃO: Com a metodologia util
izada, os resultados da vacina contra HB aplicada por via ID foi inferior à inoc
ulação IM. Tais resultados podem ser decorrentes das doses inoculadas ou de outr
os fatores, como inflamação.#^ddecs^i1#^tm^lpt^kinsuficiência renal crônica^i1#^
tm^lpt^khepatite B^i1#^tm^lpt^kimunização^i1#^len^aINTRODUCTION: Hepatitis B (HB
) may progress to cirrhosis and liver carcinoma. Its prevalence is estimated at 
3.2  percent in hemodialysis (HD) patients. HB vaccine when applied intramuscula
rly (IM) in end-stage renal disease patients often does not induce appropriate a
ntibody titers. However, there has been suggestion for intradermal (ID) to be a 
more effective inoculation method. OBJECTIVE: To compare the immune response to 
IM or ID vaccine administration on HD patients. PATIENTS AND METHODS: Thirty one
 incident HD patients were randomly assigned alternately to IM or ID vaccine ino
culation. Vaccine doses were applied at three monthly intervals, with patients b
eing followed-up for six months. Sixteen patients were assigned to IM (40 mg/dos
e) and 15 to ID (4 mg/dose) vaccine administration. HB-virus surface antibody ti
ter, hematimetric parameters, serum urea level and Kt/V were monthly evaluated. 
C-reactive protein, parathormone, ferritin, aminotransferases and albumin serum 
levels were evaluated before and at the sixth month of the initial inoculation. 
RESULTS: Urea levels were significantly higher in the ID group (P(1) = 0.031); f
erritin levels were higher in the IM (P(2) = 0.037) and C-reactive protein level
s tended to be higher in the ID group. An interim evaluation by the Safety Monit
oring Committee recommended discontinuing the study as IM vaccination had conver
ted 62.5 percent of the exposed subjects, while ID inoculation converted only 13
.3 percent. CONCLUSION: As performed, ID applied vaccine was inferior to the IM 
inoculation. Such result may depend on the inoculated doses or some other factor
, such as inflammation.#^ddecs^i2#^tm^len^khepatitis B^i2#^tm^len^kimmunization^
i2#^tm^len^kchronic kidney failure^i2#CNPq#vancouv#20#20100515#15/05/2010#201007
11#11/07/2010#v33n1a06.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_
arttext&pid=S0101-28002011000100006##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#5#1#article#102#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a06.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#6#2#article#102#<p>&nbsp;</p>     ^cY#
v33n1a06.htm##
00466000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704023400073002001300307#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#7#3#article#102#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Baixa resposta da
 vacina&ccedil;&atilde;o intrad&eacute;rmica contra hepatite B em pacientes inci
dentes em hemodi&aacute;lise</b></font></p>     ^cY#v33n1a06.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#8#4#article#102#<p>&nbsp;</p>     ^cY#
v33n1a06.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#9#5#article#102#<p>&nbsp;</p>     ^cY#
v33n1a06.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704024300074002001300317#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#10#6#article#102#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Regina H. Medeiros; Ana Elizabeth P
L  Figueiredo; Carlos Eduardo  Poli-de-Figueiredo; Domingos Ot&aacute;vio d'Avil
a; Carlos Abaet&eacute; de  los Santos</b></font></p>     ^cY#v33n1a06.htm##
00406000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704017300074002001300247#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#11#7#article#102#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Faculdade de Medicina, Pontif&iacute;c
ia Universidade Cat&oacute;lica do Rio Grande do Sul</font></p>     ^cY#v33n1a06
.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704012400074002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#12#8#article#102#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia<
/a></font></p>     ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#13#9#article#102#<p>&nbsp;</p>     ^cY
#v33n1a06.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#14#10#article#102#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a06.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#15#11#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a06.htm##
00836000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060200075002001300677#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#16#12#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O:</b> A he
patite B pode evoluir para cirrose e hepatocarcinoma. Sua preval&ecirc;ncia esti
mada &eacute; de 3,2% em pacientes em hemodi&aacute;lise (HD). A vacina para hep
atite B (HB), quando aplicada por via intramuscular (IM) em pacientes com insufi
ci&ecirc;ncia renal cr&ocirc;nica fase V, frequentemente n&atilde;o induz produ&
ccedil;&atilde;o adequada de anticorpos. A inje&ccedil;&atilde;o intrad&eacute;r
mica (ID) foi sugerida como sendo o m&eacute;todo de inocula&ccedil;&atilde;o ma
is eficiente.     ^cY#v33n1a06.htm##
00370000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013600075002001300211#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#17#13#article#102#<br>   <b>OBJETIVO: 
</b>Comparar a resposta imune &agrave; inje&ccedil;&atilde;o IM ou ID da vacina 
em indiv&iacute;duos em HD.     ^cY#v33n1a06.htm##
00870000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704063600075002001300711#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#18#14#article#102#<br>   <b>PACIENTES 
E M&Eacute;TODOS:</b> Trinta e um pacientes incidentes em HD foram randomizados 
alternativamente para vacina&ccedil;&atilde;o contra HB via IM ou ID. Dezesseis 
foram designados aleatoriamente para receber vacina IM (40 mg/dose) e 15 ID (4mg
 /dose). Os n&iacute;veis de anticorpos de superf&iacute;cie do v&iacute;rus da 
hepatite B, par&acirc;metros hematim&eacute;tricos, ureia s&eacute;rica, e Kt/V 
foram avaliados mensalmente. Prote&iacute;na-C reativa, paratorm&ocirc;nio, ferr
itina, aminotransferases e albumina foram avaliados antes da inocula&ccedil;&ati
lde;o inicial e seis meses ap&oacute;s a mesma.     ^cY#v33n1a06.htm##
00780000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054600075002001300621#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#19#15#article#102#<br>   <b>RESULTADOS
:</b> Os n&iacute;veis de ur&eacute;ia foram maiores no grupo  ID (P(1) = 0,031)
; os n&iacute;veis de ferritina foram mais elevados no IM (P(2) = 0,037). Houve 
tend&ecirc;ncia a aumento nos n&iacute;veis de prote&iacute;na C reativa no grup
o ID. A avalia&ccedil;&atilde;o do Comit&ecirc; de Monitoramento de Seguran&cced
il;a dos indiv&iacute;duos expostos recomendou a suspens&atilde;o do estudo j&aa
cute; que a inocula&ccedil;&atilde;o por via IM converteu 62,5% e a ID converteu
 apenas 13,3% dos pacientes expostos.     ^cY#v33n1a06.htm##
00532000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029800075002001300373#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#20#16#article#102#<br>   <b>CONCLUS&At
ilde;O: </b>Com a metodologia utilizada, os resultados da vacina contra HB aplic
ada por via ID foi inferior &agrave; inocula&ccedil;&atilde;o IM. Tais resultado
s podem ser decorrentes das doses inoculadas ou de outros fatores, como inflama&
ccedil;&atilde;o. </font></p>     ^cY#v33n1a06.htm##
00441000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020700075002001300282#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#21#17#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> insufici&ecirc
;ncia renal cr&ocirc;nica, hepatite B, imuniza&ccedil;&atilde;o. </font></p> <hr
 size="1" noshade>     ^cY#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#22#18#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#23#19#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#24#20#article#102#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a06.htm##
00723000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048900075002001300564#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#25#21#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A hepatite B (HB) cr&ocirc;nica pode 
progredir para cirrose e hepatocarcinoma. A incid&ecirc;ncia de HB entre pacient
es em hemodi&aacute;lise (HD) vem decrescendo de maneira marcante e progressiva 
depois que pol&iacute;ticas r&iacute;gidas de vacina&ccedil;&atilde;o foram adot
adas. <sup>1</sup> Uma pesquisa recente estimou a preval&ecirc;ncia de HB entre 
pacientes brasileiros em HD em 3,2%. <sup>2</sup></font></p>     ^cY#v33n1a06.ht
m##
01256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704102200075002001301097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#26#22#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Recomenda-se que todo paciente n&atil
de;o imunizado que come&ccedil;a HD seja vacinado. Entretanto, as taxas de seroc
onvers&atilde;o da vacina contra HB s&atilde;o baixas em pacientes renais em est
&aacute;gio avan&ccedil;ado submetidos a HD: apenas 43% a 66% desses pacientes a
lcan&ccedil;am n&iacute;veis adequados de anticorpos, em compara&ccedil;&atilde;
o a mais de 95% dos indiv&iacute;duos saud&aacute;veis. <sup>3,4</sup> A respost
a deficiente &agrave; vacina&ccedil;&atilde;o parece depender de m&uacute;ltiplo
s fatores, tais como idade, estado nutricional, presen&ccedil;a de inflama&ccedi
l;&atilde;o e redu&ccedil;&atilde;o dos n&iacute;veis de eritropoietina, al&eacu
te;m de baixa atividade de leuc&oacute;citos T e B. <sup>5</sup> Observou-se que
 a resposta imune induzida pela vacina contra HB administrada por via intramuscu
lar (IM) diferiu daquela induzida pela inocula&ccedil;&atilde;o intrad&eacute;rm
ica (ID). <sup>6</sup></font></p>     ^cY#v33n1a06.htm##
00483000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024900075002001300324#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#27#23#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo foi comparar 
as respostas &agrave; inocula&ccedil;&atilde;o IM ou ID de vacina contra HB em p
acientes n&atilde;o imunizados incidentes em HD. </font></p>     ^cY#v33n1a06.ht
m##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#28#24#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#29#25#article#102#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODO</b></fon
t></p>     ^cY#v33n1a06.htm##
00754000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052000075002001300595#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#30#26#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Este estudo de coorte randomizado adm
itiu de forma alternada pacientes incidentes em HD antes do terceiro m&ecirc;s d
e tratamento para comparar suas respostas imunes &agrave; inocula&ccedil;&atilde
;o IM ou ID da vacina contra HB. O protocolo do estudo foi aprovado pelo Comit&e
circ; de &Eacute;tica em Pesquisa da institui&ccedil;&atilde;o e cada participan
te forneceu consentimento escrito informado antes da admiss&atilde;o no estudo. 
</font></p>     ^cY#v33n1a06.htm##
02295000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704206100075002001302136#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#31#27#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trinta e um pacientes foram admitidos
 de forma alternada: dezesseis foram alocados para receber a vacina IM e quinze 
para receb&ecirc;-la por via ID. As causas da doen&ccedil;a renal em est&aacute;
gio avan&ccedil;ado foram as seguintes: diabetes mellitus em quatro indiv&iacute
;duos do grupo IM e em tr&ecirc;s do grupo ID; hipertens&atilde;o em dois de cad
a grupo; doen&ccedil;a glomerular em um paciente do grupo IM; refluxo vesicouret
eral em um de cada grupo; doen&ccedil;a polic&iacute;stica em um do grupo ID; ca
usa desconhecida em um de cada grupo. Os indiv&iacute;duos alocados no grupo IM 
foram inoculados com a vacina Engerix-B (GlaxoSmithKline Lab, Inglaterra),  40 m
g/dose/m&ecirc;s, por tr&ecirc;s meses no m&uacute;sculo deltoide. O grupo ID re
cebeu uma inocula&ccedil;&atilde;o intrad&eacute;rmica (4mg/dose) na face intern
a do antebra&ccedil;o, nos mesmos intervalos. O esquema de vacina&ccedil;&atilde
;o e a dosagem foram previamente sugeridos pelo Minist&eacute;rio de Sa&uacute;d
e do Brasil. <sup>7</sup> Os testes para os v&iacute;rus da imunodefici&ecirc;nc
ia humana adquirida e hepatite C foram negativos em todos os participantes. Nenh
um havia sido previamente vacinado contra HB nem tinha t&iacute;tulos significat
ivos de anticorpos contra o ant&iacute;geno de superf&iacute;cie da hepatite B (
Anti-HBs). Todos os pacientes admitidos no estudo receberam a mesma prescri&cced
il;&atilde;o de HD (sess&otilde;es de quatro horas, tr&ecirc;s vezes por semana,
 bicarbonato padr&atilde;o, dialisadores de polissulfona), em uma m&aacute;quina
 de di&aacute;lise Fresenius 4008 B (Fresenius Medical Care, Bad Homburg, Aleman
ha), com fluxo de dialisado mantido em 500 mL/min, fluxo sangu&iacute;neo varian
do de 250 a 300 mL/min, e heparina n&atilde;o fracionada como anticoagula&ccedil
;&atilde;o padr&atilde;o. O acesso vascular foi obtido atrav&eacute;s de f&iacut
e;stula arteriovenosa em todos os pacientes, exceto em dez, em que um cateter ce
ntral foi utilizado. </font></p>     ^cY#v33n1a06.htm##
01044000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704081000075002001300885#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#32#28#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram analisadas as seguintes vari&aa
cute;veis demogr&aacute;ficas e cl&iacute;nicas: idade; g&ecirc;nero; doen&ccedi
l;a cardiovascular; c&acirc;ncer; infec&ccedil;&atilde;o; HD vintage; acesso vas
cular por f&iacute;stula arteriovenosa ou cateter central. As seguintes vari&aac
ute;veis terap&ecirc;uticas e laboratoriais foram avaliadas mensalmente: n&uacut
e;mero de transfus&otilde;es; dose de eritropoietina; Kt/V; ureia s&eacute;rica;
 hemograma; e n&iacute;veis de Anti-HBs. As seguintes vari&aacute;veis foram med
idas no in&iacute;cio do estudo e a intervalos de seis meses: prote&iacute;na C-
reativa (PCR); ferritina; paratorm&ocirc;nio (PTH); alanina-aminotransferase (AL
T); aspartato-aminotransferase (AST); e albumina. </font></p>     ^cY#v33n1a06.h
tm##
00817000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058300075002001300658#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#33#29#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Uma avalia&ccedil;&atilde;o interina 
realizada pelo Comit&ecirc; de Monitoramento de Seguran&ccedil;a a intervalos de
 tr&ecirc;s meses recomendou a interrup&ccedil;&atilde;o do estudo, pois a maior
ia dos pacientes do grupo ID n&atilde;o atingiu n&iacute;veis protetores de anti
corpos (menos de 10 mUI/mL), que foram significativamente mais baixos do que os 
do grupo IM. Consequentemente, apenas 17 pacientes foram avaliados: nove no grup
o IM e oito no grupo ID. O seguimento total foi de seis meses. </font></p>     ^
cY#v33n1a06.htm##
01312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704107800075002001301153#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#34#30#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados foram apresentados como m&ea
cute;dia e desvio padr&atilde;o (DP), mediana e intervalo interquartil (IQ), ou 
porcentagem. O teste t de Student ou o teste de Mann-Whitney foi usado para comp
arar duas vari&aacute;veis cont&iacute;nuas; o teste do Qui-quadrado ou o teste 
exato de Fisher foi usado nas compara&ccedil;&otilde;es entre vari&aacute;veis c
ateg&oacute;ricas. ANOVA com medidas repetidas foi tamb&eacute;m usado (p<sup>(1
)</sup>, refere-se &agrave;s diferen&ccedil;as entre os grupos no in&iacute;cio 
do estudo; p<sup>(2)</sup>, diferen&ccedil;as no mesmo grupo ao longo do tempo; 
p<sup>(3)</sup>, diferen&ccedil;as entre os grupos ao longo do tempo; p<sup>(4)<
/sup>, diferen&ccedil;as entre os grupos no ponto m&eacute;dio do estudo). O pro
grama Statistical Package for Social Sciences (SPSS, vers&atilde;o 11.5 para Win
dows, SPSS Inc. , Chicago, IL, EUA) foi usado em todas as an&aacute;lises estat&
iacute;sticas. Um valor de  p <u>&lt;</u> 0,05 foi considerado significativo. </
font></p>     ^cY#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#35#31#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#36#32#article#102#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v33n1a06.htm##
01274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704104000075002001301115#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#37#33#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trinta e um pacientes foram inclu&iac
ute;dos: 16 randomizados para o grupo IM e 15 para o grupo ID. Devido &agrave; i
nterrup&ccedil;&atilde;o do estudo, apenas 17 indiv&iacute;duos completaram o pr
otocolo: nove no grupo IM e oito no grupo ID. N&atilde;o foi observada diferen&c
cedil;a significativa de idade entre os grupos (59 ± 17 vs. 57,0 ± 17,0 anos; p 
= 0,638, para os grupos IM e ID, respectivamente). A rela&ccedil;&atilde;o homem
/ mulher foi 5/4 no grupo IM e 6/2 no grupo ID (p = 0,347). O tempo de di&aacute
;lise foi de 2,2 ± 1,2 meses no grupo IM e 2,3 ± 1,4 meses no grupo ID (p = 0,86
4). Quatro indiv&iacute;duos usaram um cateter central no grupo IM e seis no gru
po ID (p = 0,353). Metade dos pacientes em ambos os grupos necessitou de pelo me
nos uma transfus&atilde;o sangu&iacute;nea. Infec&ccedil;&atilde;o bacteriana fo
i observada em dois pacientes em cada grupo. Eritropoietina foi usada na mesma p
ropor&ccedil;&atilde;o nos dois grupos. </font></p>     ^cY#v33n1a06.htm##
01644000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704141000075002001301485#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#38#34#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A <a href="/img/revistas/jbn/v33n1/a0
6tab01m.jpg">Tabela 1</a> mostra os resultados dos exames laboratoriais durante 
o estudo. Os n&iacute;veis sangu&iacute;neos de Anti-HBs e os n&iacute;veis s&ea
cute;ricos de ureia diferiram significativamente entre os grupos no in&iacute;ci
o do estudo  (p = 0,031). Durante o per&iacute;odo do estudo, apenas os n&iacute
;veis de Anti-HBs, hemat&oacute;crito, hemoglobina e ferritina apresentaram dife
ren&ccedil;a significativa (p<sup>(2) </sup>&lt; 0,001; p<sup>(2) </sup>= 0,001;
 p<sup>(2) </sup>= 0,004; p<sup>(2) </sup>= 0,037, respectivamente). Al&eacute;m
 disso, apenas os n&iacute;veis de Anti-HBs diferiram significativamente entre o
s grupos (p<sup>(3) </sup>&lt; 0,001). Ao final, apenas os t&iacute;tulos de Ant
i-HBs e os n&iacute;veis de ureia apresentaram diferen&ccedil;a significativa (p
<sup>(4) </sup>&lt; 0,001 e  p<sup>(4) </sup>= 0,035, respectivamente). No grupo
 IM, dez (62,5 %) pacientes atingiram t&iacute;tulos protetores de Anti-HBs (<su
p>3</sup>10 UI/mL), enquanto apenas dois (13,3%) pacientes no grupo ID atingiram
 t&iacute;tulos aceit&aacute;veis. A <a href="#fig1">Figura 1</a> mostra a evolu
&ccedil;&atilde;o dos t&iacute;tulos Anti-HBs durante o per&iacute;odo observado
 por grupo. As respostas diferiram significativamente do terceiro para o sexto m
&ecirc;s. </font></p>     ^cY#v33n1a06.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#39#35#article#102#<p><a name="fig1"></
a></p>     ^cY#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#40#36#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#41#37#article#102#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a06fig01.jpg"></p>     ^cY#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#42#38#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#43#39#article#102#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v33n1a06.htm##
03767000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704353300075002001303608#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#44#40#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os n&iacute;veis de Anti-HBs evocados
 pela vacina contra HB apresentaram diferen&ccedil;a significativa de acordo com
 a via de administra&ccedil;&atilde;o IM ou ID. O efeito favor&aacute;vel no gru
po IM ficou evidente cedo no curso do estudo. Ap&oacute;s a an&aacute;lise inter
ina, o Comit&ecirc; de Monitoramento de Seguran&ccedil;a sugeriu a interrup&cced
il;&atilde;o do estudo. A administra&ccedil;&atilde;o IM da vacina imunizou quas
e dois ter&ccedil;os dos pacientes expostos, um resultado semelhante &agrave;que
le obtido em popula&ccedil;&otilde;es saud&aacute;veis. <sup> 8,9</sup> Por outr
o lado, a administra&ccedil;&atilde;o ID foi eficaz apenas na minoria dos indiv&
iacute;duos inoculados. Nossos resultados apresentam uma substancial discrep&aci
rc;ncia daqueles de estudos anteriores. <sup>10,11,12</sup> Entretanto, um estud
o pr&eacute;vio comparando as vias IM e ID de inocula&ccedil;&atilde;o da vacina
 demonstrou resultados semelhantes. <sup>13</sup> Ainda assim, a dose agregada d
e ant&iacute;geno foi maior do que a estipulada no presente estudo. Ainda, a ino
cula&ccedil;&atilde;o ID foi eficaz em 94% dos pacientes quando se utilizou uma 
dose maior de vacina (20 mg) a intervalos mais curtos (6 doses/semana). <sup>14<
/sup> V&aacute;rias possibilidades podem ser consideradas para explicar as disti
ntas respostas observadas: diferentes condi&ccedil;&otilde;es cl&iacute;nicas ou
 caracter&iacute;sticas da popula&ccedil;&atilde;o, ou diferentes doses da vacin
a. Apenas pacientes incidentes em HD foram inclu&iacute;dos no presente estudo -
 nenhum deles havia sido imunizado com a vacina contra HB. Embora os t&iacute;tu
los iniciais de Anti-HBs fossem sempre inferiores a 10 UI/mL, eles foram signifi
cativamente mais altos no grupo IM. Os pacientes do grupo ID receberam uma dose 
menor de vacina e isso pode ter sido um dos fatores limitantes do estudo. No in&
iacute;cio, esse grupo tamb&eacute;m apresentou n&iacute;veis mais elevados de u
reia do que os do grupo IM, e eles permaneceram est&aacute;veis at&eacute; o fin
al do estudo. Sabe-se que indiv&iacute;duos com doen&ccedil;a renal em est&aacut
e;gio avan&ccedil;ado t&ecirc;m respostas imunes - humoral e celular - mais baix
as, mon&oacute;citos e polimorfos disfuncionais, al&eacute;m de n&iacute;veis ma
is altos de interleucina-1 e de fator de necrose tumoral. <sup>5,15 </sup>O sign
ificado desses achados n&atilde;o &eacute; claro, uma vez que menores quantidade
s de di&aacute;lise podem ser respons&aacute;veis pelas diferen&ccedil;as observ
adas. <sup>16</sup> Por outro lado, uma medida da efici&ecirc;ncia da di&aacute;
lise - Kt/V - n&atilde;o revelou diferen&ccedil;a entre os grupos. As medidas de
 hemoglobina e hemat&oacute;crito foram mais baixas no grupo IM do que no grupo 
ID no in&iacute;cio. Um estudo recente sugeriu que pacientes com n&iacute;veis m
ais baixos de hemoglobina podem apresentar menor resposta imune a vacinas. <sup>
8,15</sup> No entanto, o grupo IM apresentou uma hemoglobina m&eacute;dia maior 
do que 11,0 g/dL ao final do estudo, enquanto o grupo ID n&atilde;o atingiu tal 
n&iacute;vel. Ainda que n&atilde;o significativamente diferente, n&iacute;veis e
levados de PCR e ferritina, e maior n&uacute;mero de pacientes com um cateter ve
noso central como acesso vascular no grupo ID poderiam implicar um maior status 
inflamat&oacute;rio - a contagem de hem&aacute;cias pode ser mais baixa na prese
n&ccedil;a de inflama&ccedil;&atilde;o. <sup>17</sup></font></p>     ^cY#v33n1a0
6.htm##
01984000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704175000075002001301825#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#45#41#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A administra&ccedil;&atilde;o ID da v
acina foi menos eficaz do que a IM. No entanto, doses mais baixas da vacina ID f
oram usadas eficazmente em indiv&iacute;duos saud&aacute;veis. Al&eacute;m disso
, &eacute; importante lembrar que respostas imunes adequadas foram induzidas por
 doses mais altas da vacina ID, ou mais frequentes. <sup>9</sup> No entanto, a m
aioria dos estudos empregou baixas doses da vacina ID. <sup>4,10,11</sup> Um est
udo recente demonstrou que a revacina&ccedil;&atilde;o aumenta as taxas de seroc
onvers&atilde;o, usando-se a via ID, em pacientes est&aacute;veis em HD que n&at
ilde;o responderam &agrave; vacina&ccedil;&atilde;o IM pr&eacute;via. <sup>18</s
up> Os resultados do presente estudo contrariam esses achados. <sup>19</sup> Tal
 diferen&ccedil;a pode ser atribu&iacute;da a revacina&ccedil;&atilde;o, contra 
imuniza&ccedil;&atilde;o inicial, indiv&iacute;duos prevalentes <i>versus</i> in
cidentes em HD, condi&ccedil;&otilde;es cl&iacute;nicas dos pacientes, caracter&
iacute;sticas da popula&ccedil;&atilde;o de risco, ou ainda diferentes intervalo
s de aplica&ccedil;&atilde;o e doses da vacina. Inflama&ccedil;&atilde;o tamb&ea
cute;m pode ter sido um importante fator confundidor na resposta imune &agrave; 
vacina. <sup>20</sup> Diferentemente dos estudos pr&eacute;vios que avaliaram pa
cientes por um per&iacute;odo maior, esta coorte foi composta por pacientes inci
dentes. A interrup&ccedil;&atilde;o precoce do estudo pode ter enfraquecido pote
nciais respostas tardias. A reduzida resposta &agrave; inocula&ccedil;&atilde;o 
ID pode ter sido devida a m&uacute;ltiplos fatores, inclusive a ocorr&ecirc;ncia
 de inflama&ccedil;&atilde;o. </font></p>     ^cY#v33n1a06.htm##
00495000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026100075002001300336#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#46#42#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Concluindo, a administra&ccedil;&atil
de;o mensal ID da vacina contra a HB em pacientes incidentes em HD foi significa
tivamente menos eficaz do que a inocula&ccedil;&atilde;o IM. </font></p>     ^cY
#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#47#43#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#48#44#article#102#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>AGRADECIMENTOS</b> </font></p>    
 ^cY#v33n1a06.htm##
00395000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016100075002001300236#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#49#45#article#102#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Agradecimentos especiais a Carlos E. 
Poli-de Figueiredo, pesquisador do CNPq. </font></p>     ^cY#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#50#46#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#51#47#article#102#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a06.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021700077002001300294#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#52#48#article#102#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Mioli VA, Balestra E
, Bibiano L <i>et al. </i> Epidemiology of viral hepatitis in dialysis centers: 
a national survey. Nephron 1992; 61:278-83.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#53#49#article#102# </font></p>     ^cY
#v33n1a06.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704029200077002001300369#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#54#50#article#102#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Rom&auml;o JE Jr, Pi
nto SWL,Canziani ME, Praxedes JN, Santello JL, Moreira JCM. Censo SBN 2002: info
rma&ccedil;&otilde;es epidemiol&oacute;gicas das unidades de di&aacute;lise do B
rasil. Braz J Nephrol 2003; 25:187-98.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#55#51#article#102# </font></p>     ^cY
#v33n1a06.htm##
00527000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027900077002001300356#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#56#52#article#102#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Hassan K, Shternberg
 L, Alhaj M <i>et al. </i> The effect of erythropoietin therapy and hemoglobin l
evels on the immune response to Engerix-B vaccination in chronic kidney disease.
 Ren Fail 2003; 25:471-8.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#57#53#article#102# </font></p>     ^cY
#v33n1a06.htm##
00592000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704034400077002001300421#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#58#54#article#102#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Ghabouli MJ, Sabouri
 AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by in
tradermal administration of a recombinant hepatitis B vaccine in young healthy a
dults: comparison with standard intramuscular vaccination. Eur J Epidemiol 2004;
 19:871-5.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#59#55#article#102# </font></p>     ^cY
#v33n1a06.htm##
00634000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704038600077002001300463#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#60#56#article#102#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Stachowski J, Pollok
 M, Barth C, Maciejewski J, Baldamus CA. Non-responsiveness to hepatitis B vacci
nation in haemodialysis patients: association with impaired TCR/CD3 antigen rece
ptor expression regulating co-stimulatory processes in antigen presentation and 
recognition. Nephrol Dial Transplant 1994; 9:144-52.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#61#57#article#102# </font></p>     ^cY
#v33n1a06.htm##
00539000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704029100077002001300368#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#62#58#article#102#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Rahman F, Dahmen A, 
Herzog-Hauff S, Bocher WO, Galle PR. Cellular and humoral immune responses induc
ed by intradermal or intramuscular vaccination with the major hepatitis B surfac
e antigen. Hepatology 2000; 31:521-7.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#63#59#article#102# </font></p>     ^cY
#v33n1a06.htm##
00588000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704034000077002001300417#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#64#60#article#102#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Aranda C, Rocha C, R
enoiner E, Campos J, Carvalho M. Manual de procedimentos para vacina&ccedil;&ati
lde;o. Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de/FUNASA; 2001 &#91;<a h
ref="http://dtr2001.saude.gov.br" target="_blank">http://dtr2001.saude.gov.br</a
>&#93;    ^cY#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#65#61#article#102#. </font></p>     ^c
Y#v33n1a06.htm##
00529000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704028100077002001300358#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#66#62#article#102#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. McMaster KR 3rd, Rop
er JK, Carter JB. Intradermal hepatitis B vaccination in a 300-bed primary care 
hospital: experience with a recombinant vaccine in a fourdose schedule. Am J Inf
ect Control 1993; 21:283-8.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#67#63#article#102# </font></p>     ^cY
#v33n1a06.htm##
00554000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704030600077002001300383#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#68#64#article#102#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Baldy JL, Elisb&atil
de;o MC, Anzai ET <i>et al. </i> Intradermal vaccination of adults with three lo
w doses (2mg) of recombinant hepatitis B vaccine. I. Seroconversion rate and adv
erse effects. Mem Inst Oswaldo Cruz 2003; 98:1101-7.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#69#65#article#102# </font></p>     ^cY
#v33n1a06.htm##
00601000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704035200078002001300430#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#70#66#article#102#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Fabrizi F, Andrull
i S, Bacchini G, Corti M, Locatelli F. Intradermal <i>versus</i> intramuscular h
epatitis b re-vaccination in non-responsive chronic dialysis patients: a prospec
tive randomized study with cost-effectiveness evaluation. Nephrol Dial Transplan
t 1997; 12:1204-11.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#71#67#article#102# </font></p>     ^cY
#v33n1a06.htm##
00542000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704029300078002001300371#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#72#68#article#102#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Chang PC, Schrande
r-van der Meer AM, van Dorp WT, van Leer E. Intracutaneous <i>versus</i> intramu
scular hepatitis B vaccination in primary non-responding haemodialysis patients.
 Nephrol Dial Transplant 1996; 11:191-3.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#73#69#article#102# </font></p>     ^cY
#v33n1a06.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704028400078002001300362#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#74#70#article#102#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Charest AF, McDoug
all J, Goldstein MB. A randomized comparison of intradermal and intramuscular va
ccination against hepatitis B virus in incident chronic hemodialysis patients. A
m J Kidney Dis 2000; 36:976-82.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#75#71#article#102# </font></p>     ^cY
#v33n1a06.htm##
00595000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704034600078002001300424#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#76#72#article#102#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Somboonsilp W, Eia
m-Ong S, Tungsanga K, Tirawatanapong T. Immune response of intradermal hepatitis
 B vaccination at lower dose <i>versus</i> intramuscular vaccination at double s
tandard dose in predialytic chronic renal failure patients. J Med Assoc Thai 200
3; 86:1122-7.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#77#73#article#102# </font></p>     ^cY
#v33n1a06.htm##
00555000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704030600078002001300384#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#78#74#article#102#14#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Propst T, Propst A
, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in 
hemodialysis patients is superior in antibody response to intramuscular or subcu
taneous vaccination. Am J Kidney Dis 1998; 32:1041-5.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#79#75#article#102# </font></p>     ^cY
#v33n1a06.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704019100078002001300269#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#80#76#article#102#15#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Vlassopoulos D. Re
combinant hepatitis B vaccination in renal failure patients. Curr Pharm Biotechn
ol 2003; 4:141-51.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#81#77#article#102# </font></p>     ^cY
#v33n1a06.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704021200078002001300290#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#82#78#article#102#16#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Kovacik V, Sain M,
 Vukman V. Efficient hemodialysis improves the response to hepatitis B virus vac
cination. Intervirology 2002; 45:172-6.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#83#79#article#102# </font></p>     ^cY
#v33n1a06.htm##
00396000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704014700078002001300225#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#84#80#article#102#17#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Andrews NC. Disord
ers of iron metabolism. N Engl J Med 1999; 341:1986-9.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#85#81#article#102# </font></p>     ^cY
#v33n1a06.htm##
00579000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704033000078002001300408#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#86#82#article#102#18#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Barraclough KA, Wi
ggins KJ, Hawley CM. Intradermal <i>versus</i> intramuscular hepatitis B vaccina
tion in hemodialysis patients: a prospective open-label randomized controlled tr
ial in nonresponders to primary vaccination. Am J Kidney Dis 2009; 54:95-103.   
 ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#87#83#article#102# </font></p>     ^cY
#v33n1a06.htm##
00544000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704029500078002001300373#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#88#84#article#102#19#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Medeiros RH, Figue
iredo AE, Poli-de-Figueiredo CE, d'Avila DO, de los Santos CA. Intramuscular or 
intradermal hepatitis B vaccine administration in hemodialysis patients? &#91;le
tter&#93;. Am J Kidney Dis 2009; 54:981-2.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#89#85#article#102# </font></p>     ^cY
#v33n1a06.htm##
00515000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704026600078002001300344#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#90#86#article#102#20#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Barraclough KA, Ha
wley CM, Playford E.G. In reply to "Intramuscular or intradermal hepatitis B vac
cine administration in hemodialysis patients?" &#91;letter&#93; Am J Kidney Dis 
2009; 54:982.    ^cY#v33n1a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#91#87#article#102# </font></p>     ^cY
#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#92#88#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#93#89#article#102#<p>&nbsp;</p>     ^c
Y#v33n1a06.htm##
00434000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020000075002001300275#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#94#90#article#102#<p><a name="endb"></
a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda"><i
mg src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;nc
ia para:</b>    ^cY#v33n1a06.htm##
00284000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704005000075002001300125#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#95#91#article#102#<br>   Carlos Abaet&
eacute; de los Santos     ^cY#v33n1a06.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#96#92#article#102#<br>   Av. Ipiranga,
 6.690     ^cY#v33n1a06.htm##
00291000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704005700075002001300132#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#97#93#article#102#<br>   Porto Alegre 
- RS - Brasil  CEP: 90601-010    ^cY#v33n1a06.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#98#94#article#102#<br>   Tel: (51) 322
3-0366     ^cY#v33n1a06.htm##
00321000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008700075002001300162#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#99#95#article#102#<br>   E-mail: <a hr
ef="mailto:abaete@pucrs.br">abaete@pucrs.br</a></font></p>     ^cY#v33n1a06.htm#
#
00342000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704010700076002001300183#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#100#96#article#102#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 15/05/2010
    ^cY#v33n1a06.htm##
00293000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704005800076002001300134#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#101#97#article#102#<br>   Data de apro
va&ccedil;&atilde;o: 11/07/2010    ^cY#v33n1a06.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704009500076002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#102#98#article#102#<br>   Os autores d
eclaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33n
1a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#103#99#article#102#<p>&nbsp;</p>     ^
cY#v33n1a06.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#104#100#article#102#<p>&nbsp;</p>     
^cY#v33n1a06.htm##
00525000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028900077002001300366#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#105#101#article#102#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado no 
Curso de P&oacute;s- gradua&ccedil;&atilde;o em Medicina e Ci&ecirc;ncias da Sa&
uacute;de, Faculdade de Medicina, Pontif&iacute;cia Universidade Cat&oacute;lica
 do Rio Grande do Sul.     ^cY#v33n1a06.htm##
00376000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704014000077002001300217#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a06.htm#S#p#106#102#article#102#<br>   Este estudo
 foi registrado como <i>teste</i> em anzctr.org.au sob o n&uacute;mero de estudo
 ACTRN12609000616279. </font></p>     ^cY#v33n1a06.htm##
00582000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920100
01700110810000600127012007500133030000800208065000900216064000500225031000300230
014000700233865000900240002001300249035001000262801000800272#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a06.htm#S#c#107#1#article#20#1#^rND^sMioli^nVA#^rND^sB
alestra^nE#^rND^sBibiano^nL#et al#Epidemiology of viral hepatitis in dialysis ce
nters: a national survey^len#Nephron#19920000#1992#61#278-83#20110300#v33n1a06.h
tm#0028-2766#Nephron##
00647000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100017000950100
01900112010001900131010001900150010001900169012008200188030001500270710000200285
065000900287064000500296031000300301014000700304865000900311002001300320#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#c#108#2#article#20#2#^rND^sRomäo
^nJE Jr#^rND^sPinto^nSWL#^rND^sCanziani^nME#^rND^sPraxedes^nJN#^rND^sSantello^nJ
L#^rND^sMoreira^nJCM#Censo SBN 2002: informações epidemiológicas das unidades de
 diálise do Brasil^len#Braz J Nephrol#2#20030000#2003#25#187-98#20110300#v33n1a0
6.htm##
00645000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100020000920100
01500112810000600127012013700133030000900270065000900279064000500288031000300293
014000600296865000900302002001300311035001000324801000900334#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a06.htm#S#c#109#3#article#20#3#^rND^sHassan^nK#^rND^sS
hternberg^nL#^rND^sAlhaj^nM#et al#The effect of erythropoietin therapy and hemog
lobin levels on the immune response to Engerix-B vaccination in chronic kidney d
isease^len#Ren Fail#20030000#2003#25#471-8#20110300#v33n1a06.htm#0886-022X#Ren F
ail##
00749000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100018000950100
01700113010001900130010001900149012018000168030001600348065000900364064000500373
031000300378014000600381865000900387002001300396035001000409801001600419#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#c#110#4#article#20#4#^rND^sGhabo
uli^nMJ#^rND^sSabouri^nAH#^rND^sShoeibi^nN#^rND^sBajestan^nSN#^rND^sBaradaran^nH
#High seroprotection rate induced by intradermal administration of a recombinant
 hepatitis B vaccine in young healthy adults: comparison with standard intramusc
ular vaccination^len#Eur J Epidemiol#20040000#2004#19#871-5#20110300#v33n1a06.ht
m#0392-2990#Eur J Epidemiol##
00799000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100016000960100
01500112010002100127010001900148012021500167030002400382065000900406064000500415
031000200420014000700422865000900429002001300438035001000451801002400461#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#c#111#5#article#20#5#^rND^sStach
owski^nJ#^rND^sPollok^nM#^rND^sBarth^nC#^rND^sMaciejewski^nJ#^rND^sBaldamus^nCA#
Non-responsiveness to hepatitis B vaccination in haemodialysis patients: associa
tion with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory
 processes in antigen presentation and recognition^len#Nephrol Dial Transplant#1
9940000#1994#9#144-52#20110300#v33n1a06.htm#0931-0509#Nephrol Dial Transplant##
00691000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100016000920100
02200108010001700130010001600147012013700163030001100300065000900311064000500320
031000300325014000600328865000900334002001300343035001000356801001100366#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#c#112#6#article#20#6#^rND^sRahma
n^nF#^rND^sDahmen^nA#^rND^sHerzog-Hauff^nS#^rND^sBocher^nWO#^rND^sGalle^nPR#Cell
ular and humoral immune responses induced by intradermal or intramuscular vaccin
ation with the major hepatitis B surface antigen^len#Hepatology#20000000#2000#31
#521-7#20110300#v33n1a06.htm#0161-0538#HEPATOLOGY##
00604000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740160016000760160015000920160
01800107016001600125016001800141018004300159066000900202062002000211062000700231
065000900238064000500247037002800252865000900280002001300289#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a06.htm#S#c#113#7#article#20#7#^rND^sAranda^nC#^rND^sR
ocha^nC#^rND^sRenoiner^nE#^rND^sCampos^nJ#^rND^sCarvalho^nM#Manual de procedimen
tos para vacinação^lpt#Brasília#Ministério da Saúde#FUNASA#20010000#2001#http://
dtr2001.saude.gov.br#20110300#v33n1a06.htm##
00654000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100023000760100016000990100
01700115012013700132030002000269065000900289064000500298031000300303014000600306
865000900312002001300321035001000334801002000344#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a06.htm#S#c#114#8#article#20#8#^rND^sMcMaster 3rd^nKR#^rND^sRoper^
nJK#^rND^sCarter^nJB#Intradermal hepatitis B vaccination in a 300-bed primary ca
re hospital: experience with a recombinant vaccine in a fourdose schedule^len#Am
 J Infect Control#19930000#1993#21#283-8#20110300#v33n1a06.htm#0196-6553#Am J In
fect Control##
00678000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920100
01600110810000600126012014400132030002200276065000900298064000500307031000300312
014000700315865000900322002001300331035001000344801002200354#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a06.htm#S#c#115#9#article#20#9#^rND^sBaldy^nJL#^rND^sE
lisbão^nMC#^rND^sAnzai^nET#et al#Intradermal vaccination of adults with three lo
w doses (2mg) of recombinant hepatitis B vaccine: I. Seroconversion rate and adv
erse effects^len#Mem Inst Oswaldo Cruz#20030000#2003#98#1101-7#20110300#v33n1a06
.htm#0074-0276#Mem Inst Oswaldo Cruz##
00759000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01800113010001500131010001900146012017500165030002400340065000900364064000500373
031000300378014000800381865000900389002001300398035001000411801002400421#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#c#116#10#article#20#10#^rND^sFab
rizi^nF#^rND^sAndrulli^nS#^rND^sBacchini^nG#^rND^sCorti^nM#^rND^sLocatelli^nF#In
tradermal versus intramuscular hepatitis b re-vaccination in non-responsive chro
nic dialysis patients: a prospective randomized study with cost-effectiveness ev
aluation^len#Nephrol Dial Transplant#19970000#1997#12#1204-11#20110300#v33n1a06.
htm#0931-0509#Nephrol Dial Transplant##
00682000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100033000940100
01900127010001800146012011300164030002400277065000900301064000500310031000300315
014000600318865000900324002001300333035001000346801002400356#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a06.htm#S#c#117#11#article#20#11#^rND^sChang^nPC#^rND^
sSchrander-van der Meer^nAM#^rND^svan Dorp^nWT#^rND^svan Leer^nE#Intracutaneous 
versus intramuscular hepatitis B vaccination in primary non-responding haemodial
ysis patients^len#Nephrol Dial Transplant#19960000#1996#11#191-3#20110300#v33n1a
06.htm#0931-0509#Nephrol Dial Transplant##
00654000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960100
02000115012014100135030001600276065000900292064000500301031000300306014000700309
865000900316002001300325035001000338801001600348#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a06.htm#S#c#118#12#article#20#12#^rND^sCharest^nAF#^rND^sMcDougall
^nJ#^rND^sGoldstein^nMB#A randomized comparison of intradermal and intramuscular
 vaccination against hepatitis B virus in incident chronic hemodialysis patients
^len#Am J Kidney Dis#20000000#2000#36#976-82#20110300#v33n1a06.htm#0272-6386#Am 
J Kidney Dis##
00728000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100018000990100
01900117010002400136012017600160030001700336065000900353064000500362031000300367
014000700370865000900377002001300386035001000399801001700409#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a06.htm#S#c#119#13#article#20#13#^rND^sSomboonsilp^nW#
^rND^sEiam-Ong^nS#^rND^sTungsanga^nK#^rND^sTirawatanapong^nT#Immune response of 
intradermal hepatitis B vaccination at lower dose versus intramuscular vaccinati
on at double standard dose in predialytic chronic renal failure patients^len#J M
ed Assoc Thai#20030000#2003#86#1122-7#20110300#v33n1a06.htm#0125-2208#J Med Asso
c Thai##
00712000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01600110010001500126010001500141012015400156030001600310065000900326064000500335
031000300340014000700343865000900350002001300359035001000372801001600382#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#c#120#14#article#20#14#^rND^sPro
pst^nT#^rND^sPropst^nA#^rND^sLhotta^nK#^rND^sVogel^nW#^rND^sKonig^nP#Reinforced 
intradermal hepatitis B vaccination in hemodialysis patients is superior in anti
body response to intramuscular or subcutaneous vaccination^len#Am J Kidney Dis#1
9980000#1998#32#1041-5#20110300#v33n1a06.htm#0272-6386#Am J Kidney Dis##
00489000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780120066001000300
02200166710000200188065000900190064000500199031000200204014000700206865000900213
002001300222#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#c#121#15#art
icle#20#15#^rND^sVlassopoulos^nD#Recombinant hepatitis B vaccination in renal fa
ilure patients^len#Curr Pharm Biotechnol#2#20030000#2003#4#141-51#20110300#v33n1
a06.htm##
00580000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100014000950100
01600109012008200125030001400207065000900221064000500230031000300235014000600238
865000900244002001300253035001000266801001400276#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a06.htm#S#c#122#16#article#20#16#^rND^sKovacik^nV#^rND^sSain^nM#^r
ND^sVukman^nV#Efficient hemodialysis improves the response to hepatitis B virus 
vaccination^len#Intervirology#20020000#2002#45#172-6#20110300#v33n1a06.htm#0300-
5526#Intervirology##
00478000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120033000960300
01300129065000900142064000500151031000400156014000700160865000900167002001300176
035001000189801001300199#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a06.htm#S#
c#123#17#article#20#17#^rND^sAndrews^nNC#Disorders of iron metabolism^len#N Engl
 J Med#19990000#1999#341#1986-9#20110300#v33n1a06.htm#0028-4793#N Engl J Med##
00693000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100018001000100
01700118012018000135030001600315065000900331064000500340031000300345014000700348
865000900355002001300364035001000377801001600387#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a06.htm#S#c#124#18#article#20#18#^rND^sBarraclough^nKA#^rND^sWiggi
ns^nKJ#^rND^sHawley^nCM#Intradermal versus intramuscular hepatitis B vaccination
 in hemodialysis patients: a prospective open-label randomized controlled trial 
in nonresponders to primary vaccination^len#Am J Kidney Dis#20090000#2009#54#95-
103#20110300#v33n1a06.htm#0272-6386#Am J Kidney Dis##
00657000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100021000970100
02900118010001700147010002400164012011600188030000400304710000200308065000900310
064000500319031000300324014000600327865000900333002001300342#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a06.htm#S#c#125#19#article#20#19#^rND^sMedeiros^nRH#^r
ND^sFigueiredo^nAE#^rND^sPoli-de-Figueiredo^nCE#^rND^sd'Avila DO#^rND^sde los Sa
ntos^nCA#Intramuscular or intradermal hepatitis B vaccine administration in hemo
dialysis patients: [letter]. Am J Kidney^len#Dis#2#20090000#2009#54#981-2#201103
00#v33n1a06.htm##
00627000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100017001000100
01800117012011700135030001600252065000900268064000500277031000300282014000400285
865000900289002001300298035001000311801001600321#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a06.htm#S#c#126#20#article#20#20#^rND^sBarraclough^nKA#^rND^sHawle
y^nCM#^rND^sPlayford^nE#In reply to "Intramuscular or intradermal hepatitis B va
ccine administration in hemodialysis patients?" [letter]^len#Am J Kidney Dis#200
90000#2009#54#982#20110300#v33n1a06.htm#0272-6386#Am J Kidney Dis##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#o#1#1#article#1#
20110411#092922#v33n1a07.htm#164##
04570000000000673000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030001700106
03100030012303200020012606500090012801400090013703500100014601200790015601200820
02350100039003170100031003560100035003870100043004220100043004650100042005080100
03300550010003400583010003200617010002500649070004600674070003900720083143900759
08500100219808500250220808500210223308500320225408314590228608500100374508500280
37550850018037830850031038011170008038320720003038401120009038431110011038521140
00903863113001103872002001303883#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a0
7.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#07#JBN020#nd#J. Bras. Nefrol.#33#1
#20110300#^f50^l54#0101-2800#Nefrolitíase em pacientes pediátricos: investigação
 metabólica e anatômica^lpt#Nephrolithiasis in pediatric patients: metabolic and
 anatomical investigation^len#^rND^1A01^nLuis Alberto Batista^sPeres#^rND^1A01^n
Sarah Sella^sLanger#^rND^1A01^nRaysa Cristina^sSchmidt#^rND^1A01^nRoberto Arthur
 Bavaresco^sNacke#^rND^1A01^nPaulo Victor Muller^sFrancescon#^rND^1A01^nRogério 
Cavalcante de^sAlmeida#^rND^1A01^nRenan Macedo^sCoimbra#^rND^1A01^nTailla Michel
le^sRibas#^rND^1A01^nTiago Dahrug^sBarros#^rND^1A02^nTiemi^sMatsuo#Universidade 
Estadual do Oeste do Paraná^iA01#Universidade Estadual de Londrina^iA02#^lpt^aDe
sordens metabólicas são frequentes em pacientes com nefrolitíase pediátrica. OBJ
ETIVOS: Estudar as alterações metabólicas e anatômicas e a análise química dos c
álculos encontrados em pacientes da nossa região. MÉTODOS: Este é um estudo retr
ospectivo em 158 crianças com evidência de formação recente de cálculos, destes 
apenas 109 concluíram a investigação metabólica. A investigação laboratorial con
sistiu de duas amostras de urina de 24 horas com dosagem de cálcio, ácido úrico,
 citrato, oxalato, sódio e creatinina, cistinúria qualitativa, pH urinário segui
do de 12 horas de jejum e restrição hídrica, cultura da urina e análise química 
quando os cálculos foram disponíveis. As técnicas de imagem incluíram ultrassono
grafia do trato urinário e urografia excretora. RESULTADOS: Em 96,3% das criança
s alguma causa foi detectada. A principal alteração metabólica encontrada foi a 
hipercalciúria (73,4%). Análise química dos cálculos mostrou oxalato de cálcio e
m 90,9% dos casos. Alterações anatômicas foram encontradas em 18,0% dos paciente
s investigados, e a mais frequente foi a duplicação pieloureteral (28,6%). CONCL
USÕES:Hipercalciúria foi a desordem mais encontrada, a alteração anatômica mais 
comum foi a duplicação pieloureteral e oxalato de cálcio foi o constituinte quím
ico mais frequente. Este trabalho serviu para o conhecimento das características
 dos pacientes pediátricos portadores de nefrolitíase em nossa região.#^ddecs^i1
#^tm^lpt^knefrolitíase^i1#^tm^lpt^kcrianças^i1#^tm^lpt^kdoenças metabólicas^i1#^
len^aMetabolic disorders are frequently observed in pediatric patients with rena
l lithiasis. OBJECTIVES: Study the metabolic and anatomical alterations and perf
orm the chemical analysis of stones found in children with nephrolithiasis in ou
r region. METHODS: A retrospective study on 158 children with evidence of recent
 renal stone formation was performed. One hundred and nine children concluded th
e metabolic study. Laboratory investigation consisted in two samples of 24-hour 
urine for calcium, uric acid, citrate, oxalate, sodium and creatinine; qualitati
ve cystinuria, urinary pH following 12-hour fasting and water restriction, urine
 culture and chemical analysis when the stones were available. Renal imaging tec
hniques included, at least, renal ultrasound and excretory urogram. RESULTS: A c
ause for nephrolithiasis was identified in 96.3% of children. The main metabolic
 alteration was hypercalciuria (73.4%). Chemical analysis of stones showed calci
um oxalate in 90.9% of the cases. Anatomical alterations were found in 18.0% of 
the investigated cases and the most frequently found alteration was pyelo-ureter
al duplication (28.6%). CONCLUSIONS: Hypercalciuria was the most frequently foun
d disorder and pyelo-ureteral duplication was the most common anatomical alterat
ion; moreover, calcium oxalate was the most frequent chemical constituent. The p
resent study showed the characteristics of pediatric patients with nephrolithias
is in our region.#^ddecs^i2#^tm^len^knephrolithiasis^i2#^tm^len^kchild^i2#^tm^le
n^kmetabolic diseases^i2#vancouv#32#20101031#31/10/2010#20101223#23/12/2010#v33n
1a07.htm##
04654000000000673000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030001700106
03100030012303200020012606500090012801400090013703500100014601200930015601200960
02490100039003450100031003840100035004150100043004500100043004930100042005360100
03300578010003400611010003200645010002500677070004600702070003900748083146700787
08500100225408500250226408500210228908500320231008314870234208500100382908500280
38390850018038670850031038851170008039160720003039241120009039271110011039361140
00903947113001103956002001303967#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a0
7.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#07#JBN020#nd#J. Bras. Nefrol.#33#1
#20110300#^f50^l54#0101-2800#<b>Nefrolitíase em pacientes pediátricos</b>: <b>in
vestigação metabólica e anatômica</b>^lpt#<b>Nephrolithiasis in pediatric patien
ts</b>: <b>metabolic and anatomical investigation</b>^len#^rND^1A01^nLuis Albert
o Batista^sPeres#^rND^1A01^nSarah Sella^sLanger#^rND^1A01^nRaysa Cristina^sSchmi
dt#^rND^1A01^nRoberto Arthur Bavaresco^sNacke#^rND^1A01^nPaulo Victor Muller^sFr
ancescon#^rND^1A01^nRogério Cavalcante de^sAlmeida#^rND^1A01^nRenan Macedo^sCoim
bra#^rND^1A01^nTailla Michelle^sRibas#^rND^1A01^nTiago Dahrug^sBarros#^rND^1A02^
nTiemi^sMatsuo#Universidade Estadual do Oeste do Paraná^iA01#Universidade Estadu
al de Londrina^iA02#^lpt^aDesordens metabólicas são frequentes em pacientes com 
nefrolitíase pediátrica. <b>OBJETIVOS:</b> Estudar as alterações metabólicas e a
natômicas e a análise química dos cálculos encontrados em pacientes da nossa reg
ião. <b>MÉTODOS:</b> Este é um estudo retrospectivo em 158 crianças com evidênci
a de formação recente de cálculos, destes apenas 109 concluíram a investigação m
etabólica. A investigação laboratorial consistiu de duas amostras de urina de 24
 horas com dosagem de cálcio, ácido úrico, citrato, oxalato, sódio e creatinina,
 cistinúria qualitativa, pH urinário seguido de 12 horas de jejum e restrição hí
drica, cultura da urina e análise química quando os cálculos foram disponíveis. 
As técnicas de imagem incluíram ultrassonografia do trato urinário e urografia e
xcretora. <b>RESULTADOS:</b> Em 96,3% das crianças alguma causa foi detectada. A
 principal alteração metabólica encontrada foi a hipercalciúria (73,4%). Análise
 química dos cálculos mostrou oxalato de cálcio em 90,9% dos casos. Alterações a
natômicas foram encontradas em 18,0% dos pacientes investigados, e a mais freque
nte foi a duplicação pieloureteral (28,6%). <b>CONCLUSÕES:</b>Hipercalciúria foi
 a desordem mais encontrada, a alteração anatômica mais comum foi a duplicação p
ieloureteral e oxalato de cálcio foi o constituinte químico mais frequente. Este
 trabalho serviu para o conhecimento das características dos pacientes pediátric
os portadores de nefrolitíase em nossa região.#^ddecs^i1#^tm^lpt^knefrolitíase^i
1#^tm^lpt^kcrianças^i1#^tm^lpt^kdoenças metabólicas^i1#^len^aMetabolic disorders
 are frequently observed in pediatric patients with renal lithiasis. <b>OBJECTIV
ES:</b> Study the metabolic and anatomical alterations and perform the chemical 
analysis of stones found in children with nephrolithiasis in our region. <b>METH
ODS: </b>A retrospective study on 158 children with evidence of recent renal sto
ne formation was performed. One hundred and nine children concluded the metaboli
c study. Laboratory investigation consisted in two samples of 24-hour urine for 
calcium, uric acid, citrate, oxalate, sodium and creatinine; qualitative cystinu
ria, urinary pH following 12-hour fasting and water restriction, urine culture a
nd chemical analysis when the stones were available. Renal imaging techniques in
cluded, at least, renal ultrasound and excretory urogram. <b>RESULTS:</b> A caus
e for nephrolithiasis was identified in 96.3% of children. The main metabolic al
teration was hypercalciuria (73.4%). Chemical analysis of stones showed calcium 
oxalate in 90.9% of the cases. Anatomical alterations were found in 18.0% of the
 investigated cases and the most frequently found alteration was pyelo-ureteral 
duplication (28.6%). <b>CONCLUSIONS:</b> Hypercalciuria was the most frequently 
found disorder and pyelo-ureteral duplication was the most common anatomical alt
eration; moreover, calcium oxalate was the most frequent chemical constituent. T
he present study showed the characteristics of pediatric patients with nephrolit
hiasis in our region.#^ddecs^i2#^tm^len^knephrolithiasis^i2#^tm^len^kchild^i2#^t
m^len^kmetabolic diseases^i2#vancouv#32#20101031#31/10/2010#20101223#23/12/2010#
v33n1a07.htm##
04784000000000697000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000400107121000300111049000700114158000300121
03000160012403100030014003200020014306500090014501400090015403500100016301200790
01730120082002520100039003340100031003730100035004040100043004390100043004820100
04200525010003300567010003400600010003200634010002500666070004800691070004100739
08314840078008500100226408500250227408500210229908500320232008314940235208500100
38460850028038560850018038840850031039021170008039330720003039411120009039441110
01103953114000903964113001103973002001303984008008903997#v33n1#V:\SciELO\serial\
jbn\v33n1\markup\v33n1a07.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#
4.0#tab#07#JBN020#nd#J. Bras. Nefrol#33#1#20110300#^f50^l54#0101-2800#Nefrolitía
se em pacientes pediátricos: investigação metabólica e anatômica^lpt#Nephrolithi
asis in pediatric patients: metabolic and anatomical investigation^len#^rND^1A01
^nLuis Alberto Batista^sPeres#^rND^1A01^nSarah Sella^sLanger#^rND^1A01^nRaysa Cr
istina^sSchmidt#^rND^1A01^nRoberto Arthur Bavaresco^sNacke#^rND^1A01^nPaulo Vict
or Muller^sFrancescon#^rND^1A01^nRogério Cavalcante de^sAlmeida#^rND^1A01^nRenan
 Macedo^sCoimbra#^rND^1A01^nTailla Michelle^sRibas#^rND^1A01^nTiago Dahrug^sBarr
os#^rND^1A02^nTiemi^sMatsuo#^iA01^1Universidade Estadual do Oeste do Paraná#^iA0
2^1Universidade Estadual de Londrina#^lpt^aDesordens metabólicas são frequentes 
em pacientes com nefrolitíase pediátrica. OBJETIVOS: Estudar as alterações metab
ólicas e anatômicas e a análise química dos cálculos encontrados em pacientes da
 nossa região. MÉTODOS: Este é um estudo retrospectivo em 158 crianças com evidê
ncia de formação recente de cálculos, destes apenas 109 concluíram a investigaçã
o metabólica. A investigação laboratorial consistiu de duas amostras de urina de
 24 horas com dosagem de cálcio, ácido úrico, citrato, oxalato, sódio e creatini
na, cistinúria qualitativa, pH urinário seguido de 12 horas de jejum e restrição
 hídrica, cultura da urina e análise química quando os cálculos foram disponívei
s. As técnicas de imagem incluíram ultrassonografia do trato urinário e urografi
a excretora. RESULTADOS: Em 96,3 por cento das crianças alguma causa foi detecta
da. A principal alteração metabólica encontrada foi a hipercalciúria (73,4 por c
ento). Análise química dos cálculos mostrou oxalato de cálcio em 90,9 por cento 
dos casos. Alterações anatômicas foram encontradas em 18,0 por cento dos pacient
es investigados, e a mais frequente foi a duplicação pieloureteral (28,6 por cen
to). CONCLUSÕES:Hipercalciúria foi a desordem mais encontrada, a alteração anatô
mica mais comum foi a duplicação pieloureteral e oxalato de cálcio foi o constit
uinte químico mais frequente. Este trabalho serviu para o conhecimento das carac
terísticas dos pacientes pediátricos portadores de nefrolitíase em nossa região.
#^ddecs^i1#^tm^lpt^knefrolitíase^i1#^tm^lpt^kcrianças^i1#^tm^lpt^kdoenças metabó
licas^i1#^len^aMetabolic disorders are frequently observed in pediatric patients
 with renal lithiasis. OBJECTIVES: Study the metabolic and anatomical alteration
s and perform the chemical analysis of stones found in children with nephrolithi
asis in our region. METHODS: A retrospective study on 158 children with evidence
 of recent renal stone formation was performed. One hundred and nine children co
ncluded the metabolic study. Laboratory investigation consisted in two samples o
f 24-hour urine for calcium, uric acid, citrate, oxalate, sodium and creatinine;
 qualitative cystinuria, urinary pH following 12-hour fasting and water restrict
ion, urine culture and chemical analysis when the stones were available. Renal i
maging techniques included, at least, renal ultrasound and excretory urogram. RE
SULTS: A cause for nephrolithiasis was identified in 96.3 percent of children. T
he main metabolic alteration was hypercalciuria (73.4 percent). Chemical analysi
s of stones showed calcium oxalate in 90.9 percent of the cases. Anatomical alte
rations were found in 18.0 percent of the investigated cases and the most freque
ntly found alteration was pyelo-ureteral duplication (28.6 percent). CONCLUSIONS
: Hypercalciuria was the most frequently found disorder and pyelo-ureteral dupli
cation was the most common anatomical alteration; moreover, calcium oxalate was 
the most frequent chemical constituent. The present study showed the characteris
tics of pediatric patients with nephrolithiasis in our region.#^ddecs^i2#^tm^len
^knephrolithiasis^i2#^tm^len^kchild^i2#^tm^len^kmetabolic diseases^i2#vancouv#32
#20101031#31/10/2010#20101223#23/12/2010#v33n1a07.htm#Internet^ihttp://www.sciel
o.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100007##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#5#1#article#128#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a07.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#6#2#article#128#<p>&nbsp;</p>     ^cY#
v33n1a07.htm##
00458000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704022600073002001300299#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#7#3#article#128#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Nefrolit&iacute;a
se em pacientes pedi&aacute;tricos: investiga&ccedil;&atilde;o  metab&oacute;lic
a e anat&ocirc;mica </b></font></p>     ^cY#v33n1a07.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#8#4#article#128#<p>&nbsp;</p>     ^cY#
v33n1a07.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#9#5#article#128#<p>&nbsp;</p>     ^cY#
v33n1a07.htm##
00700000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704046700074002001300541#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#10#6#article#128#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Luis Alberto Batista Peres<sup>I</s
up>; Sarah Sella Langer<sup>I</sup>; Raysa Cristina  Schmidt<sup>I</sup>; Robert
o Arthur  Bavaresco Nacke<sup>I</sup>; Paulo Victor Muller Francescon<sup>I</sup
>; Rog&eacute;rio Cavalcante  de Almeida<sup>I</sup>; Renan Macedo  Coimbra<sup>
I</sup>; Tailla Michelle Ribas<sup>I</sup>; Tiago Dahrug Barros<sup>I</sup>; Tie
mi Matsuo<sup>II</sup></b></font></p>     ^cY#v33n1a07.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704014100074002001300215#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#11#7#article#128#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Universidade Estadual do O
este do Paran&aacute; - UNIOESTE    ^cY#v33n1a07.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704007300074002001300147#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#12#8#article#128#<br>   <sup>II</sup>U
niversidade Estadual de Londrina</font></p>     ^cY#v33n1a07.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704012400074002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#13#9#article#128#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia<
/a></font></p>     ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#14#10#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#15#11#article#128#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a07.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#16#12#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a07.htm##
00412000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017800075002001300253#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#17#13#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Desordens metab&oacute;licas s&atilde
;o frequentes em pacientes com nefrolit&iacute;ase pedi&aacute;trica.     ^cY#v3
3n1a07.htm##
00444000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021000075002001300285#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#18#14#article#128#<br>   <b>OBJETIVOS:
</b> Estudar as altera&ccedil;&otilde;es metab&oacute;licas e anat&ocirc;micas e
 a an&aacute;lise qu&iacute;mica dos c&aacute;lculos encontrados em pacientes da
 nossa regi&atilde;o.     ^cY#v33n1a07.htm##
01016000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704078200075002001300857#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#19#15#article#128#<br>   <b>M&Eacute;T
ODOS:</b> Este &eacute; um estudo retrospectivo em 158 crian&ccedil;as com evid&
ecirc;ncia de forma&ccedil;&atilde;o recente de c&aacute;lculos, destes apenas 1
09 conclu&iacute;ram a investiga&ccedil;&atilde;o metab&oacute;lica. A investiga
&ccedil;&atilde;o laboratorial consistiu de duas amostras de urina de 24 horas c
om dosagem de c&aacute;lcio, &aacute;cido &uacute;rico, citrato, oxalato, s&oacu
te;dio e creatinina, cistin&uacute;ria qualitativa, pH urin&aacute;rio seguido d
e 12 horas de jejum e restri&ccedil;&atilde;o h&iacute;drica, cultura da urina e
 an&aacute;lise qu&iacute;mica quando os c&aacute;lculos foram dispon&iacute;vei
s. As t&eacute;cnicas de imagem inclu&iacute;ram ultrassonografia do trato urin&
aacute;rio e urografia excretora.     ^cY#v33n1a07.htm##
00701000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046700075002001300542#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#20#16#article#128#<br>   <b> RESULTADO
S:</b> Em 96,3% das crian&ccedil;as alguma causa foi detectada. A principal alte
ra&ccedil;&atilde;o metab&oacute;lica encontrada foi a hipercalci&uacute;ria (73
,4%). An&aacute;lise qu&iacute;mica dos c&aacute;lculos mostrou oxalato de c&aac
ute;lcio em 90,9% dos casos. Altera&ccedil;&otilde;es anat&ocirc;micas foram enc
ontradas em 18,0% dos pacientes investigados, e a mais frequente foi a duplica&c
cedil;&atilde;o pieloureteral (28,6%).     ^cY#v33n1a07.htm##
00674000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044000075002001300515#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#21#17#article#128#<br>   <b>CONCLUS&Ot
ilde;ES:</b>Hipercalci&uacute;ria foi a desordem mais encontrada, a altera&ccedi
l;&atilde;o anat&ocirc;mica mais comum foi a duplica&ccedil;&atilde;o pielourete
ral e oxalato de c&aacute;lcio foi o constituinte qu&iacute;mico mais frequente.
 Este trabalho serviu para o conhecimento das caracter&iacute;sticas dos pacient
es pedi&aacute;tricos portadores de nefrolit&iacute;ase em nossa regi&atilde;o. 
</font></p>     ^cY#v33n1a07.htm##
00435000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020100075002001300276#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#22#18#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> nefrolit&iacut
e;ase, crian&ccedil;as, doen&ccedil;as metab&oacute;licas. </font></p> <hr size=
"1" noshade>     ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#23#19#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#24#20#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#25#21#article#128#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a07.htm##
01316000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704108200075002001301157#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#26#22#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A nefrolit&iacute;ase na faixa et&aac
ute;ria pedi&aacute;trica &eacute; relativamente infrequente. Em diferentes s&ea
cute;ries de pacientes de todas as idades com lit&iacute;ase renal, a preval&eci
rc;ncia em crian&ccedil;as varia de 2 a 2,7%. <sup>1,2</sup> Estudos recentes t&
ecirc;m mostrado que a incid&ecirc;ncia anual est&aacute; crescendo em diferente
s popula&ccedil;&otilde;es. <sup>3,4</sup> No momento do diagn&oacute;stico, a m
aioria dos c&aacute;lculos em crian&ccedil;as foi encontrada nos rins, com reman
escentes encontrados nos ureteres. <sup>5</sup> Diversos fatores predisp&otilde;
em a crian&ccedil;a a desenvolver nefrolit&iacute;ase, dentre eles anormalidades
 metab&oacute;licas e genitourin&aacute;rias s&atilde;o particularmente importan
tes; estes est&atilde;o frequentemente associados a dieta, fatores ambientais e 
causas infecciosas. A nefrolit&iacute;ase est&aacute; associada com consider&aac
ute;vel morbidade e com elevados &iacute;ndices de recorr&ecirc;ncia. <sup>6</su
p></font></p>     ^cY#v33n1a07.htm##
00951000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071700075002001300792#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#27#23#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O conhecimento da fisiopatologia da n
efrolit&iacute;ase em crian&ccedil;as tem crescido nos &uacute;ltimos anos. A ma
ior parte das crian&ccedil;as com lit&iacute;ase urin&aacute;ria tem anormalidad
es metab&oacute;licas subjacentes, sendo a hipercalci&uacute;ria a mais prevalen
te. <sup>7,8,9</sup> Outros fatores metab&oacute;licos de risco variam em frequ&
ecirc;ncia de acordo com as diferentes s&eacute;ries. <sup>10,11</sup> Algumas o
utras altera&ccedil;&otilde;es metab&oacute;licas descritas s&atilde;o hipocitra
t&uacute;ria, hiperuricos&uacute;ria, hiperoxal&uacute;ria, acidose tubular rena
l e cistin&uacute;ria. <sup>12</sup> </font></p>     ^cY#v33n1a07.htm##
01190000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704095600075002001301031#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#28#24#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em nossa regi&atilde;o, n&atilde;o ha
via nenhum estudo sobre fatores metab&oacute;licos de risco em crian&ccedil;as c
om c&aacute;lculos urin&aacute;rios. Neste estudo retrospectivo, avaliamos os fa
tores metab&oacute;licos de risco, apresenta&ccedil;&atilde;o cl&iacute;nica, hi
st&oacute;rico familiar, altera&ccedil;&otilde;es anat&ocirc;micas e an&aacute;l
ise qu&iacute;mica dos c&aacute;lculos em crian&ccedil;as com nefrolit&iacute;as
e que foram encaminhadas para nossa institui&ccedil;&atilde;o para avalia&ccedil
;&atilde;o metab&oacute;lica. Os objetivos s&atilde;o avaliar a preval&ecirc;nci
a dos principais dist&uacute;rbios metab&oacute;licos, altera&ccedil;&otilde;es 
anat&ocirc;micas e an&aacute;lise qu&iacute;mica dos c&aacute;lculos encontrados
 nas crian&ccedil;as com diagn&oacute;stico recente de nefrolit&iacute;ase na re
gi&atilde;o oeste do Paran&aacute;. </font></p>     ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#29#25#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#30#26#article#128#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>     
^cY#v33n1a07.htm##
01156000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704092200075002001300997#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#31#27#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foi realizado um estudo retrospectivo
 em 158 crian&ccedil;as do servi&ccedil;o de nefrologia do ambulat&oacute;rio ge
ral do Hospital Universit&aacute;rio do Oeste do Paran&aacute;, que apresentaram
 evid&ecirc;ncias de nefrolit&iacute;ase recente, no per&iacute;odo de 1995 a 20
10. Os crit&eacute;rios de inclus&atilde;o para os pacientes desse estudo retros
pectivo foram elimina&ccedil;&atilde;o espont&acirc;nea, endosc&oacute;pica ou c
ir&uacute;rgica de c&aacute;lculos e/ou confirma&ccedil;&atilde;o radiol&oacute;
gica da presen&ccedil;a dos mesmos no trato urin&aacute;rio nos &uacute;ltimos s
eis meses. Foram registrados os dados da urina de 24-horas de pacientes com mais
 de uma amostra, hist&oacute;ria familiar, apresenta&ccedil;&atilde;o cl&iacute;
nica, an&aacute;lise qu&iacute;mica de c&aacute;lculos renais e exames de imagem
. </font></p>     ^cY#v33n1a07.htm##
00796000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056200075002001300637#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#32#28#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A investiga&ccedil;&atilde;o laborato
rial incluiu duas ou mais amostras de urina de 24-horas, incluindo c&aacute;lcio
, &aacute;cido &uacute;rico, citrato, s&oacute;dio, creatinina e oxalato e c&aac
ute;lcio, &aacute;cido &uacute;rico, creatinina e paratorm&ocirc;nio no sangue. 
Cistin&uacute;ria qualitativa, pH urin&aacute;rio ap&oacute;s jejum e restri&cce
dil;&atilde;o h&iacute;drica de 12 horas, urocultura e an&aacute;lise qu&iacute;
mica de c&aacute;lculos foram realizados. </font></p>     ^cY#v33n1a07.htm##
01856000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704162200075002001301697#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#33#29#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os m&eacute;todos laboratoriais empre
gados e os valores de refer&ecirc;ncia adotados para amostras de urina de 24 hor
as foram: c&aacute;lcio - m&eacute;todo de espectrofotometria de absor&ccedil;&a
tilde;o at&ocirc;mica (&lt; 4,0 mg/kg); &aacute;cido &uacute;rico - m&eacute;tod
o enzim&aacute;tico da uricase (&lt; 15 mg por kg); citrato - m&eacute;todo enzi
m&aacute;tico da citrato-liase (&gt; 320 mg); s&oacute;dio - m&eacute;todo &iacu
te;on seletivo (&lt; 150 mEq); creatinina - m&eacute;todo do picrato alcalino (&
gt; 1.000 mg) e volume urin&aacute;rio - medi&ccedil;&atilde;o volum&eacute;tric
a em Becker por an&aacute;lise visual. Para as dosagens plasm&aacute;ticas, os m
&eacute;todos utilizados foram: c&aacute;lcio - m&eacute;todo colorim&eacute;tri
co (8,5-10,5 mg/dL); &aacute;cido &uacute;rico - m&eacute;todo colorim&eacute;tr
ico da uricase (2,0 a 7,0 mg/dL); creatinina - m&eacute;todo do picrato alcalino
 (0,7 a 1,4 mg/dL) e paratorm&ocirc;nio - ensaio da mol&eacute;cula intacta. Par
a os exames em amostra isolada de urina, os m&eacute;todos foram: cistin&uacute;
ria qualitativa - teste do nitroprussiato de s&oacute;dio e pH urin&aacute;rio -
 medi&ccedil;&atilde;o atrav&eacute;s de tiras reativas com sistema de indicador
 do vermelho de metila e azul de bromotimol. Foi considerado volume urin&aacute;
rio diminu&iacute;do, quando pelo menos uma das amostras apresentasse volume uri
n&aacute;rio de 24 horas menor que 15 mL/kg. Para efetuar a an&aacute;lise qu&ia
cute;mica foi utilizado o m&eacute;todo colorim&eacute;trico. </font></p>     ^c
Y#v33n1a07.htm##
00496000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026200075002001300337#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#34#30#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pacientes foram divididos em dois 
grupos conforme a idade, com ponto de corte de 10 anos, sendo que 49 pacientes a
presentavam idade inferior a 10 anos e 60 superior a 10 anos. </font></p>     ^c
Y#v33n1a07.htm##
00581000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034700075002001300422#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#35#31#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para comparar as vari&aacute;veis, os
 testes utilizados foram: qui-quadrado e o teste exato de Fisher. P &lt; 0,05 fo
i considerado estatisticamente significativo. Este estudo foi aprovado pelo Comi
t&ecirc; de &Eacute;tica em Pesquisa em Seres Humanos da UNIOESTE. </font></p>  
   ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#36#32#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#37#33#article#128#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v33n1a07.htm##
00816000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058200075002001300657#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#38#34#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As apresenta&ccedil;&otilde;es cl&iac
ute;nicas mais frequentes foram a c&oacute;lica renal (65,2%) e a hemat&uacute;r
ia (24,8%). Nos pacientes com idade inferior a 10 anos, a apresenta&ccedil;&atil
de;o cl&iacute;nica mais comum foi hemat&uacute;ria, e no grupo com mais de 10 a
nos foi a c&oacute;lica renal (p &lt; 0,05). Esses dados est&atilde;o na <a href
="/img/revistas/jbn/v33n1/a07tab01m.jpg">Tabela 1</a>. Hist&oacute;ria familiar 
de nefrolit&iacute;ase foi relatada em 80% do grupo estudado. </font></p>     ^c
Y#v33n1a07.htm##
01295000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704106100075002001301136#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#39#35#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Entre os 158 pacientes, 109 conclu&ia
cute;ram o estudo metab&oacute;lico. Em 96,3% pelo menos uma altera&ccedil;&atil
de;o foi encontrada. A idade m&eacute;dia dos pacientes foi de  11,4 ± 4,7 anos 
(variando de quatro meses a 18 anos) e 54,1% eram do sexo masculino. As principa
is altera&ccedil;&otilde;es metab&oacute;licas encontradas foram: hipercalci&uac
ute;ria (73,4%), hipocitrat&uacute;ria (32,1%) e hiperexcre&ccedil;&atilde;o de 
&aacute;cido &uacute;rico (21,1%). N&atilde;o foram estatisticamente significati
vas as diferen&ccedil;as encontradas entre as distribui&ccedil;&otilde;es de ida
de e sexo (<a href="/img/revistas/jbn/v33n1/a07tab02m.jpg">Tabelas 2</a> e <a hr
ef="/img/revistas/jbn/v33n1/a07tab03m.jpg">3</a>, p &gt; 0,05). Houve diferen&cc
edil;a significativa no n&uacute;mero de pacientes com baixo volume urin&aacute;
rio e de n&atilde;o investigados, sendo superiores no grupo acima de 10 anos (<a
 href="/img/revistas/jbn/v33n1/a07tab03m.jpg">Tabela 3</a>). </font></p>     ^cY
#v33n1a07.htm##
00537000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030300075002001300378#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#40#36#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise qu&iacute;mica dos c
&aacute;lculos revelou oxalato de c&aacute;lcio em 90,9%, carbonato de c&aacute;
lcio em 54,5%, &aacute;cido &uacute;rico em 18,2%, f&oacute;sforo e magn&eacute;
sio em 9,1% dos casos. </font></p>     ^cY#v33n1a07.htm##
00738000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050400075002001300579#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#41#37#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Altera&ccedil;&otilde;es anat&ocirc;m
icas foram encontradas em 18,1% dos investigados, sendo a duplica&ccedil;&atilde
;o pieloureteral encontrada em quatro pacientes (28,6%), cisto renal em tr&ecirc
;s (21,4%), bexiga neurog&ecirc;nica em dois (14,3%) e obstru&ccedil;&atilde;o d
a jun&ccedil;&atilde;o pielocalicial, pelve extrarrenal, rim em ferradura, rins 
polic&iacute;sticos e estenose do ureter distal em um paciente. </font></p>     
^cY#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#42#38#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#43#39#article#128#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v33n1a07.htm##
00675000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044100075002001300516#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#44#40#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Neste estudo apresentamos os principa
is fatores de risco metab&oacute;licos, a apresenta&ccedil;&atilde;o cl&iacute;n
ica, as altera&ccedil;&otilde;es anat&ocirc;micas e a hist&oacute;ria familiar d
e pacientes pedi&aacute;tricos com lit&iacute;ase renal que foram encaminhados a
 nossa institui&ccedil;&atilde;o para avalia&ccedil;&atilde;o metab&oacute;lica.
 </font></p>     ^cY#v33n1a07.htm##
00640000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040600075002001300481#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#45#41#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nefrolit&iacute;ase pode ocorrer em q
ualquer idade. A literatura tem mostrado que a m&eacute;dia de idade do diagn&oa
cute;stico varia entre 7 e 10 anos. <sup><i>3,</i></sup><sup>13</sup> Neste estu
do a idade m&eacute;dia dos pacientes foi de 11 anos, sendo que 40% apresentaram
 idade inferior a 10 anos na admiss&atilde;o. </font></p>     ^cY#v33n1a07.htm##
01365000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704113100075002001301206#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#46#42#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Anormalidades metab&oacute;licas fora
m encontradas em 96,3% dos pacientes estudados, sendo hipercalci&uacute;ria, hip
ocitrat&uacute;ria e hiperuricos&uacute;ria os tr&ecirc;s maiores fatores de ris
co metab&oacute;licos urin&aacute;rios. Esses dados s&atilde;o similares aos de 
outros estudos. <sup>11,14</sup> A distribui&ccedil;&atilde;o quanto ao sexo ent
re os pacientes pedi&aacute;tricos que completaram a investiga&ccedil;&atilde;o 
metab&oacute;lica &eacute; semelhante. Quando comparadas as altera&ccedil;&otild
e;es metab&oacute;licas entre os grupos et&aacute;rios inferior e superior a 10 
anos n&atilde;o h&aacute; diferen&ccedil;as estatisticamente significativas. A e
pidemiologia da lit&iacute;ase renal na popula&ccedil;&atilde;o pedi&aacute;tric
a n&atilde;o &eacute; t&atilde;o bem definida quanto na popula&ccedil;&atilde;o 
adulta. Na primeira d&eacute;cada de vida, a lit&iacute;ase renal foi mais preva
lente no sexo masculino, o que se inverteu na segunda d&eacute;cada de vida, sen
do mais prevalente no sexo feminino. <sup>15</sup> </font></p>     ^cY#v33n1a07.
htm##
01053000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704081900075002001300894#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#47#43#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Hipercalci&uacute;ria est&aacute; ass
ociada ao desenvolvimento de nefrolit&iacute;ase. Em crian&ccedil;as com hiperca
lci&uacute;ria, a preval&ecirc;ncia de lit&iacute;ase renal na fam&iacute;lia &e
acute; de 46 a 49%. <sup>11,16</sup> Hipercalci&uacute;ria idiop&aacute;tica tem
 sido o fator de risco metab&oacute;lico mais frequente, detectado em 40 a 69% d
os casos. <sup>17,19</sup> Uma hist&oacute;ria familiar positiva parece ser o ma
is importante fator de risco isolado. <sup>20</sup> Um grande n&uacute;mero de g
enes tem sido sugerido como respons&aacute;veis na patog&ecirc;nese da hipercalc
i&uacute;ria. <sup>21-26</sup> Neste estudo, 89,6% dos pacientes com hipercalci&
uacute;ria apresentaram hist&oacute;ria familiar positiva. </font></p>     ^cY#v
33n1a07.htm##
01042000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080800075002001300883#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#48#44#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outros dist&uacute;rbios metab&oacute
;licos principais encontrados foram hipocitrat&uacute;ria (32,1%) e hiperuricos&
uacute;ria (21,1%). At&eacute; recentemente, hipocitrat&uacute;ria era considera
da pouco frequente. <sup>10</sup> Tefekli <i>et al. </i><sup>27</sup> reconhecer
am a hipocitrat&uacute;ria como o fator de risco metab&oacute;lico mais prevalen
te em crian&ccedil;as com lit&iacute;ase renal (60,6%). Van Dervoort <i>et al. <
/i><sup>4</sup> tamb&eacute;m observaram que a hipocitrat&uacute;ria era a anorm
alidade metab&oacute;lica mais comumente encontrada, presente em 52% das crian&c
cedil;as estudadas entre 2003-2005. Hiperuricos&uacute;ria tem sido detectada em
 16% a 54% das crian&ccedil;as. <sup>28-30</sup></font></p>     ^cY#v33n1a07.htm
##
01620000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704138600075002001301461#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#49#45#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os sinais e sintomas presentes na nef
rolit&iacute;ase pedi&aacute;trica s&atilde;o dor abdominal ou em flanco com ou 
sem hemat&uacute;ria, infec&ccedil;&atilde;o do trato urin&aacute;rio e hemat&ua
cute;ria isolada. <sup>29,31</sup> A cl&aacute;ssica c&oacute;lica renal &eacute
; mais rara em crian&ccedil;as, ocorrendo com mais frequ&ecirc;ncia sintomas vag
os, como dor em flancos, ou mesmo hemat&uacute;ria indolor. <sup>32</sup> Nos pa
cientes com idade inferior a 10 anos, a apresenta&ccedil;&atilde;o cl&iacute;nic
a mais comum foi hemat&uacute;ria e no grupo com mais de 10 anos foi a c&oacute;
lica renal. Esses dados s&atilde;o concordantes com o estudo de Alpav <i>et al. 
</i><sup>31</sup> Oxalato de c&aacute;lcio &eacute; o principal componente dos c
&aacute;lculos analisados. <sup>28</sup> Neste estudo encontramos oxalato de c&a
acute;lcio em 90,9% dos c&aacute;lculos analisados. Dursun <i>et al. </i><sup>29
</sup> em avalia&ccedil;&atilde;o de 179 pacientes pedi&aacute;tricos observaram
 dor abdominal e em flancos em 56% e hemat&uacute;ria macrosc&oacute;pica em 14%
 dos casos. A principal altera&ccedil;&atilde;o anat&ocirc;mica detectada foi ob
stru&ccedil;&atilde;o da jun&ccedil;&atilde;o ureterop&eacute;lvica e oxalato de
 c&aacute;lcio foi o constituinte qu&iacute;mico mais encontrado. </font></p>   
  ^cY#v33n1a07.htm##
00851000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704061700075002001300692#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#50#46#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Altera&ccedil;&otilde;es anat&ocirc;m
icas estavam presentes em 18% dos casos em nosso estudo, das quais, duplica&cced
il;&atilde;o pieloureteral foi a mais frequente. Obstru&ccedil;&atilde;o da jun&
ccedil;&atilde;o ureterop&eacute;lvica foi a anormalidade mais comum no estudo d
e Dursun <i>et al. </i><sup>29</sup> Alpav<i> et al. </i><sup>31</sup> encontrar
am o refluxo vesicoureteral como a mais prevalente anormalidade urol&oacute;gica
 que poderia causar estase urin&aacute;ria e &agrave; forma&ccedil;&atilde;o de 
c&aacute;lculos. </font></p>     ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#51#47#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#52#48#article#128#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Otilde;ES</b></font></p>  
   ^cY#v33n1a07.htm##
01030000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704079600075002001300871#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#53#49#article#128#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Hipercalci&uacute;ria foi o dist&uacu
te;rbio metab&oacute;lico mais frequente na popula&ccedil;&atilde;o pedi&aacute;
trica estudada. A altera&ccedil;&atilde;o anat&ocirc;mica mais frequentemente en
contrada foi a duplica&ccedil;&atilde;o pieloureteral. Oxalato de c&aacute;lcio 
foi o elemento qu&iacute;mico constituinte mais frequente nos c&aacute;lculos. N
&atilde;o h&aacute; diferen&ccedil;as quanto aos dist&uacute;rbios metab&oacute;
licos entre os sexos e as faixas et&aacute;rias, mas apenas quanto &agrave; apre
senta&ccedil;&atilde;o cl&iacute;nica. Este trabalho foi importante para o conhe
cimento das caracter&iacute;sticas dos pacientes pedi&aacute;tricos com nefrolit
&iacute;ase em nossa regi&atilde;o. </font></p>     ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#54#50#article#128#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#55#51#article#128#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a07.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021500077002001300292#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#56#52#article#128#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Vahlensieck EW, Bach
 D, Hesse A. Incidence, prevalence and mortality of urolithiasis in the German F
ederal Republic. Urol Res 1982; 10:161-4.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#57#53#article#128# </font></p>     ^cY
#v33n1a07.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021900077002001300296#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#58#54#article#128#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Borghi L, Ferretti P
P, Elia GF <i>et al. </i> Epidemiological study of urinary tract stones in a Nor
thern Italian City. Br J Urol 1990; 65:231-5.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#59#55#article#128# </font></p>     ^cY
#v33n1a07.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021200077002001300289#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#60#56#article#128#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Edvardsson V, Elidot
tir H, Indridason O, Palsson R. High incidence of kidney stones in Icelandic chi
ldren. Pediatr Nephrol 2005; 20:940-4.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#61#57#article#128# </font></p>     ^cY
#v33n1a07.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025300077002001300330#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#62#58#article#128#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. VanDervoort K, Wiese
n J, Frank R<i> et al. </i> Urolithiasis in pediatric patients: a single center 
study of incidence, clinical presentation and outcome. J Urol 2007; 177:2300-5. 
   ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#63#59#article#128# </font></p>     ^cY
#v33n1a07.htm##
00435000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704018700077002001300264#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#64#60#article#128#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Gearhart JP, Herzber
g GZ, Jeffs RD. Childhood urolithiasis: experiences and advances. Pediatrics 199
1; 87:445-50.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#65#61#article#128# </font></p>     ^cY
#v33n1a07.htm##
00436000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704018800077002001300265#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#66#62#article#128#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Noe HN, Stapleton FB
, Jerkins GR, Roy S. Clinical experience with pediatric urolithiasis. J Urol 198
3; 129:1166-8.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#67#63#article#128# </font></p>     ^cY
#v33n1a07.htm##
00412000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704016400077002001300241#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#68#64#article#128#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Milliner DS, Murphy 
ME. Urolithiasis in pediatric patients. Mayo Clin Proc 1993; 68:241-8.    ^cY#v3
3n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#69#65#article#128# </font></p>     ^cY
#v33n1a07.htm##
00439000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704019100077002001300268#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#70#66#article#128#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Srivastava T, Schwad
erer A. Diagnosis and management of hypercalciuria in children. Curr Opin Pediat
r 2009; 21:214-9.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#71#67#article#128# </font></p>     ^cY
#v33n1a07.htm##
00437000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704018900077002001300266#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#72#68#article#128#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Guven AG, Koyun M, B
aysal YE <i>et al. </i>Urolithiasis in the first year of life. Pediatr Nephrol 2
010; 25:129-34.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#73#69#article#128# </font></p>     ^cY
#v33n1a07.htm##
00403000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704015400078002001300232#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#74#70#article#128#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Stapleton FB. Chil
dhood stones. Endocrinol Metab Clin North Am 2002; 31:1001-5.    ^cY#v33n1a07.ht
m##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#75#71#article#128# </font></p>     ^cY
#v33n1a07.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704025300078002001300331#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#76#72#article#128#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Spivacow FR, Negri
 AL, del Valle EE, Calvi&ntilde;o I, Fradinger E, Zanchetta JR. Metabolic risk f
actors in children with kidney stone disease. Pediatr Nephrol 2008; 23: 1129-33.
    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#77#73#article#128# </font></p>     ^cY
#v33n1a07.htm##
00407000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704015800078002001300236#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#78#74#article#128#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Worcester EM, Coe 
FL. Nephrolithiasis. Prim Care Clin Office Pract 2008; 35:369-91.    ^cY#v33n1a0
7.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#79#75#article#128# </font></p>     ^cY
#v33n1a07.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704020700078002001300285#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#80#76#article#128#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Ozokutan BH, Kucuk
ayd&#305;n M, Gunduz Z, Kabaklioglu M, Okur H, Turan C. Urolithiasis in childhoo
d. Pediatr Surg Int 2000; 16:60-3.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#81#77#article#128# </font></p>     ^cY
#v33n1a07.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704021200078002001300290#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#82#78#article#128#14#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Del Valle EE, Spiv
acow FR, Zanchetta JR. Metabolic evaluation at the time of the first renal lithi
asis episode. Medicina 1999; 59:417-22.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#83#79#article#128# </font></p>     ^cY
#v33n1a07.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704026000078002001300338#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#84#80#article#128#15#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Novak TE, Lakshman
an Y, Trock BJ, Gearhart JP, Matlaga BR. Sex prevalence of pediatric kidney ston
e disease in the United States: an epidemiologic investigation. Urology 2009; 74
:104-7.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#85#81#article#128# </font></p>     ^cY
#v33n1a07.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704025200078002001300330#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#86#82#article#128#16#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Polito C, La Manna
 A, Cioce F, Villani J, Nappi B, Di Toro R. Clinical presentation and natural co
urse of idiopathic hypercalciuria in children. Pediatr Nephrol 2000; 15:211-14. 
   ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#87#83#article#128# </font></p>     ^cY
#v33n1a07.htm##
00431000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704018200078002001300260#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#88#84#article#128#17#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Basaklar AC, Kale 
N. Experience with childhood urolithiasis. Report of 196 cases. Br J Urol 1991; 
67:203-5.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#89#85#article#128# </font></p>     ^cY
#v33n1a07.htm##
00438000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704018900078002001300267#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#90#86#article#128#18#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Stapleton FB, McKa
y CP, Noe HN. Urolithiasis in children: the role of hypercalciuria. Pediatr Ann 
1987; 16: 980-1.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#91#87#article#128# </font></p>     ^cY
#v33n1a07.htm##
00445000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704019600078002001300274#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#92#88#article#128#19#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Lieberman E. Impor
tance of metabolic contributions to urolithiasis in pediatric patients. Mayo Cli
n Proc 1993; 68:313-15.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#93#89#article#128# </font></p>     ^cY
#v33n1a07.htm##
00444000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704019500078002001300273#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#94#90#article#128#20#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Curhan GC, Willett
 WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Ne
phrol 1997; 8:1568-73.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#95#91#article#128# </font></p>     ^cY
#v33n1a07.htm##
00538000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704028900078002001300367#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#96#92#article#128#21#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Loredo-Osti JC, Ro
slin NM, Tessier J, Fujiwara TM, Morgan K, Bonnardeaux A. Segregation of urine c
alcium excretion in families ascertained for nephrolithiasis: evidence for a maj
or gene. Kidney Int 2005; 68:966-71.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#97#93#article#128# </font></p>     ^cY
#v33n1a07.htm##
00443000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704019400078002001300272#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#98#94#article#128#22#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Vezzoli G, Soldati
 L, Gambaro G. Update on primary hypercalciuria from a genetic perspective. J Ur
ol 2008; 179:1676-82.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#99#95#article#128# </font></p>     ^cY
#v33n1a07.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704023200079002001300311#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#100#96#article#128#23#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Reed BY, Heller H
J, Gitomer WL, Pak CY. Mapping a gene defect in absorptive hypercalciuria to chr
omosome 1q233-q24. J Clin Endocrinol Metab 1999; 84:3907-13.    ^cY#v33n1a07.htm
##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#101#97#article#128# </font></p>     ^c
Y#v33n1a07.htm##
00567000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704031700079002001300396#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#102#98#article#128#24#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Reed BY, Gitomer 
WL, Heller HJ <i>et al. </i> Identification and characterization of a gene with 
base substitutions associated with the absorptive hypercalciuria phenotype and l
ow spinal bone density. J Clin Endocrinol Metab 2002; 87:1476-85.    ^cY#v33n1a0
7.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#103#99#article#128# </font></p>     ^c
Y#v33n1a07.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025400080002001300334#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#104#100#article#128#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Vezzoli G, Tanin
i A, Ferrucci L <i>et al. </i>Influence of calcium-sensing receptor gene on urin
ary calcium excretion in stone-forming patients. J Am Soc Nephrol 2002; 13:2517-
23.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#105#101#article#128# </font></p>     ^
cY#v33n1a07.htm##
00479000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022800080002001300308#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#106#102#article#128#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Imamura K, Tonok
i H, Wakui K <i>et al. </i>4q33-qter deletion and absorptive hypercalciuria: rep
ort of two unrelated girls. Am J Med Genet 1998; 78:52-4.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#107#103#article#128# </font></p>     ^
cY#v33n1a07.htm##
00503000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025200080002001300332#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#108#104#article#128#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Tefekli A, Esen 
T, Ziylan O <i>et al. </i>Metabolic risk factors in pediatric and adult calcium 
oxalate urinary stone formers: is there any difference? Urol Int 2003; 70:273-77
.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#109#105#article#128# </font></p>     ^
cY#v33n1a07.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018900080002001300269#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#110#106#article#128#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Rizvi SA, Sultan
 S, Zafar MN <i>et al. </i>Evaluation of children with urolithiasis. Indian J Ur
ol 2007; 23:420-7.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#111#107#article#128# </font></p>     ^
cY#v33n1a07.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021800080002001300298#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#112#108#article#128#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Dursun I, Poyraz
oglu HM, Dusunsel R <i>et al. </i>Pediatric urolithiasis: an 8-year experience o
f single centre. Int Urol Nephrol 2008; 40:3-9.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#113#109#article#128# </font></p>     ^
cY#v33n1a07.htm##
00457000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020600080002001300286#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#114#110#article#128#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Naseri M, Varast
eh AR, Alamdaran SA. Metabolic factors associated with urinary calculi in childr
en. Iran J Kidney Dis 2010; 4:32-8.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#115#111#article#128# </font></p>     ^
cY#v33n1a07.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022600080002001300306#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#116#112#article#128#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Alpay H, Ozen A,
 Gokce I, Biyikli N. Clinical and metabolic features of urolithiasis and microli
thiasis in children. Pediatric Nephrol 2009; 24:2203-9.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#117#113#article#128# </font></p>     ^
cY#v33n1a07.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023800080002001300318#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#118#114#article#128#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Spahi MA, Heidar
j A, Shajari A. Clinical manifestations and etiology of renal stones in children
 less than 14 years age. Saudi J Kidney Dis Transpl 2010; 21:181-4.    ^cY#v33n1
a07.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#119#115#article#128# </font></p>     ^
cY#v33n1a07.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#120#116#article#128#<p>&nbsp;</p>     
^cY#v33n1a07.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#121#117#article#128#<p>&nbsp;</p>     
^cY#v33n1a07.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020000077002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#122#118#article#128#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;
ncia para:</b>    ^cY#v33n1a07.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004100077002001300118#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#123#119#article#128#<br>   Luis Albert
o Batista Peres    ^cY#v33n1a07.htm##
00291000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005500077002001300132#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#124#120#article#128#<br>   R. S&atilde
;o Paulo, 769- Ap 901- Centro    ^cY#v33n1a07.htm##
00289000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005300077002001300130#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#125#121#article#128#<br>   Cascavel - 
PR - Brasil CEP: 85801-020     ^cY#v33n1a07.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009600077002001300173#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#126#122#article#128#<br>   E-mail: <a 
href="mailto:peres@certto.com.br">peres@certto.com.br</a> </font></p>     ^cY#v3
3n1a07.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#127#123#article#128#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 31/10/201
0    ^cY#v33n1a07.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#128#124#article#128#<br>   Data de apr
ova&ccedil;&atilde;o: 23/12/2010    ^cY#v33n1a07.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#129#125#article#128#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a07.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#130#126#article#128#<p>&nbsp;</p>     
^cY#v33n1a07.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#131#127#article#128#<p>&nbsp;</p>     
^cY#v33n1a07.htm##
00447000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704021100077002001300288#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a07.htm#S#p#132#128#article#128#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado na 
Universidade Estadual do Oeste do Paran&aacute; - UNIOESTE, Cascavel, Paran&aacu
te;, Brasil. </font></p>     ^cY#v33n1a07.htm##
00577000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100014000980100
01500112012008700127030000900214065000900223064000500232031000300237014000600240
865000900246002001300255035001000268801000900278#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a07.htm#S#c#133#1#article#32#1#^rND^sVahlensieck^nEW#^rND^sBach^nD
#^rND^sHesse^nA#Incidence, prevalence and mortality of urolithiasis in the Germa
n Federal Republic^len#Urol Res#19820000#1982#10#161-4#20110300#v33n1a07.htm#030
0-5623#Urol Res##
00586000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100019000920100
01500111810000600126012007700132030001000209065000900219064000500228031000300233
014000600236865000900242002001300251035001000264801001000274#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#134#2#article#32#2#^rND^sBorghi^nL#^rND^sF
erretti^nPP#^rND^sElia^nGF#et al#Epidemiological study of urinary tract stones i
n a Northern Italian City^len#Br J Urol#19900000#1990#65#231-5#20110300#v33n1a07
.htm#0007-1331#Br J Urol##
00599000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100019000960100
02000115010001700135012005800152030001600210065000900226064000500235031000300240
014000600243865000900249002001300258035001000271801001600281#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#135#3#article#32#3#^rND^sEdvardsson^nV#^rN
D^sElidottir^nH#^rND^sIndridason^nO#^rND^sPalsson^nR#High incidence of kidney st
ones in Icelandic children^len#Pediatr Nephrol#20050000#2005#20#940-4#20110300#v
33n1a07.htm#0097-5257#Pediatr Nephrol##
00617000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760100016000970100
01500113810000600128012011000134030000700244065000900251064000500260031000400265
014000700269865000900276002001300285035001000298801000700308#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#136#4#article#32#4#^rND^sVanDervoort^nK#^r
ND^sWiesen^nJ#^rND^sFrank^nR#et al#Urolithiasis in pediatric patients: a single 
center study of incidence, clinical presentation and outcome^len#J Urol#20070000
#2007#177#2300-5#20110300#v33n1a07.htm#0022-5347#J Urol##
00551000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100019000950100
01600114012005300130030001100183065000900194064000500203031000300208014000700211
865000900218002001300227035001000240801001100250#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a07.htm#S#c#137#5#article#32#5#^rND^sGearhart^nJP#^rND^sHerzberg^n
GZ#^rND^sJeffs^nRD#Childhood urolithiasis: experiences and advances^len#Pediatri
cs#19910000#1991#87#445-50#20110300#v33n1a07.htm#0031-4005#Pediatrics##
00566000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100020000900100
01800110010001300128012005200141030000700193065000900200064000500209031000400214
014000700218865000900225002001300234035001000247801000700257#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#138#6#article#32#6#^rND^sNoe^nHN#^rND^sSta
pleton^nFB#^rND^sJerkins^nGR#^rND^sRoy^nS#Clinical experience with pediatric uro
lithiasis^len#J Urol#19830000#1983#129#1166-8#20110300#v33n1a07.htm#0022-5347#J 
Urol##
00514000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100017000950120
03900112030001500151065000900166064000500175031000300180014000600183865000900189
002001300198035001000211801001500221#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a07.htm#S#c#139#7#article#32#7#^rND^sMilliner^nDS#^rND^sMurphy^nME#Urolithiasi
s in pediatric patients^len#Mayo Clin Proc#19930000#1993#68#241-8#20110300#v33n1
a07.htm#0025-6196#Mayo Clin Proc##
00544000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100020000960120
05900116030001800175065000900193064000500202031000300207014000600210865000900216
002001300225035001000238801001800248#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a07.htm#S#c#140#8#article#32#8#^rND^sSrivastava^nT#^rND^sSchwaderer^nA#Diagnos
is and management of hypercalciuria in children^len#Curr Opin Pediatr#20090000#2
009#21#214-9#20110300#v33n1a07.htm#1040-8703#Curr Opin Pediatr##
00563000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100015000920100
01700107810000600124012004300130030001600173065000900189064000500198031000300203
014000700206865000900213002001300222035001000235801001600245#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#141#9#article#32#9#^rND^sGuven^nAG#^rND^sK
oyun^nM#^rND^sBaysal^nYE#et al#Urolithiasis in the first year of life^len#Pediat
r Nephrol#20100000#2010#25#129-34#20110300#v33n1a07.htm#0097-5257#Pediatr Nephro
l##
00503000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780120021000980300
03100119065000900150064000500159031000300164014000700167865000900174002001300183
035001000196801003100206#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#
c#142#10#article#32#10#^rND^sStapleton^nFB#Childhood stones^len#Endocrinol Metab
 Clin North Am#20020000#2002#31#1001-5#20110300#v33n1a07.htm#0889-8529#Endocrino
l Metab Clin North Am##
00669000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100016000970100
02000113010001700133010001900150010002000169012006500189030001600254065000900270
06400050027903100030028401400080028786500090029500200130030403500100031780100160
0327#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#c#143#11#article#32#
11#^rND^sSpivacow^nFR#^rND^sNegri^nAL#^rND^sdel Valle^nEE#^rND^sCalviño^nI#^rND^
sFradinger^nE#^rND^sZanchetta^nJR#Metabolic risk factors in children with kidney
 stone disease^len#Pediatr Nephrol#20080000#2008#23#1129-33#20110300#v33n1a07.ht
m#0097-5257#Pediatr Nephrol##
00474000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100014000980120
02000112030002800132710000200160065000900162064000500171031000300176014000700179
865000900186002001300195#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#
c#144#12#article#32#12#^rND^sWorcester^nEM#^rND^sCoe^nFL#Nephrolithiasis^len#Pri
m Care Clin Office Pract#2#20080000#2008#35#369-91#20110300#v33n1a07.htm##
00632000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100025000970100
01600122010002100138010001400159010001500173012003000188030001700218065000900235
06400050024403100030024901400050025286500090025700200130026603500100027980100170
0289#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#c#145#13#article#32#
13#^rND^sOzokutan^nBH#^rND^sKucukayd&#305;n^nM#^rND^sGunduz^nZ#^rND^sKabaklioglu
^nM#^rND^sOkur^nH#^rND^sTuran^nC#Urolithiasis in childhood^len#Pediatr Surg Int#
20000000#2000#16#60-3#20110300#v33n1a07.htm#0179-0358#Pediatr Surg Int##
00575000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100019000980100
02000117012007400137030000900211065000900220064000500229031000300234014000700237
865000900244002001300253035001000266801000900276#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a07.htm#S#c#146#14#article#32#14#^rND^sDel Valle^nEE#^rND^sSpivaco
w^nFR#^rND^sZanchetta^nJR#Metabolic evaluation at the time of the first renal li
thiasis episode^len#Medicina#19990000#1999#59#417-22#20110300#v33n1a07.htm#0025-
7680#MEDICINA##
00658000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100020000940100
01600114010001900130010001800149012010600167030000800273065000900281064000500290
031000300295014000600298865000900304002001300313035001000326801000800336#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#c#147#15#article#32#15#^rND^sNov
ak^nTE#^rND^sLakshmanan^nY#^rND^sTrock^nBJ#^rND^sGearhart^nJP#^rND^sMatlaga^nBR#
Sex prevalence of pediatric kidney stone disease in the United States: an epidem
iologic investigation^len#Urology#20090000#2009#74#104-7#20110300#v33n1a07.htm#0
090-4295#Urology##
00676000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01500112010001700127010001500144010001700159012008600176030001600262065000900278
06400050028703100030029201400070029586500090030200200130031103500100032480100160
0334#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#c#148#16#article#32#
16#^rND^sPolito^nC#^rND^sLa Manna^nA#^rND^sCioce^nF#^rND^sVillani^nJ#^rND^sNappi
^nB#^rND^sDi Toro^nR#Clinical presentation and natural course of idiopathic hype
rcalciuria in children^len#Pediatr Nephrol#20000000#2000#15#211-14#20110300#v33n
1a07.htm#0097-5257#Pediatr Nephrol##
00528000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100014000970120
06400111030001000175065000900185064000500194031000300199014000600202865000900208
002001300217035001000230801001000240#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a07.htm#S#c#149#17#article#32#17#^rND^sBasaklar^nAC#^rND^sKale^nN#Experience w
ith childhood urolithiasis: Report of 196 cases^len#Br J Urol#19910000#1991#67#2
03-5#20110300#v33n1a07.htm#0007-1331#Br J Urol##
00554000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100016000980100
01400114012005700128030001200185065000900197064000500206031000300211014000600214
865000900220002001300229035001000242801001200252#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a07.htm#S#c#150#18#article#32#18#^rND^sStapleton^nFB#^rND^sMcKay^n
CP#^rND^sNoe^nHN#Urolithiasis in children: the role of hypercalciuria^len#Pediat
r Ann#19870000#1987#16#980-1#20110300#v33n1a07.htm#0090-4481#Pediatr Ann##
00529000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120080000970300
01500177065000900192064000500201031000300206014000700209865000900216002001300225
035001000238801001500248#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#
c#151#19#article#32#19#^rND^sLieberman^nE#Importance of metabolic contributions 
to urolithiasis in pediatric patients^len#Mayo Clin Proc#19930000#1993#68#313-15
#20110300#v33n1a07.htm#0025-6196#Mayo Clin Proc##
00584000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01500113010001900128012004500147030001700192065000900209064000500218031000200223
014000800225865000900233002001300242035001000255801001700265#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#152#20#article#32#20#^rND^sCurhan^nGC#^rND
^sWillett^nWC#^rND^sRimm^nEB#^rND^sStampfer^nMJ#Family history and risk of kidne
y stones^len#J Am Soc Nephrol#19970000#1997#8#1568-73#20110300#v33n1a07.htm#1046
-6673#J Am Soc Nephrol##
00708000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100017001000100
01700117010001900134010001600153010002100169012011400190030001100304065000900315
06400050032403100030032901400070033286500090033900200130034803500100036180100110
0371#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a07.htm#S#c#153#21#article#32#
21#^rND^sLoredo-Osti^nJC#^rND^sRoslin^nNM#^rND^sTessier^nJ#^rND^sFujiwara^nTM#^r
ND^sMorgan^nK#^rND^sBonnardeaux^nA#Segregation of urine calcium excretion in fam
ilies ascertained for nephrolithiasis: evidence for a major gene^len#Kidney Int#
20050000#2005#68#966-71#20110300#v33n1a07.htm#0085-2538#Kidney int##
00555000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01700112012006400129030000700193065000900200064000500209031000400214014000800218
865000900226002001300235035001000248801000700258#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a07.htm#S#c#154#22#article#32#22#^rND^sVezzoli^nG#^rND^sSoldati^nL
#^rND^sGambaro^nG#Update on primary hypercalciuria from a genetic perspective^le
n#J Urol#20080000#2008#179#1676-82#20110300#v33n1a07.htm#0022-5347#J Urol##
00628000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01800110010001400128012007900142030002400221065000900245064000500254031000300259
014000800262865000900270002001300279035001000292801002400302#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#155#23#article#32#23#^rND^sReed^nBY#^rND^s
Heller^nHJ#^rND^sGitomer^nWL#^rND^sPak^nCY#Mapping a gene defect in absorptive h
ypercalciuria to chromosome 1q233-q24^len#J Clin Endocrinol Metab#19990000#1999#
84#3907-13#20110300#v33n1a07.htm#0021-972X#J Clin Endocrinol Metab##
00699000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01700111810000600128012015800134030002400292065000900316064000500325031000300330
014000800333865000900341002001300350035001000363801002400373#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#156#24#article#32#24#^rND^sReed^nBY#^rND^s
Gitomer^nWL#^rND^sHeller^nHJ#et al#Identification and characterization of a gene
 with base substitutions associated with the absorptive hypercalciuria phenotype
 and low spinal bone density^len#J Clin Endocrinol Metab#20020000#2002#87#1476-8
5#20110300#v33n1a07.htm#0021-972X#J Clin Endocrinol Metab##
00630000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01800111810000600129012010200135030001700237065000900254064000500263031000300268
014000800271865000900279002001300288035001000301801001700311#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#157#25#article#32#25#^rND^sVezzoli^nG#^rND
^sTanini^nA#^rND^sFerrucci^nL#et al#Influence of calcium-sensing receptor gene o
n urinary calcium excretion in stone-forming patients^len#J Am Soc Nephrol#20020
000#2002#13#2517-23#20110300#v33n1a07.htm#1046-6673#J Am Soc Nephrol##
00602000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01500111810000600126012008400132030001500216065000900231064000500240031000300245
014000500248865000900253002001300262035001000275801001500285#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#158#26#article#32#26#^rND^sImamura^nK#^rND
^sTonoki^nH#^rND^sWakui^nK#et al#4q33-qter deletion and absorptive hypercalciuri
a: report of two unrelated girls^len#Am J Med Genet#19980000#1998#78#52-4#201103
00#v33n1a07.htm#0148-7299#Am J Med Genet##
00621000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100014000950100
01600109810000600125012011400131030000900245065000900254064000500263031000300268
014000700271865000900278002001300287035001000300801000900310#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#159#27#article#32#27#^rND^sTefekli^nA#^rND
^sEsen^nT#^rND^sZiylan^nO#et al#Metabolic risk factors in pediatric and adult ca
lcium oxalate urinary stone formers: is there any difference?^len#Urol Int#20030
000#2003#70#273-77#20110300#v33n1a07.htm#0042-1138#Urol Int##
00528000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01600110810000600126012004500132030001400177710000200191065000900193064000500202
031000300207014000600210865000900216002001300225#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a07.htm#S#c#160#28#article#32#28#^rND^sRizvi^nSA#^rND^sSultan^nS#^
rND^sZafar^nMN#et al#Evaluation of children with urolithiasis^len#Indian J Urol#
2#20070000#2007#23#420-7#20110300#v33n1a07.htm##
00594000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100021000940100
01800115810000600133012006600139030001700205065000900222064000500231031000300236
014000400239865000900243002001300252035001000265801001700275#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a07.htm#S#c#161#29#article#32#29#^rND^sDursun^nI#^rND^
sPoyrazoglu^nHM#^rND^sDusunsel^nR#et al#Pediatric urolithiasis: an 8-year experi
ence of single centre^len#Int Urol Nephrol#20080000#2008#40#3-9#20110300#v33n1a0
7.htm#0301-1623#Int Urol Nephrol##
00540000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
02000113012006600133030001800199710000200217065000900219064000500228031000200233
014000500235865000900240002001300249#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a07.htm#S#c#162#30#article#32#30#^rND^sNaseri^nM#^rND^sVarasteh^nAR#^rND^sAlam
daran^nSA#Metabolic factors associated with urinary calculi in children^len#Iran
 J Kidney Dis#2#20100000#2010#4#32-8#20110300#v33n1a07.htm##
00578000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930100
01500107010001700122012008300139030001800222710000200240065000900242064000500251
031000300256014000700259865000900266002001300275#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a07.htm#S#c#163#31#article#32#31#^rND^sAlpay^nH#^rND^sOzen^nA#^rND
^sGokce^nI#^rND^sBiyikli^nN#Clinical and metabolic features of urolithiasis and 
microlithiasis in children^len#Pediatric Nephrol#2#20090000#2009#24#2203-9#20110
300#v33n1a07.htm##
00572000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01700111012009200128030002700220710000200247065000900249064000500258031000300263
014000600266865000900272002001300281#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a07.htm#S#c#164#32#article#32#32#^rND^sSpahi^nMA#^rND^sHeidarj^nA#^rND^sShajar
i^nA#Clinical manifestations and etiology of renal stones in children less than 
14 years age^len#Saudi J Kidney Dis Transpl#2#20100000#2010#21#181-4#20110300#v3
3n1a07.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#o#1#1#article#1#
20110411#092928#v33n1a08.htm#160##
04955000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201020
01610120089002630100035003520100044003870100049004310100037004800100032005170700
04600549070004800595070005400643083172000697085001002417085004002427085004402467
08500340251108500200254508315220256508500100408708500350409708500410413208500350
41730850021042081170008042290720003042371120009042401110011042491140009042601130
01104269002001304280#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#h#2#
1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#08#JBN020#nd#J. Bras. Nefrol.#33#1#201103
00#^f55^l61#0101-2800#Avaliação de métodos para identificar desnutrição energéti
co-protéica de pacientes em hemodiálise^lpt#Assessment of methods to identify pr
otein-energy wasting in patients on hemodialysis^len#^rND^1A01^nPatrícia Marçal^
sVegine#^rND^1A02^nAna Carolina Packness^sFernandes#^rND^1A02^nMárcia Regina Sim
as Gonçalves^sTorres#^rND^1A03^nMaria Inês Barreto^sSilva#^rND^1A01^nCarla Maria
^sAvesani#Universidade do Estado do Rio de Janeiro^iA01#UERJ^iA02^1Hospital Univ
ersitário Pedro Ernesto#Universidade Federal do Estado do Rio de Janeiro^iA03#^l
pt^aINTRODUÇÃO: O método capaz de melhor identificar desnutrição energético-prot
éica (DEP) em pacientes em hemodiálise (HD) ainda se mantém em debate. Logo, ava
liamos o estado nutricional de pacientes em HD por diferentes métodos e verifica
mos qual deles identificava o maior número de pacientes com DEP. MÉTODOS: Quinze
 pacientes em HD (52,7 ± 10 anos; 33,3% Masculino). O estado nutricional foi ava
liado por medidas antropométricas, pela avaliação subjetiva global (ASG), por al
bumina plasmática e pelo consumo alimentar (recordatório de 24 horas). A gordura
 corporal foi avaliada por antropometria. O critério de diagnóstico de DEP preco
nizado pela International Society of Renal Nutrition and Metabolism (ISRNM) foi 
empregado. RESULTADOS: Observou-se que o índice de massa corporal esteve dentro 
da normalidade (24,2 ± 4,4 kg/m²). Ao avaliar a condição nutricional pela adequa
ção da circunferência muscular do braço CMB) e da prega cutânea de tríceps (PCT)
 notou-se que a adequação da CMB esteve dentro dos parâmetros de normalidade (10
2,6 ± 13%), ao passo que a adequação da PCT esteve abaixo da normalidade (Femini
no: 75,3 ± 40,4%; Masculino: 73,5 ± 20,6%). Contudo, o percentual de gordura cor
poral esteve elevado (Feminino: 34,5 ± 7,3%; Masculino: 23,6 ± 4,2%). Com relaçã
o à ASG, a maioria dos pacientes (n = 12) apresentou algum grau de desnutrição e
 este constituiu o método que identificou o maior número de pacientes com DEP. A
o empregar os critérios da ISRNM, notou-se que apenas dois pacientes apresentara
m DEP. CONCLUSÃO: Todos os pacientes avaliados encontravam-se com DEP por algum 
dos métodos utilizados. A ASG foi o método que, isoladamente, conseguiu detectar
 o maior número de pacientes com DEP.#^ddecs^i1#^tm^lpt^kinsuficiência renal crô
nica^i1#^tm^lpt^kdesnutrição proteico-energética^i1#^tm^lpt^kavaliação nutricion
al^i1#^tm^lpt^kdiálise^i1#^len^aINTRODUCTION: The method capable of best identif
ying protein-energy wasting (PEW) in hemodialysis (HD) patients is controversial
. Thus, we assessed the nutritional status of HD patients by use of different me
thods and verified which one identified the highest number of patients with PEW.
 METHODS: The study assessed the nutritional status of 15 HD patients (age: 52.7
 ± 10.1 years; males: 33.3%) by use of anthropometric measurements, subjective g
lobal assessment (SGA), serum albumin, and dietary intake (24-hour food recall).
 Body fat was assessed by use of anthropometry. The International Society of Ren
al Nutrition and Metabolism (ISRNM) criteria were used to diagnose PEW. RESULTS:
 The body mass index (24.2 ± 4.4 kg/m²) and the percentage of standard value for
 mid-arm muscle circumference were within the normal limits (102.6 ± 13%). Never
theless, the percentage of standard value for triceps skinfold was below the nor
mal limits (females, 75.3 ± 40.4%; and males, 73.5 ± 20.6%), although a high bod
y fat percentage was observed (females, 34.5 ± 7.3%; males, 23.6 ± 4.2%). When a
ssessing the nutritional status by use of SGA, most patients (80%, n = 12) were 
malnourished, and SGA was the method that identified the highest number of patie
nts with PEW. By using the ISRNM criteria, PEW was diagnosed in only two patient
s. CONCLUSION: All patients were diagnosed with PEW by use of one of the methods
 studied. The SGA was the method that, in isolation, could detect the greatest n
umber of patients with PEW.#^ddecs^i2#^tm^len^kchronic kidney failure^i2#^tm^len
^kprotein- energy malnutrition^i2#^tm^len^knutritional assessment^i2#^tm^len^kdi
alysis^i2#vancouv#22#20101025#25/10/2010#20101228#28/12/2010#v33n1a08.htm##
05047000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201090
01610120096002700100035003660100044004010100049004450100037004940100032005310700
04600563070004800609070005400657083175900711085001002470085004002480085004402520
08500340256408500200259808315610261808500100417908500350418908500410422408500350
42650850021043001170008043210720003043291120009043321110011043411140009043521130
01104361002001304372#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#f#3#
1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#08#JBN020#nd#J. Bras. Nefrol.#33#1#201103
00#^f55^l61#0101-2800#<b>Avaliação de métodos para identificar desnutrição energ
ético-protéica de pacientes em hemodiálise</b>^lpt#<b>Assessment of methods to i
dentify protein-energy wasting in patients on hemodialysis</b>^len#^rND^1A01^nPa
trícia Marçal^sVegine#^rND^1A02^nAna Carolina Packness^sFernandes#^rND^1A02^nMár
cia Regina Simas Gonçalves^sTorres#^rND^1A03^nMaria Inês Barreto^sSilva#^rND^1A0
1^nCarla Maria^sAvesani#Universidade do Estado do Rio de Janeiro^iA01#UERJ^iA02^
1Hospital Universitário Pedro Ernesto#Universidade Federal do Estado do Rio de J
aneiro^iA03#^lpt^a<b>INTRODUÇÃO:</b> O método capaz de melhor identificar desnut
rição energético-protéica (DEP) em pacientes em hemodiálise (HD) ainda se mantém
 em debate. Logo, avaliamos o estado nutricional de pacientes em HD por diferent
es métodos e verificamos qual deles identificava o maior número de pacientes com
 DEP. <b>MÉTODOS:</b> Quinze pacientes em HD (52,7 ± 10 anos; 33,3% Masculino). 
O estado nutricional foi avaliado por medidas antropométricas, pela avaliação su
bjetiva global (ASG), por albumina plasmática e pelo consumo alimentar (recordat
ório de 24 horas). A gordura corporal foi avaliada por antropometria. O critério
 de diagnóstico de DEP preconizado pela International Society of Renal Nutrition
 and Metabolism (ISRNM) foi empregado. <b>RESULTADOS:</b> Observou-se que o índi
ce de massa corporal esteve dentro da normalidade (24,2 ± 4,4 kg/m<sup>2</sup>).
 Ao avaliar a condição nutricional pela adequação da circunferência muscular do 
braço CMB) e da prega cutânea de tríceps (PCT) notou-se que a adequação da CMB e
steve dentro dos parâmetros de normalidade (102,6 ± 13%), ao passo que a adequaç
ão da PCT esteve abaixo da normalidade (Feminino: 75,3 ± 40,4%; Masculino: 73,5 
± 20,6%). Contudo, o percentual de gordura corporal esteve elevado (Feminino: 34
,5 ± 7,3%; Masculino: 23,6 ± 4,2%). Com relação à ASG, a maioria dos pacientes (
n = 12) apresentou algum grau de desnutrição e este constituiu o método que iden
tificou o maior número de pacientes com DEP. Ao empregar os critérios da ISRNM, 
notou-se que apenas dois pacientes apresentaram DEP. <b>CONCLUSÃO: </b>Todos os 
pacientes avaliados encontravam-se com DEP por algum dos métodos utilizados. A A
SG foi o método que, isoladamente, conseguiu detectar o maior número de paciente
s com DEP.#^ddecs^i1#^tm^lpt^kinsuficiência renal crônica^i1#^tm^lpt^kdesnutriçã
o proteico-energética^i1#^tm^lpt^kavaliação nutricional^i1#^tm^lpt^kdiálise^i1#^
len^a<b>INTRODUCTION:</b> The method capable of best identifying protein-energy 
wasting (PEW) in hemodialysis (HD) patients is controversial. Thus, we assessed 
the nutritional status of HD patients by use of different methods and verified w
hich one identified the highest number of patients with PEW. <b>METHODS:</b> The
 study assessed the nutritional status of 15 HD patients (age: 52.7 ± 10.1 years
; males: 33.3%) by use of anthropometric measurements, subjective global assessm
ent (SGA), serum albumin, and dietary intake (24-hour food recall). Body fat was
 assessed by use of anthropometry. The International Society of Renal Nutrition 
and Metabolism (ISRNM) criteria were used to diagnose PEW. <b>RESULTS:</b> The b
ody mass index (24.2 ± 4.4 kg/m<sup>2</sup>) and the percentage of standard valu
e for mid-arm muscle circumference were within the normal limits (102.6 ± 13%). 
Nevertheless, the percentage of standard value for triceps skinfold was below th
e normal limits (females, 75.3 ± 40.4%; and males, 73.5 ± 20.6%), although a hig
h body fat percentage was observed (females, 34.5 ± 7.3%; males, 23.6 ± 4.2%). W
hen assessing the nutritional status by use of SGA, most patients (80%, n = 12) 
were malnourished, and SGA was the method that identified the highest number of 
patients with PEW. By using the ISRNM criteria, PEW was diagnosed in only two pa
tients. <b>CONCLUSION:</b> All patients were diagnosed with PEW by use of one of
 the methods studied. The SGA was the method that, in isolation, could detect th
e greatest number of patients with PEW.#^ddecs^i2#^tm^len^kchronic kidney failur
e^i2#^tm^len^kprotein- energy malnutrition^i2#^tm^len^knutritional assessment^i2
#^tm^len^kdialysis^i2#vancouv#22#20101025#25/10/2010#20101228#28/12/2010#v33n1a0
8.htm##
05194000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400090015903500100
01680120102001780120089002800100035003690100044004040100049004480100037004970100
03200534070004800566070005000614070005600664083177400720085001002494085004002504
08500440254408500340258808500200262208315710264208500100421308500350422308500410
42580850035042990850021043341170008043550720003043631120009043661110011043751140
00904386113001104395002001304406008008904419#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a08.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab
#08#JBN020#nd#J. Bras. Nefrol#33#1#20110300#^f55^l61#0101-2800#Avaliação de méto
dos para identificar desnutrição energético-protéica de pacientes em hemodiálise
^lpt#Assessment of methods to identify protein-energy wasting in patients on hem
odialysis^len#^rND^1A01^nPatrícia Marçal^sVegine#^rND^1A02^nAna Carolina Packnes
s^sFernandes#^rND^1A02^nMárcia Regina Simas Gonçalves^sTorres#^rND^1A03^nMaria I
nês Barreto^sSilva#^rND^1A01^nCarla Maria^sAvesani#^iA01^1Universidade do Estado
 do Rio de Janeiro#^iA02^1UERJ^2Hospital Universitário Pedro Ernesto#^iA03^1Univ
ersidade Federal do Estado do Rio de Janeiro#^lpt^aINTRODUÇÃO: O método capaz de
 melhor identificar desnutrição energético-protéica (DEP) em pacientes em hemodi
álise (HD) ainda se mantém em debate. Logo, avaliamos o estado nutricional de pa
cientes em HD por diferentes métodos e verificamos qual deles identificava o mai
or número de pacientes com DEP. MÉTODOS: Quinze pacientes em HD (52,7 ± 10 anos;
 33,3 por cento Masculino). O estado nutricional foi avaliado por medidas antrop
ométricas, pela avaliação subjetiva global (ASG), por albumina plasmática e pelo
 consumo alimentar (recordatório de 24 horas). A gordura corporal foi avaliada p
or antropometria. O critério de diagnóstico de DEP preconizado pela Internationa
l Society of Renal Nutrition and Metabolism (ISRNM) foi empregado. RESULTADOS: O
bservou-se que o índice de massa corporal esteve dentro da normalidade (24,2 ± 4
,4 kg/m²). Ao avaliar a condição nutricional pela adequação da circunferência mu
scular do braço CMB) e da prega cutânea de tríceps (PCT) notou-se que a adequaçã
o da CMB esteve dentro dos parâmetros de normalidade (102,6 ± 13 por cento), ao 
passo que a adequação da PCT esteve abaixo da normalidade (Feminino: 75,3 ± 40,4
 por cento; Masculino: 73,5 ± 20,6 por cento). Contudo, o percentual de gordura 
corporal esteve elevado (Feminino: 34,5 ± 7,3 por cento; Masculino: 23,6 ± 4,2 p
or cento). Com relação à ASG, a maioria dos pacientes (n = 12) apresentou algum 
grau de desnutrição e este constituiu o método que identificou o maior número de
 pacientes com DEP. Ao empregar os critérios da ISRNM, notou-se que apenas dois 
pacientes apresentaram DEP. CONCLUSÃO: Todos os pacientes avaliados encontravam-
se com DEP por algum dos métodos utilizados. A ASG foi o método que, isoladament
e, conseguiu detectar o maior número de pacientes com DEP.#^ddecs^i1#^tm^lpt^kin
suficiência renal crônica^i1#^tm^lpt^kdesnutrição proteico-energética^i1#^tm^lpt
^kavaliação nutricional^i1#^tm^lpt^kdiálise^i1#^len^aINTRODUCTION: The method ca
pable of best identifying protein-energy wasting (PEW) in hemodialysis (HD) pati
ents is controversial. Thus, we assessed the nutritional status of HD patients b
y use of different methods and verified which one identified the highest number 
of patients with PEW. METHODS: The study assessed the nutritional status of 15 H
D patients (age: 52.7 ± 10.1 years; males: 33.3 percent) by use of anthropometri
c measurements, subjective global assessment (SGA), serum albumin, and dietary i
ntake (24-hour food recall). Body fat was assessed by use of anthropometry. The 
International Society of Renal Nutrition and Metabolism (ISRNM) criteria were us
ed to diagnose PEW. RESULTS: The body mass index (24.2 ± 4.4 kg/m²) and the perc
entage of standard value for mid-arm muscle circumference were within the normal
 limits (102.6 ± 13 percent). Nevertheless, the percentage of standard value for
 triceps skinfold was below the normal limits (females, 75.3 ± 40.4 percent; and
 males, 73.5 ± 20.6 percent), although a high body fat percentage was observed (
females, 34.5 ± 7.3 percent; males, 23.6 ± 4.2 percent). When assessing the nutr
itional status by use of SGA, most patients (80 percent, n = 12) were malnourish
ed, and SGA was the method that identified the highest number of patients with P
EW. By using the ISRNM criteria, PEW was diagnosed in only two patients. CONCLUS
ION: All patients were diagnosed with PEW by use of one of the methods studied. 
The SGA was the method that, in isolation, could detect the greatest number of p
atients with PEW.#^ddecs^i2#^tm^len^kchronic kidney failure^i2#^tm^len^kprotein-
 energy malnutrition^i2#^tm^len^knutritional assessment^i2#^tm^len^kdialysis^i2#
vancouv#22#20101025#25/10/2010#20101228#28/12/2010#v33n1a08.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100008##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#5#1#article#134#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a08.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#6#2#article#134#<p>&nbsp;</p>     ^cY#
v33n1a08.htm##
00495000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704026300073002001300336#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#7#3#article#134#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Avalia&ccedil;&at
ilde;o de m&eacute;todos para identificar desnutri&ccedil;&atilde;o  energ&eacut
e;tico-prot&eacute;ica de pacientes em hemodi&aacute;lise</b></font></p>     ^cY
#v33n1a08.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#8#4#article#134#<p>&nbsp;</p>     ^cY#
v33n1a08.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#9#5#article#134#<p>&nbsp;</p>     ^cY#
v33n1a08.htm##
00561000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704032800074002001300402#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#10#6#article#134#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Patr&iacute;cia Mar&ccedil;al Vegin
e<sup>I</sup>; Ana Carolina Packness Fernandes<sup>II</sup>; M&aacute;rcia Regin
a Simas Gon&ccedil;alves Torres<sup>II</sup>; Maria In&ecirc;s Barreto Silva<sup
>III</sup>; Carla Maria Avesani<sup>I</sup></b></font></p>     ^cY#v33n1a08.htm#
#
00363000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704013000074002001300204#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#11#7#article#134#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Universidade do Estado do 
Rio de Janeiro - UERJ    ^cY#v33n1a08.htm##
00317000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704008400074002001300158#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#12#8#article#134#<br>   <sup>II</sup>H
ospital Universit&aacute;rio Pedro Ernesto - HUPE, UERJ    ^cY#v33n1a08.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704010400074002001300178#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#13#9#article#134#<br>   <sup>III</sup>
Universidade Federal do Estado do Rio de Janeiro - UNIRIO; UERJ</font></p>     ^
cY#v33n1a08.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#14#10#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia
</a></font></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#15#11#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#16#12#article#134#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a08.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#17#13#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a08.htm##
00690000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045600075002001300531#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#18#14#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O:</b> O m&
eacute;todo capaz de melhor identificar desnutri&ccedil;&atilde;o energ&eacute;t
ico-prot&eacute;ica (DEP) em pacientes em hemodi&aacute;lise (HD) ainda se mant&
eacute;m em debate. Logo, avaliamos o estado nutricional de pacientes em HD por 
diferentes m&eacute;todos e verificamos qual deles identificava o maior n&uacute
;mero de pacientes com DEP.     ^cY#v33n1a08.htm##
00738000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050400075002001300579#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#19#15#article#134#<br>   <b>M&Eacute;T
ODOS:</b> Quinze pacientes em HD (52,7 ± 10 anos; 33,3% Masculino). O estado nut
ricional foi avaliado por medidas antropom&eacute;tricas, pela avalia&ccedil;&at
ilde;o subjetiva global (ASG), por albumina plasm&aacute;tica e pelo consumo ali
mentar (recordat&oacute;rio de 24 horas). A gordura corporal foi avaliada por an
tropometria. O crit&eacute;rio de diagn&oacute;stico de DEP preconizado pela Int
ernational Society of Renal Nutrition and Metabolism (ISRNM) foi empregado.     
^cY#v33n1a08.htm##
01214000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704098000075002001301055#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#20#16#article#134#<br>   <b>RESULTADOS
:</b> Observou-se que o &iacute;ndice de massa corporal esteve dentro da normali
dade (24,2 ± 4,4 kg/m<sup>2</sup>). Ao avaliar a condi&ccedil;&atilde;o nutricio
nal pela adequa&ccedil;&atilde;o da circunfer&ecirc;ncia muscular do bra&ccedil;
o CMB) e da prega cut&acirc;nea de tr&iacute;ceps (PCT) notou-se que a adequa&cc
edil;&atilde;o da CMB esteve dentro dos par&acirc;metros de normalidade (102,6 ±
 13%), ao passo que a adequa&ccedil;&atilde;o da PCT esteve abaixo da normalidad
e (Feminino: 75,3 ± 40,4%; Masculino: 73,5 ± 20,6%). Contudo, o percentual de go
rdura corporal esteve elevado (Feminino: 34,5 ± 7,3%; Masculino: 23,6 ± 4,2%). C
om rela&ccedil;&atilde;o &agrave; ASG, a maioria dos pacientes (n = 12) apresent
ou algum grau de desnutri&ccedil;&atilde;o e este constituiu o m&eacute;todo que
 identificou o maior n&uacute;mero de pacientes com DEP. Ao empregar os crit&eac
ute;rios da ISRNM, notou-se que apenas dois pacientes apresentaram DEP.     ^cY#
v33n1a08.htm##
00488000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025400075002001300329#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#21#17#article#134#<br>   <b>CONCLUS&At
ilde;O: </b> Todos os pacientes avaliados encontravam-se com DEP por algum dos m
&eacute;todos utilizados. A ASG foi o m&eacute;todo que, isoladamente, conseguiu
 detectar o maior n&uacute;mero de pacientes com DEP. </font></p>     ^cY#v33n1a
08.htm##
00510000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027600075002001300351#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#22#18#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b>insufici&ecirc
;ncia renal cr&ocirc;nica, desnutri&ccedil;&atilde;o proteico-energ&eacute;tica,
 avalia&ccedil;&atilde;o nutricional, di&aacute;lise. </font></p> <hr size="1" n
oshade>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#23#19#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#24#20#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#25#21#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a08.htm##
01362000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704112800075002001301203#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#26#22#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A desnutri&ccedil;&atilde;o energ&eac
ute;tico-prot&eacute;ica (DEP) pode ocorrer em 13 a 51% dos pacientes em tratame
nto de hemodi&aacute;lise (HD). <sup>1</sup> Essa elevada preval&ecirc;ncia de D
EP &eacute; de grande preocupa&ccedil;&atilde;o por ser um importante preditor d
e morbimortalidade. <sup>2</sup> Diversos fatores contribuem para essa condi&cce
dil;&atilde;o nutricional, sendo o processo inflamat&oacute;rio uma importante c
ausa desse quadro. <sup>3</sup> Dentre as diversas causas da DEP podemos citar a
inda a baixa ingest&atilde;o energ&eacute;tica e prot&eacute;ica; a perda de nut
rientes e amino&aacute;cidos pelo dialisato; o catabolismo muscular induzido pel
a pr&oacute;pria di&aacute;lise e pela acidose metab&oacute;lica; o aumento do g
asto energ&eacute;tico que ocorre durante e at&eacute; 2 horas ap&oacute;s o pro
cedimento dial&iacute;tico; a resist&ecirc;ncia &agrave; insulina e aos horm&oci
rc;nios anab&oacute;licos, como o horm&ocirc;nio do crescimento; o estresse oxid
ativo e a inflama&ccedil;&atilde;o. <sup>3</sup></font></p>     ^cY#v33n1a08.htm
##
00720000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048600075002001300561#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#27#23#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em raz&atilde;o dessa alta preval&eci
rc;ncia de DEP na HD, fica clara a import&acirc;ncia de realiza&ccedil;&atilde;o
 da avalia&ccedil;&atilde;o nutricional para identificar as causas de risco e/ou
 deteriora&ccedil;&atilde;o do estado nutricional, al&eacute;m de se fazer o dia
gn&oacute;stico nutricional. Com isso, busca-se tra&ccedil;ar metas nutricionais
 para prevenir e/ou tratar a DEP. <sup>4</sup></font></p>     ^cY#v33n1a08.htm##
02245000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704201100075002001302086#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#28#24#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Contudo, n&atilde;o h&aacute; um marc
ador isolado que seja capaz de avaliar o estado nutricional de pacientes com DRC
, em raz&atilde;o das diversas anormalidades inerentes &agrave; pr&oacute;pria e
nfermidade. <sup>5</sup> Recentemente, tem-se dado &ecirc;nfase &agrave; avalia&
ccedil;&atilde;o subjetiva global (ASG), pois &eacute; um m&eacute;todo simples,
 de baixo-custo e validado para avalia&ccedil;&atilde;o do estado nutricional ne
ssa popula&ccedil;&atilde;o. <sup>6</sup> Al&eacute;m da ASG, rotineiramente, co
stuma-se avaliar o consumo de nutrientes, principalmente pelo registro de 3 dias
 ou pelo recordat&oacute;rio alimentar de 24 horas; a reserva de massa muscular 
e adiposa por antropometria ou bioimped&acirc;ncia el&eacute;trica e de marcador
es bioqu&iacute;micos pela albumina plasm&aacute;tica. <sup>7-9</sup> Pesquisado
res renomados dessa &aacute;rea acreditam que seja necess&aacute;rio empregar em
 conjunto v&aacute;rios par&acirc;metros para avaliar de forma adequada a condi&
ccedil;&atilde;o nutricional dessa popula&ccedil;&atilde;o, de forma a contornar
 as limita&ccedil;&otilde;es que cada um desses m&eacute;todos apresenta quando 
empregados isoladamente. Apesar de todo o esfor&ccedil;o em se aproximar do diag
n&oacute;stico nutricional preciso, faltava ainda uma normatiza&ccedil;&atilde;o
 dos par&acirc;metros nutricionais a serem aplicados nos pacientes portadores de
 DRC. Nesse sentido, o comit&ecirc; da International Society of Renal Nutrition 
and Metabolism prop&ocirc;s recentemente um painel com um conjunto de indicadore
s nutricionais que devem ser usados para identificar o paciente com DRC portador
 de DEP, em que pacientes que apresentem um item de pelo menos tr&ecirc;s dos qu
atro crit&eacute;rios propostos apresentados no <a href="/img/revistas/jbn/v33n1
/a08qd01m.jpg">Quadro 1</a> s&atilde;o classificados com desnutri&ccedil;&atilde
;o energ&eacute;tico-prot&eacute;ica. <sup>10</sup></font></p>     ^cY#v33n1a08.
htm##
00931000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704069700075002001300772#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#29#25#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No entanto, na pr&aacute;tica cl&iacu
te;nica, o nutricionista pode n&atilde;o ter dispon&iacute;vel todas essas ferra
mentas. Desta forma, &eacute; importante conhecer qual dos par&acirc;metros usad
os para avaliar o estado nutricional &eacute; capaz de identificar melhor a pres
en&ccedil;a de DEP no paciente com DRC. O presente trabalho tem como objetivo av
aliar o estado nutricional de pacientes com DRC em tratamento cr&ocirc;nico de H
D por meio de diferentes par&acirc;metros de avalia&ccedil;&atilde;o nutricional
 e verificar quais deles conseguem identificar o maior n&uacute;mero de paciente
s em HD com DEP. </font></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#30#26#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00350000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011600075002001300191#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#31#27#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODO </b></fo
nt></p>     ^cY#v33n1a08.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#32#28#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES</b></font></p>     ^cY#v
33n1a08.htm##
02049000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704181500075002001301890#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#33#29#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Este trabalho foi realizado na unidad
e de HD do Hospital Universit&aacute;rio Pedro Ernesto (HUPE), Universidade do E
stado do Rio de Janeiro (UERJ), entre novembro de 2008 a fevereiro de 2009. Fora
m inclu&iacute;dos no estudo pacientes em tratamento cr&ocirc;nico de HD durante
 esse per&iacute;odo. Os crit&eacute;rios de inclus&atilde;o neste estudo compre
endem pacientes com idade maior ou igual a 18 anos e em tratamento de HD por no 
m&iacute;nimo dois meses. Foram adotados como crit&eacute;rios de exclus&atilde;
o s&iacute;ndrome da imunodefici&ecirc;ncia adquirida (AIDS), c&acirc;ncer, gest
a&ccedil;&atilde;o, interna&ccedil;&atilde;o durante o estudo, amputa&ccedil;&at
ilde;o, isolamento de contato e doen&ccedil;a degenerativa. Dos 28 pacientes em 
tratamento cr&ocirc;nico de HD no HUPE, 10 foram exclu&iacute;dos por n&atilde;o
 atenderem aos crit&eacute;rios de inclus&atilde;o e exclus&atilde;o (2 gestante
s, 1 amputado, 1 em isolamento de contato, 4 com menos de 2 meses de HD, 1 inter
nado e 1 com mal de Alzeimer); 2 pacientes foram &agrave; &oacute;bito durante o
 estudo e 1 paciente foi internado durante a segunda visita. Sendo assim, partic
iparam um total de 15 pacientes. As causas de DRC foram glomerulopatia (n = 2); 
l&uacute;pus eritematoso sist&ecirc;mico (LES) (n = 1); doen&ccedil;a parenquima
tosa difusa bilateral (n = 2); c&aacute;lculo coraliforme bilateral (n = 1); nef
roesclerose (n = 1); hipertens&atilde;o (HAS) (n = 1); e causa desconhecida (n =
 7). As comorbidades observadas foram HAS (n=14); hepatite A (n = 1); hepatite B
 (n = 2); hepatite C (n = 1) e diabetes mellitus (DM) (n = 4). Todos os paciente
s faziam HD 3 vezes por semana, cada sess&atilde;o com dura&ccedil;&atilde;o de 
3,5 a 4 horas. </font></p>     ^cY#v33n1a08.htm##
00353000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011900075002001300194#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#34#30#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DESENHO E PROTOCOLO DO ESTUDO</b><
/font></p>     ^cY#v33n1a08.htm##
00988000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704075400075002001300829#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#35#31#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O presente estudo &eacute; de corte t
ransversal. Ap&oacute;s a obten&ccedil;&atilde;o do termo de consentimento livre
 e esclarecido, os pacientes foram entrevistados quanto aos dados demogr&aacute;
ficos e consumo alimentar. Os dados relacionados &agrave; etiologia da DRC, como
rbidades, esquema de di&aacute;lise, exames laboratoriais e peso corporal de tr&
ecirc;s meses anteriores a essa avalia&ccedil;&atilde;o foram coletados dos pron
tu&aacute;rios dos pacientes. Logo ap&oacute;s o t&eacute;rmino da sess&atilde;o
 de HD (aproximadamente 30 minutos) foram realizadas a avalia&ccedil;&atilde;o a
ntropom&eacute;trica, ASG e avalia&ccedil;&atilde;o do consumo alimentar. </font
></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#36#32#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#37#33#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>     
^cY#v33n1a08.htm##
01579000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704134500075002001301420#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#38#34#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Todas as medidas antropom&eacute;tric
as foram realizadas p&oacute;s-sess&atilde;o de HD. A aferi&ccedil;&atilde;o da 
massa corporal foi feita com aux&iacute;lio de uma balan&ccedil;a eletr&ocirc;ni
ca FILIZOLA<sup>&reg;</sup> com capacidade m&aacute;xima de 150 quilogramas (kg)
 e subdivis&otilde;es a cada 100 gramas (g). J&aacute; a estatura foi obtida com
 o aux&iacute;lio do estadi&ocirc;metro acoplado &agrave; balan&ccedil;a. O &iac
ute;ndice de massa corporal (IMC) foi obtido pela raz&atilde;o entre a massa cor
poral e o quadrado da estatura. <sup>11</sup> As pregas cut&acirc;neas do tr&iac
ute;ceps (PCT), b&iacute;ceps, subescapular e supra-il&iacute;aca foram aferidas
 com um adip&ocirc;metro calibrado da marca Lange<sup>&reg;</sup>. Tamb&eacute;m
 foi aferida a circunfer&ecirc;ncia do bra&ccedil;o (CB) com uma fita m&eacute;t
rica n&atilde;o extens&iacute;vel graduada em cent&iacute;metros. O c&aacute;lcu
lo da circunfer&ecirc;ncia muscular do bra&ccedil;o (CMB) foi feito pela seguint
e equa&ccedil;&atilde;o: CMB =CB (cm) - 3,14 x &#91;PCT (mm) &#247; 10&#93;. <su
p>12</sup> As adequa&ccedil;&otilde;es da PCT, CB e CMB foram obtidas utilizando
 a tabela com os valores de refer&ecirc;ncia adaptados por Blackburn &amp; Thorn
ton (1979). <sup>13</sup></font></p>     ^cY#v33n1a08.htm##
00928000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704069400075002001300769#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#39#35#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para aferi&ccedil;&atilde;o dos compa
rtimentos corporais (massa magra e gordura corp&oacute;rea) foi utilizada a t&ea
cute;cnica do somat&oacute;rio de quatro pregas cut&acirc;neas: bicipital, trici
pital, subescapular e supra-il&iacute;aca, utilizando-se a equa&ccedil;&atilde;o
 de Durnin &amp; Womersley (1974) para o c&aacute;lculo da densidade corporal e 
a equa&ccedil;&atilde;o de Siri (1956) para avalia&ccedil;&atilde;o do percentua
l da gordura corporal. <sup>14,15</sup> Os c&aacute;lculos foram efetuados para 
posterior classifica&ccedil;&atilde;o de acordo com Lohman <i>et al. </i>(1991).
 <sup>16</sup></font></p>     ^cY#v33n1a08.htm##
00894000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066000075002001300735#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#40#36#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o a ASG, empr
egou-se um modelo adaptado e validado para pacientes em HD. <sup>6</sup> Nesse m
odelo, o estado nutricional &eacute; pontuado de 1 a 7 pontos, sendo valores mai
s pr&oacute;ximos de 7 indicativos de pacientes bem nutridos. Com base nessa pon
tua&ccedil;&atilde;o, os pacientes com <i>score</i> 7 a 6 s&atilde;o classificad
os como bem nutridos; 5 a 3 desnutri&ccedil;&atilde;o leve a moderada e 2 e 1 de
snutridos graves. <sup>6</sup> Para dados de an&aacute;lise, foram considerados 
pacientes portadores de DEP com ASG &pound; 5. <sup> 6</sup></font></p>     ^cY#
v33n1a08.htm##
00682000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044800075002001300523#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#41#37#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os exames laboratoriais foram coletad
os dos prontu&aacute;rios m&eacute;dicos e inclu&iacute;ram: albumina (g/dL), cr
eatinina (mg/dL), colesterol (mg/dL) e ureia pr&eacute; e p&oacute;s-di&aacute;l
ise (mg/dL). Com exce&ccedil;&atilde;o da ureia, que foi coletada antes e depois
 da sess&atilde;o de HD, os exames foram sempre coletados antes da sess&atilde;o
 de HD. </font></p>     ^cY#v33n1a08.htm##
00645000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041100075002001300486#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#42#38#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O consumo alimentar foi realizado uti
lizando-se a t&eacute;cnica do recordat&oacute;rio de 24 horas de um dia com e o
utro sem HD. O software Avanutri foi utilizado para o c&aacute;lculo de consumo 
de energia e dos 3 macronutrientes. Os dados apresentados se referem &agrave; m&
eacute;dia dos dois dias avaliados (com e sem HD). </font></p>     ^cY#v33n1a08.
htm##
00598000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036400075002001300439#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#43#39#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As adequa&ccedil;&otilde;es do consum
o de energia e nutrientes para os pacientes foram comparadas segundo as recomend
a&ccedil;&otilde;es do NKF/KDOQI (2000). <sup>17</sup> Os valores de ingest&atil
de;o de energia e prote&iacute;na s&atilde;o expressos em kg de peso atual por d
ia. </font></p>     ^cY#v33n1a08.htm##
01550000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704131600075002001301391#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#44#40#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os crit&eacute;rios propostos pelo co
mit&ecirc; da International Society of Renal Nutrition and Metabolism foram util
izados para classificar o estado nutricional dos pacientes com DRC em tratamento
 dial&iacute;tico (<a href="/img/revistas/jbn/v33n1/a08qd01m.jpg">Quadro 1</a>).
 <sup>10</sup> Os crit&eacute;rios listados no documento original est&atilde;o d
escritos no <a href="/img/revistas/jbn/v33n1/a08qd01m.jpg">Quadro 1</a>. Contudo
, alguns dos crit&eacute;rios listados no trabalho original n&atilde;o foram con
siderados para o diagn&oacute;stico de DEP neste estudo, uma vez que os mesmos n
&atilde;o foram avaliados. Os crit&eacute;rios n&atilde;o considerados compreend
eram perda de peso n&atilde;o intencional de 5% em 3 meses ou de 10% em 6 meses,
 redu&ccedil;&atilde;o de massa muscular de 5% em 3 meses ou de 10% em 6 meses e
 presen&ccedil;a de pr&eacute;-albumina s&eacute;rica (transtiretina) &lt; 30 mg
/mL. Para o crit&eacute;rio de ingest&atilde;o alimentar, foi considerada a aval
ia&ccedil;&atilde;o realizada em um momento. Foram considerados como portadores 
DEP os pacientes que apresentaram 1 item de ao menos 3, dos 4 crit&eacute;rios a
presentados no <a href="/img/revistas/jbn/v33n1/a08qd01m.jpg">Quadro 1</a>. </fo
nt></p>     ^cY#v33n1a08.htm##
00443000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020900075002001300284#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#45#41#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Esse estudo foi aprovado pelo Comit&e
circ; de &Eacute;tica em Pesquisa do HUPE sobre o protocolo n&uacute;mero 2258-C
EP/HUPE. </font></p>     ^cY#v33n1a08.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012300075002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#46#42#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>AN&Aacute;LISE ESTAT&Iacute;STICA<
/b></font></p>     ^cY#v33n1a08.htm##
00815000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058100075002001300656#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#47#43#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> Os dados ser&atilde;o apresentados e
m m&eacute;dia ± desvio padr&atilde;o, uma vez que apresentavam distribui&ccedil
;&atilde;o normal. Para comparar os dados obtidos entre pacientes dos g&ecirc;ne
ros masculino e feminino foi empregado o teste-t Student para amostras independe
ntes. Foi utilizado o n&iacute;vel de signific&acirc;ncia de 0,05. Os testes for
am realizados no pacote de an&aacute;lises estat&iacute;sticas JMP IN&#169; Vers
ion 5.0 (SAS Institute Inc. , Cary, NC, EUA. <sup>24,23</sup></font></p>     ^cY
#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#48#44#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#49#45#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v33n1a08.htm##
00756000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052200075002001300597#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#50#46#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como observado na <a href="#tab1">Tab
ela 1</a>, a m&eacute;dia de idade dos pacientes encontrava-se na 5ª d&eacute;ca
da de vida, com minoria do g&ecirc;nero masculino. O acesso venoso para HD da ma
ioria dos pacientes era por fistula art&eacute;riovenosa e a m&eacute;dia do Kt/
V de ureia foi indicativa de boa efici&ecirc;ncia de di&aacute;lise. Al&eacute;m
 disso, nota-se ainda que a albumina plasm&aacute;tica esteve abaixo de 3,8 g/dL
. </font></p>     ^cY#v33n1a08.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#51#47#article#134#<p><a name="tab1"></
a></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#52#48#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#53#49#article#134#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a08tab01.jpg"></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#54#50#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
01609000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704137500075002001301450#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#55#51#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para fins de an&aacute;lise comparati
va, os dados antropom&eacute;tricos e de composi&ccedil;&atilde;o corporal foram
 avaliados por g&ecirc;nero, como pode ser visualizado na <a href="/img/revistas
/jbn/v33n1/a08tab02m.jpg">Tabela 2</a>. A m&eacute;dia do peso corporal dos home
ns n&atilde;o diferiu da m&eacute;dia de mulheres. Com rela&ccedil;&atilde;o ao 
IMC, a m&eacute;dia total dos indiv&iacute;duos foi indicativa de eutrofia, por&
eacute;m, ao estratificar por g&ecirc;nero, as mulheres apresentaram uma tend&ec
irc;ncia a maior IMC, sendo indicativa de sobrepeso. De acordo com a adequa&cced
il;&atilde;o da CB, a amostra se encontrou eutr&oacute;fica, entretanto, a popul
a&ccedil;&atilde;o masculina apresentou, em m&eacute;dia, um grau indicativo de 
desnutri&ccedil;&atilde;o leve. Ao analisar a CMB, pode-se notar que a popula&cc
edil;&atilde;o apresenta-se eutr&oacute;fica mesmo quando estratificada por g&ec
irc;nero. Ao analisar a adequa&ccedil;&atilde;o da PCT, considerada indicativa d
e reserva de tecido adiposo, nota-se a presen&ccedil;a de desnutri&ccedil;&atild
e;o moderada tanto nos homens quanto nas mulheres. Entretanto, ao analisar o per
centual de gordura, o mesmo encontra-se acima da m&eacute;dia para ambos os g&ec
irc;neros, sendo significantemente maior nas mulheres. </font></p>     ^cY#v33n1
a08.htm##
00762000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052800075002001300603#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#56#52#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o aos dados r
eferentes ao consumo alimentar, pode-se observar que a m&eacute;dia de ingest&at
ilde;o de energia foi de 22,7 ±7,0 kcal/kg de peso atual/dia, cujo valor encontr
a-se abaixo do recomendado para essa popula&ccedil;&atilde;o. De forma semelhant
e, a m&eacute;dia da ingest&atilde;o prot&eacute;ica tamb&eacute;m esteve abaixo
 do preconizado para pacientes em HD, sendo encontrado 1,0 ±0,6 g/kg de peso atu
al/dia. </font></p>     ^cY#v33n1a08.htm##
00624000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039000075002001300465#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#57#53#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Segundo a ASG, a maioria dos paciente
s (n = 12; 80%) apresentou algum grau de desnutri&ccedil;&atilde;o, sendo desnut
ri&ccedil;&atilde;o de leve &agrave; moderada presente em 10 pacientes (73,3%) e
 desnutri&ccedil;&atilde;o grave em 2 (6,7%). Apenas 3 pacientes (20%) foram cla
ssificados como bem nutridos. </font></p>     ^cY#v33n1a08.htm##
01008000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704077400075002001300849#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#58#54#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ao avaliar o estado nutricional pelos
 cinco par&acirc;metros estudados, notou-se que todos os pacientes pontuaram ao 
menos 1 dos 5 m&eacute;todos utilizados para classificar a DEP. O m&eacute;todo 
com maior n&uacute;mero de pacientes com DEP foi a ASG (n = 12; 80%), seguida do
 par&acirc;metro bioqu&iacute;mico de albumina s&eacute;rica (n = 10; 66,7%), da
 massa corporal total avaliada pelo IMC (n = 9; 60%), do consumo alimentar (n = 
9; 60%) e, por fim, da massa muscular (n = 2; 13,3%). A <a href="#fig1">Figura 1
</a> descreve a presen&ccedil;a de DEP diagnosticada por mais de um dos m&eacute
;todos avaliados. Nota-se que todos os pacientes pontuaram ao menos um desses m&
eacute;todos. </font></p>     ^cY#v33n1a08.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#59#55#article#134#<p><a name="fig1"></
a></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#60#56#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#61#57#article#134#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a08fig01.jpg"></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#62#58#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00649000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041500075002001300490#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#63#59#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quando utilizamos os crit&eacute;rios
 propostos pela International Society of Renal Nutrition and Metabolism para cla
ssificar a DEP (que n&atilde;o utiliza a ASG), notamos que apenas 13,3% (n = 2) 
dos pacientes eram considerados portadores de DEP, ou seja, que pontuavam 3 crit
&eacute;rios indicativos de desnutri&ccedil;&atilde;o. </font></p>     ^cY#v33n1
a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#64#60#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#65#61#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O </b></font></p>  
   ^cY#v33n1a08.htm##
01236000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704100200075002001301077#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#66#62#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Este trabalho avaliou o estado nutric
ional de pacientes com DRC em tratamento de HD por meio de diferentes m&eacute;t
odos de avalia&ccedil;&atilde;o nutricional, incluindo os crit&eacute;rios estab
elecidos pelo comit&ecirc; da International Society of Renal Nutrition and Metab
olism. <sup>10</sup> Os resultados obtidos mostram que a presen&ccedil;a de DEP 
variou de 13 a 80% quando avaliada isoladamente pelos diferentes m&eacute;todos 
empregados. Isso mostra que o diagn&oacute;stico de DEP quando avaliado por apen
as um m&eacute;todo pode n&atilde;o detectar a presen&ccedil;a de DEP em poss&ia
cute;veis casos positivos e levar a erros no diagn&oacute;stico nutricional. Cha
ma a aten&ccedil;&atilde;o que mesmo em uma amostra pequena, todos os pacientes 
avaliados pontuaram ao menos um dos m&eacute;todos para o diagn&oacute;stico de 
DEP, o que alerta para o elevado risco nutricional dessa popula&ccedil;&atilde;o
. </font></p>     ^cY#v33n1a08.htm##
00703000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046900075002001300544#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#67#63#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados observados s&atilde;o s
emelhantes aos de outros trabalhos que tamb&eacute;m encontram uma elevada preva
l&ecirc;ncia de DEP na HD. <sup>1,4,18</sup> O agravante da ocorr&ecirc;ncia da 
DEP na HD &eacute; a sua forte associa&ccedil;&atilde;o com aumento na morbimort
alidade,<sup>1,2</sup> maior taxa de hospitaliza&ccedil;&atilde;o e piora da qua
lidade de vida. <sup>18</sup></font></p>     ^cY#v33n1a08.htm##
00876000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064200075002001300717#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#68#64#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o nutricional
 tem como objetivo identificar as causas de risco ou deteriora&ccedil;&atilde;o 
do estado nutricional, auxiliando na terapia espec&iacute;fica e na determina&cc
edil;&atilde;o das necessidades nutricionais de cada nutriente. Conhecer e carac
terizar adequadamente o estado nutricional de uma popula&ccedil;&atilde;o em di&
aacute;lise &eacute; fundamental para tratar e prevenir o desenvolvimento e o ag
ravo da DEP, e para determinar e avaliar o impacto da terapia diet&eacute;tica s
obre o desfecho nutricional. <sup>4 </sup></font></p>     ^cY#v33n1a08.htm##
02386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704215200075002001302227#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#69#65#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Recentemente, diversos par&acirc;metr
os nutricionais t&ecirc;m sido utilizados para a implementa&ccedil;&atilde;o do 
diagn&oacute;stico de desnutri&ccedil;&atilde;o em indiv&iacute;duos com DRC. De
ntre eles, os mais comuns consistem na antropometria, bioimped&acirc;ncia el&eac
ute;trica, albumina plasm&aacute;tica e recordat&oacute;rios alimentares. <sup>1
9</sup> Contudo, n&atilde;o se sabe ainda qual ou quais desses m&eacute;todos de
vem ser empregados para detectar com maior precis&atilde;o o paciente com DEP. A
 dificuldade de se estabelecer o melhor m&eacute;todo para avaliar a DEP est&aac
ute; no fato de que todos esses par&acirc;metros apresentam limita&ccedil;&otild
e;es quando avaliados isoladamente. <sup>5</sup> Nesse sentido, a ASG tem se mos
trado eficiente por ser um instrumento que avalia a hist&oacute;ria m&eacute;dic
a, o exame cl&iacute;nico e f&iacute;sico (reservas corporais de tecido adiposo 
e muscular) do paciente. Um trabalho recente com pacientes em HD mostrou que a a
valia&ccedil;&atilde;o das reservas corporais obtida pela ASG tinha boa concord&
acirc;ncia com a avalia&ccedil;&atilde;o de reserva de tecido adiposo e muscular
 obtida por medidas objetivas desses compartimentos corporais. <sup>20</sup> Em 
outro trabalho, mostrou-se que a ASG aplicada em pacientes em HD tinha poder pre
ditivo para ocorr&ecirc;ncia de hospitaliza&ccedil;&otilde;es. <sup>6 </sup>As p
rincipais limita&ccedil;&otilde;es da ASG compreendem a baixa sensibilidade para
 avaliar pequenas mudan&ccedil;as e na varia&ccedil;&atilde;o interindividual qu
ando a mesma &eacute; realizada por uma equipe. Vale mencionar que o modelo de A
SG aplicado no presente trabalho foi recentemente validado para essa popula&cced
il;&atilde;o e, como inclui a possibilidade de n&iacute;veis de classifica&ccedi
l;&atilde;o a partir da gradua&ccedil;&atilde;o em 7 pontos, atenua a baixa sens
ibilidade para pequenas mudan&ccedil;as do estado nutricional. <sup>6</sup> No p
resente estudo, a ASG foi o m&eacute;todo que isoladamente detectou o maior n&ua
cute;mero de pacientes com DEP. </font></p>     ^cY#v33n1a08.htm##
01440000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704120600075002001301281#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#70#66#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o &agrave; an
&aacute;lise da ingest&atilde;o alimentar, a maior dificuldade est&aacute; nos f
atores que levam a  erros pertinentes ao entrevistado e aqueles pertinentes ao e
ntrevistador. Dentre os primeiros, podemos citar a incompreens&atilde;o das ques
t&otilde;es, a omiss&atilde;o, ou a superestimativa do consumo, o erro na estima
tiva do tamanho da por&ccedil;&atilde;o e falha na mem&oacute;ria do entrevistad
o. J&aacute; com rela&ccedil;&atilde;o ao entrevistador, pode ocorrer registro i
ncorreto das respostas, omiss&atilde;o intencional, descri&ccedil;&atilde;o inco
mpleta, distra&ccedil;&atilde;o devido ao ambiente da entrevista, empatia pelo e
ntrevistado e erro na convers&atilde;o das medidas caseiras em gramas. <sup>12</
sup> Particularmente para pacientes em HD, uma dificuldade encontrada &eacute; a
 mudan&ccedil;a que o paciente pode apresentar em seu padr&atilde;o alimentar en
tre os dias com e sem di&aacute;lise, j&aacute; que nos dias em que o tratamento
 dial&iacute;tico &eacute; realizado, o paciente pode ocultar uma de suas refei&
ccedil;&otilde;es di&aacute;rias. <sup>5</sup></font></p>     ^cY#v33n1a08.htm##
01827000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704159300075002001301668#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#71#67#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dentre os diversos par&acirc;metros b
ioqu&iacute;micos dispon&iacute;veis para a avalia&ccedil;&atilde;o do estado nu
tricional, a albumina tem sido a mais empregada, devido &agrave; sua estreita as
socia&ccedil;&atilde;o com as taxas de morbimortalidade nessa popula&ccedil;&ati
lde;o. <sup>21</sup> No entanto, tanto os par&acirc;metros bioqu&iacute;micos qu
anto os imunol&oacute;gicos podem sofrer altera&ccedil;&atilde;o de acordo com o
 grau de inflama&ccedil;&atilde;o do paciente. <sup>21,22</sup> De fato, j&aacut
e; est&aacute; bem descrito na literatura que um percentual importante de pacien
tes em HD apresenta valores de prote&iacute;na C-reativa elevados, os quais s&at
ilde;o indicativos de um quadro de inflama&ccedil;&atilde;o. Como a albumina &ea
cute; uma prote&iacute;na de fase aguda negativa, que fica com sua s&iacute;ntes
e hep&aacute;tica reduzida em quadros inflamat&oacute;rios, n&atilde;o se sabe s
e sua estreita associa&ccedil;&atilde;o com as taxas de morbimortalidade seja de
corrente de quadro de DEP ou de inflama&ccedil;&atilde;o ou ainda da congru&ecir
c;ncia de ambas as condi&ccedil;&otilde;es. <sup>21</sup> Sendo assim, o uso iso
lado da albumina s&eacute;rica como marcador de desnutri&ccedil;&atilde;o nesta 
popula&ccedil;&atilde;o pode n&atilde;o ser adequado. <sup>21,22</sup> Em nosso 
trabalho, 10 pacientes apresentaram valores de albumina plasm&aacute;tica abaixo
 de 3,8 g/dL, sendo que todos esses pacientes tamb&eacute;m apresentaram ASG de 
indicativa de algum grau de DEP. </font></p>     ^cY#v33n1a08.htm##
01537000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704130300075002001301378#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#72#68#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Pela dificuldade em diagnosticar o pa
ciente portador de DEP, o comit&ecirc; da International Society of Renal Nutriti
on and Metabolism se reuniu com o objetivo de criar crit&eacute;rios capazes de 
diagnosticar a DEP. Os crit&eacute;rios sugeridos por esse comit&ecirc; (<a href
="/img/revistas/jbn/v33n1/a08qd01m.jpg">Quadro 1</a>) incluem a avalia&ccedil;&a
tilde;o da massa corporal, massa muscular, par&acirc;metros bioqu&iacute;micos e
 de consumo alimentar. Dessa forma, busca-se contornar as dificuldades de empreg
ar um m&eacute;todo isolado para avaliar o estado nutricional. <sup>10</sup> No 
presente estudo, 3 crit&eacute;rios propostos no trabalho original n&atilde;o fo
ram considerados, embora todos os par&acirc;metros propostos pelo comit&ecirc; d
a ISRNM (massa corporal, massa muscular, par&acirc;metros bioqu&iacute;micos e d
e consumo alimentar) tenham sido avaliados.Quando foi aplicada a proposta desse 
comit&ecirc;, notamos que apenas 2 pacientes (13,3%) avaliados nessa amostra ser
iam considerados desnutridos. Desse modo, destacamos a import&acirc;ncia da real
iza&ccedil;&atilde;o de mais estudos de avalia&ccedil;&atilde;o do estado nutric
ional de pacientes em HD que empreguem esses crit&eacute;rios. </font></p>     ^
cY#v33n1a08.htm##
00965000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704073100075002001300806#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#73#69#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dentre os pacientes em HD avaliados n
esse estudo, 80% (n = 12) foram diagnosticados com desnutri&ccedil;&atilde;o de 
acordo com a ASG. At&eacute; que se tenha estabelecido um m&eacute;todo padr&ati
lde;o ouro para se diagnosticar desnutri&ccedil;&atilde;o nessa popula&ccedil;&a
tilde;o, a ASG parece ser o m&eacute;todo capaz de detectar o maior n&uacute;mer
o de pacientes com DEP. A baixa sensibilidade da ASG para detectar pequenas muda
n&ccedil;as no estado nutricional &eacute; uma limita&ccedil;&atilde;o conhecida
 e merece ser estudada, no sentido de melhor adequar seu poder de avalia&ccedil;
&atilde;o do estado nutricional longitudinalmente. </font></p>     ^cY#v33n1a08.
htm##
00630000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039600075002001300471#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#74#70#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Considerando a import&acirc;ncia da i
dentifica&ccedil;&atilde;o da desnutri&ccedil;&atilde;o para se iniciar medidas 
de controle e monitoramento da sa&uacute;de do paciente, a ASG apresenta abrang&
ecirc;ncia suficiente para que os verdadeiramente desnutridos n&atilde;o fiquem 
sem aten&ccedil;&atilde;o especial. </font></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#75#71#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#76#72#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>   
  ^cY#v33n1a08.htm##
00637000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040300075002001300478#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#77#73#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em conclus&atilde;o, dentre os par&ac
irc;metros nutricionais empregados para avaliar o estado nutricional de paciente
s em HD, a ASG que &eacute; um m&eacute;todo simples, de baixo custo e de alta a
plicabilidade na pr&aacute;tica cl&iacute;nica, foi o que detectou o maior n&uac
ute;mero de pacientes com DEP. <sup>2</sup></font></p>     ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#78#74#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a08.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#79#75#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a08.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023000077002001300307#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#80#76#article#134#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Qureshi AR, Alvestra
nd A, Danielsson A et al. Factors predicting malnutrition in hemodialysis patien
ts: a cross-sectional study. Kidney Int 1998; 53:773-82.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#81#77#article#134# </font></p>     ^cY
#v33n1a08.htm##
00557000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704030900077002001300386#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#82#78#article#134#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Marcen R, Teruel JL,
 de la Cal MA, G&aacute;mez C. The impact of malnutrition in morbidity and morta
lity in stable hemodialysis patients. Spanish Cooperative Study of Nutrition in 
Hemodialysis. Nephrol Dial Transplant 1997; 12:2324-31.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#83#79#article#134# </font></p>     ^cY
#v33n1a08.htm##
00492000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024400077002001300321#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#84#80#article#134#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Avesani CM, Carrero 
JJ, Axelsson J, Qureshi AR, Lindholm B, Stenvinkel P. Inflammation and wasting i
n chronic kidney disease: partners in crime. Kidney Int 2006; 70:8-13.    ^cY#v3
3n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#85#81#article#134# </font></p>     ^cY
#v33n1a08.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027100077002001300348#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#86#82#article#134#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Valenzuela RGV, Giff
oni AG, Cuppari L, Canziani MEF. Estado nutricional de pacientes com insufici&ec
irc;ncia renal cr&ocirc;nica em hemodi&aacute;lise no Amazonas. Rev Assoc Med Br
as 2003; 49:72-8.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#87#83#article#134# </font></p>     ^cY
#v33n1a08.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704029200077002001300369#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#88#84#article#134#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Kamimura MA, Avesani
 CM, Cuppari L. M&eacute;todos de avalia&ccedil;&atilde;o nutricional no pacient
e com doen&ccedil;a renal cr&ocirc;nica. In: CRUZ, J. Atualidades em Nefrologia.
1.ed. S&atilde;o Paulo: Sarvier, 2006.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#89#85#article#134# </font></p>     ^cY
#v33n1a08.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025900077002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#90#86#article#134#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Steiber A, Leon JB, 
Secker D <i>et al. </i> Multicenter study of the validity and reliability of sub
jective global assessment in the hemodialysis population. J Ren Nutr 2007; 17:33
6-42.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#91#87#article#134# </font></p>     ^cY
#v33n1a08.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025900077002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#92#88#article#134#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Kalantar-Zadeh K, Kl
einer M, Dunne E, Lee GH, Luft FC. A modified quantitative subjective global ass
essment of nutrition for dialysis patients. Nephrol Dial Transplant 1999; 14:173
2-38.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#93#89#article#134# </font></p>     ^cY
#v33n1a08.htm##
00415000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704016700077002001300244#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#94#90#article#134#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Steinman TI. Serum a
lbumin: its significance in patients with ESRD. Semin Dial 2000; 13:4048.    ^cY
#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#95#91#article#134# </font></p>     ^cY
#v33n1a08.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022400077002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#96#92#article#134#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Johansen KL, Young B
, Kaysen GA, Chertow GM. Association of body size with outcomes among patients b
eginning dialysis. Am J Clin Nutr 2004; 80:324-32.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#97#93#article#134# </font></p>     ^cY
#v33n1a08.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704026500078002001300343#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#98#94#article#134#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Fouque D, Kalantar
-Zadeh K, Kopple J <i>et al. </i> A proposed nomenclature and diagnostic criteri
a for protein-energy wasting in acute and chronic kidney disease. Kidney Int 200
8; 73:391-8.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#99#95#article#134# </font></p>     ^cY
#v33n1a08.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704021500079002001300294#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#100#96#article#134#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. World Health Orga
nization. Obesity: preventing and managing the global epidemic. Report of WHO, C
onsultation on Obesity. Genebra: WHO, 1997.    ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#101#97#article#134# </font></p>     ^c
Y#v33n1a08.htm##
00617000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704036700079002001300446#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#102#98#article#134#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Kamimura MA, Baxm
ann A, Sampaio LR, Cuppari L. Avalia&ccedil;&atilde;o nutricional. In: CUPPARI, 
L. Guias de Medicina ambulatorial e hospitalar UNIFESP/Escola Paulista de Medici
na: Nutri&ccedil;&atilde;o - Nutri&ccedil;&atilde;o Cl&iacute;nica no Adulto. 2.
ed. S&atilde;o Paulo: Manole, 2005.    ^cY#v33n1a08.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#103#99#article#134# </font></p>     ^c
Y#v33n1a08.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018900080002001300269#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#104#100#article#134#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Blackburn GL, Th
ornton PA. Nutritional assessment of the hospitalized patient. Med Clin North Am
 1979; 63:1103-15.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#105#101#article#134# </font></p>     ^
cY#v33n1a08.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027000080002001300350#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#106#102#article#134#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Durnin JVGA, Wom
ersley I. Body fat assessed from total body density ad its estimation from skinf
old thickness: measurement on 481 men and women aged from 16 to 72 years. Br J N
utr 1974; 32:77-97.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#107#103#article#134# </font></p>     ^
cY#v33n1a08.htm##
00526000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027500080002001300355#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#108#104#article#134#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Siri WE (1961). 
Body composition from fluid analysis and density: analysis of methods. In: Broze
k J, Henschel A (eds). Techniques for measuring body composition. Washington: Na
tional Research Council.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#109#105#article#134# </font></p>     ^
cY#v33n1a08.htm##
00450000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019900080002001300279#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#110#106#article#134#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Lohman TG, Roche
 AF, Martorelli R. Anthropometric standardization reference manual. Champaign: A
bridged Edition, p.91, 1991.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#111#107#article#134# </font></p>     ^
cY#v33n1a08.htm##
00516000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026500080002001300345#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#112#108#article#134#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. National Kidney 
Foundation I. Kidney Disease-Dialysis Outcome Quality Initiative: K/DOQI. Clinic
al practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2
000; 35:1-140.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#113#109#article#134# </font></p>     ^
cY#v33n1a08.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025000080002001300330#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#114#110#article#134#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Kalantar-zadeh K
. Recent advances in understanding the malnutrition-inflammation-caquexia syndro
me in chronic kidney disease patients: What is next? Semin Dial 2005; 18:365-9. 
   ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#115#111#article#134# </font></p>     ^
cY#v33n1a08.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022700080002001300307#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#116#112#article#134#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Cano NJM, miolan
e-Debouit M, L&eacute;ger J, heng AE. Assessment of body protein: energy status 
in chronic kidney disease. Semin Nephrol 2009; 29:59-66.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#117#113#article#134# </font></p>     ^
cY#v33n1a08.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#118#114#article#134#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Carrero JJ, Chmi
elewski M, Axelsson J <i>et al. </i> Muscle atrophy, inflammation and clinical o
utcome in incident and prevalent dialysis patients. Clin Nutr 2008; 27:557-64.  
  ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#119#115#article#134# </font></p>     ^
cY#v33n1a08.htm##
00542000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029100080002001300371#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#120#116#article#134#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Kaysen GA, Eiser
ich JP. The role of oxidative stress-altered lipoprotein structure and function 
and microinflammation on cardiovascular risk in patients with minor renal dysfun
ction. J Am Soc Nephrol 2004; 15:538-48.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#121#117#article#134# </font></p>     ^
cY#v33n1a08.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025900080002001300339#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#122#118#article#134#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Santos NS, Draib
e SA, Kamimura MA <i>et al. </i> Is serum albumin a marker of nutritional status
 in hemodialysis patients without evidence of inflammation? Artif Organs 2003; 2
7:681-6.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#123#119#article#134# </font></p>     ^
cY#v33n1a08.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#124#120#article#134#<p>&nbsp;</p>     
^cY#v33n1a08.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#125#121#article#134#<p>&nbsp;</p>     
^cY#v33n1a08.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020000077002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#126#122#article#134#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;
ncia para:</b>    ^cY#v33n1a08.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003500077002001300112#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#127#123#article#134#<br>   Carla Maria
 Avesani     ^cY#v33n1a08.htm##
00298000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006200077002001300139#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#128#124#article#134#<br>   Universidad
e do Estado do Rio de Janeiro - UERJ    ^cY#v33n1a08.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009900077002001300176#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#129#125#article#134#<br>   R S&atilde;
o Francisco Xavier, 524, 12º andar, Bloco D, sala 12.029, Maracan&atilde;    ^cY
#v33n1a08.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#130#126#article#134#<br>   Rio de Jane
iro - RJ - Brasil CEP: 20550-900    ^cY#v33n1a08.htm##
00287000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005100077002001300128#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#131#127#article#134#<br>   Tel. : 55 (
21) 2334-0270, Ramal 215     ^cY#v33n1a08.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010900077002001300186#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#132#128#article#134#<br>   E-mail: <a 
href="mailto:carla.avesani@gmail.com.br">carla.avesani@gmail.com.br</a></font></
p>     ^cY#v33n1a08.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#133#129#article#134#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 25/10/201
0    ^cY#v33n1a08.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#134#130#article#134#<br>   Data de apr
ova&ccedil;&atilde;o: 28/12/2010    ^cY#v33n1a08.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#135#131#article#134#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a08.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#136#132#article#134#<p>&nbsp;</p>     
^cY#v33n1a08.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#137#133#article#134#<p>&nbsp;</p>     
^cY#v33n1a08.htm##
00366000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704013000077002001300207#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a08.htm#S#p#138#134#article#134#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi  realizado no
 HUPE/UERJ. </font></p>     ^cY#v33n1a08.htm##
00606000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100020000940100
02000114810000600134012008600140030001100226065000900237064000500246031000300251
014000700254865000900261002001300270035001000283801001100293#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#139#1#article#22#1#^rND^sQureshi^nAR#^rND^
sAlvestrand^nA#^rND^sDanielsson^nA#et al#Factors predicting malnutrition in hemo
dialysis patients: a cross-sectional study^len#Kidney Int#19980000#1998#53#773-8
2#20110300#v33n1a08.htm#0085-2538#Kidney int##
00697000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100017000920100
02000109010001500129012014600144030002400290065000900314064000500323031000300328
014000800331865000900339002001300348035001000361801002400371#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#140#2#article#22#2#^rND^sMarcen^nR#^rND^sT
eruel^nJL#^rND^sde la Cal^nMA#^rND^sGámez^nC#The impact of malnutrition in morbi
dity and mortality in stable hemodialysis patients: Spanish Cooperative Study of
 Nutrition in Hemodialysis^len#Nephrol Dial Transplant#19970000#1997#12#2324-31#
20110300#v33n1a08.htm#0931-0509#Nephrol Dial Transplant##
00662000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940100
01800112010001800130010001800148010002000166012007400186030001100260065000900271
06400050028003100030028501400050028886500090029300200130030203500100031580100110
0325#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#c#141#3#article#22#3
#^rND^sAvesani^nCM#^rND^sCarrero^nJJ#^rND^sAxelsson^nJ#^rND^sQureshi^nAR#^rND^sL
indholm^nB#^rND^sStenvinkel^nP#Inflammation and wasting in chronic kidney diseas
e: partners in crime^len#Kidney Int#20060000#2006#70#8-13#20110300#v33n1a08.htm#
0085-2538#Kidney int##
00642000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100018000980100
01700116010002000133012009500153030001900248065000900267064000500276031000300281
014000500284865000900289002001300298035001000311801001900321#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#142#4#article#22#4#^rND^sValenzuela^nRGV#^
rND^sGiffoni^nAG#^rND^sCuppari^nL#^rND^sCanziani^nMEF#Estado nutricional de paci
entes com insuficiência renal crônica em hemodiálise no Amazonas^lpt#Rev Assoc M
ed Bras#20030000#2003#49#72-8#20110300#v33n1a08.htm#0004-5241#Rev Assoc Med Bras
##
00594000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100018000950100
01700113012007400130016001400204018003000218063000200248066001000250062000800260
065000900268064000500277865000900282002001300291#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a08.htm#S#c#143#5#article#22#5#^rND^sKamimura^nMA#^rND^sAvesani^nC
M#^rND^sCuppari^nL#Métodos de avaliação nutricional no paciente com doença renal
 crônica^lpt#^rND^sCRUZ^nJ#Atualidades em Nefrologia^lpt#1#São Paulo#Sarvier#200
60000#2006#20110300#v33n1a08.htm##
00627000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100015000930100
01600108810000600124012011700130030001100247065000900258064000500267031000300272
014000700275865000900282002001300291035001000304801001100314#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#144#6#article#22#6#^rND^sSteiber^nA#^rND^s
Leon^nJB#^rND^sSecker^nD#et al#Multicenter study of the validity and reliability
 of subjective global assessment in the hemodialysis population^len#J Ren Nutr#2
0070000#2007#17#336-42#20110300#v33n1a08.htm#1051-2276#J Ren Nutr##
00672000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100024000760100017001000100
01500117010001400132010001500146012009200161030002400253065000900277064000500286
031000300291014000800294865000900302002001300311035001000324801002400334#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#c#145#7#article#22#7#^rND^sKalan
tar-Zadeh^nK#^rND^sKleiner^nM#^rND^sDunne^nE#^rND^sLee^nGH#^rND^sLuft^nFC#A modi
fied quantitative subjective global assessment of nutrition for dialysis patient
s^len#Nephrol Dial Transplant#19990000#1999#14#1732-38#20110300#v33n1a08.htm#093
1-0509#Nephrol Dial Transplant##
00464000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760120058000950300
01100153710000200164065000900166064000500175031000300180014000500183865000900188
002001300197#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#c#146#8#arti
cle#22#8#^rND^sSteinman^nTI#Serum albumin: its significance in patients with ESR
D^len#Semin Dial#2#20000000#2000#13#4048#20110300#v33n1a08.htm##
00610000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100015000950100
01700110010001800127012007700145030001500222065000900237064000500246031000300251
014000700254865000900261002001300270035001000283801001500293#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#147#9#article#22#9#^rND^sJohansen^nKL#^rND
^sYoung^nB#^rND^sKaysen^nGA#^rND^sChertow^nGM#Association of body size with outc
omes among patients beginning dialysis^len#Am J Clin Nutr#20040000#2004#80#324-3
2#20110300#v33n1a08.htm#0002-9165#Am J Clin Nutr##
00634000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100024000940100
01600118810000600134012011500140030001100255065000900266064000500275031000300280
014000600283865000900289002001300298035001000311801001100321#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#148#10#article#22#10#^rND^sFouque^nD#^rND^
sKalantar-Zadeh^nK#^rND^sKopple^nJ#et al#A proposed nomenclature and diagnostic 
criteria for protein-energy wasting in acute and chronic kidney disease^len#Kidn
ey Int#20080000#2008#73#391-8#20110300#v33n1a08.htm#0085-2538#Kidney int##
00479000000000229000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750170026000780180097001040660
00800201062000400209065000900213064000500222865000900227002001300236#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#c#149#11#article#22#11#World Health 
Organization#Obesity: preventing and managing the global epidemic. Report of WHO
, Consultation on Obesity^len#Genebra#WHO#19970000#1997#20110300#v33n1a08.htm##
00672000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970100
01800114010001700132012002600149016001700175018012300192063000200315066001000317
062000700327065000900334064000500343865000900348002001300357#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#150#12#article#22#12#^rND^sKamimura^nMA#^r
ND^sBaxmann^nA#^rND^sSampaio^nLR#^rND^sCuppari^nL#Avaliação nutricional^lpt#^rND
^sCUPPARI^nL#Guias de Medicina ambulatorial e hospitalar UNIFESP/Escola Paulista
 de Medicina: Nutrição - Nutrição Clínica no Adulto^lpt#2#São Paulo#Manole#20050
000#2005#20110300#v33n1a08.htm##
00543000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100019000980120
05500117030001800172065000900190064000500199031000300204014000800207865000900215
002001300224035001000237801001800247#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a08.htm#S#c#151#13#article#22#13#^rND^sBlackburn^nGL#^rND^sThornton^nPA#Nutrit
ional assessment of the hospitalized patient^len#Med Clin North Am#19790000#1979
#63#1103-15#20110300#v33n1a08.htm#0025-7125#Med Clin North Am##
00616000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100019000970120
14700116030001000263065000900273064000500282031000300287014000600290865000900296
002001300305035001000318801001000328#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a08.htm#S#c#152#14#article#22#14#^rND^sDurnin^nJVGA#^rND^sWomersley^nI#Body fa
t assessed from total body density ad its estimation from skinfold thickness: me
asurement on 481 men and women aged from 16 to 72 years^len#Br J Nutr#19740000#1
974#32#77-97#20110300#v33n1a08.htm#0007-1145#Br J Nutr##
00548000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120074000930160
01600167016001800183018004600201066001100247062002600258865000900284002001300293
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#c#153#15#article#22#15#^
rND^sSiri^nWE#Body composition from fluid analysis and density: analysis of meth
ods^len#^rED^sBrozek^nJ#^rED^sHenschel^nA#Techniques for measuring body composit
ion^len#Washington#National Research Council#20110300#v33n1a08.htm##
00515000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160017000780160016000950160
02000111018005200131066001000183062001700193014000300210065000900213064000500222
865000900227002001300236#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#
c#154#16#article#22#16#^rND^sLohman^nTG#^rND^sRoche^nAF#^rND^sMartorelli^nR#Anth
ropometric standardization reference manual^len#Champaign#Abridged Edition#91#19
910000#1991#20110300#v33n1a08.htm##
00592000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750110029000780120132001070300
01600239065000900255064000500264031000300269014000600272865000900278002001300287
035001000300801001600310#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#
c#155#17#article#22#17#National Kidney Foundation I#Kidney Disease-Dialysis Outc
ome Quality Initiative: K/DOQI. Clinical practice guidelines for nutrition in ch
ronic renal failure^len#Am J Kidney Dis#20000000#2000#35#1-140#20110300#v33n1a08
.htm#0272-6386#Am J Kidney Dis##
00549000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100024000780120135001020300
01100237710000200248065000900250064000500259031000300264014000600267865000900273
002001300282#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a08.htm#S#c#156#18#art
icle#22#18#^rND^sKalantar-zadeh^nK#Recent advances in understanding the malnutri
tion-inflammation-caquexia syndrome in chronic kidney disease patients: What is 
next?^len#Semin Dial#2#20050000#2005#18#365-9#20110300#v33n1a08.htm##
00606000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100025000940100
01500119010001500134012007200149030001400221065000900235064000500244031000300249
014000600252865000900258002001300267035001000280801001400290#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#157#19#article#22#19#^rND^sCano^nNJM#^rND^
smiolane-Debouit^nM#^rND^sLéger^nJ#^rND^sheng^nAE#Assessment of body protein: en
ergy status in chronic kidney disease^len#Semin Nephrol#20090000#2009#29#59-66#2
0110300#v33n1a08.htm#0270-9295#Semin Nephrol##
00617000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100021000960100
01800117810000600135012009800141030001000239065000900249064000500258031000300263
014000700266865000900273002001300282035001000295801001000305#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#158#20#article#22#20#^rND^sCarrero^nJJ#^rN
D^sChmielewski^nM#^rND^sAxelsson^nJ#et al#Muscle atrophy, inflammation and clini
cal outcome in incident and prevalent dialysis patients^len#Clin Nutr#20080000#2
008#27#557-64#20110300#v33n1a08.htm#0261-5614#Clin Nutr##
00644000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950120
16200114030001700276065000900293064000500302031000300307014000700310865000900317
002001300326035001000339801001700349#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a08.htm#S#c#159#21#article#22#21#^rND^sKaysen^nGA#^rND^sEiserich^nJP#The role 
of oxidative stress-altered lipoprotein structure and function and microinflamma
tion on cardiovascular risk in patients with minor renal dysfunction^len#J Am So
c Nephrol#20040000#2004#15#538-48#20110300#v33n1a08.htm#1046-6673#J Am Soc Nephr
ol##
00630000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01900112810000600131012011000137030001300247065000900260064000500269031000300274
014000600277865000900283002001300292035001000305801001300315#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a08.htm#S#c#160#22#article#22#22#^rND^sSantos^nNS#^rND
^sDraibe^nSA#^rND^sKamimura^nMA#et al#Is serum albumin a marker of nutritional s
tatus in hemodialysis patients without evidence of inflammation^len#Artif Organs
#20030000#2003#27#681-6#20110300#v33n1a08.htm#0160-564X#Artif Organs##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#o#1#1#article#1#
20110411#092937#v33n1a09.htm#223##
04873000000000709000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101200780
01610120068002390100045003070100028003520100039003800100048004190100039004670700
04500506070005100551070004700602070009600649083148400745085001002229085004002239
08500400227908500490231908500350236808500260240308500330242908314570246208500100
39190850035039290850040039640850035040040850028040390850032040671170008040990720
00304107112000904110111001104119114000904130113001104139002001304150#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#IL
US#TAB#09#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f62^l68#0101-2800#Efeitos do
 treinamento muscular inspiratório nos pacientes em hemodiálise^lpt#Effects of i
nspiratory muscle training in hemodialysis patients^len#^rND^1A01 A02^nVanessa G
iendruczak da^sSilva#^rND^1A04^nCarolina^sAmaral#^rND^1A01 A04^nMariane Borba^sM
onteiro#^rND^1A01 A04^nDaniela Meirelles do^sNascimento#^rND^1A03^nJaqueline Reg
ina^sBoschetti#Rede Metodista de Educação do Sul - IPA^iA01#FUC^iA02^1Instituto 
de Cardiologia de Porto Alegre#Universidade Federal do Rio Grande do Sul^iA03#Ir
mandade da Santa Casa de Misericórdia de Porto Alegre^iA04^1Unidade do Serviço d
e Hemodiálise#^lpt^aINTRODUÇÃO: A doença renal crônica associada ao tratamento h
emodialítico pode apresentar uma diversidade de complicações músculo-esquelética
s, além de trazer repercussões à função pulmonar. OBJETIVO: Avaliar os efeitos d
o treinamento muscular inspiratório na força muscular inspiratória, função pulmo
nar e capacidade funcional em pacientes com insuficiência renal crônica submetid
os à hemodiálise. MÉTODO: Ensaio clínico não controlado, composto por 15 indivíd
uos com diagnóstico médico de insuficiência renal crônica, submetidos à hemodiál
ise. Foram avaliados pressões inspiratória máxima (PImáx) e expiratória máxima (
PEmáx) através da manovacuometria; função pulmonar pela espirometria e a capacid
ade funcional através da distância percorrida e consumo de oxigênio obtido no te
ste da caminhada dos seis minutos (TC6M). No período de oito semanas, foi aplica
do o protocolo de treinamento muscular respiratório (TMI) durante a sessão de he
modiálise, com carga estabelecida de 40% da PImáx e uma frequência semanal de tr
ês dias alternados. RESULTADOS: Houve um aumento significativo na variável distâ
ncia percorrida após o treinamento (455 ± 98 versus 558 ± 121; p = 0,003). Não f
oram encontradas diferenças estatísticas na comparação antes e após treinamento 
nas demais variáveis do estudo. CONCLUSÃO: O estudo não apresentou diferença est
atística na força muscular respiratória, na função pulmonar e no consumo de oxig
ênio. Observou-se apenas um aumento na distância do TC6M.#^ddecs^i1#^tm^lpt^kins
uficiência renal crônica^i1#^tm^lpt^kfisioterapia^i1^sespecialidade#^tm^lpt^kuni
dades hospitalares de hemodiálise^i1#^tm^lpt^kfalência renal crônica^i1#^tm^lpt^
kdiálise renal^i1#^tm^lpt^kterapia respiratória^i1#^len^aINTRODUCTION: Chronic k
idney disease associated with hemodialysis can have a variety of musculoskeletal
 complications, in addition to repercussions in pulmonary function. OBJECTIVE: T
o evaluate the effects of inspiratory muscle training on inspiratory muscle stre
ngth, pulmonary function, and functional capacity in patients with chronic kidne
y failure undergoing hemodialysis. METHOD: Non-controlled clinical trial, compri
sing 15 individuals diagnosed with chronic kidney failure and undergoing hemodia
lysis. Maximum inspiratory (PImax) and expiratory (PEmax) pressures were assesse
d by use of pressure vacuum meter reading. Pulmonary function was assessed by us
e of spirometry. Functional capacity was assessed by use of walked distance and 
oxygen consumption obtained in the six-minute walk test (6MWT). For eight weeks,
 the inspiratory muscle training (IMT) protocol was applied during hemodialysis 
sessions, with load set to 40% of PImax and weekly frequency of three alternate 
days. RESULTS: A significant increase in the walked distance was observed after 
training (455.5 ± 98 versus 557.8 ± 121.0; p = 0.003). No statistically signific
ant difference was observed in the other variables when comparing their pre- and
 posttraining values. CONCLUSION: The study showed no statistically significant 
difference in respiratory muscle strength, pulmonary function, and oxygen consum
ption. An increase in the walked distance was observed in the 6MWT.#^ddecs^i2#^t
m^len^kchronic kidney failure^i2#^tm^len^kphysical therapy^i2^sspecialty#^tm^len
^khospital dialysis unit^i2#^tm^len^kkidney dialysis^i2#^tm^len^krespiratory the
rapy^i2#vancouv#40#20100726#26/07/2010#20101229#29/12/2010#v33n1a09.htm##
05037000000000709000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101200850
01610120075002460100045003210100028003660100039003940100048004330100039004810700
04500520070005100565070004700616070009600663083155900759085001002318085004002328
08500400236808500490240808500350245708500260249208500330251808315320255108500100
40830850035040930850040041280850035041680850028042030850032042311170008042630720
00304271112000904274111001104283114000904294113001104303002001304314#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#IL
US#TAB#09#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f62^l68#0101-2800#<b>Efeitos
 do treinamento muscular inspiratório nos pacientes em hemodiálise</b>^lpt#<b>Ef
fects of inspiratory muscle training in hemodialysis patients</b>^len#^rND^1A01 
A02^nVanessa Giendruczak da^sSilva#^rND^1A04^nCarolina^sAmaral#^rND^1A01 A04^nMa
riane Borba^sMonteiro#^rND^1A01 A04^nDaniela Meirelles do^sNascimento#^rND^1A03^
nJaqueline Regina^sBoschetti#Rede Metodista de Educação do Sul - IPA^iA01#FUC^iA
02^1Instituto de Cardiologia de Porto Alegre#Universidade Federal do Rio Grande 
do Sul^iA03#Irmandade da Santa Casa de Misericórdia de Porto Alegre^iA04^1Unidad
e do Serviço de Hemodiálise#^lpt^a<b>INTRODUÇÃO:</b> A doença renal crônica asso
ciada ao tratamento hemodialítico pode apresentar uma diversidade de complicaçõe
s músculo-esqueléticas, além de trazer repercussões à função pulmonar. <b>OBJETI
VO: </b>Avaliar os efeitos do treinamento muscular inspiratório na força muscula
r inspiratória, função pulmonar e capacidade funcional em pacientes com insufici
ência renal crônica submetidos à hemodiálise. <b>MÉTODO:</b> Ensaio clínico não 
controlado, composto por 15 indivíduos com diagnóstico médico de insuficiência r
enal crônica, submetidos à hemodiálise. Foram avaliados pressões inspiratória má
xima (PI<sub>máx</sub>) e expiratória máxima (PE<sub>máx</sub>) através da manov
acuometria; função pulmonar pela espirometria e a capacidade funcional através d
a distância percorrida e consumo de oxigênio obtido no teste da caminhada dos se
is minutos (TC6M). No período de oito semanas, foi aplicado o protocolo de trein
amento muscular respiratório (TMI) durante a sessão de hemodiálise, com carga es
tabelecida de 40% da PI<sub>máx</sub> e uma frequência semanal de três dias alte
rnados. <b>RESULTADOS:</b> Houve um aumento significativo na variável distância 
percorrida após o treinamento (455 ± 98 <i>versus</i> 558 ± 121; p = 0,003). Não
 foram encontradas diferenças estatísticas na comparação antes e após treinament
o nas demais variáveis do estudo. <b>CONCLUSÃO: </b>O estudo não apresentou dife
rença estatística na força muscular respiratória, na função pulmonar e no consum
o de oxigênio. Observou-se apenas um aumento na distância do TC6M.#^ddecs^i1#^tm
^lpt^kinsuficiência renal crônica^i1#^tm^lpt^kfisioterapia^i1^sespecialidade#^tm
^lpt^kunidades hospitalares de hemodiálise^i1#^tm^lpt^kfalência renal crônica^i1
#^tm^lpt^kdiálise renal^i1#^tm^lpt^kterapia respiratória^i1#^len^a<b>INTRODUCTIO
N:</b> Chronic kidney disease associated with hemodialysis can have a variety of
 musculoskeletal complications, in addition to repercussions in pulmonary functi
on. <b>OBJECTIVE:</b> To evaluate the effects of inspiratory muscle training on 
inspiratory muscle strength, pulmonary function, and functional capacity in pati
ents with chronic kidney failure undergoing hemodialysis. <b>METHOD:</b> Non-con
trolled clinical trial, comprising 15 individuals diagnosed with chronic kidney 
failure and undergoing hemodialysis. Maximum inspiratory (PI<sub>max</sub>) and 
expiratory (PE<sub>max</sub>) pressures were assessed by use of pressure vacuum 
meter reading. Pulmonary function was assessed by use of spirometry. Functional 
capacity was assessed by use of walked distance and oxygen consumption obtained 
in the six-minute walk test (6MWT). For eight weeks, the inspiratory muscle trai
ning (IMT) protocol was applied during hemodialysis sessions, with load set to 4
0% of PI<sub>max</sub> and weekly frequency of three alternate days. <b>RESULTS:
</b> A significant increase in the walked distance was observed after training (
455.5 ± 98 <i>versus</i> 557.8 ± 121.0; p = 0.003). No statistically significant
 difference was observed in the other variables when comparing their pre- and po
sttraining values. <b>CONCLUSION:</b> The study showed no statistically signific
ant difference in respiratory muscle strength, pulmonary function, and oxygen co
nsumption. An increase in the walked distance was observed in the 6MWT.#^ddecs^i
2#^tm^len^kchronic kidney failure^i2#^tm^len^kphysical therapy^i2^sspecialty#^tm
^len^khospital dialysis unit^i2#^tm^len^kkidney dialysis^i2#^tm^len^krespiratory
 therapy^i2#vancouv#40#20100726#26/07/2010#20101229#29/12/2010#v33n1a09.htm##
05027000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400090015903500100
01680120078001780120068002560100045003240100028003690100039003970100048004360100
03900484070004700523070005300570070004900623070009800672083149300770085001002263
08500400227308500400231308500490235308500350240208500260243708500330246308314640
24960850010039600850035039700850040040050850035040450850028040800850032041081170
00804140072000304148112000904151111001104160114000904171113001104180002001304191
008008904204#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#l#4#1#articl
e#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab#09#JBN020#nd#J. Bras. Nefrol#33
#1#20110300#^f62^l68#0101-2800#Efeitos do treinamento muscular inspiratório nos 
pacientes em hemodiálise^lpt#Effects of inspiratory muscle training in hemodialy
sis patients^len#^rND^1A01 A02^nVanessa Giendruczak da^sSilva#^rND^1A04^nCarolin
a^sAmaral#^rND^1A01 A04^nMariane Borba^sMonteiro#^rND^1A01 A04^nDaniela Meirelle
s do^sNascimento#^rND^1A03^nJaqueline Regina^sBoschetti#^iA01^1Rede Metodista de
 Educação do Sul - IPA#^iA02^1FUC^2Instituto de Cardiologia de Porto Alegre#^iA0
3^1Universidade Federal do Rio Grande do Sul#^iA04^1Irmandade da Santa Casa de M
isericórdia de Porto Alegre^2Unidade do Serviço de Hemodiálise#^lpt^aINTRODUÇÃO:
 A doença renal crônica associada ao tratamento hemodialítico pode apresentar um
a diversidade de complicações músculo-esqueléticas, além de trazer repercussões 
à função pulmonar. OBJETIVO: Avaliar os efeitos do treinamento muscular inspirat
ório na força muscular inspiratória, função pulmonar e capacidade funcional em p
acientes com insuficiência renal crônica submetidos à hemodiálise. MÉTODO: Ensai
o clínico não controlado, composto por 15 indivíduos com diagnóstico médico de i
nsuficiência renal crônica, submetidos à hemodiálise. Foram avaliados pressões i
nspiratória máxima (PImáx) e expiratória máxima (PEmáx) através da manovacuometr
ia; função pulmonar pela espirometria e a capacidade funcional através da distân
cia percorrida e consumo de oxigênio obtido no teste da caminhada dos seis minut
os (TC6M). No período de oito semanas, foi aplicado o protocolo de treinamento m
uscular respiratório (TMI) durante a sessão de hemodiálise, com carga estabeleci
da de 40 por cento da PImáx e uma frequência semanal de três dias alternados. RE
SULTADOS: Houve um aumento significativo na variável distância percorrida após o
 treinamento (455 ± 98 versus 558 ± 121; p = 0,003). Não foram encontradas difer
enças estatísticas na comparação antes e após treinamento nas demais variáveis d
o estudo. CONCLUSÃO: O estudo não apresentou diferença estatística na força musc
ular respiratória, na função pulmonar e no consumo de oxigênio. Observou-se apen
as um aumento na distância do TC6M.#^ddecs^i1#^tm^lpt^kinsuficiência renal crôni
ca^i1#^tm^lpt^kfisioterapia^i1^sespecialidade#^tm^lpt^kunidades hospitalares de 
hemodiálise^i1#^tm^lpt^kfalência renal crônica^i1#^tm^lpt^kdiálise renal^i1#^tm^
lpt^kterapia respiratória^i1#^len^aINTRODUCTION: Chronic kidney disease associat
ed with hemodialysis can have a variety of musculoskeletal complications, in add
ition to repercussions in pulmonary function. OBJECTIVE: To evaluate the effects
 of inspiratory muscle training on inspiratory muscle strength, pulmonary functi
on, and functional capacity in patients with chronic kidney failure undergoing h
emodialysis. METHOD: Non-controlled clinical trial, comprising 15 individuals di
agnosed with chronic kidney failure and undergoing hemodialysis. Maximum inspira
tory (PImax) and expiratory (PEmax) pressures were assessed by use of pressure v
acuum meter reading. Pulmonary function was assessed by use of spirometry. Funct
ional capacity was assessed by use of walked distance and oxygen consumption obt
ained in the six-minute walk test (6MWT). For eight weeks, the inspiratory muscl
e training (IMT) protocol was applied during hemodialysis sessions, with load se
t to 40 percent of PImax and weekly frequency of three alternate days. RESULTS: 
A significant increase in the walked distance was observed after training (455.5
 ± 98 versus 557.8 ± 121.0; p = 0.003). No statistically significant difference 
was observed in the other variables when comparing their pre- and posttraining v
alues. CONCLUSION: The study showed no statistically significant difference in r
espiratory muscle strength, pulmonary function, and oxygen consumption. An incre
ase in the walked distance was observed in the 6MWT.#^ddecs^i2#^tm^len^kchronic 
kidney failure^i2#^tm^len^kphysical therapy^i2^sspecialty#^tm^len^khospital dial
ysis unit^i2#^tm^len^kkidney dialysis^i2#^tm^len^krespiratory therapy^i2#vancouv
#40#20100726#26/07/2010#20101229#29/12/2010#v33n1a09.htm#Internet^ihttp://www.sc
ielo.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100009##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#5#1#article#179#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a09.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#6#2#article#179#<p>&nbsp;</p>     ^cY#
v33n1a09.htm##
00429000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704019700073002001300270#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#7#3#article#179#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Efeitos do treina
mento muscular inspirat&oacute;rio nos  pacientes em hemodi&aacute;lise</b></fon
t></p>     ^cY#v33n1a09.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#8#4#article#179#<p>&nbsp;</p>     ^cY#
v33n1a09.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#9#5#article#179#<p>&nbsp;</p>     ^cY#
v33n1a09.htm##
00526000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704029300074002001300367#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#10#6#article#179#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Vanessa Giendruczak da Silva<sup>I,
II</sup>; Carolina Amaral<sup>IV</sup>; Mariane Borba  Monteiro<sup>I,IV</sup>; 
Daniela Meirelles do Nascimento<sup>I,IV</sup>; Jaqueline Regina Boschetti<sup>I
II</sup></b></font></p>     ^cY#v33n1a09.htm##
00370000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704013700074002001300211#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#11#7#article#179#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Rede Metodista de  Educa&c
cedil;&atilde;o do Sul - IPA    ^cY#v33n1a09.htm##
00305000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704007200074002001300146#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#12#8#article#179#<br>   <sup>II</sup>I
nstituto de Cardiologia de Porto Alegre FUC    ^cY#v33n1a09.htm##
00311000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704007800074002001300152#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#13#9#article#179#<br>   <sup>III</sup>
Universidade Federal do Rio Grande do Sul - UFRGS    ^cY#v33n1a09.htm##
00387000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015300075002001300228#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#14#10#article#179#<br>   <sup>IV</sup>
Unidade do Servi&ccedil;o de Hemodi&aacute;lise da Irmandade da Santa Casa de Mi
seric&oacute;rdia de Porto Alegre</font></p>     ^cY#v33n1a09.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#15#11#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia
</a></font></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#16#12#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#17#13#article#179#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a09.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#18#14#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a09.htm##
00599000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036500075002001300440#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#19#15#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O:</b> A do
en&ccedil;a renal cr&ocirc;nica associada ao tratamento hemodial&iacute;tico pod
e apresentar uma diversidade de complica&ccedil;&otilde;es m&uacute;sculo-esquel
&eacute;ticas, al&eacute;m de trazer repercuss&otilde;es &agrave; fun&ccedil;&at
ilde;o pulmonar.     ^cY#v33n1a09.htm##
00526000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029200075002001300367#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#20#16#article#179#<br>   <b>OBJETIVO: 
</b> Avaliar os efeitos do treinamento muscular inspirat&oacute;rio na for&ccedi
l;a muscular inspirat&oacute;ria, fun&ccedil;&atilde;o pulmonar e capacidade fun
cional em pacientes com insufici&ecirc;ncia renal cr&ocirc;nica submetidos &agra
ve; hemodi&aacute;lise.     ^cY#v33n1a09.htm##
01135000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090100075002001300976#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#21#17#article#179#<br>   <b>M&Eacute;T
ODO:</b> Ensaio cl&iacute;nico n&atilde;o controlado, composto por 15 indiv&iacu
te;duos com diagn&oacute;stico m&eacute;dico de insufici&ecirc;ncia renal cr&oci
rc;nica, submetidos &agrave; hemodi&aacute;lise. Foram avaliados press&otilde;es
 inspirat&oacute;ria m&aacute;xima (PI<sub>m&aacute;x</sub>) e expirat&oacute;ri
a m&aacute;xima (PE<sub>m&aacute;x</sub>) atrav&eacute;s da manovacuometria; fun
&ccedil;&atilde;o pulmonar pela espirometria e a capacidade funcional atrav&eacu
te;s da dist&acirc;ncia percorrida e consumo de oxig&ecirc;nio obtido no teste d
a caminhada dos seis minutos (TC6M). No per&iacute;odo de oito semanas, foi apli
cado o protocolo de treinamento muscular respirat&oacute;rio (TMI) durante a ses
s&atilde;o de hemodi&aacute;lise, com carga estabelecida de 40% da PI<sub>m&aacu
te;x</sub> e uma frequ&ecirc;ncia semanal de tr&ecirc;s dias alternados.     ^cY
#v33n1a09.htm##
00585000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035100075002001300426#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#22#18#article#179#<br>   <b>RESULTADOS
:</b> Houve um aumento significativo na vari&aacute;vel dist&acirc;ncia percorri
da ap&oacute;s o treinamento  (455 ± 98 <i>versus</i> 558 ± 121; p = 0,003). N&a
tilde;o foram encontradas diferen&ccedil;as estat&iacute;sticas na compara&ccedi
l;&atilde;o antes e ap&oacute;s treinamento nas demais vari&aacute;veis do estud
o.     ^cY#v33n1a09.htm##
00523000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028900075002001300364#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#23#19#article#179#<br>   <b>CONCLUS&At
ilde;O: </b> O estudo n&atilde;o apresentou diferen&ccedil;a estat&iacute;stica 
na for&ccedil;a muscular respirat&oacute;ria, na fun&ccedil;&atilde;o pulmonar e
 no consumo de oxig&ecirc;nio. Observou-se apenas um aumento na dist&acirc;ncia 
do TC6M. </font></p>     ^cY#v33n1a09.htm##
00572000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033800075002001300413#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#24#20#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b>insufici&ecirc
;ncia renal cr&ocirc;nica, fisioterapia (especialidade), unidades hospitalares d
e hemodi&aacute;lise, fal&ecirc;ncia renal cr&ocirc;nica, di&aacute;lise renal<b
>, </b>terapia respirat&oacute;ria. </font></p> <hr size="1" noshade>     ^cY#v3
3n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#25#21#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#26#22#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#27#23#article#179#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a09.htm##
01044000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704081000075002001300885#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#28#24#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A doen&ccedil;a renal cr&ocirc;nica (
DRC) &eacute; a deteriora&ccedil;&atilde;o persistente e progressiva da taxa de 
filtra&ccedil;&atilde;o glomerular, com consequente s&iacute;ndrome ur&ecirc;mic
a, apresentada por um conjunto de transtornos que afetam diversos sistemas do or
ganismo. <sup>1</sup> Essa deteriora&ccedil;&atilde;o renal pode estar relaciona
da com diabete mellitus, nefroesclerose hipertensiva, tabagismo, s&iacute;ndrome
 coronariana aguda e dislipidemia. <sup>2</sup> Ainda, a DRC representa o est&aa
cute;gio irrevers&iacute;vel da insufici&ecirc;ncia renal, para o qual os pacien
tes necessitam de tratamento dial&iacute;tico ou mesmo transplante renal para ma
nuten&ccedil;&atilde;o de suas vidas. <sup>3</sup></font></p>     ^cY#v33n1a09.h
tm##
01077000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084300075002001300918#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#29#25#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O Censo de Di&aacute;lise da Sociedad
e Brasileira de Nefrologia de 2009 estimou em 77.589 o n&uacute;mero de paciente
s em di&aacute;lise no Brasil e destes, 86,7% representam o sistema &uacute;nico
 de sa&uacute;de (SUS). Os &uacute;ltimos dados mostram uma tend&ecirc;ncia para
 a redu&ccedil;&atilde;o desta taxa de crescimento no &uacute;ltimo per&iacute;o
do analisado. A redu&ccedil;&atilde;o do ritmo de crescimento detectada poderia 
ser explicada de duas formas: por uma real redu&ccedil;&atilde;o no n&uacute;mer
o de pacientes em di&aacute;lise no &uacute;ltimo ano (pouco prov&aacute;vel) ou
 mais provavelmente por uma imprecis&atilde;o na estimativa de 2008, devido a um
 percentual de respostas dos Centros de Di&aacute;lise abaixo de 50%. <sup>4</su
p> </font></p>     ^cY#v33n1a09.htm##
01613000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704137900075002001301454#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#30#26#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A hemodi&aacute;lise (HD) substitui p
arcialmente a fun&ccedil;&atilde;o renal, reverte os sintomas ur&ecirc;micos e p
reserva a vida dos pacientes com doen&ccedil;a renal cr&ocirc;nica (DRC) em est&
aacute;gio final, por&eacute;m altera&ccedil;&otilde;es degenerativas persistem 
como, por exemplo, a desnutri&ccedil;&atilde;o, que pode estar presente em pacie
ntes com DRC, agravando a perda muscular e predispondo a situa&ccedil;&otilde;es
 de fadiga, com aumento da frequ&ecirc;ncia e trabalho respirat&oacute;rios. <su
p>5,6,7</sup> Entre as altera&ccedil;&otilde;es pulmonares encontradas, as mais 
frequentes s&atilde;o as desordens obstrutivas, como a limita&ccedil;&atilde;o a
o fluxo a&eacute;reo nas vias a&eacute;reas distais<sup>8,9 </sup>e reduzida cap
acidade de difus&atilde;o pulmonar. <sup>9,10 </sup>Al&eacute;m disso, estudos d
a d&eacute;cada de 80 observaram um consumo de oxig&ecirc;nio (VO<sub>2</sub>) r
eduzido nos pacientes com DRC, sendo semelhantes ao de indiv&iacute;duos sedent&
aacute;rios. <sup>11-15 </sup>No entanto, os efeitos fisiol&oacute;gicos e as po
ss&iacute;veis altera&ccedil;&otilde;es pulmonares cr&ocirc;nicas decorrentes do
 tratamento com terapia de substitui&ccedil;&atilde;o renal nos pacientes nefrop
atas ainda s&atilde;o pouco conhecidos. <sup>9,10,16</sup> </font></p>     ^cY#v
33n1a09.htm##
00884000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704065000075002001300725#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#31#27#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marchesan, Krug, Moreira <i>et al. </
i> (2008) realizaram um estudo com treinamento de for&ccedil;a muscular respirat
&oacute;ria em pacientes com DRC submetidos &agrave; HD atrav&eacute;s da utiliz
a&ccedil;&atilde;o da manovacuometria. Os dados obtidos ap&oacute;s 15 semanas d
e treinamento foi uma melhora, estatisticamente significativa (p &lt; 0,05), nas
 vari&aacute;veis resist&ecirc;ncia aer&oacute;bica, press&otilde;es inspirat&oa
cute;ria e expirat&oacute;ria m&aacute;xima PI<sub>m&aacute;x</sub> e PE<sub>m&a
acute;x </sub>no grupo experimental. <sup>17</sup></font></p>     ^cY#v33n1a09.h
tm##
00736000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050200075002001300577#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#32#28#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Desta forma, o objetivo deste estudo 
consiste em avaliar os efeitos do treinamento muscular inspirat&oacute;rio (TMI)
 com rela&ccedil;&atilde;o &agrave; for&ccedil;a muscular inspirat&oacute;ria, f
un&ccedil;&atilde;o pulmonar e capacidade funcional em pacientes com DRC submeti
dos &agrave; HD, bem como, correlacionar as vari&aacute;veis dist&acirc;ncia per
corrida, PI<sub>m&aacute;x</sub> e consumo de VO<sub>2</sub>. </font></p>     ^c
Y#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#33#29#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010300075002001300178#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#34#30#article#179#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODO</b></font></p>     ^
cY#v33n1a09.htm##
00708000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047400075002001300549#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#35#31#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A pesquisa caracteriza-se por um ensa
io cl&iacute;nico n&atilde;o controlado com amostra de conveni&ecirc;ncia, compo
sta por indiv&iacute;duos com diagn&oacute;stico cl&iacute;nico de DRC, submetid
os &agrave; HD no per&iacute;odo de abril a setembro de 2007, no Ambulat&oacute;
rio de Hemodi&aacute;lise da Policl&iacute;nica Santa Clara do Complexo Hospital
ar Santa Casa de Porto Alegre/RS. </font></p>     ^cY#v33n1a09.htm##
01205000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704097100075002001301046#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#36#32#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram inclu&iacute;dos no estudo paci
entes submetidos &agrave; HD por um per&iacute;odo m&iacute;nimo de tr&ecirc;s m
eses e frequ&ecirc;ncia m&iacute;nima de terapia dial&iacute;tica de tr&ecirc;s 
vezes por semana. Os crit&eacute;rios de exclus&atilde;o pr&eacute;estabelecidos
 foram: di&aacute;lise por cateter em art&eacute;ria femoral ou cateter na veia 
jugular; press&atilde;o arterial (PA) <u>&gt;</u> 220/110 mmHg ou <u>&lt;</u> 10
0/60 mmHg; press&atilde;o arterial m&eacute;dia (PAM) &lt; 60 mmHg; uso de anti-
 hipertensivo at&eacute; uma hora antes da hemodi&aacute;lise; diab&eacute;ticos
 n&atilde;o controlados; angina classe III e IV; arritmias card&iacute;acas; al&
eacute;m de confus&atilde;o mental, presen&ccedil;a de comorbidades e altera&cce
dil;&otilde;es osteoarticulares ou musculoesquel&eacute;ticas que limitassem o t
este de caminhada dos seis minutos (TC6M) e o TMI. </font></p>     ^cY#v33n1a09.
htm##
00415000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018100075002001300256#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#37#33#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Todos os pacientes assinaram espontan
eamente o termo de consentimento livre e esclarecido (TCLE). </font></p>     ^cY
#v33n1a09.htm##
01092000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704085800075002001300933#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#38#34#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Inicialmente, foram convidados a part
icipar do estudo 102 pacientes, destes, 27 aceitaram participar. Os demais indiv
&iacute;duos convidados negaram-se a participar por indisponibilidade de hor&aac
ute;rio e/ou falta de interesse. Al&eacute;m disso, oito pacientes foram exclu&i
acute;dos: tr&ecirc;s por altera&ccedil;&otilde;es osteoarticulares e musculoesq
uel&eacute;ticas, um por apresentar cateter na veia jugular direita, dois devido
 &agrave; resposta hipertensiva durante a realiza&ccedil;&atilde;o da manovacuom
etria, assim como na espirometria, e dois por apresentarem comorbidades. Quatro 
pacientes foram considerados perdas: um &oacute;bito, um devido &agrave; retirad
a do TCLE e dois por baixa ades&atilde;o ao protocolo, resultando em uma amostra
 de 15 pacientes. </font></p>     ^cY#v33n1a09.htm##
00508000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027400075002001300349#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#39#35#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O estudo foi aprovado pelo Comit&ecir
c; de &Eacute;tica e Pesquisa do Centro Universit&aacute;rio Metodista IPA e do 
Complexo Hospitalar Santa Casa de Miseric&oacute;rdia de Porto Alegre/RS. </font
></p>     ^cY#v33n1a09.htm##
01076000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084200075002001300917#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#40#36#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O protocolo de avalia&ccedil;&atilde;
o teve in&iacute;cio ap&oacute;s o primeiro contato com os pacientes para a assi
natura do TCLE e o preenchimento dos dados individuais da ficha de avalia&ccedil
;&atilde;o fisioterap&ecirc;utica. Entre os dados coletados, havia as seguintes 
informa&ccedil;&otilde;es: dados de identifica&ccedil;&atilde;o, aspectos cl&iac
ute;nicos (queixa principal, etiologia e ano do diagn&oacute;stico da IRC, tempo
 e frequ&ecirc;ncia semanal do tratamento dial&iacute;tico) e exame f&iacute;sic
o (sinais vitais, ausculta card&iacute;aca e pulmonar, tipo de t&oacute;rax, tip
o muscular respirat&oacute;rio, mobilidade tor&aacute;cica, expansibilidade pulm
onar, altura, peso corporal, &iacute;ndice de massa corporal e biotipo corporal)
. </font></p>     ^cY#v33n1a09.htm##
00831000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059700075002001300672#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#41#37#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Todos os indiv&iacute;duos foram subm
etidos ao mesmo protocolo de avalia&ccedil;&atilde;o, sendo mensurados, PI<sub> 
m&aacute;x</sub>,  PE<sub> m&aacute;x</sub>, fun&ccedil;&atilde;o pulmonar e cap
acidade funcional antes e ao t&eacute;rmino de oito semanas de interven&ccedil;&
atilde;o com TMI. Os indiv&iacute;duos foram avaliados duas horas antes da reali
za&ccedil;&atilde;o da HD, sem interfer&ecirc;ncia na rotina semanal dos indiv&i
acute;duos (segunda, quarta, sexta ou ter&ccedil;a, quinta e s&aacute;bado). </f
ont></p>     ^cY#v33n1a09.htm##
00730000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049600075002001300571#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#42#38#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A PI<sub>m&aacute;x</sub> e PE<sub>m&
aacute;x</sub> foram mensuradas atrav&eacute;s da manovacuometria, com a utiliza
&ccedil;&atilde;o de um manovacu&ocirc;metro digital da marca Globalmed<sup>&reg
;</sup> (modelo MVD 300, Brasil) previamente revisado e calibrado. A PI<sub>m&aa
cute;x</sub> foi mensurada a partir do volume residual e a PE<sub>m&aacute;x</su
b> a partir da capacidade pulmonar total. <sup>18</sup> </font></p>     ^cY#v33n
1a09.htm##
00755000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052100075002001300596#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#43#39#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A fun&ccedil;&atilde;o pulmonar foi a
valiada pela espirometria, atrav&eacute;s do espir&ocirc;metro da marca MR (mode
lo Spirodoc, It&aacute;lia). Os volumes pulmonares espirom&eacute;tricos, como c
apacidade vital for&ccedil;ada (CVF), volume expirat&oacute;rio for&ccedil;ado n
o primeiro segundo (VEF<sub>1</sub>) e &iacute;ndice de Tiffenau (VEF<sub>1</sub
> / CVF ), foram mensurados a partir da capacidade pulmonar total. <sup>19</sup>
 </font></p>     ^cY#v33n1a09.htm##
00517000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028300075002001300358#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#44#40#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ambos os testes foram realizados com 
o paciente na posi&ccedil;&atilde;o sentada e seguiram as recomenda&ccedil;&otil
de;es das Diretrizes para Testes de Fun&ccedil;&atilde;o Pulmonar. <sup>18,19</s
up></font></p>     ^cY#v33n1a09.htm##
01176000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094200075002001301017#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#45#41#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A capacidade funcional foi verificada
 atrav&eacute;s do c&aacute;lculo do VO<sub>2 m&aacute;x </sub>indireto (VO<sub>
2</sub>= -2,344 + 0,044 x dist&acirc;ncia)<sup>20</sup> a partir do TC6M. Para a
 mensura&ccedil;&atilde;o da satura&ccedil;&atilde;o perif&eacute;rica de oxig&e
circ;nio (SpO<sub>2</sub>) e frequ&ecirc;ncia card&iacute;aca (FC), foi utilizad
o um ox&iacute;metro (Nonin<sup>&reg;</sup> modelo 9500, Estados Unidos) posicio
nado no dedo indicador do paciente. Para a mensura&ccedil;&atilde;o da press&ati
lde;o arterial (PA), foi utilizado um esfigmoman&ocirc;metro aner&oacute;ide (BI
C<sup>&reg;</sup> modelo M&aacute;ster 040, Brasil) e um estetosc&oacute;pio (BI
C<sup>&reg;</sup>, modelo Standart, Brasil) com o paciente na posi&ccedil;&atild
e;o sentada, com bra&ccedil;o semifletido e apoiado na altura do cora&ccedil;&at
ilde;o. <sup>21</sup> </font></p>     ^cY#v33n1a09.htm##
00684000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045000075002001300525#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#46#42#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foi utilizada tamb&eacute;m para o TC
6M a escala de Borg modificada, que &eacute; um marcador descritivo de esfor&cce
dil;o f&iacute;sico subjetivo de dispn&eacute;ia e de fadiga em membros inferior
es (MsIs) graduada em uma escala que varia de 0 a 10. <sup>22</sup> Para a reali
za&ccedil;&atilde;o do TC6M foi utilizado um corredor plano, de 27 metros de com
primento. </font></p>     ^cY#v33n1a09.htm##
00810000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704057600075002001300651#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#47#43#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pacientes foram orientados a camin
har na sua velocidade m&aacute;xima, sem desacelerar e a completar o maior n&uac
ute;mero de voltas poss&iacute;vel. No in&iacute;cio e imediatamente ap&oacute;s
 o 6º minuto do teste, foram mensuradas as vari&aacute;veis: FC, frequ&ecirc;nci
a respirat&oacute;ria (FR), SpO<sub>2</sub> e sensa&ccedil;&atilde;o de dispn&ea
cute;ia e esfor&ccedil;o em MsIs por meio da escala de Borg modificada. Ao final
 do teste, foi registrada a dist&acirc;ncia percorrida. </font></p>     ^cY#v33n
1a09.htm##
00710000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047600075002001300551#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#48#44#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s o per&iacute;odo de avali
a&ccedil;&atilde;o, os pacientes iniciaram com o protocolo de TMI durante a di&a
acute;lise, utilizando o aparelho Threshold Loaded IMT<sup>&reg;</sup>. Esse tre
inamento teve dura&ccedil;&atilde;o total de oito semanas, com frequ&ecirc;ncia 
semanal de tr&ecirc;s dias alternados, n&atilde;o modificando a rotina do ambula
t&oacute;rio de hemodi&aacute;lise. </font></p>     ^cY#v33n1a09.htm##
00574000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034000075002001300415#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#49#45#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O Threshold Loaded IMT<sup> &reg; </s
up>&eacute; um incentivador respirat&oacute;rio de carga press&oacute;rica linea
r em que o paciente faz uso de um clipe nasal e respira por um bucal com uma res
ist&ecirc;ncia no ramo inspirat&oacute;rio. <sup>23,24</sup></font></p>     ^cY#
v33n1a09.htm##
00898000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066400075002001300739#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#50#46#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pacientes realizaram o TMI na posi
&ccedil;&atilde;o sentada, com carga estabelecida de 40% da PI<sub>m&aacute;x</s
ub>, mensurada no dia da avalia&ccedil;&atilde;o. As manobras foram realizadas e
m uma s&eacute;rie de cinco repeti&ccedil;&otilde;es, com intervalos de um minut
o entre elas, totalizando 15 minutos de treinamento nas primeiras quatro semanas
. A dura&ccedil;&atilde;o do TMI foi aumentada at&eacute; que as sess&otilde;es 
de exerc&iacute;cio completassem 30 minutos nas &uacute;ltimas quatro semanas, s
eguindo o protocolo adaptado de Riedemann (2005). <sup>25</sup> </font></p>     
^cY#v33n1a09.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#51#47#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>AN&Aacute;LISE ESTAT&Iacute;STICA 
</b></font></p>     ^cY#v33n1a09.htm##
01077000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084300075002001300918#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#52#48#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados utilizados para realizar a a
n&aacute;lise estat&iacute;stica foram armazenados em uma planilha do Microsoft 
Excel 2003 com m&eacute;dia e desvio padr&atilde;o (MD ± DP). Para as vari&aacut
e;veis cont&iacute;nuas e com distribui&ccedil;&atilde;o normal foi utilizado o 
teste t para amostras pareadas e para as vari&aacute;veis cont&iacute;nuas com d
istribui&ccedil;&atilde;o anormal foi utilizado o teste de Wilcoxon. Para verifi
car a exist&ecirc;ncia de correla&ccedil;&atilde;o entre duas ou mais vari&aacut
e;veis, foi utilizado o teste de correla&ccedil;&atilde;o de Pearson. Para essas
 an&aacute;lises foi utilizado o programa SPSS (Statiscal Package for the Social
 Sciences) 15.0. O n&iacute;vel de signific&acirc;ncia adotado foi de p &lt; 0,0
5. </font></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#53#49#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#54#50#article#179#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v33n1a09.htm##
00675000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044100075002001300516#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#55#51#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A pesquisa foi realizada com quinze i
ndiv&iacute;duos (n = 15) com IRC, sendo oito homens (53,3%), apresentando idade
 entre 21 e 73 anos com m&eacute;dia de 45,0 ± 13,7 anos submetidos &agrave; hem
odi&aacute;lise tr&ecirc;s vezes por semana durante 61,4 ± 32,3 meses. As caract
er&iacute;sticas do grupo estudado encontram-se na <a href="#tab1">Tabela 1</a>.
 </font></p>     ^cY#v33n1a09.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#56#52#article#179#<p><a name="tab1"></
a></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#57#53#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#58#54#article#179#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a09tab01.jpg"></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#59#55#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00638000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040400075002001300479#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#60#56#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dentre as causas mais frequentes da D
RC na amostra estudada, pode-se ressaltar: rins polic&iacute;sticos (33,3%), hip
ertens&atilde;o arterial sist&ecirc;mica (20%), glomerulonefrite cr&ocirc;nica (
13,3%), nefrite cr&ocirc;nica (6,6%), diabete mellitus (6.6%), uropatia obstruti
va (6,6%) e etiologia desconhecida (13,3%). </font></p>     ^cY#v33n1a09.htm##
00551000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031700075002001300392#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#61#57#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pacientes n&atilde;o apresentaram 
varia&ccedil;&otilde;es significativas dos n&iacute;veis de hemoglobina antes e 
ap&oacute;s o treinamento (11,3 ± 1,3 g/dl <i>versus </i>11,1 ± 1,6 g/dl;  p = 0
,44) (<a href="#tab1">Tabela 1</a>). </font></p>     ^cY#v33n1a09.htm##
00591000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035700075002001300432#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#62#58#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A <a href="/img/revistas/jbn/v33n1/a0
9tab02m.jpg">Tabela 2</a> apresenta os resultados da manovacuometria e espiromet
ria antes e ap&oacute;s o treinamento. Nenhuma dessas vari&aacute;veis apresento
u diferen&ccedil;a estatisticamente significativa ap&oacute;s o treinamento. </f
ont></p>     ^cY#v33n1a09.htm##
00855000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062100075002001300696#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#63#59#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na <a href="/img/revistas/jbn/v33n1/a
09tab03m.jpg">tabela 3</a> est&atilde;o demonstrados os dados obtidos atrav&eacu
te;s do TC6M antes e ap&oacute;s o TMI. N&atilde;o foram observadas diferen&cced
il;as estatisticamente significativas nas vari&aacute;veis FR, FC, SpO<sub>2</su
b>, sensa&ccedil;&atilde;o de fadiga dos MsIs e VO<sub>2m&aacute;x</sub> ap&oacu
te;s o treinamento. No entanto, houve uma melhora estatisticamente significativa
 na sensa&ccedil;&atilde;o de dispn&eacute;ia (p = 0,046) e dist&acirc;ncia perc
orrida  (p = 0,003). </font></p>     ^cY#v33n1a09.htm##
00979000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074500075002001300820#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#64#60#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Neste estudo foi encontrada correla&c
cedil;&atilde;o estatisticamente significativa entre a dist&acirc;ncia percorrid
a e a PI<sub>m&aacute;x</sub> antes do treinamento (r = 0,578, p = 0,024), de ac
ordo com a <a href="#fig1">Figura 1</a>. As mesmas vari&aacute;veis, ap&oacute;s
 dois meses de interven&ccedil;&atilde;o, tamb&eacute;m apresentaram correla&cce
dil;&atilde;o positiva (r = 0,741; p = 0,002), conforme <a href="#fig2">Figura 2
</a>. Houve correla&ccedil;&atilde;o significativa entre o VO<sub>2m&aacute;x </
sub>e a PI<sub>m&aacute;x</sub> antes e ap&oacute;s a interven&ccedil;&atilde;o 
(r = 0,578 e p = 0,024; r = 0,603 e p = 0,017, respectivamente). </font></p>    
 ^cY#v33n1a09.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#65#61#article#179#<p><a name="fig1"></
a></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#66#62#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#67#63#article#179#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a09fig01.jpg"></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#68#64#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#69#65#article#179#<p><a name="fig2"></
a></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#70#66#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#71#67#article#179#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a09fig02.jpg"></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#72#68#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#73#69#article#179#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O </b></font></p>  
   ^cY#v33n1a09.htm##
01242000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704100800075002001301083#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#74#70#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Pacientes em tratamento hemodial&iacu
te;tico apresentam muitas anormalidades, possivelmente devido &agrave;s adapta&c
cedil;&otilde;es das c&eacute;lulas &agrave;s altera&ccedil;&otilde;es do ambien
te interno. Entre elas, encontramos mudan&ccedil;as nos capilares, enzimas, prot
e&iacute;nas contr&aacute;teis<sup>9,26</sup> e tamb&eacute;m anormalidades mito
condriais. <sup>9,27</sup> Al&eacute;m disso, os pacientes que realizam tratamen
to dial&iacute;tico podem apresentar diminui&ccedil;&atilde;o da funcionalidade 
e da aptid&atilde;o f&iacute;sica, <sup>2,9,28-30</sup> com diminui&ccedil;&atil
de;o da for&ccedil;a muscular perif&eacute;rica. <sup>9,31-33</sup> Desta forma,
 a fraqueza muscular presente nos pacientes com DRC submetidos &agrave; HD pode 
ser decorrente da presen&ccedil;a da atrofia muscular. Esse fato interfere no fu
ncionamento e na estrutura normal das fibras musculoesquel&eacute;ticas. <sup>9,
31</sup></font></p>     ^cY#v33n1a09.htm##
00822000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058800075002001300663#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#75#71#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os mecanismos potenciais pelos quais 
a doen&ccedil;a renal cr&ocirc;nica pode interferir negativamente na musculatura
 esquel&eacute;tica s&atilde;o multifatoriais e complexos, podendo ser resultant
es das altera&ccedil;&otilde;es existentes na perfus&atilde;o muscular, nas tran
sfer&ecirc;ncias de substratos e no catabolismo intermediado por fatores como a 
acidose metab&oacute;lica, uso de corticoester&oacute;ides e libera&ccedil;&atil
de;o  de citocinas pr&oacute;-inflamat&oacute;rias. <sup>9,27</sup> </font></p> 
    ^cY#v33n1a09.htm##
00800000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056600075002001300641#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#76#72#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As altera&ccedil;&otilde;es na fun&cc
edil;&atilde;o respirat&oacute;ria est&atilde;o entre as condi&ccedil;&otilde;es
 mais frequentes apresentadas por esses pacientes. <sup>8,9,10</sup> Contudo, ap
esar das repercuss&otilde;es pulmonares advindas da DRC, os efeitos fisiol&oacut
e;gicos e as poss&iacute;veis altera&ccedil;&otilde;es pulmonares presentes nos 
pacientes em tratamento com terapia de substitui&ccedil;&atilde;o renal ainda s&
atilde;o pouco conhecidos. <sup>9,10,16</sup> </font></p>     ^cY#v33n1a09.htm##
00724000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049000075002001300565#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#77#73#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No estudo de Bush e Gabriel (1991), f
oram analisados pacientes com v&aacute;rios graus de IRC que participavam de um 
programa de HD h&aacute; 2,1 anos, comparando-os com pacientes que n&atilde;o re
alizavam tratamento dial&iacute;tico. A an&aacute;lise indicou anormalidades na 
capacidade de difus&atilde;o pulmonar em 70% dos pacientes que realizavam a tera
pia de substitui&ccedil;&atilde;o. <sup>9,16</sup></font></p>     ^cY#v33n1a09.h
tm##
01120000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704088600075002001300961#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#78#74#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em 2008, Schardong, Lukrafka e Garcia
 avaliaram a fun&ccedil;&atilde;o pulmonar, a for&ccedil;a muscular respirat&oac
ute;ria e a qualidade de vida em 30 pacientes com DRC e que realizavam HD. Os au
tores encontraram diminui&ccedil;&atilde;o nos valores da fun&ccedil;&atilde;o p
ulmonar, assim como, valores abaixo do previsto para PI<sub>m&aacute;x</sub> e n
enhum paciente atingiu valores de normalidade para PE<sub>m&aacute;x. </sub><sup
>9</sup> No presente estudo, a fun&ccedil;&atilde;o pulmonar n&atilde;o apresent
ou diferen&ccedil;a estatisticamente significativa na compara&ccedil;&atilde;o a
ntes e ap&oacute;s ap&oacute;s TMI, provavelmente este achado deva-se ao fato de
 que o TMI destina-se &agrave; melhora da for&ccedil;a inspirat&oacute;ria e n&a
tilde;o dos volumes e capacidades pulmonares. </font></p>     ^cY#v33n1a09.htm##
00695000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046100075002001300536#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#79#75#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Apesar da escassez de estudos que ana
lisam o TMI em pacientes com IRC, j&aacute; est&aacute; bem documentada a efetiv
idade desta abordagem em pacientes com doen&ccedil;a pulmonar obstrutiva cr&ocir
c;nica (DPOC), os quais, assim como os pacientes com DRC, apresentam altera&cced
il;&otilde;es sist&ecirc;micas que predisp&otilde;em &agrave; fraqueza muscular.
 <sup>25,34-38</sup> </font></p>     ^cY#v33n1a09.htm##
01839000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704160500075002001301680#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#80#76#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marchesan <i>et al. </i>(2008) estuda
ram 11 pacientes com IRC, que realizavam HD, na cidade de Cruz Alta - RS. Destes
, seis constitu&iacute;ram o grupo controle (GC) e cinco o grupo experimental (G
E). O treinamento muscular respirat&oacute;rio foi realizado com o GE utilizando
-se um manovacu&ocirc;metro, com limite operacional de +300 cmH<sub>2</sub>0 a -
300 cmH<sub>2</sub>0. O mesmo foi prescrito a partir dos valores individuais obt
idos na prova de manovacuometria. A intensidade progrediu a cada 15 sess&otilde;
es de treinamento, tendo iniciado com 50% da carga m&aacute;xima (CM); passando 
para 55% at&eacute; a 30ª sess&atilde;o e a partir da 31ª a 45ª sess&atilde;o fo
i utilizado 60% da CM. O treinamento foi realizado tamb&eacute;m durante a HD, a
ssim como na presente pesquisa. Esse estudo foi realizado em um per&iacute;odo d
e 15 semanas, em que os pacientes realizaram trinta manobras inspirat&oacute;ria
s (PI<sub>m&aacute;x</sub>) e trinta manobras expirat&oacute;rias (PE<sub>m&aacu
te;x</sub>), com frequ&ecirc;ncia de tr&ecirc;s vezes na semana e dura&ccedil;&a
tilde;o de aproximadamente 20 minutos. Os autores encontraram aumento significat
ivo da PI<sub>m&aacute;x</sub> (p = 0,04) para o GE, comparado com o GC. Na comp
ara&ccedil;&atilde;o intragrupo, verificou-se um aumento significativo (p &lt; 0
,05) somente para o GE, nas vari&aacute;veis: PI<sub>m&aacute;x</sub> e PE<sub>m
&aacute;x </sub>e resist&ecirc;ncia aer&oacute;bia, atrav&eacute;s da manovacuom
etria e TC6M, respectivamente. <sup>17</sup> </font></p>     ^cY#v33n1a09.htm##
01229000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704099500075002001301070#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#81#77#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na presente pesquisa, a m&eacute;dia 
da PI<sub>max</sub> para o treinamento foi de 27,0 ± 11,6 cmH<sub>2</sub>O e, ap
&oacute;s dois meses de interven&ccedil;&atilde;o, observou-se um aumento da PI<
sub>m&aacute;x</sub>, embora estatisticamente n&atilde;o tenha sido identificada
 uma diferen&ccedil;a significativa para essa vari&aacute;vel. Houve um aumento 
significativo da dist&acirc;ncia percorrida no TC6M e essa melhora no desempenho
 n&atilde;o poderia ser justificada por mudan&ccedil;as no controle da anemia, j
&aacute; que o n&iacute;vel de hemoglobina permaneceu constante entre os dois mo
mentos de avalia&ccedil;&atilde;o. A correla&ccedil;&atilde;o positiva e signifi
cativa obtida entre a dist&acirc;ncia percorrida e a PI<sub>m&aacute;x</sub> ap&
oacute;s o treinamento sugere que a for&ccedil;a muscular inspirat&oacute;ria co
ntribui com a toler&acirc;ncia ao exerc&iacute;cio e capacidade funcional. </fon
t></p>     ^cY#v33n1a09.htm##
01254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704102000075002001301095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#82#78#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O conjunto de adapta&ccedil;&otilde;e
s morfol&oacute;gicas e funcionais decorrentes do treinamento f&iacute;sico perm
ite ao organismo maior capacidade para responder a esse estresse. <sup>39</sup> 
O aumento do d&eacute;bito card&iacute;aco, proporcional &agrave; intensidade do
 exerc&iacute;cio, &eacute; essencial para suprir as grandes quantidades de oxig
&ecirc;nio e outros nutrientes necess&aacute;rios aos m&uacute;sculos ativos. <s
up>40</sup> Embora este estudo n&atilde;o tenha demonstrado altera&ccedil;&otild
e;es significativas no VO<sub>2m&aacute;x</sub>, houve correla&ccedil;&atilde;o 
positiva e significativa entre essa vari&aacute;vel e a PI<sub>max</sub>. Esse f
ato pode estar associado &agrave;s condi&ccedil;&otilde;es cardiovasculares da p
opula&ccedil;&atilde;o estudada, ainda capaz de produzir aumento do d&eacute;bit
o card&iacute;aco (DC) e, portanto, da oferta de oxig&ecirc;nio para os tecidos 
perif&eacute;ricos. </font></p>     ^cY#v33n1a09.htm##
00799000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056500075002001300640#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#83#79#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sugere-se que novos estudos possam se
r realizados, com medidas diretas de DC e diferen&ccedil;a arteriovenosa de oxig
&ecirc;nio no intuito de melhor investigar os efeitos do TMI nessas vari&aacute;
veis com pacientes com DRC submetidos &agrave; HD. Tamb&eacute;m se faz necess&a
acute;rio estudos que avaliem a melhora da fun&ccedil;&atilde;o pulmonar desses 
pacientes por meio de t&eacute;cnicas de fisioterapia respirat&oacute;ria para m
elhora dos volumes e capacidades pulmonares. </font></p>     ^cY#v33n1a09.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012300075002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#84#80#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>LIMITA&Ccedil;&Atilde;O DO ESTUDO<
/b></font></p>     ^cY#v33n1a09.htm##
00789000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055500075002001300630#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#85#81#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> Muitos pacientes negaram-se a partic
ipar do estudo devido ao longo tempo de seguimento, prejudicando assim o tamanho
 da amostra. Outro fator relevante para o estudo seria a pesquisa com um grupo c
ontrole e a sele&ccedil;&atilde;o de pacientes jovens com menos comorbidades do 
que a m&eacute;dia da popula&ccedil;&atilde;o em HD. Al&eacute;m disso, o estudo
 poderia ter avaliado o aspecto nutricional e a rea&ccedil;&atilde;o inflamat&oa
cute;ria desses indiv&iacute;duos. </font></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#86#82#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#87#83#article#179#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>   
  ^cY#v33n1a09.htm##
00519000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028500075002001300360#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#88#84#article#179#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O TMI por oito semanas proporcionou a
umento significativo da dist&acirc;ncia percorrida no TC6M pelos pacientes em HD
, mas sem altera&ccedil;&atilde;o nos demais par&acirc;metros avaliados. <sup>3<
/sup></font></p>     ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#89#85#article#179#<p>&nbsp;</p>     ^c
Y#v33n1a09.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#90#86#article#179#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a09.htm##
00666000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704041800077002001300495#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#91#87#article#179#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Sehgal AR. Doen&cced
il;a Renal Terminal: causas e consequ&ecirc;ncias. Epidemiologia e resultados da
 doen&ccedil;a renal terminal. <i>In</i>: Hrick DE, Sedor JR. Ganz MB, editores.
 Segredos em Nefrologia: respostas necess&aacute;rias ao dia a dia em rounds, na
 cl&iacute;nica, em exames, orais e escritos. Porto Alegre: Artmed 2002, pp. 177
-78.    ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#92#88#article#179# </font></p>     ^cY
#v33n1a09.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024300077002001300320#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#93#89#article#179#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Martins MRI, Cestari
no CB.Qualidade de vida de pessoas com doen&ccedil;a renal cr&ocirc;nica em trat
amento hemodial&iacute;tico. Rev Latino Am Enfermagem 2005; 13:670-6.    ^cY#v33
n1a09.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#94#90#article#179# </font></p>     ^cY
#v33n1a09.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023200077002001300309#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#95#91#article#179#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Cheema BSB, Sing MAF
. Exercise training in patients receiving maintenance hemodialysis: a systematic
 review of clinical trials. Am J Nephrol 2005; 25:352-364.    ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#96#92#article#179# </font></p>     ^cY
#v33n1a09.htm##
00603000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704035500077002001300432#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#97#93#article#179#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Censo de Di&aacute;l
ise da Sociedade Brasileira de Nefrologia 2009 &#91;p&aacute;gina na internet&#9
3;. Local de publica&ccedil;&atilde;o: Dispon&iacute;vel em: <a href="http://www
.sbn.org.br/leigos/index.php?censo" target="_blank">http://www.sbn.org.br/leigos
/index.php?censo</a>.    ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#98#94#article#179# </font></p>     ^cY
#v33n1a09.htm##
00527000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027900077002001300356#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#99#95#article#179#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Kamimura MA, Draibe 
SA, Sigulem DM, Cuppari L. M&eacute;todos de avalia&ccedil;&atilde;o da composi&
ccedil;&atilde;o corporal em pacientes submetidos &agrave; hemodi&aacute;lise. R
ev Nutr 2004; 17:97- 105.    ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#100#96#article#179# </font></p>     ^c
Y#v33n1a09.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704025200078002001300330#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#101#97#article#179#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Machado MGR. Treina
mento muscular respirat&oacute;rio. <i>In</i>: Azeredo CAC, editor. Fisioterapia
 Respirat&oacute;ria Moderna, 4 ed. S&atilde;o Paulo: Manole, 2002, pp. 207-21. 
   ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#102#98#article#179# </font></p>     ^c
Y#v33n1a09.htm##
00568000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704031900078002001300397#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#103#99#article#179#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Regenga MM. Fisiote
rapia no paciente cardiopata grave na terapia intensiva. <i>In</i>: Regenga MM, 
editor. Fisioterapia em Cardiologia: da unidade de terapia intensiva &agrave; re
abilita&ccedil;&atilde;o. S&atilde;o Paulo: Roca, 2000, pp. 47-65.    ^cY#v33n1a
09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#104#100#article#179# </font></p>     ^
cY#v33n1a09.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704027300079002001300352#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#105#101#article#179#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Mahmoud BL, Abdulk
ader A, El-Sharkawy MS, Khalil HH. Assessment of pulmonary functions in chronic 
renal failure patients with different haemodialysis regimens. J Egypt Soc Parasi
tol 2004; 34:1025-40.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#106#102#article#179# </font></p>     ^
cY#v33n1a09.htm##
00561000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704031100079002001300390#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#107#103#article#179#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Schardong JT, Lukr
afka LJ, Garcia DV. Avalia&ccedil;&atilde;o da fun&ccedil;&atilde;o pulmonar e d
a qualidade de vida em pacientes com doen&ccedil;a renal cr&ocirc;nica submetido
s &agrave; hemodi&aacute;lise. J Bras Nefrol 2008; 30:40-7.    ^cY#v33n1a09.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#108#104#article#179# </font></p>     ^
cY#v33n1a09.htm##
00473000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022200080002001300302#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#109#105#article#179#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Herrero JA, Alva
rez-Sala JL, Coronel F <i>et al. </i> Pulmonary diffusing capacity in chronic di
alysis Patients. Respir M&eacute;d 2002; 96:487-92.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#110#106#article#179# </font></p>     ^
cY#v33n1a09.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023200080002001300312#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#111#107#article#179#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Painter P, Messe
r-Rehak D, Hanson P, Zimmerman SW, Glasse NR. Exercise capacity in hemodialysis,
 CAPD, and renal transplant patients. Nephron 1986; 42:47-51.    ^cY#v33n1a09.ht
m##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#112#108#article#179# </font></p>     ^
cY#v33n1a09.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025000080002001300330#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#113#109#article#179#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Latos D, Strimel
 D, Drews M, Allison TG. Acid-base and electrolyte changes following maximal and
 submaximal exercise in hemodialysis patients. Am J Kidney Dis 1987; 10:439-45. 
   ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#114#110#article#179# </font></p>     ^
cY#v33n1a09.htm##
00453000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020200080002001300282#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#115#111#article#179#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Barnea H, Drory 
Y, Iaina A <i>et al. </i> Exercise tolerance in patients on chronic hemodialysis
. Isr J Med Sci 1980; 16:17-21.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#116#112#article#179# </font></p>     ^
cY#v33n1a09.htm##
00450000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019900080002001300279#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#117#113#article#179#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Kettner-Melsheim
er A, Weiss M, Huber W. Physical work capacity in chronic renal diasease. Int J 
Artif Organs 1987; 10:23-30.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#118#114#article#179# </font></p>     ^
cY#v33n1a09.htm##
00408000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015700080002001300237#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#119#115#article#179#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Johansen KL. Exe
rcise and chronic kidney disease. Sort M&eacute;d 2005; 35:485-99.    ^cY#v33n1a
09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#120#116#article#179# </font></p>     ^
cY#v33n1a09.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#121#117#article#179#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Bush A, Gabriel 
R. Pulmonary function in chronic renal failure: effects of dialysis and transpla
ntation. Torax 1991; 46:424-8.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#122#118#article#179# </font></p>     ^
cY#v33n1a09.htm##
00678000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704042700080002001300507#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#123#119#article#179#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Marchesan M, Kru
g RR, Moreira PR, Krug MR. Efeitos do treinamento de for&ccedil;a muscular respi
rat&oacute;ria na capacidade funcional de pacientes com insufici&ecirc;ncia rena
l cr&ocirc;nica. Revista Digital Buenos Aires 2008; 13:119 &#91;acesso em 20 mai
o 2008; <a href="http://www.efdeportes.com/" target="_blank">http://www.efdeport
es.com/</a>&#93;    ^cY#v33n1a09.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#124#120#article#179#. </font></p>     
^cY#v33n1a09.htm##
00433000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018200080002001300262#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#125#121#article#179#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Souza RB. Press&
otilde;es respirat&oacute;rias est&aacute;ticas m&aacute;ximas. J Pneumol 2002; 
28:S155-65.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#126#122#article#179# </font></p>     ^
cY#v33n1a09.htm##
00377000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704012600080002001300206#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#127#123#article#179#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Pereira CAC. Esp
irometria. J Pneumol 2002; 8:S1-82.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#128#124#article#179# </font></p>     ^
cY#v33n1a09.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023800080002001300318#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#129#125#article#179#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Chatterjee S; Ch
atterjee P; Mukher Jee PS; Bandyopadhyay A. Validity of Queen's College Step Tes
t for Use with Young Indian Men. Br J Sports Med 2004;(38): 289-91.    ^cY#v33n1
a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#130#126#article#179# </font></p>     ^
cY#v33n1a09.htm##
00464000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021300080002001300293#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#131#127#article#179#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Mion Jr D, Macha
do CA, Gomes MAM <i>et al. </i> IV Diretrizes Brasileiras de Hipertens&atilde;o 
Arterial. Arq Bras Cardiol 2004; 82:S7-22.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#132#128#article#179# </font></p>     ^
cY#v33n1a09.htm##
00568000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031700080002001300397#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#133#129#article#179#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Silva LCC, Rubim
 AS, Silva LMC. Teste de exerc&iacute;cio cardiopulmonar - fase I (Teste da cami
nhada dos seis minutos). In: Silva CCL, Rubim AS, editores. Avalia&ccedil;&atild
e;o funcional pulmonar. Rio de Janeiro: Revinter; 2000, pp. 60-64.    ^cY#v33n1a
09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#134#130#article#179# </font></p>     ^
cY#v33n1a09.htm##
00552000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030100080002001300381#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#135#131#article#179#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Costa D. Cinesio
terapia, reeduca&ccedil;&atilde;o funcional respirat&oacute;ria e reabilita&cced
il;&atilde;o pulmonar. In: Costa, D (editor). Fisioterapia Respirat&oacute;ria B
&aacute;sica. S&atilde;o Paulo: Atheneu; 2004, pp.    ^cY#v33n1a09.htm##
00264000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002800077002001300105#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#136#132#article#179# 71-84. </font></p
>     ^cY#v33n1a09.htm##
00587000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033600080002001300416#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#137#133#article#179#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Webber BA, Pryor
 JA, Bethune DD, Potter HM, Mckenzie D. T&eacute;cnicas Fisoter&aacute;picas. <i
>In</i>: Pryor, J.A; Webber, B.A, editores. Fisioterapia para problemas respirat
&oacute;rios e card&iacute;acos. 2 ed. S&atilde;o Paulo: Guanabara Koogan;  2002
, pp.    ^cY#v33n1a09.htm##
00265000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002900077002001300106#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#138#134#article#179# 97-145. </font></
p>     ^cY#v33n1a09.htm##
00589000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033800080002001300418#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#139#135#article#179#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Ser&oacute;n P, 
Riedemann P, Munoz S, Doussoulin A,Villarroel P, Cea X. Effect of inspiratory mu
scle training on muscle strength and quality of life in patients with chronic ai
rflow limitation: a randomized controlled trial. Rev. Arch Bronconeumol 2005; 41
:601-6.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#140#136#article#179# </font></p>     ^
cY#v33n1a09.htm##
00487000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023600080002001300316#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#141#137#article#179#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Kouidi E, Albani
 M, Natsis K <i>et al. </i> The effects of exercise training on muscle atrophy i
n haemodyalisis patients. Neprol Dial Transplant 1998; 13:685-99.    ^cY#v33n1a0
9.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#142#138#article#179# </font></p>     ^
cY#v33n1a09.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021500080002001300295#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#143#139#article#179#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Adams GR, Vaziri
 ND. Skeletal muscle dysfunction in chronic renal failure: effects of exercise. 
Am J Physiol Renal Physiol 2006; 290:753-61.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#144#140#article#179# </font></p>     ^
cY#v33n1a09.htm##
00468000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021700080002001300297#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#145#141#article#179#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Perneger TV, Les
ki M, Chopard-Storermann C, Martin PY. Assessment of health status in chronic he
modialysis patients. J Nephrol 2003; 16:252-9.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#146#142#article#179# </font></p>     ^
cY#v33n1a09.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021800080002001300298#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#147#143#article#179#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Blake C, Codd M,
 Cassidy A, O'Meara YM. Physical function, employment and quality of life in end
-stage renal disease. J Nephrol 2000; 13:141-9.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#148#144#article#179# </font></p>     ^
cY#v33n1a09.htm##
00517000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026600080002001300346#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#149#145#article#179#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. V&aacute;zquez I
, Valderr&aacute;bano F, Jofr&eacute; R <i>et al. </i> Psychosocial factors and 
quality of life in young hemodialysis patients with low comorbidity. J Nephrol 2
003; 16:886-94.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#150#146#article#179# </font></p>     ^
cY#v33n1a09.htm##
00416000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016500080002001300245#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#151#147#article#179#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Prezant DJ. Effe
ct of uremia and its treatment on pulmonary function. Lung 1990; 168:1-14.    ^c
Y#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#152#148#article#179# </font></p>     ^
cY#v33n1a09.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021000080002001300290#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#153#149#article#179#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Kouidi E, Lacovi
des A, Iordanidis P <i>et al. </i> Exercise renal rehabilitation program: psycho
social effects. Nephron 1997; 77:152-8.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#154#150#article#179# </font></p>     ^
cY#v33n1a09.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#155#151#article#179#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Oh-Park M, Fast 
A, Gopal S <i>et al. </i> Exercise for the dialyzed: aerobic and strength traini
ng during hemodialysis. Am J Phys Med Rehabil 2002; 81:814-21.    ^cY#v33n1a09.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#156#152#article#179# </font></p>     ^
cY#v33n1a09.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022700080002001300307#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#157#153#article#179#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Beckerman M, Mag
adle R, Weiner M, Weiner P. The effects of 1 Yer of specific inspiratory muscle 
training in patients with COPD. Chest 2005; 128:3177-82.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#158#154#article#179# </font></p>     ^
cY#v33n1a09.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027200080002001300352#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#159#155#article#179#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Larson J, Klim M
, Sharp J, Larson D. Inspiratory muscle training with a pressure threshold breat
hing device in patients with chronic obstructive pulmonary disease. Am Rev Resp 
Dis 1988; 138:689-96.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#160#156#article#179# </font></p>     ^
cY#v33n1a09.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022000080002001300300#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#161#157#article#179#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Belman MJ, Shadm
eher R. Targeted resistive ventilatory muscle training in chronic obstructive pu
lmonary disease. J Apple Physol 1988; 65:2726-35.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#162#158#article#179# </font></p>     ^
cY#v33n1a09.htm##
00503000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025200080002001300332#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#163#159#article#179#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Weiner P Magadle
 R, Beckerman M, Weiner M, Berar-Yanay N. Comparison of specific expiratory, ins
piratory, and combined muscle training programs in COPD. Chest 2003; 124:1357-64
.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#164#160#article#179# </font></p>     ^
cY#v33n1a09.htm##
00492000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024100080002001300321#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#165#161#article#179#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Magadle R, Mconn
ell A, Beckerman M, Weiner P. Inspiratory muscle training in pulmonary rehabilit
ation program in COPD patients. Respiratory Medicine 2007; 101:1500-5.    ^cY#v3
3n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#166#162#article#179# </font></p>     ^
cY#v33n1a09.htm##
00479000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022800080002001300308#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#167#163#article#179#39#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. N&oacute;brega L
CA, Castro TRR, Negr&atilde;o EC <i>et al. </i> Diretriz de reabilita&ccedil;&at
ilde;o card&iacute;aca. Arq Bras Cardiol 2005; 84:431-40.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#168#164#article#179# </font></p>     ^
cY#v33n1a09.htm##
00584000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033300080002001300413#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#169#165#article#179#40#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Guyton AC, Hall 
JE. Fluxo sangu&iacute;neo muscular e d&eacute;bito card&iacute;aco, durante o E
xerc&iacute;cio Tratado de Fisiologia M&eacute;dica, 10ª edi&ccedil;&atilde;o. <
i>In</i>: Guyton AC, Hall JE editores. Rio de Janeiro: Guanabara Koogan, 2002, p
p.    ^cY#v33n1a09.htm##
00265000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002900077002001300106#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#170#166#article#179# 213-21. </font></
p>     ^cY#v33n1a09.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#171#167#article#179#<p>&nbsp;</p>     
^cY#v33n1a09.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#172#168#article#179#<p>&nbsp;</p>     
^cY#v33n1a09.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020000077002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#173#169#article#179#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;
ncia para:</b>    ^cY#v33n1a09.htm##
00281000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004500077002001300122#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#174#170#article#179#<br>   Vanessa Gie
ndruczak  da Silva     ^cY#v33n1a09.htm##
00297000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006100077002001300138#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#175#171#article#179#<br>   Rua Cip&oac
ute;, 850/240, Bairro Passo d'Areia    ^cY#v33n1a09.htm##
00292000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005600077002001300133#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#176#172#article#179#<br>   Porto Alegr
e - RS - Brasil CEP: 91360-370    ^cY#v33n1a09.htm##
00347000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704011100077002001300188#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#177#173#article#179#<br>   E-mail: <a 
href="mailto:fisiot_vanessa@yahoo.com.br">fisiot_vanessa@yahoo.com.br</a></font>
</p>     ^cY#v33n1a09.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#178#174#article#179#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 26/07/201
0    ^cY#v33n1a09.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#179#175#article#179#<br>   Data de apr
ova&ccedil;&atilde;o: 29/12/2010    ^cY#v33n1a09.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#180#176#article#179#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a09.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#181#177#article#179#<p>&nbsp;</p>     
^cY#v33n1a09.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#182#178#article#179#<p>&nbsp;</p>     
^cY#v33n1a09.htm##
00418000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704018200077002001300259#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a09.htm#S#p#183#179#article#179#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado na 
Irmandade da Santa Casa de Miseric&oacute;rdia de Porto Alegre. </font></p>     
^cY#v33n1a09.htm##
00710000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760120103000930160
01600196016001600212016001500228018011400243066001300357062000700370065000900377
064000500386014000700391865000900398002001300407#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a09.htm#S#c#184#1#article#40#1#^rND^sSehgal^nAR#Doença Renal Termi
nal: causas e consequências. Epidemiologia e resultados da doença renal terminal
^lpt#^rED^sHrick^nDE#^rED^sSedor^nJR#^rED^sGanz^nMB#Segredos em Nefrologia: resp
ostas necessárias ao dia a dia em rounds, na clínica, em exames, orais e escrito
s^lpt#Porto Alegre#Artmed#20020000#2002#177-78#20110300#v33n1a09.htm##
00539000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100020000950120
08600115030002500201710000200226065000900228064000500237031000300242014000600245
865000900251002001300260#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#185#2#article#40#2#^rND^sMartins^nMRI#^rND^sCestarino^nCB#Qualidade de vida de
 pessoas com doença renal crônica em tratamento hemodialítico^lpt#Rev Latino Am 
Enfermagem#2#20050000#2005#13#670-6#20110300#v33n1a09.htm##
00580000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100016000940120
10900110030001300219065000900232064000500241031000300246014000800249865000900257
002001300266035001000279801001300289#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a09.htm#S#c#186#3#article#40#3#^rND^sCheema^nBSB#^rND^sSing^nMAF#Exercise trai
ning in patients receiving maintenance hemodialysis: a systematic review of clin
ical trials^len#Am J Nephrol#20050000#2005#25#352-364#20110300#v33n1a09.htm#0250
-8095#Am J Nephrol##
00389000000000181000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740180064000760370045001408650
00900185002001300194#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#c#18
7#4#article#40#4#Censo de Diálise da Sociedade Brasileira de Nefrologia 2009^lpt
#http://www.sbn.org.br/leigos/index.php?censo#20110300#v33n1a09.htm##
00580000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100017000950100
01800112010001700130012008600147030000900233710000200242065000900244064000500253
031000300258014000700261865000900268002001300277#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a09.htm#S#c#188#5#article#40#5#^rND^sKamimura^nMA#^rND^sDraibe^nSA
#^rND^sSigulem^nDM#^rND^sCuppari^nL#Métodos de avaliação da composição corporal 
em pacientes submetidos à hemodiálise^lpt#Rev Nutr#2#20040000#2004#17#97-105#201
10300#v33n1a09.htm##
00525000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760120038000950160
01900133018003800152063000200190066001000192062000700202014000200209065000900211
064000500220865000900225002001300234#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a09.htm#S#c#189#6#article#40#6#^rND^sMachado^nMGR#Treinamento muscular respira
tório^lpt#^rED^sAzeredo^nCAC#Fisioterapia Respiratória Moderna^lpt#4#São Paulo#M
anole#p#20020000#2002#20110300#v33n1a09.htm##
00578000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760120067000940160
01800161018008000179066001000259062000500269014000200274065000900276064000500285
865000900290002001300299#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#190#7#article#40#7#^rND^sRegenga^nMM#Fisioterapia no paciente cardiopata grave
 na terapia intensiva^lpt#^rED^sRegenga^nMM#Fisioterapia em Cardiologia: da unid
ade de terapia intensiva à reabilitação^lpt#São Paulo#Roca#p#20000000#2000#20110
300#v33n1a09.htm##
00666000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100020000940100
02200114010001700136012011000153030002200263065000900285064000500294031000300299
014000800302865000900310002001300319035001000332801002200342#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#191#8#article#40#8#^rND^sMahmoud^nBL#^rND^
sAbdulkader^nA#^rND^sEl-Sharkawy^nMS#^rND^sKhalil^nHH#Assessment of pulmonary fu
nctions in chronic renal failure patients with different haemodialysis regimens^
len#J Egypt Soc Parasitol#20040000#2004#34#1025-40#20110300#v33n1a09.htm#0253-58
90#J Egypt Soc Parasitol##
00623000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100019000960100
01700115012011900132030001400251065000900265064000500274031000300279014000500282
865000900287002001300296035001000309801001400319#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a09.htm#S#c#192#9#article#40#9#^rND^sSchardong^nJT#^rND^sLukrafka^
nLJ#^rND^sGarcia^nDV#Avaliação da função pulmonar e da qualidade de vida em paci
entes com doença renal crônica submetidos à hemodiálise^lpt#J Bras Nefrol#200800
00#2008#30#40-7#20110300#v33n1a09.htm#0101-2800#J Bras Nefrol##
00553000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100023000960100
01700119810000600136012006200142030001100204710000200215065000900217064000500226
031000300231014000700234865000900241002001300250#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a09.htm#S#c#193#10#article#40#10#^rND^sHerrero^nJA#^rND^sAlvarez-S
ala^nJL#^rND^sCoronel^nF#et al#Pulmonary diffusing capacity in chronic dialysis 
Patients^len#Respir Méd#2#20020000#2002#96#487-92#20110300#v33n1a09.htm##
00630000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100022000950100
01600117010002000133010001700153012007500170030000800245065000900253064000500262
031000300267014000600270865000900276002001300285035001000298801000800308#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#c#194#11#article#40#11#^rND^sPai
nter^nP#^rND^sMesser-Rehak^nD#^rND^sHanson^nP#^rND^sZimmerman^nSW#^rND^sGlasse^n
NR#Exercise capacity in hemodialysis, CAPD, and renal transplant patients^len#Ne
phron#19860000#1986#42#47-51#20110300#v33n1a09.htm#0028-2766#Nephron##
00638000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01500110010001800125012010500143030001600248065000900264064000500273031000300278
014000700281865000900288002001300297035001000310801001600320#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#195#12#article#40#12#^rND^sLatos^nD#^rND^s
Strimel^nD#^rND^sDrews^nM#^rND^sAllison^nTG#Acid-base and electrolyte changes fo
llowing maximal and submaximal exercise in hemodialysis patients^len#Am J Kidney
 Dis#19870000#1987#10#439-45#20110300#v33n1a09.htm#0272-6386#Am J Kidney Dis##
00574000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940100
01500109810000600124012005900130030001400189065000900203064000500212031000300217
014000600220865000900226002001300235035001000248801001400258#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#196#13#article#40#13#^rND^sBarnea^nH#^rND^
sDrory^nY#^rND^sIaina^nA#et al#Exercise tolerance in patients on chronic hemodia
lysis^len#Isr J Med Sci#19800000#1980#16#17-21#20110300#v33n1a09.htm#0021-2180#I
sr J Med Sci##
00572000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100028000780100015001060100
01500121012005300136030001900189065000900208064000500217031000300222014000600225
865000900231002001300240035001000253801001900263#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a09.htm#S#c#197#14#article#40#14#^rND^sKettner-Melsheimer^nA#^rND^
sWeiss^nM#^rND^sHuber^nW#Physical work capacity in chronic renal diasease^len#In
t J Artif Organs#19870000#1987#10#23-30#20110300#v33n1a09.htm#0391-3988#Int J Ar
tif Organs##
00448000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120040000970300
00900137710000200146065000900148064000500157031000300162014000700165865000900172
002001300181#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#c#198#15#art
icle#40#15#^rND^sJohansen^nKL#Exercise and chronic kidney disease^len#Sort Méd#2
#20050000#2005#35#485-99#20110300#v33n1a09.htm##
00543000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100017000920120
08900109030000600198065000900204064000500213031000300218014000600221865000900227
002001300236035001000249801000600259#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a09.htm#S#c#199#16#article#40#16#^rND^sBush^nA#^rND^sGabriel^nR#Pulmonary func
tion in chronic renal failure: effects of dialysis and transplantation^len#Torax
#19910000#1991#46#424-8#20110300#v33n1a09.htm#0049-4143#TORAX##
00721000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01800112010001500130012012700145030002900272710000200301065000900303064000500312
03100030031702000040032011000090032410900130033303700270034686500090037300200130
0382#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#c#200#17#article#40#
17#^rND^sMarchesan^nM#^rND^sKrug^nRR#^rND^sMoreira^nPR#^rND^sKrug^nMR#Efeitos do
 treinamento de força muscular respiratória na capacidade funcional de pacientes
 com insuficiência renal crônica^lpt#Revista Digital Buenos Aires#2#20080000#200
8#13#119#20080520#20 maio 2008#http://www.efdeportes.com/#20110300#v33n1a09.htm#
#
00482000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120045000940300
01000139065000900149064000500158031000300163014000800166865000900174002001300183
035001000196801001000206#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#201#18#article#40#18#^rND^sSouza^nRB#Pressões respiratórias estáticas máximas^
lpt#J Pneumol#20020000#2002#28#S155-65#20110300#v33n1a09.htm#0102-3586#J Pneumol
##
00454000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120017000970300
01000114065000900124064000500133031000200138014000600140865000900146002001300155
035001000168801001000178#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#202#19#article#40#19#^rND^sPereira^nCAC#Espirometria^lpt#J Pneumol#20020000#20
02#8#S1-82#20110300#v33n1a09.htm#0102-3586#J Pneumol##
00624000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100020000980100
02100118010002300139012007200162030001600234065000900250064000500259032000300264
014000700267865000900274002001300283035001000296801001600306#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#203#20#article#40#20#^rND^sChatterjee^nS#^
rND^sChatterjee^nP#^rND^sMukher Jee^nPS#^rND^sBandyopadhyay^nA#Validity of Queen
's College Step Test for Use with Young Indian Men^len#Br J Sports Med#20040000#
2004#38#289-91#20110300#v33n1a09.htm#0306-3674#Br J Sports Med##
00581000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01700113810000600130012005400136030001700190065000900207064000500216031000300221
014000600224865000900230002001300239035001000252801001700262#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#204#21#article#40#21#^rND^sMion Jr^nD#^rND
^sMachado^nCA#^rND^sGomes^nMAM#et al#IV Diretrizes Brasileiras de Hipertensão Ar
terial^lpt#Arq Bras Cardiol#20040000#2004#82#S7-22#20110300#v33n1a09.htm#0066-78
2X#Arq Bras Cardiol##
00642000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01700111012008400128016001700212016001600229018003300245066001500278062000900293
014000200302065000900304064000500313865000900318002001300327#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#205#22#article#40#22#^rND^sSilva^nLCC#^rND
^sRubim^nAS#^rND^sSilva^nLMC#Teste de exercício cardiopulmonar: fase I (Teste da
 caminhada dos seis minutos)^len#^rED^sSilva^nCCL#^rED^sRubim^nAS#Avaliação func
ional pulmonar^lpt#Rio de Janeiro#Revinter#p#20000000#2000#20110300#v33n1a09.htm
##
00549000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120078000930160
01500171018003700186066001000223062000800233014000600241065000900247064000500256
865000900261002001300270#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#206#23#article#40#23#^rND^sCosta^nD#Cinesioterapia, reeducação funcional respi
ratória e reabilitação pulmonar^lpt#^rND^sCosta^nD#Fisioterapia Respiratória Bás
ica^lpt#São Paulo#Atheneu#71-84#20040000#2004#20110300#v33n1a09.htm##
00693000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01800111010001700129010001800146012002700164016001600191016001800207018005800225
06300020028306600100028506200170029501400070031206500090031906400050032886500090
0333002001300342#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#c#207#24
#article#40#24#^rND^sWebber^nBA#^rND^sPryor^nJA#^rND^sBethune^nDD#^rND^sPotter^n
HM#^rND^sMckenzie^nD#Técnicas Fisoterápicas^lpt#^rED^sPryor^nJA#^rED^sWebber^nB.
A#Fisioterapia para problemas respiratórios e cardíacos^lpt#2#São Paulo#Guanabar
a Koogan#97-145#20020000#2002#20110300#v33n1a09.htm##
00758000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930100
01500112010002000127010002000147010001300167012016100180030001800341065000900359
06400050036803100030037301400060037686500090038200200130039103500100040480100180
0414#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#c#208#25#article#40#
25#^rND^sSerón^nP#^rND^sRiedemann^nP#^rND^sMunoz^nS#^rND^sDoussoulin^nA#^rND^sVi
llarroel^nP#^rND^sCea^nX#Effect of inspiratory muscle training on muscle strengt
h and quality of life in patients with chronic airflow limitation: a randomized 
controlled trial. Rev^len#Arch Bronconeumol#20050000#2005#41#601-6#20110300#v33n
1a09.htm#0300-2896#Arch Bronconeumol##
00574000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01600110810000600126012008100132030002300213710000200236065000900238064000500247
031000300252014000700255865000900262002001300271#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a09.htm#S#c#209#26#article#40#26#^rND^sKouidi^nE#^rND^sAlbani^nM#^
rND^sNatsis^nK#et al#The effects of exercise training on muscle atrophy in haemo
dyalisis patients^len#Neprol Dial Transplant#2#19980000#1998#13#685-99#20110300#
v33n1a09.htm##
00531000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940120
07800111030002700189710000200216065000900218064000500227031000400232014000700236
865000900243002001300252#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#210#27#article#40#27#^rND^sAdams^nGR#^rND^sVaziri^nND#Skeletal muscle dysfunct
ion in chronic renal failure: effects of exercise^len#Am J Physiol Renal Physiol
#2#20060000#2006#290#753-61#20110300#v33n1a09.htm##
00599000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
02800112010001700140012006500157030001000222065000900232064000500241031000300246
014000600249865000900255002001300264035001000277801001000287#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#211#28#article#40#28#^rND^sPerneger^nTV#^r
ND^sLeski^nM#^rND^sChopard-Storermann^nC#^rND^sMartin^nPY#Assessment of health s
tatus in chronic hemodialysis patients^len#J Nephrol#20030000#2003#16#252-9#2011
0300#v33n1a09.htm#1120-3625#J Nephrol##
00600000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930100
01700107010001800124012008100142030001000223065000900233064000500242031000300247
014000600250865000900256002001300265035001000278801001000288#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#212#29#article#40#29#^rND^sBlake^nC#^rND^s
Codd^nM#^rND^sCassidy^nA#^rND^sO'Meara^nYM#Physical function, employment and qua
lity of life in end-stage renal disease^len#J Nephrol#20000000#2000#13#141-9#201
10300#v33n1a09.htm#1120-3625#J Nephrol##
00613000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100022000950100
01500117810000600132012009700138030001000235065000900245064000500254031000300259
014000700262865000900269002001300278035001000291801001000301#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#213#30#article#40#30#^rND^sVázquez^nI#^rND
^sValderrábano^nF#^rND^sJofré^nR#et al#Psychosocial factors and quality of life 
in young hemodialysis patients with low comorbidity^len#J Nephrol#20030000#2003#
16#886-94#20110300#v33n1a09.htm#1120-3625#J Nephrol##
00488000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120061000960300
00500157065000900162064000500171031000400176014000500180865000900185002001300194
035001000207801000500217#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#214#31#article#40#31#^rND^sPrezant^nDJ#Effect of uremia and its treatment on p
ulmonary function^len#Lung#19900000#1990#168#1-14#20110300#v33n1a09.htm#0341-204
0#Lung##
00576000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
02000113810000600133012006400139030000800203065000900211064000500220031000300225
014000600228865000900234002001300243035001000256801000800266#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#215#32#article#40#32#^rND^sKouidi^nE#^rND^
sLacovides^nA#^rND^sIordanidis^nP#et al#Exercise renal rehabilitation program: p
sychosocial effects^len#Nephron#19970000#1997#77#152-8#20110300#v33n1a09.htm#002
8-2766#Nephron##
00613000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100014000950100
01500109810000600124012008100130030002200211065000900233064000500242031000300247
014000700250865000900257002001300266035001000279801002200289#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#216#33#article#40#33#^rND^sOh-Park^nM#^rND
^sFast^nA#^rND^sGopal^nS#et al#Exercise for the dialyzed: aerobic and strength t
raining during hemodialysis^len#Am J Phys Med Rehabil#20020000#2002#81#814-21#20
110300#v33n1a09.htm#0894-9115#Am J Phys Med Rehabil##
00605000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970100
01600114010001600130012008700146030000600233065000900239064000500248031000400253
014000800257865000900265002001300274035001000287801000600297#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#217#34#article#40#34#^rND^sBeckerman^nM#^r
ND^sMagadle^nR#^rND^sWeiner^nM#^rND^sWeiner^nP#The effects of 1 Yer of specific 
inspiratory muscle training in patients with COPD^len#Chest#20050000#2005#128#31
77-82#20110300#v33n1a09.htm#0012-3692#Chest##
00660000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100014000940100
01500108010001600123012013000139030001600269065000900285064000500294031000400299
014000700303865000900310002001300319035001000332801001600342#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#218#35#article#40#35#^rND^sLarson^nJ#^rND^
sKlim^nM#^rND^sSharp^nJ#^rND^sLarson^nD#Inspiratory muscle training with a press
ure threshold breathing device in patients with chronic obstructive pulmonary di
sease^len#Am Rev Resp Dis#19880000#1988#138#689-96#20110300#v33n1a09.htm#0003-08
05#Am Rev Resp Dis##
00536000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950120
09200114030001500206710000200221065000900223064000500232031000300237014000800240
865000900248002001300257#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#
c#219#36#article#40#36#^rND^sBelman^nMJ#^rND^sShadmeher^nR#Targeted resistive ve
ntilatory muscle training in chronic obstructive pulmonary disease^len#J Apple P
hysol#2#19880000#1988#65#2726-35#20110300#v33n1a09.htm##
00649000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01900111010001600130010002100146012009800167030000600265065000900271064000500280
031000400285014000800289865000900297002001300306035001000319801000600329#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a09.htm#S#c#220#37#article#40#37#^rND^sWei
ner^nP#^rND^sMagadle^nR#^rND^sBeckerman^nM#^rND^sWeiner^nM#^rND^sBerar-Yanay^nN#
Comparison of specific expiratory, inspiratory, and combined muscle training pro
grams in COPD^len#Chest#20030000#2003#124#1357-64#20110300#v33n1a09.htm#0012-369
2#Chest##
00634000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01900113010001600132012008500148030002100233065000900254064000500263031000400268
014000700272865000900279002001300288035001000301801002100311#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#221#38#article#40#38#^rND^sMagadle^nR#^rND
^sMconnell^nA#^rND^sBeckerman^nM#^rND^sWeiner^nP#Inspiratory muscle training in 
pulmonary rehabilitation program in COPD patients^len#Respiratory Medicine#20070
000#2007#101#1500-5#20110300#v33n1a09.htm#0954-6111#Respiratory medicine##
00568000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100018000970100
01700115810000600132012003800138030001700176065000900193064000500202031000300207
014000700210865000900217002001300226035001000239801001700249#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a09.htm#S#c#222#39#article#40#39#^rND^sNóbrega^nLCA#^r
ND^sCastro^nTRR#^rND^sNegrão^nEC#et al#Diretriz de reabilitação cardíaca^lpt#Arq
 Bras Cardiol#20050000#2005#84#431-40#20110300#v33n1a09.htm#0066-782X#Arq Bras C
ardiol##
00604000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950120
10900110016001700219016001500236066001500251062001700266014000700283065000900290
064000500299865000900304002001300313#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a09.htm#S#c#223#40#article#40#40#^rND^sGuyton^nAC#^rND^sHall^nJE#Fluxo sanguín
eo muscular e débito cardíaco, durante o Exercício Tratado de Fisiologia Médica,
 10ª edição^lpt#^rED^sGuyton^nAC#^rED^sHall^nJE#Rio de Janeiro#Guanabara Koogan#
213-21#20020000#2002#20110300#v33n1a09.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#o#1#1#article#1#
20110411#092946#v33n1a10.htm#200##
05063000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030001700106
03100030012303200020012606500090012801400090013703500100014601200850015601200900
02410100041003310100038003720100034004100100031004440700057004750700050005320700
04200582083172000624085001002344085004002354085002102394085003402415085002202449
08500380247108316700250908500100417908500350418908500210422408500350424508500210
42800850037043011170008043380720003043461120009043491110010043581140009043681130
01104377002001304388#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#h#2#
1#article#1#oa#pt#br1.1#1#4.0#TAB#10#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f
69^l77#0101-2800#Impacto do hábito de jantar sobre o perfil dietético de pacient
es em hemodiálise^lpt#Effects of customary dinner on dietetical profile of patie
nts undergoing hemodialysis^len#^rND^1A01^nMarcia Machado Cunha^sRibeiro#^rND^1A
02^nMelissa Luciana de^sAraújo#^rND^1A01^nMichele Pereira^sNetto#^rND^1A03^nLuca
s Maciel^sCunha#Universidade José do Rosário Vellano - UNIFENAS^iA01^sMG#Centro 
Universitário UNA^iA02^cBelo Horizonte^sMG#Universidade Federal de Minas Gerais^
iA03#^lpt^aOBJETIVO: Analisar os efeitos do comportamento alimentar, entre o háb
ito de jantar ou não jantar, no perfil de ingestão de macronutrientes e micronut
rientes de pacientes com insuficiência renal crônica em hemodiálise. MÉTODO: Est
udo transversal em uma clínica de diálise de Belo Horizonte, em Minas Gerais. Pa
rticiparam do estudo 90 pacientes em tratamento hemodialítico. Foram coletados d
ados pessoais, clínicos e dietéticos (registro alimentar de três dias). Foi cons
iderado jantar uma refeição completa e não jantar a sua ausência ou substituição
 por lanches. As estimativas das quantidades de nutrientes ingeridos foram feita
s em software específico Dietwin®. RESULTADOS: Os valores de carboidrato, tiamin
a, riboflavina, ácido ascórbico, cálcio e selênio ingeridos não apresentaram dif
erença entre os grupos de pacientes que jantavam e não jantavam (p &gt; 0,05). O
s valores de Índice de Massa Corporal (IMC), energia, proteína, lipídeos, niacin
a, ácido pantotênico, piridoxina, ácido fólico, cobalamina, potássio, fósforo, z
inco e magnésio ingeridos apresentaram diferença entre estes mesmos grupos (p < 
0,05). Quanto às proporções de adequação desses nutrientes, o grupo dos que jant
ava apresentou maiores percentuais (p < 0,05), exceto para carboidratos, lipídeo
s, ácido pantotênico, ácido ascórbico, potássio, cálcio e zinco. Nenhum dos paci
entes apresentou valores adequados de ingestão de piridoxina, ácido fólico e sel
ênio. Energia, ácido pantotênico e zinco apresentaram baixos percentuais de adeq
uação em ambos os grupos. CONCLUSÃO: Conclui-se que o hábito de jantar influenci
a positivamente no consumo de macro e micronutrientes em pacientes com insuficiê
ncia renal crônica submetidos à hemodiálise.#^ddecs^i1#^tm^lpt^kinsuficiência re
nal crônica^i1#^tm^lpt^kminerais^i1#^tm^lpt^kavaliação nutricional^i1#^tm^lpt^kv
itaminas^i1#^tm^lpt^kdeficiências nutricionais^i1#^len^aINTRODUCTION: To assess 
the effects of the habit of having evening dinner on the dietary macro- and micr
onutrient profile of chronic kidney failure patients on hemodialysis. METHODS: C
ross-sectional study carried out at a dialysis clinic at the city of Belo Horizo
nte, state of Minas Gerais. The study comprised 90 patients undergoing hemodialy
sis. Personal, clinical, and dietary (three-day food record) data were collected
. The habit of having dinner was considered as having a complete evening meal, a
nd the lack of that habit was considered as not having it or replacing it by a f
ast meal. The amounts of nutrient intake were estimated in the specific software
 Dietwin®. RESULTS: The carbohydrate, thiamine, riboflavin, ascorbic acid, calci
um, and selenium intake values showed no difference between the group having a c
omplete evening meal and that not having it (p &gt; 0.05). Both groups did not d
iffer in the following: body mass index, and energy, protein, lipid, niacin, pan
tothenic acid, pyridoxine, folic acid, cobalamin, potassium, phosphorus, zinc, a
nd magnesium intake values (p < 0.05). Regarding nutrient adequacy, the complete
 evening meal group performed better than the other group, except for carbohydra
tes, lipids, pantothenic acid, ascorbic acid, potassium, calcium, and zinc (p < 
0.05). None of the patients showed the adequate pyridoxine, folic acid, and sele
nium intake values. Few patients in both groups showed adequate energy, pantothe
nic acid, and zinc intake values. CONCLUSION: The habit of having a complete eve
ning meal influenced positively the micro and macronutrient intakes in chronic k
idney failure patients on hemodialysis.#^ddecs^i2#^tm^len^kchronic kidney failur
e^i2#^tm^len^kminerals^i2#^tm^len^knutritional assessment^i2#^tm^len^kvitamins^i
2#^tm^len^knutritional deficiencies^i2#vancouv#38#20100912#12/9/2010#20101230#30
/12/2010#v33n1a10.htm##
05167000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030001700106
03100030012303200020012606500090012801400090013703500100014601200920015601200970
02480100041003450100038003860100034004240100031004580700057004890700050005460700
04200596083176500638085001002403085004002413085002102453085003402474085002202508
08500380253008317150256808500100428308500350429308500210432808500350434908500210
43840850037044051170008044420720003044501120009044531110010044621140009044721130
01104481002001304492#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#f#3#
1#article#1#oa#pt#br1.1#1#4.0#TAB#10#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f
69^l77#0101-2800#<b>Impacto do hábito de jantar sobre o perfil dietético de paci
entes em hemodiálise</b>^lpt#<b>Effects of customary dinner on dietetical profil
e of patients undergoing hemodialysis</b>^len#^rND^1A01^nMarcia Machado Cunha^sR
ibeiro#^rND^1A02^nMelissa Luciana de^sAraújo#^rND^1A01^nMichele Pereira^sNetto#^
rND^1A03^nLucas Maciel^sCunha#Universidade José do Rosário Vellano - UNIFENAS^iA
01^sMG#Centro Universitário UNA^iA02^cBelo Horizonte^sMG#Universidade Federal de
 Minas Gerais^iA03#^lpt^a<b>OBJETIVO: </b>Analisar os efeitos do comportamento a
limentar, entre o hábito de jantar ou não jantar, no perfil de ingestão de macro
nutrientes e micronutrientes de pacientes com insuficiência renal crônica em hem
odiálise. <b>MÉTODO:</b> Estudo transversal em uma clínica de diálise de Belo Ho
rizonte, em Minas Gerais. Participaram do estudo 90 pacientes em tratamento hemo
dialítico. Foram coletados dados pessoais, clínicos e dietéticos (registro alime
ntar de três dias). Foi considerado jantar uma refeição completa e não jantar a 
sua ausência ou substituição por lanches. As estimativas das quantidades de nutr
ientes ingeridos foram feitas em software específico Dietwin<sup>®</sup>. <b>RES
ULTADOS:</b> Os valores de carboidrato, tiamina, riboflavina, ácido ascórbico, c
álcio e selênio ingeridos não apresentaram diferença entre os grupos de paciente
s que jantavam e não jantavam (p &gt; 0,05). Os valores de Índice de Massa Corpo
ral (IMC), energia, proteína, lipídeos, niacina, ácido pantotênico, piridoxina, 
ácido fólico, cobalamina, potássio, fósforo, zinco e magnésio ingeridos apresent
aram diferença entre estes mesmos grupos (p &lt; 0,05). Quanto às proporções de 
adequação desses nutrientes, o grupo dos que jantava apresentou maiores percentu
ais (p &lt; 0,05), exceto para carboidratos, lipídeos, ácido pantotênico, ácido 
ascórbico, potássio, cálcio e zinco. Nenhum dos pacientes apresentou valores ade
quados de ingestão de piridoxina, ácido fólico e selênio. Energia, ácido pantotê
nico e zinco apresentaram baixos percentuais de adequação em ambos os grupos. <b
>CONCLUSÃO: </b>Conclui-se que o hábito de jantar influencia positivamente no co
nsumo de macro e micronutrientes em pacientes com insuficiência renal crônica su
bmetidos à hemodiálise.#^ddecs^i1#^tm^lpt^kinsuficiência renal crônica^i1#^tm^lp
t^kminerais^i1#^tm^lpt^kavaliação nutricional^i1#^tm^lpt^kvitaminas^i1#^tm^lpt^k
deficiências nutricionais^i1#^len^a<b>INTRODUCTION:</b> To assess the effects of
 the habit of having evening dinner on the dietary macro- and micronutrient prof
ile of chronic kidney failure patients on hemodialysis. <b>METHODS:</b> Cross-se
ctional study carried out at a dialysis clinic at the city of Belo Horizonte, st
ate of Minas Gerais. The study comprised 90 patients undergoing hemodialysis. Pe
rsonal, clinical, and dietary (three-day food record) data were collected. The h
abit of having dinner was considered as having a complete evening meal, and the 
lack of that habit was considered as not having it or replacing it by a fast mea
l. The amounts of nutrient intake were estimated in the specific software Dietwi
n<sup>®</sup>. <b>RESULTS:</b> The carbohydrate, thiamine, riboflavin, ascorbic 
acid, calcium, and selenium intake values showed no difference between the group
 having a complete evening meal and that not having it (p &gt; 0.05). Both group
s did not differ in the following: body mass index, and energy, protein, lipid, 
niacin, pantothenic acid, pyridoxine, folic acid, cobalamin, potassium, phosphor
us, zinc, and magnesium intake values (p &lt; 0.05). Regarding nutrient adequacy
, the complete evening meal group performed better than the other group, except 
for carbohydrates, lipids, pantothenic acid, ascorbic acid, potassium, calcium, 
and zinc (p &lt; 0.05). None of the patients showed the adequate pyridoxine, fol
ic acid, and selenium intake values. Few patients in both groups showed adequate
 energy, pantothenic acid, and zinc intake values. <b>CONCLUSION:</b> The habit 
of having a complete evening meal influenced positively the micro and macronutri
ent intakes in chronic kidney failure patients on hemodialysis.#^ddecs^i2#^tm^le
n^kchronic kidney failure^i2#^tm^len^kminerals^i2#^tm^len^knutritional assessmen
t^i2#^tm^len^kvitamins^i2#^tm^len^knutritional deficiencies^i2#vancouv#38#201009
12#12/9/2010#20101230#30/12/2010#v33n1a10.htm##
05199000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000400107121000300111049000700114158000300121
03000160012403100030014003200020014306500090014501400090015403500100016301200850
01730120090002580100041003480100038003890100034004270100031004610700059004920700
05200551070004400603083172000647085001002367085004002377085002102417085003402438
08500220247208500380249408316700253208500100420208500350421208500210424708500350
42680850021043030850037043241170008043610720003043691120009043721110010043811140
00904391113001104400002001304411008008904424#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a10.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#tab#10#J
BN020#nd#J. Bras. Nefrol#33#1#20110300#^f69^l77#0101-2800#Impacto do hábito de j
antar sobre o perfil dietético de pacientes em hemodiálise^lpt#Effects of custom
ary dinner on dietetical profile of patients undergoing hemodialysis^len#^rND^1A
01^nMarcia Machado Cunha^sRibeiro#^rND^1A02^nMelissa Luciana de^sAraújo#^rND^1A0
1^nMichele Pereira^sNetto#^rND^1A03^nLucas Maciel^sCunha#^iA01^1Universidade Jos
é do Rosário Vellano - UNIFENAS^sMG#^iA02^1Centro Universitário UNA^cBelo Horizo
nte^sMG#^iA03^1Universidade Federal de Minas Gerais#^lpt^aOBJETIVO: Analisar os 
efeitos do comportamento alimentar, entre o hábito de jantar ou não jantar, no p
erfil de ingestão de macronutrientes e micronutrientes de pacientes com insufici
ência renal crônica em hemodiálise. MÉTODO: Estudo transversal em uma clínica de
 diálise de Belo Horizonte, em Minas Gerais. Participaram do estudo 90 pacientes
 em tratamento hemodialítico. Foram coletados dados pessoais, clínicos e dietéti
cos (registro alimentar de três dias). Foi considerado jantar uma refeição compl
eta e não jantar a sua ausência ou substituição por lanches. As estimativas das 
quantidades de nutrientes ingeridos foram feitas em software específico Dietwin®
. RESULTADOS: Os valores de carboidrato, tiamina, riboflavina, ácido ascórbico, 
cálcio e selênio ingeridos não apresentaram diferença entre os grupos de pacient
es que jantavam e não jantavam (p &gt; 0,05). Os valores de Índice de Massa Corp
oral (IMC), energia, proteína, lipídeos, niacina, ácido pantotênico, piridoxina,
 ácido fólico, cobalamina, potássio, fósforo, zinco e magnésio ingeridos apresen
taram diferença entre estes mesmos grupos (p < 0,05). Quanto às proporções de ad
equação desses nutrientes, o grupo dos que jantava apresentou maiores percentuai
s (p < 0,05), exceto para carboidratos, lipídeos, ácido pantotênico, ácido ascór
bico, potássio, cálcio e zinco. Nenhum dos pacientes apresentou valores adequado
s de ingestão de piridoxina, ácido fólico e selênio. Energia, ácido pantotênico 
e zinco apresentaram baixos percentuais de adequação em ambos os grupos. CONCLUS
ÃO: Conclui-se que o hábito de jantar influencia positivamente no consumo de mac
ro e micronutrientes em pacientes com insuficiência renal crônica submetidos à h
emodiálise.#^ddecs^i1#^tm^lpt^kinsuficiência renal crônica^i1#^tm^lpt^kminerais^
i1#^tm^lpt^kavaliação nutricional^i1#^tm^lpt^kvitaminas^i1#^tm^lpt^kdeficiências
 nutricionais^i1#^len^aINTRODUCTION: To assess the effects of the habit of havin
g evening dinner on the dietary macro- and micronutrient profile of chronic kidn
ey failure patients on hemodialysis. METHODS: Cross-sectional study carried out 
at a dialysis clinic at the city of Belo Horizonte, state of Minas Gerais. The s
tudy comprised 90 patients undergoing hemodialysis. Personal, clinical, and diet
ary (three-day food record) data were collected. The habit of having dinner was 
considered as having a complete evening meal, and the lack of that habit was con
sidered as not having it or replacing it by a fast meal. The amounts of nutrient
 intake were estimated in the specific software Dietwin®. RESULTS: The carbohydr
ate, thiamine, riboflavin, ascorbic acid, calcium, and selenium intake values sh
owed no difference between the group having a complete evening meal and that not
 having it (p &gt; 0.05). Both groups did not differ in the following: body mass
 index, and energy, protein, lipid, niacin, pantothenic acid, pyridoxine, folic 
acid, cobalamin, potassium, phosphorus, zinc, and magnesium intake values (p < 0
.05). Regarding nutrient adequacy, the complete evening meal group performed bet
ter than the other group, except for carbohydrates, lipids, pantothenic acid, as
corbic acid, potassium, calcium, and zinc (p < 0.05). None of the patients showe
d the adequate pyridoxine, folic acid, and selenium intake values. Few patients 
in both groups showed adequate energy, pantothenic acid, and zinc intake values.
 CONCLUSION: The habit of having a complete evening meal influenced positively t
he micro and macronutrient intakes in chronic kidney failure patients on hemodia
lysis.#^ddecs^i2#^tm^len^kchronic kidney failure^i2#^tm^len^kminerals^i2#^tm^len
^knutritional assessment^i2#^tm^len^kvitamins^i2#^tm^len^knutritional deficienci
es^i2#vancouv#38#20100912#12/9/2010#20101230#30/12/2010#v33n1a10.htm#Internet^ih
ttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100010##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#5#1#article#158#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a10.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#6#2#article#158#<p>&nbsp;</p>     ^cY#
v33n1a10.htm##
00443000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704021100073002001300284#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#7#3#article#158#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Impacto do h&aacu
te;bito de jantar sobre o perfil diet&eacute;tico de pacientes em hemodi&aacute;
lise </b></font></p>     ^cY#v33n1a10.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#8#4#article#158#<p>&nbsp;</p>     ^cY#
v33n1a10.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#9#5#article#158#<p>&nbsp;</p>     ^cY#
v33n1a10.htm##
00480000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704024700074002001300321#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#10#6#article#158#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Marcia Machado Cunha Ribeiro<sup>I<
/sup>; Melissa Luciana  de Ara&uacute;jo<sup>II</sup>; Michele Pereira Netto<sup
>I</sup>; Lucas Maciel Cunha<sup>III</sup></b></font></p>     ^cY#v33n1a10.htm##
00404000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704017100074002001300245#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#11#7#article#158#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Universidade Jos&eacute; d
o Ros&aacute;rio Vellano -  UNIFENAS, Campus Belo Horizonte/MG    ^cY#v33n1a10.h
tm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704009700074002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#12#8#article#158#<br>   <sup>II</sup>C
entro Universit&aacute;rio UNA, Campus Guajajaras, Belo Horizonte/MG    ^cY#v33n
1a10.htm##
00319000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704008600074002001300160#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#13#9#article#158#<br>   <sup>III</sup>
Universidade Federal  de Minas Gerais - UFMG </font></p>     ^cY#v33n1a10.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#14#10#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia
</a></font></p>     ^cY#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#15#11#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#16#12#article#158#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a10.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#17#13#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a10.htm##
00571000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033700075002001300412#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#18#14#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJETIVO: </b> Analisar os efeitos
 do comportamento alimentar, entre o h&aacute;bito de jantar ou n&atilde;o janta
r, no perfil de ingest&atilde;o de macronutrientes e micronutrientes de paciente
s com insufici&ecirc;ncia renal cr&ocirc;nica em hemodi&aacute;lise.     ^cY#v33
n1a10.htm##
00813000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704057900075002001300654#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#19#15#article#158#<br>   <b>M&Eacute;T
ODO:</b> Estudo transversal em uma cl&iacute;nica de di&aacute;lise de Belo Hori
zonte, em Minas Gerais. Participaram do estudo 90 pacientes em tratamento hemodi
al&iacute;tico. Foram coletados dados pessoais, cl&iacute;nicos e diet&eacute;ti
cos (registro alimentar de tr&ecirc;s dias). Foi considerado jantar uma refei&cc
edil;&atilde;o completa e n&atilde;o jantar a sua aus&ecirc;ncia ou substitui&cc
edil;&atilde;o por lanches. As estimativas das quantidades de nutrientes ingerid
os foram feitas em software espec&iacute;fico Dietwin<sup>&reg;</sup>.     ^cY#v
33n1a10.htm##
01396000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704116200075002001301237#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#20#16#article#158#<br>   <b>RESULTADOS
:</b> Os valores de carboidrato, tiamina, riboflavina, &aacute;cido asc&oacute;r
bico, c&aacute;lcio e sel&ecirc;nio ingeridos n&atilde;o apresentaram diferen&cc
edil;a entre os grupos de pacientes que jantavam e n&atilde;o jantavam (p &gt; 0
,05). Os valores de &Iacute;ndice de Massa Corporal (IMC), energia, prote&iacute
;na, lip&iacute;deos, niacina, &aacute;cido pantot&ecirc;nico, piridoxina, &aacu
te;cido f&oacute;lico, cobalamina, pot&aacute;ssio, f&oacute;sforo, zinco e magn
&eacute;sio ingeridos apresentaram diferen&ccedil;a entre estes mesmos grupos  (
p &lt; 0,05). Quanto &agrave;s propor&ccedil;&otilde;es de adequa&ccedil;&atilde
;o desses nutrientes, o grupo dos que jantava apresentou maiores percentuais  (p
 &lt; 0,05), exceto para carboidratos, lip&iacute;deos, &aacute;cido pantot&ecir
c;nico, &aacute;cido asc&oacute;rbico, pot&aacute;ssio, c&aacute;lcio e zinco. N
enhum dos pacientes apresentou valores adequados de ingest&atilde;o de piridoxin
a, &aacute;cido f&oacute;lico e sel&ecirc;nio. Energia, &aacute;cido pantot&ecir
c;nico e zinco apresentaram baixos percentuais de adequa&ccedil;&atilde;o em amb
os os grupos.     ^cY#v33n1a10.htm##
00488000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025400075002001300329#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#21#17#article#158#<br>   <b>CONCLUS&At
ilde;O: </b> Conclui-se que o h&aacute;bito de jantar influencia positivamente n
o consumo de macro e micronutrientes em pacientes com insufici&ecirc;ncia renal 
cr&ocirc;nica submetidos &agrave; hemodi&aacute;lise. </font></p>     ^cY#v33n1a
10.htm##
00494000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026000075002001300335#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#22#18#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b>insufici&ecirc
;ncia renal cr&ocirc;nica, minerais, avalia&ccedil;&atilde;o nutricional, vitami
nas, defici&ecirc;ncias nutricionais. </font></p> <hr size="1" noshade>     ^cY#
v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#23#19#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#24#20#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#25#21#article#158#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a10.htm##
01292000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704105800075002001301133#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#26#22#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Altera&ccedil;&otilde;es na estrutura
 da dieta v&ecirc;m sendo observadas em diversos pa&iacute;ses em desenvolviment
o. <sup>1</sup> A transi&ccedil;&atilde;o nutricional que ocorre no Brasil ocasi
ona mudan&ccedil;as no perfil de alimentos ingeridos e a crescente substitui&cce
dil;&atilde;o dos alimentos ricos em fibras, vitaminas e minerais, por produtos 
industrializados. <sup>2,3,4</sup> A redu&ccedil;&atilde;o do consumo de aliment
os que comumente comp&otilde;em as principais refei&ccedil;&otilde;es dos brasil
eiros, bem como o crescimento do consumo do p&atilde;o franc&ecirc;s, apontam o 
"lanche" como substituto do jantar. <sup>2</sup> Tais transforma&ccedil;&otilde;
es promovem a forma&ccedil;&atilde;o de novos padr&otilde;es diet&eacute;ticos e
 estas diversas pr&aacute;ticas alimentares podem oferecer diferentes resultados
 em rela&ccedil;&atilde;o ao atendimento das necessidades nutricionais, <sup>3</
sup> podendo gerar diversas car&ecirc;ncias nutricionais. </font></p>     ^cY#v3
3n1a10.htm##
00667000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043300075002001300508#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#27#23#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A desnutri&ccedil;&atilde;o encontra-
se como um dos principais determinantes de morbidade e mortalidade em pacientes 
em hemodi&aacute;lise,<sup>5,6</sup> e est&aacute; associada a uma expectativa d
e vida reduzida, pois pode ser prejudicial tamb&eacute;m sobre os resultados das
 complica&ccedil;&otilde;es infecciosas e cardiovasculares. <sup>7</sup> </font>
</p>     ^cY#v33n1a10.htm##
01165000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704093100075002001301006#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#28#24#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A desnutri&ccedil;&atilde;o energ&eac
ute;tico-prot&eacute;ica (DPE) n&atilde;o &eacute; a &uacute;nica forma de desnu
tri&ccedil;&atilde;o no paciente com insufici&ecirc;ncia renal cr&ocirc;nica (IR
C) em hemodi&aacute;lise, podendo apresentar defici&ecirc;ncia de alguns micronu
trientes como vitaminas do complexo B, vitamina C, ferro e zinco. <sup>8</sup> D
urante o procedimento dial&iacute;tico, al&eacute;m de a&ccedil;&atilde;o catab&
oacute;lica, s&atilde;o perdidos amino&aacute;cidos, pept&iacute;deos e vitamina
s hidrossol&uacute;veis para o dialisato. Entre as vitaminas hidrossol&uacute;ve
is, piridoxina, &aacute;cido asc&oacute;rbico e &aacute;cido f&oacute;lico t&eci
rc;m sido indicadas como as mais propensas a defici&ecirc;ncias,<sup>9-10</sup> 
sendo na maioria das vezes necess&aacute;ria sua suplementa&ccedil;&atilde;o. <s
up>5</sup> </font></p>     ^cY#v33n1a10.htm##
01522000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704128800075002001301363#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#29#25#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Segundo a Resolu&ccedil;&atilde;o RDC
 nº154 de 2004, o profissional nutricionista passa a compor a equipe m&iacute;ni
ma para o funcionamento das cl&iacute;nicas de di&aacute;lise. <sup>11</sup> A i
mport&acirc;ncia deste profissional na equipe deve-se &agrave; necessidade de ad
equa&ccedil;&atilde;o das necessidades nutricionais e a interven&ccedil;&otilde;
es mais eficazes. V&aacute;rios fatores levam o paciente com IRC a dist&uacute;r
bios metab&oacute;licos, hormonais e gastrointestinais e a ingest&atilde;o alime
ntar inadequada; tais como restri&ccedil;&otilde;es rigorosas na dieta, uso de m
edicamentos que podem influenciar na absor&ccedil;&atilde;o de nutrientes, di&aa
cute;lise insuficiente e constantes enfermidades intercorrentes. Al&eacute;m dis
so, a uremia, a acidose metab&oacute;lica, a anorexia, n&aacute;useas, v&ocirc;m
itos e perda de nutrientes no dialisato s&atilde;o fatores que interferem e aume
ntam o catabolismo prot&eacute;ico. <sup>5,6,12</sup> Evid&ecirc;ncias apontam q
ue o estado nutricional do paciente com insufici&ecirc;ncia renal come&ccedil;a 
a decair quando a redu&ccedil;&atilde;o das taxas de filtra&ccedil;&atilde;o glo
merular ainda s&atilde;o modestas. <sup>13</sup></font></p>     ^cY#v33n1a10.htm
##
00771000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053700075002001300612#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#30#26#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Devido &agrave; escassez de estudos q
ue abordem o perfil diet&eacute;tico, os h&aacute;bitos alimentares e suas inter
fer&ecirc;ncias na ingest&atilde;o de micronutrientes em pacientes adultos com I
RC em tratamento hemodial&iacute;tico, o presente estudo objetivou analisar o co
mportamento alimentar desta popula&ccedil;&atilde;o, no que se refere ao h&aacut
e;bito de jantar e n&atilde;o jantar, juntamente com ingest&atilde;o de macro e 
micronutrientes. </font></p>     ^cY#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#31#27#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#32#28#article#158#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>MATERIAL E M&Eacute;TODOS</b></fon
t></p>     ^cY#v33n1a10.htm##
01457000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704122300075002001301298#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#33#29#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trata-se de um estudo transversal, re
alizado no primeiro trimestre de 2010, com pacientes de hemodi&aacute;lise de um
a cl&iacute;nica de di&aacute;lise, CENEMGE - Centro Nefrol&oacute;gico de Minas
 Gerais, em Belo Horizonte/ MG, que realizavam di&aacute;lise tr&ecirc;s vezes n
a semana em um per&iacute;odo de quatro horas di&aacute;rias. Esse estudo foi ap
rovado pelo Comit&ecirc; de &Eacute;tica da UNIFENAS sob o parecer de nº04/2010.
 Dos 183 pacientes em tratamento hemodial&iacute;tico, 90 participaram da pesqui
sa. A sele&ccedil;&atilde;o destes pacientes foi realizada aleatoriamente e a di
vis&atilde;o dos grupos foi feita a <i>posteriori. </i> Foram exclu&iacute;dos o
s pacientes que apresentavam idade inferior a 18 anos, problemas neurol&oacute;g
icos e psiqui&aacute;tricos, com surdez, mudez, defici&ecirc;ncia visual, doen&c
cedil;as card&iacute;acas, neopl&aacute;sicas e pulmonares graves, com per&iacut
e;odo inferior a tr&ecirc;s meses de tratamento de hemodi&aacute;lise, pacientes
 que n&atilde;o apresentavam h&aacute;bitos alimentares definidos e sub ou super
estima&ccedil;&atilde;o de ingest&atilde;o alimentar evidente. </font></p>     ^
cY#v33n1a10.htm##
01296000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704106200075002001301137#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#34#30#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram coletados atrav&eacute;s de ent
revista direta com o paciente dados pessoais (idade, sexo), socioecon&ocirc;mico
s (escolaridade, renda familiar, estado conjugal). Paladar e olfa&ccedil;&atilde
;o foram pesquisados atrav&eacute;s de perguntas diretas se preservados ou n&ati
lde;o. Quanto ao apetite, se este se apresentava normal, aumentado ou diminu&iac
ute;do. Em rela&ccedil;&atilde;o &agrave; fun&ccedil;&atilde;o intestinal, os pa
cientes foram arguidos a respeito da sua normalidade, diarr&eacute;ia ou obstipa
&ccedil;&atilde;o. Tamb&eacute;m se perguntou a estes sujeitos se havia ocorr&ec
irc;ncias de n&aacute;useas e enj&ocirc;os. Al&eacute;m disso, foi questionado a
os entrevistados h&aacute;bitos (h&aacute;bitos de jantar e frequ&ecirc;ncia ali
mentar), ades&atilde;o &agrave;s recomenda&ccedil;&otilde;es nutricionais e cl&i
acute;nicas (doen&ccedil;as de base e comorbidades). O entrevistador foi previam
ente treinado para evitar indu&ccedil;&atilde;o de respostas. </font></p>     ^c
Y#v33n1a10.htm##
02387000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704215300075002001302228#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#35#31#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os inqu&eacute;ritos alimentares serv
iram de subs&iacute;dios para a sele&ccedil;&atilde;o dos pacientes que realizav
am o jantar ou n&atilde;o. O estudo considerou a refei&ccedil;&atilde;o jantar c
omo uma refei&ccedil;&atilde;o similar ao almo&ccedil;o, composta por cereais, l
egumes, verduras e prepara&ccedil;&atilde;o prot&eacute;ica (carnes, ovos). Logo
, pacientes que n&atilde;o realizavam a refei&ccedil;&atilde;o jantar foram aque
les que n&atilde;o a consumiam ou a substitu&iacute;am por outro padr&atilde;o d
e refei&ccedil;&atilde;o como, por exemplo, lanches. Para a quantifica&ccedil;&a
tilde;o do consumo alimentar foram utilizadas as aplica&ccedil;&otilde;es de tr&
ecirc;s inqu&eacute;ritos alimentares, dois pelo m&eacute;todo retrospectivo rec
ordat&oacute;rio 24 horas, sendo um dia de hemodi&aacute;lise, um dia de semana 
sem procedimento dial&iacute;tico e um registro alimentar de um dia de final de 
semana. As coletas de dados dos dois recordat&oacute;rios foram realizadas imedi
atamente antes ou durante a sess&atilde;o de di&aacute;lise em dias diferentes e
 o registro alimentar foi preenchido pelo paciente ou familiar previamente instr
u&iacute;do. A associa&ccedil;&atilde;o desses m&eacute;todos foi utilizada para
 conhecer melhor a estrutura diet&eacute;tica dos pacientes durante toda a seman
a. As quantidades dos alimentos consumidos foram estimadas em medidas caseiras, 
ilustradas por um registro fotogr&aacute;fico<sup>14</sup> e apresentadas ao pac
iente para certifica&ccedil;&atilde;o da quantidade alimentar ingerida e posteri
ormente convertidas em gramas ou mililitros. Foi utilizado software de nutri&cce
dil;&atilde;o Dietwin (Vers&atilde;o 8.0) para a quantifica&ccedil;&atilde;o die
t&eacute;tica dos recordat&oacute;rios e tabelas da Taco e Dietwin, para informa
&ccedil;&otilde;es nutricionais dos alimentos conforme prepara&ccedil;&atilde;o 
consumida pelos pacientes (crus ou cozidos). Os resultados obtidos dos recordat&
oacute;rios alimentares foram comparados com tabelas de refer&ecirc;ncia para pa
cientes com IRC. <sup>15-16</sup></font></p>     ^cY#v33n1a10.htm##
00919000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704068500075002001300760#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#36#32#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram analisados par&acirc;metros bio
qu&iacute;micos ureia pr&eacute;, ureia p&oacute;s, creatinina, albumina (verde 
de bromcresol),<sup>6</sup> pot&aacute;ssio s&eacute;rico, f&oacute;sforo s&eacu
te;rico. A efici&ecirc;ncia da di&aacute;lise foi estimada atrav&eacute;s do Kt/
V (Daugirdas II). <sup>6</sup> Como par&acirc;metro antropom&eacute;trico, foi u
tilizado o c&aacute;lculo de &iacute;ndice de massa corporal (IMC), raz&atilde;o
 do peso e o quadrado da altura, sendo este o peso seco, pois o estado de hidrat
a&ccedil;&atilde;o pode influenciar significativamente essa avalia&ccedil;&atild
e;o. </font></p>     ^cY#v33n1a10.htm##
01340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704110600075002001301181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#37#33#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise estat&iacute;stica d
as vari&aacute;veis foi realizada mediante o c&aacute;lculo dos intervalos com 9
5% de confian&ccedil;a, das frequ&ecirc;ncias, medianas e valores extremos (m&ia
cute;nimo e m&aacute;ximo). A verifica&ccedil;&atilde;o da n&atilde;o parametric
idade das vari&aacute;veis quantitativas foi avaliada pelo teste "W" de Shapiro-
Wilk. Nas an&aacute;lises estat&iacute;sticas inferenciais, o teste de Mann &amp
; Whitney foi utilizado para compara&ccedil;&otilde;es entre dois grupos experim
entais. <sup>17</sup> Tamb&eacute;m foram realizadas as compara&ccedil;&otilde;e
s entre propor&ccedil;&otilde;es de grupos de pacientes. <sup>18</sup> As vari&a
acute;veis, brutas ou transformadas, que apresentaram distribui&ccedil;&atilde;o
 param&eacute;trica foram comparadas atrav&eacute;s do teste t de Student, consi
derando diferentes aquelas cujo n&iacute;vel de signific&acirc;ncia foi igual ou
 inferior a 5%. <sup>17</sup> Para as an&aacute;lises foi utilizado o programa S
tata, vers&atilde;o 10.0. </font></p>     ^cY#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#38#34#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#39#35#article#158#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v33n1a10.htm##
01346000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704111200075002001301187#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#40#36#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pacientes apresentaram maior predo
min&acirc;ncia do sexo masculino (63,3% ± 10,0%). A maior parte dos indiv&iacute
;duos concentrou-se na faixa et&aacute;ria de 46 a 75 anos (68,9% ± 11,5%), send
o que a m&eacute;dia de idade foi de 55,9 ± 14,7 anos (variando de 19 a 87 anos)
. Com rela&ccedil;&atilde;o &agrave;s caracter&iacute;sticas socioecon&ocirc;mic
as, verificou-se o predom&iacute;nio de indiv&iacute;duos casados ou em uni&atil
de;o est&aacute;vel (68,9% ± 11,5%). Quanto ao grau de escolaridade, 62,2% (± 12
,7%) dos indiv&iacute;duos n&atilde;o estudaram al&eacute;m do ensino fundamenta
l. Com rela&ccedil;&atilde;o &agrave; renda familiar, houve uma maior propor&cce
dil;&atilde;o de indiv&iacute;duos de baixa renda, com at&eacute; tr&ecirc;s sal
&aacute;rios m&iacute;nimos (51,6% ± 14,4%). Nas vari&aacute;veis turno, sexo, t
empo de di&aacute;lise, frequ&ecirc;ncia das diferentes comorbidades e frequ&eci
rc;ncia das doen&ccedil;as de base n&atilde;o foram verificadas diferen&ccedil;a
s significativas (p &lt; 0,05). </font></p>     ^cY#v33n1a10.htm##
01226000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704099200075002001301067#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#41#37#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o aos sinais c
l&iacute;nicos e sintomas da popula&ccedil;&atilde;o estudada, os achados eviden
ciaram que a grande maioria n&atilde;o apresentava n&aacute;usea ou enj&ocirc;o 
(87,8% ± 6,8%) e apresentava preservados paladar (94,4% ± 4,8%), olfa&ccedil;&at
ilde;o (94,4% ± 4,8%) e apetite (77,8% ± 8,6%). A fun&ccedil;&atilde;o intestina
l apresentou-se normal em 83,3% (± 7,7%) dos pacientes, embora 14,4% (± 7,3%) ap
resentaram obstipa&ccedil;&atilde;o. A principal doen&ccedil;a de base diagnosti
cada foi nefroesclerose hipertensiva (53,3% ± 10,4), seguida de nefropatia diab&
eacute;tica (22,2% ± 8,6%), glomerulopatias (11,1% ± 6,5%), rim polic&iacute;sti
co (6,7% ± 5,2%), dentre outras. Al&eacute;m disso, as principais comorbidades f
oram hipertens&atilde;o arterial sist&ecirc;mica (97,8% ± 3,1%), <i>diabetes mel
litus</i> (30% ± 9,5%), 27,8% (± 9,3%) com cardiopatias, dentre outras. </font><
/p>     ^cY#v33n1a10.htm##
01040000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080600075002001300881#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#42#38#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quando analisados os h&aacute;bitos a
limentares, a maioria dos indiv&iacute;duos fracionava suas refei&ccedil;&otilde
;es em 4-5 vezes ao dia e possu&iacute;am o h&aacute;bito de jantar, realizando 
suas refei&ccedil;&otilde;es no domic&iacute;lio. A maioria afirmou seguir as or
ienta&ccedil;&otilde;es nutricionais, sendo essas orienta&ccedil;&otilde;es inic
iais ao tratamento e mensais, por material impresso ou verbal realizado por nutr
icionista. Cerca da metade (47 pacientes) realizava as t&eacute;cnicas de proces
samento de pot&aacute;ssio. A escolha pessoal foi o maior motivo para a n&atilde
;o ades&atilde;o das recomenda&ccedil;&otilde;es nutricionais (<a href="/img/rev
istas/jbn/v33n1/a10tab01m.jpg">Tabela 1</a>). </font></p>     ^cY#v33n1a10.htm##
00692000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045800075002001300533#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#43#39#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">V&aacute;rios nutrientes apresentaram
 diferen&ccedil;as nos valores de ingest&atilde;o entre os pacientes que realiza
vam o jantar em rela&ccedil;&atilde;o aos que n&atilde;o jantavam, com exce&cced
il;&atilde;o do carboidrato, tiamina, riboflavina, &aacute;cido asc&oacute;rbico
, c&aacute;lcio e o sel&ecirc;nio (<a href="/img/revistas/jbn/v33n1/a10tab02m.jp
g">Tabela 2</a>). </font></p>     ^cY#v33n1a10.htm##
00668000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043400075002001300509#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#44#40#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As propor&ccedil;&otilde;es de adequa
&ccedil;&atilde;o dos nutrientes quanto ao h&aacute;bito alimentar de jantar for
am mostradas na <a href="/img/revistas/jbn/v33n1/a10tab03m.jpg">Tabela 3</a>, e 
indicam que pacientes que jantavam ingeriram maiores quantidades da maioria dos 
nutrientes quando comparados com os que n&atilde;o jantavam. <sup>24</sup></font
></p>     ^cY#v33n1a10.htm##
00575000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034100075002001300416#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#45#41#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados antropom&eacute;tricos e bio
qu&iacute;micos foram relacionados de acordo com o h&aacute;bito de jantar ou n&
atilde;o jantar e apenas o IMC apresentou signific&acirc;ncia  (p &lt; 0,05) (<a
 href="/img/revistas/jbn/v33n1/a10tab04m.jpg">Tabela 4</a>). </font></p>     ^cY
#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#46#42#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#47#43#article#158#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v33n1a10.htm##
02211000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704197700075002001302052#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#48#44#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No grupo avaliado a maior parte da po
pula&ccedil;&atilde;o era do sexo masculino, assim como no censo 2008<sup>19</su
p> e v&aacute;rios outros trabalhos brasileiros. <sup>20-25 </sup>Houve predomin
&acirc;ncia de adultos e idosos, o que diferiu das pesquisas de Cabral <i>et al<
/i>. <sup>20</sup> e Freitas <i>et al. </i>,<sup>26</sup> possivelmente devido &
agrave;s preval&ecirc;ncias de doen&ccedil;as de base. A baixa escolaridade e a 
baixa renda, como verificado em outros trabalhos,<sup>20,21,25,26,27 </sup>poder
iam influenciar na compreens&atilde;o e ades&atilde;o &agrave;s orienta&ccedil;&
otilde;es nutricionais dadas aos pacientes pelo setor de nutri&ccedil;&atilde;o 
e poderiam contribuir para a baixa taxa de adequa&ccedil;&atilde;o dos nutriente
s da dieta. A principal doen&ccedil;a de base entre os pacientes estudados foi n
efrosclerose hipertensiva, seguida de nefropatia diab&eacute;tica, assim como no
 censo 2008,<sup>19</sup> e nos estudos de Cardozo <i>et al. </i>,<sup>22</sup> 
Batista <i>et al</i>. ,<sup>24</sup> e Morais <i>et al</i>. ,<sup>28</sup> que n
ormalmente s&atilde;o agravos que surgem na idade adulta ou em idosos.Tais frequ
&ecirc;ncias observadas diferiram dos trabalhos de Cabral <i>et al</i>. ,<sup>20
</sup> Santos <i>et al</i>. ,<sup>25</sup> Freitas <i>et al</i>. <sup>26</sup> e
 Valenzuela <i>et al</i>. ;<sup>27</sup> que tiveram como principal etiologia da
 doen&ccedil;a renal cr&ocirc;nica (DRC) a glomerulonefrite cr&ocirc;nica, que n
ormalmente acomete popula&ccedil;&otilde;es mais jovens. Os valores m&eacute;dio
s de IMC encontrados foram similares aos resultados de Valenzuela <i>et al</i>. 
,<sup>27</sup> por&eacute;m tratam-se de grupos distintos, sendo necess&aacute;r
ios outros estudos para tal compara&ccedil;&atilde;o. Em rela&ccedil;&atilde;o a
os exames bioqu&iacute;micos, o estudo n&atilde;o encontrou signific&acirc;ncia 
entre os grupos. </font></p>     ^cY#v33n1a10.htm##
01140000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090600075002001300981#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#49#45#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quanto aos h&aacute;bitos alimentares
, verificou-se que grande parte da popula&ccedil;&atilde;o possu&iacute;a o h&aa
cute;bito de jantar e fracionava suas refei&ccedil;&otilde;es em 4-5 vezes ao di
a, em seus domic&iacute;lios, sugerindo que a fam&iacute;lia possa ter grande in
flu&ecirc;ncia nos h&aacute;bitos alimentares dos pacientes. Portanto, novos est
udos devem ser conduzidos para verificar tal hip&oacute;tese. Os grupos de pacie
ntes que jantavam e n&atilde;o jantavam n&atilde;o apresentaram diferen&ccedil;a
s quanto ao turno de di&aacute;lise, sexo, tempo de di&aacute;lise, frequ&ecirc;
ncia das diferentes comorbidades e frequ&ecirc;ncia das doen&ccedil;as de base e
studadas, possivelmente devido &agrave; amostra ser aleat&oacute;ria e a sele&cc
edil;&atilde;o dos grupos ter sido realizada <i>a posteriori. </i></font></p>   
  ^cY#v33n1a10.htm##
01186000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704095200075002001301027#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#50#46#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Diferen&ccedil;as de ingest&atilde;o 
cal&oacute;rica e prot&eacute;ica foram verificadas entre os grupos de pessoas q
ue jantavam e que n&atilde;o jantavam. O grupo de pacientes que jantava apresent
ou maiores valores medianos desses par&acirc;metros. Entretanto, n&atilde;o ocor
reram diferen&ccedil;as entre as propor&ccedil;&otilde;es de pacientes energetic
amente adequados. A maior parte dos pacientes estava inadequada nos dois grupos.
 No entanto, os valores de IMC apresentaram-se maiores nos pacientes que n&atild
e;o realizavam o jantar, o que mostra que a avalia&ccedil;&atilde;o do consumo e
nerg&eacute;tico deve ser considerada em conjunto &agrave; condi&ccedil;&atilde;
o corporal do paciente juntamente com os &iacute;ndices de adequa&ccedil;&atilde
;o (35 kcal/kg/dia pacientes at&eacute; 60 anos e <u>&gt;</u> 30 kcal/kg/dia <u>
&gt;</u> 60 anos). <sup>16</sup></font></p>     ^cY#v33n1a10.htm##
01236000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704100200075002001301077#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#51#47#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O consumo prot&eacute;ico de aproxima
damente 30% dos pacientes com h&aacute;bito de jantar, e aproximadamente 50% dos
 que n&atilde;o jantam, esteve abaixo da recomenda&ccedil;&atilde;o 1,2 g/kg/dia
, conforme diretrizes de nutri&ccedil;&atilde;o do NKF-K/DOQI. <sup>15</sup> Val
ores de ingest&atilde;o prot&eacute;ica abaixo das recomenda&ccedil;&otilde;es c
oncordam com resultados de v&aacute;rios outros estudos,<sup>20,24,26-29</sup> o
 que sugere balan&ccedil;o nitrogenado negativo, o que comprometeria o estado nu
tricional do paciente em hemodi&aacute;lise. Estudos de Slomowitz <i>et al. </i>
<sup>30</sup> indicam que alguns pacientes n&atilde;o conseguem manter balan&cce
dil;o prot&eacute;ico com ingest&atilde;o energ&eacute;tica em torno de 25 e 35 
kcal/kg/dia e ingest&atilde;o prot&eacute;ica de 1,1 g/kg/dia, precisando de ing
est&atilde;o um pouco maior, 1,2 g/kg/dia, sem que haja toxicidade ur&ecirc;mica
. </font></p>     ^cY#v33n1a10.htm##
01084000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704085000075002001300925#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#52#48#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Entre o grupo dos que n&atilde;o jant
avam, valores de consumo lip&iacute;dico encontraram-se maiores do que em pacien
tes com o h&aacute;bito de jantar. Associado a esse achado, os valores de carboi
dratos foram semelhantes entre os grupos, sugerindo que os lanches normalmente s
ubstitutos do jantar s&atilde;o mais ricos em lip&iacute;deos e possuem menores 
quantidades de prote&iacute;nas. Semelhan&ccedil;as de adequa&ccedil;&atilde;o e
m valores de carboidratos tamb&eacute;m foram encontradas em outros estudos. <su
p>21</sup> Uma ingest&atilde;o equilibrada de carboidratos e lip&iacute;deos &ea
cute; importante para suprir a necessidade cal&oacute;rica total e para que as p
rote&iacute;nas ingeridas n&atilde;o sejam utilizadas como fonte de energia. <su
p>10</sup></font></p>     ^cY#v33n1a10.htm##
01380000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704114600075002001301221#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#53#49#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Existem poucos estudos relacionados a
o consumo de micronutrientes na popula&ccedil;&atilde;o dos pacientes com IRC. A
s vitaminas hidrossol&uacute;veis fazem parte de um grupo de vitaminas que, norm
almente, s&atilde;o perdidas no procedimento hemodial&iacute;tico, nas t&eacute;
cnicas de processamento para retirada do pot&aacute;ssio, devido &agrave; interf
er&ecirc;ncia de medica&ccedil;&otilde;es na sua absor&ccedil;&atilde;o, na excr
e&ccedil;&atilde;o ou no metabolismo das vitaminas. <sup>31</sup> Al&eacute;m di
sso, as restri&ccedil;&otilde;es diet&eacute;ticas com baixos teores de f&oacute
;sforo e pot&aacute;ssio podem contribuir para a limita&ccedil;&atilde;o da inge
st&atilde;o de alimentos como frutas, hortali&ccedil;as, latic&iacute;nios, carn
es e outros alimentos ricos em vitaminas. <sup>32</sup> No presente estudo, veri
ficou-se a baixa adequa&ccedil;&atilde;o dessas vitaminas no consumo alimentar d
os pacientes, mesmo quando comparados com os que tinham o h&aacute;bito de janta
r, se diferindo ainda mais quando n&atilde;o realizavam o jantar. </font></p>   
  ^cY#v33n1a10.htm##
00927000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704069300075002001300768#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#54#50#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Mais da metade da popula&ccedil;&atil
de;o apresentou valores adequados de ingest&atilde;o das vitaminas tiamina, ribo
flavina e niacina. Entretanto, a porcentagem de adequa&ccedil;&atilde;o encontro
u-se maior em pacientes que realizavam o jantar, sugerindo que a maior ingest&at
ilde;o de fontes prot&eacute;icas, cereais, legumes e verduras possa contribuir 
para estes resultados. Allman <i>et al. </i><sup>33</sup> relataram n&atilde;o s
er comum a incid&ecirc;ncia de defici&ecirc;ncia dessas vitaminas em pacientes e
m hemodi&aacute;lise, talvez pela grande biodisponibilidade desses nutrientes no
s alimentos. </font></p>     ^cY#v33n1a10.htm##
00764000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053000075002001300605#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#55#51#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quanto &agrave; ingest&atilde;o de &a
acute;cido pantot&ecirc;nico houve diferen&ccedil;a em rela&ccedil;&atilde;o ao 
h&aacute;bito de jantar ou n&atilde;o jantar, embora em ambas as popula&ccedil;&
otilde;es, a propor&ccedil;&atilde;o de pacientes com ingest&atilde;o adequada s
eja baixa e semelhante. Tais resultados indicam rela&ccedil;&atilde;o com baixo 
consumo nesta popula&ccedil;&atilde;o de fontes alimentares dessa vitamina. <sup
>35</sup> </font></p>     ^cY#v33n1a10.htm##
01054000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704082000075002001300895#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#56#52#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os valores de ingest&atilde;o de piri
doxina e o &aacute;cido f&oacute;lico estiveram abaixo das recomenda&ccedil;&oti
lde;es<sup>15</sup> em todos os pacientes analisados neste estudo. Allman <i>et 
al. </i><sup>33</sup> sugerem que a suplementa&ccedil;&atilde;o e a orienta&cced
il;&atilde;o alimentar sejam necess&aacute;rias para adequa&ccedil;&atilde;o des
ses valores, j&aacute; que a defici&ecirc;ncia dessas vitaminas pode comprometer
 o metabolismo da homociste&iacute;na e propiciar maiores riscos aterog&ecirc;ni
cos,<sup>31</sup> al&eacute;m de quadros de anemias e tamb&eacute;m por estar as
sociada ao metabolismo de triptofano, o que pode levar a altera&ccedil;&otilde;e
s depressivas, ins&ocirc;nia e irritabilidade. <sup>35</sup></font></p>     ^cY#
v33n1a10.htm##
01124000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704089000075002001300965#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#57#53#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No presente estudo, pacientes com h&a
acute;bito de jantar apresentaram valores maiores de adequa&ccedil;&atilde;o de 
ingest&atilde;o de cobalamina quando comparados ao grupo dos que n&atilde;o jant
avam. O consumo adequado dessa vitamina auxilia no metabolismo do &aacute;cido f
&oacute;lico e, consequentemente, no da homociste&iacute;na, uma vez que a defic
i&ecirc;ncia de &aacute;cido f&oacute;lico neste estudo e segundo outros autores
 foi relevante. <sup>33</sup> Segundo Descombes <i>et al. </i><sup>9</sup> a sup
lementa&ccedil;&atilde;o de cobalamina n&atilde;o &eacute; necess&aacute;ria dev
ido a sua defici&ecirc;ncia ser incomum em pacientes com IRC. Isso sugere que, u
ma adequa&ccedil;&atilde;o no consumo alimentar seja suficiente para alcan&ccedi
l;ar as recomenda&ccedil;&otilde;es nutricionais. </font></p>     ^cY#v33n1a10.h
tm##
00606000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037200075002001300447#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#58#54#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o &agrave; ing
est&atilde;o do &aacute;cido asc&oacute;rbico, n&atilde;o houve diferen&ccedil;a
 entre os grupos. Estes resultados se explicam devido ao fato de os alimentos fo
ntes, como as frutas c&iacute;tricas, n&atilde;o serem comuns nessa refei&ccedil
;&atilde;o. </font></p>     ^cY#v33n1a10.htm##
00791000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055700075002001300632#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#59#55#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Entre o consumo diet&eacute;tico dos 
minerais, o estudo demonstrou que a grande maioria dos pacientes n&atilde;o apre
sentou ingest&atilde;o excessiva de pot&aacute;ssio, o que corrobora com o resul
tado do estudo de Scapin <i>et al. </i><sup>29</sup> Embora n&atilde;o tenha hav
ido diferen&ccedil;a na propor&ccedil;&atilde;o de adequa&ccedil;&atilde;o dos g
rupos, os indiv&iacute;duos que jantam possivelmente ingerem maior quantidade de
 alimentos fonte de pot&aacute;ssio. </font></p>     ^cY#v33n1a10.htm##
00580000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034600075002001300421#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#60#56#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quanto &agrave; ingest&atilde;o de f&
oacute;sforo, notou-se que a maior parte dos indiv&iacute;duos n&atilde;o estava
 acima dos valores recomendados, de forma semelhante ao observado por Valenzuela
 <i>et al. </i><sup>27 </sup>e Pinto <i>et al. </i><sup> 34</sup> </font></p>   
  ^cY#v33n1a10.htm##
01553000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704131900075002001301394#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#61#57#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Pacientes com IRC em hemodi&aacute;li
se possuem necessidade de dieta hiperproteica, e as fontes de prote&iacute;na co
mumente s&atilde;o ricas em f&oacute;sforo. As orienta&ccedil;&otilde;es de rest
ri&ccedil;&atilde;o de f&oacute;sforo da dieta s&atilde;o importantes para que h
aja a homeostase do c&aacute;lcio e do f&oacute;sforo na manuten&ccedil;&atilde;
o da massa &oacute;ssea, uma vez que a hemodi&aacute;lise n&atilde;o &eacute; um
 m&eacute;todo eficiente de remo&ccedil;&atilde;o deste mineral. Os alimentos ri
cos em c&aacute;lcio comumente s&atilde;o ricos em f&oacute;sforo, logo, pacient
es com IRC em hemodi&aacute;lise, em geral, n&atilde;o devem consumir grandes qu
antidades de tais alimentos. <sup>6,16</sup> Neste estudo, a quantidade de c&aac
ute;lcio ingerida e a propor&ccedil;&atilde;o de indiv&iacute;duos com ingest&at
ilde;o adequada deste mineral n&atilde;o diferiu nas popula&ccedil;&otilde;es qu
e jantava ou n&atilde;o jantava. Os resultados dos estudos de Cabral <i>et al. <
/i>,<sup>20</sup> Batista <i>et al. </i>,<sup>24</sup> Freitas <i>et al. </i>,<s
up>26</sup> Valenzuela <i>et al. </i><sup>27</sup> foram semelhantes aos deste e
studo, com valores abaixo do limite m&aacute;ximo recomendado. <sup>15,16</sup><
/font></p>     ^cY#v33n1a10.htm##
01138000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090400075002001300979#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#62#58#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A ingest&atilde;o de sel&ecirc;nio n&
atilde;o diferiu nos grupos de pacientes que jantavam ou n&atilde;o e nenhum del
es obteve o valor m&iacute;nimo recomendado para pacientes saud&aacute;veis,<sup
>35</sup> uma vez que n&atilde;o foram encontrados na literatura valores de refe
r&ecirc;ncia de ingest&atilde;o desse nutriente para pacientes com IRC em hemodi
&aacute;lise. Tais resultados se devem &agrave; ingest&atilde;o de sel&ecirc;nio
 estar primariamente associada &agrave; ingest&atilde;o de fontes prot&eacute;ic
as,<sup>10</sup> al&eacute;m disso, a quantidade desse mineral &eacute; muito va
ri&aacute;vel de acordo com o tipo de solo. <sup>35</sup> Outro fator relevante 
&eacute; o fato das tabelas brasileiras de composi&ccedil;&atilde;o de alimentos
 serem deficit&aacute;rias quanto aos valores de sel&ecirc;nio. </font></p>     
^cY#v33n1a10.htm##
00977000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074300075002001300818#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#63#59#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o aos valores 
de ingest&atilde;o de magn&eacute;sio, foram constatadas diferen&ccedil;as entre
 os grupos de pacientes que jantavam e n&atilde;o jantavam sugerindo rela&ccedil
;&atilde;o com o consumo prot&eacute;ico, al&eacute;m das maiores fontes de magn
&eacute;sio serem vegetais folhosos, legumes, e castanhas,<sup>35</sup> tamb&eac
ute;m ricos em pot&aacute;ssio e de consumo moderado por pacientes com IRC em he
modi&aacute;lise. A propor&ccedil;&atilde;o de adequa&ccedil;&atilde;o apresenta
 diferen&ccedil;a entre os grupos que jantam e n&atilde;o jantam, e os maiores v
alores encontram-se nos pacientes com h&aacute;bito de jantar. </font></p>     ^
cY#v33n1a10.htm##
01086000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704085200075002001300927#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#64#60#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De forma semelhante ao presente estud
o, a baixa ingest&atilde;o de zinco pode ser observada em pacientes com IRC em h
emodi&aacute;lise nos estudos de Cabral <i>et al. </i><sup>36</sup> O h&aacute;b
ito de jantar n&atilde;o influenciou significativamente na propor&ccedil;&atilde
;o de indiv&iacute;duos com ingest&atilde;o adequada desse mineral. Conforme tra
balho de Mafra e Cozzolino,<sup>37</sup> que obtiveram m&eacute;dia de ingest&at
ilde;o de 6,3 mg/dia, o consumo deste mineral ficou reduzido principalmente com 
uma dieta lipoproteica. A defici&ecirc;ncia de zinco em pacientes com IRC em hem
odi&aacute;lise tem sido ligada aos sintomas de perda do apetite, diminui&ccedil
;&atilde;o do paladar e do olfato;<sup>6</sup> fato este n&atilde;o observado ne
ste estudo. </font></p>     ^cY#v33n1a10.htm##
00756000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052200075002001300597#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#65#61#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados refor&ccedil;am a impor
t&acirc;ncia de um trabalho em conjunto entre o m&eacute;dico e o nutricionista 
com o objetivo de avaliar individualmente uma poss&iacute;vel suplementa&ccedil;
&atilde;o de vitaminas e minerais levando em considera&ccedil;&atilde;o seus h&a
acute;bitos alimentares para adequa&ccedil;&atilde;o &agrave;s necessidades de i
ngest&atilde;o segundo recomenda&ccedil;&otilde;es da literatura. <sup>15,16</su
p></font></p>     ^cY#v33n1a10.htm##
01002000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704076800075002001300843#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#66#62#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nos estudos diet&eacute;ticos n&atild
e;o existe um m&eacute;todo padr&atilde;o ouro para avaliar a ingest&atilde;o al
imentar. As ferramentas existentes, tais como recordat&oacute;rio e registro ali
mentar, s&atilde;o consideradas eficientes quando bem aplicadas,<sup>38</sup> de
 forma que esses m&eacute;todos s&atilde;o frequentemente utilizados em pesquisa
s. Tais ferramentas s&atilde;o pass&iacute;veis de vi&eacute;s uma vez que o rel
ato do paciente pode sofrer sub ou superestima&ccedil;&atilde;o do consumo diet&
eacute;tico. Portanto, a import&acirc;ncia de uma boa transcri&ccedil;&atilde;o 
do relato do paciente poderia minimizar esta limita&ccedil;&atilde;o da t&eacute
;cnica. </font></p>     ^cY#v33n1a10.htm##
00640000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040600075002001300481#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#67#63#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outra quest&atilde;o a ser discutida 
&eacute; o fato de as tabelas brasileiras n&atilde;o apresentarem informa&ccedil
;&otilde;es completas a respeito de todos os nutrientes encontrados nos alimento
s. Isso possui grande relev&acirc;ncia, uma vez que seria extremamente important
e a avalia&ccedil;&atilde;o delas nas dietas. </font></p>     ^cY#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#68#64#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#69#65#article#158#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Atilde;O</b></font></p>   
  ^cY#v33n1a10.htm##
01466000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704123200075002001301307#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#70#66#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Conclui-se que o h&aacute;bito de jan
tar influencia positivamente no consumo de macro e micronutrientes em pacientes 
com IRC submetidos &agrave; hemodi&aacute;lise, uma vez que esses pacientes apre
sentaram valores mais adequados de ingest&atilde;o destes compostos, de acordo c
om as recomenda&ccedil;&otilde;es espec&iacute;ficas para esta popula&ccedil;&at
ilde;o. O nutricionista, membro da equipe multidisciplinar, tem habilidades para
 conhecer, avaliar e adequar individualmente &agrave; ingest&atilde;o alimentar 
de seus pacientes. Sua atua&ccedil;&atilde;o como educador nutricional pode cont
ribuir para a promo&ccedil;&atilde;o de mudan&ccedil;as de h&aacute;bitos alimen
tares, estimulando os pacientes ao retorno do h&aacute;bito de jantar. Al&eacute
;m disso, esse profissional, juntamente com o m&eacute;dico, deve planejar a sup
lementa&ccedil;&atilde;o das poss&iacute;veis car&ecirc;ncias nutricionais verif
icadas. O acompanhamento nutricional individualizado torna-se primordial para a 
manuten&ccedil;&atilde;o e a recupera&ccedil;&atilde;o do estado nutricional, o 
que contribuir&aacute; para uma melhor qualidade de vida dos pacientes. </font><
/p>     ^cY#v33n1a10.htm##
00573000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033900075002001300414#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#71#67#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Devido &agrave; escassez de trabalhos
 brasileiros, tornam-se necess&aacute;rios mais estudos para ampliar o conhecime
nto do comportamento alimentar e sua influ&ecirc;ncia no perfil diet&eacute;tico
 de macro e micronutrientes desta popula&ccedil;&atilde;o. </font></p>     ^cY#v
33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#72#68#article#158#<p>&nbsp;</p>     ^c
Y#v33n1a10.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#73#69#article#158#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a10.htm##
00418000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704017000077002001300247#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#74#70#article#158#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Popkin BM. The nutri
tion transition and obesity in the developing world. J Nutr 2001; 131:871-3.    
^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#75#71#article#158# </font></p>     ^cY
#v33n1a10.htm##
00566000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704031800077002001300395#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#76#72#article#158#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bleil SI. O padr&ati
lde;o alimentar ocidental: considera&ccedil;&otilde;es sobre a mudan&ccedil;a de
 h&aacute;bitos no Brasil. N&uacute;cleo de Estudo e Pesquisas em Alimenta&ccedi
l;&atilde;o da UNICAMP. Revista Cadernos de Debate 1998; 6:1-25.    ^cY#v33n1a10
.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#77#73#article#158# </font></p>     ^cY
#v33n1a10.htm##
00552000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704030400077002001300381#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#78#74#article#158#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Barreto SAJ, Cyrillo
 DC. An&aacute;lise da composi&ccedil;&atilde;o dos gastos com alimenta&ccedil;&
atilde;o no Munic&iacute;pio de S&atilde;o Paulo (Brasil) na d&eacute;cada de 19
90. Rev Sa&uacute;de P&uacute;blica 2001; 35:52-9.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#79#75#article#158# </font></p>     ^cY
#v33n1a10.htm##
00454000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020600077002001300283#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#80#76#article#158#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Pinheiro KAPN. Hist&
oacute;ria dos h&aacute;bitos alimentares ocidentais. Universitas Ci&ecirc;ncias
 da Sa&uacute;de 2005; 3:173-90.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#81#77#article#158# </font></p>     ^cY
#v33n1a10.htm##
00611000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704036300077002001300440#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#82#78#article#158#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Cuppari L, Avesani C
M, Mendon&ccedil;a COG, Martini LA, Monte VCM. Doen&ccedil;as Renais. <i>In</i>:
 CUPPARI, L. Guia de Nutri&ccedil;&atilde;o: nutri&ccedil;&atilde;o cl&iacute;ni
ca no adulto (Guia de medicina ambulatorial e hospitalar). 2. ed. S&atilde;o Pau
lo: Manole, 2005; 10:189-220.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#83#79#article#158# </font></p>     ^cY
#v33n1a10.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025200077002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#84#80#article#158#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Martins C, Riella MC
. Nutri&ccedil;&atilde;o e Hemodi&aacute;lise. <i>In</i>: Riella MC. Martins C. 
Nutri&ccedil;&atilde;o e o Rim. Rio de janeiro: Guanabara Koogan, 2001, pp. 4.  
  ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#85#81#article#158# </font></p>     ^cY
#v33n1a10.htm##
00412000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704016400077002001300241#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#86#82#article#158#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Laville M, Fouque D.
 Nutritional aspects in hemodialysis. Kidney Inter 2000; 58:s133-s139.    ^cY#v3
3n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#87#83#article#158# </font></p>     ^cY
#v33n1a10.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022900077002001300306#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#88#84#article#158#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Erten Y, Kayatas M. 
Zinc deficiency: prevalence and causes in hemodialysis patients and effect on ce
llular immune response. Transplant Proc 1998; 30:850-1.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#89#85#article#158# </font></p>     ^cY
#v33n1a10.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022100077002001300298#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#90#86#article#158#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Descombes E, Hanck A
B, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need fo
r supplementation. Kidney Int 1993; 43:1319-28.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#91#87#article#158# </font></p>     ^cY
#v33n1a10.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704025500078002001300333#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#92#88#article#158#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Martins C. Vitamin
as e oligoelementos na insufici&ecirc;ncia renal. <i>In</i>: Riella MC, Martins 
C. Nutri&ccedil;&atilde;o e o Rim. Rio de janeiro: Guanabara Koogan 2001; 5:43-5
7.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#93#89#article#158# </font></p>     ^cY
#v33n1a10.htm##
00596000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704034700078002001300425#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#94#90#article#158#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Ag&ecirc;ncia Naci
onal de Vigil&acirc;ncia Sanit&aacute;ria (Brasil). Resolu&ccedil;&atilde;o nº 1
54, de 15 de junho de 2004. Regulamento T&eacute;cnico para o Funcionamento dos 
Servi&ccedil;os de Di&aacute;lise. Di&aacute;rio Oficial da Uni&atilde;o, 17 de 
junho de 2004.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#95#91#article#158# </font></p>     ^cY
#v33n1a10.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704027100078002001300349#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#96#92#article#158#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Lombardo ME, Cusum
ano A. Diagn&oacute;stico, prevenci&oacute;n y tratamiento de la desnutrici&oacu
te;n em hemodi&aacute;lisis cr&ocirc;nica. Rev Nefrol Dial y Transpl, Buenos Air
es 1996; 40:15-26.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#97#93#article#158# </font></p>     ^cY
#v33n1a10.htm##
00462000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704021300078002001300291#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#98#94#article#158#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Mehrotra R, Kopple
 JD. Nutritional management of maintenance dialysis patients: why aren't we doin
g better? Annu Rev Nutr 2001; 21:343-79.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#99#95#article#158# </font></p>     ^cY
#v33n1a10.htm##
00435000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704018500079002001300264#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#100#96#article#158#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Lopes RPS. Botelh
o RBA. &Aacute;lbum fotogr&aacute;fico de por&ccedil;&otilde;es alimentares. Ed.
 Metha, 2008.    ^cY#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#101#97#article#158# </font></p>     ^c
Y#v33n1a10.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704021300079002001300292#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#102#98#article#158#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Clinical practice
 guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foun
dation. Am J Kidney Dis 2000; 35:S1-S140.    ^cY#v33n1a10.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#103#99#article#158# </font></p>     ^c
Y#v33n1a10.htm##
00541000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029000080002001300370#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#104#100#article#158#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Kalantar-Zadeh K
, Kopple JD. Controle nutricional dos pacientes em hemodi&aacute;lise de manuten
&ccedil;&atilde;o. <i>In</i>: kopple, JD; Massry, SG. Cuidados Nutricionais das 
Doen&ccedil;as Renais 2006; 25:391-422.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#105#101#article#158# </font></p>     ^
cY#v33n1a10.htm##
00470000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021900080002001300299#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#106#102#article#158#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Sampaio IBM. Est
at&iacute;stica Aplicada &agrave; Experimenta&ccedil;&atilde;o Animal. 2.ed. Bel
o Horizonte: FEPMVZ-Editora, 2002, 265 p. Ilust.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#107#103#article#158# </font></p>     ^
cY#v33n1a10.htm##
00597000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704034600080002001300426#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#108#104#article#158#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Nogueira MLG, Nu
nes LLC, Pinto D, Ribeiro AJF, Silva CQ, Siqueira AL. Introdu&ccedil;&atilde;o &
agrave; Bioestat&iacute;stica. Departamento de Estat&iacute;stica do Instituto d
e Ci&ecirc;ncias Exatas da Universidade Federal de Minas Gerais, Belo Horizonte,
 1997, pp. 215.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#109#105#article#158# </font></p>     ^
cY#v33n1a10.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#110#106#article#158#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Sesso R, Lopes A
A, Thom&eacute; FS, Bevilacqua JL, Rom&atilde;o Jr JE, Lugon J. Relat&oacute;rio
 do Censo Brasileiro de Di&aacute;lise, 2008. J.Bras.Nefrol 2008; 30(4):233-8.  
  ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#111#107#article#158# </font></p>     ^
cY#v33n1a10.htm##
00454000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020300080002001300283#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#112#108#article#158#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Cabral PC, Diniz
 AS, Arruda KG. Avalia&ccedil;&atilde;o nutricional de pacientes em hemodi&aacut
e;lise. Rev Nutr 2005; 18:29-40.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#113#109#article#158# </font></p>     ^
cY#v33n1a10.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#114#110#article#158#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Koehnlein EA, Ya
mada AN, Giannasi ACB. Avalia&ccedil;&atilde;o do estudo nutricional de paciente
s em hemodi&aacute;lise. Acta Sci Health Sci 2008; 30:65-71.    ^cY#v33n1a10.htm
##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#115#111#article#158# </font></p>     ^
cY#v33n1a10.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#116#112#article#158#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Cardozo MT, Viei
ra IO, Campanella LCA. Altera&ccedil;&otilde;es nutricionais em pacientes renais
 cr&ocirc;nicos em programa de hemodi&aacute;lise. Rev Bras Nutr Clin 2006; 21:2
84-9.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#117#113#article#158# </font></p>     ^
cY#v33n1a10.htm##
00572000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032100080002001300401#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#118#114#article#158#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Nerbass FB, Cupp
ari L, Avesani CM, Luz Filho HA. Diminui&ccedil;&atilde;o do f&oacute;sforo s&ea
cute;rico ap&oacute;s interven&ccedil;&atilde;o nutricional em pacientes hiperfo
sfat&ecirc;micos em hemodi&aacute;lise. J Bras Nefrol 2008; 30:288-93.    ^cY#v3
3n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#119#115#article#158# </font></p>     ^
cY#v33n1a10.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024500080002001300325#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#120#116#article#158#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Batista T, Vieir
a IO, Azevedo LC. Avalia&ccedil;&atilde;o nutricional de pacientes mantidos em p
rograma de hemodi&aacute;lise cr&ocirc;nica. J Bras Nefrol 2004; 3:113-20.    ^c
Y#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#121#117#article#158# </font></p>     ^
cY#v33n1a10.htm##
00563000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031200080002001300392#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#122#118#article#158#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Santos PR, Coelh
o MR, Gomes NP, Josu&eacute; EPJ. Associa&ccedil;&atilde;o de indicadores nutric
ionais com qualidade de vida em pacientes portadores de doen&ccedil;a renal cr&o
circ;nica em hemodi&aacute;lise. J Bras Nefrol 2006; 2:57-64.    ^cY#v33n1a10.ht
m##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#123#119#article#158# </font></p>     ^
cY#v33n1a10.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025300080002001300333#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#124#120#article#158#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Freitas ATVS, Va
z IMF, Forn&eacute;s NS. Estado nutricional de pacientes em hemodi&aacute;lise n
o Hospital Universit&aacute;rio de Goi&acirc;na-GO. J Bras Nefrol 2009; 31:125-3
1.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#125#121#article#158# </font></p>     ^
cY#v33n1a10.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027200080002001300352#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#126#122#article#158#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Valenzuela RGV, 
Giffoni AG, Cuppari L, Canziani MEF. Estado nutricional de pacientes com insufic
i&ecirc;ncia renal cr&ocirc;nica em hemodi&aacute;lise no Amazonas. Rev Assoc Me
d Bras 2003; 49:72-8.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#127#123#article#158# </font></p>     ^
cY#v33n1a10.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022300080002001300303#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#128#124#article#158#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Morais AAC, Silv
a MAT, Faintuch J <i>et al. </i> Correlation of nutritional status and food inta
ke in hemodialysis patients.Clinics 2005; 60:185-92.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#129#125#article#158# </font></p>     ^
cY#v33n1a10.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026900080002001300349#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#130#126#article#158#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Scapin G, Carval
ho CZ, Rabito EI. Avalia&ccedil;&atilde;o nutricional de pacientes em hemodi&aac
ute;lise: ingest&atilde;o alimentar e composi&ccedil;&atilde;o corporal. Rev Nut
rol 2008; 1:10-15.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#131#127#article#158# </font></p>     ^
cY#v33n1a10.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023900080002001300319#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#132#128#article#158#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Slomowitz LA, Mo
nteon FJ, Grosvenor M <i>et al. </i> Effect of energy intake on nutritional stat
us in maintenance hemodialysis patients. Kidney Int 1989; 35:704-11.    ^cY#v33n
1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#133#129#article#158# </font></p>     ^
cY#v33n1a10.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028900080002001300369#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#134#130#article#158#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Chazot C, Koople
 JD. Metabolismo e demanda de vitaminas nas doen&ccedil;as renais e na insufici&
ecirc;ncia renal. <i>In</i>: Kopple, JD; Massry, SG. Cuidados nutricionais das d
oen&ccedil;as renais 2006; 20:281-320.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#135#131#article#158# </font></p>     ^
cY#v33n1a10.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025300080002001300333#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#136#132#article#158#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Kalantar-Zadeh K
, Kopple JD, Deepak S <i>et al. </i> Food intake characteristics of hemodialysis
 patients as obstained by food frequency questionnaire. J Ren Nutr 2002; 12:17-3
1.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#137#133#article#158# </font></p>     ^
cY#v33n1a10.htm##
00447000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019600080002001300276#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#138#134#article#158#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Allman MA, Trusw
ell AS, Tiller DJ. Vitamin suplementation of pacients receiving hemodialysis. Me
d J Aust 1989; 150:130-3.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#139#135#article#158# </font></p>     ^
cY#v33n1a10.htm##
00617000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704036600080002001300446#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#140#136#article#158#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Pinto DE, Ullman
n LS, Burmeister MM, Antonello IC, Pizzato A. Associa&ccedil;&atilde;o entre ing
est&atilde;o energ&eacute;tica, prot&eacute;ica e de f&oacute;sforo em pacientes
 portadores de doen&ccedil;a renal cr&ocirc;nica em tratamento hemodial&iacute;t
ico. J Bras Nefrol 2009; 31:269-76.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#141#137#article#158# </font></p>     ^
cY#v33n1a10.htm##
00413000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016200080002001300242#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#142#138#article#158#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Cozzolino SMF. B
iodisponibilidade dos nutrientes. 3.ed. S&atilde;o Paulo: Manole, 2009.    ^cY#v
33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#143#139#article#158# </font></p>     ^
cY#v33n1a10.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#144#140#article#158#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Cabral PC, Diniz
 AS. Altera&ccedil;&otilde;es metab&oacute;licas e funcionais do zinco em pacien
tes com insufici&ecirc;ncia renal cr&ocirc;nica. Rev Bras Nutr Clin 2003; 18(1):
31-6.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#145#141#article#158# </font></p>     ^
cY#v33n1a10.htm##
00554000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030300080002001300383#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#146#142#article#158#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Mafra D, Cozzoli
no SMF. Anemia na insufici&ecirc;ncia renal cr&ocirc;nica e suas implica&ccedil;
&otilde;es na distribui&ccedil;&atilde;o do zinco corporal &#91;Tese&#93;. S&ati
lde;o Paulo: Universidade de S&atilde;o Paulo, 2001.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#147#143#article#158# </font></p>     ^
cY#v33n1a10.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#148#144#article#158#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Fisberg RM, Mart
ini LA, Slater B. M&eacute;todos de inqu&eacute;ritos alimentares. <i>In</i>: Fi
sberg RM, Slater B, Marchioni DML, Martini LA. S&atilde;o Paulo: Manole, 2005, p
p.1-31.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#149#145#article#158# </font></p>     ^
cY#v33n1a10.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#150#146#article#158#<p>&nbsp;</p>     
^cY#v33n1a10.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#151#147#article#158#<p>&nbsp;</p>     
^cY#v33n1a10.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020000077002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#152#148#article#158#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;
ncia para:</b>    ^cY#v33n1a10.htm##
00286000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005000077002001300127#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#153#149#article#158#<br>   M&aacute;rc
ia Machado Cunha Ribeiro    ^cY#v33n1a10.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006500077002001300142#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#154#150#article#158#<br>   Rua Goitac&
aacute;zes, nº1889, Bairro Barro Preto     ^cY#v33n1a10.htm##
00292000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005600077002001300133#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#155#151#article#158#<br>   Belo Horizo
nte - MG Brasil CEP: 30190-052    ^cY#v33n1a10.htm##
00413000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704017700077002001300254#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#156#152#article#158#<br>   E-mail: <a 
href="mailto:marciaribeiro1@uol.com.br">marciaribeiro1@uol.com.br</a>; <a href="
mailto:nutricao@cenemge.com.br">nutricao@cenemge.com.br</a></font></p>     ^cY#v
33n1a10.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#157#153#article#158#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de subimiss&atilde;o: 12/9/201
0    ^cY#v33n1a10.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#158#154#article#158#<br>   Data de apr
ova&ccedil;&atilde;o: 30/12/2010    ^cY#v33n1a10.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#159#155#article#158#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a10.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#160#156#article#158#<p>&nbsp;</p>     
^cY#v33n1a10.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#161#157#article#158#<p>&nbsp;</p>     
^cY#v33n1a10.htm##
00408000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704017200077002001300249#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a10.htm#S#p#162#158#article#158#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado no 
Centro Nefrol&oacute;gico de Minas Gerais -  CENEMGE. </font></p>     ^cY#v33n1a
10.htm##
00494000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760120065000930300
00700158065000900165064000500174031000400179014000600183865000900189002001300198
035001000211801000700221#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#
c#163#1#article#38#1#^rND^sPopkin^nBM#The nutrition transition and obesity in th
e developing world^len#J Nutr#20010000#2001#131#871-3#20110300#v33n1a10.htm#0022
-3166#J Nutr##
00559000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760120141000920300
02700233710000200260065000900262064000500271031000200276014000500278865000900283
002001300292#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#164#2#arti
cle#38#2#^rND^sBleil^nSI#O padrão alimentar ocidental: considerações sobre a mud
ança de hábitos no Brasil. Núcleo de Estudo e Pesquisas em Alimentação da UNICAM
P^lpt#Revista Cadernos de Debate#2#19980000#1998#6#1-25#20110300#v33n1a10.htm##
00549000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100018000950120
10600113030001800219710000200237065000900239064000500248031000300253014000500256
865000900261002001300270#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#
c#165#3#article#38#3#^rND^sBarreto^nSAJ#^rND^sCyrillo^nDC#Análise da composição 
dos gastos com alimentação no Município de São Paulo (Brasil) na década de 1990^
lpt#Rev Saúde Pública#2#20010000#2001#35#52-9#20110300#v33n1a10.htm##
00476000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760120048000970300
03000145710000200175065000900177064000500186031000200191014000700193865000900200
002001300209#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#166#4#arti
cle#38#4#^rND^sPinheiro^nKAPN#História dos hábitos alimentares ocidentais^lpt#Un
iversitas Ciências da Saúde#2#20050000#2005#3#173-90#20110300#v33n1a10.htm##
00685000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100018000930100
02000111010001800131010001700149012001900166016001700185018009400202063000200296
06600100029806200070030806500090031506400050032401400080032986500090033700200130
0346#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#167#5#article#38#5
#^rND^sCuppari^nL#^rND^sAvesani^nCM#^rND^sMendonça^nCOG#^rND^sMartini^nLA#^rND^s
Monte^nVCM#Doenças Renais^lpt#^rND^sCUPPARI^nL#Guia de Nutrição: nutrição clínic
a no adulto (Guia de medicina ambulatorial e hospitalar)^lpt#2#São Paulo#Manole#
20050000#2005#189-220#20110300#v33n1a10.htm##
00552000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930120
02700110016001700137016001700154018002100171066001500192062001700207014000200224
065000900226064000500235865000900240002001300249#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a10.htm#S#c#168#6#article#38#6#^rND^sMartins^nC#^rND^sRiella^nMC#N
utrição e Hemodiálise^lpt#^rND^sRiella^nMC#^rND^sMartins^nC#Nutrição e o Rim^lpt
#Rio de janeiro#Guanabara Koogan#4#20010000#2001#20110300#v33n1a10.htm##
00479000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930120
04000109030001300149710000200162065000900164064000500173031000300178014001000181
865000900191002001300200#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#
c#169#7#article#38#7#^rND^sLaville^nM#^rND^sFouque^nD#Nutritional aspects in hem
odialysis^len#Kidney Inter#2#20000000#2000#58#s133-s139#20110300#v33n1a10.htm##
00580000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100017000910120
10700108030001600215065000900231064000500240031000300245014000600248865000900254
002001300263035001000276801001600286#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a10.htm#S#c#170#8#article#38#8#^rND^sErten^nY#^rND^sKayatas^nM#Zinc deficiency
: prevalence and causes in hemodialysis patients and effect on cellular immune r
esponse^len#Transplant Proc#19980000#1998#30#850-1#20110300#v33n1a10.htm#0041-13
45#Transplant Proc##
00585000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100016000950100
01600111012008900127030001100216065000900227064000500236031000300241014000800244
865000900252002001300261035001000274801001100284#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a10.htm#S#c#171#9#article#38#9#^rND^sDescombes^nE#^rND^sHanck^nAB#
^rND^sFellay^nG#Water soluble vitamins in chronic hemodialysis patients and need
 for supplementation^len#Kidney Int#19930000#1993#43#1319-28#20110300#v33n1a10.h
tm#0085-2538#Kidney int##
00538000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780120054000950160
01700149016001700166018002100183066001500204062001700219065000900236064000500245
865000900250002001300259#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#
c#172#10#article#38#10#^rND^sMartins^nC#Vitaminas e oligoelementos na insuficiên
cia renal^lpt#^rND^sRiella^nMC#^rND^sMartins^nC#Nutrição e o Rim^lpt#Rio de jane
iro#Guanabara Koogan#20010000#2001#20110300#v33n1a10.htm##
00523000000000217000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750170041000780180111001190620
02400230065000900254064002000263865000900283002001300292#v33n1#V:\SciELO\serial\
jbn\v33n1\markup\v33n1a10.htm#S#c#173#11#article#38#11#Agência Nacional de Vigil
ância Sanitária#Resolução nº 154, de 15 de junho de 2004: Regulamento Técnico pa
ra o Funcionamento dos Serviços de Diálise^lpt#Diário Oficial da União#20040617#
17 de junho de 2004#20110300#v33n1a10.htm##
00553000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100018000970120
08500115030004000200710000200240065000900242064000500251031000300256014000600259
865000900265002001300274#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#
c#174#12#article#38#12#^rND^sLombardo^nME#^rND^sCusumano^nA#Diagnóstico, prevenc
ión y tratamiento de la desnutrición em hemodiálisis crônica^les#Rev Nefrol Dial
 y Transpl, Buenos Aires#2#19960000#1996#40#15-26#20110300#v33n1a10.htm##
00564000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960120
08900113030001400202065000900216064000500225031000300230014000700233865000900240
002001300249035001000262801001400272#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a10.htm#S#c#175#13#article#38#13#^rND^sMehrotra^nR#^rND^sKopple^nJD#Nutritiona
l management of maintenance dialysis patients: why aren't we doing better?^len#A
nnu Rev Nutr#20010000#2001#21#343-79#20110300#v33n1a10.htm#0199-9885#Annu Rev Nu
tr##
00435000000000229000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160017000780160019000950180
04500114062001000159065000900169064000500178865000900183002001300192#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#176#14#article#38#14#^rND^sLopes^n
RPS#^rND^sBotelho^nRBA#Álbum fotográfico de porções alimentares^lpt#Ed. Metha#20
080000#2008#20110300#v33n1a10.htm##
00529000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750120108000780300016001860650
00900202064000500211031000300216014000800219865000900227002001300236035001000249
801001600259#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#177#15#art
icle#38#15#Clinical practice guidelines for nutrition in chronic renal failure: 
K/DOQI, National Kidney Foundation^len#Am J Kidney Dis#20000000#2000#35#S1-S140#
20110300#v33n1a10.htm#0272-6386#Am J Kidney Dis##
00576000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100024000780100017001020120
06800119016001700187016001700204018004500221065000900266064000500275014000800280
865000900288002001300297#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#
c#178#16#article#38#16#^rND^sKalantar-Zadeh^nK#^rND^sKopple^nJD#Controle nutrici
onal dos pacientes em hemodiálise de manutenção^lpt#^rND^skopple^nJD#^rND^sMassr
y^nSG#Cuidados Nutricionais das Doenças Renais^lpt#20060000#2006#391-422#2011030
0#v33n1a10.htm##
00456000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160019000780180049000970630
00200146066001500148062001500163065000900178064000500187865000900192002001300201
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#179#17#article#38#17#^
rND^sSampaio^nIBM#Estatística Aplicada à Experimentação Animal^lpt#2#Belo Horizo
nte#FEPMVZ-Editora#20020000#2002#20110300#v33n1a10.htm##
00657000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160020000780160017000980160
01500115016001900130016001600149016001900165018003200184062010000216066001500316
065000900331064000500340865000900345002001300354#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a10.htm#S#c#180#18#article#38#18#^rND^sNogueira^nMLG#^rND^sNunes^n
LLC#^rND^sPinto^nD#^rND^sRibeiro^nAJF#^rND^sSilva^nCQ#^rND^sSiqueira^nAL#Introdu
ção à Bioestatística^lpt#Departamento de Estatística do Instituto de Ciências Ex
atas da Universidade Federal de Minas Gerais#Belo Horizonte#19970000#1997#201103
00#v33n1a10.htm##
00620000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930100
01600109010002100125010001900146010001500165012005100180030001400231710000200245
06500090024706400050025603100030026103200020026401400060026686500090027200200130
0281#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#181#19#article#38#
19#^rND^sSesso^nR#^rND^sLopes^nAA#^rND^sThomé^nFS#^rND^sBevilacqua^nJL#^rND^sRom
ão Jr^nJE#^rND^sLugon^nJ#Relatório do Censo Brasileiro de Diálise, 2008^lpt#J.Br
as.Nefrol#2#20080000#2008#30#4#233-8#20110300#v33n1a10.htm##
00516000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01700111012005400128030000900182710000200191065000900193064000500202031000300207
014000600210865000900216002001300225#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a10.htm#S#c#182#20#article#38#20#^rND^sCabral^nPC#^rND^sDiniz^nAS#^rND^sArruda
^nKG#Avaliação nutricional de pacientes em hemodiálise^lpt#Rev Nutr#2#20050000#2
005#18#29-40#20110300#v33n1a10.htm##
00544000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100017000980100
02000115012006400135030002000199710000200219065000900221064000500230031000300235
014000600238865000900244002001300253#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a10.htm#S#c#183#21#article#38#21#^rND^sKoehnlein^nEA#^rND^sYamada^nAN#^rND^sGi
annasi^nACB#Avaliação do estudo nutricional de pacientes em hemodiálise^lpt#Acta
 Sci Health Sci#2#20080000#2008#30#65-71#20110300#v33n1a10.htm##
00563000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
02200113012008400135030001900219710000200238065000900240064000500249031000300254
014000600257865000900263002001300272#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a10.htm#S#c#184#22#article#38#22#^rND^sCardozo^nMT#^rND^sVieira^nIO#^rND^sCamp
anella^nLCA#Alterações nutricionais em pacientes renais crônicos em programa de 
hemodiálise^lpt#Rev Bras Nutr Clin#2#20060000#2006#21#284-9#20110300#v33n1a10.ht
m##
00645000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
01800113010002000131012010800151030001400259065000900273064000500282031000300287
014000700290865000900297002001300306035001000319801001400329#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a10.htm#S#c#185#23#article#38#23#^rND^sNerbass^nFB#^rN
D^sCuppari^nL#^rND^sAvesani^nCM#^rND^sLuz Filho^nHA#Diminuição do fósforo sérico
 após intervenção nutricional em pacientes hiperfosfatêmicos em hemodiálise^lpt#
J Bras Nefrol#20080000#2008#30#288-93#20110300#v33n1a10.htm#0101-2800#J Bras Nef
rol##
00586000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01800112012008300130030001400213065000900227064000500236031000200241014000700243
865000900250002001300259035001000272801001400282#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a10.htm#S#c#186#24#article#38#24#^rND^sBatista^nT#^rND^sVieira^nIO
#^rND^sAzevedo^nLC#Avaliação nutricional de pacientes mantidos em programa de he
modiálise crônica^lpt#J Bras Nefrol#20040000#2004#3#113-20#20110300#v33n1a10.htm
#0101-2800#J Bras Nefrol##
00657000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01600112010001700128012012800145030001400273065000900287064000500296031000200301
014000600303865000900309002001300318035001000331801001400341#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a10.htm#S#c#187#25#article#38#25#^rND^sSantos^nPR#^rND
^sCoelho^nMR#^rND^sGomes^nNP#^rND^sJosué^nEPJ#Associação de indicadores nutricio
nais com qualidade de vida em pacientes portadores de doença renal crônica em he
modiálise^lpt#J Bras Nefrol#20060000#2006#2#57-64#20110300#v33n1a10.htm#0101-280
0#J Bras Nefrol##
00594000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100015000980100
01700113012009000130030001400220065000900234064000500243031000300248014000700251
865000900258002001300267035001000280801001400290#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a10.htm#S#c#188#26#article#38#26#^rND^sFreitas^nATVS#^rND^sVaz^nIM
F#^rND^sFornés^nNS#Estado nutricional de pacientes em hemodiálise no Hospital Un
iversitário de Goiâna-GO^lpt#J Bras Nefrol#20090000#2009#31#125-31#20110300#v33n
1a10.htm#0101-2800#J Bras Nefrol##
00644000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100018001000100
01700118010002000135012009500155030001900250065000900269064000500278031000300283
014000500286865000900291002001300300035001000313801001900323#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a10.htm#S#c#189#27#article#38#27#^rND^sValenzuela^nRGV
#^rND^sGiffoni^nAG#^rND^sCuppari^nL#^rND^sCanziani^nMEF#Estado nutricional de pa
cientes com insuficiência renal crônica em hemodiálise no Amazonas^lpt#Rev Assoc
 Med Bras#20030000#2003#49#72-8#20110300#v33n1a10.htm#0004-5241#Rev Assoc Med Br
as##
00590000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
01800113810000600131012007900137030000800216065000900224064000500233031000300238
014000700241865000900248002001300257035001000270801000800280#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a10.htm#S#c#190#28#article#38#28#^rND^sMorais^nAAC#^rN
D^sSilva^nMAT#^rND^sFaintuch^nJ#et al#Correlation of nutritional status and food
 intake in hemodialysis patients^len#Clinics#20050000#2005#60#185-92#20110300#v3
3n1a10.htm#1807-5932#Clinics##
00561000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
01700113012009600130030001100226710000200237065000900239064000500248031000200253
014000600255865000900261002001300270#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a10.htm#S#c#191#29#article#38#29#^rND^sScapin^nG#^rND^sCarvalho^nCZ#^rND^sRabi
to^nEI#Avaliação nutricional de pacientes em hemodiálise: ingestão alimentar e c
omposição corporal^lpt#Rev Nutrol#2#20080000#2008#1#10-15#20110300#v33n1a10.htm#
#
00608000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100018000980100
01900116810000600135012008700141030001100228065000900239064000500248031000300253
014000700256865000900263002001300272035001000285801001100295#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a10.htm#S#c#192#30#article#38#30#^rND^sSlomowitz^nLA#^
rND^sMonteon^nFJ#^rND^sGrosvenor^nM#et al#Effect of energy intake on nutritional
 status in maintenance hemodialysis patients^len#Kidney Int#19890000#1989#35#704
-11#20110300#v33n1a10.htm#0085-2538#Kidney int##
00583000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940120
08300111016001700194016001700211018004500228065000900273064000500282014000800287
865000900295002001300304#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#
c#193#31#article#38#31#^rND^sChazot^nC#^rND^sKoople^nJD#Metabolismo e demanda de
 vitaminas nas doenças renais e na insuficiência renal^lpt#^rND^sKopple^nJD#^rND
^sMassry^nSG#Cuidados nutricionais das doenças renais^lpt#20060000#2006#281-320#
20110300#v33n1a10.htm##
00622000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100024000780100017001020100
01600119810000600135012010200141030001100243065000900254064000500263031000300268
014000600271865000900277002001300286035001000299801001100309#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a10.htm#S#c#194#32#article#38#32#^rND^sKalantar-Zadeh^
nK#^rND^sKopple^nJD#^rND^sDeepak^nS#et al#Food intake characteristics of hemodia
lysis patients as obstained by food frequency questionnaire^len#J Ren Nutr#20020
000#2002#12#17-31#20110300#v33n1a10.htm#1051-2276#J Ren Nutr##
00561000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950100
01700114012006200131030001100193065000900204064000500213031000400218014000600222
865000900228002001300237035001000250801001100260#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a10.htm#S#c#195#33#article#38#33#^rND^sAllman^nMA#^rND^sTruswell^n
AS#^rND^sTiller^nDJ#Vitamin suplementation of pacients receiving hemodialysis^le
n#Med J Aust#19890000#1989#150#130-3#20110300#v33n1a10.htm#0025-729X#Med J Aust#
#
00708000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
02100112010002000133010001700153012014000170030001400310065000900324064000500333
031000300338014000700341865000900348002001300357035001000370801001400380#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#196#34#article#38#34#^rND^sPin
to^nDE#^rND^sUllmann^nLS#^rND^sBurmeister^nMM#^rND^sAntonello^nIC#^rND^sPizzato^
nA#Associação entre ingestão energética, protéica e de fósforo em pacientes port
adores de doença renal crônica em tratamento hemodialítico^lpt#J Bras Nefrol#200
90000#2009#31#269-76#20110300#v33n1a10.htm#0101-2800#J Bras Nefrol##
00434000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160021000780180038000990630
00200137066001000139062000700149065000900156064000500165865000900170002001300179
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#197#35#article#38#35#^
rND^sCozzolino^nSMF#Biodisponibilidade dos nutrientes^lpt#3#São Paulo#Manole#200
90000#2009#20110300#v33n1a10.htm##
00550000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950120
09400111030001900205710000200224065000900226064000500235031000300240032000200243
014000500245865000900250002001300259#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a10.htm#S#c#198#36#article#38#36#^rND^sCabral^nPC#^rND^sDiniz^nAS#Alterações m
etabólicas e funcionais do zinco em pacientes com insuficiência renal crônica^lp
t#Rev Bras Nutr Clin#2#20030000#2003#18#1#31-6#20110300#v33n1a10.htm##
00523000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160015000780160021000930180
09500114066001000209062002600219065000900245064000500254865000900259002001300268
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#199#37#article#38#37#^
rND^sMafra^nD#^rND^sCozzolino^nSMF#Anemia na insuficiência renal crônica e suas 
implicações na distribuição do zinco corporal^lpt#São Paulo#Universidade de São 
Paulo#20010000#2001#20110300#v33n1a10.htm##
00610000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01600114012003800130016001800168016001600186016002100202016001800223066001000241
062000700251014000200258065000900260064000500269865000900274002001300283#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a10.htm#S#c#200#38#article#38#38#^rND^sFis
berg^nRM#^rND^sMartini^nLA#^rND^sSlater^nB#Métodos de inquéritos alimentares^lpt
#^rND^sFisberg^nRM#^rND^sSlater^nB#^rND^sMarchioni^nDML#^rND^sMartini^nLA#São Pa
ulo#Manole#p#20050000#2005#20110300#v33n1a10.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#o#1#1#article#1#
20110411#092958#v33n1a11.htm#245##
04806000000000625000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201210
01610120099002820100030003810100028004110100027004390100032004660100034004980100
04700532070006400579083164300643085001002286085004002296085003802336085002002374
08316150239408500100400908500350401908500360405408500260409011700080411607200030
4124112000904127111001104136114000904147113001104156002001304167#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#T
AB#11#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f74^l81#0101-2800#Morfologia e f
unção cardíacas em pacientes renais crônicos, com ou sem diurese residual, em tr
atamento hemodialítico^lpt#Cardiac morphology and function in patients with and 
without residual diuresis on hemodialysis^len#^rND^1A01^nSalustiano^sAraujo#^rND
^1A01^nHelton P.^sLemes#^rND^1A01^nDanny A.^sCunha#^rND^1A01^nVinicius S.^sQueir
oz#^rND^1A01^nDaniela D.^sNascimento#^rND^1A01^nSebastião Rodrigues^sFerreira Fi
lho#Universidade Federal de Uberlândia^iA01^cUberlândia^sMG^pBrasil#^lpt^aEm pac
ientes com doença renal crônica (DRC) em hemodiálise (HD), a hipertrofia ventric
ular esquerda (HVE) está relacionada ao aumento do índice de resistência vascula
r periférica (IRVP) total e à sobrecarga de volume. A presença da diurese residu
al (DR) nesses pacientes possibilita maior controle volêmico. Avaliamos as modif
icações morfofuncionais do ventrículo esquerdo (VE) em pacientes com DRC em HD c
om e sem diurese residual. Trinta e um pacientes não diabéticos foram divididos 
em dois grupos: com diurese residual (DR+) (n = 17) e sem diurese residual (DR-)
 (n = 14). Em ambos os grupos, DR+ vs. DR-, ocorreram diferenças no índice cardí
aco (3,9 ± 0,20 vs. 3,0 ± 0,21 L/min/m²; p = 0,0056), no índice sistólico (54 ± 
2,9 vs. 45 ± 3,3 mL/b/m²; p = 0,04), no volume diastólico final (141 ± 6,7 vs. 1
12 ± 7,6 mL; p = 0,008), no diâmetro diastólico final (52 ± 0,79 vs. 48 ± 1,12 m
m; p = 0,0072) e no IRVP total (1.121 ± 56 vs. 1.529 ± 111 dina.seg.cm-5; p = 0,
001). O grupo DR+ apresentou menor espessamento relativo de parede (ERP) do que 
o DR- (0,38 ± 0,01 vs. 0,45 ± 0,01; p = 0,0008). A fração de ejeção (66,00 ± 1,2
4 vs. 66,0 ± 1,46%; p = 0,873) e o índice de massa ventricular esquerda (132 ± 6
,0 vs. 130 ± 8,3 g/m; p = 0,798) foram similares em ambos os grupos. O volume de
 diurese residual correlacionou-se com o espessamento da parede ventricular (r =
 0,42; p = 0,0186) e com o índice de resistência vascular periférica (r = -0,48;
 p = 0,0059). Em conclusão, a presença ou não da diurese residual, em pacientes 
com doença renal crônica e em hemodiálise, pode ser responsável por modificações
 na função cardíaca sistólica.#^ddecs^i1#^tm^lpt^kinsuficiência renal crônica^i1
#^tm^lpt^kremodelamento ventricular^i1#^tm^lpt^kdiurese^i1#^len^aIn patients wit
h chronic renal failure on hemodialysis, left ventricular hypertrophy is related
 to the increase in total peripheral vascular resistance and volume overload. Th
e presence of residual diuresis enables greater control of the volemia of these.
 We evaluated the morpho-functional changes of the left ventricle in patients wi
th chronic kidney disease on hemodyalisis treatment with and without residual di
uresis. A total of 31 non diabetic patients were studied and they were divided i
nto two groups: with residual diuresis (RD+) (n = 17) and without residual diure
sis (RD-) (n = 14). In both groups, RD+ vs. RD-, using data from a Doppler echoc
ardiogram differences were found, respectively, in the cardiac index (3.9 ± 0.2 
vs. 3.0 ± 0.2 L/min/m²; p = 0.0056), systolic index (54 ± 2.9 vs. 45 ± 3.3 mL/b/
m²; p = 0.04), end diastolic volume (141 ± 6.7 vs. 112 ± 7.6 mL; p = 0.008), end
 diastolic diameter (52 ± 0.7 vs. 48 ± 1.1 mm; p = 0.0072) and total peripheral 
resistance index (1121 ± 56 vs. 1529 ± 111 dyne.sec.cm-5; p = 0.001). RD+ had lo
wer relative wall thickness than RD- (0.38 ± 0.01 vs. 0.45 ± 0.01; p = 0.0008). 
The ejection fraction and the left ventricular mass index were similar in both g
roups. The urinary 24-hour volume correlated with the relative wall thickness (r
 = -0.42; p = 0.0186) and with peripheral resistance index (r = -0.48; p = 0.005
9). In conclusion, there were distinct ventricular geometric patterns and differ
ent functional performances between RD+ and RD- groups. The presence of residual
 diuresis can be responsible by these modifications in systolic function.#^ddecs
^i2#^tm^len^kchronic kidney failure^i2#^tm^len^kventricular remodelling^i2#^tm^l
en^kstroke volume^i2#vancouv#56#20101001#01/10/2010#20110106#06/01/2011#v33n1a11
.htm##
04998000000000625000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201280
01610120106002890100030003950100028004250100027004530100032004800100034005120100
04700546070006400593083173900657085001002396085004002406085003802446085002002484
08316970250408500100420108500350421108500360424608500260428211700080430807200030
4316112000904319111001104328114000904339113001104348002001304359#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#T
AB#11#JBN020#nd#J. Bras. Nefrol.#33#1#20110300#^f74^l81#0101-2800#<b>Morfologia 
e função cardíacas em pacientes renais crônicos, com ou sem diurese residual, em
 tratamento hemodialítico</b>^lpt#<b>Cardiac morphology and function in patients
 with and without residual diuresis on hemodialysis</b>^len#^rND^1A01^nSalustian
o^sAraujo#^rND^1A01^nHelton P.^sLemes#^rND^1A01^nDanny A.^sCunha#^rND^1A01^nVini
cius S.^sQueiroz#^rND^1A01^nDaniela D.^sNascimento#^rND^1A01^nSebastião Rodrigue
s^sFerreira Filho#Universidade Federal de Uberlândia^iA01^cUberlândia^sMG^pBrasi
l#^lpt^aEm pacientes com doença renal crônica (DRC) em hemodiálise (HD), a hiper
trofia ventricular esquerda (HVE) está relacionada ao aumento do índice de resis
tência vascular periférica (IRVP) total e à sobrecarga de volume. A presença da 
diurese residual (DR) nesses pacientes possibilita maior controle volêmico. Aval
iamos as modificações morfofuncionais do ventrículo esquerdo (VE) em pacientes c
om DRC em HD com e sem diurese residual. Trinta e um pacientes não diabéticos fo
ram divididos em dois grupos: com diurese residual (DR+) (n = 17) e sem diurese 
residual (DR-) (n = 14). Em ambos os grupos, DR+ <i>vs. </i>DR-, ocorreram difer
enças no índice cardíaco (3,9 ± 0,20 <i>vs</i>. 3,0 ± 0,21 L/min/m<sup>2</sup>; 
p = 0,0056), no índice sistólico (54 ± 2,9 <i>vs</i>. 45 ± 3,3 mL/b/m<sup>2</sup
>; p = 0,04), no volume diastólico final (141 ± 6,7 <i>vs</i>. 112 ± 7,6 mL; p =
 0,008), no diâmetro diastólico final (52 ± 0,79 <i>vs</i>. 48 ± 1,12 mm; p = 0,
0072) e no IRVP total (1.121 ± 56 <i>vs</i>. 1.529 ± 111 dina.seg.cm<sup>-5</sup
>; p = 0,001). O grupo DR+ apresentou menor espessamento relativo de parede (ERP
) do que o DR- (0,38 ± 0,01 <i>vs</i>. 0,45 ± 0,01; p = 0,0008). A fração de eje
ção (66,00 ± 1,24 <i>vs</i>. 66,0 ± 1,46%; p = 0,873) e o índice de massa ventri
cular esquerda (132 ± 6,0 <i>vs</i>. 130 ± 8,3 g/m; p = 0,798) foram similares e
m ambos os grupos. O volume de diurese residual correlacionou-se com o espessame
nto da parede ventricular (r = 0,42; p = 0,0186) e com o índice de resistência v
ascular periférica (r = -0,48; p = 0,0059). Em conclusão, a presença ou não da d
iurese residual, em pacientes com doença renal crônica e em hemodiálise, pode se
r responsável por modificações na função cardíaca sistólica.#^ddecs^i1#^tm^lpt^k
insuficiência renal crônica^i1#^tm^lpt^kremodelamento ventricular^i1#^tm^lpt^kdi
urese^i1#^len^aIn patients with chronic renal failure on hemodialysis, left vent
ricular hypertrophy is related to the increase in total peripheral vascular resi
stance and volume overload. The presence of residual diuresis enables greater co
ntrol of the volemia of these. We evaluated the morpho-functional changes of the
 left ventricle in patients with chronic kidney disease on hemodyalisis treatmen
t with and without residual diuresis. A total of 31 non diabetic patients were s
tudied and they were divided into two groups: with residual diuresis (RD+) (n = 
17) and without residual diuresis (RD-) (n = 14). In both groups, RD+ <i>vs</i>.
 RD-, using data from a Doppler echocardiogram differences were found, respectiv
ely, in the cardiac index (3.9 ± 0.2 <i>vs</i>. 3.0 ± 0.2 L/min/m<sup>2</sup>; p
 = 0.0056), systolic index (54 ± 2.9 <i>vs</i>. 45 ± 3.3 mL/b/m<sup>2</sup>; p =
 0.04), end diastolic volume (141 ± 6.7 <i>vs</i>. 112 ± 7.6 mL; p = 0.008), end
 diastolic diameter (52 ± 0.7 <i>vs</i>. 48 ± 1.1 mm; p = 0.0072) and total peri
pheral resistance index (1121 ± 56 <i>vs</i>. 1529 ± 111 dyne.sec.cm<sup>-5</sup
>; p = 0.001). RD+ had lower relative wall thickness than RD- (0.38 ± 0.01 <i>vs
</i>. 0.45 ± 0.01; p = 0.0008). The ejection fraction and the left ventricular m
ass index were similar in both groups. The urinary 24-hour volume correlated wit
h the relative wall thickness (r = -0.42; p = 0.0186) and with peripheral resist
ance index (r = -0.48; p = 0.0059). In conclusion, there were distinct ventricul
ar geometric patterns and different functional performances between RD+ and RD- 
groups. The presence of residual diuresis can be responsible by these modificati
ons in systolic function.#^ddecs^i2#^tm^len^kchronic kidney failure^i2#^tm^len^k
ventricular remodelling^i2#^tm^len^kstroke volume^i2#vancouv#56#20101001#01/10/2
010#20110106#06/01/2011#v33n1a11.htm##
04943000000000649000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400090015903500100
01680120121001780120099002990100030003980100027004280100026004550100031004810100
03300512010004700545070006600592083165200658085001002310085004002320085003802360
08500200239808316150241808500100403308500350404308500360407808500260411411700080
41400720003041481120009041511110011041601140009041711130011041800020013041910080
08904204#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#l#4#1#article#1#
^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab#11#JBN020#nd#J. Bras. Nefrol#33#1#2
0110300#^f74^l81#0101-2800#Morfologia e função cardíacas em pacientes renais crô
nicos, com ou sem diurese residual, em tratamento hemodialítico^lpt#Cardiac morp
hology and function in patients with and without residual diuresis on hemodialys
is^len#^rND^1A01^nSalustiano^sAraujo#^rND^1A01^nHelton P^sLemes#^rND^1A01^nDanny
 A^sCunha#^rND^1A01^nVinicius S^sQueiroz#^rND^1A01^nDaniela D^sNascimento#^rND^1
A01^nSebastião Rodrigues^sFerreira Filho#^iA01^1Universidade Federal de Uberlând
ia^cUberlândia^sMG^pBrasil#^lpt^aEm pacientes com doença renal crônica (DRC) em 
hemodiálise (HD), a hipertrofia ventricular esquerda (HVE) está relacionada ao a
umento do índice de resistência vascular periférica (IRVP) total e à sobrecarga 
de volume. A presença da diurese residual (DR) nesses pacientes possibilita maio
r controle volêmico. Avaliamos as modificações morfofuncionais do ventrículo esq
uerdo (VE) em pacientes com DRC em HD com e sem diurese residual. Trinta e um pa
cientes não diabéticos foram divididos em dois grupos: com diurese residual (DR+
) (n = 17) e sem diurese residual (DR-) (n = 14). Em ambos os grupos, DR+ vs. DR
-, ocorreram diferenças no índice cardíaco (3,9 ± 0,20 vs. 3,0 ± 0,21 L/min/m²; 
p = 0,0056), no índice sistólico (54 ± 2,9 vs. 45 ± 3,3 mL/b/m²; p = 0,04), no v
olume diastólico final (141 ± 6,7 vs. 112 ± 7,6 mL; p = 0,008), no diâmetro dias
tólico final (52 ± 0,79 vs. 48 ± 1,12 mm; p = 0,0072) e no IRVP total (1.121 ± 5
6 vs. 1.529 ± 111 dina.seg.cm-5; p = 0,001). O grupo DR+ apresentou menor espess
amento relativo de parede (ERP) do que o DR- (0,38 ± 0,01 vs. 0,45 ± 0,01; p = 0
,0008). A fração de ejeção (66,00 ± 1,24 vs. 66,0 ± 1,46 por cento; p = 0,873) e
 o índice de massa ventricular esquerda (132 ± 6,0 vs. 130 ± 8,3 g/m; p = 0,798)
 foram similares em ambos os grupos. O volume de diurese residual correlacionou-
se com o espessamento da parede ventricular (r = 0,42; p = 0,0186) e com o índic
e de resistência vascular periférica (r = -0,48; p = 0,0059). Em conclusão, a pr
esença ou não da diurese residual, em pacientes com doença renal crônica e em he
modiálise, pode ser responsável por modificações na função cardíaca sistólica.#^
ddecs^i1#^tm^lpt^kinsuficiência renal crônica^i1#^tm^lpt^kremodelamento ventricu
lar^i1#^tm^lpt^kdiurese^i1#^len^aIn patients with chronic renal failure on hemod
ialysis, left ventricular hypertrophy is related to the increase in total periph
eral vascular resistance and volume overload. The presence of residual diuresis 
enables greater control of the volemia of these. We evaluated the morpho-functio
nal changes of the left ventricle in patients with chronic kidney disease on hem
odyalisis treatment with and without residual diuresis. A total of 31 non diabet
ic patients were studied and they were divided into two groups: with residual di
uresis (RD+) (n = 17) and without residual diuresis (RD-) (n = 14). In both grou
ps, RD+ vs. RD-, using data from a Doppler echocardiogram differences were found
, respectively, in the cardiac index (3.9 ± 0.2 vs. 3.0 ± 0.2 L/min/m²; p = 0.00
56), systolic index (54 ± 2.9 vs. 45 ± 3.3 mL/b/m²; p = 0.04), end diastolic vol
ume (141 ± 6.7 vs. 112 ± 7.6 mL; p = 0.008), end diastolic diameter (52 ± 0.7 vs
. 48 ± 1.1 mm; p = 0.0072) and total peripheral resistance index (1121 ± 56 vs. 
1529 ± 111 dyne.sec.cm-5; p = 0.001). RD+ had lower relative wall thickness than
 RD- (0.38 ± 0.01 vs. 0.45 ± 0.01; p = 0.0008). The ejection fraction and the le
ft ventricular mass index were similar in both groups. The urinary 24-hour volum
e correlated with the relative wall thickness (r = -0.42; p = 0.0186) and with p
eripheral resistance index (r = -0.48; p = 0.0059). In conclusion, there were di
stinct ventricular geometric patterns and different functional performances betw
een RD+ and RD- groups. The presence of residual diuresis can be responsible by 
these modifications in systolic function.#^ddecs^i2#^tm^len^kchronic kidney fail
ure^i2#^tm^len^kventricular remodelling^i2#^tm^len^kstroke volume^i2#vancouv#56#
20101001#01/10/2010#20110106#06/01/2011#v33n1a11.htm#Internet^ihttp://www.scielo
.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100011##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#5#1#article#185#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a11.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#6#2#article#185#<p>&nbsp;</p>     ^cY#
v33n1a11.htm##
00492000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704026000073002001300333#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#7#3#article#185#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Morfologia e fun&
ccedil;&atilde;o card&iacute;acas em pacientes renais cr&ocirc;nicos, com  ou se
m diurese residual, em tratamento hemodial&iacute;tico</b></font></p>     ^cY#v3
3n1a11.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#8#4#article#185#<p>&nbsp;</p>     ^cY#
v33n1a11.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#9#5#article#185#<p>&nbsp;</p>     ^cY#
v33n1a11.htm##
00460000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704022700074002001300301#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#10#6#article#185#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Salustiano Araujo; Helton P. Lemes;
 Danny A. Cunha; Vinicius S. Queiroz; Daniela D. Nascimento; Sebasti&atilde;o Ro
drigues Ferreira Filho</b></font></p>     ^cY#v33n1a11.htm##
00393000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704016000074002001300234#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#11#7#article#185#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Universidade Federal de Uberl&acirc;nd
ia - UFU,  Uberl&acirc;ndia, MG, Brasil</font></p>     ^cY#v33n1a11.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704012400074002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#12#8#article#185#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia<
/a></font></p>     ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#13#9#article#185#<p>&nbsp;</p>     ^cY
#v33n1a11.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#14#10#article#185#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a11.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#15#11#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a11.htm##
02354000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704212000075002001302195#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#16#12#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em pacientes com doen&ccedil;a renal 
cr&ocirc;nica (DRC) em hemodi&aacute;lise (HD), a hipertrofia ventricular esquer
da (HVE) est&aacute; relacionada ao aumento do &iacute;ndice de resist&ecirc;nci
a vascular perif&eacute;rica (IRVP) total e &agrave; sobrecarga de volume. A pre
sen&ccedil;a da diurese residual (DR) nesses pacientes possibilita maior control
e vol&ecirc;mico. Avaliamos as modifica&ccedil;&otilde;es morfofuncionais do ven
tr&iacute;culo esquerdo (VE) em pacientes com DRC em HD com e sem diurese residu
al. Trinta e um pacientes n&atilde;o diab&eacute;ticos foram divididos em dois g
rupos: com diurese residual (DR+) (n = 17) e sem diurese residual (DR-) (n = 14)
. Em ambos os grupos, DR+ <i>vs. </i> DR-, ocorreram diferen&ccedil;as no &iacut
e;ndice card&iacute;aco (3,9 ± 0,20 <i>vs</i>. 3,0 ± 0,21 L/min/m<sup>2</sup>; p
 = 0,0056), no &iacute;ndice sist&oacute;lico (54 ± 2,9 <i>vs</i>. 45 ± 3,3 mL/b
/m<sup>2</sup>; p = 0,04), no volume diast&oacute;lico final (141 ± 6,7 <i>vs</i
>. 112 ± 7,6 mL; p = 0,008), no di&acirc;metro diast&oacute;lico final (52 ± 0,7
9 <i>vs</i>. 48 ± 1,12 mm;  p = 0,0072) e no IRVP total (1.121 ± 56 <i>vs</i>. 1
.529 ± 111 dina.seg.cm<sup>-5</sup>; p = 0,001). O grupo DR+ apresentou menor es
pessamento relativo de parede (ERP) do que o DR- (0,38 ± 0,01 <i>vs</i>. 0,45 ± 
0,01; p = 0,0008). A fra&ccedil;&atilde;o de eje&ccedil;&atilde;o (66,00 ± 1,24 
<i>vs</i>. 66,0 ± 1,46%; p = 0,873) e o &iacute;ndice de massa ventricular esque
rda (132 ± 6,0 <i>vs</i>. 130 ± 8,3 g/m; p = 0,798) foram similares em ambos os 
grupos. O volume de diurese residual correlacionou-se com o espessamento da pare
de ventricular (r = 0,42; p = 0,0186) e com o &iacute;ndice de resist&ecirc;ncia
 vascular perif&eacute;rica (r = -0,48; p = 0,0059). Em conclus&atilde;o, a pres
en&ccedil;a ou n&atilde;o da diurese residual, em pacientes com doen&ccedil;a re
nal cr&ocirc;nica e em hemodi&aacute;lise, pode ser respons&aacute;vel por modif
ica&ccedil;&otilde;es na fun&ccedil;&atilde;o card&iacute;aca sist&oacute;lica. 
</font></p>     ^cY#v33n1a11.htm##
00439000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020500075002001300280#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#17#13#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> insufici&ecirc
;ncia renal cr&ocirc;nica, remodelamento ventricular, diurese. </font></p> <hr s
ize="1" noshade>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#18#14#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#19#15#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#20#16#article#185#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a11.htm##
01402000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704116800075002001301243#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#21#17#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Embora a taxa de filtra&ccedil;&atild
e;o glomerular seja bastante baixa em pacientes com doen&ccedil;a renal cr&ocirc
;nica (DRC), os volumes di&aacute;rios de diurese residual podem variar de an&ua
cute;ria a poli&uacute;ria em indiv&iacute;duos diferentes. A preserva&ccedil;&a
tilde;o da diurese residual (DR) auxilia na depura&ccedil;&atilde;o de subst&aci
rc;ncias de baixo e m&eacute;dio pesos moleculares, permitindo assim maior remo&
ccedil;&atilde;o de fluido<sup>1</sup> , melhora do estado nutricional<sup>2,3</
sup> e da qualidade de vida<sup>4</sup> do paciente, al&eacute;m da manuten&cced
il;&atilde;o parcial de algumas fun&ccedil;&otilde;es endocrinas do rim. <sup>5<
/sup> Durante o tratamento conservador de pacientes com DRC,<sup>6</sup> observa
-se que o decl&iacute;nio do r&iacute;tmode filtra&ccedil;&atilde;o glomerular e
st&aacute; associado &agrave; hipertrofia ventr&iacute;cular esquerda (HVE). <su
p>7-11</sup> A presen&ccedil;a de HVE, por sua vez, constitui em importante fato
r independente de risco cardiovascular para os pacientes com DRC. <sup>7,8,12,13
 </sup> </font></p>     ^cY#v33n1a11.htm##
01470000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704123600075002001301311#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#22#18#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pacientes quando emterapia renal s
ubstitutiva (TRS) - est&aacute;gio V<sup>6 </sup>- podem apresentar maior ou me-
nor decl&iacute;nio da  fun&ccedil;&atilde;o renal residual (FRR) na dependencia
 do m&eacute;todo dial&iacute;tico utilizado. <sup>14 </sup>Assim, os pacientes 
em hemodi&aacute;lise (HD) reduzem a FRR com maior rapidez do que aqueles em di&
aacute;lise peritoneal (DP). <sup>14-17</sup> A redu&ccedil;&atilde;o da FRR est
&aacute; associada com a progress&atilde;o da HVE e &agrave; maior mortalidade c
ardiovascular em pacientes em DP<sup>12,18,19</sup>. Nos pacientes submetidos ao
 tratamento hemodial&iacute;tico, a pressen&ccedil;a de HVE &eacute; relatada em
 v&aacute;rios estudos;<sup>9,10,12,20,21</sup> entretanto, poucos estudos refer
em a HVE associada aos aspectos morfol&oacute;gicos e funcionais do ventr&iacute
;culo esquerdo (VE) e suas rela&ccedil;&otilde;es com diferentes volumes de diur
ese residual. Assim, o objetivo do presente estudo foi o de verificar as poss&ia
cute;veis diferen&ccedil;as morfologicas e funcionais do VE de pacientes em hemo
di&aacute;lise cr&ocirc;nica que apresentam ou n&atilde;o diurese residual. </fo
nt></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#23#19#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011700075002001300192#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#24#20#article#185#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODOS </b></f
ont></p>     ^cY#v33n1a11.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#25#21#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES/PROTOCOLO</b> </font></p
>     ^cY#v33n1a11.htm##
02101000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704186700075002001301942#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#26#22#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trata-se deum estudo transversal cujo
s pacientes foram recrutados em uma cl&iacute;nica particular de hemodi&aacute;l
ise. Como crit&eacute;rios de inclus&atilde;o eram necessarios ser portadores de
 DRC e estarem em tratamento hemodial&iacute;tico, regularmente tr&ecirc;s vezes
 por semana, e que concordaram em participar do estudo. . Foram exclu&iacute;dos
os pacientes com tempo de tratamento hemodial&iacute;tico menor do que tr&ecirc;
s meses, hist&oacute;ria cl&iacute;nica pregressa de doen&ccedil;a cardiovascula
r, diab&eacute;ticos e com press&atilde;o arterial sist&ecirc;mica n&atilde;o-co
ntrolada. Ao ecocardiograma, pacientes com fra&ccedil;&atilde;o de eje&ccedil;&a
tilde;o (FE) <u>&lt;</u> 55% e com altera&ccedil;&atilde;o segmentar na contrati
lidade do VE tamb&eacute;m foram exclu&iacute;dos. <sup>22,23</sup> Assim, dois 
grupos foram criados: DR+, constitu&iacute;do de pacientes com diurese residual 
di&aacute;ria <u>&gt;</u> 100 mL/24 horas (n = 17; 11&#9794; e 6&#9792;), e DR- 
constitu&iacute;do de pacientes com diurese residual di&aacute;ria &lt; 100 mL/2
4 horas (n = 14; 9&#9794; e 5&#9792;) (<a href="/img/revistas/jbn/v33n1/a11tab01
m.jpg">Tabela 1</a>). Os grupos foram avaliados quanto aos asp&eacute;ctos cl&ia
cute;nicos e laboratoriais:: press&atilde;o arterial sist&oacute;lica (PAS), pre
ss&atilde;o arterial diast&oacute;lica (PAD), dura&ccedil;&atilde;o do tratament
o hemodial&iacute;tico (DTH), volume urin&aacute;rio de 24 horas (VU<sub>24hs</s
ub>), hemoglobina (Hb), c&aacute;lcio s&eacute;rico (Ca), paratorm&ocirc;nio (PT
H), albumina s&eacute;rica (Alb) e &iacute;ndice de resist&ecirc;ncia vascular p
erif&eacute;rica (IRVP) total. Esse estudo foi previamente aprovado pelo Comit&e
circ; de &Eacute;tica da Universidade Federal de Uberl&acirc;ndia. </font></p>  
   ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#27#23#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#28#24#article#185#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS </b></font></p>    
 ^cY#v33n1a11.htm##
02961000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704272700075002001302802#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#29#25#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A PAS e a PAD foram imediatamente obt
idas antes da sess&atilde;o de HD utilizando o bra&ccedil;o oposto &agrave; f&ia
cute;stula AV e representavam a m&eacute;dia das &uacute;ltimas dez sess&otilde;
es. A press&atilde;o arterial m&eacute;dia (PAM) foi calculada usando a f&oacute
;rmula PAD + (PAS-PAD/3), e o IRVP total foi calculado usando a f&oacute;rmula (
PAM-PVC/DC) x 80, onde PVC &eacute; a press&atilde;o venosa central, que sempre 
foi considerada valor igual a zero (dina.seg.cm<sup>-5</sup>). <sup>24,25</sup> 
Os valores press&oacute;ricos foram expressos em mmHg. O VU<sub>24hs </sub>(mL) 
foi coletado durante o per&iacute;odo interdial&iacute;tico. O ganho ponderal in
terdial&iacute;tico (GPI) representa a diferen&ccedil;a entre o peso corporal im
ediatamente ap&oacute;s a sess&atilde;o de HD e o peso obtido imediatamente ante
s da pr&oacute;xima sess&atilde;o de HD. O valor do GPI considerado foi a m&eacu
te;dia aritm&eacute;tica das &uacute;ltimas dez sess&otilde;es de HD. A avalia&c
cedil;&atilde;o da adequa&ccedil;&atilde;o da di&aacute;lise foi realizada atrav
&eacute;s do  Kt/V. O Kt/V &eacute; definido como o clearance de ur&eacute;ia do
 dialisador (K, obtido do fabricante em mL/min), multiplicado pela dura&ccedil;&
atilde;o do tratamento dial&iacute;tico (t, em minutos) dividido pelo volume de 
distribui&ccedil;&atilde;o de ur&eacute;ia no corpo (V, em mL). Valores bioqu&ia
cute;micos plasm&aacute;ticos foram obtidos atrav&eacute;s de m&eacute;todos pad
ronizados previamente descritos. <sup>26-28</sup> O ecocardiograma por Doppler u
tilizou um transdutor Acuson-Aspen<sup>&reg;</sup> C2-4 Mhz e foi realizado 20 h
oras ap&oacute;s o t&eacute;rmino da sess&atilde;o de HD, no per&iacute;odo inte
rdial&iacute;tico, por um examinador experiente e cego quanto ao protocolo. As v
ari&aacute;veis ecocardiograficas  foram analisadas de acordo com os crit&eacute
;rios da <i>American Society of Echocardiography</i>. <sup>22,29-31</sup> Para d
eterminar a espessura relativa da parede (ERP), foi utilizada a medida da espess
ura da parede posterior (EPP) do VE. <sup>32-35 </sup>Os seguintes par&acirc;met
ros tamb&eacute;m foram avaliados: Fra&ccedil;&atilde;o de eje&ccedil;&atilde;o 
(FE), &iacute;ndice sist&oacute;lico (IS), &iacute;ndice card&iacute;aco (IC), v
olume diast&oacute;lico final (VDF) do VE, di&acirc;metro diast&oacute;lico fina
l (DDF) do VE, espessura septal interventricular (ESIV) e &iacute;ndice de massa
 do VE (IMVE). <sup>22,24,35</sup> Al&eacute;m disso, o fluxo sangu&iacute;neo n
a f&iacute;stula arteriovenosa (FS<sub>AV</sub>) foi avaliado com o mesmo equipa
mento ecocardiogr&aacute;fico. <sup>37,38</sup></font></p>     ^cY#v33n1a11.htm#
#
00359000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012500075002001300200#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#30#26#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b> AN&Aacute;LISE ESTAT&Iacute;STICA
 </b></font></p>     ^cY#v33n1a11.htm##
01279000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704104500075002001301120#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#31#27#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O programa GraphPad Prism, vers&atild
e;o 5.0 para Windows (GraphPad Software, San Diego Calif&oacute;rnia, EUA) foi u
sado na an&aacute;lise estat&iacute;stica. Testes<i> t</i> e de Wilcoxon foram c
onduzidos para comparar as m&eacute;dias entre os grupos. Valores &lt; 0,05 fora
m considerados significantes. O coeficiente de correla&ccedil;&atilde;o utilizad
o foi o coeficiente de Pearson. Os dados foram apresentados como m&eacute;dias ±
 erro padr&atilde;o (&Chi; ± EP). Teste de regress&atilde;o m&uacute;ltipla foi 
realizado quando H0: resist&ecirc;ncia vascular n&atilde;o era uma vari&aacute;v
el dependente do tempo de tratamento e/ou da diurese residual e/ ou do PTH e/ou 
da press&atilde;o arterial m&eacute;dia; enquanto H1: resist&ecirc;ncia vascular
 era dependente de pelo menos uma das vari&aacute;veis citadas acima. O programa
 Bioestat 5.0 foi usado para esses c&aacute;lculos e o erro alfa = 0,05 foi cons
iderado como n&iacute;vel de decis&atilde;o. </font></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#32#28#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#33#29#article#185#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS </b></font></p>     ^cY
#v33n1a11.htm##
00538000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030400075002001300379#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#34#30#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Caracter&iacute;sticas cl&iacute;nica
s e laboratoriais de ambos os grupos s&atilde;o apresentadas nas <a href="/img/r
evistas/jbn/v33n1/a11tab01m.jpg">Tabelas 1</a> e <a href="/img/revistas/jbn/v33n
1/a11tab02m.jpg">2</a>. </font></p>     ^cY#v33n1a11.htm##
00356000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012200075002001300197#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#35#31#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DADOS MORFOL&Oacute;GICOS DO VE </
b></font></p>     ^cY#v33n1a11.htm##
01029000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704079500075002001300870#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#36#32#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A espessura relativa da parede (ERP) 
foi significantemente menor no grupo DR+ do que no grupo DR- (0,38 ± 0,01 <i>vs<
/i>. 0,45 ± 0,01; p = 0,0008) (<a href="#fig1">Figura 1</a>). Correla&ccedil;&ot
ilde;es significantes foram encontradas entre a ERP e o tempo de HD (r = 0,40; p
 = 0,024), &iacute;ndice sist&oacute;lico (r = - 0,61; p = 0,0003), &iacute;ndic
e card&iacute;aco (r = -0,56; p = 0,001) e VU<sub>24hs</sub> (r = -0,42; p = 0,0
1). O DDF foi maior no grupo DR+ (52 ± 0,7 <i>vs</i>. 48 ± 1,1; p = 0,0072), e e
ncontramos correla&ccedil;&atilde;o positiva significante entre o DDF e o VU<sub
>24hs</sub> (r = 0,41; p = 0,022) e correla&ccedil;&atilde;o negativa entre o DD
F e a ERP (r = -0,60; p = 0,0003). </font></p>     ^cY#v33n1a11.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#37#33#article#185#<p><a name="fig1"></
a></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#38#34#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#39#35#article#185#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a11fig01.jpg"></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#40#36#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00379000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014500075002001300220#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#41#37#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b> FUN&Ccedil;&Atilde;O DO VE E DADO
S HEMODIN&Acirc;MICOS</b></font></p>     ^cY#v33n1a11.htm##
01137000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090300075002001300978#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#42#38#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> O &iacute;ndice card&iacute;aco dos 
pacientes foi significantemente mais alto no grupo DR+ do que no grupo DR- (3,9 
± 0,2 <i>vs</i>. 3,0 ± 0,2 L/min/m<sup>2</sup>; p = 0,0056). Foi observada corre
la&ccedil;&atilde;o significante e negativa entre o IC e a ERP (r = -0,56; p = 0
,001). O IS foi significantemente mais alto no grupo DR+ (54 ± 2,9 <i>vs</i>. 45
 ± 3,3 mL/b/m<sup>2</sup>; p = 0,0403), bem como o VDF (141 ± 6 <i>vs</i>. 112 ±
 7 mL; p = 0,0081). O IRVP total era significantemente mais baixo no grupo DR+ (
1,121 ± 56 <i>vs</i>. 1,529 ± 111 dina.seg.cm<sup>-5</sup>; p = 0,001) (<a href=
"#fig1">Figura 1</a>, <a href="/img/revistas/jbn/v33n1/a11tab01m.jpg">Tabela 1</
a>). O BFAV n&atilde;o era estatisticamente diferente entre os grupos DR+ e DR- 
(1,8 ± 0,6 <i>vs</i>. 1,4 ± 0,6 L/ min/m<sup>2</sup>; p = ns). </font></p>     ^
cY#v33n1a11.htm##
01460000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704122600075002001301301#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#43#39#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> Foi observada correla&ccedil;&otilde
;es positivas e significantes entre o &iacute;ndice sist&oacute;lico e o &iacute
;ndice de massa ventricular esquerda (r = 0,51; p = 0,0039), entre o &iacute;ndi
ce de resist&ecirc;ncia perif&eacute;rica total e a espessura relativa da parede
 (r = 0,51; p = 0,0036), e negativas entre o &iacute;ndice sist&oacute;lico e a 
espessura relativa da parede (r = -0,61; p = 0,0003). O IRVP total se correlacio
nou com o IC, IS, ERP e VU<sub>24h</sub> (<a href="#fig2">Figuras 2</a> e <a hre
f="#fig3">3</a>) (<a href="/img/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>).
 Para a an&aacute;lise de regress&atilde;o m&uacute;ltipla, o IRVP total foi con
siderado como uma vari&aacute;vel dependente, enquanto o tempo de tratamento, di
urese residual, PTH e PAM foram considerados como as vari&aacute;veis que poderi
am influenciar o &iacute;ndice de resist&ecirc;ncia perif&eacute;rica. Foi obser
vado que a regress&atilde;o F = 4,26; p = 0,041 rejeitou H0 e os seguintes coefi
cientes parciais: tempo (t: -1,47; p = 0,152); diurese residual (t: -3,35; p = 0
,0023); PAM (t: 0,490; p = 0,490) e PTH (t: = 0,498; p = 0,6225). </font></p>   
  ^cY#v33n1a11.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#44#40#article#185#<p><a name="fig2"></
a></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#45#41#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#46#42#article#185#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a11fig02.jpg"></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#47#43#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#48#44#article#185#<p><a name="fig3"></
a></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#49#45#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#50#46#article#185#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a11fig03.jpg"></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#51#47#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#52#48#article#185#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O </b></font></p>  
   ^cY#v33n1a11.htm##
02346000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704211200075002001302187#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#53#49#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A espessura relativa da parede &eacut
e; uma das vari&aacute;veis utilizadas para definir o padr&atilde;o geom&eacute;
trico do VE. <sup>22.32.39</sup> Portanto, em nosso estudo, observamos que os pa
cientes no grupo DR+ e DR- apresentavam valores similares de MVE e diferentes va
lores de ERP (<a href="/img/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>). Ess
es dados sugerem que ambos os grupos apresentariam morfologias ventriculares dis
tintas e que a resist&ecirc;ncia de carga e volume imposto ao VE seriam de difer
entes magnitudes. Isso se torna mais evidente ao observamos correla&ccedil;&atil
de;o positiva entre a resist&ecirc;ncia perif&eacute;rica e a ERP, sugerindo que
, para diferentes valores de resist&ecirc;ncia, h&aacute; valores diferentes de 
espessura da parede posterior (<a href="#fig2">Figura 2</a>). A aus&ecirc;ncia d
e diurese residual pode ter contribu&iacute;do para os valores mais altos de res
ist&ecirc;ncia perif&eacute;rica e estado hipervol&ecirc;mico no grupo an&uacute
;rico. Embora o ganho ponderal interdial&iacute;tico n&atilde;o tenha sido signi
ficante entre os grupos devido ao pequeno tamanho da amostra, o grupo sem diures
e era cerca de 20% mais pesado do que o grupo com volume urin&aacute;rio. Nossos
 dados tamb&eacute;m mostraram que a diurese de baixo volume coexistia com altos
 valores de resist&ecirc;ncia perif&eacute;rica (<a href="#fig2">Figura 2</a>). 
Wang <i>et al. </i>observaram que a MVE aumentava em pacientes submetidos &agrav
e; di&aacute;lise peritoneal que apresentavam valores mais baixos de taxa de fil
tra&ccedil;&atilde;o glomerular. <sup>9 </sup>Entretanto, esses auto-res observa
ram di&acirc;metros diast&oacute;licos finais similares entre os grupos avaliado
s, o que difere dos achados em nosso estudo. Uma das poss&iacute;veis raz&otilde
;es para esses achados diversos pode ser o tipo de di&aacute;lise, enquanto outr
a raz&atilde;o pode ser o fato de os autores n&atilde;o terem correlacionado mod
ifica&ccedil;&otilde;es no VE com o VU<sub>24h</sub> em seus pacientes. </font><
/p>     ^cY#v33n1a11.htm##
01032000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704079800075002001300873#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#54#50#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o &agrave;s ca
racter&iacute;sticas funcionais do VE, observamos que o IC e o IS eram mais baix
os nos pacientes an&uacute;ricos (DR-) (<a href="/img/revistas/jbn/v33n1/a11tab0
2m.jpg">Tabela 2</a>). Esse achado pode ser explicado pelos menores valores enco
ntrados no di&acirc;metro diast&oacute;lico final VE no grupo DR- (<a href="/img
/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>). As diferen&ccedil;as morfol&oa
cute;gicas dos VE entre os dois grupos foram respons&aacute;veis pelos diferente
s valores do IC e IS. Assim, pacientes com DRC submetidos &agrave; tratamento co
m HD que perdem diurese residual podem apresentar altera&ccedil;&otilde;es na ge
ometria e fun&ccedil;&atilde;o do VE. </font></p>     ^cY#v33n1a11.htm##
00796000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056200075002001300637#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#55#51#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Embora Faguli <i>et al. </i>tenham de
monstrado HVE na maioria dos pacientes estudados submetidos &agrave; HD, esses a
utores n&atilde;o exclu&iacute;ram pacientes com patologias que poderiam interfe
rir com o processo de remodelamento mioc&aacute;rdico, tais como <i>diabetes mel
litus</i>, cardiomiopatia isqu&ecirc;mica ou hipertens&atilde;o arterial sist&ec
irc;mica; al&eacute;m disso, n&atilde;o correlacionaram seus achados com o volum
e urin&aacute;rio residual. <sup>40 </sup></font></p>     ^cY#v33n1a11.htm##
01457000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704122300075002001301298#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#56#52#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em pacientes com DRC, a DR diminuiu p
rogressivamente com o tempo na terapia renal substitutiva. Em nosso estudo, o gr
upo an&uacute;rico (DR-) passou mais tempo em tratamento hemodial&iacute;tico do
 que o grupo com diurese (DR+) e a perda de volume urin&aacute;rio somente acont
eceu em pacientes com maior tempo de tratamento. As raz&otilde;es para a perda d
a DR podem ser explicadas pelas altera&ccedil;&otilde;es relacionadas &agrave; d
oen&ccedil;a de base que causou a DRC ou pelo processo inflamat&oacute;rio cont&
iacute;nuo, anemia e comorbidades associadas. <sup>12,17,41-43</sup> A dura&cced
il;&atilde;o do tempo de tratamento com HD poderia aumentar os riscos potenciais
 ao VE. Esses riscos decorrem do tratamento em si e da progress&atilde;o da doen
&ccedil;a. Entretanto, ao realizar a regress&atilde;o m&uacute;ltipla e definir 
a carga imposta ao VE como vari&aacute;vel dependente, observamos signific&acirc
;ncia estat&iacute;stica apenas para diurese residual (p = 0,05). Esses dados fo
ram mais relevantes porque os pacientes eram normotensos, assim o componente de 
volume da PA poderia ser maior do que o componente resistivo . </font></p>     ^
cY#v33n1a11.htm##
01405000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704117100075002001301246#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#57#53#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nesse estudo, as altera&ccedil;&otild
e;es card&iacute;acas morfofuncionais n&atilde;o podiam ser atribu&iacute;das ao
s n&iacute;veis de press&atilde;o encontrados, por que os grupos DR+ e DR- apres
entavam valores de PAS e PAD similares (<a href="/img/revistas/jbn/v33n1/a11tab0
1m.jpg">Tabela 1</a>). O mesmo poderia ser dito a respeito do uso de medicamento
s antihipertensivos, j&aacute; que n&atilde;o havia diferen&ccedil;a no n&uacute
;mero de antihipertensivos usados em ambos os grupos (<a href="/img/revistas/jbn
/v33n1/a11tab01m.jpg">Tabela 1</a>). Gunal <i>et al. </i> demonstraram que o uso
 de antihipertensivos contribuem para redu&ccedil;&otilde;es no &iacute;ndice de
 massa do VE em somente 6% dos pacientes em HD<sup>11</sup>. Entretanto, nossos 
resultados demonstraram que ambos os grupos DR+ e DR- n&atilde;o apresentaram di
feren&ccedil;as em seus valores de &iacute;ndice de massa do VE (p &gt; 0,05) (<
a href="/img/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>), indicando que o ef
eito dos medicamentos usados n&atilde;o interferiu substancialmente com nossos r
esultados. </font></p>     ^cY#v33n1a11.htm##
00883000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064900075002001300724#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#58#54#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A presen&ccedil;a de anemia &eacute; 
outro fator que poderia estar relacionado &agrave; presen&ccedil;a da HVE. <sup>
44,45</sup> O papel da anemia como causa de HVE em pacientes submetidos &agrave;
 di&aacute;lise tem sido bem estabelecido; a corre&ccedil;&atilde;o da anemia co
m eritropoietina resulta na regress&atilde;o parcial da HVE. <sup>46</sup> Nesse
 estudo, o n&iacute;vel de Hb permaneceu relativamente normal e n&atilde;o houve
 diferen&ccedil;a nos n&iacute;veis de Hb entre grupos estudados (<a href="/img/
revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>). </font></p>     ^cY#v33n1a11.ht
m##
02732000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704249800075002001302573#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#59#55#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Tem sido demonstrado que a hipoalbumi
nemia est&aacute; envolvida na hipertrofia e dilata&ccedil;&atilde;o ventricular
es e insufici&ecirc;ncia card&iacute;aca e por fim, diminui a sobreviv&ecirc;nci
a dos pacientes. <sup>47-51</sup> O estudo CANUSA demonstrou que a concentra&cce
dil;&atilde;o s&eacute;rica de albumina estava fortemente correlacionada com a m
ortalidade. <sup>3,52</sup> Em nosso estudo, os valores de albumina s&eacute;ric
a eram normais e n&atilde;o encontramos diferen&ccedil;as significantes entre os
 dois grupos (<a href="/img/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>). Por
tanto, acreditamos que as altera&ccedil;&otilde;es card&iacute;acas encontradas 
em nosso estudo n&atilde;o poderiam ter sido causadas por essa vari&aacute;vel. 
A hipocalcemia persistente &eacute; considerada um fator patog&ecirc;nico na red
u&ccedil;&atilde;o da fun&ccedil;&atilde;o sist&oacute;lica do VE. <sup>53 </sup
>Entretanto, os n&iacute;veis de c&aacute;lcio s&eacute;rico em nosso estudo per
maneceram dentro dos valores normais e n&atilde;o houve diferen&ccedil;a entre o
s grupos (<a href="/img/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>). O hiper
paratireoidismo secund&aacute;rio &eacute; comum em pacientes ur&ecirc;micos e e
ssa complica&ccedil;&atilde;o contribui para o desenvolvimento de disfun&ccedil;
&atilde;o sist&oacute;lica do VE<sup>54 </sup>e HVE. <sup>55 </sup>Os n&iacute;v
eis s&eacute;ricos de PTH entre os grupos n&atilde;o eram estatisticamente signi
ficantes (<a href="/img/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>). O FS<su
b>AV </sub>&eacute; outro fator importante que contribui para a morfologia e fun
&ccedil;&atilde;o card&iacute;acas. <sup>38,56 </sup>Em nosso estudo, todas as f
&iacute;stulas foram examinadas utilizando seu fluxo sangu&iacute;neo e n&atilde
;o havia diferen&ccedil;a significante entre os grupos (<a href="/img/revistas/j
bn/v33n1/a11tab02m.jpg">Tabela 2</a>). Al&eacute;m disso, as altera&ccedil;&otil
de;es morfol&oacute;gicas e funcionais podem ser atribu&iacute;das &agrave;s dif
erentes taxas de remo&ccedil;&atilde;o de solutos no processo de HD; entretanto,
 elas n&atilde;o eram diferentes entre os grupos DR+ e DR-. &Eacute; digno de no
ta que a medida de Kt/V em nosso estudo n&atilde;o levou em considera&ccedil;&at
ilde;o a remo&ccedil;&atilde;o de solutos promovida pela diurese residual (<a hr
ef="/img/revistas/jbn/v33n1/a11tab02m.jpg">Tabela 2</a>). </font></p>     ^cY#v3
3n1a11.htm##
00783000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054900075002001300624#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#60#56#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com base em nossos achados, conclu&ia
cute;mos que os diferentes valores de IC e IS encontrados nesses grupos podem se
r atribu&iacute;dos &agrave; padr&otilde;es geom&eacute;tricos distintos do VE q
ue s&atilde;o determinados pela resist&ecirc;ncia perif&eacute;rica total e pela
 presen&ccedil;a de DR. Assim, a preserva&ccedil;&atilde;o da diurese parece inf
luenciar a morfologia e fun&ccedil;&atilde;o do VE em pacientes com insufici&eci
rc;ncia renal cr&ocirc;nica. </font></p>     ^cY#v33n1a11.htm##
00744000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051000075002001300585#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#61#57#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como limita&ccedil;&otilde;es desse e
studo, &eacute; necess&aacute;rio observar que o presente &eacute; um estudo tra
nsversal e os dados dos pacientes representam o momento quando as vari&aacute;ve
is foram observadas e poderiam n&atilde;o expressar a exata progress&atilde;o da
 doen&ccedil;a no paciente. Al&eacute;m disso, o pequeno tamanho da amostra pode
ria induzir um erro alfa em suas an&aacute;lises estat&iacute;sticas. </font></p
>     ^cY#v33n1a11.htm##
00421000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018700075002001300262#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#62#58#article#185#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Acreditamos que novos estudos prospec
tivos devam ser conduzidos a fim de confirmar tal hip&oacute;tese. </font></p>  
   ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#63#59#article#185#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00342000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#64#60#article#185#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS </b></font></p> 
    ^cY#v33n1a11.htm##
00399000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704015100077002001300228#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#65#61#article#185#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Wang AY. The "heart"
 of peritoneal dialysis. Perit Dial Int 2007;2:S228-S232.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#66#62#article#185# </font></p>     ^cY
#v33n1a11.htm##
00546000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704029800077002001300375#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#67#63#article#185#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Maiorca R, Brunori G
, Zubani R<i> et al</i>. Predictive value of dialysis adequacy and nutritional i
ndices for mortality and morbidity in CAPD and HD patients. A longitudinal study
. Nephrol Dial Transplant 1995; 10:2295-305.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#68#64#article#185# </font></p>     ^cY
#v33n1a11.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026600077002001300343#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#69#65#article#185#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Adequacy of dialysis
 and nutrition in continuous peritoneal dialysis: association with clinical outc
omes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996
; 7:198-207.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#70#66#article#185# </font></p>     ^cY
#v33n1a11.htm##
00656000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704040800077002001300485#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#71#67#article#185#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Termorshuizen F, Kor
evaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT. The relative impor
tance of residual renal function compared with peritoneal clearance for patient 
survival and quality of life: an analysis of the Netherlands Cooperative Study o
n the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41:1293-302.    ^c
Y#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#72#68#article#185# </font></p>     ^cY
#v33n1a11.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027100077002001300348#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#73#69#article#185#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Nolph KD, Prowant BF
, Moore HL, Reyad SE. Hematocrit and residual renal creatinine clearance in pati
ents undergoing continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int
 1990; 10:279-82.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#74#70#article#185# </font></p>     ^cY
#v33n1a11.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021800077002001300295#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#75#71#article#185#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. K/DOQI clinical prac
tice guidelines for chronic kidney disease: evaluation, classification, and stra
tification. Am J Kidney Dis 2002; 39:S1-266.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#76#72#article#185# </font></p>     ^cY
#v33n1a11.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025200077002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#77#73#article#185#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Foley RN, Parfrey PS
, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ve
ntricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5:2024-31.  
  ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#78#74#article#185# </font></p>     ^cY
#v33n1a11.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027300077002001300350#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#79#75#article#185#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Levy D, Garrison RJ,
 Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographic
ally determined left ventricular mass in the Framingham Heart Study. N Engl J Me
d 1990; 322:1561-6.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#80#76#article#185# </font></p>     ^cY
#v33n1a11.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025600077002001300333#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#81#77#article#185#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Wang AY, Wang M, Woo
 J <i>et al</i>. A novel association between residual renal function and left ve
ntricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62:639-4
7.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#82#78#article#185# </font></p>     ^cY
#v33n1a11.htm##
00473000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704022400078002001300302#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#83#79#article#185#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Parfrey PS, Harnet
t JD, Griffiths SM<i> et al</i>. The clinical course of left ventricular hypertr
ophy in dialysis patients. Nephron 1990; 55:114-20.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#84#80#article#185# </font></p>     ^cY
#v33n1a11.htm##
00553000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704030400078002001300382#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#85#81#article#185#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Gunal AI, Kirciman
 E, Guler M, Yavuzkir M, Celiker H. Should the preservation of residual renal fu
nction cost volume overload and its consequence left ventricular hypertrophy in 
new hemodialysis patients? Ren Fail 2004; 26:405-9.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#86#82#article#185# </font></p>     ^cY
#v33n1a11.htm##
00582000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704033300078002001300411#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#87#83#article#185#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Wang AY, Wang M, W
oo J <i>et al</i>. Inflammation, residual kidney function, and cardiac hypertrop
hy are interrelated and combine adversely to enhance mortality and cardiovascula
r death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15:2186-94.
    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#88#84#article#185# </font></p>     ^cY
#v33n1a11.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704025000078002001300328#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#89#85#article#185#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Verdecchia P, Cari
ni G, Circo A <i>et al</i>. Left ventricular mass and cardiovascular morbidity i
n essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38:1829-35.   
 ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#90#86#article#185# </font></p>     ^cY
#v33n1a11.htm##
00503000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704025400078002001300332#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#91#87#article#185#14#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Lang SM, Bergner A
, Topfer M, Schiffl H. Preservation of residual renal function in dialysis patie
nts: effects of dialysis-technique-related factors. Perit Dial Int 2001; 21:52-7
.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#92#88#article#185# </font></p>     ^cY
#v33n1a11.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704024700078002001300325#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#93#89#article#185#15#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Horinek A, Misra M
. Does residual renal function decline more rapidly in hemodialysis than in peri
toneal dialysis? How good is the evidence? Adv Perit Dial 2004; 20:137-40.    ^c
Y#v33n1a11.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#94#90#article#185# </font></p>     ^cY
#v33n1a11.htm##
00487000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704023800078002001300316#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#95#91#article#185#16#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Lysaght MJ, Vonesh
 EF, Gotch F <i>et al</i>. The influence of dialysis treatment modality on the d
ecline of remaining renal function. ASAIO Trans 1991; 37:598-604.    ^cY#v33n1a1
1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#96#92#article#185# </font></p>     ^cY
#v33n1a11.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704023500078002001300313#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#97#93#article#185#17#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Marron B, Remon C,
 Perez-Fontan M, Quiros P, Ortiz A. Benefits of preserving residual renal functi
on in peritoneal dialysis. Kidney Int Suppl 2008; 108:S42-S51.    ^cY#v33n1a11.h
tm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#98#94#article#185# </font></p>     ^cY
#v33n1a11.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704020300078002001300281#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#99#95#article#185#18#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Levin A. Clinical 
epidemiology of cardiovascular disease in chronic kidney disease prior to dialys
is. Semin Dial 2003; 16:101-5.    ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#100#96#article#185# </font></p>     ^c
Y#v33n1a11.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704024600079002001300325#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#101#97#article#185#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. McMahon LP, Roger
 SD, Levin A. Development, prevention, and potential reversal of left ventricula
r hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15:1640-7.    ^c
Y#v33n1a11.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#102#98#article#185# </font></p>     ^c
Y#v33n1a11.htm##
00476000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704022600079002001300305#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#103#99#article#185#20#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Harnett JD, Parfr
ey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD. Left ventricular hypertroph
y in end-stage renal disease. Nephron 1988; 48:107-15.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#104#100#article#185# </font></p>     ^
cY#v33n1a11.htm##
00435000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018400080002001300264#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#105#101#article#185#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. London GM, Parfr
ey PS. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 199
7; 4:194-211.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#106#102#article#185# </font></p>     ^
cY#v33n1a11.htm##
00716000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704046500080002001300545#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#107#103#article#185#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Lang RM, Bierig 
M, Devereux RB<i> et al. </i> Recommendations for chamber quantification: a repo
rt from the American Society of Echocardiographys Guidelines and Standards Commi
ttee and the Chamber Quantification Writing Group, developed in conjunction with
 the European Association of Echocardiography, a branch of the European Society 
of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-63.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#108#104#article#185# </font></p>     ^
cY#v33n1a11.htm##
00556000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030500080002001300385#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#109#105#article#185#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Nishimura RA, Ta
jik AJ, Shub C, Miller FA, Jr. , Ilstrup DM, Harrison CE. Role of two-dimensiona
l echocardiography in the prediction of in-hospital complications after acute my
ocardial infarction. J Am Coll Cardiol 1984; 4:1080-7.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#110#106#article#185# </font></p>     ^
cY#v33n1a11.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025400080002001300334#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#111#107#article#185#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Marchais SJ, Gue
rin AP, Pannier BM, Levy BI, Safar ME, London GM. Wave reflections and cardiac h
ypertrophy in chronic uremia. Influence of body size. Hypertension 1993; 22:876-
83.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#112#108#article#185# </font></p>     ^
cY#v33n1a11.htm##
00515000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026400080002001300344#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#113#109#article#185#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Ferreira Filho S
R, de Castro Rodrigues FF, Oliveira PC, Nery MA. Systemic hemodynamic changes in
 older hypertensive patients after drinking water or eating a meal. Hypertension
 2007;49:e31.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#114#110#article#185# </font></p>     ^
cY#v33n1a11.htm##
00681000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704043000080002001300510#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#115#111#article#185#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Burnett RW, Covi
ngton AK, Fogh-Andersen N<i> et al</i>. Use of ion-selective electrodes for bloo
d-electrolyte analysis. Recommendations for nomenclature, definitions and conven
tions. International Federation of Clinical Chemistry and Laboratory Medicine (I
FCC). Scientific Division Working Group on Selective Electrodes. Clin Chem Lab M
ed 2000; 38:363-70.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#116#112#article#185# </font></p>     ^
cY#v33n1a11.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#117#113#article#185#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Chromy V, Rozkos
na K, Sedlak P. Determination of serum creatinine by Jaffe method and how to cal
ibrate to eliminate matrix interference problems. Clin Chem Lab Med 2008; 46:112
7-33.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#118#114#article#185# </font></p>     ^
cY#v33n1a11.htm##
00445000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019400080002001300274#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#119#115#article#185#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Javed MU, Michel
angeli F. Enzymatic method for assaying calcium in serum with Ca++ -ATPase. Exp 
Mol Med 2003; 35:17-22.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#120#116#article#185# </font></p>     ^
cY#v33n1a11.htm##
00537000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028600080002001300366#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#121#117#article#185#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Harnett JD, Murp
hy B, Collingwood P, Purchase L, Kent G, Parfrey PS. The reliability and validit
y of echocardiographic measurement of left ventricular mass index in hemodialysi
s patients. Nephron 1993; 65:212-4.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#122#118#article#185# </font></p>     ^
cY#v33n1a11.htm##
00628000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704037700080002001300457#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#123#119#article#185#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Schiller NB, Sha
h PM, Crawford M<i> et al. </i>Recommendations for quantitation of the left vent
ricle by two-dimensional echocardiography. American Society of Echocardiography 
Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocard
iograms. J Am Soc Echocardiogr 1989; 2:358-67.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#124#120#article#185# </font></p>     ^
cY#v33n1a11.htm##
00517000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026600080002001300346#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#125#121#article#185#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Sahn DJ, DeMaria
 A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocar
diography: results of a survey of echocardiographic measurements. Circulation 19
78; 58:1072-83.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#126#122#article#185# </font></p>     ^
cY#v33n1a11.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024800080002001300328#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#127#123#article#185#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Ganau A, Devereu
x RB, Roman MJ<i> et al. </i> Patterns of left ventricular hypertrophy and geome
tric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-8.   
 ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#128#124#article#185# </font></p>     ^
cY#v33n1a11.htm##
00380000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704012900080002001300209#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#129#125#article#185#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Ford LE. Heart s
ize. Circulation Res 1976; 39:297-303.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#130#126#article#185# </font></p>     ^
cY#v33n1a11.htm##
00400000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704014900080002001300229#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#131#127#article#185#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Gaash WH. LV rad
ius to wall thickness ratio. Am J Cardiol 1979;43:1189-94.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#132#128#article#185# </font></p>     ^
cY#v33n1a11.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021000080002001300290#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#133#129#article#185#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Fast JH. Limits 
of reproducibility of left ventricular wall thickness and mass by M-mode echocar
diography. Neth J Med 1989; 34:297-301.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#134#130#article#185# </font></p>     ^
cY#v33n1a11.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025400080002001300334#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#135#131#article#185#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Zoccali C, Bened
etto FA, Mallamaci F<i> et al. </i>Prognostic impact of the indexation of left v
entricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12:2768-
74.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#136#132#article#185# </font></p>     ^
cY#v33n1a11.htm##
00473000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022200080002001300302#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#137#133#article#185#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Miller PE, Tolwa
ni A, Luscy CP<i> et al. </i>Predictors of adequacy of arteriovenous fistulas in
 hemodialysis patients. Kidney Int 1999; 56:275-80.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#138#134#article#185# </font></p>     ^
cY#v33n1a11.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021400080002001300294#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#139#135#article#185#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Robbin ML, Chamb
erlain NE, Lockhart ME<i> et al</i>. Hemodialysis arteriovenous fistula maturity
: US evaluation. Radiology 2002; 225:59-64.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#140#136#article#185# </font></p>     ^
cY#v33n1a11.htm##
00462000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021100080002001300291#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#141#137#article#185#39#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. de SG. Left vent
ricular geometry and hypotension in end-stage renal disease: a mechanical perspe
ctive. J Am Soc Nephrol 2003; 14:2421-7.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#142#138#article#185# </font></p>     ^
cY#v33n1a11.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027200080002001300352#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#143#139#article#185#40#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Fagugli RM, Pasi
ni P, Quintaliani G<i> et al. </i>Association between extracellular water, left 
ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transp
lant 2003; 18:2332-8.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#144#140#article#185# </font></p>     ^
cY#v33n1a11.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026900080002001300349#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#145#141#article#185#41#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Jacobs LH, van d
e Kerkhof JJ, Mingels AM<i> et al</i>. Inflammation, overhydration and cardiac b
iomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transpla
nt 2010; 25:243-8.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#146#142#article#185# </font></p>     ^
cY#v33n1a11.htm##
00476000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022500080002001300305#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#147#143#article#185#42#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Krediet RT. How 
to preserve residual renal function in patients with chronic kidney disease and 
on dialysis? Nephrol Dial Transplant 2006; 21:42-ii46.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#148#144#article#185# </font></p>     ^
cY#v33n1a11.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025900080002001300339#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#149#145#article#185#43#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Yang PY, Lin JL,
 Lin-Tan DT<i> et al</i>. Residual daily urine volume association with inflammat
ion and nutrition status in maintenance hemodialysis patients. Ren Fail 2009; 31
:423-30.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#150#146#article#185# </font></p>     ^
cY#v33n1a11.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025100080002001300331#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#151#147#article#185#44#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Silberberg JS, R
ahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ven
tricular hypertrophy in end-stage renal disease. Am J Cardiol 1989; 15:64:222-4.
    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#152#148#article#185# </font></p>     ^
cY#v33n1a11.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#153#149#article#185#45#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. Stojimirovic B, 
Petrovic D, Obrenovic R. Left ventricular hypertrophy in patients on hemodialysi
s: importance of anemia. Med Pregl 2007; 60:155-9.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#154#150#article#185# </font></p>     ^
cY#v33n1a11.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028200080002001300362#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#155#151#article#185#46#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Silberberg J, Ra
cine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dia
lysis patients following correction of anemia with recombinant human erythropoie
tin. Can J Cardiol 1990; 6:1-4.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#156#152#article#185# </font></p>     ^
cY#v33n1a11.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#157#153#article#185#47#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Foley RN, Parfre
y PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidi
ty, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7:728-36.  
  ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#158#154#article#185# </font></p>     ^
cY#v33n1a11.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#159#155#article#185#48#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Moon KH, Song IS
, Yang WS<i> et al</i>. Hypoalbuminemia as a risk factor for progressive left-ve
ntricular hypertrophy in hemodialysis patients. Am J Nephrol 2000; 20:396-401.  
  ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#160#156#article#185# </font></p>     ^
cY#v33n1a11.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026800080002001300348#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#161#157#article#185#49#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. Suda T, Hiroshig
e K, Ohta T<i> et al. </i> The contribution of residual renal function to overal
l nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 
2000; 15:396-401.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#162#158#article#185# </font></p>     ^
cY#v33n1a11.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025900080002001300339#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#163#159#article#185#50#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. Fine A, Cox D. M
odest reduction of serum albumin in continuous ambulatory peritoneal dialysis pa
tients is common and of no apparent clinical consequence. Am J Kidney Dis 1992; 
20:50-4.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#164#160#article#185# </font></p>     ^
cY#v33n1a11.htm##
00532000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028100080002001300361#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#165#161#article#185#51#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">51. Struijk DG, Kred
iet RT, Koomen GC, Boeschoten EW, Arisz L. The effect of serum albumin at the st
art of continuous ambulatory peritoneal dialysis treatment on patient survival. 
Perit Dial Int 1994; 14:121-6.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#166#162#article#185# </font></p>     ^
cY#v33n1a11.htm##
00530000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027900080002001300359#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#167#163#article#185#52#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">52. Bargman JM, Thor
pe KE, Churchill DN. Relative contribution of residual renal function and perito
neal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am S
oc Nephrol 2001; 12:2158-62.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#168#164#article#185# </font></p>     ^
cY#v33n1a11.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024400080002001300324#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#169#165#article#185#53#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">53. Feldman AM, Fivu
sh B, Zahka KG, Ouyang P, Baughman KL. Congestive cardiomyopathy in patients on 
continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1988; 11:76-9.    ^cY
#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#170#166#article#185# </font></p>     ^
cY#v33n1a11.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022400080002001300304#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#171#167#article#185#54#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">54. Drueke T, Fauche
t M, Fleury J<i> et al</i>. Effect of parathyroidectomy on left-ventricular func
tion in haemodialysis patients. Lancet 1980; 1:112-4.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#172#168#article#185# </font></p>     ^
cY#v33n1a11.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#173#169#article#185#55#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">55. London GM, De Ve
rnejoul MC, Fabiani F<i> et al</i>. Secondary hyperparathyroidism and cardiac hy
pertrophy in hemodialysis patients. Kidney Int 1987; 32:900-7.    ^cY#v33n1a11.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#174#170#article#185# </font></p>     ^
cY#v33n1a11.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028500080002001300365#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#175#171#article#185#56#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">56. Anderson CB, Cod
d JR, Graff RA, Groce MA, Harter HR, Newton WT. Cardiac failure and upper extrem
ity arteriovenous dialysis fistulas. Case reports and a review of the literature
. Arch Intern Med 1976; 136:292-7.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#176#172#article#185# </font></p>     ^
cY#v33n1a11.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#177#173#article#185#<p>&nbsp;</p>     
^cY#v33n1a11.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#178#174#article#185#<p>&nbsp;</p>     
^cY#v33n1a11.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020000077002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#179#175#article#185#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;
ncia para:</b>    ^cY#v33n1a11.htm##
00293000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005700077002001300134#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#180#176#article#185#<br>   Sebasti&ati
lde;o Rodrigues  Ferreira Filho    ^cY#v33n1a11.htm##
00286000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005000077002001300127#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#181#177#article#185#<br>   Rua Para&ia
cute;ba 3055,  Umuarama     ^cY#v33n1a11.htm##
00298000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006200077002001300139#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#182#178#article#185#<br>   Uberl&acirc
;ndia - MG - Brasil  CEP: 38400-000     ^cY#v33n1a11.htm##
00347000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704011100077002001300188#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#183#179#article#185#<br>   E-mail: <a 
href="mailto:ferreirafilho1952@gmail.com">ferreirafilho1952@gmail.com</a></font>
</p>     ^cY#v33n1a11.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010800077002001300185#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#184#180#article#185#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 01/10/201
0.    ^cY#v33n1a11.htm##
00296000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006000077002001300137#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#185#181#article#185#<br>   Data de apr
ova&ccedil;&atilde;o: 06/01/2011.     ^cY#v33n1a11.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#186#182#article#185#<br>   Os autores 
declaram a  inexist&ecirc;ncia de conflitos de interesse.</font></p>     ^cY#v33
n1a11.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#187#183#article#185#<p>&nbsp;</p>     
^cY#v33n1a11.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#188#184#article#185#<p>&nbsp;</p>     
^cY#v33n1a11.htm##
00422000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704018600077002001300263#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a11.htm#S#p#189#185#article#185#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"> O referido estudo foi  realizado n
a Universidade  Federal de Uberl&acirc;ndia,  Minas Gerais, Brasil. </font></p> 
    ^cY#v33n1a11.htm##
00484000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760120039000910300
01500130065000900145064000500154031000200159014001000161865000900171002001300180
035001000193801001500203#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#
c#190#1#article#56#1#^rND^sWang^nAY#The "heart" of peritoneal dialysis^len#Perit
 Dial Int#20070000#2007#2#S228-S232#20110300#v33n1a11.htm#0896-8608#Perit Dial I
nt##
00680000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930100
01600110810000600126012014000132030002400272065000900296064000500305031000300310
014000900313865000900322002001300331035001000344801002400354#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#191#2#article#56#2#^rND^sMaiorca^nR#^rND^s
Brunori^nG#^rND^sZubani^nR#et al#Predictive value of dialysis adequacy and nutri
tional indices for mortality and morbidity in CAPD and HD patients: A longitudin
al study^len#Nephrol Dial Transplant#19950000#1995#10#2295-305#20110300#v33n1a11
.htm#0931-0509#Nephrol Dial Transplant##
00582000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740120162000760300017002380650
00900255064000500264031000200269014000800271865000900279002001300288035001000301
801001700311#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#192#3#arti
cle#56#3#Adequacy of dialysis and nutrition in continuous peritoneal dialysis: a
ssociation with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study
 Group^len#J Am Soc Nephrol#19960000#1996#7#198-207#20110300#v33n1a11.htm#1046-6
673#J Am Soc Nephrol##
00831000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100023000760100019000990100
01700118010002000135010002100155010001800176012022100194030001600415065000900431
06400050044003100030044501400090044886500090045700200130046603500100047980100160
0489#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#193#4#article#56#4
#^rND^sTermorshuizen^nF#^rND^sKorevaar^nJC#^rND^sDekker^nFW#^rND^svan Manen^nJG#
^rND^sBoeschoten^nEW#^rND^sKrediet^nRT#The relative importance of residual renal
 function compared with peritoneal clearance for patient survival and quality of
 life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialy
sis (NECOSAD)-2^len#Am J Kidney Dis#20030000#2003#41#1293-302#20110300#v33n1a11.
htm#0272-6386#Am J Kidney Dis##
00657000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920100
01600110010001600126012012700142030001500269065000900284064000500293031000300298
014000700301865000900308002001300317035001000330801001500340#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#194#5#article#56#5#^rND^sNolph^nKD#^rND^sP
rowant^nBF#^rND^sMoore^nHL#^rND^sReyad^nSE#Hematocrit and residual renal creatin
ine clearance in patients undergoing continuous ambulatory peritoneal dialysis (
CAPD)^len#Perit Dial Int#19900000#1990#10#279-82#20110300#v33n1a11.htm#0896-8608
#Perit Dial Int##
00533000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740120115000760300016001910650
00900207064000500216031000300221014000700224865000900231002001300240035001000253
801001600263#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#195#6#arti
cle#56#6#K/DOQI clinical practice guidelines for chronic kidney disease: evaluat
ion, classification, and stratification^len#Am J Kidney Dis#20020000#2002#39#S1-
266#20110300#v33n1a11.htm#0272-6386#Am J Kidney Dis##
00676000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920100
01800110010001500128010001700143010001600160012008400176030001700260065000900277
06400050028603100020029101400080029386500090030100200130031003500100032380100170
0333#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#196#7#article#56#7
#^rND^sFoley^nRN#^rND^sParfrey^nPS#^rND^sHarnett^nJD#^rND^sKent^nGM#^rND^sMurray
^nDC#^rND^sBarre^nPE#The prognostic importance of left ventricular geometry in u
remic cardiomyopathy^len#J Am Soc Nephrol#19950000#1995#5#2024-31#20110300#v33n1
a11.htm#1046-6673#J Am Soc Nephrol##
00675000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100019000900100
01700109010001700126010001900143012011600162030001300278065000900291064000500300
031000400305014000700309865000900316002001300325035001000338801001300348#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#197#8#article#56#8#^rND^sLevy^
nD#^rND^sGarrison^nRJ#^rND^sSavage^nDD#^rND^sKannel^nWB#^rND^sCastelli^nWP#Progn
ostic implications of echocardiographically determined left ventricular mass in 
the Framingham Heart Study^len#N Engl J Med#19900000#1990#322#1561-6#20110300#v3
3n1a11.htm#0028-4793#N Engl J Med##
00625000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100014000910100
01300105810000600118012012100124030001100245065000900256064000500265031000300270
014000700273865000900280002001300289035001000302801001100312#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#198#9#article#56#9#^rND^sWang^nAY#^rND^sWa
ng^nM#^rND^sWoo^nJ#et al#A novel association between residual renal function and
 left ventricular hypertrophy in peritoneal dialysis patients^len#Kidney Int#200
20000#2002#62#639-47#20110300#v33n1a11.htm#0085-2538#Kidney int##
00591000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
02000114810000600134012007700140030000800217065000900225064000500234031000300239
014000700242865000900249002001300258035001000271801000800281#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#199#10#article#56#10#^rND^sParfrey^nPS#^rN
D^sHarnett^nJD#^rND^sGriffiths^nSM#et al#The clinical course of left ventricular
 hypertrophy in dialysis patients^len#Nephron#19900000#1990#55#114-20#20110300#v
33n1a11.htm#0028-2766#Nephron##
00703000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01500112010001800127010001700145012015400162030000900316065000900325064000500334
031000300339014000600342865000900348002001300357035001000370801000900380#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#200#11#article#56#11#^rND^sGun
al^nAI#^rND^sKirciman^nE#^rND^sGuler^nM#^rND^sYavuzkir^nM#^rND^sCeliker^nH#Shoul
d the preservation of residual renal function cost volume overload and its conse
quence left ventricular hypertrophy in new hemodialysis patients^len#Ren Fail#20
040000#2004#26#405-9#20110300#v33n1a11.htm#0886-022X#Ren Fail##
00709000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930100
01300107810000600120012019000126030001700316065000900333064000500342031000300347
014000800350865000900358002001300367035001000380801001700390#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#201#12#article#56#12#^rND^sWang^nAY#^rND^s
Wang^nM#^rND^sWoo^nJ#et al#Inflammation, residual kidney function, and cardiac h
ypertrophy are interrelated and combine adversely to enhance mortality and cardi
ovascular death risk of peritoneal dialysis patients^len#J Am Soc Nephrol#200400
00#2004#15#2186-94#20110300#v33n1a11.htm#1046-6673#J Am Soc Nephrol##
00627000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100016000980100
01500114810000600129012009700135030001800232065000900250064000500259031000300264
014000800267865000900275002001300284035001000297801001800307#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#202#13#article#56#13#^rND^sVerdecchia^nP#^
rND^sCarini^nG#^rND^sCirco^nA#et al#Left ventricular mass and cardiovascular mor
bidity in essential hypertension: the MAVI study^len#J Am Coll Cardiol#20010000#
2001#38#1829-35#20110300#v33n1a11.htm#0735-1097#J Am Coll Cardiol##
00641000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01600110010001700126012011200143030001500255065000900270064000500279031000300284
014000500287865000900292002001300301035001000314801001500324#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#203#14#article#56#14#^rND^sLang^nSM#^rND^s
Bergner^nA#^rND^sTopfer^nM#^rND^sSchiffl^nH#Preservation of residual renal funct
ion in dialysis patients: effects of dialysis-technique-related factors^len#Peri
t Dial Int#20010000#2001#21#52-7#20110300#v33n1a11.htm#0896-8608#Perit Dial Int#
#
00599000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950120
12500110030001500235065000900250064000500259031000300264014000700267865000900274
002001300283035001000296801001500306#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a11.htm#S#c#204#15#article#56#15#^rND^sHorinek^nA#^rND^sMisra^nM#Does residual
 renal function decline more rapidly in hemodialysis than in peritoneal dialysis
: How good is the evidence?^len#Adv Perit Dial#20040000#2004#20#137-40#20110300#
v33n1a11.htm#1197-8554#Adv Perit Dial##
00609000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
01500113810000600128012009200134030001200226065000900238064000500247031000300252
014000800255865000900263002001300272035001000285801001200295#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#205#16#article#56#16#^rND^sLysaght^nMJ#^rN
D^sVonesh^nEF#^rND^sGotch^nF#et al#The influence of dialysis treatment modality 
on the decline of remaining renal function^len#ASAIO Trans#19910000#1991#37#598-
604#20110300#v33n1a11.htm#0889-7190#ASAIO Trans##
00642000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940100
02200109010001600131010001500147012007400162030001700236065000900253064000500262
031000400267014000800271865000900279002001300288035001000301801001700311#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#206#17#article#56#17#^rND^sMar
ron^nB#^rND^sRemon^nC#^rND^sPerez-Fontan^nM#^rND^sQuiros^nP#^rND^sOrtiz^nA#Benef
its of preserving residual renal function in peritoneal dialysis^len#Kidney Int 
Suppl#20080000#2008#108#S42-S51#20110300#v33n1a11.htm#0098-6577#Kidney Int Suppl
##
00501000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120096000930300
01100189710000200200065000900202064000500211031000300216014000600219865000900225
002001300234#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#207#18#art
icle#56#18#^rND^sLevin^nA#Clinical epidemiology of cardiovascular disease in chr
onic kidney disease prior to dialysis^len#Semin Dial#2#20030000#2003#16#101-5#20
110300#v33n1a11.htm##
00617000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01500112012011000127030001700237065000900254064000500263031000300268014000700271
865000900278002001300287035001000300801001700310#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a11.htm#S#c#208#19#article#56#19#^rND^sMcMahon^nLP#^rND^sRoger^nSD
#^rND^sLevin^nA#Development, prevention, and potential reversal of left ventricu
lar hypertrophy in chronic kidney disease^len#J Am Soc Nephrol#20040000#2004#15#
1640-7#20110300#v33n1a11.htm#1046-6673#J Am Soc Nephrol##
00642000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
02000114010001600134010001500150010001900165012006000184030000800244065000900252
06400050026103100030026601400070026986500090027600200130028503500100029880100080
0308#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#209#20#article#56#
20#^rND^sHarnett^nJD#^rND^sParfrey^nPS#^rND^sGriffiths^nSM#^rND^sGault^nMH#^rND^
sBarre^nP#^rND^sGuttmann^nRD#Left ventricular hypertrophy in end-stage renal dis
ease^len#Nephron#19880000#1988#48#107-15#20110300#v33n1a11.htm#0028-2766#Nephron
##
00541000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950120
05200113030002100165065000900186064000500195031000200200014000800202865000900210
002001300219035001000232801002100242#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a11.htm#S#c#210#21#article#56#21#^rND^sLondon^nGM#^rND^sParfrey^nPS#Cardiac di
sease in chronic uremia: pathogenesis^len#Adv Ren Replace Ther#19970000#1997#4#1
94-211#20110300#v33n1a11.htm#1073-4449#Adv Ren Replace Ther##
00845000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930100
01900109810000600128012030800134030002200442065000900464064000500473031000300478
014000800481865000900489002001300498035001000511801002200521#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#211#22#article#56#22#^rND^sLang^nRM#^rND^s
Bierig^nM#^rND^sDevereux^nRB#et al#Recommendations for chamber quantification: a
 report from the American Society of Echocardiographys Guidelines and Standards 
Committee and the Chamber Quantification Writing Group, developed in conjunction
 with the European Association of Echocardiography, a branch of the European Soc
iety of Cardiology^len#J Am Soc Echocardiogr#20050000#2005#18#1440-63#20110300#v
33n1a11.htm#0894-7317#J Am Soc Echocardiogr##
00746000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100016000980100
01400114010001700128010000900145010001800154010001900172012012600191030001800317
06500090033506400050034403100020034901400070035186500090035800200130036703500100
0380801001800390#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#212#23
#article#56#23#^rND^sNishimura^nRA#^rND^sTajik^nAJ#^rND^sShub^nC#^rND^sMiller^nF
A#^rND^sJr#^rND^sIlstrup^nDM#^rND^sHarrison^nCE#Role of two-dimensional echocard
iography in the prediction of in-hospital complications after acute myocardial i
nfarction^len#J Am Coll Cardiol#19840000#1984#4#1080-7#20110300#v33n1a11.htm#073
5-1097#J Am Coll Cardiol##
00675000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970100
01800114010001500132010001600147010001700163012008700180030001300267065000900280
06400050028903100030029401400070029786500090030400200130031303500100032680100130
0336#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#213#24#article#56#
24#^rND^sMarchais^nSJ#^rND^sGuerin^nAP#^rND^sPannier^nBM#^rND^sLevy^nBI#^rND^sSa
far^nME#^rND^sLondon^nGM#Wave reflections and cardiac hypertrophy in chronic ure
mia: Influence of body size^len#Hypertension#19930000#1993#22#876-83#20110300#v3
3n1a11.htm#0194-911X#Hypertension##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100025000780100030001030100
01900133010001500152012010200167030001300269065000900282064000500291031000300296
014000400299865000900303002001300312035001000325801001300335#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#214#25#article#56#25#^rND^sFerreira Filho^
nSR#^rND^sde Castro Rodrigues^nFF#^rND^sOliveira^nPC#^rND^sNery^nMA#Systemic hem
odynamic changes in older hypertensive patients after drinking water or eating a
 meal^len#Hypertension#20070000#2007#49#e31#20110300#v33n1a11.htm#0194-911X#Hype
rtension##
00807000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960100
02300116810000600139012026800145030001800413065000900431064000500440031000300445
014000700448865000900455002001300464035001000477801001800487#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#215#26#article#56#26#^rND^sBurnett^nRW#^rN
D^sCovington^nAK#^rND^sFogh-Andersen^nN#et al#Use of ion-selective electrodes fo
r blood-electrolyte analysis: Recommendations for nomenclature, definitions and 
conventions. International Federation of Clinical Chemistry and Laboratory Medic
ine (IFCC). Scientific Division Working Group on Selective Electrodes^len#Clin C
hem Lab Med#20000000#2000#38#363-70#20110300#v33n1a11.htm#1434-6621#Clin Chem La
b Med##
00628000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01600112012011700128030001800245065000900263064000500272031000300277014000800280
865000900288002001300297035001000310801001800320#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a11.htm#S#c#216#27#article#56#27#^rND^sChromy^nV#^rND^sRozkosna^nK
#^rND^sSedlak^nP#Determination of serum creatinine by Jaffe method and how to ca
librate to eliminate matrix interference problems^len#Clin Chem Lab Med#20080000
#2008#46#1127-33#20110300#v33n1a11.htm#1434-6621#Clin Chem Lab Med##
00510000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100022000940120
06900116030001200185710000200197065000900199064000500208031000300213014000600216
865000900222002001300231#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#
c#217#28#article#56#28#^rND^sJaved^nMU#^rND^sMichelangeli^nF#Enzymatic method fo
r assaying calcium in serum with Ca++ -ATPase^len#Exp Mol Med#2#20030000#2003#35
#17-22#20110300#v33n1a11.htm##
00702000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
02100112010001800133010001400151010001800165012012200183030000800305065000900313
06400050032203100030032701400060033086500090033600200130034503500100035880100080
0368#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#218#29#article#56#
29#^rND^sHarnett^nJD#^rND^sMurphy^nB#^rND^sCollingwood^nP#^rND^sPurchase^nL#^rND
^sKent^nG#^rND^sParfrey^nPS#The reliability and validity of echocardiographic me
asurement of left ventricular mass index in hemodialysis patients^len#Nephron#19
930000#1993#65#212-4#20110300#v33n1a11.htm#0028-2766#Nephron##
00758000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01800112810000600130012022100136030002200357065000900379064000500388031000200393
014000700395865000900402002001300411035001000424801002200434#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#219#30#article#56#30#^rND^sSchiller^nNB#^r
ND^sShah^nPM#^rND^sCrawford^nM#et al#Recommendations for quantitation of the lef
t ventricle by two-dimensional echocardiography: American Society of Echocardiog
raphy Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Ec
hocardiograms^len#J Am Soc Echocardiogr#19890000#1989#2#358-67#20110300#v33n1a11
.htm#0894-7317#J Am Soc Echocardiogr##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01600110010001600126012012500142030001200267065000900279064000500288031000300293
014000800296865000900304002001300313035001000326801001200336#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#220#31#article#56#31#^rND^sSahn^nDJ#^rND^s
DeMaria^nA#^rND^sKisslo^nJ#^rND^sWeyman^nA#Recommendations regarding quantitatio
n in M-mode echocardiography: results of a survey of echocardiographic measureme
nts^len#Circulation#19780000#1978#58#1072-83#20110300#v33n1a11.htm#0009-7322#Cir
culation##
00624000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930100
01600112810000600128012009600134030001800230065000900248064000500257031000300262
014000700265865000900272002001300281035001000294801001800304#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#221#32#article#56#32#^rND^sGanau^nA#^rND^s
Devereux^nRB#^rND^sRoman^nMJ#et al#Patterns of left ventricular hypertrophy and 
geometric remodeling in essential hypertension^len#J Am Coll Cardiol#19920000#19
92#19#1550-8#20110300#v33n1a11.htm#0735-1097#J Am Coll Cardiol##
00427000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120015000930300
01600108710000200124065000900126064000500135031000300140014000800143865000900151
002001300160#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#222#33#art
icle#56#33#^rND^sFord^nLE#Heart size^len#Circulation Res#2#19760000#1976#39#297-
303#20110300#v33n1a11.htm##
00481000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120038000940300
01300132065000900145064000500154031000300159014000800162865000900170002001300179
035001000192801001300202#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#
c#223#34#article#56#34#^rND^sGaash^nWH#LV radius to wall thickness ratio^len#Am 
J Cardiol#19790000#1979#43#1189-94#20110300#v33n1a11.htm#0002-9149#Am J Cardiol#
#
00539000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120101000930300
01100194065000900205064000500214031000300219014000800222865000900230002001300239
035001000252801001100262#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#
c#224#35#article#56#35#^rND^sFast^nJH#Limits of reproducibility of left ventricu
lar wall thickness and mass by M-mode echocardiography^len#Neth J Med#19890000#1
989#34#297-301#20110300#v33n1a11.htm#0300-2977#Neth J Med##
00630000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100020000950100
01900115810000600134012009700140030001700237065000900254064000500263031000300268
014000800271865000900279002001300288035001000301801001700311#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#225#36#article#56#36#^rND^sZoccali^nC#^rND
^sBenedetto^nFA#^rND^sMallamaci^nF#et al#Prognostic impact of the indexation of 
left ventricular mass in patients undergoing dialysis^len#J Am Soc Nephrol#20010
000#2001#12#2768-74#20110300#v33n1a11.htm#1046-6673#J Am Soc Nephrol##
00592000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01600112810000600128012007800134030001100212065000900223064000500232031000300237
014000700240865000900247002001300256035001000269801001100279#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#226#37#article#56#37#^rND^sMiller^nPE#^rND
^sTolwani^nA#^rND^sLuscy^nCP#et al#Predictors of adequacy of arteriovenous fistu
las in hemodialysis patients^len#Kidney Int#19990000#1999#56#275-80#20110300#v33
n1a11.htm#0085-2538#Kidney int##
00583000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100022000950100
01900117810000600136012006300142030001000205065000900215064000500224031000400229
014000600233865000900239002001300248035001000261801001000271#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#227#38#article#56#38#^rND^sRobbin^nML#^rND
^sChamberlain^nNE#^rND^sLockhart^nME#et al#Hemodialysis arteriovenous fistula ma
turity: US evaluation^len#Radiology#20020000#2002#225#59-64#20110300#v33n1a11.ht
m#0033-8419#Radiology##
00545000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100012000780120099000900300
01700189065000900206064000500215031000300220014000700223865000900230002001300239
035001000252801001700262#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#
c#228#39#article#56#39#^rND^sde SG#Left ventricular geometry and hypotension in 
end-stage renal disease: a mechanical perspective^len#J Am Soc Nephrol#20030000#
2003#14#2421-7#20110300#v33n1a11.htm#1046-6673#J Am Soc Nephrol##
00655000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
02100112810000600133012011000139030002400249065000900273064000500282031000300287
014000700290865000900297002001300306035001000319801002400329#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#229#40#article#56#40#^rND^sFagugli^nRM#^rN
D^sPasini^nP#^rND^sQuintaliani^nG#et al#Association between extracellular water,
 left ventricular mass and hypertension in haemodialysis patients^len#Nephrol Di
al Transplant#20030000#2003#18#2332-8#20110300#v33n1a11.htm#0931-0509#Nephrol Di
al Transplant##
00652000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100025000950100
01800120810000600138012010300144030002400247065000900271064000500280031000300285
014000600288865000900294002001300303035001000316801002400326#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#230#41#article#56#41#^rND^sJacobs^nLH#^rND
^svan de Kerkhof^nJJ#^rND^sMingels^nAM#et al#Inflammation, overhydration and car
diac biomarkers in haemodialysis patients: a longitudinal study^len#Nephrol Dial
 Transplant#20100000#2010#25#243-8#20110300#v33n1a11.htm#0931-0509#Nephrol Dial 
Transplant##
00567000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120100000960300
02400196065000900220064000500229031000300234014000800237865000900245002001300254
035001000267801002400277#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#
c#231#42#article#56#42#^rND^sKrediet^nRT#How to preserve residual renal function
 in patients with chronic kidney disease and on dialysis^len#Nephrol Dial Transp
lant#20060000#2006#21#42-ii46#20110300#v33n1a11.htm#0931-0509#Nephrol Dial Trans
plant##
00627000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930100
01800107810000600125012012000131030000900251065000900260064000500269031000300274
014000700277865000900284002001300293035001000306801000900316#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#232#43#article#56#43#^rND^sYang^nPY#^rND^s
Lin^nJL#^rND^sLin-Tan^nDT#et al#Residual daily urine volume association with inf
lammation and nutrition status in maintenance hemodialysis patients^len#Ren Fail
#20090000#2009#31#423-30#20110300#v33n1a11.htm#0886-022X#Ren Fail##
00648000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100016000990100
01700115010002000132012009800152030001300250065000900263064000500272031000300277
031000300280014000600283865000900289002001300298035001000311801001300321#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#233#44#article#56#44#^rND^sSil
berberg^nJS#^rND^sRahal^nDP#^rND^sPatton^nDR#^rND^sSniderman^nAD#Role of anemia 
in the pathogenesis of left ventricular hypertrophy in end-stage renal disease^l
en#Am J Cardiol#19890000#1989#15#64#222-4#20110300#v33n1a11.htm#0002-9149#Am J C
ardiol##
00585000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100018001000100
01900118012008300137030001000220065000900230064000500239031000300244014000600247
865000900253002001300262035001000275801001000285#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a11.htm#S#c#234#45#article#56#45#^rND^sStojimirovic^nB#^rND^sPetro
vic^nD#^rND^sObrenovic^nR#Left ventricular hypertrophy in patients on hemodialys
is: importance of anemia^len#Med Pregl#20070000#2007#60#155-9#20110300#v33n1a11.
htm#0025-8105#Med Pregl##
00668000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100016000980100
01500114010002000129012013700149030001400286065000900300064000500309031000200314
014000400316865000900320002001300329035001000342801001400352#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#235#46#article#56#46#^rND^sSilberberg^nJ#^
rND^sRacine^nN#^rND^sBarre^nP#^rND^sSniderman^nAD#Regression of left ventricular
 hypertrophy in dialysis patients following correction of anemia with recombinan
t human erythropoietin^len#Can J Cardiol#19900000#1990#6#1-4#20110300#v33n1a11.h
tm#0828-282X#Can J Cardiol##
00674000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01800112010001500130010001700145010001600162012008100178030001700259065000900276
06400050028503100020029001400070029286500090029900200130030803500100032180100170
0331#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#236#47#article#56#
47#^rND^sFoley^nRN#^rND^sParfrey^nPS#^rND^sHarnett^nJD#^rND^sKent^nGM#^rND^sMurr
ay^nDC#^rND^sBarre^nPE#Hypoalbuminemia, cardiac morbidity, and mortality in end-
stage renal disease^len#J Am Soc Nephrol#19960000#1996#7#728-36#20110300#v33n1a1
1.htm#1046-6673#J Am Soc Nephrol##
00621000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100015000930100
01500108810000600123012010700129030001300236065000900249064000500258031000300263
014000800266865000900274002001300283035001000296801001300306#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#237#48#article#56#48#^rND^sMoon^nKH#^rND^s
Song^nIS#^rND^sYang^nWS#et al#Hypoalbuminemia as a risk factor for progressive l
eft-ventricular hypertrophy in hemodialysis patients^len#Am J Nephrol#20000000#2
000#20#396-401#20110300#v33n1a11.htm#0250-8095#Am J Nephrol##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100019000920100
01400111810000600125012011200131030002400243065000900267064000500276031000300281
014000800284865000900292002001300301035001000314801002400324#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#238#49#article#56#49#^rND^sSuda^nT#^rND^sH
iroshige^nK#^rND^sOhta^nT#et al#The contribution of residual renal function to o
verall nutritional status in chronic haemodialysis patients^len#Nephrol Dial Tra
nsplant#20000000#2000#15#396-401#20110300#v33n1a11.htm#0931-0509#Nephrol Dial Tr
ansplant##
00611000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100013000920120
14200105030001600247065000900263064000500272031000300277014000500280865000900285
002001300294035001000307801001600317#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a11.htm#S#c#239#50#article#56#50#^rND^sFine^nA#^rND^sCox^nD#Modest reduction o
f serum albumin in continuous ambulatory peritoneal dialysis patients is common 
and of no apparent clinical consequence^len#Am J Kidney Dis#19920000#1992#20#50-
4#20110300#v33n1a11.htm#0272-6386#Am J Kidney Dis##
00686000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01700114010002100131010001500152012012000167030001500287065000900302064000500311
031000300316014000600319865000900325002001300334035001000347801001500357#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#240#51#article#56#51#^rND^sStr
uijk^nDG#^rND^sKrediet^nRT#^rND^sKoomen^nGC#^rND^sBoeschoten^nEW#^rND^sArisz^nL#
The effect of serum albumin at the start of continuous ambulatory peritoneal dia
lysis treatment on patient survival^len#Perit Dial Int#19940000#1994#14#121-6#20
110300#v33n1a11.htm#0896-8608#Perit Dial Int##
00650000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
02000113012013600133030001700269065000900286064000500295031000300300014000800303
865000900311002001300320035001000333801001700343#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a11.htm#S#c#241#52#article#56#52#^rND^sBargman^nJM#^rND^sThorpe^nK
E#^rND^sChurchill^nDN#Relative contribution of residual renal function and perit
oneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study^len#J 
Am Soc Nephrol#20010000#2001#12#2158-62#20110300#v33n1a11.htm#1046-6673#J Am Soc
 Nephrol##
00650000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01600112010001600128010001900144012008700163030001600250065000900266064000500275
031000300280014000500283865000900288002001300297035001000310801001600320#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#242#53#article#56#53#^rND^sFel
dman^nAM#^rND^sFivush^nB#^rND^sZahka^nKG#^rND^sOuyang^nP#^rND^sBaughman^nKL#Cong
estive cardiomyopathy in patients on continuous ambulatory peritoneal dialysis^l
en#Am J Kidney Dis#19880000#1988#11#76-9#20110300#v33n1a11.htm#0272-6386#Am J Ki
dney Dis##
00590000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01600111810000600127012008700133030000700220065000900227064000500236031000200241
014000600243865000900249002001300258035001000271801000700281#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#243#54#article#56#54#^rND^sDrueke^nT#^rND^
sFauchet^nM#^rND^sFleury^nJ#et al#Effect of parathyroidectomy on left-ventricula
r function in haemodialysis patients^len#Lancet#19800000#1980#1#112-4#20110300#v
33n1a11.htm#0099-5355#Lancet##
00603000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100023000950100
01700118810000600135012008300141030001100224065000900235064000500244031000300249
014000600252865000900258002001300267035001000280801001100290#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a11.htm#S#c#244#55#article#56#55#^rND^sLondon^nGM#^rND
^sDe Vernejoul^nMC#^rND^sFabiani^nF#et al#Secondary hyperparathyroidism and card
iac hypertrophy in hemodialysis patients^len#Kidney Int#19870000#1987#32#900-7#2
0110300#v33n1a11.htm#0085-2538#Kidney int##
00709000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01600112010001600128010001700144010001700161012011700178030001600295065000900311
06400050032003100040032501400060032986500090033500200130034403500100035780100160
0367#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a11.htm#S#c#245#56#article#56#
56#^rND^sAnderson^nCB#^rND^sCodd^nJR#^rND^sGraff^nRA#^rND^sGroce^nMA#^rND^sHarte
r^nHR#^rND^sNewton^nWT#Cardiac failure and upper extremity arteriovenous dialysi
s fistulas: Case reports and a review of the literature^len#Arch Intern Med#1976
0000#1976#136#292-7#20110300#v33n1a11.htm#0003-9926#Arch Intern Med##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#o#1#1#article#1#
20110411#093006#v33n1a12.htm#163##
05721000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201130
01610120102002740100028003760100034004040100042004380100045004800700039005250700
06200564083201300626085001002639085002602649085003202675085002802707085002102735
08500210275608320650277708500100484208500270485208500220487908500400490108500330
49410850021049741170008049950720003050031120009050061110011050151140009050261130
01105035002001305046#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#h#2#
1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#12#JBN020#nd#J. Bras. Nefrol.#33#1#201103
00#^f86^l92#0101-2800#Comparação entre citrato trissódico e heparina como soluçã
o para selo de cateter em pacientes em hemodiálise^lpt#Comparison of trisodium c
itrate and heparin as catheter-locking solution in hemodialysis patients^len#^rN
D^nJosé Luís^sBevilacqua#^rND^1A01^nJaelson Guilhem^sGomes#^rND^1A01^nVanderson 
Farley Brito^sSantos#^rND^1A02^nMaria Eugênia Fernandes^sCanziani#Instituto de H
emodiálise Sorocaba^iA01#Universidade Federal São Paulo^iA02^1Disciplina de Nefr
ologia#^lpt^aINTRODUÇÃO: A elevada incidência de pacientes iniciando ou sendo ma
ntidos em tratamento dialítico através de cateteres venosos tem aumentado o núme
ro de infecções da corrente sanguínea relacionadas aos cateteres e suas consequê
ncias, obrigando a busca de substâncias que tenham propriedades anticoagulantes 
e que também impeçam a contaminação dos mesmos. OBJETIVOS: Comparar a utilização
 de heparina e citrato trissódico como selo de cateteres de longa permanência qu
anto à ocorrência de pirogenia, bacteremia, internações hospitalares relacionada
s à infecção, trombose e óbito. MÉTODOS: Estudo retrospectivo por meio de dados 
do registro de infecção do Programa de Controle e Prevenção de Infecções e Event
os Adversos, onde foram incluídos todos os pacientes que entre abril de 2006 e m
arço de 2008 utilizaram cateteres de longa permanência. Nos primeiros 365 dias, 
o selo do cateter foi feito com heparina (Grupo Heparina) e nos 365 dias seguint
es foi feito com citrato trissódico a 46,7% (Grupo Citrato). Sessenta e cinco pa
cientes fizeram parte do estudo utilizando noventa e dois cateteres. Os grupos f
oram comparados para ocorrência de pirogenia, bacteremia, hospitalização, trombo
se de cateter e óbito. RESULTADOS: A ocorrência de bacteremia relacionada ao cat
eter e o tempo de hospitalização foram significantemente menores no Grupo Citrat
o. Houve uma tendência a menor ocorrência de hospitalização relacionada à infecç
ão de acesso no Grupo Citrato (p = 0.055), e não houve diferença quanto à trombo
se de cateteres levando a disfunção. O tempo livre de bacteremia e de hospitaliz
ação foram maiores no Grupo Citrato. A ocorrência de bacteremia esteve associada
 a ser diabético e a pertencer ao Grupo Heparina. Na análise multivariada, apena
s pertencer ao Grupo Heparina esteve associada à sua ocorrência. CONCLUSÃO: O us
o de citrato a 46,7% reduziu de maneira efetiva episódios de bacteremia e intern
ações hospitalares em pacientes submetidos à hemodiálise através de cateteres de
 longa permanência.#^ddecs^i1#^tm^lpt^kdiálise renal^i1#^tm^lpt^kcateteres de de
mora^i1#^tm^lpt^kanticoagulantes^i1#^tm^lpt^kcitratos^i1#^tm^lpt^kinfecção^i1#^l
en^aINTRODUCTION: The high incidence of patients beginning dialysis treatment wi
th venous catheters, as well as the growing number of patients with permanent ca
theter access, has increased catheter- related blood infections and their conseq
uences. Thus the search for substances with anticoagulant properties that also p
revent catheter contamination is necessary. OBJECTIVE: This study aimed at compa
ring heparin and trisodium citrate used as long-term catheter locking solutions 
regarding the occurrence of pyrogenic reaction, bacteremia, infection- related h
ospitalizations, thrombosis, and death. METHODS: Retrospective study on the infe
ction data from the Infection and Adverse Event Prevention Control Program regis
try, which included all hemodialysis patients using long-term catheters from Apr
il, 2006 to March, 2008. During the first 365 days, catheters were locked with h
eparin (Heparin group) and, during the following 365 days, with 46.7% trisodium 
citrate (Citrate group). Sixty-five patients were included in the study using 92
 catheters. The groups were compared regarding the occurrence of pyrogenic react
ion, bacteremia, hospitalization, catheter thrombosis, and death. RESULTS: The c
atheter-related bacteremia episodes were significantly lower and hospitalization
 time was significantly shorter in the Citrate group when compared with those in
 the Heparin group. A tendency towards a lower occurrence of access site infecti
on-related hospitalization was observed in the Citrate group (p = 0.055), and no
 difference was observed in catheter thrombosis leading to dysfunction between g
roups. Bacteremia-free and hospitalization-free times were longer in the Citrate
 group. The occurrence of bacteremia was associated with the presence of diabete
s and heparin use. In multivariate analysis, being in the Heparin group was the 
only factor associated with bacteremia. CONCLUSION: The use of 46.7% citrate sol
ution effectively reduced bacteremia episodes and hospitalization in chronic kid
ney disease patients on hemodialysis with long-term catheters.#^ddecs^i2#^tm^len
^krenal dialysis^i2#^tm^len^kcatheters^i2#^tm^len^kcatheter-related infections^i
2#^tm^len^kanticoagulant agents^i2#^tm^len^kcitrates^i2#vancouv#25#20101124#24/1
1/2010#20110107#07/01/2011#v33n1a12.htm##
05805000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400090014203500100015101201200
01610120109002810100028003900100034004180100042004520100045004940700039005390700
06200578083204800640085001002688085002602698085003202724085002802756085002102784
08500210280508321000282608500100492608500270493608500220496308500400498508500330
50250850021050581170008050790720003050871120009050901110011050991140009051101130
01105119002001305130#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#f#3#
1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#12#JBN020#nd#J. Bras. Nefrol.#33#1#201103
00#^f86^l92#0101-2800#<b>Comparação entre citrato trissódico e heparina como sol
ução para selo de cateter em pacientes em hemodiálise</b>^lpt#<b>Comparison of t
risodium citrate and heparin as catheter-locking solution in hemodialysis patien
ts</b>^len#^rND^nJosé Luís^sBevilacqua#^rND^1A01^nJaelson Guilhem^sGomes#^rND^1A
01^nVanderson Farley Brito^sSantos#^rND^1A02^nMaria Eugênia Fernandes^sCanziani#
Instituto de Hemodiálise Sorocaba^iA01#Universidade Federal São Paulo^iA02^1Disc
iplina de Nefrologia#^lpt^a<b>INTRODUÇÃO:</b> A elevada incidência de pacientes 
iniciando ou sendo mantidos em tratamento dialítico através de cateteres venosos
 tem aumentado o número de infecções da corrente sanguínea relacionadas aos cate
teres e suas consequências, obrigando a busca de substâncias que tenham propried
ades anticoagulantes e que também impeçam a contaminação dos mesmos. <b>OBJETIVO
S:</b> Comparar a utilização de heparina e citrato trissódico como selo de catet
eres de longa permanência quanto à ocorrência de pirogenia, bacteremia, internaç
ões hospitalares relacionadas à infecção, trombose e óbito. <b>MÉTODOS:</b> Estu
do retrospectivo por meio de dados do registro de infecção do Programa de Contro
le e Prevenção de Infecções e Eventos Adversos, onde foram incluídos todos os pa
cientes que entre abril de 2006 e março de 2008 utilizaram cateteres de longa pe
rmanência. Nos primeiros 365 dias, o selo do cateter foi feito com heparina (Gru
po Heparina) e nos 365 dias seguintes foi feito com citrato trissódico a 46,7% (
Grupo Citrato). Sessenta e cinco pacientes fizeram parte do estudo utilizando no
venta e dois cateteres. Os grupos foram comparados para ocorrência de pirogenia,
 bacteremia, hospitalização, trombose de cateter e óbito. <b>RESULTADOS:</b> A o
corrência de bacteremia relacionada ao cateter e o tempo de hospitalização foram
 significantemente menores no Grupo Citrato. Houve uma tendência a menor ocorrên
cia de hospitalização relacionada à infecção de acesso no Grupo Citrato (p = 0.0
55), e não houve diferença quanto à trombose de cateteres levando a disfunção. O
 tempo livre de bacteremia e de hospitalização foram maiores no Grupo Citrato. A
 ocorrência de bacteremia esteve associada a ser diabético e a pertencer ao Grup
o Heparina. Na análise multivariada, apenas pertencer ao Grupo Heparina esteve a
ssociada à sua ocorrência. <b>CONCLUSÃO: </b>O uso de citrato a 46,7% reduziu de
 maneira efetiva episódios de bacteremia e internações hospitalares em pacientes
 submetidos à hemodiálise através de cateteres de longa permanência.#^ddecs^i1#^
tm^lpt^kdiálise renal^i1#^tm^lpt^kcateteres de demora^i1#^tm^lpt^kanticoagulante
s^i1#^tm^lpt^kcitratos^i1#^tm^lpt^kinfecção^i1#^len^a<b>INTRODUCTION:</b> The hi
gh incidence of patients beginning dialysis treatment with venous catheters, as 
well as the growing number of patients with permanent catheter access, has incre
ased catheter- related blood infections and their consequences. Thus the search 
for substances with anticoagulant properties that also prevent catheter contamin
ation is necessary. <b>OBJECTIVE:</b> This study aimed at comparing heparin and 
trisodium citrate used as long-term catheter locking solutions regarding the occ
urrence of pyrogenic reaction, bacteremia, infection- related hospitalizations, 
thrombosis, and death. <b>METHODS:</b> Retrospective study on the infection data
 from the Infection and Adverse Event Prevention Control Program registry, which
 included all hemodialysis patients using long-term catheters from April, 2006 t
o March, 2008. During the first 365 days, catheters were locked with heparin (He
parin group) and, during the following 365 days, with 46.7% trisodium citrate (C
itrate group). Sixty-five patients were included in the study using 92 catheters
. The groups were compared regarding the occurrence of pyrogenic reaction, bacte
remia, hospitalization, catheter thrombosis, and death. <b>RESULTS:</b> The cath
eter-related bacteremia episodes were significantly lower and hospitalization ti
me was significantly shorter in the Citrate group when compared with those in th
e Heparin group. A tendency towards a lower occurrence of access site infection-
related hospitalization was observed in the Citrate group (p = 0.055), and no di
fference was observed in catheter thrombosis leading to dysfunction between grou
ps. Bacteremia-free and hospitalization-free times were longer in the Citrate gr
oup. The occurrence of bacteremia was associated with the presence of diabetes a
nd heparin use. In multivariate analysis, being in the Heparin group was the onl
y factor associated with bacteremia. <b>CONCLUSION:</b> The use of 46.7% citrate
 solution effectively reduced bacteremia episodes and hospitalization in chronic
 kidney disease patients on hemodialysis with long-term catheters.#^ddecs^i2#^tm
^len^krenal dialysis^i2#^tm^len^kcatheters^i2#^tm^len^kcatheter-related infectio
ns^i2#^tm^len^kanticoagulant agents^i2#^tm^len^kcitrates^i2#vancouv#25#20101124#
24/11/2010#20110107#07/01/2011#v33n1a12.htm##
05887000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400090015903500100
01680120113001780120102002910100028003930100034004210100042004550100045004970700
04100542070006400583083203100647085001002678085002602688085003202714085002802746
08500210277408500210279508320790281608500100489508500270490508500220493208500400
49540850033049940850021050271170008050480720003050561120009050591110011050681140
00905079113001105088002001305099008008905112#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a12.htm#S#l#4#1#article#1#^mjan./mar.^a2011#oa#pt#br1.1#1#4.0#ilus#tab
#12#JBN020#nd#J. Bras. Nefrol#33#1#20110300#^f86^l92#0101-2800#Comparação entre 
citrato trissódico e heparina como solução para selo de cateter em pacientes em 
hemodiálise^lpt#Comparison of trisodium citrate and heparin as catheter-locking 
solution in hemodialysis patients^len#^rND^nJosé Luís^sBevilacqua#^rND^1A01^nJae
lson Guilhem^sGomes#^rND^1A01^nVanderson Farley Brito^sSantos#^rND^1A02^nMaria E
ugênia Fernandes^sCanziani#^iA01^1Instituto de Hemodiálise Sorocaba#^iA02^1Unive
rsidade Federal São Paulo^2Disciplina de Nefrologia#^lpt^aINTRODUÇÃO: A elevada 
incidência de pacientes iniciando ou sendo mantidos em tratamento dialítico atra
vés de cateteres venosos tem aumentado o número de infecções da corrente sanguín
ea relacionadas aos cateteres e suas consequências, obrigando a busca de substân
cias que tenham propriedades anticoagulantes e que também impeçam a contaminação
 dos mesmos. OBJETIVOS: Comparar a utilização de heparina e citrato trissódico c
omo selo de cateteres de longa permanência quanto à ocorrência de pirogenia, bac
teremia, internações hospitalares relacionadas à infecção, trombose e óbito. MÉT
ODOS: Estudo retrospectivo por meio de dados do registro de infecção do Programa
 de Controle e Prevenção de Infecções e Eventos Adversos, onde foram incluídos t
odos os pacientes que entre abril de 2006 e março de 2008 utilizaram cateteres d
e longa permanência. Nos primeiros 365 dias, o selo do cateter foi feito com hep
arina (Grupo Heparina) e nos 365 dias seguintes foi feito com citrato trissódico
 a 46,7 por cento (Grupo Citrato). Sessenta e cinco pacientes fizeram parte do e
studo utilizando noventa e dois cateteres. Os grupos foram comparados para ocorr
ência de pirogenia, bacteremia, hospitalização, trombose de cateter e óbito. RES
ULTADOS: A ocorrência de bacteremia relacionada ao cateter e o tempo de hospital
ização foram significantemente menores no Grupo Citrato. Houve uma tendência a m
enor ocorrência de hospitalização relacionada à infecção de acesso no Grupo Citr
ato (p = 0.055), e não houve diferença quanto à trombose de cateteres levando a 
disfunção. O tempo livre de bacteremia e de hospitalização foram maiores no Grup
o Citrato. A ocorrência de bacteremia esteve associada a ser diabético e a perte
ncer ao Grupo Heparina. Na análise multivariada, apenas pertencer ao Grupo Hepar
ina esteve associada à sua ocorrência. CONCLUSÃO: O uso de citrato a 46,7 por ce
nto reduziu de maneira efetiva episódios de bacteremia e internações hospitalare
s em pacientes submetidos à hemodiálise através de cateteres de longa permanênci
a.#^ddecs^i1#^tm^lpt^kdiálise renal^i1#^tm^lpt^kcateteres de demora^i1#^tm^lpt^k
anticoagulantes^i1#^tm^lpt^kcitratos^i1#^tm^lpt^kinfecção^i1#^len^aINTRODUCTION:
 The high incidence of patients beginning dialysis treatment with venous cathete
rs, as well as the growing number of patients with permanent catheter access, ha
s increased catheter- related blood infections and their consequences. Thus the 
search for substances with anticoagulant properties that also prevent catheter c
ontamination is necessary. OBJECTIVE: This study aimed at comparing heparin and 
trisodium citrate used as long-term catheter locking solutions regarding the occ
urrence of pyrogenic reaction, bacteremia, infection- related hospitalizations, 
thrombosis, and death. METHODS: Retrospective study on the infection data from t
he Infection and Adverse Event Prevention Control Program registry, which includ
ed all hemodialysis patients using long-term catheters from April, 2006 to March
, 2008. During the first 365 days, catheters were locked with heparin (Heparin g
roup) and, during the following 365 days, with 46.7 percent trisodium citrate (C
itrate group). Sixty-five patients were included in the study using 92 catheters
. The groups were compared regarding the occurrence of pyrogenic reaction, bacte
remia, hospitalization, catheter thrombosis, and death. RESULTS: The catheter-re
lated bacteremia episodes were significantly lower and hospitalization time was 
significantly shorter in the Citrate group when compared with those in the Hepar
in group. A tendency towards a lower occurrence of access site infection-related
 hospitalization was observed in the Citrate group (p = 0.055), and no differenc
e was observed in catheter thrombosis leading to dysfunction between groups. Bac
teremia-free and hospitalization-free times were longer in the Citrate group. Th
e occurrence of bacteremia was associated with the presence of diabetes and hepa
rin use. In multivariate analysis, being in the Heparin group was the only facto
r associated with bacteremia. CONCLUSION: The use of 46.7 percent citrate soluti
on effectively reduced bacteremia episodes and hospitalization in chronic kidney
 disease patients on hemodialysis with long-term catheters.#^ddecs^i2#^tm^len^kr
enal dialysis^i2#^tm^len^kcatheters^i2#^tm^len^kcatheter-related infections^i2#^
tm^len^kanticoagulant agents^i2#^tm^len^kcitrates^i2#vancouv#25#20101124#24/11/2
010#20110107#07/01/2011#v33n1a12.htm#Internet^ihttp://www.scielo.br/scielo.php?s
cript=sci_arttext&pid=S0101-28002011000100012##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#5#1#article#134#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v33n1a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#6#2#article#134#<p>&nbsp;</p>     ^cY#
v33n1a12.htm##
00493000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704026100073002001300334#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#7#3#article#134#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Compara&ccedil;&a
tilde;o entre citrato triss&oacute;dico e heparina como  solu&ccedil;&atilde;o p
ara selo de cateter em pacientes em hemodi&aacute;lise </b></font></p>     ^cY#v
33n1a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#8#4#article#134#<p>&nbsp;</p>     ^cY#
v33n1a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#9#5#article#134#<p>&nbsp;</p>     ^cY#
v33n1a12.htm##
00504000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704027100074002001300345#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#10#6#article#134#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Jos&eacute; Lu&iacute;s Bevilacqua<
sup>I</sup>; Jaelson Guilhem Gomes<sup>II</sup>; Vanderson Farley Brito Santos<s
up>II</sup>; Maria Eug&ecirc;nia  Fernandes Canziani<sup>III</sup></b></font></p
>     ^cY#v33n1a12.htm##
00352000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704011900074002001300193#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#11#7#article#134#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Gradua&ccedil;&atilde;o em
 Medicina     ^cY#v33n1a12.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704007400074002001300148#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#12#8#article#134#<br>   <sup>II</sup>I
nstituto de Hemodi&aacute;lise Sorocaba - IHS    ^cY#v33n1a12.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704011800074002001300192#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#13#9#article#134#<br>   <sup>III</sup>
Disciplina de Nefrologia, Universidade Federal S&atilde;o Paulo - UNIFESP/EPM</f
ont></p>     ^cY#v33n1a12.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#14#10#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia
</a></font></p>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#15#11#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#16#12#article#134#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a12.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#17#13#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a12.htm##
00768000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053400075002001300609#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#18#14#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O:</b> A el
evada incid&ecirc;ncia de pacientes iniciando ou sendo mantidos em tratamento di
al&iacute;tico atrav&eacute;s de cateteres venosos tem aumentado o n&uacute;mero
 de infec&ccedil;&otilde;es da corrente sangu&iacute;nea relacionadas aos catete
res e suas consequ&ecirc;ncias, obrigando a busca de subst&acirc;ncias que tenha
m propriedades anticoagulantes e que tamb&eacute;m impe&ccedil;am a contamina&cc
edil;&atilde;o dos mesmos.    ^cY#v33n1a12.htm##
00562000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032800075002001300403#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#19#15#article#134#<br>   <b>OBJETIVOS:
</b> Comparar a utiliza&ccedil;&atilde;o de heparina e citrato triss&oacute;dico
 como selo de cateteres de longa perman&ecirc;ncia quanto &agrave; ocorr&ecirc;n
cia de pirogenia, bacteremia, interna&ccedil;&otilde;es hospitalares relacionada
s &agrave; infec&ccedil;&atilde;o, trombose e &oacute;bito.     ^cY#v33n1a12.htm
##
00989000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704075500075002001300830#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#20#16#article#134#<br>   <b>M&Eacute;T
ODOS:</b> Estudo retrospectivo por meio de dados do registro de infec&ccedil;&at
ilde;o do Programa de Controle e Preven&ccedil;&atilde;o de Infec&ccedil;&otilde
;es e Eventos Adversos, onde foram inclu&iacute;dos todos os pacientes que entre
 abril de 2006 e mar&ccedil;o de 2008 utilizaram cateteres de longa perman&ecirc
;ncia. Nos primeiros 365 dias, o selo do cateter foi feito com heparina (Grupo H
eparina) e nos 365 dias seguintes foi feito com citrato triss&oacute;dico a 46,7
% (Grupo Citrato). Sessenta e cinco pacientes fizeram parte do estudo utilizando
 noventa e dois cateteres. Os grupos foram comparados para ocorr&ecirc;ncia de p
irogenia, bacteremia, hospitaliza&ccedil;&atilde;o, trombose de cateter e &oacut
e;bito.    ^cY#v33n1a12.htm##
01007000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704077300075002001300848#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#21#17#article#134#<br>   <b>RESULTADOS
:</b> A ocorr&ecirc;ncia de bacteremia relacionada ao cateter e o tempo de hospi
taliza&ccedil;&atilde;o foram significantemente menores no Grupo Citrato. Houve 
uma tend&ecirc;ncia a menor ocorr&ecirc;ncia de hospitaliza&ccedil;&atilde;o rel
acionada &agrave; infec&ccedil;&atilde;o de acesso no Grupo Citrato  (p = 0.055)
, e n&atilde;o houve diferen&ccedil;a quanto &agrave; trombose de cateteres leva
ndo a disfun&ccedil;&atilde;o. O tempo livre de bacteremia e de hospitaliza&cced
il;&atilde;o foram maiores no Grupo Citrato. A ocorr&ecirc;ncia de bacteremia es
teve associada a ser diab&eacute;tico e a pertencer ao Grupo Heparina. Na an&aac
ute;lise multivariada, apenas pertencer ao Grupo Heparina esteve associada &agra
ve; sua ocorr&ecirc;ncia.    ^cY#v33n1a12.htm##
00519000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028500075002001300360#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#22#18#article#134#<br>   <b>CONCLUS&At
ilde;O: </b> O uso de citrato a 46,7% reduziu de maneira efetiva epis&oacute;dio
s de bacteremia e interna&ccedil;&otilde;es hospitalares em pacientes submetidos
 &agrave; hemodi&aacute;lise atrav&eacute;s de cateteres de longa perman&ecirc;n
cia. </font></p>     ^cY#v33n1a12.htm##
00456000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022200075002001300297#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#23#19#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b>di&aacute;lise
 renal, cateteres de demora, anticoagulantes, citratos, infec&ccedil;&atilde;o. 
</font></p> <hr size="1" noshade>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#24#20#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#25#21#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#26#22#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a12.htm##
00771000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053700075002001300612#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#27#23#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O aumento da incid&ecirc;ncia da Doen
&ccedil;a Renal Cr&ocirc;nica est&aacute;gio V, especialmente relacionada &agrav
e;s doen&ccedil;as cr&ocirc;nico- degenerativas, tem assumido n&uacute;meros ala
rmantes nos &uacute;ltimos anos em todo mundo<sup>1</sup> e n&atilde;o tem sido 
diferente no Brasil.<sup>2</sup> Esses pacientes em sua maioria iniciam a terapi
a dial&iacute;tica em hemodi&aacute;lise atrav&eacute;s de um cateter venoso cen
tral.<sup>3</sup></font></p>     ^cY#v33n1a12.htm##
01142000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090800075002001300983#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#28#24#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Apesar de iniciativas implementadas n
os &uacute;ltimos anos para reduzir a utiliza&ccedil;&atilde;o de cateteres e pr
&oacute;teses como o programa Fistula First,<sup>4</sup> nos Estados Unidos da A
m&eacute;rica cerca de 70% dos pacientes iniciam em hemodi&aacute;lise utilizand
o um cateter venoso central<sup>5</sup>. Al&eacute;m disso, em algumas regi&otil
de;es do pa&iacute;s, os cateteres representam at&eacute; 40% dos acessos vascul
ares na popula&ccedil;&atilde;o submetida &agrave; hemodi&aacute;lise. Vale ress
altar que muitos estudos publicados mostram que o risco relativo de morte &eacut
e; de at&eacute; 1,5 vezes maior e o risco relativo de infec&ccedil;&atilde;o &e
acute; 7,6 vezes maior em pacientes com cateteres venosos centrais quando compar
ados &agrave;queles com f&iacute;stula arteriovenosa. <sup>5,6</sup></font></p> 
    ^cY#v33n1a12.htm##
00927000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704069300075002001300768#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#29#25#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os eventos infecciosos constituem a s
egunda causa de mortalidade em pacientes submetidos a tratamento dial&iacute;tic
o. <sup>7</sup> As infec&ccedil;&otilde;es de cateteres utilizados como acesso v
ascular s&atilde;o graves, e podem tornar-se sist&ecirc;micas com focos metast&a
acute;ticos. <sup>8</sup> V&aacute;rias alternativas t&ecirc;m sido utilizadas p
ara minimizar tais riscos, como a utiliza&ccedil;&atilde;o de subst&acirc;ncias 
qu&iacute;micas que reduziriam a incid&ecirc;ncia de infec&ccedil;&otilde;es rel
acionadas aos cateteres quando utilizadas como selo no per&iacute;odo interdial&
iacute;tico. </font></p>     ^cY#v33n1a12.htm##
00773000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053900075002001300614#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#30#26#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A heparina tem sido a subst&acirc;nci
a utilizada como selo, especialmente por sua propriedade anticoagulante. Entreta
nto, com a maior frequ&ecirc;ncia da utiliza&ccedil;&atilde;o de cateteres e oco
rr&ecirc;ncias de infec&ccedil;&otilde;es, outras subst&acirc;ncias como citrato
 de s&oacute;dio, &aacute;lcool e EDTA t&ecirc;m sido buscadas para serem utiliz
adas como selo, isoladas ou em associa&ccedil;&atilde;o com antibi&oacute;ticos.
 <sup>9,10,11</sup></font></p>     ^cY#v33n1a12.htm##
00636000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040200075002001300477#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#31#27#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo foi comparar 
a utiliza&ccedil;&atilde;o de heparina e de citrato triss&oacute;dico como selo 
de cateteres de longa perman&ecirc;ncia quanto &agrave; ocorr&ecirc;ncia de piro
genia, bacteremia, interna&ccedil;&otilde;es hospitalares relacionadas a infec&c
cedil;&atilde;o, trombose e &oacute;bito. </font></p>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#32#28#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#33#29#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font></p>     
^cY#v33n1a12.htm##
00737000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050300075002001300578#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#34#30#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Este estudo &eacute; uma an&aacute;li
se retrospectiva dos dados relacionados &agrave; infec&ccedil;&atilde;o e catete
res registrados nos relat&oacute;rios mensais do Programa de Controle e Preven&c
cedil;&atilde;o de Infec&ccedil;&otilde;es e Eventos Adversos (PCPIEA) na unidad
e sat&eacute;lite de hemodi&aacute;lise - Instituto de Hemodi&aacute;lise Soroca
ba - no per&iacute;odo de abril de 2006 a mar&ccedil;o de 2008.</font></p>     ^
cY#v33n1a12.htm##
01192000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704095800075002001301033#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#35#31#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados foram agrupados em 2 per&iac
ute;odos, de 01 de abril de 2006 a 31 de mar&ccedil;o de 2007, constituindo o Gr
upo Heparina onde se utilizava solu&ccedil;&atilde;o de heparina (1.500 U/mL. ) 
como selo do cateter ao final da sess&atilde;o de hemodi&aacute;lise e o segundo
 per&iacute;odo de 01 de abril de 2007 a 31 de mar&ccedil;o de 2008 onde tivemos
 o Grupo Citrato no qual o selo do cateter foi realizado com solu&ccedil;&atilde
;o de citrato triss&oacute;dico a 46,7%. Os cateteres foram manipulados em todas
 as sess&otilde;es de hemodi&aacute;lise de maneira ass&eacute;ptica, segundo o 
protocolo do servi&ccedil;o, sendo realizado ao final das sess&otilde;es "flush"
 com solu&ccedil;&atilde;o fisiol&oacute;gica a 0,9% e em seguida injetada solu&
ccedil;&atilde;o de citrato ou de heparina, exatamente no volume de preenchiment
o da luz preconizado pelo fabricante. </font></p>     ^cY#v33n1a12.htm##
00705000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047100075002001300546#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#36#32#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A popula&ccedil;&atilde;o inclu&iacut
e;da no estudo foi composta por 65 pacientes em hemodi&aacute;lise, maiores de 1
8 anos e com cateter de dupla luz de longa perman&ecirc;ncia como acesso vascula
r para hemodi&aacute;lise. Destes, 31 (48%) fizeram parte do Grupo Heparina e 34
, (52%) do Grupo Citrato. Por se tratar de estudo cont&iacute;nuo, 17 pacientes 
pertenceram a ambos os grupos. </font></p>     ^cY#v33n1a12.htm##
00854000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062000075002001300695#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#37#33#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Noventa e dois cateteres foram utiliz
ados durante o estudo, sendo 49 no Grupo Heparina e 43 cateteres no Grupo Citrat
o. Os cateteres foram todos Permcath<sup>&reg;</sup> Quinton de tamanho vari&aac
ute;vel (36 a 40 cm) de acordo com a sua posi&ccedil;&atilde;o de inser&ccedil;&
atilde;o e biotipo do paciente, &agrave; exce&ccedil;&atilde;o de 3 cateteres in
seridos em veia femoral, os quais foram todos split catheter Medcomp<sup>&reg;</
sup> de 52 cm. Todos os cateteres foram implantados em sala de hemodin&acirc;mic
a sob fluoroscopia. </font></p>     ^cY#v33n1a12.htm##
00500000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026600075002001300341#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#38#34#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os eventos avaliados foram: ocorr&eci
rc;ncia de pirogenia, bacteremia, trombose ou obstru&ccedil;&atilde;o parcial le
vando a baixo fluxo, hospitaliza&ccedil;&atilde;o e &oacute;bito. </font></p>   
  ^cY#v33n1a12.htm##
00895000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066100075002001300736#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#39#35#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Rea&ccedil;&atilde;o pirog&ecirc;nica
 foi definida como epis&oacute;dio com presen&ccedil;a s&uacute;bita e inexplica
da de pelo menos dois dos seguintes sintomas / sinais: febre, calafrios, tremore
s, sudorese, hipotens&atilde;o ou taquicardia em paciente com cateter de dupla l
uz de longa perman&ecirc;ncia, onde nenhuma outra causa estivesse presente para 
justific&aacute;-los e com hemocultura negativa. <sup>12</sup> Epis&oacute;dios 
que ocorreram do in&iacute;cio at&eacute; seis horas ap&oacute;s o t&eacute;rmin
o da sess&atilde;o de hemodi&aacute;lise foram considerados. </font></p>     ^cY
#v33n1a12.htm##
01081000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084700075002001300922#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#40#36#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Bacteremia relacionada ao cateter foi
 definida como a presen&ccedil;a de infec&ccedil;&atilde;o da corrente sangu&iac
ute;nea constatada por pelo menos uma hemocultura positiva coletada de veia peri
f&eacute;rica na presen&ccedil;a de sinais e sintomas como febre, calafrios e/ou
 hipotens&atilde;o, sem evid&ecirc;ncia que o s&iacute;tio de origem da infec&cc
edil;&atilde;o fosse outro que n&atilde;o o cateter. <sup>13</sup> Durante o est
udo, as hemoculturas foram todas realizadas pelo mesmo Laborat&oacute;rio de Pat
ologia Cl&iacute;nica utilizando o Sistema Hemobac Trif&aacute;sico<sup>&reg;</s
up> e a coleta delas ocorreu em todos os epis&oacute;dios de calafrios e tremore
s, havendo ou n&atilde;o febre, em pacientes com cateteres de longa perman&ecirc
;ncia. </font></p>     ^cY#v33n1a12.htm##
00992000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704075800075002001300833#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#41#37#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Trombose foi definida como a persiste
nte incapacidade de realizar sess&otilde;es de hemodi&aacute;lise atrav&eacute;s
 de cateter de dupla luz de longa perman&ecirc;ncia com fluxo de sangue igual ou
 superior a 200 mL/min. Antes da retirada, como rotina, os cateteres que apresen
tavam baixo fluxo sem evid&ecirc;ncia de apresentarem dobras ou estarem mal posi
cionados receberam ativador de plasminog&ecirc;nio tecidual recombinante (rTPA -
 2,5 mg em cada haste do cateter) durante 1 hora e considerou-se como sucesso na
 desobstru&ccedil;&atilde;o, quando se conseguiu fluxo de sangue superior a 250 
mL/min por pelo menos duas sess&otilde;es consecutivas de hemodi&aacute;lise. </
font></p>     ^cY#v33n1a12.htm##
00444000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021000075002001300285#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#42#38#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Definimos hospitaliza&ccedil;&atilde;
o como toda admiss&atilde;o hospitalar por infec&ccedil;&atilde;o relacionada ao
 cateter. </font></p>     ^cY#v33n1a12.htm##
01245000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704101100075002001301086#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#43#39#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o quanto &agr
ave; presen&ccedil;a de sangramento pelo orif&iacute;cio de sa&iacute;da do cate
ter ou qualquer outro local foi realizada durante todo o per&iacute;odo do estud
o. Al&eacute;m disso, os pacientes foram orientados a relatar qualquer sintoma r
elacionado &agrave; infus&atilde;o da solu&ccedil;&atilde;o de citrato, incluind
o mal estar precordial, gosto met&aacute;lico na boca ou formigamento perioral. 
Quando qualquer desses sintomas foi relatado, a infus&atilde;o era imediatamente
 suspensa. Pela alta concentra&ccedil;&atilde;o utilizada, a infus&atilde;o foi 
sempre realizada com seringas separadas para o lado arterial e para o lado venos
o, sendo ambas com capacidade para 3 mL e sempre preenchidas com o volume descri
to pelo fabricante do cateter para os lados arterial e venoso. O procedimento de
 fechamento do cateter foi sempre realizado por 2 t&eacute;cnicos de enfermagem 
treinados. </font></p>     ^cY#v33n1a12.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012300075002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#44#40#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>AN&Aacute;LISE ESTAT&Iacute;STICA<
/b></font></p>     ^cY#v33n1a12.htm##
01390000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704115600075002001301231#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#45#41#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> O teste de Wilk-Shapiro foi utilizad
o para analisar a distribui&ccedil;&atilde;o das vari&aacute;veis, sendo que aqu
elas com distribui&ccedil;&atilde;o normal foram apresentadas como m&eacute;dia 
± desvio padr&atilde;o, enquanto que as n&atilde;o normais foram apresentadas co
mo mediana e extremos. As vari&aacute;veis categ&oacute;ricas foram apresentadas
 em propor&ccedil;&otilde;es e avaliadas pelo teste Qui-quadrado. A compara&cced
il;&atilde;o entre dois grupos foi realizada utilizando-se o teste t de Student 
ou o teste de Mann-Whitney, quando apropriado. Curvas de sobrevida e livre de ev
ento foram estimadas pelo m&eacute;todo de Kaplan-Meier e comparadas pelo teste 
log rank nas an&aacute;lises univariadas. Uma an&aacute;lise regress&atilde;o lo
g&iacute;stica foi realizada para identificar as vari&aacute;veis independentes 
que se associaram &agrave; ocorr&ecirc;ncia de bacteremia. Um valor de p &lt; 0,
05 foi considerado significante. Todas as an&aacute;lises foram realizadas utili
zando o programa SPSS for Windows (vers&atilde;o 13; SPSS Inc, Chicago, IL).</fo
nt></p>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#46#42#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#47#43#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v33n1a12.htm##
00732000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049800075002001300573#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#48#44#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O grupo foi composto de 65 pacientes,
 predominantemente por mulheres de meia idade em hemodi&aacute;lise h&aacute; ap
roximadamente 4 anos. Um total de 92 cateteres foi utilizado, sendo o s&iacute;t
io de inser&ccedil;&atilde;o de 74 em veia jugular interna, 13 em veia subcl&aac
ute;via e 5 em veia femoral. Cinquenta e cinco cateteres eram cateteres definiti
vos, ou seja, pacientes sem outra possibilidade de acesso.</font></p>     ^cY#v3
3n1a12.htm##
00734000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050000075002001300575#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#49#45#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados demogr&aacute;ficos e cl&iac
ute;nicos dos grupos Heparina e Citrato est&atilde;o mostrados na <a href="/img/
revistas/jbn/v33n1/a12tab01m.jpg">Tabela 1</a>. N&atilde;o foram observadas dife
ren&ccedil;as significativas entre os grupos. Dos 92 cateteres, 49 no Grupo Hepa
rina e 43 no Grupo Citrato, perfizeram um total de 5.102 cateteres/dia no Grupo 
Heparina e 5.693 cateteres/dia no Grupo Citrato (p = 0.29). </font></p>     ^cY#
v33n1a12.htm##
00734000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050000075002001300575#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#50#46#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os eventos observados em cada grupo d
urante o estudo est&atilde;o descritos na <a href="/img/revistas/jbn/v33n1/a12ta
b02m.jpg">Tabela 2</a>. Das 17 rea&ccedil;&otilde;es pirog&ecirc;nicas observada
s, 11 (65%) ocorreram no Grupo Heparina e 6 (35%) no Grupo Citrato. O &iacute;nd
ice de pirogenia foi de 2,16 e 1,05 epis&oacute;dios/1.000 cateteres/dia para o 
Grupo Heparina e Grupo Citrato, respectivamente (p = 0,23). </font></p>     ^cY#
v33n1a12.htm##
00916000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704068200075002001300757#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#51#47#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ocorreram 18 epis&oacute;dios de bact
eremia relacionadas ao cateter, sendo que desses 17 no Grupo Heparina e apenas u
m epis&oacute;dio no Grupo Citrato. O &iacute;ndice de bacteremia no Grupo Hepar
ina foi de 3,33 epis&oacute;dios/1.000 cateteres/dia e no Grupo Citrato de 0,18 
epis&oacute;dios/1.000 cateteres/dia (p &lt; 0,001). No Grupo Heparina, em 76,5%
 das hemoculturas foram identificados microorganismos Gram negativos (com predom
&iacute;nio de Pseudomonas, seguido de Acinetobacter e <i>Serratia</i> sp. ). <i
>S. aureus</i> foi identificado no &uacute;nico epis&oacute;dio do Grupo Citrato
. </font></p>     ^cY#v33n1a12.htm##
00798000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056400075002001300639#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#52#48#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A ocorr&ecirc;ncia de bacteremia este
ve associada &agrave; presen&ccedil;a de diabetes e a pertencer ao Grupo Heparin
a (<a href="/img/revistas/jbn/v33n1/a12tab03m.jpg">Tabela 3</a>). Na an&aacute;l
ise de regress&atilde;o multivariada, pertencer ao Grupo Heparina foi o &uacute;
nico fator independente associado &agrave; ocorr&ecirc;ncia de bacteremia (coefi
ciente </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">
 = -3,06, IC 95% 0,005 - 0,402; p = 0,005). </font></p>     ^cY#v33n1a12.htm##
01043000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080900075002001300884#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#53#49#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O n&uacute;mero de cateteres com trom
bose que necessitaram ser removidos em decorr&ecirc;ncia de problemas de baixo f
luxo (inferior a 250 mL/min. ) foi semelhante entre os grupos, assim como o uso 
de trombol&iacute;tico (rTPA - ativador de plasminog&ecirc;nio tecidual recombin
ante). Houve uma tend&ecirc;ncia a maior taxa de hospitaliza&ccedil;&atilde;o re
lacionada &agrave; infec&ccedil;&atilde;o no Grupo Heparina (p = 0,055). No tota
l as hospitaliza&ccedil;&otilde;es perfizeram 204 leitos/dia, sendo maior no Gru
po Heparina (151 leitos/dia <i>vs. </i> 53 leitos.dia,  p &lt; 0,001; Grupo Hepa
rina e Citrato, respectivamente). A ocorr&ecirc;ncia de &oacute;bito n&atilde;o 
diferiu significativamente entre os dois grupos. </font></p>     ^cY#v33n1a12.ht
m##
00672000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043800075002001300513#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#54#50#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As curvas de tempo livre de eventos d
e pirogenia, bacteremia e hospitaliza&ccedil;&atilde;o dos grupos Grupo Heparina
 e Grupo Citrato est&atilde;o apresentadas na <a href="#fig1">Figura 1</a>. O te
mpo livre de bacteremia foi significantemente maior no grupo Grupo Citrato (p &l
t; 0,001), bem como o tempo livre de hospitaliza&ccedil;&atilde;o (p = 0,02). </
font></p>     ^cY#v33n1a12.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#55#51#article#134#<p><a name="fig1"></
a></p>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#56#52#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#57#53#article#134#<p align="center"><i
mg src="/img/revistas/jbn/v33n1/a12fig01.jpg"></p>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#58#54#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00835000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060100075002001300676#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#59#55#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Durante o per&iacute;odo de estudo, f
oram realizados 4.316 procedimentos de preenchimento da luz do lado arterial e v
enoso de cateteres p&oacute;s-hemodi&aacute;lise (selo do cateter), sendo 2.090 
no Grupo Heparina e 2.226 no Grupo Citrato. Nenhum sangramento anormal foi detec
tado. No Grupo Citrato um paciente apresentou arritmia com hipotens&atilde;o e o
utro parestesia de l&aacute;bios e gosto met&aacute;lico na boca, que cessaram e
m at&eacute; 1 minuto ap&oacute;s a interrup&ccedil;&atilde;o da infus&atilde;o.
 </font></p>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#60#56#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#61#57#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v33n1a12.htm##
00667000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043300075002001300508#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#62#58#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados encontrados neste estud
o mostram que a utiliza&ccedil;&atilde;o de citrato, como selo de cateter venoso
 quando comparado a heparina, esteve associada a menor ocorr&ecirc;ncia de bacte
remia relacionada ao cateter. Al&eacute;m disso, pacientes em uso de citrato pas
saram menos dias hospitalizados que aqueles em uso de heparina como selo.</font>
</p>     ^cY#v33n1a12.htm##
00973000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704073900075002001300814#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#63#59#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na literatura, a incid&ecirc;ncia de 
bacteremia relacionada a cateter de hemodi&aacute;lise varia de 1,6 a 5,5 epis&o
acute;dios/1.000 cateteres/dia, sendo essa varia&ccedil;&atilde;o parcialmente e
xplicada pelas t&eacute;cnicas utilizadas na manipula&ccedil;&atilde;o dos catet
eres, pela utiliza&ccedil;&atilde;o de diferentes subst&acirc;ncias como selo, a
ssim como diferentes concentra&ccedil;&otilde;es das mesmas. A utiliza&ccedil;&a
tilde;o de citrato tem sido associada &agrave; redu&ccedil;&atilde;o da incid&ec
irc;ncia de bacteremia devido a seu efeito bactericida quando usado em concentra
&ccedil;&otilde;es superiores a 23%. <sup>14,15,16,17</sup></font></p>     ^cY#v
33n1a12.htm##
01078000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084400075002001300919#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#64#60#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Alguns estudos, entretanto, n&atilde;
o demonstraram diferen&ccedil;as quando se utilizou citrato ou heparina. <sup>18
,19,20 </sup>Em um desses estudos, que foi aleat&oacute;rio e controlado, n&atil
de;o demonstrou superioridade do citrato sobre a heparina, entretanto, os pr&oac
ute;prios autores justificam esse resultado pela baixa ocorr&ecirc;ncia de event
os nos dois grupos (menor que 0,7 epis&oacute;diosde bacteremia/1.000 cateteres/
dia). <sup>21</sup> No presente estudo, a incid&ecirc;ncia de bacteremia foi sig
nificativamente reduzida no Grupo Citrato, o que n&atilde;o ocorreu nos epis&oac
ute;dios de pirogenia, provavelmente em fun&ccedil;&atilde;o da a&ccedil;&atilde
;o bactericida do citrato triss&oacute;dico estar restrita &agrave; luz do catet
er. </font></p>     ^cY#v33n1a12.htm##
01020000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704078600075002001300861#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#65#61#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outro aspecto relevante neste estudo 
&eacute; a elevada incid&ecirc;ncia de bact&eacute;rias Gram negativas presentes
 em mais de 75% das hemoculturas. Um aumento na incid&ecirc;ncia de bacteremias 
por agentes Gram negativos tem sido relatada nos &uacute;ltimos anos sendo que a
 maioria dos estudos relata uma incid&ecirc;ncia de at&eacute; 45%. <sup>22</sup
> O achado do presente estudo ressalta a necessidade de cada Unidade de Di&aacut
e;lise conhecer os agentes etiol&oacute;gicos das infec&ccedil;&otilde;es incide
ntes em sua popula&ccedil;&atilde;o, pois essa informa&ccedil;&atilde;o deve nor
tear a terap&ecirc;utica inicial, que &eacute; empiricamente praticada em cada i
nstitui&ccedil;&atilde;o. </font></p>     ^cY#v33n1a12.htm##
00849000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704061500075002001300690#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#66#62#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O n&uacute;mero de dias de hospitaliz
a&ccedil;&otilde;es foi menor no Grupo Citrato, assim como foi mais longo o temp
o livre de hospitaliza&ccedil;&atilde;o. Embora haja relatos na literatura, indi
cando a infec&ccedil;&atilde;o relacionada ao cateter como causa importante de h
ospitaliza&ccedil;&otilde;es, at&eacute; onde sabemos, n&atilde;o foi poss&iacut
e;vel encontrar relatos de redu&ccedil;&atilde;o de hospitaliza&ccedil;&otilde;e
s atribu&iacute;das ao uso de quaisquer das subst&acirc;ncias utilizadas como se
lo de cateter. </font></p>     ^cY#v33n1a12.htm##
00953000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071900075002001300794#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#67#63#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A disfun&ccedil;&atilde;o do cateter,
 al&eacute;m das causas mec&acirc;nicas como dobras, proximidade das pontas em r
ela&ccedil;&atilde;o &agrave; parede do vaso, se d&aacute; em sua maioria pela f
orma&ccedil;&atilde;o de uma capa de fibrina que acaba por envolver todo o catet
er, ultrapassando inclusive sua extremidade impedindo com isso a aspira&ccedil;&
atilde;o do sangue, parcial ou totalmente. N&atilde;o foram encontradas diferen&
ccedil;as quanto &agrave; disfun&ccedil;&atilde;o do cateter relacionada &agrave
; trombose nos dois grupos estudados, em conformidade com a maioria dos trabalho
s previamente publicados. <sup>23</sup></font></p>     ^cY#v33n1a12.htm##
01668000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704143400075002001301509#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#68#64#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Vale ressaltar a baixa incid&ecirc;nc
ia de efeitos colaterais na utiliza&ccedil;&atilde;o do citrato no presente estu
do. Nos Estados Unidos da Am&eacute;rica, a utiliza&ccedil;&atilde;o de citrato 
como selo &eacute; rara em fun&ccedil;&atilde;o de alerta publicado pelo FDA ap&
oacute;s ocorr&ecirc;ncia fatal com seu uso. <sup>24</sup> Os efeitos adversos d
o uso de citrato em concentra&ccedil;&otilde;es elevadas parecem estar relaciona
dos &agrave; queda brusca na concentra&ccedil;&atilde;o dos &iacute;ons c&aacute
;lcio levando a arritmia card&iacute;aca grave. <sup>25</sup> A utiliza&ccedil;&
atilde;o de um protocolo r&iacute;gido, com duas seringas preenchidas com o volu
me exato da luz arterial e venosa conforme a especifica&ccedil;&atilde;o do fabr
icante do cateter e infundidas lentamente ap&oacute;s uma infus&atilde;o r&aacut
e;pida de 10 mL de solu&ccedil;&atilde;o fisiol&oacute;gica em cada l&uacute;men
, parece ser suficiente para evitar as complica&ccedil;&otilde;es relacionadas a
 essa terap&ecirc;utica. Al&eacute;m disso, os sintomas mais frequentes, pareste
sia e gosto met&aacute;lico, foram raros neste estudo e desapareceram em at&eacu
te; 1 minuto ap&oacute;s interrup&ccedil;&atilde;o da infus&atilde;o. &Eacute; i
mportante ressaltar que o efeito a longo prazo da utiliza&ccedil;&atilde;o do ci
trato ainda precisa ser avaliado. </font></p>     ^cY#v33n1a12.htm##
00729000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049500075002001300570#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#69#65#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Apesar de ser um estudo retrospectivo
 com an&aacute;lise sequencial, fazendo com que alguns pacientes e cateteres per
tencessem aos dois grupos do estudo, este &eacute; o primeiro relato nacional da
 experi&ecirc;ncia com a utiliza&ccedil;&atilde;o dessa subst&acirc;ncia, que mo
stra diferen&ccedil;as consistentes entre a utiliza&ccedil;&atilde;o de citrato 
e heparina como selo de cateter de hemodi&aacute;lise. </font></p>     ^cY#v33n1
a12.htm##
00761000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052700075002001300602#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#70#66#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em conclus&atilde;o, o uso de citrato
 reduziu de maneira efetiva epis&oacute;dios de bacteremia e interna&ccedil;&oti
lde;es hospitalares em pacientes renais cr&ocirc;nicos submetidos &agrave; hemod
i&aacute;lise. Portanto, a utiliza&ccedil;&atilde;o do selo de citrato parece co
nstituir uma valiosa ferramenta que permite uma maior sobrevida dos cateteres, c
ada dia mais necess&aacute;rios no manejo de pacientes em tratamento dial&iacute
;tico. </font></p>     ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#71#67#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#72#68#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>AGRADECIMENTOS</b></font></p>     
^cY#v33n1a12.htm##
00645000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041100075002001300486#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#73#69#article#134#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Agradecemos &agrave; Dra. Maria da Gr
a&ccedil;a Bueno Marabezi que deu a primeira formata&ccedil;&atilde;o &agrave; P
CPIEA; &agrave; administradora Rosania Aparecida Ver&ocirc;nica e ao tecn&oacute
;logo Carlos Eduardo Guimar&atilde;es pelas grandes contribui&ccedil;&otilde;es 
&agrave;s nossas reuni&otilde;es mensais da PCPIEA.</font></p>     ^cY#v33n1a12.
htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#74#70#article#134#<p>&nbsp;</p>     ^c
Y#v33n1a12.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#75#71#article#134#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a12.htm##
00538000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704029000077002001300367#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#76#72#article#134#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Dor A, Pauly MV, Eic
hleay MA <i>et al</i>. End-stage renal disease and economic incentives: the Inte
rnational Study of Health Care Organization and Financing (ISHCOF). Int J Health
 Care Financing Econ 2008; 7:73-111.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#77#73#article#134# </font></p>     ^cY
#v33n1a12.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020800077002001300285#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#78#74#article#134#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Sesso R, Lopes AA, T
hom&eacute; FA <i>et al</i>. Relat&oacute;rio do Censo Brasileiro de Di&aacute;l
ise. J Bras Nefrol 2008; 30:233-8.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#79#75#article#134# </font></p>     ^cY
#v33n1a12.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704032500077002001300402#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#80#76#article#134#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. US Renal Data System
. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage R
enal Disease in the United States. Bethesda, MD: National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases, 2010.    ^cY#v
33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#81#77#article#134# </font></p>     ^cY
#v33n1a12.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020100077002001300278#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#82#78#article#134#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Spergel MS. Has the 
Fistula First Breakthrough Initiative Caused an Increase in Catheter Prevalence?
 Semin Dial 2008; 21:550-2.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#83#79#article#134# </font></p>     ^cY
#v33n1a12.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023400077002001300311#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#84#80#article#134#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Rayner HC, Pisoni RL
. The Increasing Use of Hemodialysis Catheter: Evidence from the DOPPS on Its Si
gnificance and Ways to Reverse It. Semin Dial 2010; 23:6-10.    ^cY#v33n1a12.htm
##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#85#81#article#134# </font></p>     ^cY
#v33n1a12.htm##
00431000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704018300077002001300260#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#86#82#article#134#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Beathard GA, Urbanes
 A. Infection Associated with Tunneled Hemodialysis Catheter. Semin Dial 2008; 2
1:528-38.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#87#83#article#134# </font></p>     ^cY
#v33n1a12.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704032500077002001300402#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#88#84#article#134#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. US Renal Data System
. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage R
enal Disease in the United States. Bethesda, MD: National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases, 2007.    ^cY#v
33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#89#85#article#134# </font></p>     ^cY
#v33n1a12.htm##
00508000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026000077002001300337#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#90#86#article#134#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Katneni R, Hedayati 
SS. Central venous catheter-related bacteremia in chronic hemodialysis patients:
 epidemiology and evidence-based management. Nature Reviews Nephrology 2007; 3:2
56-66.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#91#87#article#134# </font></p>     ^cY
#v33n1a12.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024100077002001300318#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#92#88#article#134#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Saxena AK, Panhotra 
BR. Haemodialysis catheter-related bloodstream infections: current treatment opt
ions and strategies for prevention. Swiss Med Wkly 2005; 13:127-38.    ^cY#v33n1
a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#93#89#article#134# </font></p>     ^cY
#v33n1a12.htm##
00596000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704034700078002001300425#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#94#90#article#134#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Broom JK, O'Shea S
, Govindarajulu S <i>et al</i>. Rationale and design of the HEALTHY-CATH trial: 
A randomised controlled trial of Heparin versus EthAnolLock THerapY for the prev
ention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrol 2
009; 10:23-28.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#95#91#article#134# </font></p>     ^cY
#v33n1a12.htm##
00535000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704028600078002001300364#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#96#92#article#134#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Biernat JC, dos Sa
ntos F, dos Santos AMG <i>et al</i>. Contamina&ccedil;&atilde;o do L&uacute;men 
de Cateter de Hemodi&aacute;lise: Preven&ccedil;&atilde;o e Tratamento com M-EDT
A. J Bras Nefrol 2008; 30:105-12.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#97#93#article#134# </font></p>     ^cY
#v33n1a12.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704022600078002001300304#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#98#94#article#134#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Association for th
e Advancement of Medical Instru-mentation. AAMI Standards and Recommended Practi
ces. Dialysis, Volume 3. Arlington, VA: 1998 Edition.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#99#95#article#134# </font></p>     ^cY
#v33n1a12.htm##
00654000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704040400079002001300483#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#100#96#article#134#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Centers for Disea
se Control and Prevention (CDC). Guidelines for preventions of intravascular cat
heter-related infections. MMWR August 09, 2002; Vol 51, Nº RR-10. Avaiable from 
website: URL: <a href="http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm" ta
rget="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm</a>.    ^cY#
v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#101#97#article#134# </font></p>     ^c
Y#v33n1a12.htm##
00549000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704029900079002001300378#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#102#98#article#134#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Weijmer MC, van d
en Dorpel MA, van de Ven PJG <i>et al</i>. Randomized, clinical trial comparison
 of trisodium citrate 30% and heparin as catheter-locking solution in hemodialys
is patients. J Am Soc Nephrol 2005; 16:2769-77.    ^cY#v33n1a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#103#99#article#134# </font></p>     ^c
Y#v33n1a12.htm##
00447000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019600080002001300276#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#104#100#article#134#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Ash S, Mankus RA
, Sutton JM <i>et al</i>. Concentrate sodium citrate (23%) for catheter lock. He
modial Int 2000; 4:22-31.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#105#101#article#134# </font></p>     ^
cY#v33n1a12.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#106#102#article#134#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Winnett G, Nolan
 J, Miller M <i>et al</i>. Trisodium citrate 46.7% selectively and safely reduce
s staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant 2008; 23:
3592-8.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#107#103#article#134# </font></p>     ^
cY#v33n1a12.htm##
00473000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022200080002001300302#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#108#104#article#134#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Pierce DA, Rocco
 MV. Trisodium citrate: an alternative to unfractionated heparin for hemodialysi
s catheter dwells. Pharmacotherapy 2010; 30:1150-8.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#109#105#article#134# </font></p>     ^
cY#v33n1a12.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028500080002001300365#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#110#106#article#134#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Buturovic J, Pon
ikvar R, Kandus A <i>et al</i>. Filling hemodialysis catheters in the interdialy
tic period: Heparin versus citrate versus polygeline: a prospective randomized s
tudy. Artif Organs 1998; 22:945-7.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#111#107#article#134# </font></p>     ^
cY#v33n1a12.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032200080002001300402#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#112#108#article#134#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Stas KJF, Vanwal
leghem J, De Moor B <i>et al</i>. Trisodium citrate 30% vs. heparin 5% as cathet
er lock in the interdialytic period in twin or double-lumen dialysis catheters f
or intermittent haemodialysis. Nephrol Dial Transplant 2001; 16:1521-2.    ^cY#v
33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#113#109#article#134# </font></p>     ^
cY#v33n1a12.htm##
00539000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028800080002001300368#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#114#110#article#134#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Hendrickx L, Kuy
pers D, Evenepoel P <i>et al</i>. A comparative prospective study on the use of 
low concentrate citrate lock versus heparin lock in permanent dialysis catheters
. Int J Artif Organs 2001; 24:208-11.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#115#111#article#134# </font></p>     ^
cY#v33n1a12.htm##
00528000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027700080002001300357#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#116#112#article#134#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Power A, Duncan 
N, Singh SK <i>et al</i>. Sodium Citrate Versus Heparin Catheter Locks for Cuffe
d Central Venous Catheters: A Single-Center Randomized Controlled Trial. Am J Ki
dney Dis 2009; 53:1034-41.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#117#113#article#134# </font></p>     ^
cY#v33n1a12.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023800080002001300318#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#118#114#article#134#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Lafrance JP, Rah
me E, Lelorier J <i>et al</i>. Vascular Access-Related Infections: definitions, 
incidence rates, and risk factors. Am J Kidney Dis 2008; 52:982-93.    ^cY#v33n1
a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#119#115#article#134# </font></p>     ^
cY#v33n1a12.htm##
00487000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023600080002001300316#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#120#116#article#134#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. MacRae JM, Dojni
novic I, Djurdjev O <i>et al</i>. Citrate 4% versus Heparin and the Reduction of
 Thrombosis Study (CHARTS). Clin J Am Soc Nephrol 2008; 3:369-74.    ^cY#v33n1a1
2.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#121#117#article#134# </font></p>     ^
cY#v33n1a12.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026200080002001300342#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#122#118#article#134#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. US Food and Drug
 Administration: FDA issues warning on tricitrasol dialysis catheter anticoagula
nt. FDA Talk Paper T00-16. Rockville, MD, US Department of Health and Human Serv
ices, 2000.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#123#119#article#134# </font></p>     ^
cY#v33n1a12.htm##
00457000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020600080002001300286#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#124#120#article#134#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Bunker JP, Bendi
xen HH, Murphy AJ. Hemodynamic effects of intravenously administered Sodium Citr
ate. New Eng J Med 1962; 266:372-7.    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#125#121#article#134# </font></p>     ^
cY#v33n1a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#126#122#article#134#<p>&nbsp;</p>     
^cY#v33n1a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#127#123#article#134#<p>&nbsp;</p>     
^cY#v33n1a12.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020000077002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#128#124#article#134#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;
ncia para:</b>    ^cY#v33n1a12.htm##
00286000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005000077002001300127#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#129#125#article#134#<br>   Jos&eacute;
 Lu&iacute;s Bevilacqua     ^cY#v33n1a12.htm##
00297000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006100077002001300138#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#130#126#article#134#<br>   Rua Eul&aac
ute;lia Silva, 454 Jardim Faculdade    ^cY#v33n1a12.htm##
00290000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005400077002001300131#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#131#127#article#134#<br>   Sorocaba - 
SP - Brasil  CEP: 18030-230     ^cY#v33n1a12.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009300077002001300170#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#132#128#article#134#<br>   E-mail: <a 
href="mailto:bevi@dglnet.com.br">bevi@dglnet.com.br</a></font></p>     ^cY#v33n1
a12.htm##
00342000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010600077002001300183#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#133#129#article#134#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o 24/11/2010
    ^cY#v33n1a12.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#134#130#article#134#<br>   Data de apr
ova&ccedil;&atilde;o: 07/01/2011    ^cY#v33n1a12.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#135#131#article#134#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#136#132#article#134#<p>&nbsp;</p>     
^cY#v33n1a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#137#133#article#134#<p>&nbsp;</p>     
^cY#v33n1a12.htm##
00428000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704019200077002001300269#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a12.htm#S#p#138#134#article#134#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado no 
Instituto de Hemodi&aacute;lise Sorocaba - IHS, S&atilde;o Paulo, Brasil. </font
></p>     ^cY#v33n1a12.htm##
00628000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100013000760100016000890100
01900105810000600124012012800130030003300258710000200291065000900293064000500302
031000200307014000700309865000900316002001300325#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a12.htm#S#c#139#1#article#25#1#^rND^sDor^nA#^rND^sPauly^nMV#^rND^s
Eichleay^nMA#et al#End-stage renal disease and economic incentives: the Internat
ional Study of Health Care Organization and Financing (ISHCOF)^len#Int J Health 
Care Financing Econ#2#20080000#2008#7#73-111#20110300#v33n1a12.htm##
00559000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100016000910100
01600107810000600123012004500129030001400174065000900188064000500197031000300202
014000600205865000900211002001300220035001000233801001400243#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#140#2#article#25#2#^rND^sSesso^nR#^rND^sLo
pes^nAA#^rND^sThomé^nFA#et al#Relatório do Censo Brasileiro de Diálise^lpt#J Bra
s Nefrol#20080000#2008#30#233-8#20110300#v33n1a12.htm#0101-2800#J Bras Nefrol##
00589000000000229000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740170021000760180127000970660
00300224062009600227065000900323064000500332865000900337002001300346#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#c#141#3#article#25#3#US Renal Data S
ystem#USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Sta
ge Renal Disease in the United States. Bethesda,^len#MD#National Institutes of H
ealth, National Institute of Diabetes and Digestive and Kidney Diseases#20100000
#2010#20110300#v33n1a12.htm##
00498000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760120092000940300
01100186710000200197065000900199064000500208031000300213014000600216865000900222
002001300231#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#c#142#4#arti
cle#25#4#^rND^sSpergel^nMS#Has the Fistula First Breakthrough Initiative Caused 
an Increase in Catheter Prevalence^len#Semin Dial#2#20080000#2008#21#550-2#20110
300#v33n1a12.htm##
00549000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930120
11600110030001100226710000200237065000900239064000500248031000300253014000500256
865000900261002001300270#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#
c#143#5#article#25#5#^rND^sRayner^nHC#^rND^sPisoni^nRL#The Increasing Use of Hem
odialysis Catheter: Evidence from the DOPPS on Its Significance and Ways to Reve
rse It^len#Semin Dial#2#20100000#2010#23#6-10#20110300#v33n1a12.htm##
00498000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100017000950120
06100112030001100173710000200184065000900186064000500195031000300200014000700203
865000900210002001300219#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#
c#144#6#article#25#6#^rND^sBeathard^nGA#^rND^sUrbanes^nA#Infection Associated wi
th Tunneled Hemodialysis Catheter^len#Semin Dial#2#20080000#2008#21#528-38#20110
300#v33n1a12.htm##
00589000000000229000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740170021000760180127000970660
00300224062009600227065000900323064000500332865000900337002001300346#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#c#145#7#article#25#7#US Renal Data S
ystem#USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Sta
ge Renal Disease in the United States. Bethesda,^len#MD#National Institutes of H
ealth, National Institute of Diabetes and Digestive and Kidney Diseases#20070000
#2007#20110300#v33n1a12.htm##
00575000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100019000930120
12400112030002600236710000200262065000900264064000500273031000200278014000700280
865000900287002001300296#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#
c#146#8#article#25#8#^rND^sKatneni^nR#^rND^sHedayati^nSS#Central venous catheter
-related bacteremia in chronic hemodialysis patients: epidemiology and evidence-
based management^len#Nature Reviews Nephrology#2#20070000#2007#3#256-66#20110300
#v33n1a12.htm##
00556000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100019000930120
11500112030001500227710000200242065000900244064000500253031000300258014000700261
865000900268002001300277#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a12.htm#S#
c#147#9#article#25#9#^rND^sSaxena^nAK#^rND^sPanhotra^nBR#Haemodialysis catheter-
related bloodstream infections: current treatment options and strategies for pre
vention^len#Swiss Med Wkly#2#20050000#2005#13#127-38#20110300#v33n1a12.htm##
00686000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
02300110810000600133012019800139030001200337710000200349065000900351064000500360
031000300365014000600368865000900374002001300383#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a12.htm#S#c#148#10#article#25#10#^rND^sBroom^nJK#^rND^sO'Shea^nS#^
rND^sGovindarajulu^nS#et al#Rationale and design of the HEALTHY-CATH trial: A ra
ndomised controlled trial of Heparin versus EthAnolLock THerapY for the preventi
on of Catheter Associated infecTion in Haemodialysis patients^len#BMC Nephrol#2#
20090000#2009#10#23-28#20110300#v33n1a12.htm##
00617000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960100
02200116810000600138012008700144030001400231065000900245064000500254031000300259
014000700262865000900269002001300278035001000291801001400301#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#149#11#article#25#11#^rND^sBiernat^nJC#^rN
D^sdos Santos^nF#^rND^sdos Santos^nAMG#et al#Contaminação do Lúmen de Cateter de
 Hemodiálise: Prevenção e Tratamento com M-EDTA^lpt#J Bras Nefrol#20080000#2008#
30#105-12#20110300#v33n1a12.htm#0101-2800#J Bras Nefrol##
00451000000000217000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750170060000780180045001380660
01400183065000900197064000500206865000900211002001300220#v33n1#V:\SciELO\serial\
jbn\v33n1\markup\v33n1a12.htm#S#c#150#12#article#25#12#Association for the Advan
cement of Medical Instru-mentation#AAMI Standards and Recommended Practices^len#
Arlington^eVA#19980000#1998#20110300#v33n1a12.htm##
00605000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750110043000780120076001210300
00500197065000900202064001600211031000300227032000600230037005400236865000900290
002001300299035001000312801000500322#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a12.htm#S#c#151#13#article#25#13#Centers for Disease Control and Prevention#Gu
idelines for preventions of intravascular catheter-related infections^len#MMWR#2
0020809#August 09, 2002#51#RR-10#http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110
a1.htm#20110300#v33n1a12.htm#0149-2195#MMWR##
00675000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100025000960100
02200121810000600143012013300149030001700282065000900299064000500308031000300313
014000800316865000900324002001300333035001000346801001700356#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#152#14#article#25#14#^rND^sWeijmer^nMC#^rN
D^svan den Dorpel^nMA#^rND^svan de Ven^nPJG#et al#Randomized, clinical trial com
parison of trisodium citrate 30% and heparin as catheter-locking solution in hem
odialysis patients^len#J Am Soc Nephrol#20050000#2005#16#2769-77#20110300#v33n1a
12.htm#1046-6673#J Am Soc Nephrol##
00535000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100013000780100017000910100
01700108810000600125012005500131030001300186710000200199065000900201064000500210
031000200215014000600217865000900223002001300232#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a12.htm#S#c#153#15#article#25#15#^rND^sAsh^nS#^rND^sMankus^nRA#^rN
D^sSutton^nJM#et al#Concentrate sodium citrate (23%) for catheter lock^len#Hemod
ial Int#2#20000000#2000#4#22-31#20110300#v33n1a12.htm##
00642000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
01600110810000600126012010400132030002400236065000900260064000500269031000300274
014000700277865000900284002001300293035001000306801002400316#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#154#16#article#25#16#^rND^sWinnett^nG#^rND
^sNolan^nJ#^rND^sMiller^nM#et al#Trisodium citrate 46: 7% selectively and safely
 reduces staphylococcal catheter-related bacteraemia^len#Nephrol Dial Transplant
#20080000#2008#23#3592-8#20110300#v33n1a12.htm#0931-0509#Nephrol Dial Transplant
##
00574000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950120
09700111030001600208065000900224064000500233031000300238014000700241865000900248
002001300257035001000270801001600280#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a12.htm#S#c#155#17#article#25#17#^rND^sPierce^nDA#^rND^sRocco^nMV#Trisodium ci
trate: an alternative to unfractionated heparin for hemodialysis catheter dwells
^len#Pharmacotherapy#20100000#2010#30#1150-8#20110300#v33n1a12.htm#0277-0008#Pha
rmacotherapy##
00657000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100018000970100
01600115810000600131012013700137030001300274065000900287064000500296031000300301
014000600304865000900310002001300319035001000332801001300342#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#156#18#article#25#18#^rND^sButurovic^nJ#^r
ND^sPonikvar^nR#^rND^sKandus^nA#et al#Filling hemodialysis catheters in the inte
rdialytic period: Heparin versus citrate versus polygeline: a prospective random
ized study^len#Artif Organs#19980000#1998#22#945-7#20110300#v33n1a12.htm#0160-56
4X#Artif Organs##
00705000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100022000940100
01700116810000600133012016000139030002400299065000900323064000500332031000300337
014000700340865000900347002001300356035001000369801002400379#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#157#19#article#25#19#^rND^sStas^nKJF#^rND^
sVanwalleghem^nJ#^rND^sDe Moor^nB#et al#Trisodium citrate 30% vs: heparin 5% as 
catheter lock in the interdialytic period in twin or double-lumen dialysis cathe
ters for intermittent haemodialysis^len#Nephrol Dial Transplant#20010000#2001#16
#1521-2#20110300#v33n1a12.htm#0931-0509#Nephrol Dial Transplant##
00666000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970100
01900114810000600133012013100139030001900270065000900289064000500298031000300303
014000700306865000900313002001300322035001000335801001900345#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#158#20#article#25#20#^rND^sHendrickx^nL#^r
ND^sKuypers^nD#^rND^sEvenepoel^nP#et al#A comparative prospective study on the u
se of low concentrate citrate lock versus heparin lock in permanent dialysis cat
heters^len#Int J Artif Organs#20010000#2001#24#208-11#20110300#v33n1a12.htm#0391
-3988#Int J Artif Organs##
00652000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930100
01600109810000600125012013000131030001600261065000900277064000500286031000300291
014000800294865000900302002001300311035001000324801001600334#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#159#21#article#25#21#^rND^sPower^nA#^rND^s
Duncan^nN#^rND^sSingh^nSK#et al#Sodium Citrate Versus Heparin Catheter Locks for
 Cuffed Central Venous Catheters: A Single-Center Randomized Controlled Trial^le
n#Am J Kidney Dis#20090000#2009#53#1034-41#20110300#v33n1a12.htm#0272-6386#Am J 
Kidney Dis##
00613000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01800112810000600130012008700136030001600223065000900239064000500248031000300253
014000700256865000900263002001300272035001000285801001600295#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a12.htm#S#c#160#22#article#25#22#^rND^sLafrance^nJP#^r
ND^sRahme^nE#^rND^sLelorier^nJ#et al#Vascular Access-Related Infections: definit
ions, incidence rates, and risk factors^len#Am J Kidney Dis#20080000#2008#52#982
-93#20110300#v33n1a12.htm#0272-6386#Am J Kidney Dis##
00575000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100020000950100
01800115810000600133012007700139030002200216710000200238065000900240064000500249
031000200254014000700256865000900263002001300272#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a12.htm#S#c#161#23#article#25#23#^rND^sMacRae^nJM#^rND^sDojninovic
^nI#^rND^sDjurdjev^nO#et al#Citrate 4% versus Heparin and the Reduction of Throm
bosis Study (CHARTS)^len#Clin J Am Soc Nephrol#2#20080000#2008#3#369-74#20110300
#v33n1a12.htm##
00515000000000217000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750180126000780660010002040620
04700214065000900261064000500270865000900275002001300284#v33n1#V:\SciELO\serial\
jbn\v33n1\markup\v33n1a12.htm#S#c#162#24#article#25#24#US Food and Drug Administ
ration: FDA issues warning on tricitrasol dialysis catheter anticoagulant. FDA T
alk Paper T00-16^len#Rockville#MD, US Department of Health and Human Services#20
000000#2000#20110300#v33n1a12.htm##
00540000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950100
01700114012006900131030001400200710000200214065000900216064000500225031000400230
014000600234865000900240002001300249#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a12.htm#S#c#163#25#article#25#25#^rND^sBunker^nJP#^rND^sBendixen^nHH#^rND^sMur
phy^nAJ#Hemodynamic effects of intravenously administered Sodium Citrate^len#New
 Eng J Med#2#19620000#1962#266#372-7#20110300#v33n1a12.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#o#1#1#article#1#
20110411#093035#v33n1a13.htm#468##
04024000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400100014203500100015201201960
01620120172003580100032005300100041005620700042006030700047006450831132006920850
01001824085003301834085004001867085004101907085003401948085003201982085002402014
08500480203808309810208608500100306708500350307708500350311208500380314708500280
31850850039032130850024032520850041032761170008033170720004033251120009033291110
01103338002001303349#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#h#2#
1#article#1#ra#pt#br1.1#1#4.0#ILUS#TAB#13#JBN110#nd#J. Bras. Nefrol.#33#1#201103
00#^f93^l108#0101-2800#Doença renal crônica: importância do diagnóstico precoce,
 encaminhamento imediato e abordagem interdisciplinar estruturada para melhora d
o desfecho em pacientes ainda não submetidos à diálise^lpt#Chronic kidney diseas
e: importance of early diagnosis, immediate referral and structured interdiscipl
inary approach to improve outcomes in patients not yet on dialysis^len#^rND^1A01
^nMarcus Gomes^sBastos#^rND^1A01^nGianna Mastroianni^sKirsztajn#Universidade Fed
eral de Juiz de Fora^iA01#Universidade Federal de São Paulo^iA02^pBrasil#^lpt^aA
tualmente, é amplamente aceita a definição da doença renal crônica (DRC) que se 
baseia em alterações na taxa de filtração glomerular e/ou presença de lesão pare
nquimatosa mantidas por pelo menos três meses. Embora os critérios para diagnóst
ico de DRC estejam agora bem mais claros, a proporção de pacientes com DRC em es
tágio avançado vista pela primeira vez por nefrologista imediatamente antes do i
nício de tratamento dialítico ainda é inaceitável. O diagnóstico precoce e o enc
aminhamento imediato para o nefrologista são etapas essenciais no manuseio desse
s pacientes, pois possibilitam a educação pré-diálise e a implementação de medid
as preventivas que retardam ou mesmo interrompem a progressão para os estágios m
ais avançados da DRC, assim como diminuem morbidade e mortalidade iniciais. Nest
a revisão, discutimos a complexidade da DRC, a multiplicidade de intervenções at
ualmente recomendadas na sua prevenção secundária e diferentes modelos de presta
ção de cuidados à saúde, além de examinarmos o racional do atendimento interdisc
iplinar e a evolução dos pacientes seguidos em clínicas que já adotaram esse mod
elo.#^ddecs^i1#^tm^lpt^kdoença renal crônica^i1#^tm^lpt^kinsuficiência renal crô
nica^i1#^tm^lpt^ktaxa de filtração glomerular^i1#^tm^lpt^kreferência e consulta^
i1#^tm^lpt^kdiagnóstico precoce^i1#^tm^lpt^kproteinúria^i1#^tm^lpt^kclínica de a
tenção interdisciplinar^i1#^len^aAt present, chronic kidney disease (CKD) is bro
adly defined on the basis of changes in the glomerular filtration rate and/or th
e presence of parenchymal damage present for at least 3 months. Although the dia
gnosis of CKD is now quite straightforward, the proportion of patients with end-
stage renal disease seen by a nephrologist for the first time immediately before
 the initiation of dialysis is still unacceptable. Early diagnosis and immediate
 nephrology referral are key steps in management because enable predialysis educ
ation, allow implementation of preventive measures that delay or even halt progr
ession of CKD to end stage renal disease, as well as decrease initial morbidity 
and mortality. In this review, we discuss the complexity of CKD and the multipli
city of interventions currently recommended in its secondary prevention, differe
nt models of healthcare delivery, and examine the rational and outcomes of patie
nts followed in interdisciplinary care clinics.#^ddecs^i2#^tm^len^kchronic kidne
y disease^i2#^tm^len^kchronic kidney failure^i2#^tm^len^kreferral and consultati
on^i2#^tm^len^kearly diagnosis^i2#^tm^len^kglomerular filtration rate^i2#^tm^len
^kproteinuria^i2#^tm^len^kinterdisciplinary care model^i2#vancouv#122#20110127#2
7/01/2011#v33n1a13.htm##
04052000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000170011103100030012803200020013106500090013301400100014203500100015201202100
01620120186003720100032005580100041005900700042006310700047006730831132007200850
01001852085003301862085004001895085004101935085003401976085003202010085002402042
08500480206608309810211408500100309508500350310508500350314008500380317508500280
32130850039032410850024032800850041033041170008033450720004033531120009033571110
01103366002001303377#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#f#3#
1#article#1#ra#pt#br1.1#1#4.0#ILUS#TAB#13#JBN110#nd#J. Bras. Nefrol.#33#1#201103
00#^f93^l108#0101-2800#<b>Doença renal crônica</b>: <b>importância do diagnóstic
o precoce, encaminhamento imediato e abordagem interdisciplinar estruturada para
 melhora do desfecho em pacientes ainda não submetidos à diálise</b>^lpt#<b>Chro
nic kidney disease</b>: <b>importance of early diagnosis, immediate referral and
 structured interdisciplinary approach to improve outcomes in patients not yet o
n dialysis</b>^len#^rND^1A01^nMarcus Gomes^sBastos#^rND^1A01^nGianna Mastroianni
^sKirsztajn#Universidade Federal de Juiz de Fora^iA01#Universidade Federal de Sã
o Paulo^iA02^pBrasil#^lpt^aAtualmente, é amplamente aceita a definição da doença
 renal crônica (DRC) que se baseia em alterações na taxa de filtração glomerular
 e/ou presença de lesão parenquimatosa mantidas por pelo menos três meses. Embor
a os critérios para diagnóstico de DRC estejam agora bem mais claros, a proporçã
o de pacientes com DRC em estágio avançado vista pela primeira vez por nefrologi
sta imediatamente antes do início de tratamento dialítico ainda é inaceitável. O
 diagnóstico precoce e o encaminhamento imediato para o nefrologista são etapas 
essenciais no manuseio desses pacientes, pois possibilitam a educação pré-diális
e e a implementação de medidas preventivas que retardam ou mesmo interrompem a p
rogressão para os estágios mais avançados da DRC, assim como diminuem morbidade 
e mortalidade iniciais. Nesta revisão, discutimos a complexidade da DRC, a multi
plicidade de intervenções atualmente recomendadas na sua prevenção secundária e 
diferentes modelos de prestação de cuidados à saúde, além de examinarmos o racio
nal do atendimento interdisciplinar e a evolução dos pacientes seguidos em clíni
cas que já adotaram esse modelo.#^ddecs^i1#^tm^lpt^kdoença renal crônica^i1#^tm^
lpt^kinsuficiência renal crônica^i1#^tm^lpt^ktaxa de filtração glomerular^i1#^tm
^lpt^kreferência e consulta^i1#^tm^lpt^kdiagnóstico precoce^i1#^tm^lpt^kproteinú
ria^i1#^tm^lpt^kclínica de atenção interdisciplinar^i1#^len^aAt present, chronic
 kidney disease (CKD) is broadly defined on the basis of changes in the glomerul
ar filtration rate and/or the presence of parenchymal damage present for at leas
t 3 months. Although the diagnosis of CKD is now quite straightforward, the prop
ortion of patients with end-stage renal disease seen by a nephrologist for the f
irst time immediately before the initiation of dialysis is still unacceptable. E
arly diagnosis and immediate nephrology referral are key steps in management bec
ause enable predialysis education, allow implementation of preventive measures t
hat delay or even halt progression of CKD to end stage renal disease, as well as
 decrease initial morbidity and mortality. In this review, we discuss the comple
xity of CKD and the multiplicity of interventions currently recommended in its s
econdary prevention, different models of healthcare delivery, and examine the ra
tional and outcomes of patients followed in interdisciplinary care clinics.#^dde
cs^i2#^tm^len^kchronic kidney disease^i2#^tm^len^kchronic kidney failure^i2#^tm^
len^kreferral and consultation^i2#^tm^len^kearly diagnosis^i2#^tm^len^kglomerula
r filtration rate^i2#^tm^len^kproteinuria^i2#^tm^len^kinterdisciplinary care mod
el^i2#vancouv#122#20110127#27/01/2011#v33n1a13.htm##
04158000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000160012903100030014503200020014806500090015001400100015903500100
01690120196001790120172003750100032005470100041005790700044006200700049006640831
13200713085001001845085003301855085004001888085004101928085003401969085003202003
08500240203508500480205908309810210708500100308808500350309808500350313308500380
31680850028032060850039032340850024032730850041032971170008033380720004033461120
00903350111001103359002001303370008008903383#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a13.htm#S#l#4#1#article#1#^mjan./mar.^a2011#ra#pt#br1.1#1#4.0#ilus#tab
#13#JBN110#nd#J. Bras. Nefrol#33#1#20110300#^f93^l108#0101-2800#Doença renal crô
nica: importância do diagnóstico precoce, encaminhamento imediato e abordagem in
terdisciplinar estruturada para melhora do desfecho em pacientes ainda não subme
tidos à diálise^lpt#Chronic kidney disease: importance of early diagnosis, immed
iate referral and structured interdisciplinary approach to improve outcomes in p
atients not yet on dialysis^len#^rND^1A01^nMarcus Gomes^sBastos#^rND^1A01^nGiann
a Mastroianni^sKirsztajn#^iA01^1Universidade Federal de Juiz de Fora#^iA02^1Univ
ersidade Federal de São Paulo^pBrasil#^lpt^aAtualmente, é amplamente aceita a de
finição da doença renal crônica (DRC) que se baseia em alterações na taxa de fil
tração glomerular e/ou presença de lesão parenquimatosa mantidas por pelo menos 
três meses. Embora os critérios para diagnóstico de DRC estejam agora bem mais c
laros, a proporção de pacientes com DRC em estágio avançado vista pela primeira 
vez por nefrologista imediatamente antes do início de tratamento dialítico ainda
 é inaceitável. O diagnóstico precoce e o encaminhamento imediato para o nefrolo
gista são etapas essenciais no manuseio desses pacientes, pois possibilitam a ed
ucação pré-diálise e a implementação de medidas preventivas que retardam ou mesm
o interrompem a progressão para os estágios mais avançados da DRC, assim como di
minuem morbidade e mortalidade iniciais. Nesta revisão, discutimos a complexidad
e da DRC, a multiplicidade de intervenções atualmente recomendadas na sua preven
ção secundária e diferentes modelos de prestação de cuidados à saúde, além de ex
aminarmos o racional do atendimento interdisciplinar e a evolução dos pacientes 
seguidos em clínicas que já adotaram esse modelo.#^ddecs^i1#^tm^lpt^kdoença rena
l crônica^i1#^tm^lpt^kinsuficiência renal crônica^i1#^tm^lpt^ktaxa de filtração 
glomerular^i1#^tm^lpt^kreferência e consulta^i1#^tm^lpt^kdiagnóstico precoce^i1#
^tm^lpt^kproteinúria^i1#^tm^lpt^kclínica de atenção interdisciplinar^i1#^len^aAt
 present, chronic kidney disease (CKD) is broadly defined on the basis of change
s in the glomerular filtration rate and/or the presence of parenchymal damage pr
esent for at least 3 months. Although the diagnosis of CKD is now quite straight
forward, the proportion of patients with end-stage renal disease seen by a nephr
ologist for the first time immediately before the initiation of dialysis is stil
l unacceptable. Early diagnosis and immediate nephrology referral are key steps 
in management because enable predialysis education, allow implementation of prev
entive measures that delay or even halt progression of CKD to end stage renal di
sease, as well as decrease initial morbidity and mortality. In this review, we d
iscuss the complexity of CKD and the multiplicity of interventions currently rec
ommended in its secondary prevention, different models of healthcare delivery, a
nd examine the rational and outcomes of patients followed in interdisciplinary c
are clinics.#^ddecs^i2#^tm^len^kchronic kidney disease^i2#^tm^len^kchronic kidne
y failure^i2#^tm^len^kreferral and consultation^i2#^tm^len^kearly diagnosis^i2#^
tm^len^kglomerular filtration rate^i2#^tm^len^kproteinuria^i2#^tm^len^kinterdisc
iplinary care model^i2#vancouv#122#20110127#27/01/2011#v33n1a13.htm#Internet^iht
tp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100013##
00375000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704014300073002001300216#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#5#1#article#342#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO DE REVIS&Atilde
;O</b> REVIEW ARTICLE</font></p>     ^cY#v33n1a13.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#6#2#article#342#<p>&nbsp;</p>     ^cY#
v33n1a13.htm##
00579000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704034700073002001300420#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#7#3#article#342#<p><a name="enda"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Doen&ccedil;a ren
al cr&ocirc;nica: import&acirc;ncia do diagn&oacute;stico precoce, encaminhament
o imediato e abordagem interdisciplinar estruturada para melhora do desfecho em 
pacientes ainda n&atilde;o submetidos &agrave; di&aacute;lise</b></font></p>    
 ^cY#v33n1a13.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#8#4#article#342#<p>&nbsp;</p>     ^cY#
v33n1a13.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#9#5#article#342#<p>&nbsp;</p>     ^cY#
v33n1a13.htm##
00373000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704014000074002001300214#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#10#6#article#342#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Marcus Gomes  Bastos; Gianna Mastro
ianni Kirsztajn</b></font></p>     ^cY#v33n1a13.htm##
00420000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704018700074002001300261#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#11#7#article#342#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Universidade Federal de Juiz de Fora (
UFJF) e Universidade Federal de S&atilde;o Paulo (Unifesp), Brasil</font></p>   
  ^cY#v33n1a13.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704012400074002001300198#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#12#8#article#342#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia<
/a></font></p>     ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#13#9#article#342#<p>&nbsp;</p>     ^cY
#v33n1a13.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#14#10#article#342#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a13.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#15#11#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n
1a13.htm##
01777000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704154300075002001301618#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#16#12#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Atualmente, &eacute; amplamente aceit
a a defini&ccedil;&atilde;o da doen&ccedil;a renal cr&ocirc;nica (DRC) que se ba
seia em altera&ccedil;&otilde;es na taxa de filtra&ccedil;&atilde;o glomerular e
/ou presen&ccedil;a de les&atilde;o parenquimatosa mantidas por pelo menos tr&ec
irc;s meses. Embora os crit&eacute;rios para diagn&oacute;stico de DRC estejam a
gora bem mais claros, a propor&ccedil;&atilde;o de pacientes com DRC em est&aacu
te;gio avan&ccedil;ado vista pela primeira vez por nefrologista imediatamente an
tes do in&iacute;cio de tratamento dial&iacute;tico ainda &eacute; inaceit&aacut
e;vel. O diagn&oacute;stico precoce e o encaminhamento imediato para o nefrologi
sta s&atilde;o etapas essenciais no manuseio desses pacientes, pois possibilitam
 a educa&ccedil;&atilde;o pr&eacute;-di&aacute;lise e a implementa&ccedil;&atild
e;o de medidas preventivas que retardam ou mesmo interrompem a progress&atilde;o
 para os est&aacute;gios mais avan&ccedil;ados da DRC, assim como diminuem morbi
dade e mortalidade iniciais. Nesta revis&atilde;o, discutimos a complexidade da 
DRC, a multiplicidade de interven&ccedil;&otilde;es atualmente recomendadas na s
ua preven&ccedil;&atilde;o secund&aacute;ria e diferentes modelos de presta&cced
il;&atilde;o de cuidados &agrave; sa&uacute;de, al&eacute;m de examinarmos o rac
ional do atendimento interdisciplinar e a evolu&ccedil;&atilde;o dos pacientes s
eguidos em cl&iacute;nicas que j&aacute; adotaram esse modelo. </font></p>     ^
cY#v33n1a13.htm##
00617000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038300075002001300458#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#17#13#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> doen&ccedil;a 
renal cr&ocirc;nica, insufici&ecirc;ncia renal cr&ocirc;nica, taxa de filtra&cce
dil;&atilde;o glomerular, refer&ecirc;ncia e consulta, diagn&oacute;stico precoc
e, protein&uacute;ria, cl&iacute;nica de aten&ccedil;&atilde;o interdisciplinar.
 </font></p> <hr size="1" noshade>     ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#18#14#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#19#15#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#20#16#article#342#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v33n1a13.htm##
01120000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704088600075002001300961#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#21#17#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A nefrologia tem passado por grandes 
mudan&ccedil;as desde o in&iacute;cio dos anos 60, quando emergiu como especiali
dade m&eacute;dica. Inicialmente, o foco da nefrologia foi a terapia renal subst
itutiva (TRS) - di&aacute;lise e transplante renal - como forma estabelecida de 
tratamento para os pacientes que evolu&iacute;am para doen&ccedil;a renal cr&oci
rc;nica em est&aacute;gio terminal (DRET) (DRET). Foi quando proliferaram os v&a
acute;rios programas de TRS, tanto na rede de sa&uacute;de p&uacute;blica como n
a rede privada. A Nefrologia brasileira rapidamente alcan&ccedil;ou os n&iacute;
veis de excel&ecirc;ncia internacionais. Contudo, nesse per&iacute;odo, muito po
uca aten&ccedil;&atilde;o foi dada &agrave;s medidas preventivas de perda da tax
a de filtra&ccedil;&atilde;o glomerular (TFG).</font></p>     ^cY#v33n1a13.htm##
01281000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704104700075002001301122#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#22#18#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A partir da d&eacute;cada passada, fi
cou evidente que a progress&atilde;o da Doen&ccedil;a Renal Cr&ocirc;nica (DRC) 
em pacientes com diferentes patologias renais (e sob cuidado dos nefrologistas) 
poderia ser retardada ou at&eacute; interrompida com medidas tais como controle 
rigoroso da press&atilde;o arterial, emprego de medicamentos que bloqueiam o eix
o renina-angiotensina-aldosterona (ERAA), s&oacute; para mencionar algumas. <sup
>1</sup> Paralelamente a estas observa&ccedil;&otilde;es, foram publicados estud
os populacionais e em grupos de risco para DRC, quando se demonstrou que a preva
l&ecirc;ncia da doen&ccedil;a era muito maior do que conhecido anteriormente. <s
up>1</sup> Estas observa&ccedil;&otilde;es despertaram a aten&ccedil;&atilde;o d
as comunidades nefrol&oacute;gicas internacionais e brasileira que, de diferente
s maneiras, iniciaram a&ccedil;&otilde;es para lidar com o problema da DRC, cons
iderada a grande epidemia deste mil&ecirc;nio. </font></p>     ^cY#v33n1a13.htm#
#
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#23#19#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014000075002001300215#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#24#20#article#342#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>EPIDEMIOLOGIA DA DOEN&Ccedil;A REN
AL CR&Ocirc;NICA</b></font></p>     ^cY#v33n1a13.htm##
01277000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704104300075002001301118#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#25#21#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A DRC tem recebido cada vez mais aten
&ccedil;&atilde;o da comunidade cient&iacute;fica internacional, j&aacute; que s
ua elevada preval&ecirc;ncia vem sendo demonstrada em estudos recentes. Particul
armente significante &eacute; a an&aacute;lise transversal do National Health an
d Nutrition Examination Survey (NHANES), conduzida entre 1999 e 2004, que envolv
eu uma amostra representativa da popula&ccedil;&atilde;o de adultos n&atilde;o i
nstitucionalizados dos EUA, com 20 anos de idade ou mais (n = 13.233). A preval&
ecirc;ncia da DRC foi determinada com base na presen&ccedil;a de albumin&uacute;
ria persistente (&gt; 30 mg/g) e diminui&ccedil;&atilde;o na TFG estimada usando
 a equa&ccedil;&atilde;o abreviada do estudo Modification of Diet in Renal Disea
se (MDRD), reexpressa para creatinina s&eacute;rica padr&atilde;o. Essa an&aacut
e;lise revelou que aproximadamente 13% da popula&ccedil;&atilde;o adulta dos EUA
 tem DRC est&aacute;gios 1 a 4.<sup>2</sup></font></p>     ^cY#v33n1a13.htm##
01386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704115200075002001301227#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#26#22#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No Brasil, estudos epidemiol&oacute;g
icos abrangentes sobre DRC que empregam a nova defini&ccedil;&atilde;o da doen&c
cedil;a ainda n&atilde;o foram realizados. Entretanto, um estudo sobre TRS basea
do em dados coletados em janeiro de 2009 revelou que havia 77.589 pacientes em d
i&aacute;lise no Brasil e que a preval&ecirc;ncia e a incid&ecirc;ncia de DRET c
orrespondiam a cerca de 405 e 144 por milh&atilde;o na popula&ccedil;&atilde;o, 
respectivamente. <sup>3</sup> Enquanto o n&uacute;mero de brasileiros nos difere
ntes est&aacute;gios pr&eacute;-di&aacute;lise da DRC n&atilde;o for conhecido c
om exatid&atilde;o, uma an&aacute;lise dos dados laboratoriais de adultos utiliz
ando a nova defini&ccedil;&atilde;o de DRC revelou que 2,3% dos indiv&iacute;duo
s avaliados tinham TFG &lt; 45mL/min/1,73m<sup>2</sup> ou DRC est&aacute;gios 3B
, 4 e 5. Extrapolando-se esses resultados para a popula&ccedil;&atilde;o adulta 
brasileira, sugere-se que cerca de 2,9 milh&otilde;es de brasileiros teriam um t
er&ccedil;o ou menos da TFG dos indiv&iacute;duos normais. <sup>4</sup> </font><
/p>     ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#27#23#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00384000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015000075002001300225#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#28#24#article#342#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DEFINI&Ccedil;&Atilde;O DE DOEN&Cc
edil;A RENAL CR&Ocirc;NICA</b></font></p>     ^cY#v33n1a13.htm##
01301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704106700075002001301142#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#29#25#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em 2002, a Kidney Disease Outcome Qua
lity Initiative (KDOQI), patrocinada pela National Kidney Foundation, publicou u
ma diretriz sobre DRC que compreendia avalia&ccedil;&atilde;o, classifica&ccedil
;&atilde;o e estratifica&ccedil;&atilde;o de risco.<sup>1</sup> Nesse importante
 documento, uma nova estrutura conceitual para o diagn&oacute;stico de DRC foi p
roposta e aceita mundialmente nos anos seguintes. A defini&ccedil;&atilde;o &eac
ute; baseada em tr&ecirc;s componentes: (1) um componente anat&ocirc;mico ou est
rutural (marcadores de dano renal); (2) um componente funcional (baseado na TFG)
 e (3) um componente temporal.<sup>1</sup> Com base nessa defini&ccedil;&atilde;
o, seria portador de DRC qualquer indiv&iacute;duo que, independente da causa, a
presentasse TFG &lt; 60 mL/min/1,73m<sup>2</sup> ou a TFG &gt; 60 mL/min/1,73m<s
up>2</sup> associada a pelo menos um marcador de dano renal parenquimatoso (por 
exemplo, protein&uacute;ria) presente h&aacute; pelo menos 3 meses.</font></p>  
   ^cY#v33n1a13.htm##
01502000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704126800075002001301343#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#30#26#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A KDOQI<sup>1</sup> tamb&eacute;m sug
eriu que a DRC deveria ser classificada em est&aacute;gios baseados na TFG, como
 mostrado na <a href="/img/revistas/jbn/v33n1/a13tab01m.jpg">Tabela 1</a>. Prote
in&uacute;ria (ou albumin&uacute;ria) &eacute; apresentada como marcador de dano
 renal na tabela, j&aacute; que &eacute; mais frequentemente utilizada para esse
 fim; mas outros marcadores de dano renal tamb&eacute;m podem ser empregados, ta
is como outras altera&ccedil;&otilde;es na urina (por exemplo, hemat&uacute;ria 
glomerular), imagens ultrassonogr&aacute;ficas anormais (por exemplo, cistos na 
doen&ccedil;a renal polic&iacute;stica do adulto) ou altera&ccedil;&otilde;es hi
stopatol&oacute;gicas vistas em bi&oacute;psias renais (por exemplo, altera&cced
il;&otilde;es glomerulares com ou sem envolvimento t&uacute;bulo- intersticial).
 Esse sistema de classifica&ccedil;&atilde;o da DRC &eacute; &uacute;til, porque
 padroniza a terminologia, evitando dessa forma a ambiguidade e a sobreposi&cced
il;&atilde;o dos termos que est&atilde;o atualmente em uso. Isso por sua vez fac
ilita a comunica&ccedil;&atilde;o entre os profissionais de sa&uacute;de envolvi
dos no cuidado ao paciente. </font></p>     ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#31#27#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00411000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017700075002001300252#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#32#28#article#342#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OTIMIZA&Ccedil;&Atilde;O DOS CUIDA
DOS AO PACIENTE COM DOEN&Ccedil;A RENAL CR&Ocirc;NICA</b></font></p>     ^cY#v33
n1a13.htm##
00590000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035600075002001300431#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#33#29#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O tratamento ideal da DRC &eacute; ba
seado em tr&ecirc;s pilares de apoio: 1) diagn&oacute;stico precoce da doen&cced
il;a, 2) encaminhamento imediato para tratamento nefrol&oacute;gico e 3) impleme
nta&ccedil;&atilde;o de medidas para preservar a fun&ccedil;&atilde;o renal.</fo
nt></p>     ^cY#v33n1a13.htm##
00368000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013400075002001300209#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#34#30#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DIAGN&Oacute;STICO PRECOCE DA DOEN
&Ccedil;A </b></font></p>     ^cY#v33n1a13.htm##
00802000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056800075002001300643#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#35#31#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A aus&ecirc;ncia de sintomas nos paci
entes que se encontram nos est&aacute;gios iniciais da DRC exige que os m&eacute
;dicos mantenham sempre um n&iacute;vel adequado de suspei&ccedil;&atilde;o, esp
ecialmente naqueles pacientes com fatores de risco m&eacute;dico ou sociodemogr&
aacute;fico para DRC. Como mencionado anteriormente, altera&ccedil;&otilde;es fu
ncionais, principalmente na TFG, s&atilde;o um importante componente no diagn&oa
cute;stico e classifica&ccedil;&atilde;o da DRC.</font></p>     ^cY#v33n1a13.htm
##
01730000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704149600075002001301571#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#36#32#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A TFG &eacute; a melhor medida geral 
da fun&ccedil;&atilde;o renal e a mais facilmente compreendida pelos m&eacute;di
cos e pacientes. Ela &eacute; definida como a capacidade dos rins de eliminar um
a subst&acirc;ncia do sangue e &eacute; expressa como o volume de sangue que &ea
cute; completamente depurado em uma unidade de tempo. Normalmente, o rim filtra 
o sangue e elimina os produtos finais do metabolismo prot&eacute;ico, enquanto p
reserva solutos espec&iacute;ficos, prote&iacute;nas (particularmente albumina) 
e componentes celulares. Na maioria das doen&ccedil;as renais progressivas, a TF
G diminui com o tempo como resultado da diminui&ccedil;&atilde;o no n&uacute;mer
o total de n&eacute;frons ou redu&ccedil;&atilde;o na TFG por n&eacute;fron, dec
orrentes de altera&ccedil;&otilde;es fisiol&oacute;gicas e farmacol&oacute;gicas
 na hemodin&acirc;mica glomerular. A TFG pode estar reduzida bem antes do in&iac
ute;cio dos sintomas e se correlaciona com a gravidade da DRC. <sup>1,5,6</sup> 
A ocorr&ecirc;ncia do aumento na press&atilde;o de filtra&ccedil;&atilde;o ou de
 hipertrofia glomerular explica a observa&ccedil;&atilde;o de TFG est&aacute;vel
 ou quase normal, mesmo quando o n&uacute;mero de n&eacute;frons &eacute; reduzi
do. Isso &eacute; algumas vezes observado na nefropatia diab&eacute;tica inicial
, quando a TFG pode apresentar um aumento de at&eacute; 40% acima do valor norma
l. <sup>7</sup> </font></p>     ^cY#v33n1a13.htm##
01569000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704133500075002001301410#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#37#33#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A melhor, e de fato, a &uacute;nica m
aneira correta de medir a TFG &eacute; determinar o <i>clearance</i> de subst&ac
irc;ncias ex&oacute;genas como a inulina,iotalamato-I<sup>125</sup>, EDTA (&Aacu
te;cido etilenodiaminotetraac&eacute;tico), DTPA-Tc<sup>99m </sup>(&aacute;cido 
dietilenotriaminopent&aacute;cetico marcado com tecn&eacute;cio<sup>99m</sup>) o
u iohexol. Esses agentes preenchem o crit&eacute;rio de marcador ideal de filtra
&ccedil;&atilde;o, j&aacute; que s&atilde;o excretados do corpo via filtra&ccedi
l;&atilde;o glomerular e n&atilde;o est&atilde;o sujeitos a secre&ccedil;&atilde
;o e/ou reabsor&ccedil;&atilde;o quando passam atrav&eacute;s dos t&uacute;bulos
 renais. <sup>8</sup> Como essas subst&acirc;ncias n&atilde;o est&atilde;o prese
ntes na circula&ccedil;&atilde;o e, consequentemente, precisam ser infundidas, a
 medida desses <i>clearances</i> &eacute; dif&iacute;cil, requer tempo do pacien
te e da equipe cl&iacute;nica e tem sido utilizada em geral de forma restrita, p
ara fins de pesquisa ou em condi&ccedil;&otilde;es patol&oacute;gicas espec&iacu
te;ficas nas quais as t&eacute;cnicas de <i>clearance </i>mais simples n&atilde;
o oferecem informa&ccedil;&otilde;es suficientes para guiar as decis&otilde;es m
&eacute;dicas. </font></p>     ^cY#v33n1a13.htm##
01321000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704108700075002001301162#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#38#34#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na pr&aacute;tica cl&iacute;nica, a T
FG &eacute; avaliada por meio da mensura&ccedil;&atilde;o de n&iacute;veis de su
bst&acirc;ncias que s&atilde;o normalmente produzidas pelo corpo. A ur&eacute;ia
, o primeiro marcador end&oacute;geno utilizado, n&atilde;o &eacute; completamen
te confi&aacute;vel, j&aacute; que seus n&iacute;veis s&atilde;o mais vulner&aac
ute;veis a mudan&ccedil;as por raz&otilde;es n&atilde;o relacionadas com a TFG. 
Uma dieta com alto consumo de prote&iacute;nas, destrui&ccedil;&atilde;o tedicua
l, hemorragia gastrointestinal de grande monta e terapia com corticoster&oacute;
ides podem determinar um aumento nos n&iacute;veis de ur&eacute;ia plasm&aacute;
tica, enquanto uma dieta pobre em prote&iacute;nas e doen&ccedil;a hep&aacute;ti
ca podem levar a uma redu&ccedil;&atilde;o. Al&eacute;m disso, 40-50% da ur&eacu
te;ia filtrada pode ser reabsorvida pelos t&uacute;bulos, embora a propor&ccedil
;&atilde;o esteja reduzida na insufici&ecirc;ncia renal avan&ccedil;ada. <sup>5,
9</sup></font></p>     ^cY#v33n1a13.htm##
02200000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704196600075002001302041#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#39#35#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">At&eacute; pouco tempo, a creatinina 
plasm&aacute;tica era considerada o marcador end&oacute;geno cujo perfil mais se
 assemelhava &agrave;quele de uma subst&acirc;ncia end&oacute;gena ideal para me
dir a TFG. A creatinina &eacute; quase exclusivamente um produto do metabolismo 
da creatina e da fosfocreatina no m&uacute;sculo esquel&eacute;tico, embora a in
gest&atilde;o de carne tamb&eacute;m possa contribuir levemente para os n&iacute
;veis dessa subst&acirc;ncia no sangue. Sua gera&ccedil;&atilde;o &eacute; relat
ivamente constante durante o dia e diretamente proporcional &agrave; massa muscu
lar. <sup>5,9</sup> A creatinina &eacute; livremente filtrada nos glom&eacute;ru
los e n&atilde;o &eacute; reabsorvida, mas at&eacute; 15% dela s&atilde;o ativam
ente secretados pelos t&uacute;bulos. &Eacute; importante lembrar que crom&oacut
e;genos n&atilde;o creatinina tamb&eacute;m s&atilde;o detectados quando o m&eac
ute;todo cl&aacute;ssico do picrato alcalino &eacute; utilizado, o que superesti
ma os n&iacute;veis s&eacute;ricos de creatinina. As duas maiores limita&ccedil;
&otilde;es para utilizar a creatinina como marcador da TFG s&atilde;o: 1) Como a
 creatinina &eacute; produzida nos m&uacute;sculos, a creatinina s&eacute;rica d
epende da massa muscular e deveria ser ajustada para fatores relacionados &agrav
e; massa muscular quando usada como par&acirc;metro para determina&ccedil;&atild
e;o da TFG; e 2) a rela&ccedil;&atilde;o inversa da creatinina com a TFG n&atild
e;o &eacute; uma rela&ccedil;&atilde;o direta, o que significa que o n&iacute;ve
l de creatinina s&oacute; aumentar&aacute; ap&oacute;s a TFG ter deca&iacute;do 
para cerca de 50%-60% de seu n&iacute;vel normal. <sup>10,11</sup> Assim, o uso 
isolado da creatinina s&eacute;rica para estimar a TFG &eacute; insatisfat&oacut
e;rio e leva a atrasos no diagn&oacute;stico e no tratamento da DRC. <sup>1,6,10
</sup></font></p>     ^cY#v33n1a13.htm##
01928000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704169400075002001301769#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#40#36#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Clinicamente, o m&eacute;todo mais ut
ilizado para obter informa&ccedil;&otilde;es sobre a TFG &eacute; a depura&ccedi
l;&atilde;o de creatinina, com coleta de urina ao longo de 24 horas, no qual a e
xcre&ccedil;&atilde;o de creatinina urin&aacute;ria em 24 horas &eacute; dividid
a pela concentra&ccedil;&atilde;o de creatinina s&eacute;rica. Infelizmente, dep
ura&ccedil;&atilde;o de creatinina n&atilde;o preenche o crit&eacute;rio de um m
arcador ideal para TFG, j&aacute; que, como mencionado anteriormente, a creatini
na &eacute; excretada n&atilde;o somente via filtra&ccedil;&atilde;o glomerular,
 mas tamb&eacute;m via secre&ccedil;&atilde;o no t&uacute;bulo proximal. <sup>1,
5,9</sup> Entretanto, o principal problema com depura&ccedil;&atilde;o de creati
nina &eacute; a necessidade de coletar urina por 24 horas, que &eacute; inconven
iente para os pacientes e, portanto, as coletas s&atilde;o frequentemente imprec
isas. Isso &eacute; particularmente verdadeiro em algumas situa&ccedil;&otilde;e
s cl&iacute;nicas (por exemplo, indiv&iacute;duos muito idosos ou com defici&eci
rc;ncia cognitiva). Atualmente, a determina&ccedil;&atilde;o da TFG pela depura&
ccedil;&atilde;o de creatinina &eacute; recomendada, quando a TFG for &gt; 60 mL
/min, em extremos de idade e tamanho corporal, desnutri&ccedil;&atilde;o grave, 
obesidade, doen&ccedil;a do aparelho m&uacute;sculoesquel&eacute;tico, paraplegi
a ou quadriplegia, dieta vegetariana, fun&ccedil;&atilde;o renal com altera&cced
il;&otilde;es r&aacute;pidas e c&aacute;lculo de ajuste de dosagem de medicament
os potencialmente nefrot&oacute;xicos. <sup>1,9</sup> </font></p>     ^cY#v33n1a
13.htm##
00954000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072000075002001300795#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#41#37#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para contornar algumas das limita&cce
dil;&otilde;es encontradas na determina&ccedil;&atilde;o da TFG atrav&eacute;s d
a creatinina s&eacute;rica ou da depura&ccedil;&atilde;o de creatinina, v&aacute
;rias f&oacute;rmulas destinadas a estimar a TFG t&ecirc;m sido publicadas. Essa
s f&oacute;rmulas usam vari&aacute;veis demogr&aacute;ficas e cl&iacute;nicas co
nhecidas como substitutos para os fatores fisiol&oacute;gicos n&atilde;o mensura
dos que afetam o n&iacute;vel de creatinina s&eacute;rica. As f&oacute;rmulas ma
is comumente utilizadas s&atilde;o as de Cockcroft e Gault (CG),<sup>12 </sup>MD
RD<sup>13</sup> e CKD-EPI. <sup>14</sup></font></p>     ^cY#v33n1a13.htm##
01111000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704087700075002001300952#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#42#38#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A f&oacute;rmula CG foi a primeira de
ssas equa&ccedil;&otilde;es a ganhar aceita&ccedil;&atilde;o e estima a depura&c
cedil;&atilde;o de creatinina. Em sua descri&ccedil;&atilde;o original, a equa&c
cedil;&atilde;o CG baseou-se na excre&ccedil;&atilde;o urin&aacute;ria de creati
nina em homens caucasianos hospitalizados, com idade de 18 a 92 anos, e com fun&
ccedil;&atilde;o renal normal. N&atilde;o foi padronizada para uma &aacute;rea d
e superf&iacute;cie corporal de 1,73 m<sup>2 </sup>e uma corre&ccedil;&atilde;o 
para mulheres foi necess&aacute;ria. <sup>12</sup> Ela sistematicamente superest
ima a TFG, porque a secre&ccedil;&atilde;o de creatinina tubular e o aumento no 
peso devido &agrave; obesidade ou sobrecarga de fluidos n&atilde;o s&atilde;o le
vados em considera&ccedil;&atilde;o. </font></p>     ^cY#v33n1a13.htm##
01443000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704120900075002001301284#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#43#39#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A equa&ccedil;&atilde;o do MDRD para 
estimativa da TFG foi originalmente desenvolvida com base nos dados do estudo Mo
dification of Diet in Renal Disease (MDRD) em pacientes com DRC e n&atilde;o inc
luiu indiv&iacute;duos saud&aacute;veis. O padr&atilde;o-ouro usado no desenvolv
imento da equa&ccedil;&atilde;o MDRD foi o <i>clearance</i> de iotalamato-I<sup>
125</sup> e, portanto, ela estima a TFG (em mL/min/1,73m<sup>2</sup>) e n&atilde
;o a depura&ccedil;&atilde;o de creatinina. <sup>13</sup> Em sua vers&atilde;o o
riginal, a equa&ccedil;&atilde;o MDRD requer determina&ccedil;&otilde;es de albu
mina e ur&eacute;ia nitrogenada s&eacute;ricas. Atualmente, uma f&oacute;rmula d
o MDRD abreviada com "quatro vari&aacute;veis" tem sido recomendada, porque seu 
desempenho &eacute; t&atilde;o bom quanto a equa&ccedil;&atilde;o inicial. <sup>
15</sup> A TFG calculada com a equa&ccedil;&atilde;o do MDRD e a TFG real s&atil
de;o muito pr&oacute;ximas para  resultados &lt; 60 mL/min/1,73m<sup>2</sup>, en
quanto a TFG excede a taxa estimada por um valor pequeno quando a TFG &eacute; &
gt; 60 mL/min/1,73m<sup>2</sup>. <sup>16-18</sup></font></p>     ^cY#v33n1a13.ht
m##
01035000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080100075002001300876#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#44#40#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O grupo <i>Chronic Kidney Disease Epi
demiology Collaboration</i> (CKD-EPI) recentemente desenvolveu, a partir de coor
te que incluiu indiv&iacute;duos com e sem DRC, uma nova equa&ccedil;&atilde;o q
ue &eacute; uma varia&ccedil;&atilde;o da f&oacute;rmula do MDRD. <sup>14</sup> 
A equa&ccedil;&atilde;o, denominada de CKD-EPI usa as mesmas quatro vari&aacute;
veis que a equa&ccedil;&atilde;o do MDRD, mas, comparativamente, apresenta melho
r desempenho e previs&atilde;o de risco. As observa&ccedil;&otilde;es de menor v
i&eacute;s e maior acur&aacute;cia da equa&ccedil;&atilde;o CKD-EPI, particularm
ente nas faixas de TFG &gt;60 mL/min/1,73 m<sup>2</sup>, do estudo MDRD para uso
 cl&iacute;nico de rotina. <sup>13</sup> </font></p>     ^cY#v33n1a13.htm##
02480000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704224600075002001302321#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#45#41#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Atualmente, as f&oacute;rmulas para a
valia&ccedil;&atilde;o da TFG est&atilde;o dispon&iacute;veis em programas para 
<i>palmtops</i>, computadores e <i>i-phones</i> e est&atilde;o amplamente dissem
inadas na internet (por exemplo, em <i>websites</i> da Sociedade Brasileira de N
efrologia e da <i>National Kidney Foundation</i>). Entretanto, a maioria dos pro
fissionais, particularmente aqueles que trabalham em cl&iacute;nicas de aten&cce
dil;&atilde;o prim&aacute;ria &agrave; sa&uacute;de ainda n&atilde;o tem acesso 
imediato a esses equipamentos de computa&ccedil;&atilde;o e precisa calcular a T
FG manualmente. Esse processo de certa forma tedioso e que demanda tempo desenco
raja os profissionais da sa&uacute;de, particularmente aqueles que n&atilde;o s&
atilde;o nefrologistas, em avaliar a TFG de forma rotineira e, assim, pode atras
ar o diagn&oacute;stico e o encaminhamento nefrol&oacute;gico. Para contornar es
sa situa&ccedil;&atilde;o, recentemente desenvolvemos duas tabelas, uma para mul
heres e outra para homens, que permitem que os profissionais de sa&uacute;de est
imem a TFG imediatamente assim que tiverem em m&atilde;os o n&iacute;vel de crea
tinina s&eacute;rica e a idade do paciente. <sup>19</sup> Essas tabelas s&atilde
;o baseadas na f&oacute;rmula do estudo MDRD de quatro vari&aacute;veis,<sup>14<
/sup> na qual o componente etnia negra (importante para estimar a TFG na popula&
ccedil;&atilde;o negra dos EUA, mas sem impacto na popula&ccedil;&atilde;o brasi
leira) foi exclu&iacute;da. As tabelas mostram os valores de TFG que corresponde
m a valores espec&iacute;ficos de creatinina s&eacute;rica nos limites 0,5-5,0 m
g/dL e nas faixas et&aacute;rias de 18 a 80 anos. Al&eacute;m disso, os diferent
es est&aacute;gios da DRC s&atilde;o indicados por cores diferentes, facilitando
, assim, o estadiamento da DRC. <sup>18</sup> Embora reconhe&ccedil;amos que a e
qua&ccedil;&atilde;o do estudo MDRD ainda n&atilde;o foi validada de forma defin
itiva no Brasil, sugerimos o uso dessas tabelas no atendimento prim&aacute;rio &
agrave; sa&uacute;de e entre os n&atilde;o nefrologistas, como ferramenta para f
acilitar o diagn&oacute;stico precoce da DRC. </font></p>     ^cY#v33n1a13.htm##
02244000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704201000075002001302085#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#46#42#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Finalmente, &eacute; importante menci
onar o interesse recente pela cistatina C como marcador end&oacute;geno da TFG. 
A cistatina C &eacute; uma prote&iacute;na b&aacute;sica n&atilde;o glicosilada,
 com baixa massa molecular (13 kD) que faz parte da superfam&iacute;lia de inibi
dores de protease de ciste&iacute;na. Ela &eacute; produzida por todas as c&eacu
te;lulas nucleadas, &eacute; livremente filtrada no glom&eacute;rulo e &eacute; 
reabsorvida e catabolizada pelas c&eacute;lulas epiteliais tubulares; somente pe
quenas quantidades s&atilde;o excretadas na urina. Consequentemente, embora a ci
statina C seja filtrada pelos glom&eacute;rulos, seu <i>clearance</i> urin&aacut
e;rio n&atilde;o pode ser medido, o que torna o estudo dos fatores que afetam se
u <i>clearance</i> e gera&ccedil;&atilde;o dif&iacute;ceis de realizar. Al&eacut
e;m disso, h&aacute; evid&ecirc;ncia preliminar de que os n&iacute;veis s&eacute
;ricos de cistatina C s&atilde;o influenciados pelo uso de corticoster&oacute;id
es<sup>20</sup> e est&atilde;o relacionados a idade, sexo, peso, altura, tabagis
mo e n&iacute;vel de prote&iacute;na C reativa, mesmo ap&oacute;s o ajuste para 
a depura&ccedil;&atilde;o da creatinina. <sup>21</sup> No momento, o papel cl&ia
cute;nico para a mensura&ccedil;&atilde;o da cistatina C ainda n&atilde;o foi el
ucidado, mas ainda existe a possibilidade de que ela venha a ser um marcador &ua
cute;til de disfun&ccedil;&atilde;o renal precoce, como parte de programas de ra
streamento. Devido ao fato de a cistatina C n&atilde;o depender da massa muscula
r, ela parece ser mais sens&iacute;vel do que a equa&ccedil;&atilde;o do estudo 
MDRD no diagn&oacute;stico precoce da DRC,<sup>22</sup> particularmente na popul
a&ccedil;nao de idosos. <sup>23</sup> Al&eacute;m disso, tem-se sugerido que a c
istatina C pode ter um papel na previs&atilde;o de pacientes com DRC com maior r
isco de complica&ccedil;&otilde;es. <sup>24</sup> </font></p>     ^cY#v33n1a13.h
tm##
02023000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704178900075002001301864#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#47#43#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A defini&ccedil;&atilde;o de DRC tamb
&eacute;m &eacute; baseada na documenta&ccedil;&atilde;o do dano renal parenquim
atoso. Como mencionado anteriormente, a albumin&uacute;ria &eacute; o principal 
marcador do dano renal parenquimatoso. A albumin&uacute;ria ou a protein&uacute;
ria (albumin&uacute;ria &gt; 300 mg/dia) pode ser determinada pelo teste com fit
as reagentes, que &eacute; de baixo custo e de f&aacute;cil aplica&ccedil;&atild
e;o, embora seja importante reconhecer que o teste &eacute; n&atilde;o espec&iac
ute;fico, semiquantitativo e n&atilde;o se mostra sens&iacute;vel o suficiente p
ara detectar n&iacute;veis de albumina &lt; 300 mg/L. Quando a protein&uacute;ri
a &eacute; detectada, o pr&oacute;ximo passo &eacute; a sua quantifica&ccedil;&a
tilde;o, o que pode ser feito na urina de 24 horas ou em uma amostra de urina is
olada (nesse caso, a concentra&ccedil;&atilde;o de protein&uacute;ria ou albumin
&uacute;ria &eacute; dividida pela concentra&ccedil;&atilde;o de creatinina urin
&aacute;ria, a fim de corrigir para a varia&ccedil;&atilde;o no volume urin&aacu
te;rio). <sup>25</sup> Os indiv&iacute;duos que pertencem ao grupo de risco para
 DRC, mas apresentam resultado negativo para protein&uacute;ria no teste com fit
a reagente, deveriam ser testados com rela&ccedil;&atilde;o &agrave; presen&cced
il;a de microalbumin&uacute;ria, o que pode ser feito com v&aacute;rios m&eacute
;todos, atualmente dispon&iacute;veis, que utilizam anticorpos (radioimunoensaio
, turbidimetria, nefelometria e ELISA) ou cromatografia l&iacute;quida de alto d
esempenho (HPLC), que medem n&atilde;o somente a albumina imunorreativa, mas tam
b&eacute;m a albumina intacta n&atilde;o imunoreativa. <sup>26</sup> </font></p>
     ^cY#v33n1a13.htm##
00491000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025700075002001300332#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#48#44#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Na <a href="/img/revistas/jbn/v33n1/a
13fig01m.jpg">Figura 1</a>, propomos um procedimento de triagem baseado na TFG e
stimada e na medida de albumin&uacute;ria. <sup>27</sup> </font></p>     ^cY#v33
n1a13.htm##
00781000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054700075002001300622#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#49#45#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O teste com fita reagente tamb&eacute
;m pode detectar outras anormalidades na urina. Por exemplo, um teste positivo p
ara sangue oculto pode ser devido &agrave; presen&ccedil;a de hemat&uacute;ria e
 imp&otilde;e um estudo confirmat&oacute;rio, preferivelmente com microscopia de
 contraste de fase. <sup>28</sup> Outras anormalidades, tais como bacteri&uacute
;ria, pi&uacute;ria e glicos&uacute;ria podem dar ind&iacute;cios de qual seria 
a causa subjacente da DRC. </font></p>     ^cY#v33n1a13.htm##
00382000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014800075002001300223#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#50#46#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ENCAMINHAMENTO PRECOCE PARA TRATAM
ENTO  NEFROL&Oacute;GICO</b></font></p>     ^cY#v33n1a13.htm##
01713000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704147900075002001301554#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#51#47#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O segundo pilar de apoio do tratament
o ideal para a DRC &eacute; o encaminhamento imediato de pacientes para acompanh
amento pelo nefrologista ou pela equipe de nefrologia. A literatura tem muitos e
xemplos de cuidados sub&oacute;timos &agrave; DRC fornecidos por outros especial
istas m&eacute;dicos antes do encaminhamento para o atendimento nefrol&oacute;gi
co. Por exemplo, Roubicek <i>et al.</i><sup>29</sup> compararam pacientes com DR
C que haviam sido encaminhados precocemente (EP) ao nefrologista, definido por p
er&iacute;odo <u>&gt;</u> 16 semanas antes do in&iacute;cio da di&aacute;lise, e
 aqueles com encaminhamento tardio (ET), definido por &lt; 16 semanas e seguimen
to antes do in&iacute;cio da di&aacute;lise. Foi observado que, comparados aos p
acientes com ET, os pacientes com EP passavam menos dias no hospital ap&oacute;s
 a di&aacute;lise ser iniciada, tinham menor probabilidade de necessitar de di&a
acute;lise de urg&ecirc;ncia, melhor controle da press&atilde;o arterial e menos
 edema agudo de pulm&atilde;o. Eles tamb&eacute;m apresentavam maior probabilida
de de iniciar a di&aacute;lise com um acesso vascular permanente e, sendo assim,
 tinham menor probabilidade de necessitar de um acesso venoso central tempor&aac
ute;rio. Al&eacute;m disso, os pacientes com ET tinham maior probabilidade de mo
rrer no primeiro ano de di&aacute;lise do que os pacientes com EP.<sup>30</sup><
/font></p>     ^cY#v33n1a13.htm##
01413000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704117900075002001301254#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#52#48#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em um estudo mais recente, McLaughlin
 <i>et al. </i><sup>31</sup> avaliaram o custo financeiro do tratamento da DRC e
m pacientes que foram encaminhados precoce ou tardiamente ao nefrologista. Os de
sfechos desse estudo foram custo total do atendimento ao paciente, anos de vida 
dos pacientes, anos de vida livre de TRS e dias de hospitaliza&ccedil;&atilde;o.
 Para os grupos com encaminhamento precoce e tardio, os custos m&eacute;dios tot
ais em cinco anos foram US$87.711,00 e US$110.056,00, respectivamente; as m&eacu
te;dias dos anos de vida dos pacientes foram 3,53 e 3,36 anos, respectivamente, 
e os anos de vida dos pacientes livres de TRS foram 2,18 e 1,76 anos, respectiva
mente. Al&eacute;m disso, pacientes com acompanhamento nefrol&oacute;gico precoc
e passaram metade do tempo no hospital (25 dias) quando comparados &agrave;quele
s encaminhados tardiamente (41 dias). Finalmente, tem-se mostrado que os pacient
es apresentam maior probabilidade de progredir para &oacute;bito durante o prime
iro ano de di&aacute;lise quando s&atilde;o encaminhados tardiamente ao nefrolog
ista. <sup>30</sup></font></p>     ^cY#v33n1a13.htm##
01564000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704133000075002001301405#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#53#49#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Esses achados enfatizam a import&acir
c;ncia de lembrar e encorajar outros profissionais da sa&uacute;de, especialment
e cardiologistas, endocrinologistas, cl&iacute;nicos gerais, urologistas e geria
tras, que frequentemente lidam com pacientes em risco para DRC, de encaminhar pa
cientes para acompanhamento conjunto com um nefrologista ou equipe especializada
 em nefrologia o mais r&aacute;pido poss&iacute;vel. Isso &eacute; particularmen
te importante nos casos em que d&eacute;ficit de fun&ccedil;&atilde;o renal e pr
otein&uacute;ria de grande monta (&gt; 1 g/dia) j&aacute; est&atilde;o presentes
. Os benef&iacute;cios potenciais do encaminhamento precoce incluem a identifica
&ccedil;&atilde;o e o tratamento das causas revers&iacute;veis da insufici&ecirc
;ncia renal; o diagn&oacute;stico e corre&ccedil;&atilde;o de fatores que pioram
 a fun&ccedil;&atilde;o renal (por exemplo, o uso de agentes nefrot&oacute;xicos
); a estabiliza&ccedil;&atilde;o da TFG; a identifica&ccedil;&atilde;o e a corre
&ccedil;&atilde;o de grandes complica&ccedil;&otilde;es e as morbidades mais pre
valentes na DRC; e a obten&ccedil;&atilde;o de melhores par&acirc;metros bioqu&i
acute;micos, psicol&oacute;gicos e f&iacute;sicos no in&iacute;cio da TRS. <sup>
1,6</sup> </font></p>     ^cY#v33n1a13.htm##
00408000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017400075002001300249#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#54#50#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>IMPLEMENTA&Ccedil;&Atilde;O DE MED
IDAS PARA PRESERVAR A  FUN&Ccedil;&Atilde;O RENAL </b></font></p>     ^cY#v33n1a
13.htm##
01321000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704108700075002001301162#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#55#51#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O terceiro pilar de apoio do tratamen
to ideal da DRC &eacute; a implementa&ccedil;&atilde;o de medidas nefroprotetora
s. O curso da DRC &eacute; frequentemente assintom&aacute;tico, at&eacute; que a
 doen&ccedil;a atinge seu est&aacute;gio avan&ccedil;ado, o que resulta na busca
 de cuidados m&eacute;dicos por parte do paciente quando ele ou ela j&aacute; ap
resenta uma ou mais complica&ccedil;&otilde;es da doen&ccedil;a e/ou comorbidade
s. N&atilde;o se sabe ainda quantos pacientes com DRC evoluir&atilde;o para DRET
 e quais pacientes apresentam maior risco de necessitar de TRS. Entretanto, &eac
ute; razo&aacute;vel concluir que as interven&ccedil;&otilde;es que diminuem ou 
estabilizam a progress&atilde;o da DRC e previnem a ocorr&ecirc;ncia de DRET ter
&atilde;o maior impacto se forem implementadas precocemente. Al&eacute;m disso, 
&eacute; sempre importante enfatizar que o tratamento bem-sucedido da doen&ccedi
l;a de base tamb&eacute;m &eacute; muito importante na preven&ccedil;&atilde;o d
e DRET.</font></p>     ^cY#v33n1a13.htm##
00720000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048600075002001300561#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#56#52#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Claramente, a probabilidade de progre
ss&atilde;o da DRC &eacute; determinada por intera&ccedil;&otilde;es complexas q
ue envolvem v&aacute;rios fatores cl&iacute;nicos, ambientais e gen&eacute;ticos
. Os principais fatores cl&iacute;nicos s&atilde;o idade, sexo, diabetes, hipert
ens&atilde;o, protein&uacute;ria, anemia, complica&ccedil;&otilde;es metab&oacut
e;licas, obesidade, tabagismo e dislipidemia. </font></p>     ^cY#v33n1a13.htm##
01483000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704124900075002001301324#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#57#53#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sabe-se, por exemplo, que as  etiolog
ias mais comuns das nefropatias que determinam DRC e DRET t&ecirc;m tend&ecirc;n
cias familiares. Assim, &eacute; imperativo que os nefrologistas e m&eacute;dico
s da aten&ccedil;&atilde;o prim&aacute;ria &agrave; sa&uacute;de identifiquem es
ses indiv&iacute;duos que t&ecirc;m na fam&iacute;lia um parente com DRC avan&cc
edil;ada, particularmente aqueles que precisam de di&aacute;lise ou transplante 
renal, j&aacute; que esses indiv&iacute;duos s&atilde;o particularmente propenso
s a desenvolver doen&ccedil;as do par&ecirc;nquima renal. De fato, um estudo de 
pacientes dialisados incidentes mostrou que 20% deles relataram ter um parente d
e primeiro ou segundo grau com DRET, e hist&oacute;rico familiar positivo foi ma
is comum em pacientes com doen&ccedil;a renal diab&eacute;tica ou DRC decorrente
 de glomerulonefrite do que naqueles com DRC associada &agrave; hipertens&atilde
;o ou outras causas. <sup>32</sup> Assim, enquanto os genes para insufici&ecirc;
ncia renal n&atilde;o forem identificados, &eacute; razo&aacute;vel que o hist&o
acute;rico familiar possa servir como marcador de risco para futura doen&ccedil;
a renal. </font></p>     ^cY#v33n1a13.htm##
00857000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062300075002001300698#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#58#54#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Atualmente, h&aacute; tratamentos efe
tivos que reduzem a perda da fun&ccedil;&atilde;o renal e podem servir para a pr
even&ccedil;&atilde;o prim&aacute;ria da DRC. Por exemplo, um estudo de paciente
s hipertensos com diabetes tipo 2 sem nefropatia revelou que, comparados com out
ros medicamentos anti-hipertensivos, o tratamento com inibidor de enzima convers
ora da angiotensina (IECA), ao longo de  um per&iacute;odo de seguimento de 48 m
eses, diminuiu em 50%a ocorr&ecirc;ncia de  microalbumin&uacute;ria, um marcador
 de DRC. <sup>33</sup> </font></p>     ^cY#v33n1a13.htm##
01420000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704118600075002001301261#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#59#55#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Mas a realidade do dia a dia do nefro
logista no que tange a  mudar o curso natural da DRC ainda est&aacute; no n&iacu
te;vel de preven&ccedil;&atilde;o secund&aacute;ria. &Eacute; de grande import&a
circ;ncia que a press&atilde;o arterial (PA) de pacientes com DRC seja controlad
a de forma rigorosa, pois isso minimizar&aacute; a progress&atilde;o da DRC e re
duzir&aacute; o risco de doen&ccedil;a cardiovascular. <sup>34</sup> O estudo <i
>Multiple Risk Factor Intervention Trial</i> respaldou essa observa&ccedil;&atil
de;o ao mostrar que a PA mais alta era um fator de risco independente para a pro
gress&atilde;o para DRET. <sup>35</sup> Vale lembrar que a  Organiza&ccedil;&ati
lde;o Mundial da Sa&uacute;de (OMS)<sup>36</sup> e o KDOQI<sup>37</sup> recomend
am, de um modo geral, valores de PA <u>&lt;</u> 130/85 mmHg (<u>&lt;</u> 140/90 
mmHg em pacientes com mais de 60 anos de idade) como ideais para pacientes com D
RC. A <a href="/img/revistas/jbn/v33n1/a13tab02m.jpg">Tabela 2</a> sumariza as r
ecomenda&ccedil;&otilde;es sobre as medidas de PA e medicamentos anti-hipertensi
vos na DRC. <sup>37</sup> </font></p>     ^cY#v33n1a13.htm##
00919000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704068500075002001300760#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#60#56#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Atualmente, a hipertens&atilde;o na D
RC pode ser tratada com v&aacute;rios tipos de medicamentos e n&atilde;o &eacute
; raro que dois ou mais agentes anti-hipertensivos sejam necess&aacute;rios para
 se atingir o controle ideal da PA. <sup>38</sup> A classe de medicamentos bloqu
eadores do SRAA &eacute; considerada especialmente importante da redu&ccedil;&at
ilde;o da velocidade de progress&atilde;o da DRC, com v&aacute;rios estudos rece
ntes mostrando que os inibidores de SRAA efetivamente diminuem a progress&atilde
;o da DRC diab&eacute;tica<sup>39</sup> e n&atilde;o diab&eacute;tica. <sup>40</
sup> </font></p>     ^cY#v33n1a13.htm##
01366000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704113200075002001301207#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#61#57#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outro importante aspecto da progress&
atilde;o da DRC &eacute; a ocorr&ecirc;ncia de protein&uacute;ria, ou, mais espe
cificamente, albumin&uacute;ria. Inicialmente interpretada como simplesmente um 
indicador de dano glomerular, a albumin&uacute;ria &eacute; atualmente vista com
o prejudicial ao rim, constituindo-se em um dos principais fatores de risco para
 a progress&atilde;o da DRC e doen&ccedil;as cardiovasculares. <sup>41,42,43 </s
up>O grau de protein&uacute;ria correlaciona-se com a magnitude do dano renal em
 diferentes modelos animais<sup>44</sup> e humanos,<sup>45</sup> e sua redu&cced
il;&atilde;o est&aacute; associada com a estabiliza&ccedil;&atilde;o da TFG. <su
p>41</sup> Atualmente, os bloqueadores do SRAA s&atilde;o preferidos a outros me
dicamentos para tratar DRC diab&eacute;tica e n&atilde;o diab&eacute;tica, porqu
e eles conciliam a redu&ccedil;&atilde;o da protein&uacute;ria com um controle m
uito bom da PA, melhora na inflama&ccedil;&atilde;o e estabiliza&ccedil;&atilde;
o da fun&ccedil;&atilde;o renal. <sup>41,46.47</sup></font></p>     ^cY#v33n1a13
.htm##
01208000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704097400075002001301049#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#62#58#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ainda n&atilde;o est&aacute; claro se
 um controle glic&ecirc;mico rigoroso &eacute; protetor em pacientes com nefropa
tia diab&eacute;tica, embora valha a pena mencionar que, no estudo de Fioretto <
i>et al. </i><sup>48</sup>, alcan&ccedil;ar euglicemia ap&oacute;s o transplante
 de p&acirc;ncreas se associou com a regress&atilde;o da glomeruloesclerose diab
&eacute;tica. De qualquer forma, a maioria dos autores recomenda controle glic&e
circ;mico adequado como uma estrat&eacute;gia para evitar ou diminuir as complic
a&ccedil;&otilde;es macro e microvasculares do diabetes. Em particular, tanto pa
ra o diabetes tipo 1<sup>49</sup>, como para o tipo 2<sup>50</sup>,  o controle 
glic&ecirc;mico intensivo tem sido recomendado para a preven&ccedil;&atilde;o pr
im&aacute;ria de microalbumin&uacute;ria e para diminuir a progress&atilde;o da 
microalbumin&uacute;ria para macroalbumin&uacute;ria. </font></p>     ^cY#v33n1a
13.htm##
01396000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704116200075002001301237#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#63#59#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Por muitos anos, tem-se reconhecido o
 efeito adverso da obesidade nos desfechos renais em pacientes com doen&ccedil;a
s renais prim&aacute;rias em geral,<sup>51</sup> bem como em pacientes com hiper
tens&atilde;o e diabetes tipo 2,<sup>52</sup> as duas causas mais comuns de DRC.
 A obesidade pode determinar aumento no tamanho glomerular e anormalidades na fu
n&ccedil;&atilde;o glomerular; tamb&eacute;m pode causar uma forma especial de g
lomeruloesclerose segmentar e focal (GESF), com grave protein&uacute;ria e &eacu
te; frequentemente acompanhada por r&aacute;pida perda da fun&ccedil;&atilde;o r
enal. <sup>53,54</sup> A revers&atilde;o da obesidade melhora a albumin&uacute;r
ia<sup>55,56</sup> e a hiperfiltra&ccedil;&atilde;o glomerular em pacientes com 
obesidade m&oacute;rbida. <sup>57</sup> Al&eacute;m disso, um estudo que avaliou
 o impacto da obesidade na TFG durante 25 anos de acompanhamento revelou que pac
ientes obesos submetidos &agrave; nefrectomia unilateral apresentavam maior perd
a da fun&ccedil;&atilde;o renal do que pacientes n&atilde;o obesos. <sup>58</sup
> </font></p>     ^cY#v33n1a13.htm##
01767000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704153300075002001301608#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#64#60#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A anemia &eacute; uma complica&ccedil
;&atilde;o comum em pacientes com DRC e baseado nas evid&ecirc;ncias, os pacient
es com os valores mais baixos de hemoglobina t&ecirc;m desfechos piores do que a
queles com valores mais altos de hemoglobina. A natureza aparentemente robusta d
essa associa&ccedil;&atilde;o, apoiada por consequ&ecirc;ncias fisiol&oacute;gic
as conhecidas da anemia (incluindo fadiga, intoler&acirc;ncia ao exerc&iacute;ci
o, defici&ecirc;ncia cognitiva e exacerba&ccedil;&atilde;o da doen&ccedil;a card
iovascular) tem levado a maior parte dos m&eacute;dicos a tratar a anemia em pac
ientes com DRC. As diretrizes da KDOQI recomendam avaliar os pacientes com rela&
ccedil;&atilde;o &agrave; anemia se os n&iacute;veis de hemoglobina (Hb) forem &
lt; 13,5 g/dL em homens adultos ou &lt; 12,0 g/dL em mulheres adultas. <sup>59 <
/sup>As diretrizes brasileiras recomendam a avalia&ccedil;&atilde;o se os n&iacu
te;veis de Hb forem &lt; 13 g/dL em homens adultos e &lt; 12 g/dL em mulheres e 
homens com idade &gt; 65 anos. <sup>60</sup> Ambas diretrizes recomendam avaliar
 as reservas de ferro, vitamina B12 e os n&iacute;veis de folato antes de consid
erar terapia com agentes estimuladores da eritropoiese (AEE). As reservas de fer
ro s&atilde;o consideradas adequadas se os n&iacute;veis de ferritina s&eacute;r
ica forem &gt; 100 ng/mL e a satura&ccedil;&atilde;o da transferrina (SATT) &gt;
 20% em pacientes pr&eacute;-di&aacute;lise com DRC. </font></p>     ^cY#v33n1a1
3.htm##
02798000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704256400075002001302639#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#65#61#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O uso de AEE e os n&iacute;veis-alvo 
de Hb t&ecirc;m sido o objeto de muitos estudos e debates. Nos estudos cl&iacute
;nicos iniciais, realizados em pacientes em di&aacute;lise, AEE eram administrad
os aos pacientes que frequentemente apresentavam n&iacute;veis muito baixos de H
b (<u>&lt;</u> 7 g/dL), e sua anemia era parcialmente corrigida para n&iacute;ve
is de Hb entre 10 e 12 g/dL. <sup>61,62</sup> Esses pacientes experimentaram uma
 melhora dram&aacute;tica em sua qualidade de vida. Estudos subsequentes expandi
ram o uso de AEE para pacientes com DRC ainda n&atilde;o submetidos &agrave; di&
aacute;lise, que tamb&eacute;m apresentavam n&iacute;veis de Hb de 8 g/dL<sup>63
-65</sup> e confirmaram que a corre&ccedil;&atilde;o parcial da anemia era alcan
&ccedil;ada sem causar deteriora&ccedil;&atilde;o na fun&ccedil;&atilde;o renal.
 <sup>66,67</sup> V&aacute;rios estudos cl&iacute;nicos prospectivos, entretanto
, n&atilde;o forneceram evid&ecirc;ncias definitivas de que o tratamento da anem
ia melhora os resultados em pacientes com DRC submetidos &agrave; di&aacute;lise
<sup>68</sup> e naqueles em tratamento conservador. <sup>69-71</sup> Resta saber
 como conciliar os achados desses importantes estudos controlados randomizados c
om aqueles de estudos observacionais que mostraram um efeito totalmente diferent
e dos n&iacute;veis de Hb em seus desfechos. Embora ainda n&atilde;o tenhamos um
a resposta definitiva a essa pergunta, &eacute; importante perceber que a sa&uac
ute;de do paciente, o n&iacute;vel de Hb atingido e a dose de AEE usada est&atil
de;o interligados e deveriam ser considerados quando se institui o tratamento da
 anemia em pacientes com DRC. A esse respeito, &eacute; interessante mencionar o
 estudo recente de Goodkin <i>et al. </i><sup>72</sup> sobre  os efeitos dos n&i
acute;veis de Hb em pacientes submetidos &agrave; hemodi&aacute;lise mant&ecirc;
m naturalmente concentra&ccedil;&otilde;es mais altas de Hb sem transfus&atilde;
o ou terapia eritropoi&eacute;tica. Comparados com outros pacientes, aqueles com
 Hb &gt; 12 g/dL e sem terapia eritropoi&eacute;tica apresentavam menor risco de
 mortalidade n&atilde;o ajustado, o que n&atilde;o foi observado ap&oacute;s aju
ste completo do modelo (risco relativo, 0,98; IC95%: 0,80 a 1,19). Os autores co
nclu&iacute;ram que a concentra&ccedil;&atilde;o de Hb que se mant&eacute;m natu
ralmente &gt; 12 g/dL n&atilde;o se associa com aumento da mortalidade em pacien
tes submetidos &agrave; hemodi&aacute;lise. </font></p>     ^cY#v33n1a13.htm##
00764000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053000075002001300605#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#66#62#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com base nesses estudos, <i>KDOQI Ini
tiative</i>,<sup>73 </sup><i>European Renal Best Practice guidelines</i><sup>74 
</sup>e <i>Food and Drug Administration</i> (FDA) recomendam uma varia&ccedil;&a
tilde;o-alvo de Hb de 11 a 12 g/dL ao se prescrever AEE. Mais estudos s&atilde;o
 necess&aacute;rios para avaliar se a concentra&ccedil;&atilde;o de Hb &gt; 12 g
/dL &eacute; aceit&aacute;vel e segura em todos os pacientes com DRC sem terapia
 com AEE. </font></p>     ^cY#v33n1a13.htm##
01945000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704171100075002001301786#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#67#63#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A hiperfosfatemia estimula diretament
e a libera&ccedil;&atilde;o do paratireoidiano (PTH) das gl&acirc;ndulas paratir
e&oacute;ides e inibe a s&iacute;ntese de 1,25-dihidroxivitamina D, o que leva a
o hiperparatireoidismo secund&aacute;rio e defici&ecirc;ncia de vitamina D ativa
. Embora as altera&ccedil;&otilde;es do metabolismo da vitamina D e o equil&iacu
te;brio do fosfato s&atilde;o documentados precocemente no curso da DRC, dist&ua
cute;rbios graves geralmente ocorrem somente quando o paciente atinge o est&aacu
te;gio 3B e est&aacute;gios superiores da doen&ccedil;a (TFG &lt; 45 mL/min por 
1,73m<sup>2</sup>). <sup>75,76</sup> A principal consequ&ecirc;ncia da hiperfosf
atemia e da defici&ecirc;ncia de vitamina D &eacute; a  hipocalcemia, que est&aa
cute; associada com anormalidades na homeostase &oacute;ssea e com aumento da fr
agilidade &oacute;ssea e fraturas, conhecidas como osteodistrofia renal. <sup>77
,78</sup> Al&eacute;m disso, o desequil&iacute;brio do produto c&aacute;lcio-f&o
acute;sforo e do metabolismo da vitamina D tamb&eacute;m t&ecirc;m sido associad
os &agrave; calcifica&ccedil;&atilde;o vascular e de tecidos moles, aumento de e
ventos cardiovasculares e morte. <sup>79-81</sup> Embora n&atilde;o haja evid&ec
irc;ncia de benef&iacute;cio no longo prazo,<sup>82</sup> as diretrizes do KDOQI
 recomendam uma combina&ccedil;&atilde;o de restri&ccedil;&atilde;o de f&oacute;
sforo na dieta, quelantes de f&oacute;sforo e suplementa&ccedil;&atilde;o de vit
amina D para manter os n&iacute;veis s&eacute;ricos de c&aacute;lcio, f&oacute;s
foro e PTH intacto dentro dos limites-alvo recomendados. <sup>83</sup> </font></
p>     ^cY#v33n1a13.htm##
01363000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704112900075002001301204#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#68#64#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A DRC est&aacute; associada com acido
se metab&oacute;lica (AM), mas AM digna de tratamento raramente ocorre at&eacute
; que a TFG diminua a n&iacute;veis &lt; 30 mL/min/1,73 m<sup>2</sup>. <sup> 76<
/sup> A acidose metab&oacute;lica tem efeitos adversos que afetam os ossos, a nu
tri&ccedil;&atilde;o e o metabolismo na DRC. <sup>84</sup> Diretrizes atuais rec
omendam manter os n&iacute;veis de bicarbonato s&eacute;rico <u>&gt;</u> 22 mEq/
L para ajudar a prevenir essas complica&ccedil;&otilde;es. Al&eacute;m disso, do
is estudos recentes em seres humanos demonstraram que a corre&ccedil;&atilde;o d
a acidose metab&oacute;lica com bicarbonato de s&oacute;dio<sup>85</sup> ou citr
ato de s&oacute;dio<sup>86</sup> diminuem a velocidade de progress&atilde;o da D
RC para DRET. Mais estudos s&atilde;o necess&aacute;rios para provar que esse tr
atamento adjunto promissor e de baixo custo se aplica a pacientes com DRC por di
ferentes causas, com o fim de retardar a progress&atilde;o da doen&ccedil;a e me
lhorar o estado nutricional do indiv&iacute;duo. </font></p>     ^cY#v33n1a13.ht
m##
01461000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704122700075002001301302#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#69#65#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Finalmente, &eacute; importante menci
onar que h&aacute; outras abordagens terap&ecirc;uticas cuja efetividade na prev
en&ccedil;&atilde;o da progress&atilde;o da DRC ainda precisam ser provadas de f
orma definitiva. Uma delas &eacute; a ingest&atilde;o de prote&iacute;nas. Embor
a a restri&ccedil;&atilde;o &agrave; ingest&atilde;o de prote&iacute;nas possa r
eduzir a progress&atilde;o da DRC diab&eacute;tica e n&atilde;o diab&eacute;tica
,<sup>87</sup> os efeitos cl&iacute;nicos s&atilde;o provavelmente t&atilde;o pe
quenos que as diretrizes recomendam dietas com 0,5 g/kg/dia a 1,0 g/kg/dia de pr
ote&iacute;nas com o objetivo de prevenir a desnutri&ccedil;&atilde;o<sup>88</su
p> e a sobrecarga di&aacute;ria de &aacute;cido<sup>89</sup> e de f&oacute;sforo
<sup>90</sup> derivada da ingest&atilde;o e do catabolismo  de prote&iacute;nas 
observados com o decl&iacute;nio da fun&ccedil;&atilde;o renal. &Eacute; aconsel
h&aacute;vel que os pacientes que estejam iniciando uma dieta com baixa ingest&a
tilde;o de prote&iacute;nas apresentem bom estado nutricional e estejam sob os c
uidados de uma nutricionista especializada em doen&ccedil;a renal. </font></p>  
   ^cY#v33n1a13.htm##
01691000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704145700075002001301532#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#70#66#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">N&atilde;o est&aacute; claro se a hip
erlipidemia tem um impacto adverso na progress&atilde;o da DRC. De forma similar
, os efeitos ben&eacute;ficos da estatina sobre a TFG ainda s&atilde;o motivo de
 controv&eacute;rsia. Estudos utilizando estatinas mostraram menor perda da fun&
ccedil;&atilde;o renal em animais<sup>91</sup> e humanos. <sup>92</sup> Entretan
to, enquanto o tratamento com 10 mg e 80 mg de atorvastatina aumentou a TFG de 3
,5 mL/min/1,73m<sup>2</sup> e 5,2 mL/min/1,73m<sup>2</sup>, respectivamente,<sup
>93</sup> o tratamento com 40 mg de pravastatina n&atilde;o resultou em qualquer
 mudan&ccedil;a na TFG. <sup>94</sup> O uso das estatinas &eacute; t&atilde;o se
guro nos pacientes com DRC quanto na popula&ccedil;&atilde;o em geral e seus pos
s&iacute;veis efeitos salutares podem ser o resultado de propriedades l&iacute;p
ide- dependentes e l&iacute;pide-independentes. Embora n&atilde;o haja dados ref
erentes &agrave; preven&ccedil;&atilde;o prim&aacute;ria, a utiliza&ccedil;&atil
de;o de medicamentos hipolipemiantes como preven&ccedil;&atilde;o secund&aacute;
ria parecem reduzir a mortalidade cardiovascular em pacientes que se encontram e
m todos os est&aacute;gios de DRC. <sup>95</sup> De qualquer maneira, mais estud
os ainda s&atilde;o necess&aacute;rios at&eacute; que se estabele&ccedil;am reco
menda&ccedil;&otilde;es mais precisas nessa &aacute;rea. </font></p>     ^cY#v33
n1a13.htm##
01390000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704115600075002001301231#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#71#67#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O tabagismo est&aacute; associado com
 progress&atilde;o acelerada da doen&ccedil;a renal em pacientes com nefropatia 
diab&eacute;tica e n&atilde;o diab&eacute;tica, juntamente com o risco aumentado
 de doen&ccedil;a cardiovascular. <sup>96</sup> O fumo tem efeitos vasoconstrito
res, tromboemb&oacute;licos e diretos no endot&eacute;lio vascular e &eacute; um
 fator de risco independente para insufici&ecirc;ncia renal em homens com doen&c
cedil;as renais. <sup>97</sup> O fumo, juntamente com a hipertens&atilde;o arter
ial e a doen&ccedil;a vascular, &eacute; um forte preditor do aumento dos n&iacu
te;veis s&eacute;ricos de creatinina em pacientes n&atilde;o diab&eacute;ticos c
om 65 anos ou mais. <sup>98</sup> Al&eacute;m disso, se pacientes com diabetes t
ipo 2 pararem de fumar, o risco de doen&ccedil;a renal &eacute; reduzido em 30%.
 <sup>99</sup> Portanto, enquanto os efeitos danosos do fumo na progress&atilde;
o da DRC ainda n&atilde;o forem estabelecidos de forma definitiva, est&aacute; c
laro que esse h&aacute;bito deveria ser desencorajado em pacientes com DRC. </fo
nt></p>     ^cY#v33n1a13.htm##
01032000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704079800075002001300873#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#72#68#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em resumo, os objetivos do tratamento
 otimizado da DRC baseiam-se no diagn&oacute;stico precoce, encaminhamento em mo
mento oportuno para tratamento nefrol&oacute;gico e terapias que retardem a prog
ress&atilde;o da doen&ccedil;a e previnam complica&ccedil;&otilde;es cardiovascu
lares. A fim de atingir esses objetivos, &eacute; importante estimar a TFG e med
ir a albumin&uacute;ria regularmente em pacientes que apresentem risco de DRC, e
ncaminhar precocemente os casos rec&eacute;m-diagnosticados para acompanhamento 
conjunto com especialistas em nefrologia e garantir bom controle da PA, protein&
uacute;ria, diabetes, peso, anemia, hiperparatireoidismo secund&aacute;rio, disl
ipidemia e desnutri&ccedil;&atilde;o. </font></p>     ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#73#69#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00398000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016400075002001300239#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#74#70#article#342#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>MODELOS DE TRATAMENTO CL&Iacute;NI
CO DA DOEN&Ccedil;A RENAL CR&Ocirc;NICA </b></font></p>     ^cY#v33n1a13.htm##
00630000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039600075002001300471#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#75#71#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para prop&oacute;sitos did&aacute;tic
os, o tratamento da DRC pode ser dividido em tr&ecirc;s modelos: 1) pacientes se
m acompanhamento ou com tratamento cl&iacute;nico n&atilde;o nefrol&oacute;gico;
 2) pacientes em tratamento nefrol&oacute;gico convencional; e 3) pacientes em t
ratamento com base multidisciplinar.</font></p>     ^cY#v33n1a13.htm##
01941000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704170700075002001301782#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#76#72#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Infelizmente, como anteriormente menc
ionado, n&atilde;o &eacute; incomum pacientes com DRC serem encaminhados ao trat
amento nefrol&oacute;gico quando j&aacute; est&atilde;o na fase avan&ccedil;ada 
da doen&ccedil;a necessitando de terapia dial&iacute;tica de urg&ecirc;ncia ou e
merg&ecirc;ncia. No momento, n&atilde;o h&aacute; um consenso na literatura sobr
e o momento ideal de encaminhamento ao tratamento nefrol&oacute;gico durante o c
urso da DRC. Alguns autores<sup>100,101</sup> utilizaram tr&ecirc;s meses antes 
da TRS a fim de definir o encaminhamento precoce, embora seja prov&aacute;vel qu
e o tratamento nefrol&oacute;gico precoce durante seis meses seria ainda melhor,
 e o seguimento por um ano poderia ser o ideal. <sup>102</sup> O per&iacute;odo 
m&iacute;nimo de cuidados nefrol&oacute;gicos antes da TRS &eacute; ditado por v
&aacute;rios fatores. Por exemplo, &eacute; preciso considerar o tempo necess&aa
cute;rio para estabelecimento de f&iacute;stula arteriovenosa (FAV) para hemodi&
aacute;lise. &Eacute; f&aacute;cil imaginar ser necess&aacute;rio esperar v&aacu
te;rios dias ap&oacute;s o pedido at&eacute; que o procedimento seja autorizado,
 ap&oacute;s o qual o paciente precisa aguardar pela consulta com um cirurgi&ati
lde;o vascular, efetuar pela reserva da sala de cirurgia e, finalmente, a confec
&ccedil;&atilde;o da FAV. Al&eacute;m disso, a FAV, de maneira ideal, n&atilde;o
 deve ser puncionada por pelo menos 60 a 90 dias. Se, por acaso, a FAV n&atilde;
o se desenvolver, levar&aacute; pelo menos mais 60 a 90 dias at&eacute; que uma 
nova f&iacute;stula possa ser criada e canulada pela primeira vez. </font></p>  
   ^cY#v33n1a13.htm##
01806000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704157200075002001301647#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#77#73#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Se um paciente com DRC progredir para
 DRET e n&atilde;o tiver acesso &agrave; terapia dial&iacute;tica, ele ou ela in
evitavelmente morrer&aacute;. Entretanto, ser acompanhado por m&eacute;dico n&at
ilde;o garante que a TRS ser&aacute; realizada com par&acirc;metros cl&iacute;ni
cos recomendados pelas diretrizes da DRC para preven&ccedil;&atilde;o das  morbi
dades e mortalidade. <sup>1,88,103,104</sup> Por exemplo, Batista <i>et al. </i>
<sup>105</sup> retrospectivamente revisaram os prontu&aacute;rios de pacientes q
ue eram atendidos em uma cl&iacute;nica especializada em diabetes e hipertens&at
ilde;o. Dentre 146 pacientes que foram identificados como portadores de DRC, 32 
(19%) estavam no est&aacute;gio 3, 40 (42%) no est&aacute;gio 4, e 27 (39%) no e
st&aacute;gio 5. Em apenas 50 (34,4%) dos pacientes a PA estava controlada e s&o
acute; 65% deles estavam sendo tratados com bloqueadores do SRAA. O controle gli
c&ecirc;mico adequado foi observado em 65% dos pacientes diab&eacute;ticos. Regi
stros de protein&uacute;ria e Hb foram encontrados em apenas 24% e 28% dos pront
u&aacute;rios, respectivamente. N&atilde;o foram encontrados registros de n&iacu
te;veis de c&aacute;lcio, f&oacute;sforo, bicarbonato de s&oacute;dio ou albumin
a. O estudo mostra que, a despeito de ter acesso a cuidados m&eacute;dicos, uma 
alta propor&ccedil;&atilde;o de pacientes com DRC avan&ccedil;ada secund&aacute;
ria a hipertens&atilde;o e/ou diabetes n&atilde;o recebe o cuidado cl&iacute;nic
o adequado. </font></p>     ^cY#v33n1a13.htm##
02058000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704182400075002001301899#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#78#74#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Embora tenham sido realizados estudos
 sobre os efeitos ben&eacute;ficos do encaminhamento precoce para atendimento ne
frol&oacute;gicos,<sup>106,107</sup> o cuidado nefrol&oacute;gico em si n&atilde
;o &eacute; garantia de sucesso no tratamento da DRC. Por exemplo, Kausz <i>et a
l. </i><sup>108</sup> analisaram retrospectivamente os registros de 602 paciente
s com DRC (definida como creatinina s&eacute;rica <u>&gt;</u> 1,5 mg/dL em mulhe
res e <u>&gt;</u> 2,0 mg/dL em homens) que foram tratados entre outubro de 1994 
e setembro de 1998 em cinco cl&iacute;nicas nefrol&oacute;gicas na &aacute;rea d
e Boston, Massachusetts, Estados Unidos. Na primeira visita, o n&iacute;vel m&ea
cute;dio de creatinina s&eacute;rica e TFG dos pacientes era de 3,2 mg/dL e 22,3
 mL/min/1,73m<sup>2</sup>, respectivamente. Era digno de nota que muito embora 3
8% dos pacientes tivessem um hemat&oacute;crito  &lt; 30%, apenas 18% deles subm
etidos &agrave; avalia&ccedil;&atilde;o da reserva de ferro. Al&eacute;m disso, 
dos pacientes com hemat&oacute;crito &lt; 30%, apenas 59% foram tratados com EPO
 e, desses, apenas 47% receberam suplementa&ccedil;&atilde;o de ferro. Al&eacute
;m disso, muito embora 55% dos pacientes apresentassem altera&ccedil;&otilde;es 
no metabolismo de c&aacute;lcio e f&oacute;sforo, o PTH foi medido em apenas 15%
 de todos os casos. Adicionalmente, o perfil lip&iacute;dico foi avaliado em men
os da metade dos pacientes e somente 65% dos pacientes diab&eacute;ticos (que co
nstitu&iacute;am 49% de toda a amostra de pacientes) eram tratados com bloqueado
res do SRAA. Finalmente, dos pacientes que vieram a necessitar de  di&aacute;lis
e, em apenas 41% a FAV foi preparada antes do in&iacute;cio da terapia dial&iacu
te;tica. <sup>108</sup> </font></p>     ^cY#v33n1a13.htm##
01134000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090000075002001300975#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#79#75#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outro estudo realizado em um centro d
e excel&ecirc;ncia em tratamento nefrol&oacute;gico concluiu que pacientes ainda
 n&atilde;o submetidos &agrave; di&aacute;lise que receberam tratamento nefrol&o
acute;gico padr&atilde;o por v&aacute;rios anos, antes do in&iacute;cio da di&aa
cute;lise, apresentaram melhor sobrevida no longo prazo do que aqueles cujo per&
iacute;odo de acompanhamento nefrol&oacute;gico foi mais curto. <sup>106</sup> D
eve ser observado, entretanto, que nesse estudo, na tabela que apresenta os par&
acirc;metros de PA e exames laboratoriais, os n&iacute;veis m&eacute;dios de Hb 
de 9,5 ± 1,9 g/dL foram documentados nos pacientes em acompanhamento nefrol&oacu
te;gico por mais de 6 anos. Esses baixos n&iacute;veis de Hb s&atilde;o sugestiv
os de tratamento inadequado da anemia. <sup>73,103,104</sup></font></p>     ^cY#
v33n1a13.htm##
01185000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704095100075002001301026#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#80#76#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O terceiro modelo de tratamento da DR
C &eacute; baseado no cuidado interdisciplinar (CID). Deve ser observado, entret
anto, que esse modelo de cuidado de pacientes com DRC n&atilde;o &eacute;, na ve
rdade, uma proposta nova. Em 1993, uma confer&ecirc;ncia de consenso patrocinado
 pelo <i>National Institutes of Health</i> prop&ocirc;s que pacientes com DRC fo
ssem encaminhados a uma equipe "renal"constitu&iacute;da por nefrologista, nutri
cionista, enfermeiro, assistente social e profissional de sa&uacute;de mental em
 algum momento ap&oacute;s o encaminhamento ao nefrologista. <sup>109 </sup>A de
speito dos estudos randomizados de CID em outras doen&ccedil;as cr&ocirc;nicas t
erem mostrado resultados na morbidade e mortalidade,<sup>110-114</sup> at&eacute
; hoje os estudos de efetividade desse modelo de cuidado na DRC s&atilde;o limit
ados e os resultados incertos. </font></p>     ^cY#v33n1a13.htm##
00754000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052000075002001300595#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#81#77#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">H&aacute; aproximadamente 13 anos, Le
vin <i>et al. </i><sup>115</sup> foram capazes de mostrar o impacto positivo nos
 desfechos quantitativos, tais como menor taxa de in&iacute;cios urgentes de ter
apia dial&iacute;tica, menos dias de hospitaliza&ccedil;&atilde;o no primeiro m&
ecirc;s de TRS e menor custo de tratamento dos pacientes acompanhados interdisci
plinar, quando comparados com aqueles acompanhados somente por um nefrologista. 
</font></p>     ^cY#v33n1a13.htm##
00766000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053200075002001300607#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#82#78#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Yeoh <i>et al. </i><sup>116</sup> com
pararam 68 pacientes que participaram de um programa de educa&ccedil;&atilde;o p
r&eacute;-di&aacute;lise com 35 pacientes que n&atilde;o participaram, e observa
ram que aqueles que participaram do programa na cl&iacute;nica interdisciplinar 
apresentaram menos visitas ao pronto-socorro, hospitaliza&ccedil;&otilde;es mais
 curtas e menos cateteres tempor&aacute;rios utilizados no in&iacute;cio da di&a
acute;lise. </font></p>     ^cY#v33n1a13.htm##
01421000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704118700075002001301262#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#83#79#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dois outros estudos, com desenho muit
o similar, tamb&eacute;m compararam os pacientes acompanhados por atendimento in
terdisciplinar com aqueles que n&atilde;o o eram. Curtis <i>et al. </i><sup>101 
</sup>demonstraram n&iacute;veis de Hb, albumina e c&aacute;lcio s&eacute;rico s
ignificantemente mais altos na &eacute;poca do in&iacute;cio da di&aacute;lise e
m pacientes tratados em um cl&iacute;nica interdisciplinar para DRC do que aquel
es acompanhados apenas pelo nefrologista. No estudo de Goldstein <i>et al. ,</i>
<sup>100 </sup>os pacientes acompanhados por uma equipe interdisciplinar apresen
tavam melhores par&acirc;metros em termos de albumina s&eacute;rica, hemoglobina
 e metabolismo mineral, e mais frequentemente iniciavam a di&aacute;lise com uma
 FAV madura em vez de utilizar acesso tempor&aacute;rio para di&aacute;lise. Em 
ambos os estudos foi observado que, apesar e serem submetidos a igual exposi&cce
dil;&atilde;o ao cuidado nefrol&oacute;gico ap&oacute;s o in&iacute;cio da di&aa
cute;lise, os pacientes previamente expostos ao atendimento interdisciplinar apr
esentavam maior sobrevida. </font></p>     ^cY#v33n1a13.htm##
01176000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094200075002001301017#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#84#80#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com o objetivo de determinar a associ
a&ccedil;&atilde;o entre o atendimento interdisciplinar, sobrevida e risco de ho
spitaliza&ccedil;&atilde;o, Hemmelgarn <i>et al. </i><sup>117 </sup>acompanharam
 por 3 anos pacientes ambulatoriais com DRC submetidos ou n&atilde;o a atendimen
to interdisciplinar, pareados 1:1. Um modelo de regress&atilde;o de Cox foi usad
o para determinar a associa&ccedil;&atilde;o entre o atendimento interdisciplina
r e o risco de morte e hospitaliza&ccedil;&atilde;o. Observou-se que os paciente
s submetidos a atendimento interdisciplinar apresentavam redu&ccedil;&atilde;o s
ignificante no risco de mortalidade por todas as causas e, embora n&atilde;o est
atisticamente significante, uma tend&ecirc;ncia &agrave; diminui&ccedil;&atilde;
o de risco de hospitaliza&ccedil;&atilde;o por todas as causas e especificamente
 as cardiovasculares. </font></p>     ^cY#v33n1a13.htm##
02741000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704250700075002001302582#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#85#81#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Embora outros estudos realizados em c
rian&ccedil;as<sup>118 </sup>e adultos<sup>117-121 </sup>acompanhados em cl&iacu
te;nicas multidisciplinares indiquem melhores vari&aacute;veis de desfecho e mai
or probabilidade de atingir os objetivos do K/DOQI no in&iacute;cio da di&aacute
;lise, resultados negativos do atendimento interdisciplinar t&ecirc;m sido relat
ados. Harris <i>et al. </i><sup>122 </sup>estudaram 437 pacientes com DRC com de
pura&ccedil;&atilde;o estimada de creatinina de &lt; 50 mL/min que recebiam cuid
ados prim&aacute;rios em uma cl&iacute;nica de medicina interna acad&ecirc;mica 
urbana e dividiram em dois grupos: um grupo recebeu tratamento caso-intensivo, a
dministrado durante os primeiros dois anos ap&oacute;s a inclus&atilde;o no estu
do, que consistia em consultas repetidas mandat&oacute;rias em uma cl&iacute;nic
a de cuidados nefrol&oacute;gicos que contava com dois nefrologistas, uma enferm
eira renal, uma nutricionista renal e uma assistente social. Os pacientes contro
le receberam o cuidado usual. Ao final do estudo, os autores n&atilde;o encontra
ram diferen&ccedil;as nos desfechos renais, uso de servi&ccedil;os de sa&uacute;
de ou mortalidade no primeiro, segundo ou terceiro ao quinto anos ap&oacute;s a 
inclus&atilde;o no estudo, muito embora houvesse significantemente mais visitas 
ambulatoriais entre os pacientes submetidos &agrave; interven&ccedil;&atilde;o, 
principalmente devido &agrave;s visitas extras &agrave; cl&iacute;nica de tratam
ento nefrol&oacute;gico. Eles conclu&iacute;ram que o atendimento interdisciplin
ar era o "estado da arte" no tratamento, embora essa estrat&eacute;gia n&atilde;
o tenha efeitos nos resultados do tratamento em pacientes com DRC acompanhados a
 n&iacute;vel de aten&ccedil;&atilde;o prim&aacute;ria a sa&uacute;de. Entretant
o, deve ser observado que nesse estudo, o atendimento m&eacute;dico ficava aos c
uidados de um m&eacute;dico da aten&ccedil;&atilde;o prim&aacute;ria &agrave; sa
&uacute;de e a cl&iacute;nica multidisciplinar fornecia basicamente a educa&cced
il;&atilde;o. Assim, considerando a falta de controle sobre as interven&ccedil;&
otilde;es m&eacute;dicas, &eacute; poss&iacute;vel que a falha em demonstrar qua
lquer diferen&ccedil;a significante entre os dois modelos deva-se &agrave; falta
 de implementa&ccedil;&atilde;o das recomenda&ccedil;&otilde;es, e n&atilde;o &a
grave; falta de efetividade do atendimento interdisciplinar em si. </font></p>  
   ^cY#v33n1a13.htm##
00795000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056100075002001300636#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#86#82#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O motivo pelo qual de o tratamento in
terdisciplinar resultar em melhores desfechos no tratamento da DRC do que o trat
amento nefrol&oacute;gico convencional ainda n&atilde;o est&aacute; completament
e entendido. O atendimento interdisciplinar faz sentido e sua premissa b&aacute;
sica &eacute; que pacientes com doen&ccedil;as complexas e multifacetadas, tais 
como a DRC, precisam de tratamento centralizado e especializado, fornecido por d
iferentes profissionais da sa&uacute;de. </font></p>     ^cY#v33n1a13.htm##
02149000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704191500075002001301990#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#87#83#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Assim, o aconselhamento diet&eacute;t
ico em rela&ccedil;&atilde;o ao consumo de sal e prote&iacute;na, assegurando a 
ader&ecirc;ncia &agrave; terapia medicamentosa, a ajuda com as quest&otilde;es a
dministrativas para obten&ccedil;&atilde;o de medicamentos especiais sem custo (
EPO e calcitriol), aconselhamento sobre controle de peso ou sobre parar de fumar
, minimiza&ccedil;&atilde;o do absente&iacute;smo na cl&iacute;nica, apoio psico
l&oacute;gico, melhora no controle da PA e o uso de medicamentos renoprotetores 
e cardioprotetores, otimiza&ccedil;&atilde;o do controle glic&ecirc;mico, o trat
amento da anemia e dos dist&uacute;rbios do metabolismo mineral, corre&ccedil;&a
tilde;o do equil&iacute;brio &aacute;cido-b&aacute;sico, a inser&ccedil;&atilde;
o de cateter peritoneal eletivamente planejada ou f&iacute;stula funcionante, co
m in&iacute;cio oportuno de terapia dial&iacute;tica, incentivo ao transplante p
reemptivo, manuten&ccedil;&atilde;o da sa&uacute;de oral e  programa de reabilit
a&ccedil;&atilde;o de exerc&iacute;cios. Acesso mais f&aacute;cil a outros espec
ialistas (urologistas, cirurgi&otilde;es vasculares, cardiologistas, ginecologis
tas) s&atilde;o mais f&aacute;cil e efetivamente implementados quando essas tare
fas que demandam tempo s&atilde;o compartilhadas pelos nefrologistas, e enfermei
ras, nutricionistas, assistentes sociais, psic&oacute;logos e, em alguns program
as, farmac&ecirc;uticos, dentistas e educadores f&iacute;sicos. Embora seja dif&
iacute;cil identificar quais interven&ccedil;&otilde;es no atendimento interdisc
iplinar melhoram os desfechos, o acompanhamento estruturado dos pacientes, inter
a&ccedil;&otilde;es entre os membros da equipe e pronta implementa&ccedil;&atild
e;o de interven&ccedil;&otilde;es previamente planejadas podem ser, em parte, a 
explica&ccedil;&atilde;o para tal. </font></p>     ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#88#84#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#89#85#article#342#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUS&Otilde;ES</b></font></p>  
   ^cY#v33n1a13.htm##
01516000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704128200075002001301357#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#90#86#article#342#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A DRC &eacute; um problema de grande 
relev&acirc;ncia e &eacute; reconhecida como uma doen&ccedil;a complexa que exig
e m&uacute;ltiplas abordagens no seu tratamento. Embora a implementa&ccedil;&ati
lde;o da medicina baseada em evid&ecirc;ncia para a pr&aacute;tica cl&iacute;nic
a tenha resultado em avan&ccedil;os significantes no tratamento da DRC, faz-se n
ecess&aacute;ria uma melhor prepara&ccedil;&atilde;o do paciente que inicia a TR
S, assim como a redu&ccedil;&atilde;o das taxas de mortalidade e hospitaliza&cce
dil;&atilde;o. O diagn&oacute;stico precoce, encaminhamento imediato e institui&
ccedil;&atilde;o de medidas para diminuir/ interromper a progress&atilde;o da DR
C est&atilde;o entre as estrat&eacute;gias-chave para melhorar os desfechos. A t
riste observa&ccedil;&atilde;o &eacute;, entretanto, que a chance de morte super
a a de iniciar a TRS &agrave; medida que a DRC progride, mesmo quando os pacient
es recebem cuidados m&eacute;dicos padr&atilde;o. O modelo de atendimento interd
isciplinar, ao oferecer os cuidados necess&aacute;rios, de forma abrangente e or
ganizada, parece ser a melhor forma de tratar a DRC, embora mais estudos nessa &
aacute;rea ainda sejam necess&aacute;rios.</font></p>     ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#91#87#article#342#<p>&nbsp;</p>     ^c
Y#v33n1a13.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#92#88#article#342#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v33n1a13.htm##
00476000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022800077002001300305#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#93#89#article#342#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. K/DOQI clinical prac
tice guidelines for chronic kidney disease: evaluation, classification and strat
ification. Am J Kidney Dis 2002; 39:(Suppl 2):S1-S246.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#94#90#article#342# </font></p>     ^cY
#v33n1a13.htm##
00487000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023900077002001300316#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#95#91#article#342#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Saydah S, Eberhardt 
M, Rios-Burrows N <i>et al. </i>Prevalence of chronic kidney disease and associa
ted risk factors - United States, 1999-2004. MMWR 2007; 56:161-5.    ^cY#v33n1a1
3.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#96#92#article#342# </font></p>     ^cY
#v33n1a13.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020400077002001300281#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#97#93#article#342#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Sesso RCC, Lopes AA,
 Thom&eacute; FS, Lugon JR, Burdman EA. Censo Brasileiro de Di&aacute;lise, 2009
. J Bras Nefol 2010; 32:380-4.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#98#94#article#342# </font></p>     ^cY
#v33n1a13.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704028500077002001300362#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#99#95#article#342#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Fernandes N, Bastos 
RMR, Bastos MG. Diagn&oacute;stico da doen&ccedil;a renal cr&ocirc;nica a partir
 da filtra&ccedil;&atilde;o glomerular estimada: CKD-EPI ou MDRD &#91;Resumo&#93
;. Congr Bras Nefrol 2010; 506.    ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#100#96#article#342# </font></p>     ^c
Y#v33n1a13.htm##
00416000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704016700078002001300245#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#101#97#article#342#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Levey AS. Measureme
nt of renal function in chronic renal disease. Kidney Int 1990; 38:167-84.    ^c
Y#v33n1a13.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#102#98#article#342# </font></p>     ^c
Y#v33n1a13.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704022600078002001300304#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#103#99#article#342#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Praxedes JN. Diretr
izes sobre hipertens&atilde;o arterial e uso de anti-hipertensivos na doen&ccedi
l;a renal cr&ocirc;nica. J Bras Nefrol 2004; 26:44-6.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#104#100#article#342# </font></p>     ^
cY#v33n1a13.htm##
00412000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704016200079002001300241#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#105#101#article#342#7#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Parving HH. Diabet
ic nephropathy: prevention and treatment. Kidney Int 2001; 60:2041-55.    ^cY#v3
3n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#106#102#article#342# </font></p>     ^
cY#v33n1a13.htm##
00537000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704028700079002001300366#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#107#103#article#342#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Steinman TI, Perro
ne RD, Hunsicker LG, MDRD Study Group. GFR determination in chronic renal failur
e by 3 radionuclide markers and inulin: coeficient of variation of the methods (
abstract). Kidney Int 1989; 35:201.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#108#104#article#342# </font></p>     ^
cY#v33n1a13.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704022800079002001300307#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#109#105#article#342#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Stevens LA, Coresh
 J, Greene T, Levey AS. Assessing kidney function - Measured and estimated glome
rular filtration rate. New Engl J Med 2006; 354:2473-83.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#110#106#article#342# </font></p>     ^
cY#v33n1a13.htm##
00473000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022200080002001300302#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#111#107#article#342#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Shemesh O, Golbe
tz H, Kriss JP, Meyers BD. Limitations of creatinine as a filtration marker in g
lomerulopathic patients. Kidney Int 1985; 28:830-8.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#112#108#article#342# </font></p>     ^
cY#v33n1a13.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026900080002001300349#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#113#109#article#342#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Pinto PS, Silva 
FJ, Munch ECSM <i>et al. </i>Inadequabilidade da creatinina s&eacute;rica na ide
ntifica&ccedil;&atilde;o precoce da disfun&ccedil;&atilde;o renal. J Bras Nefrol
 2004; 26:196-201.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#114#110#article#342# </font></p>     ^
cY#v33n1a13.htm##
00431000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018000080002001300260#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#115#111#article#342#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Cockcroft DW, Ga
ult MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 
16:31-41.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#116#112#article#342# </font></p>     ^
cY#v33n1a13.htm##
00528000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027700080002001300357#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#117#113#article#342#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Levey AS, Bosch 
JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glo
merular filtration rate from serum creatinine: a new prediction equation. Ann In
tern Med 1999; 130:461-70.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#118#114#article#342# </font></p>     ^
cY#v33n1a13.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021000080002001300290#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#119#115#article#342#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Levey AS, Steven
s LA, Schmid CH, <i>et al. </i> A new equation to estimate glomerular filtration
 rate. Ann Intern Med 2009; 150:604-12.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#120#116#article#342# </font></p>     ^
cY#v33n1a13.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024800080002001300328#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#121#117#article#342#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Levey AS, Greene
 T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration ra
te from serum creatinine &#91;Abstract&#93;. J Am Soc Nephrol 2000; 11:A0828.   
 ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#122#118#article#342# </font></p>     ^
cY#v33n1a13.htm##
00555000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030400080002001300384#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#123#119#article#342#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Chronic Kidney D
isease Epidemiology Collaboration. Using standardized serum creatinine values in
 the modification of diet in renal disease study equation for estimating glomeru
lar filtration rate. Ann Intern Med 2006; 145:247-54.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#124#120#article#342# </font></p>     ^
cY#v33n1a13.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021200080002001300292#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#125#121#article#342#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Rule AD, Gussak 
HM, Pond GR <i>et al. </i> Measured and estimated GFR in healthy potential kidne
y donors. Am J Kidney Dis 2004; 43:112-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#126#122#article#342# </font></p>     ^
cY#v33n1a13.htm##
00511000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026000080002001300340#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#127#123#article#342#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Lin J, Knight EL
, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomer
ular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003; 14
:2573-80.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#128#124#article#342# </font></p>     ^
cY#v33n1a13.htm##
00450000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019900080002001300279#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#129#125#article#342#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Bastos RMR, Bast
os MG. Tabela de c&aacute;lculo imediato da filtra&ccedil;&atilde;o glomerular. 
J Bras Nefrol 2005; 27:40-3.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#130#126#article#342# </font></p>     ^
cY#v33n1a13.htm##
00522000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027100080002001300351#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#131#127#article#342#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Bokenkamp A, Dom
anetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C serum concentratio
ns underestimate glomerular filtration rate in renal transplant patients. Clin C
hem 1999; 45:1866-8.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#132#128#article#342# </font></p>     ^
cY#v33n1a13.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027000080002001300350#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#133#129#article#342#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Knight EL, Verha
ve JC, Spiegelman D <i>et al. </i> Factors influencing serum cystatin C levels o
ther than renal function and the impact on renal function measurement. Kidney In
t 2004; 65:1416-21.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#134#130#article#342# </font></p>     ^
cY#v33n1a13.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028500080002001300365#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#135#131#article#342#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Hoek FJ, Kemperm
ann FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the C
ockcroft-Gault formula for the estimation of glomerular filtration rate. Nephrol
 Dial Transplant 2003; 18:2024-31.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#136#132#article#342# </font></p>     ^
cY#v33n1a13.htm##
00498000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024700080002001300327#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#137#133#article#342#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Shlipak MG, Katz
 R, Kestenhbaum B <i>et al. </i> Rate of kidney function decline in older adults
: a comparison using creatinine and cystatin C. Am J Nephrol 2009; 30:171-8.    
^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#138#134#article#342# </font></p>     ^
cY#v33n1a13.htm##
00493000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024200080002001300322#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#139#135#article#342#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Peralta CA, Katz
 R, Sarnak MJ, <i>et al. </i> Cystatin C identifies chronic kidney disease patie
nts at higher risk for complications. J Am Soc Nephrol 2011; 22:147-55.    ^cY#v
33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#140#136#article#342# </font></p>     ^
cY#v33n1a13.htm##
00623000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704037200080002001300452#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#141#137#article#342#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Ruggenenti P, Ga
spari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning 
urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular
 filtration rate, and end stage renal failure in chronic renal disease in patien
ts without diabetes. BMJ 1998; 316:504-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#142#138#article#342# </font></p>     ^
cY#v33n1a13.htm##
00492000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024100080002001300321#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#143#139#article#342#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Comper WD, Jerum
s G, Osicka TM. Differences in urinary albumin detected by four immunoassays and
 high-performance liquid chromatography. Clin Biochem 2004; 37:105-11.    ^cY#v3
3n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#144#140#article#342# </font></p>     ^
cY#v33n1a13.htm##
00488000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023700080002001300317#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#145#141#article#342#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Kirsztajn GM, Ba
stos MG. Proposta de padroniza&ccedil;&atilde;o de um programa de rastreamento d
a doen&ccedil;a renal cr&ocirc;nica. J Bras Nefrol 2007; 29:18-22.    ^cY#v33n1a
13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#146#142#article#342# </font></p>     ^
cY#v33n1a13.htm##
00429000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017800080002001300258#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#147#143#article#342#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Fairley KF, Birc
h DF. Microscopic urinalysis in glomerulonephritis. Kidney Int 1993; 42(Suppl. )
:S9-12.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#148#144#article#342# </font></p>     ^
cY#v33n1a13.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#149#145#article#342#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Roubicek C, Brun
et P, Huiart L <i>et al. </i> Timing of nephrology referral: influence on mortal
ity and morbidity. Am J Kidney Dis 2000; 36:35-41.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#150#146#article#342# </font></p>     ^
cY#v33n1a13.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#151#147#article#342#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Israni A, Korzel
ius C, Toensend R, Mesler D. Management of chronic kidney disease in an Academic
 Primary Care Clinic. Am J Nephrol 2003; 23:47-54.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#152#148#article#342# </font></p>     ^
cY#v33n1a13.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026300080002001300343#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#153#149#article#342#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. McLaughlin K, Ma
nns B, ulleton B, Donaldson, Taub K. An economic evaluation of early versus late
 referral of patients with progressive renal insufficiency. Am J Kidney Dis 2001
; 38:1122-8.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#154#150#article#342# </font></p>     ^
cY#v33n1a13.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#155#151#article#342#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Freedman BI, Sou
cie JM, McClellan WM. Family history of end-stage renal disease among incident d
ialysis patients. J Am Soc Nephrol 1997; 8:1942-5.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#156#152#article#342# </font></p>     ^
cY#v33n1a13.htm##
00453000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020200080002001300282#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#157#153#article#342#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Ruggenenti P, Fa
ssi A, Llieva AP <i>et al. </i> Preventing microalbuminuria in type 2 diabetes. 
N Engl J Med 2004; 351:1941-51.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#158#154#article#342# </font></p>     ^
cY#v33n1a13.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023200080002001300312#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#159#155#article#342#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Dasgupta I, Made
ley RJ, Pringle MAL, Savill J, Burden RP. Management of hypertension in patients
 developing end-stage renal failure. Q J Med 1999; 92:519-25.    ^cY#v33n1a13.ht
m##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#160#156#article#342# </font></p>     ^
cY#v33n1a13.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022600080002001300306#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#161#157#article#342#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Klag MJ, Wheton 
PK, Randall BL <i>et al. </i> End-stage renal disease in African-American and wh
ite men: 16-year MRFIT findings. JAMA 1997; 277:1293-8.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#162#158#article#342# </font></p>     ^
cY#v33n1a13.htm##
00498000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024700080002001300327#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#163#159#article#342#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. 1999 World Healt
h Organization-International Society of Hypertension guidelines for the manageme
nt of hypertension. Guidelines subcommittee. J Hypertension 1999; 17:151-83.    
^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#164#160#article#342# </font></p>     ^
cY#v33n1a13.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022300080002001300303#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#165#161#article#342#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. K/DOQI clinical 
practice guideline on hypertension and antihypertensive agents in chronic kidney
 disease. Am J Kidney Dis 2004; 43(Suppl 1):S1-S290.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#166#162#article#342# </font></p>     ^
cY#v33n1a13.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022300080002001300303#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#167#163#article#342#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Palmer BF. Manag
ement of hypertension in patients with chronic kidney disease and diabetes melli
tus. American Journal of Medicine 2008; 121:S16-S22.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#168#164#article#342# </font></p>     ^
cY#v33n1a13.htm##
00515000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026400080002001300344#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#169#165#article#342#39#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Lewis EJ, Hunsic
ker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angi
otensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;
 329:1456-62.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#170#166#article#342# </font></p>     ^
cY#v33n1a13.htm##
00544000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029300080002001300373#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#171#167#article#342#40#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. The GISEN Group.
 Randomised placebo-controlled trial of effect of ramipril on decline in glomeru
lar filtration rate and risk of terminal renal failure in proteinuric, non-diabe
tic nephropathy. Lancet 1997; 349:1857-63.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#172#168#article#342# </font></p>     ^
cY#v33n1a13.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#173#169#article#342#41#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Ruggenenti P, Sc
hieppati A, Remuzzi G. Progression, remission, regression of chronic renal disea
ses. Lancet 2001; 357:1601-08.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#174#170#article#342# </font></p>     ^
cY#v33n1a13.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021600080002001300296#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#175#171#article#342#42#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Santos AMR, Lemo
s CCS, Bregman R. Protein&uacute;ria - marcador cl&aacute;ssico de comprometimen
to glomerular. J Bras Nefrol 2001; 23:217-20.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#176#172#article#342# </font></p>     ^
cY#v33n1a13.htm##
00652000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704040100080002001300481#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#177#173#article#342#43#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Marcello Tonelli
, Powell Jose, Gary Curhan, Frank Sacks, Eugene Braunwald, Marc Pfeffer, for the
 Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impai
red kidney function, and adverse outcomes in people with coronary disease: analy
sis of a previously conducted randomised trial. BMJ 2006; 332:1426-32.    ^cY#v3
3n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#178#174#article#342# </font></p>     ^
cY#v33n1a13.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021400080002001300294#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#179#175#article#342#44#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Remuzzi G, Berta
ni T. Is glomerulosclerosis a consequence of altered glomerular permeability to 
macromolecules? Kidney Int 1990; 38:384-94.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#180#176#article#342# </font></p>     ^
cY#v33n1a13.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#181#177#article#342#45#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. Williams PS, Fas
s G, Bone JM. Renal pathology and proteinuria determine progression in untreated
 mild/moderate chronic renal failure. Q J Med 1988; 67:343-54.    ^cY#v33n1a13.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#182#178#article#342# </font></p>     ^
cY#v33n1a13.htm##
00511000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026000080002001300340#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#183#179#article#342#46#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Brenner BM, Coop
er ME, De Zeeuw D <i>et al. </i> Effects of losartan on renal and cardiovascular
 outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 3
45:861-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#184#180#article#342# </font></p>     ^
cY#v33n1a13.htm##
00587000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033600080002001300416#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#185#181#article#342#47#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Nakao N, Yoshimu
ra A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotens
in-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabet
ic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361:11
7-24.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#186#182#article#342# </font></p>     ^
cY#v33n1a13.htm##
00413000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016200080002001300242#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#187#183#article#342#48#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Fioretto P, Stef
fes MW, Sutherland DE, Goetz FC, Mauer M. N Engl J Med 1998; 339:69-75.    ^cY#v
33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#188#184#article#342# </font></p>     ^
cY#v33n1a13.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026200080002001300342#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#189#185#article#342#49#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. The Diabetes Con
trol and Complications Trial (DCCT) Research Group. Effect of intensive therapy 
on the development and progression of nephropathy in the DCCT. Kidney Int 1995; 
47:1703-20.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#190#186#article#342# </font></p>     ^
cY#v33n1a13.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024400080002001300324#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#191#187#article#342#50#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. UK Prospective D
iabetes Study. Tight blood pressure control and risk of macrovascular and microv
ascular complications in type 2 diabetes. UKPDS 38. BMJ 1998; 317:703-13.    ^cY
#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#192#188#article#342# </font></p>     ^
cY#v33n1a13.htm##
00422000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017100080002001300251#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#193#189#article#342#51#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">51. Praga M. Obesity
: a neglected culprit in renal disease. Nephrol Dial Transplant 2002; 17:1157-9.
    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#194#190#article#342# </font></p>     ^
cY#v33n1a13.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022900080002001300309#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#195#191#article#342#52#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">52. Hall JE, Kuo JJ,
 Silva AA, Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney
 disease. Curr Opinion Nephrol Hypertens 2003; 12:195-200.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#196#192#article#342# </font></p>     ^
cY#v33n1a13.htm##
00468000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021700080002001300297#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#197#193#article#342#53#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">53. Weisinger JR, Ke
mpson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of mas
sive obesity. Ann Intern Med 1974; 81:440-447.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#198#194#article#342# </font></p>     ^
cY#v33n1a13.htm##
00459000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020800080002001300288#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#199#195#article#342#54#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">54. Kambham N, Marko
witz GS, ValeriAM <i>et al. </i> Obesity related glomerulopathy: an emerging epi
demic. Kidney Int 2001; 59:1498-1509.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#200#196#article#342# </font></p>     ^
cY#v33n1a13.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024800080002001300328#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#201#197#article#342#55#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">55. Morales E, Valer
o MA, Leon M <i>et al. </i> Beneficial effects of weight loss in overweight pati
ents with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319-27.   
 ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#202#198#article#342# </font></p>     ^
cY#v33n1a13.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023000080002001300310#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#203#199#article#342#56#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">56. Bello AK, de Zee
uw D, El Nahas M <i>et al. </i> Impact of weight change on albuminuria in the ge
neral population. Nephrol Dial Transplant 2007; 22:1619-27.    ^cY#v33n1a13.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#204#200#article#342# </font></p>     ^
cY#v33n1a13.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022000080002001300300#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#205#201#article#342#57#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">57. Chagnac AWT, Kor
zets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity
. Am J Physiol Renal Physiol 2000; 278:F817-F822.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#206#202#article#342# </font></p>     ^
cY#v33n1a13.htm##
00508000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025700080002001300337#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#207#203#article#342#58#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">58. Praga M, Hernand
ez E, Herrero JC <i>et al. </i> Influence of obesity on the appearance of protei
nuria and renal insufficiency after unilateral nephrectomy. Kdney Int 2000; 58:2
111-8.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#208#204#article#342# </font></p>     ^
cY#v33n1a13.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023000080002001300310#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#209#205#article#342#59#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">59. Clinical practic
e guidelines and clinical practice recommendations for anemia in chronic kidney 
disease in adults. Am J Kidney Dis 2006; 47(Suppl):S1-S145.    ^cY#v33n1a13.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#210#206#article#342# </font></p>     ^
cY#v33n1a13.htm##
00473000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022200080002001300302#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#211#207#article#342#60#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">60. Ribeiro Alves MA
, Gordan PA. Diagn&oacute;stico de anemia em pacientes portadores de doen&ccedil
;a renal cr&ocirc;nica. J Bras Nefrol 2007; 29:4-6.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#212#208#article#342# </font></p>     ^
cY#v33n1a13.htm##
00525000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027400080002001300354#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#213#209#article#342#61#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">61. Winearls CG, Pip
pard MJ, Downing MR <i>et al. </i> Effect of human erythropoietin derived from r
ecombinant DNA on the anaemia of patients maintained by chronic haemodialysis. L
ancet 1986; 328:1175-8.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#214#210#article#342# </font></p>     ^
cY#v33n1a13.htm##
00548000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029700080002001300377#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#215#211#article#342#62#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">62. Eschbach JW, Egr
ie JC, Downing MR <i>et al. </i> Correction of the anemia of end-stage renal dis
ease with recombinant human erythropoietin: results of a combined Phase I and II
 clinical trial. N Engl J Med 1987; 316:73-78.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#216#212#article#342# </font></p>     ^
cY#v33n1a13.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024400080002001300324#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#217#213#article#342#63#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">63. Eschbach JW, Kel
ly MR, Haley R, <i>et al. </i> Treatment of the anemia of progressive renal fail
ure with recombinant human erythropoietin. N Engl J Med 1989; 321:158-63.    ^cY
#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#218#214#article#342# </font></p>     ^
cY#v33n1a13.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028900080002001300369#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#219#215#article#342#64#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">64. Revicki DA, Brow
n RE, Feeny DH <i>et al. </i> Health-related quality of life associated with rec
ombinant human erythropoietin therapy for predialysis chronic renal disease pati
ents. Am J Kidney Dis 1995; 25:548-54.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#220#216#article#342# </font></p>     ^
cY#v33n1a13.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025300080002001300333#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#221#217#article#342#65#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">65. Muirhead N, Barg
man J, Burgess E <i>et al. </i> Evidence-based recommendations for the clinical 
use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26(Suppl 1):S1-S2
4.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#222#218#article#342# </font></p>     ^
cY#v33n1a13.htm##
00593000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704034200080002001300422#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#223#219#article#342#66#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">66. The US Recombina
nt Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlle
d study of the therapeutic use of recombinant human erythropoietin for anemia as
sociated with chronic renal failure in predialysis patients. Am J Kidney Dis 199
1; 18:50-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#224#220#article#342# </font></p>     ^
cY#v33n1a13.htm##
00511000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026000080002001300340#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#225#221#article#342#67#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">67. Roth D, Smith RD
, Schulman G <i>et al. </i> Effects of recombinant human erythropoietin on renal
 function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 2
4:777-84.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#226#222#article#342# </font></p>     ^
cY#v33n1a13.htm##
00541000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029000080002001300370#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#227#223#article#342#68#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">68. Besarab A, Bolto
n WK, Browne JK <i>et al. </i> The effects of normal as compared with low hemato
crit values in patients with cardiac disease who are receiving hemodialysis and 
epoetin. N Engl J Med 1998; 339:584-90.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#228#224#article#342# </font></p>     ^
cY#v33n1a13.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024500080002001300325#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#229#225#article#342#69#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">69. Dru&#776;eke TB,
 Locatelli F, Clyne N <i>et al. </i> Normalization of hemoglobin level in patien
ts with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-84.    ^c
Y#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#230#226#article#342# </font></p>     ^
cY#v33n1a13.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021600080002001300296#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#231#227#article#342#70#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">70. Singh AK, Szczec
h L, Tang KL <i>et al. </i> Correction of anemia with epoetin alfa in chronic ki
dney disease. N Engl J Med 2006; 355:2085-98.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#232#228#article#342# </font></p>     ^
cY#v33n1a13.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022900080002001300309#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#233#229#article#342#71#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">71. Pfeffer MA, Burd
mann EA, Chen CY <i>et al. </i> A trial of darbepoetin alfa in type 2 diabetes a
nd chronic kidney disease. N Engl J Med 2009; 361:2019-32.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#234#230#article#342# </font></p>     ^
cY#v33n1a13.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028500080002001300365#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#235#231#article#342#72#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">72. Goodkin DA, Full
er DS, Robinson BM <i>et al. </i> Naturally occurring higher hemoglobin concentr
ation does not increase mortality among hemodialysis patients. J Am Soc Nephrol 
2010 &#91;Epub ahead of print&#93;    ^cY#v33n1a13.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#236#232#article#342#. </font></p>     
^cY#v33n1a13.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028200080002001300362#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#237#233#article#342#73#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">73. National Kidney 
Foundation. K/DOQI clinical practice guidelines and clinical practice recommenda
tions for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am
 J Kidney Dis 2007; 50:474-530.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#238#234#article#342# </font></p>     ^
cY#v33n1a13.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032200080002001300402#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#239#235#article#342#74#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">74. Locatelli F, Cov
ic A, Eckardt KU, Wiecek A, Vanholder R. Anaemia management in patients with chr
onic kidney disease: a position statement by the Anaemia Working Group of Europe
an Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24:348-54.    ^cY#v
33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#240#236#article#342# </font></p>     ^
cY#v33n1a13.htm##
00561000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031000080002001300390#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#241#237#article#342#75#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">75. Levin A, Bakris 
GL, Molitch M <i>et al. </i> Prevalence of abnormal serum vitamin D, PTH, calciu
m, and phosphorus in patients with chronic kidney disease: results of the study 
to evaluate early kidney disease. Kidney Int 2007; 71:31-8.    ^cY#v33n1a13.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#242#238#article#342# </font></p>     ^
cY#v33n1a13.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023000080002001300310#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#243#239#article#342#76#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">76. Hsu CY, Chertow 
GM. Elevations of serum phosphorus and potassium in mild to moderate chronic ren
al insufficiency. Nephrol Dial Transplant 2002; 17:1419-25.    ^cY#v33n1a13.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#244#240#article#342# </font></p>     ^
cY#v33n1a13.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021600080002001300296#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#245#241#article#342#77#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">77. Atsumi K, Kushid
a K, Yamazaki K <i>et al. </i> Risk factors for vertebral fractures in renal ost
eodystrophy. Am J Kidney Dis 1999; 33:287-93.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#246#242#article#342# </font></p>     ^
cY#v33n1a13.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022600080002001300306#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#247#243#article#342#78#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">78. Ensrud KE, Lui L
-Y, Taylor BC <i>et al. </i> Renal function and risk of hip and vertebral fractu
res among older women. Arch Intern Med 2007; 167:133-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#248#244#article#342# </font></p>     ^
cY#v33n1a13.htm##
00545000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029400080002001300374#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#249#245#article#342#79#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">79. Ganesh SK, Stack
 AG, Levin NW <i>et al. </i> Association of elevated serum PO(4), Ca PO(4) produ
ct, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis 
patients. J Am Soc Nephrol 2001; 12:2131-8.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#250#246#article#342# </font></p>     ^
cY#v33n1a13.htm##
00493000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024200080002001300322#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#251#247#article#342#80#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">80. Kestenbaum B, Sa
mpson JN, Rudser KD <i>et al. </i> Serum phosphorus levels and mortality risk am
ong people with chronic kidney disease. JAm Soc Nephrol 2005; 16:520-8.    ^cY#v
33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#252#248#article#342# </font></p>     ^
cY#v33n1a13.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#253#249#article#342#81#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">81. Tonelli M, Sacks
 F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphorus level and card
iovascular event rate in people with coronary disease. Circulation 2005; 112:262
7-33.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#254#250#article#342# </font></p>     ^
cY#v33n1a13.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#255#251#article#342#82#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">82. Palmer SC, McGre
gor DO, Macaskill P <i>et al. </i> Meta-analysis: vitamin D compounds in chronic
 kidney disease. Ann Intern Med. 2007; 147:840-53.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#256#252#article#342# </font></p>     ^
cY#v33n1a13.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023000080002001300310#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#257#253#article#342#83#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">83. National Kidney 
Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease 
in chronic kidney disease. Am J Kidney Dis 2003; 42:S1-201.    ^cY#v33n1a13.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#258#254#article#342# </font></p>     ^
cY#v33n1a13.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020500080002001300285#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#259#255#article#342#84#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">84. Kraut JA, Kurtz 
I. Metabolic Acidosis of CKD: diagnosis, clinical characteristics, and treatment
. Am J Kidney Dis 2005; 45:978-93.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#260#256#article#342# </font></p>     ^
cY#v33n1a13.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025100080002001300331#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#261#257#article#342#85#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">85. de Brito-Ashurst
 I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progre
ssion of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20:2075-84.
    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#262#258#article#342# </font></p>     ^
cY#v33n1a13.htm##
00542000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029100080002001300371#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#263#259#article#342#86#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">86. Phisitkul S, Kha
nna A, Simoni J <i>et al. </i> Amelioration of metabolic acidosis in patients wi
th low GFR reduced kidney endothelin production and kidney injury, and better pr
eserved GFR. Kidney Int 2010; 77:617-23.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#264#260#article#342# </font></p>     ^
cY#v33n1a13.htm##
00522000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027100080002001300351#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#265#261#article#342#87#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">87. Peterson JC, Adl
er S, Burkart JM <i>et al. </i> Blood pressure, proteinuria, and the progression
 of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern M
ed 1995; 123:754-65.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#266#262#article#342# </font></p>     ^
cY#v33n1a13.htm##
00602000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704035100080002001300431#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#267#263#article#342#88#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">88. Caring for Austr
alians with Renal Impairment. Part 2. Early Kidney Disease Guidelines. Preventio
n of progression of kidney disease. Available at: <a href="http://www.kidney.org
.au/cari" target="_blank">http://www.kidney.org.au/cari</a> &#91;acessado em 29 
de maio de 2007&#93;    ^cY#v33n1a13.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#268#264#article#342#. </font></p>     
^cY#v33n1a13.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020500080002001300285#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#269#265#article#342#89#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">89. Kraut JA, Kurtz 
I. Metabolic Acidosis of CKD: diagnosis, clinical characteristics, and treatment
. Am J Kidney Dis 2005; 45:978-93.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#270#266#article#342# </font></p>     ^
cY#v33n1a13.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027200080002001300352#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#271#267#article#342#90#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">90. Hruska K, Slatop
olsky E. Disorders of phosphorus, calcium, and magnesium metabolism, in Schrier 
R, Gottschalk C (eds): diseases of the kidney, vol 3. London, UK, Little, Brown,
 1996, pp. 2477-2526.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#272#268#article#342# </font></p>     ^
cY#v33n1a13.htm##
00503000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025200080002001300332#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#273#269#article#342#91#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">91. Zoja C, Corna D,
 Camozzi D <i>et al. </i> How to fully protect the kidney in a severe model of p
rogressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13:2898-908
.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#274#270#article#342# </font></p>     ^
cY#v33n1a13.htm##
00596000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704034500080002001300425#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#275#271#article#342#92#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">92. Tonelli M, Moye 
L, Sacks FM <i>et al. </i> The Cholesterol and Recurrent Events (CARE) Trial Inv
estigators. Effect of pravastatin on loss of renal function in people with moder
ate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 200
3; 14:1605-13.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#276#272#article#342# </font></p>     ^
cY#v33n1a13.htm##
00606000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704035500080002001300435#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#277#273#article#342#93#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">93. Shepherd J, Kast
elein JJ, Bittner V <i>et al. </i> Treating to new targets investigators. Effect
 of intensive lipid lowering with atorvastatin on renal function in patients wit
h coronary heart disease: the treating to new targets (TNT) study. Clin J Am Soc
 Nephrol 2007; 2:1131-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#278#274#article#342# </font></p>     ^
cY#v33n1a13.htm##
00608000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704035700080002001300437#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#279#275#article#342#94#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">94. Atthobari J, Bra
ntsma AH, Gansevoort RT <i>et al. </i>; PREVEND study group. The effect of stati
ns on urinary albumin excretion and glomerular filtration rate: results from bot
h a randomized clinical trial and an observational cohort study. Nephrol Dial Tr
ansplant 2006; 21:3106-14.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#280#276#article#342# </font></p>     ^
cY#v33n1a13.htm##
00587000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033600080002001300416#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#281#277#article#342#95#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">95. Bakris G, Vassal
otti J, Ritz E <i>et al. </i>; CKD Consensus Working Group. National Kidney Foun
dation consensus conference on cardiovascular and kidney diseases and diabetes r
isk: an integrated therapeutic approach to reduce events. Kidney Int 2010; 78:72
6-36.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#282#278#article#342# </font></p>     ^
cY#v33n1a13.htm##
00411000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016000080002001300240#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#283#279#article#342#96#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">96. Orth SR, Ritz E,
 Schrier RW. The renal risks of smoking. Kidney Int 1997; 51:1669-77.    ^cY#v33
n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#284#280#article#342# </font></p>     ^
cY#v33n1a13.htm##
00487000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023600080002001300316#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#285#281#article#342#97#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">97. Orth S, Stockman
n A, Conradt C <i>et al. </i> Smoking as a risk factor for end-stage renal failu
re in men with primary renal disease. Kidney Int 1998; 54:926-31.    ^cY#v33n1a1
3.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#286#282#article#342# </font></p>     ^
cY#v33n1a13.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026200080002001300342#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#287#283#article#342#98#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">98. Bleyer A, Sheman
ski L, Burke G, Hansen K, Appel R. Tobacco, hypertension, and vascular disease: 
risk factors for renal function decline in an older population. Kidney Int 2000;
 57:2072-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#288#284#article#342# </font></p>     ^
cY#v33n1a13.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021200080002001300292#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#289#285#article#342#99#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">99. Ritz E, Ogata H,
 Orth SR. Smoking a factor promoting onset and progression diabetic nephropathy.
 Diabets Metab 2000; 26(Suppl 4):S54-S63.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#290#286#article#342# </font></p>     ^
cY#v33n1a13.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704024300081002001300324#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#291#287#article#342#100#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">100. Goldstein M, Y
assa T, Dacouris N, McFarlane P. Multidisciplinary predialysis care and morbidit
y and mortality of patients on dialysis. Am J Kidney Dis 2004; 44:706-14.    ^cY
#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#292#288#article#342# </font></p>     ^
cY#v33n1a13.htm##
00415000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704016300081002001300244#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#293#289#article#342#101#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">101. Curtis BM, Rav
ani P, Malberti F <i>et al. </i> Nephrol Dial Transplant 2005; 20:147-54.    ^cY
#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#294#290#article#342# </font></p>     ^
cY#v33n1a13.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704020800081002001300289#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#295#291#article#342#102#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">102. Mendelssohn D.
 Coping with the CKD epidemic: the promise of muldisciplinary team-based care. N
ephrol Dial Transplant 2005; 20:10-12.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#296#292#article#342# </font></p>     ^
cY#v33n1a13.htm##
00526000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704027400081002001300355#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#297#293#article#342#103#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">103. Early Identifi
cation and Management of Chronic Kidney Disease in Adults in Primary and Seconda
ry Care. &#91;<a href="http://www.nice.org.uk/cg73" target="_blank">http://www.n
ice.org.uk/cg73</a>&#93;    ^cY#v33n1a13.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#298#294#article#342#. </font></p>     
^cY#v33n1a13.htm##
00457000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704020500081002001300286#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#299#295#article#342#104#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">104. Levin A, Hemme
lgarn B, Culleton B <i>et al. </i> Guidelines for the management of chronic kidn
ey disease. CMAJ 2008; 179:1154-62.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#300#296#article#342# </font></p>     ^
cY#v33n1a13.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704024800081002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#301#297#article#342#105#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">105. Batista LKC, P
inheiro HS, Fuchs RC <i>et al. </i> Manuseio da doen&ccedil;a renal cr&ocirc;nic
a em pacientes com hipertens&atilde;o e diabetes. J Bras Nefrol 2005; 27:8-14.  
  ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#302#298#article#342# </font></p>     ^
cY#v33n1a13.htm##
00538000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704028600081002001300367#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#303#299#article#342#106#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">106. Jungers P, Mas
sy ZA, Nguyen-Khoa T <i>et al. </i> Longer duration of predialysis nephrological
 care is associated with improved long-term survival of dialysis patients. Nephr
ol Dial Transplant 2001; 16:2357-64.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#304#300#article#342# </font></p>     ^
cY#v33n1a13.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704021500081002001300296#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#305#301#article#342#107#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">107. Tzamaloukas AH
, Raj DSC. Referral of patients with chronic kidney disease to the nephrologist:
 why and when. Perit Dial Int 2008; 28:343-6.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#306#302#article#342# </font></p>     ^
cY#v33n1a13.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704024800081002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#307#303#article#342#108#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">108. Kausz AT, Khan
 SS, Abichandani R <i>et al. </i> Management of patients with chronic renal insu
fficiency in the Northeastern United States. J Am Soc Nephrol 2001; 12:1501-7.  
  ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#308#304#article#342# </font></p>     ^
cY#v33n1a13.htm##
00421000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704016900081002001300250#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#309#305#article#342#109#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">109. NIH Consensus 
Statement: morbidity and mortality of dialysis. Ann Intern Med 1994; 121:62-70. 
   ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#310#306#article#342# </font></p>     ^
cY#v33n1a13.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704028400081002001300365#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#311#307#article#342#110#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">110. Montgomery EB,
 Leiberman A, Singh G <i>et al. </i> (PROPATH advisory board): Patient education
 and health promotion can be effective in Parkinson's disease: randomized contro
l trial. Am J Med 1994; 97:429-35.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#312#308#article#342# </font></p>     ^
cY#v33n1a13.htm##
00561000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704030900081002001300390#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#313#309#article#342#111#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">111. Vliet Vlieland
 TP, Zwimderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM. A randomised clini
cal trial of in-patient multidisciplinary treatment versus routine outpatient ca
re in rheumatoid arthritis. Br J Rheumatol 1996; 35:475-82.    ^cY#v33n1a13.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#314#310#article#342# </font></p>     ^
cY#v33n1a13.htm##
00517000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704026500081002001300346#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#315#311#article#342#112#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">112. Rich MW, Beckh
am V, Wittenberg C <i>et al. </i> A multidisciplinary intervention to prevent th
e readmission of elderly patients with congestive heart failure. N Engl J Med 19
95; 333:1190-5.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#316#312#article#342# </font></p>     ^
cY#v33n1a13.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704018800081002001300269#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#317#313#article#342#113#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">113. Gabel M, Hilto
n NE, Nathanson SD. Multidisciplinary breast cancer clinics. Do they work? Cance
r 1997; 79:2380-4.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#318#314#article#342# </font></p>     ^
cY#v33n1a13.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704025300081002001300334#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#319#315#article#342#114#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">114. Norris SL, Nic
holas PJ, Caspersen CJ <i>et al. </i> The effectiveness of disease and case mana
gement for people with diabetes. A systematic review. Am J Prev Med 2002; 22:15-
38.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#320#316#article#342# </font></p>     ^
cY#v33n1a13.htm##
00537000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704028500081002001300366#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#321#317#article#342#115#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">115. Levin A, Lewis
 M, Mortiboy P <i>et al. </i> Multidisciplinary predialysis programs: quantifica
tion and limitations of their impact on patient outcomes in two Canadian setting
s. Am J Kidney Dis 1997; 29:533-40.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#322#318#article#342# </font></p>     ^
cY#v33n1a13.htm##
00453000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704020100081002001300282#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#323#319#article#342#116#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">116. Yeoh HH, Tiqui
a HS, Abcar AC <i>et al. </i> Impact of predialysis care on clinical outcomes. H
emodialysis Int 2003; 7:338-41.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#324#320#article#342# </font></p>     ^
cY#v33n1a13.htm##
00551000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704029900081002001300380#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#325#321#article#342#117#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">117. Hemmelgarn BR,
 Manns BJ, Zhang J <i>et al. </i>; The Alberta Kidney Disease Network. Associati
on between Multidisciplinary Care and Survival for Elderly Patients with Chronic
 Kidney Disease. J Am Soc Nephrol 2007; 18:993-9.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#326#322#article#342# </font></p>     ^
cY#v33n1a13.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704026200081002001300343#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#327#323#article#342#118#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">118. Menon S, Valen
tini RP, Kapur G, Layfield S, Mattoo TK. Effectiveness of a multidisciplinary cl
inic in managing children with chronic kidney disease. Clin J Am Soc Nephrol 200
9; 4:1170-5.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#328#324#article#342# </font></p>     ^
cY#v33n1a13.htm##
00537000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704028500081002001300366#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#329#325#article#342#119#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">119. Levin A, Lewis
 M, Mortiboy P <i>et al. </i> Multidisciplinary Predialysis Programs: quantifica
tion and limitations of their impact on patient outcomes in two Canadian setting
s. Am J Kidney Dis 1997; 29:533-40.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#330#326#article#342# </font></p>     ^
cY#v33n1a13.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704024500081002001300326#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#331#327#article#342#120#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">120. Fenton A, Saya
r Z, Dodds A, Dasgupta I. Multidisciplinary care improves outcome of patients wi
th stage 5. Chronic kidney disease. Nephron Clin Pract 2010; 115:c283-c288.    ^
cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#332#328#article#342# </font></p>     ^
cY#v33n1a13.htm##
00522000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704027000081002001300351#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#333#329#article#342#121#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">121. Wei S-Y, Chang
 Y-Y, Mau L-W, Lin M-Y <i>et al</i>. Chronic kidney disease care program improve
s quality of pre-end-stage renal disease care and reduces medical costs. Nephrol
ogy 2010; 15:108-15.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#334#330#article#342# </font></p>     ^
cY#v33n1a13.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000400077704024800081002001300329#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#335#331#article#342#122#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">122. Harris LE, Luf
t FC, Rudy DW, Kesterson JG, Tierney WM. Effects of multidisciplinary case manag
ement in patients with chronic renal insufficiency. Am J Med 1998; 105:464-71.  
  ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#336#332#article#342# </font></p>     ^
cY#v33n1a13.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#337#333#article#342#<p>&nbsp;</p>     
^cY#v33n1a13.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#338#334#article#342#<p>&nbsp;</p>     
^cY#v33n1a13.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704020000077002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#339#335#article#342#<p><a name="endb">
</a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda">
<img src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;
ncia para:</b>    ^cY#v33n1a13.htm##
00267000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003100077002001300108#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#340#336#article#342#<br>   Marcus G. B
astos    ^cY#v33n1a13.htm##
00265000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002900077002001300106#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#341#337#article#342#<br>   NIEPEN - UF
JF     ^cY#v33n1a13.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#342#338#article#342#<br>   Rua Jos&eac
ute; Louren&ccedil;o Kelmer 1.300, S&atilde;o Pedro     ^cY#v33n1a13.htm##
00292000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005600077002001300133#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#343#339#article#342#<br>   Juiz de For
a - MG - Brasil CEP: 36036-330    ^cY#v33n1a13.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009900077002001300176#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#344#340#article#342#<br>   E-mail: <a 
href="mailto:marcusgb@terra.com.br">marcusgb@terra.com.br</a></font></p>     ^cY
#v33n1a13.htm##
00350000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704011400077002001300191#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#345#341#article#342#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Data de aprova&ccedil;&atilde;o: 27
/01/2011    ^cY#v33n1a13.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a13.htm#S#p#346#342#article#342#<br>   Os autores 
declaram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33
n1a13.htm##
00550000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750120114000770300016001910650
00900207064000500216031000300221032000400224014000800228865000900236002001300245
035001000258801001600268#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#347#1#article#122#1#K/DOQI clinical practice guidelines for chronic kidney dis
ease: evaluation, classification and stratification^len#Am J Kidney Dis#20020000
#2002#39#^s2#S1-S246#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00603000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100016000770100019000930100
02200112810000600134012009600140030000500236065000900241064000500250031000300255
014000600258865000900264002001300273035001000286801000500296#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#348#2#article#122#2#^rND^sSaydah^nS#^rND^s
Eberhardt^nM#^rND^sRios-Burrows^nN#et al#Prevalence of chronic kidney disease an
d associated risk factors - United States, 1999-2004^len#MMWR#20070000#2007#56#1
61-5#20110300#v33n1a13.htm#0149-2195#MMWR##
00560000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100017000770100016000940100
01600110010001600126010001800142012003800160030001300198710000200211065000900213
064000500222031000300227014000600230865000900236002001300245#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#349#3#article#122#3#^rND^sSesso^nRCC#^rND^
sLopes^nAA#^rND^sThomé^nFS#^rND^sLugon^nJR#^rND^sBurdman^nEA#Censo Brasileiro de
 Diálise, 2009^lpt#J Bras Nefol#2#20100000#2010#32#380-4#20110300#v33n1a13.htm##
00565000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100019000770100018000960100
01700114012010800131030001800239710000200257065000900259064000500268020000400273
865000900277002001300286#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#350#4#article#122#4#^rND^sFernandes^nN#^rND^sBastos^nRMR#^rND^sBastos^nMG#Diag
nóstico da doença renal crônica a partir da filtração glomerular estimada: CKD-E
PI ou MDRD [Resumo]^lpt#Congr Bras Nefrol#2#20100000#2010#506#20110300#v33n1a13.
htm##
00496000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100016000770120059000930300
01100152065000900163064000500172031000300177014000700180865000900187002001300196
035001000209801001100219#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#351#5#article#122#5#^rND^sLevey^nAS#Measurement of renal function in chronic r
enal disease^len#Kidney Int#19900000#1990#38#167-84#20110300#v33n1a13.htm#0085-2
538#Kidney int##
00538000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100019000770120094000960300
01400190065000900204064000500213031000300218014000500221865000900226002001300235
035001000248801001400258#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#352#6#article#122#6#^rND^sPraxedes^nJN#Diretrizes sobre hipertensão arterial e
 uso de anti-hipertensivos na doença renal crônica^lpt#J Bras Nefrol#20040000#20
04#26#44-6#20110300#v33n1a13.htm#0101-2800#J Bras Nefrol##
00491000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100018000770120051000950300
01100146065000900157064000500166031000300171014000800174865000900182002001300191
035001000204801001100214#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#353#7#article#122#7#^rND^sParving^nHH#Diabetic nephropathy: prevention and tre
atment^len#Kidney Int#20010000#2001#60#2041-55#20110300#v33n1a13.htm#0085-2538#K
idney int##
00663000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100019000770100018000960100
02000114011001700134012013500151030001100286065000900297064000500306031000300311
014000400314865000900318002001300327035001000340801001100350#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#354#8#article#122#8#^rND^sSteinman^nTI#^rN
D^sPerrone^nRD#^rND^sHunsicker^nLG#MDRD Study Group#GFR determination in chronic
 renal failure by 3 radionuclide markers and inulin: coeficient of variation of 
the methods (abstract)^len#Kidney Int#19890000#1989#35#201#20110300#v33n1a13.htm
#0085-2538#Kidney int##
00579000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080004000711180002000750100018000770100016000950100
01600111010001600127012008100143030001500224710000200239065000900241064000500250
031000400255014000800259865000900267002001300276#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#355#9#article#122#9#^rND^sStevens^nLA#^rND^sCoresh^nJ#
^rND^sGreene^nT#^rND^sLevey^nAS#Assessing kidney function: Measured and estimate
d glomerular filtration rate^len#New Engl J Med#2#20060000#2006#354#2473-83#2011
0300#v33n1a13.htm##
00606000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100017000960100
01600113010001700129012008100146030001100227065000900238064000500247031000300252
014000600255865000900261002001300270035001000283801001100293#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#356#10#article#122#10#^rND^sShemesh^nO#^rN
D^sGolbetz^nH#^rND^sKriss^nJP#^rND^sMeyers^nBD#Limitations of creatinine as a fi
ltration marker in glomerulopathic patients^len#Kidney Int#19850000#1985#28#830-
8#20110300#v33n1a13.htm#0085-2538#Kidney int##
00608000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100016000950100
01800111810000600129012008600135030001400221065000900235064000500244031000300249
014000800252865000900260002001300269035001000282801001400292#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#357#11#article#122#11#^rND^sPinto^nPS#^rND
^sSilva^nFJ#^rND^sMunch^nECSM#et al#Inadequabilidade da creatinina sérica na ide
ntificação precoce da disfunção renal^lpt#J Bras Nefrol#20040000#2004#26#196-201
#20110300#v33n1a13.htm#0101-2800#J Bras Nefrol##
00525000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100016000990120
06100115030000800176065000900184064000500193031000300198014000600201865000900207
002001300216035001000229801000800239#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#358#12#article#122#12#^rND^sCockcroft^nDW#^rND^sGault^nMH#Predicti
on of creatinine clearance from serum creatinine^len#Nephron#19760000#1976#16#31
-41#20110300#v33n1a13.htm#0028-2766#Nephron##
00701000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100016000950100
01600111010001600127010001600143010001400159012011500173030001500288065000900303
06400050031203100040031701400070032186500090032800200130033703500100035080100150
0360#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#359#13#article#122
#13#^rND^sLevey^nAS#^rND^sBosch^nJP#^rND^sLewis^nJB#^rND^sGreene^nT#^rND^sRogers
^nN#^rND^sRoth^nD#A more accurate method to estimate glomerular filtration rate 
from serum creatinine: a new prediction equation^len#Ann Intern Med#19990000#199
9#130#461-70#20110300#v33n1a13.htm#0003-4819#Ann Intern Med##
00583000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100018000950100
01700113810000600130012005800136030001500194065000900209064000500218031000400223
014000700227865000900234002001300243035001000256801001500266#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#360#14#article#122#14#^rND^sLevey^nAS#^rND
^sStevens^nLA#^rND^sSchmid^nCH#et al#A new equation to estimate glomerular filtr
ation rate^len#Ann Intern Med#20090000#2009#150#604-12#20110300#v33n1a13.htm#000
3-4819#Ann Intern Med##
00602000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100016000950100
01600111010001500127012011500142030000800257710000200265065000900267064000500276
031000300281014000600284865000900290002001300299#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#361#15#article#122#15#^rND^sLevey^nAS#^rND^sGreene^nT#
^rND^sKusek^nJW#^rND^sBeck^nGJ#A simplified equation to predict glomerular filtr
ation rate from serum creatinine &#91;Abstract&#93;: J Am Soc^len#Nephrol#2#2000
0000#2000#11#A0828#20110300#v33n1a13.htm##
00631000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760110050000790120149001290300
01500278065000900293064000500302031000400307014000700311865000900318002001300327
035001000340801001500350#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#362#16#article#122#16#Chronic Kidney Disease Epidemiology Collaboration#Using 
standardized serum creatinine values in the modification of diet in renal diseas
e study equation for estimating glomerular filtration rate^len#Ann Intern Med#20
060000#2006#145#247-54#20110300#v33n1a13.htm#0003-4819#Ann Intern Med##
00587000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100017000940100
01500111810000600126012006600132030001600198065000900214064000500223031000300228
014000600231865000900237002001300246035001000259801001600269#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#363#17#article#122#17#^rND^sRule^nAD#^rND^
sGussak^nHM#^rND^sPond^nGR#et al#Measured and estimated GFR in healthy potential
 kidney donors^len#Am J Kidney Dis#20040000#2004#43#112-9#20110300#v33n1a13.htm#
0272-6386#Am J Kidney Dis##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100013000790100017000920100
01600109010001600125012011600141030001700257065000900274064000500283031000300288
014000800291865000900299002001300308035001000321801001700331#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#364#18#article#122#18#^rND^sLin^nJ#^rND^sK
night^nEL#^rND^sHogan^nML#^rND^sSingh^nAK#A comparison of prediction equations f
or estimating glomerular filtration rate in adults without kidney disease^len#J 
Am Soc Nephrol#20030000#2003#14#2573-80#20110300#v33n1a13.htm#1046-6673#J Am Soc
 Nephrol##
00529000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100017000970120
05500114030001400169065000900183064000500192031000300197014000500200865000900205
002001300214035001000227801001400237#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#365#19#article#122#19#^rND^sBastos^nRMR#^rND^sBastos^nMG#Tabela de
 cálculo imediato da filtração glomerular^lpt#J Bras Nefrol#20050000#2005#27#40-
3#20110300#v33n1a13.htm#0101-2800#J Bras Nefrol##
00690000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100020000980100
01500118010001800133010001400151010001700165012010600182030001000288065000900298
06400050030703100030031201400070031586500090032200200130033103500100034480100100
0354#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#366#20#article#122
#20#^rND^sBokenkamp^nA#^rND^sDomanetzki^nM#^rND^sZinck^nR#^rND^sSchumann^nG#^rND
^sByrd^nD#^rND^sBrodehl^nJ#Cystatin C serum concentrations underestimate glomeru
lar filtration rate in renal transplant patients^len#Clin Chem#19990000#1999#45#
1866-8#20110300#v33n1a13.htm#0009-9147#Clin Chem##
00640000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100018000960100
02000114810000600134012011900140030001100259065000900270064000500279031000300284
014000800287865000900295002001300304035001000317801001100327#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#367#21#article#122#21#^rND^sKnight^nEL#^rN
D^sVerhave^nJC#^rND^sSpiegelman^nD#et al#Factors influencing serum cystatin C le
vels other than renal function and the impact on renal function measurement^len#
Kidney Int#20040000#2004#65#1416-21#20110300#v33n1a13.htm#0085-2538#Kidney int##
00664000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100021000940100
01800115012013600133030002400269065000900293064000500302031000300307014000800310
865000900318002001300327035001000340801002400350#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#368#22#article#122#22#^rND^sHoek^nFJ#^rND^sKempermann^
nFA#^rND^sKrediet^nRT#A comparison between cystatin C, plasma creatinine and the
 Cockcroft-Gault formula for the estimation of glomerular filtration rate^len#Ne
phrol Dial Transplant#20030000#2003#18#2024-31#20110300#v33n1a13.htm#0931-0509#N
ephrol Dial Transplant##
00619000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100014000970100
02100111810000600132012009800138030001300236065000900249064000500258031000300263
014000600266865000900272002001300281035001000294801001300304#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#369#23#article#122#23#^rND^sShlipak^nMG#^r
ND^sKatz^nR#^rND^sKestenhbaum^nB#et al#Rate of kidney function decline in older 
adults: a comparison using creatinine and cystatin C^len#Am J Nephrol#20090000#2
009#30#171-8#20110300#v33n1a13.htm#0250-8095#Am J Nephrol##
00617000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100014000970100
01700111810000600128012009100134030001700225065000900242064000500251031000300256
014000700259865000900266002001300275035001000288801001700298#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#370#24#article#122#24#^rND^sPeralta^nCA#^r
ND^sKatz^nR#^rND^sSarnak^nMJ#et al#Cystatin C identifies chronic kidney disease 
patients at higher risk for complications^len#J Am Soc Nephrol#20110000#2011#22#
147-55#20110300#v33n1a13.htm#1046-6673#J Am Soc Nephrol##
00750000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100017000990100
01500116010001700131012023600148030000400384065000900388064000500397031000400402
014000600406865000900412002001300421035001000434801000400444#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#371#25#article#122#25#^rND^sRuggenenti^nP#
^rND^sGaspari^nF#^rND^sPerna^nA#^rND^sRemuzzi^nG#Cross sectional longitudinal st
udy of spot morning urine protein: creatinine ratio, 24 hour urine protein excre
tion rate, glomerular filtration rate, and end stage renal failure in chronic re
nal disease in patients without diabetes^len#BMJ#19980000#1998#316#504-9#2011030
0#v33n1a13.htm#0959-8138#BMJ##
00609000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100016000960100
01700112012010800129030001300237065000900250064000500259031000300264014000700267
865000900274002001300283035001000296801001300306#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#372#26#article#122#26#^rND^sComper^nWD#^rND^sJerums^nG
#^rND^sOsicka^nTM#Differences in urinary albumin detected by four immunoassays a
nd high-performance liquid chromatography^len#Clin Biochem#20040000#2004#37#105-
11#20110300#v33n1a13.htm#0009-9120#Clin Biochem##
00561000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100017000990120
08400116030001400200065000900214064000500223031000300228014000600231865000900237
002001300246035001000259801001400269#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#373#27#article#122#27#^rND^sKirsztajn^nGM#^rND^sBastos^nMG#Propost
a de padronização de um programa de rastreamento da doença renal crônica^lpt#J B
ras Nefrol#20070000#2007#29#18-22#20110300#v33n1a13.htm#0101-2800#J Bras Nefrol#
#
00537000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100016000970120
04900113030001100162065000900173064000500182031000300187032000800190014000600198
865000900204002001300213035001000226801001100236#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#374#28#article#122#28#^rND^sFairley^nKF#^rND^sBirch^nD
F#Microscopic urinalysis in glomerulonephritis^len#Kidney Int#19930000#1993#42#^
sSuppl#S9-12#20110300#v33n1a13.htm#0085-2538#Kidney int##
00596000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100016000970100
01600113810000600129012007200135030001600207065000900223064000500232031000300237
014000600240865000900246002001300255035001000268801001600278#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#375#29#article#122#29#^rND^sRoubicek^nC#^r
ND^sBrunet^nP#^rND^sHuiart^nL#et al#Timing of nephrology referral: influence on 
mortality and morbidity^len#Am J Kidney Dis#20000000#2000#36#35-41#20110300#v33n
1a13.htm#0272-6386#Am J Kidney Dis##
00607000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100019000950100
01800114010001600132012007600148030001300224065000900237064000500246031000300251
014000600254865000900260002001300269035001000282801001300292#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#376#30#article#122#30#^rND^sIsrani^nA#^rND
^sKorzelius^nC#^rND^sToensend^nR#^rND^sMesler^nD#Management of chronic kidney di
sease in an Academic Primary Care Clinic^len#Am J Nephrol#20030000#2003#23#47-54
#20110300#v33n1a13.htm#0250-8095#Am J Nephrol##
00669000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100015000990100
01700114010001600131010001400147012010600161030001600267065000900283064000500292
031000300297014000700300865000900307002001300316035001000329801001600339#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#377#31#article#122#31#^rND^sMc
Laughlin^nK#^rND^sManns^nB#^rND^sulleton^nB#^rND^sDonaldson#^rND^sTaub^nK#An eco
nomic evaluation of early versus late referral of patients with progressive rena
l insufficiency^len#Am J Kidney Dis#20010000#2001#38#1122-8#20110300#v33n1a13.ht
m#0272-6386#Am J Kidney Dis##
00593000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100017000980100
02000115012007900135030001700214065000900231064000500240031000200245014000700247
865000900254002001300263035001000276801001700286#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#378#32#article#122#32#^rND^sFreedman^nBI#^rND^sSoucie^
nJM#^rND^sMcClellan^nWM#Family history of end-stage renal disease among incident
 dialysis patients^len#J Am Soc Nephrol#19970000#1997#8#1942-5#20110300#v33n1a13
.htm#1046-6673#J Am Soc Nephrol##
00574000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100015000990100
01700114810000600131012005100137030001300188065000900201064000500210031000400215
014000800219865000900227002001300236035001000249801001300259#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#379#33#article#122#33#^rND^sRuggenenti^nP#
^rND^sFassi^nA#^rND^sLlieva^nAP#et al#Preventing microalbuminuria in type 2 diab
etes^len#N Engl J Med#20040000#2004#351#1941-51#20110300#v33n1a13.htm#0028-4793#
N Engl J Med##
00631000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100018000970100
01900115010001600134010001700150012007800167030000800245065000900253064000500262
031000300267014000700270865000900277002001300286035001000299801000800309#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#380#34#article#122#34#^rND^sDa
sgupta^nI#^rND^sMadeley^nRJ#^rND^sPringle^nMAL#^rND^sSavill^nJ#^rND^sBurden^nRP#
Management of hypertension in patients developing end-stage renal failure^len#Q 
J Med#19990000#1999#92#519-25#20110300#v33n1a13.htm#0033-5622#Q J Med##
00590000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100017000940100
01800111810000600129012008600135030000500221065000900226064000500235031000400240
014000700244865000900251002001300260035001000273801000500283#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#381#35#article#122#35#^rND^sKlag^nMJ#^rND^
sWheton^nPK#^rND^sRandall^nBL#et al#End-stage renal disease in African-American 
and white men: 16-year MRFIT findings^len#JAMA#19970000#1997#277#1293-8#20110300
#v33n1a13.htm#0098-7484#JAMA##
00528000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760120144000790300015002237100
00200238065000900240064000500249031000300254014000700257865000900264002001300273
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#382#36#article#122#36#
1999 World Health Organization-International Society of Hypertension guidelines 
for the management of hypertension: Guidelines subcommittee^len#J Hypertension#2
#19990000#1999#17#151-83#20110300#v33n1a13.htm##
00547000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760120109000790300016001880650
00900204064000500213031000300218032000400221014000800225865000900233002001300242
035001000255801001600265#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#383#37#article#122#37#K/DOQI clinical practice guideline on hypertension and a
ntihypertensive agents in chronic kidney disease^len#Am J Kidney Dis#20040000#20
04#43#^s1#S1-S290#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00571000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790120093000960300
02900189065000900218064000500227031000400232014000800236865000900244002001300253
035001000266801002900276#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#384#38#article#122#38#^rND^sPalmer^nBF#Management of hypertension in patients 
with chronic kidney disease and diabetes mellitus^len#American Journal of Medici
ne#20080000#2008#121#S16-S22#20110300#v33n1a13.htm#0002-9343#American Journal of
 Medicine##
00661000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100020000950100
01500115010001600130011003400146012008300180030001300263065000900276064000500285
031000400290014000800294865000900302002001300311035001000324801001300334#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#385#39#article#122#39#^rND^sLe
wis^nEJ#^rND^sHunsicker^nLG#^rND^sBain^nRP#^rND^sRohde^nRD#for the Collaborative
 Study Group#The effect of angiotensin-converting-enzyme inhibition on diabetic 
nephropathy^len#N Engl J Med#19930000#1993#329#1456-62#20110300#v33n1a13.htm#002
8-4793#N Engl J Med##
00611000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760110015000790120179000940300
00700273065000900280064000500289031000400294014000800298865000900306002001300315
035001000328801000700338#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#386#40#article#122#40#The GroupGISEN#Randomised placebo-controlled trial of ef
fect of ramipril on decline in glomerular filtration rate and risk of terminal r
enal failure in proteinuric, non-diabetic nephropathy^len#Lancet#19970000#1997#3
49#1857-63#20110300#v33n1a13.htm#0099-5355#Lancet##
00563000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100020000990100
01700119012006500136030000700201065000900208064000500217031000400222014000800226
865000900234002001300243035001000256801000700266#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#387#41#article#122#41#^rND^sRuggenenti^nP#^rND^sSchiep
pati^nA#^rND^sRemuzzi^nG#Progression, remission, regression of chronic renal dis
eases^len#Lancet#20010000#2001#357#1601-08#20110300#v33n1a13.htm#0099-5355#Lance
t##
00570000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100017000970100
01700114012006500131030001400196065000900210064000500219031000300224014000700227
865000900234002001300243035001000256801001400266#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#388#42#article#122#42#^rND^sSantos^nAMR#^rND^sLemos^nC
CS#^rND^sBregman^nR#Proteinúria: marcador clássico de comprometimento glomerular
^lpt#J Bras Nefrol#20010000#2001#23#217-20#20110300#v33n1a13.htm#0101-2800#J Bra
s Nefrol##
00812000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100023000790100018001020100
01800120010001800138010002300156010001900179011006100198012014900259030000400408
06500090041206400050042103100040042601400080043086500090043800200130044703500100
0460801000400470#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#389#43
#article#122#43#^rND^sMarcello Tonelli#^rND^sPowell Jose#^rND^sGary Curhan#^rND^
sFrank Sacks#^rND^sEugene Braunwald#^rND^sMarc Pfeffer#for the Cholesterol and R
ecurrent Events Trial Investigators#Proteinuria, impaired kidney function, and a
dverse outcomes in people with coronary disease: analysis of a previously conduc
ted randomised trial^len#BMJ#20060000#2006#332#1426-32#20110300#v33n1a13.htm#095
9-8138#BMJ##
00562000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100017000960120
09300113030001100206065000900217064000500226031000300231014000700234865000900241
002001300250035001000263801001100273#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#390#44#article#122#44#^rND^sRemuzzi^nG#^rND^sBertani^nT#Is glomeru
losclerosis a consequence of altered glomerular permeability to macromolecules^l
en#Kidney Int#19900000#1990#38#384-94#20110300#v33n1a13.htm#0085-2538#Kidney int
##
00596000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100014000980100
01500112012010700127030000800234065000900242064000500251031000300256014000700259
865000900266002001300275035001000288801000800298#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#391#45#article#122#45#^rND^sWilliams^nPS#^rND^sFass^nG
#^rND^sBone^nJM#Renal pathology and proteinuria determine progression in untreat
ed mild/moderate chronic renal failure^len#Q J Med#19880000#1988#67#343-54#20110
300#v33n1a13.htm#0033-5622#Q J Med##
00632000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100017000970100
01800114810000600132012011000138030001300248065000900261064000500270031000400275
014000600279865000900285002001300294035001000307801001300317#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#392#46#article#122#46#^rND^sBrenner^nBM#^r
ND^sCooper^nME#^rND^sDe Zeeuw^nD#et al#Effects of losartan on renal and cardiova
scular outcomes in patients with type 2 diabetes and nephropathy^len#N Engl J Me
d#20010000#2001#345#861-9#20110300#v33n1a13.htm#0028-4793#N Engl J Med##
00752000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100019000940100
01600113010001600129010001600145010001600161012017800177030000700355065000900362
06400050037103100040037601400070038086500090038700200130039603500100040980100070
0419#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#393#47#article#122
#47#^rND^sNakao^nN#^rND^sYoshimura^nA#^rND^sMorita^nH#^rND^sTakada^nM#^rND^sKaya
no^nT#^rND^sIdeura^nT#Combination treatment of angiotensin-II receptor blocker a
nd angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPER
ATE): a randomized controlled trial^len#Lancet#20030000#2003#361#117-24#20110300
#v33n1a13.htm#0099-5355#Lancet##
00551000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100018000970100
02100115010001600136010001500152030001300167065000900180064000500189031000400194
014000600198865000900204002001300213035001000226801001300236#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#394#48#article#122#48#^rND^sFioretto^nP#^r
ND^sSteffes^nMW#^rND^sSutherland^nDE#^rND^sGoetz^nFC#^rND^sMauer^nM#N Engl J Med
#19980000#1998#339#69-75#20110300#v33n1a13.htm#0028-4793#N Engl J Med##
00578000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760110060000790120094001390300
01100233065000900244064000500253031000300258014000800261865000900269002001300278
035001000291801001100301#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#395#49#article#122#49#The Diabetes Control and Complications Trial Research Gr
oup#Effect of intensive therapy on the development and progression of nephropath
y in the DCCT^len#Kidney Int#19950000#1995#47#1703-20#20110300#v33n1a13.htm#0085
-2538#Kidney int##
00560000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760110030000790120120001090300
00400229065000900233064000500242031000400247014000700251865000900258002001300267
035001000280801000400290#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#396#50#article#122#50#UK Prospective Diabetes Study#Tight blood pressure contr
ol and risk of macrovascular and microvascular complications in type 2 diabetes:
 UKPDS 38^len#BMJ#19980000#1998#317#703-13#20110300#v33n1a13.htm#0959-8138#BMJ##
00514000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790120050000940300
02400144065000900168064000500177031000300182014000700185865000900192002001300201
035001000214801002400224#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#397#51#article#122#51#^rND^sPraga^nM#Obesity: a neglected culprit in renal dis
ease^len#Nephrol Dial Transplant#20020000#2002#17#1157-9#20110300#v33n1a13.htm#0
931-0509#Nephrol Dial Transplant##
00618000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100014000940100
01600108010001600124010001300140010001600153012005500169030003100224710000200255
065000900257064000500266031000300271014000800274865000900282002001300291#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#398#52#article#122#52#^rND^sHa
ll^nJE#^rND^sKuo^nJJ#^rND^sSilva^nAA#^rND^sPaula^nRB#^rND^sLiu^nJ#^rND^sTallam^n
L#Obesity-associated hypertension and kidney disease^len#Curr Opinion Nephrol Hy
pertens#2#20030000#2003#12#195-200#20110300#v33n1a13.htm##
00605000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100018000990100
01900117010001800136012006200154030001500216065000900231064000500240031000300245
014000800248865000900256002001300265035001000278801001500288#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#399#53#article#122#53#^rND^sWeisinger^nJR#
^rND^sKempson^nRL#^rND^sEldridge^nFL#^rND^sSwenson^nRS#The nephrotic syndrome: a
 complication of massive obesity^len#Ann Intern Med#19740000#1974#81#440-447#201
10300#v33n1a13.htm#0003-4819#Ann Intern Med##
00579000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100020000960100
01700116810000600133012005700139030001100196065000900207064000500216031000300221
014001000224865000900234002001300243035001000256801001100266#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#400#54#article#122#54#^rND^sKambham^nN#^rN
D^sMarkowitz^nGS#^rND^sValeri^nAM#et al#Obesity related glomerulopathy: an emerg
ing epidemic^len#Kidney Int#20010000#2001#59#1498-1509#20110300#v33n1a13.htm#008
5-2538#Kidney int##
00623000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100017000960100
01400113810000600127012010000133030001600233065000900249064000500258031000300263
014000700266865000900273002001300282035001000295801001600305#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#401#55#article#122#55#^rND^sMorales^nE#^rN
D^sValero^nMA#^rND^sLeon^nM#et al#Beneficial effects of weight loss in overweigh
t patients with chronic proteinuric nephropathies^len#Am J Kidney Dis#20030000#2
003#41#319-27#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00613000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100018000950100
01800113810000600131012006900137030002400206065000900230064000500239031000300244
014000800247865000900255002001300264035001000277801002400287#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#402#56#article#122#56#^rND^sBello^nAK#^rND
^sde Zeeuw^nD#^rND^sEl Nahas^nM#et al#Impact of weight change on albuminuria in 
the general population^len#Nephrol Dial Transplant#20070000#2007#22#1619-27#2011
0300#v33n1a13.htm#0931-0509#Nephrol Dial Transplant##
00591000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100017000980100
01700115010001600132010001600148012004600164030002700210710000200237065000900239
064000500248031000400253014001000257865000900267002001300276#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#403#57#article#122#57#^rND^sChagnac^nAWT#^
rND^sKorzets^nA#^rND^sRamadan^nE#^rND^sHirsch^nJ#^rND^sGafter^nU#Glomerular hemo
dynamics in severe obesity^len#Am J Physiol Renal Physiol#2#20000000#2000#278#F8
17-F822#20110300#v33n1a13.htm##
00596000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100019000940100
01800113810000600131012011100137030001000248710000200258065000900260064000500269
031000300274014000700277865000900284002001300293#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#404#58#article#122#58#^rND^sPraga^nM#^rND^sHernandez^n
E#^rND^sHerrero^nJC#et al#Influence of obesity on the appearance of proteinuria 
and renal insufficiency after unilateral nephrectomy^len#Kdney Int#2#20000000#20
00#58#2111-8#20110300#v33n1a13.htm##
00560000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760120118000790300016001970650
00900213064000500222031000300227032000800230014000800238865000900246002001300255
035001000268801001600278#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#405#59#article#122#59#Clinical practice guidelines and clinical practice recom
mendations for anemia in chronic kidney disease in adults^len#Am J Kidney Dis#20
060000#2006#47#^sSuppl#S1-S145#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00553000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100024000790100017001030120
07400120030001400194065000900208064000500217031000300222014000400225865000900229
002001300238035001000251801001400261#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#406#60#article#122#60#^rND^sRibeiro Alves^nMA#^rND^sGordan^nPA#Dia
gnóstico de anemia em pacientes portadores de doença renal crônica^lpt#J Bras Ne
frol#20070000#2007#29#4-6#20110300#v33n1a13.htm#0101-2800#J Bras Nefrol##
00640000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100018000980100
01800116810000600134012012700140030000700267065000900274064000500283031000400288
014000700292865000900299002001300308035001000321801000700331#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#407#61#article#122#61#^rND^sWinearls^nCG#^
rND^sPippard^nMJ#^rND^sDowning^nMR#et al#Effect of human erythropoietin derived 
from recombinant DNA on the anaemia of patients maintained by chronic haemodialy
sis^len#Lancet#19860000#1986#328#1175-8#20110300#v33n1a13.htm#0099-5355#Lancet##
00669000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100016000980100
01800114810000600132012014700138030001300285065000900298064000500307031000400312
014000600316865000900322002001300331035001000344801001300354#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#408#62#article#122#62#^rND^sEschbach^nJW#^
rND^sEgrie^nJC#^rND^sDowning^nMR#et al#Correction of the anemia of end-stage ren
al disease with recombinant human erythropoietin: results of a combined Phase I 
and II clinical trial^len#N Engl J Med#19870000#1987#316#73-78#20110300#v33n1a13
.htm#0028-4793#N Engl J Med##
00615000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100016000980100
01500114810000600129012009500135030001300230065000900243064000500252031000400257
014000700261865000900268002001300277035001000290801001300300#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#409#63#article#122#63#^rND^sEschbach^nJW#^
rND^sKelly^nMR#^rND^sHaley^nR#et al#Treatment of the anemia of progressive renal
 failure with recombinant human erythropoietin^len#N Engl J Med#19890000#1989#32
1#158-63#20110300#v33n1a13.htm#0028-4793#N Engl J Med##
00664000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100016000970100
01600113810000600129012013900135030001600274065000900290064000500299031000300304
014000700307865000900314002001300323035001000336801001600346#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#410#64#article#122#64#^rND^sRevicki^nDA#^r
ND^sBrown^nRE#^rND^sFeeny^nDH#et al#Health-related quality of life associated wi
th recombinant human erythropoietin therapy for predialysis chronic renal diseas
e patients^len#Am J Kidney Dis#19950000#1995#25#548-54#20110300#v33n1a13.htm#027
2-6386#Am J Kidney Dis##
00635000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100017000970100
01700114810000600131012009200137030001600229065000900245064000500254031000300259
032000400262014000700266865000900273002001300282035001000295801001600305#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#411#65#article#122#65#^rND^sMu
irhead^nN#^rND^sBargman^nJ#^rND^sBurgess^nE#et al#Evidence-based recommendations
 for the clinical use of recombinant human erythropoietin^len#Am J Kidney Dis#19
950000#1995#26#^s1#S1-S24#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00670000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760110064000790120175001430300
01600318065000900334064000500343031000300348014000500351865000900356002001300365
035001000378801001600388#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#412#66#article#122#66#The US Recombinant Human Erythropoietin Predialysis Stud
y Group#Double-blind, placebo-controlled study of the therapeutic use of recombi
nant human erythropoietin for anemia associated with chronic renal failure in pr
edialysis patients^len#Am J Kidney Dis#19910000#1991#18#50-9#20110300#v33n1a13.h
tm#0272-6386#Am J Kidney Dis##
00635000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100014000790100016000930100
01800109810000600127012011200133030001600245065000900261064000500270031000300275
014000700278865000900285002001300294035001000307801001600317#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#413#67#article#122#67#^rND^sRoth^nD#^rND^s
Smith^nRD#^rND^sSchulman^nG#et al#Effects of recombinant human erythropoietin on
 renal function in chronic renal failure predialysis patients^len#Am J Kidney Di
s#19940000#1994#24#777-84#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00662000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100017000960100
01700113810000600130012014100136030001300277065000900290064000500299031000400304
014000700308865000900315002001300324035001000337801001300347#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#414#68#article#122#68#^rND^sBesarab^nA#^rN
D^sBolton^nWK#^rND^sBrowne^nJK#et al#The effects of normal as compared with low 
hematocrit values in patients with cardiac disease who are receiving hemodialysi
s and epoetin^len#N Engl J Med#19980000#1998#339#584-90#20110300#v33n1a13.htm#00
28-4793#N Engl J Med##
00612000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100019000970100
01500116810000600131012008900137030001300226065000900239064000500248031000400253
014000800257865000900265002001300274035001000287801001300297#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#415#69#article#122#69#^rND^sDru¨eke^nTB#^r
ND^sLocatelli^nF#^rND^sClyne^nN#et al#Normalization of hemoglobin level in patie
nts with chronic kidney disease and anemia^len#N Engl J Med#20060000#2006#355#20
71-84#20110300#v33n1a13.htm#0028-4793#N Engl J Med##
00588000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100017000950100
01500112810000600127012006900133030001300202065000900215064000500224031000400229
014000800233865000900241002001300250035001000263801001300273#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#416#70#article#122#70#^rND^sSingh^nAK#^rND
^sSzczech^nL#^rND^sTang^nKL#et al#Correction of anemia with epoetin alfa in chro
nic kidney disease^len#N Engl J Med#20060000#2006#355#2085-98#20110300#v33n1a13.
htm#0028-4793#N Engl J Med##
00601000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100019000970100
01500116810000600131012007800137030001300215065000900228064000500237031000400242
014000800246865000900254002001300263035001000276801001300286#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#417#71#article#122#71#^rND^sPfeffer^nMA#^r
ND^sBurdmann^nEA#^rND^sChen^nCY#et al#A trial of darbepoetin alfa in type 2 diab
etes and chronic kidney disease^len#N Engl J Med#20090000#2009#361#2019-32#20110
300#v33n1a13.htm#0028-4793#N Engl J Med##
00609000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100017000970100
01900114810000600133012011200139030001700251065000900268064000500277865000900282
002001300291035001000304801001700314#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#418#72#article#122#72#^rND^sGoodkin^nDA#^rND^sFuller^nDS#^rND^sRob
inson^nBM#et al#Naturally occurring higher hemoglobin concentration does not inc
rease mortality among hemodialysis patients^len#J Am Soc Nephrol#20100000#2010#2
0110300#v33n1a13.htm#1046-6673#J Am Soc Nephrol##
00610000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760110027000790120149001060300
01600255065000900271064000500280031000300285014000800288865000900296002001300305
035001000318801001600328#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#419#73#article#122#73#National Kidney Foundation#K/DOQI clinical practice guid
elines and clinical practice recommendations for anemia in chronic kidney diseas
e: 2007 update of hemoglobin target^len#Am J Kidney Dis#20070000#2007#50#474-530
#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00737000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100015000980100
01800113010001600131010001900147012015300166030002400319065000900343064000500352
031000300357014000700360865000900367002001300376035001000389801002400399#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#420#74#article#122#74#^rND^sLo
catelli^nF#^rND^sCovic^nA#^rND^sEckardt^nKU#^rND^sWiecek^nA#^rND^sVanholder^nR#A
naemia management in patients with chronic kidney disease: a position statement 
by the Anaemia Working Group of European Renal Best Practice (ERBP)^len#Nephrol 
Dial Transplant#20090000#2009#24#348-54#20110300#v33n1a13.htm#0931-0509#Nephrol 
Dial Transplant##
00680000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100017000940100
01700111810000600128012016800134030001100302065000900313064000500322031000300327
014000500330865000900335002001300344035001000357801001100367#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#421#75#article#122#75#^rND^sLevin^nA#^rND^
sBakris^nGL#^rND^sMolitch^nM#et al#Prevalence of abnormal serum vitamin D, PTH, 
calcium, and phosphorus in patients with chronic kidney disease: results of the 
study to evaluate early kidney disease^len#Kidney Int#20070000#2007#71#31-8#2011
0300#v33n1a13.htm#0085-2538#Kidney int##
00591000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100014000790100018000930120
09700111030002400208065000900232064000500241031000300246014000800249865000900257
002001300266035001000279801002400289#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#422#76#article#122#76#^rND^sHsu^nCY#^rND^sChertow^nGM#Elevations o
f serum phosphorus and potassium in mild to moderate chronic renal insufficiency
^len#Nephrol Dial Transplant#20020000#2002#17#1419-25#20110300#v33n1a13.htm#0931
-0509#Nephrol Dial Transplant##
00591000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100017000950100
01800112810000600130012006500136030001600201065000900217064000500226031000300231
014000700234865000900241002001300250035001000263801001600273#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#423#77#article#122#77#^rND^sAtsumi^nK#^rND
^sKushida^nK#^rND^sYamazaki^nK#et al#Risk factors for vertebral fractures in ren
al osteodystrophy^len#Am J Kidney Dis#19990000#1999#33#287-93#20110300#v33n1a13.
htm#0272-6386#Am J Kidney Dis##
00600000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100014000960100
01700110810000600127012007700133030001600210065000900226064000500235031000400240
014000600244865000900250002001300259035001000272801001600282#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#424#78#article#122#78#^rND^sEnsrud^nKE#^rN
D^sLui L-Y#^rND^sTaylor^nBC#et al#Renal function and risk of hip and vertebral f
ractures among older women^len#Arch Intern Med#20070000#2007#167#133-9#20110300#
v33n1a13.htm#0003-9926#Arch Intern Med##
00670000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100016000960100
01600112810000600128012014400134030001700278065000900295064000500304031000300309
014000700312865000900319002001300328035001000341801001700351#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#425#79#article#122#79#^rND^sGanesh^nSK#^rN
D^sStack^nAG#^rND^sLevin^nNW#et al#Association of elevated serum PO(4), Ca PO(4)
 product, and parathyroid hormone with cardiac mortality risk in chronic hemodia
lysis patients^len#J Am Soc Nephrol#20010000#2001#12#2131-8#20110300#v33n1a13.ht
m#1046-6673#J Am Soc Nephrol##
00581000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100020000790100018000990100
01700117810000600134012008800140030001600228710000200244065000900246064000500255
031000300260014000600263865000900269002001300278#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#426#80#article#122#80#^rND^sKestenbaum^nB#^rND^sSampso
n^nJN#^rND^sRudser^nKD#et al#Serum phosphorus levels and mortality risk among pe
ople with chronic kidney disease^len#JAm Soc Nephrol#2#20050000#2005#16#520-8#20
110300#v33n1a13.htm##
00659000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100015000960100
01700111010001300128010001600141012010600157030001200263065000900275064000500284
031000400289014000800293865000900301002001300310035001000323801001200333#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#427#81#article#122#81#^rND^sTo
nelli^nM#^rND^sSacks^nF#^rND^sPfeffer^nM#^rND^sGao^nZ#^rND^sCurhan^nG#Relation b
etween serum phosphorus level and cardiovascular event rate in people with coron
ary disease^len#Circulation#20050000#2005#112#2627-33#20110300#v33n1a13.htm#0009
-7322#Circulation##
00594000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100019000960100
01900115810000600134012006500140030001500205065000900220064000500229031000400234
014000700238865000900245002001300254035001000267801001500277#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#428#82#article#122#82#^rND^sPalmer^nSC#^rN
D^sMcGregor^nDO#^rND^sMacaskill^nP#et al#Meta-analysis: vitamin D compounds in c
hronic kidney disease^len#Ann Intern Med#20070000#2007#147#840-53#20110300#v33n1
a13.htm#0003-4819#Ann Intern Med##
00558000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760110027000790120098001060300
01600204065000900220064000500229031000300234014000700237865000900244002001300253
035001000266801001600276#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#429#83#article#122#83#National Kidney Foundation#K/DOQI clinical practice guid
elines for bone metabolism and disease in chronic kidney disease^len#Am J Kidney
 Dis#20030000#2003#42#S1-201#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00558000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100015000950120
08200110030001600192065000900208064000500217031000300222014000700225865000900232
002001300241035001000254801001600264#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#430#84#article#122#84#^rND^sKraut^nJA#^rND^sKurtz^nI#Metabolic Aci
dosis of CKD: diagnosis, clinical characteristics, and treatment^len#Am J Kidney
 Dis#20050000#2005#45#978-93#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00641000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100026000790100019001050100
01800124010001700142012008900159030001700248065000900265064000500274031000300279
014000800282865000900290002001300299035001000312801001700322#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#431#85#article#122#85#^rND^sde Brito-Ashur
st^nI#^rND^sVaragunam^nM#^rND^sRaftery^nMJ#^rND^sYaqoob^nMM#Bicarbonate suppleme
ntation slows progression of CKD and improves nutritional status^len#J Am Soc Ne
phrol#20090000#2009#20#2075-84#20110300#v33n1a13.htm#1046-6673#J Am Soc Nephrol#
#
00661000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100016000980100
01600114810000600130012014500136030001100281065000900292064000500301031000300306
014000700309865000900316002001300325035001000338801001100348#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#432#86#article#122#86#^rND^sPhisitkul^nS#^
rND^sKhanna^nA#^rND^sSimoni^nJ#et al#Amelioration of metabolic acidosis in patie
nts with low GFR reduced kidney endothelin production and kidney injury, and bet
ter preserved GFR^len#Kidney Int#20100000#2010#77#617-23#20110300#v33n1a13.htm#0
085-2538#Kidney int##
00645000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100015000980100
01800113810000600131012011900137030001500256065000900271064000500280031000400285
014000700289865000900296002001300305035001000318801001500328#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#433#87#article#122#87#^rND^sPeterson^nJC#^
rND^sAdler^nS#^rND^sBurkart^nJM#et al#Blood pressure, proteinuria, and the progr
ession of renal disease: The Modification of Diet in Renal Disease Study^len#Ann
 Intern Med#19950000#1995#123#754-65#20110300#v33n1a13.htm#0003-4819#Ann Intern 
Med##
00511000000000217000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760170045000790180089001240370
03000213110000900243109001900252865000900271002001300280#v33n1#V:\SciELO\serial\
jbn\v33n1\markup\v33n1a13.htm#S#c#434#88#article#122#88#Caring for Australians w
ith Renal Impairment#Part 2. Early Kidney Disease Guidelines: Prevention of prog
ression of kidney disease^len#http://www.kidney.org.au/cari#20070529#29 de maio 
de 2007#20110300#v33n1a13.htm##
00558000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100015000950120
08200110030001600192065000900208064000500217031000300222014000700225865000900232
002001300241035001000254801001600264#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#435#89#article#122#89#^rND^sKraut^nJA#^rND^sKurtz^nI#Metabolic Aci
dosis of CKD: diagnosis, clinical characteristics, and treatment^len#Am J Kidney
 Dis#20050000#2005#45#978-93#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00543000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760160016000790160021000950180
12800116066000700244062001400251065000900265064000500274865000900279002001300288
#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#436#90#article#122#90#
^rND^sHruska^nK#^rND^sSlatopolsky^nE#Disorders of phosphorus, calcium, and magne
sium metabolism, in Schrier R, Gottschalk C (eds): diseases of the kidney, vol 3
^len#London#Little, Brown#19960000#1996#20110300#v33n1a13.htm##
00628000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100014000790100015000930100
01700108810000600125012010300131030001700234065000900251064000500260031000300265
014000900268865000900277002001300286035001000299801001700309#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#437#91#article#122#91#^rND^sZoja^nC#^rND^s
Corna^nD#^rND^sCamozzi^nD#et al#How to fully protect the kidney in a severe mode
l of progressive nephropathy: a multidrug approach^len#J Am Soc Nephrol#20020000
#2002#13#2898-908#20110300#v33n1a13.htm#1046-6673#J Am Soc Nephrol##
00721000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100017000790100014000960100
01600110810000600126012019600132030001700328065000900345064000500354031000300359
014000800362865000900370002001300379035001000392801001700402#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#438#92#article#122#92#^rND^sTonelli^nM#^rN
D^sMoye^nL#^rND^sSacks^nFM#et al#The Cholesterol and Recurrent Events (CARE) Tri
al Investigators: Effect of pravastatin on loss of renal function in people with
 moderate chronic renal insufficiency and cardiovascular disease^len#J Am Soc Ne
phrol#20030000#2003#14#1605-13#20110300#v33n1a13.htm#1046-6673#J Am Soc Nephrol#
#
00694000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100018000790100020000970100
01700117810000600134012019500140030002200335710000200357065000900359064000500368
031000200373014000700375865000900382002001300391#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#439#93#article#122#93#^rND^sShepherd^nJ#^rND^sKastelei
n^nJJ#^rND^sBittner^nV#et al#Treating to new targets investigators: Effect of in
tensive lipid lowering with atorvastatin on renal function in patients with coro
nary heart disease: the treating to new targets (TNT) study^len#Clin J Am Soc Ne
phrol#2#20070000#2007#2#1131-9#20110300#v33n1a13.htm##
00718000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100019000790100019000980110
03900117012016700156030002400323065000900347064000500356031000300361014000800364
865000900372002001300381035001000394801002400404#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#440#94#article#122#94#^rND^sAtthobari^nJ#^rND^sBrantsm
a^nAH#Gansevoort RT et alPREVEND study group#The effect of statins on urinary al
bumin excretion and glomerular filtration rate: results from both a randomized c
linical trial and an observational cohort study^len#Nephrol Dial Transplant#2006
0000#2006#21#3106-14#20110300#v33n1a13.htm#0931-0509#Nephrol Dial Transplant##
00676000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100020000950100
01400115810000600129012016100135030001100296065000900307064000500316031000300321
014000700324865000900331002001300340035001000353801001100363#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#441#95#article#122#95#^rND^sBakris^nG#^rND
^sVassalotti^nJ#^rND^sRitz^nE#et al#National Kidney Foundation consensus confere
nce on cardiovascular and kidney diseases and diabetes risk: an integrated thera
peutic approach to reduce events^len#Kidney Int#20100000#2010#78#726-36#20110300
#v33n1a13.htm#0085-2538#Kidney int##
00526000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100015000790100014000940100
01800108012003100126030001100157065000900168064000500177031000300182014000800185
865000900193002001300202035001000215801001100225#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#442#96#article#122#96#^rND^sOrth^nSR#^rND^sRitz^nE#^rN
D^sSchrier^nRW#The renal risks of smoking^len#Kidney Int#19970000#1997#51#1669-7
7#20110300#v33n1a13.htm#0085-2538#Kidney int##
00606000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100014000790100019000930100
01700112810000600129012009100135030001100226065000900237064000500246031000300251
014000700254865000900261002001300270035001000283801001100293#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#443#97#article#122#97#^rND^sOrth^nS#^rND^s
Stockmann^nA#^rND^sConradt^nC#et al#Smoking as a risk factor for end-stage renal
 failure in men with primary renal disease^len#Kidney Int#19980000#1998#54#926-3
1#20110300#v33n1a13.htm#0085-2538#Kidney int##
00664000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100016000790100019000950100
01500114010001600129010001500145012011200160030001100272065000900283064000500292
031000300297014000700300865000900307002001300316035001000329801001100339#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#444#98#article#122#98#^rND^sBl
eyer^nA#^rND^sShemanski^nL#^rND^sBurke^nG#^rND^sHansen^nK#^rND^sAppel^nR#Tobacco
, hypertension, and vascular disease: risk factors for renal function decline in
 an older population^len#Kidney Int#20000000#2000#57#2072-9#20110300#v33n1a13.ht
m#0085-2538#Kidney int##
00554000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080004000721180003000760100014000790100015000930100
01500108012007400123030001400197710000200211065000900213064000500222031000300227
032000400230014000800234865000900242002001300251#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#445#99#article#122#99#^rND^sRitz^nE#^rND^sOgata^nH#^rN
D^sOrth^nSR#Smoking a factor promoting onset and progression diabetic nephropath
y^len#Diabets Metab#2#20000000#2000#26#^s4#S54-S63#20110300#v33n1a13.htm##
00633000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100019000810100015001000100
01800115010001900133012009100152030001600243065000900259064000500268031000300273
014000700276865000900283002001300292035001000305801001600315#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#446#100#article#122#100#^rND^sGoldstein^nM
#^rND^sYassa^nT#^rND^sDacouris^nN#^rND^sMcFarlane^nP#Multidisciplinary predialys
is care and morbidity and mortality of patients on dialysis^len#Am J Kidney Dis#
20040000#2004#44#706-14#20110300#v33n1a13.htm#0272-6386#Am J Kidney Dis##
00504000000000289000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100017000810100016000980100
01800114810000600132012001700138030001100155710000200166065000900168064000500177
031000300182014000700185865000900192002001300201#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#447#101#article#122#101#^rND^sCurtis^nBM#^rND^sRavani^
nP#^rND^sMalberti^nF#et al#Nephrol Dial^len#Transplant#2#20050000#2005#20#147-54
#20110300#v33n1a13.htm##
00552000000000265000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100021000810120081001020300
02400183065000900207064000500216031000300221014000600224865000900230002001300239
035001000252801002400262#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#
c#448#102#article#122#102#^rND^sMendelssohn^nD#Coping with the CKD epidemic: the
 promise of muldisciplinary team-based care^len#Nephrol Dial Transplant#20050000
#2005#20#10-12#20110300#v33n1a13.htm#0931-0509#Nephrol Dial Transplant##
00419000000000181000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770180106000810370028001878650
00900215002001300224#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#44
9#103#article#122#103#Early Identification and Management of Chronic Kidney Dise
ase in Adults in Primary and Secondary Care^len#http://www.nice.org.uk/cg73#2011
0300#v33n1a13.htm##
00570000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100015000810100020000960100
01800116810000600134012006000140030000500200065000900205064000500214031000400219
014000800223865000900231002001300240035001000253801000500263#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#450#104#article#122#104#^rND^sLevin^nA#^rN
D^sHemmelgarn^nB#^rND^sCulleton^nB#et al#Guidelines for the management of chroni
c kidney disease^len#CMAJ#20080000#2008#179#1154-62#20110300#v33n1a13.htm#0820-3
946#CMAJ##
00602000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100019000810100019001000100
01600119810000600135012007700141030001400218065000900232064000500241031000300246
014000500249865000900254002001300263035001000276801001400286#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#451#105#article#122#105#^rND^sBatista^nLKC
#^rND^sPinheiro^nHS#^rND^sFuchs^nRC#et al#Manuseio da doença renal crônica em pa
cientes com hipertensão e diabetes^lpt#J Bras Nefrol#20050000#2005#27#8-14#20110
300#v33n1a13.htm#0101-2800#J Bras Nefrol##
00670000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100017000810100016000980100
02100114810000600135012012200141030002400263065000900287064000500296031000300301
014000800304865000900312002001300321035001000334801002400344#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#452#106#article#122#106#^rND^sJungers^nP#^
rND^sMassy^nZA#^rND^sNguyen-Khoa^nT#et al#Longer duration of predialysis nephrol
ogical care is associated with improved long-term survival of dialysis patients^
len#Nephrol Dial Transplant#20010000#2001#16#2357-64#20110300#v33n1a13.htm#0931-
0509#Nephrol Dial Transplant##
00568000000000277000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100022000810100015001030120
08700118030001500205065000900220064000500229031000300234014000600237865000900243
002001300252035001000265801001500275#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a13.htm#S#c#453#107#article#122#107#^rND^sTzamaloukas^nAH#^rND^sRaj^nDSC#Refer
ral of patients with chronic kidney disease to the nephrologist: why and when^le
n#Perit Dial Int#20080000#2008#28#343-6#20110300#v33n1a13.htm#0896-8608#Perit Di
al Int##
00625000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100016000810100015000970100
02100112810000600133012009400139030001700233065000900250064000500259031000300264
014000700267865000900274002001300283035001000296801001700306#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#454#108#article#122#108#^rND^sKausz^nAT#^r
ND^sKhan^nSS#^rND^sAbichandani^nR#et al#Management of patients with chronic rena
l insufficiency in the Northeastern United States^len#J Am Soc Nephrol#20010000#
2001#12#1501-7#20110300#v33n1a13.htm#1046-6673#J Am Soc Nephrol##
00486000000000253000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770120065000810300015001460650
00900161064000500170031000400175014000600179865000900185002001300194035001000207
801001500217#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#455#109#ar
ticle#122#109#NIH Consensus Statement: morbidity and mortality of dialysis^len#A
nn Intern Med#19940000#1994#121#62-70#20110300#v33n1a13.htm#0003-4819#Ann Intern
 Med##
00627000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100021000810100019001020100
01500121810000600136012010900142030000900251065000900260064000500269031000300274
014000700277865000900284002001300293035001000306801000900316#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#456#110#article#122#110#^rND^sMontgomery^n
EB#^rND^sLeiberman^nA#^rND^sSingh^nG#et al#Patient education and health promotio
n can be effective in Parkinson's disease: randomized control trial^len#Am J Med
#19940000#1994#97#429-35#20110300#v33n1a13.htm#0002-9343#Am J Med##
00716000000000313000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100025000810100021001060100
02400127010002000151010001600171012012900187030001500316065000900331064000500340
031000300345014000700348865000900355002001300364035001000377801001500387#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#457#111#article#122#111#^rND^s
Vliet Vlieland^nTP#^rND^sZwimderman^nAH#^rND^sVandenbroucke^nJP#^rND^sBreedveld^
nFC#^rND^sHazes^nJM#A randomised clinical trial of in-patient multidisciplinary 
treatment versus routine outpatient care in rheumatoid arthritis^len#Br J Rheuma
tol#19960000#1996#35#475-82#20110300#v33n1a13.htm#0263-7103#Br J Rheumatol##
00638000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100015000810100017000960100
02000113810000600133012011400139030001300253065000900266064000500275031000400280
014000700284865000900291002001300300035001000313801001300323#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#458#112#article#122#112#^rND^sRich^nMW#^rN
D^sBeckham^nV#^rND^sWittenberg^nC#et al#A multidisciplinary intervention to prev
ent the readmission of elderly patients with congestive heart failure^len#N Engl
 J Med#19950000#1995#333#1190-5#20110300#v33n1a13.htm#0028-4793#N Engl J Med##
00552000000000289000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100015000810100017000960100
02000113012005900133030000700192065000900199064000500208031000300213014000700216
865000900223002001300232035001000245801000700255#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#459#113#article#122#113#^rND^sGabel^nM#^rND^sHilton^nN
E#^rND^sNathanson^nSD#Multidisciplinary breast cancer clinics: Do they work?^len
#Cancer#19970000#1997#79#2380-4#20110300#v33n1a13.htm#0008-543X#Cancer##
00627000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100017000810100019000980100
02000117810000600137012009900143030001400242065000900256064000500265031000300270
014000600273865000900279002001300288035001000301801001400311#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#460#114#article#122#114#^rND^sNorris^nSL#^
rND^sNicholas^nPJ#^rND^sCaspersen^nCJ#et al#The effectiveness of disease and cas
e management for people with diabetes: A systematic review^len#Am J Prev Med#200
20000#2002#22#15-38#20110300#v33n1a13.htm#0749-3797#Am J Prev Med##
00661000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100015000810100015000960100
01800111810000600129012013600135030001600271065000900287064000500296031000300301
014000700304865000900311002001300320035001000333801001600343#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#461#115#article#122#115#^rND^sLevin^nA#^rN
D^sLewis^nM#^rND^sMortiboy^nP#et al#Multidisciplinary predialysis programs: quan
tification and limitations of their impact on patient outcomes in two Canadian s
ettings^len#Am J Kidney Dis#19970000#1997#29#533-40#20110300#v33n1a13.htm#0272-6
386#Am J Kidney Dis##
00541000000000289000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100015000810100017000960100
01600113810000600129012005200135030001700187710000200204065000900206064000500215
031000200220014000700222865000900229002001300238#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#462#116#article#122#116#^rND^sYeoh^nHH#^rND^sTiquia^nH
S#^rND^sAbcar^nAC#et al#Impact of predialysis care on clinical outcomes^len#Hemo
dialysis Int#2#20030000#2003#7#338-41#20110300#v33n1a13.htm##
00639000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100021000810100016001020100
01500118810000600133012010900139030001700248065000900265064000500274031000300279
014000600282865000900288002001300297035001000310801001700320#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#463#117#article#122#117#^rND^sHemmelgarn^n
BR#^rND^sManns^nBJ#^rND^sZhang^nJ#et al#Association between Multidisciplinary Ca
re and Survival for Elderly Patients with Chronic Kidney Disease^len#J Am Soc Ne
phrol#20070000#2007#18#993-9#20110300#v33n1a13.htm#1046-6673#J Am Soc Nephrol##
00634000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100015000810100020000960100
01500116010001800131010001700149012009700166030002200263710000200285065000900287
064000500296031000200301014000700303865000900310002001300319#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#464#118#article#122#118#^rND^sMenon^nS#^rN
D^sValentini^nRP#^rND^sKapur^nG#^rND^sLayfield^nS#^rND^sMattoo^nTK#Effectiveness
 of a multidisciplinary clinic in managing children with chronic kidney disease^
len#Clin J Am Soc Nephrol#2#20090000#2009#4#1170-5#20110300#v33n1a13.htm##
00661000000000301000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100015000810100015000960100
01800111810000600129012013600135030001600271065000900287064000500296031000300301
014000700304865000900311002001300320035001000333801001600343#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a13.htm#S#c#465#119#article#122#119#^rND^sLevin^nA#^rN
D^sLewis^nM#^rND^sMortiboy^nP#et al#Multidisciplinary Predialysis Programs: quan
tification and limitations of their impact on patient outcomes in two Canadian s
ettings^len#Am J Kidney Dis#19970000#1997#29#533-40#20110300#v33n1a13.htm#0272-6
386#Am J Kidney Dis##
00599000000000289000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100016000810100015000970100
01500112010001800127012009300145030001900238710000200257065000900259064000500268
031000400273014001000277865000900287002001300296#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a13.htm#S#c#466#120#article#122#120#^rND^sFenton^nA#^rND^sSayar^nZ
#^rND^sDodds^nA#^rND^sDasgupta^nI#Multidisciplinary care improves outcome of pat
ients with stage 5: Chronic kidney disease^len#Nephron Clin Pract#2#20100000#201
0#115#c283-c288#20110300#v33n1a13.htm##
00657000000000313000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100014000810100016000950100
01400111010001500125810000600140012011900146030001100265065000900276064000500285
031000300290014000700293865000900300002001300309035001000322801001100332#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#467#121#article#122#121#^rND^s
Wei S-Y#^rND^sChang Y-Y#^rND^sMau L-W#^rND^sLin^nM-Y#et al#Chronic kidney diseas
e care program improves quality of pre-end-stage renal disease care and reduces 
medical costs^len#Nephrology#20100000#2010#15#108-15#20110300#v33n1a13.htm#1320-
5358#NEPHROLOGY##
00649000000000313000450000400060000070200470000670500020005370600020005570000040
00577010004000617090008000657080004000731180004000770100017000810100015000980100
01500113010002000128010001800148012009400166030000900260065000900269064000500278
031000400283014000700287865000900294002001300303035001000316801000900326#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a13.htm#S#c#468#122#article#122#122#^rND^s
Harris^nLE#^rND^sLuft^nFC#^rND^sRudy^nDW#^rND^sKesterson^nJG#^rND^sTierney^nWM#E
ffects of multidisciplinary case management in patients with chronic renal insuf
ficiency^len#Am J Med#19980000#1998#105#464-71#20110300#v33n1a13.htm#0002-9343#A
m J Med##
00273000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00300100#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#o#1#1#article#1#
20110411#093046#v33n1a14.htm#90##
04171000000000601000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089121000300094049000700097158000300104030001700107
03100030012403200020012706500090012901400110013803500100014901200670015901200580
02260100038002840100049003220100032003710100047004030700035004500700061004850831
46000546085001002006085003302016085003002049085002402079083130702103085001003410
08500330342008500290345308500240348211700080350607200020351411200090351611100110
3525114000903536113001103545002001303556#v33n1#V:\SciELO\serial\jbn\v33n1\markup
\v33n1a14.htm#S#h#2#1#article#1#cr#pt#br1.1#1#4.0#ILUS#14#JBN120#nd#J. Bras. Nef
rol.#33#1#20110300#^f109^l112#0101-2800#Nefroma mesoblástico congênito subtipo c
elular: relato de caso^lpt#Cellular congenital mesoblastic nephroma: case report
^len#^rND^1A01 A02^nLina Gomes dos^sSantos#^rND^1A01^nJuliana de Sousa Ribeiro d
e^sCarvalho#^rND^1A01^nMarcela Aguiar^sReis#^rND^1A01^nRayli Lauro Jennyfer Bran
dão^sSales#Universidade Federal do Piauí^iA01#Hospital São Marcos^iA02^1Laborató
rio de Anatomia Patológica#^lpt^aINTRODUÇÃO: Nefroma Mesoblástico Con-gênito é u
ma rara neoplasia renal pediátrica. Apresenta dois subtipos histológicos, clássi
co e celular, sendo o último de pior prognóstico e responsável por aproximadamen
te dois terços dos casos. Esse tumor ainda é um desafio diagnóstico aos patologi
stas devido à similaridade com outras neoplasias pediátricas renais mais frequen
tes. RELATO DO CASO: Criança do gênero feminino, 2 anos e 9 meses de idade, foi 
encaminhada a serviço médico com referência em oncologia apresentando massa rena
l à esquerda. Após nefrectomia, o estudo do espécime mostrou, macroscopicamente,
 extensa área tumoral granular, brancoacinzentada, ocupando aproximadamente todo
 o rim, invadindo seio renal, cápsula e gordura perirrenal, com áreas de hemorra
gia e necrose. Histologicamente, caracterizava-se pela presença de células fusif
ormes e mitoses, sem atipias celulares. O diagnóstico foi de Nefroma Mesoblástic
o Congênito subtipo celular e a paciente foi submetida a quimioterapia. Durante 
o primeiro ano de tratamento, houve recidiva do tumor, apresentando-se irressecá
vel e sem resposta a nova quimioterapia. A paciente foi a óbito aos 4 anos de id
ade. DISCUSSÃO: O subtipo celular do nefroma mesoblástico tende a ser mais agres
sivo, apresentando uma taxa de sobrevivência de 85%, comparada com 100% para a v
ariante clássica. Geralmente, a recorrência ocorre no primeiro ano de tratamento
, principalmente quando o subtipo é o celular.#^ddecs^i1#^tm^lpt^knefroma mesobl
ástico^i1#^tm^lpt^kneoplasias renais^i1#^tm^lpt^knefrectomia^i1#^len^aINTRODUCTI
ON: Congenital Mesoblastic Nephroma (CMN) is a rare pediatric renal tumor. It co
mprises two histological subtypes, namely classic and cellular, with the second 
accounting for two thirds of all cases and being more often associated with poor
 prognosis. It remains a diagnostic challenge for pathologists due to its simila
rity with other more frequent pediatric kidney neoplasms. CASE REPORT: We descri
be the case of a 2-year- old girl who presented with a left renal mass. After ne
phrectomy, the specimen analysis showed, on gross examination, an extensive, gra
nular and whitish tumor lesion occupying almost the entire kidney, invading the 
renal sinus, capsule and perirenal fat, with areas of hemorrhage and necrosis. H
istologically, it was characterized by ovoid spindle cells, mitoses and no cell 
atypia, which led to a diagnosis of cellular mesoblastic nephroma. Adjuvant chem
otherapy was carried out, but tumor recurrence occurred in the first year, prese
nting as an unresectable tumor that did not respond to adjuvant chemotherapy and
 the patient died at 4 years of age. DISCUSSION: The cellular variant tends to b
e more aggressive, with a survival rate of 85% versus 100% for the classic varia
nt. Recurrence generally occurs in the first year, particularly with the cellula
r variant.#^ddecs^i2#^tm^len^kmesoblastic nephroma^i2#^tm^len^kkidney neoplasms^
i2#^tm^len^knephrectomy^i2#vancouv#9#20100719#07/19/2010#20101223#12/23/2010#v33
n1a14.htm##
04248000000000601000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089121000300094049000700097158000300104030001700107
03100030012403200020012706500090012901400110013803500100014901200810015901200720
02400100038003120100049003500100032003990100047004310700035004780700061005130831
48100574085001002055085003302065085003002098085002402128083133502152085001003487
08500330349708500290353008500240355911700080358307200020359111200090359311100110
3602114000903613113001103622002001303633#v33n1#V:\SciELO\serial\jbn\v33n1\markup
\v33n1a14.htm#S#f#3#1#article#1#cr#pt#br1.1#1#4.0#ILUS#14#JBN120#nd#J. Bras. Nef
rol.#33#1#20110300#^f109^l112#0101-2800#<b>Nefroma mesoblástico congênito subtip
o celular</b>: <b>relato de caso</b>^lpt#<b>Cellular congenital mesoblastic neph
roma</b>: <b>case report</b>^len#^rND^1A01 A02^nLina Gomes dos^sSantos#^rND^1A01
^nJuliana de Sousa Ribeiro de^sCarvalho#^rND^1A01^nMarcela Aguiar^sReis#^rND^1A0
1^nRayli Lauro Jennyfer Brandão^sSales#Universidade Federal do Piauí^iA01#Hospit
al São Marcos^iA02^1Laboratório de Anatomia Patológica#^lpt^a<b>INTRODUÇÃO:</b> 
Nefroma Mesoblástico Con-gênito é uma rara neoplasia renal pediátrica. Apresenta
 dois subtipos histológicos, clássico e celular, sendo o último de pior prognóst
ico e responsável por aproximadamente dois terços dos casos. Esse tumor ainda é 
um desafio diagnóstico aos patologistas devido à similaridade com outras neoplas
ias pediátricas renais mais frequentes. <b>RELATO DO CASO:</b> Criança do gênero
 feminino, 2 anos e 9 meses de idade, foi encaminhada a serviço médico com refer
ência em oncologia apresentando massa renal à esquerda. Após nefrectomia, o estu
do do espécime mostrou, macroscopicamente, extensa área tumoral granular, branco
acinzentada, ocupando aproximadamente todo o rim, invadindo seio renal, cápsula 
e gordura perirrenal, com áreas de hemorragia e necrose. Histologicamente, carac
terizava-se pela presença de células fusiformes e mitoses, sem atipias celulares
. O diagnóstico foi de Nefroma Mesoblástico Congênito subtipo celular e a pacien
te foi submetida a quimioterapia. Durante o primeiro ano de tratamento, houve re
cidiva do tumor, apresentando-se irressecável e sem resposta a nova quimioterapi
a. A paciente foi a óbito aos 4 anos de idade. <b>DISCUSSÃO:</b> O subtipo celul
ar do nefroma mesoblástico tende a ser mais agressivo, apresentando uma taxa de 
sobrevivência de 85%, comparada com 100% para a variante clássica. Geralmente, a
 recorrência ocorre no primeiro ano de tratamento, principalmente quando o subti
po é o celular.#^ddecs^i1#^tm^lpt^knefroma mesoblástico^i1#^tm^lpt^kneoplasias r
enais^i1#^tm^lpt^knefrectomia^i1#^len^a<b>INTRODUCTION:</b> Congenital Mesoblast
ic Nephroma (CMN) is a rare pediatric renal tumor. It comprises two histological
 subtypes, namely classic and cellular, with the second accounting for two third
s of all cases and being more often associated with poor prognosis. It remains a
 diagnostic challenge for pathologists due to its similarity with other more fre
quent pediatric kidney neoplasms. <b>CASE REPORT:</b> We describe the case of a 
2-year- old girl who presented with a left renal mass. After nephrectomy, the sp
ecimen analysis showed, on gross examination, an extensive, granular and whitish
 tumor lesion occupying almost the entire kidney, invading the renal sinus, caps
ule and perirenal fat, with areas of hemorrhage and necrosis. Histologically, it
 was characterized by ovoid spindle cells, mitoses and no cell atypia, which led
 to a diagnosis of cellular mesoblastic nephroma. Adjuvant chemotherapy was carr
ied out, but tumor recurrence occurred in the first year, presenting as an unres
ectable tumor that did not respond to adjuvant chemotherapy and the patient died
 at 4 years of age. <b>DISCUSSION:</b> The cellular variant tends to be more agg
ressive, with a survival rate of 85% <i>versus</i> 100% for the classic variant.
 Recurrence generally occurs in the first year, particularly with the cellular v
ariant.#^ddecs^i2#^tm^len^kmesoblastic nephroma^i2#^tm^len^kkidney neoplasms^i2#
^tm^len^knephrectomy^i2#vancouv#9#20100719#07/19/2010#20101223#12/23/2010#v33n1a
14.htm##
04337000000000625000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107121000300112049000700115158000300122
03000160012503100030014103200020014406500090014601400110015503500100016601200670
01760120058002430100038003010100049003390100032003880100047004200700037004670700
06300504083147800567085001002045085003302055085003002088085002402118083132102142
08500100346308500330347308500290350608500240353511700080355907200020356711200090
3569111001103578114000903589113001103598002001303609008008903622#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#l#4#1#article#1#^mjan./mar.^a2011#cr#pt#
br1.1#1#4.0#ilus#14#JBN120#nd#J. Bras. Nefrol#33#1#20110300#^f109^l112#0101-2800
#Nefroma mesoblástico congênito subtipo celular: relato de caso^lpt#Cellular con
genital mesoblastic nephroma: case report^len#^rND^1A01 A02^nLina Gomes dos^sSan
tos#^rND^1A01^nJuliana de Sousa Ribeiro de^sCarvalho#^rND^1A01^nMarcela Aguiar^s
Reis#^rND^1A01^nRayli Lauro Jennyfer Brandão^sSales#^iA01^1Universidade Federal 
do Piauí#^iA02^1Hospital São Marcos^2Laboratório de Anatomia Patológica#^lpt^aIN
TRODUÇÃO: Nefroma Mesoblástico Con-gênito é uma rara neoplasia renal pediátrica.
 Apresenta dois subtipos histológicos, clássico e celular, sendo o último de pio
r prognóstico e responsável por aproximadamente dois terços dos casos. Esse tumo
r ainda é um desafio diagnóstico aos patologistas devido à similaridade com outr
as neoplasias pediátricas renais mais frequentes. RELATO DO CASO: Criança do gên
ero feminino, 2 anos e 9 meses de idade, foi encaminhada a serviço médico com re
ferência em oncologia apresentando massa renal à esquerda. Após nefrectomia, o e
studo do espécime mostrou, macroscopicamente, extensa área tumoral granular, bra
ncoacinzentada, ocupando aproximadamente todo o rim, invadindo seio renal, cápsu
la e gordura perirrenal, com áreas de hemorragia e necrose. Histologicamente, ca
racterizava-se pela presença de células fusiformes e mitoses, sem atipias celula
res. O diagnóstico foi de Nefroma Mesoblástico Congênito subtipo celular e a pac
iente foi submetida a quimioterapia. Durante o primeiro ano de tratamento, houve
 recidiva do tumor, apresentando-se irressecável e sem resposta a nova quimioter
apia. A paciente foi a óbito aos 4 anos de idade. DISCUSSÃO: O subtipo celular d
o nefroma mesoblástico tende a ser mais agressivo, apresentando uma taxa de sobr
evivência de 85 por cento, comparada com 100 por cento para a variante clássica.
 Geralmente, a recorrência ocorre no primeiro ano de tratamento, principalmente 
quando o subtipo é o celular.#^ddecs^i1#^tm^lpt^knefroma mesoblástico^i1#^tm^lpt
^kneoplasias renais^i1#^tm^lpt^knefrectomia^i1#^len^aINTRODUCTION: Congenital Me
soblastic Nephroma (CMN) is a rare pediatric renal tumor. It comprises two histo
logical subtypes, namely classic and cellular, with the second accounting for tw
o thirds of all cases and being more often associated with poor prognosis. It re
mains a diagnostic challenge for pathologists due to its similarity with other m
ore frequent pediatric kidney neoplasms. CASE REPORT: We describe the case of a 
2-year- old girl who presented with a left renal mass. After nephrectomy, the sp
ecimen analysis showed, on gross examination, an extensive, granular and whitish
 tumor lesion occupying almost the entire kidney, invading the renal sinus, caps
ule and perirenal fat, with areas of hemorrhage and necrosis. Histologically, it
 was characterized by ovoid spindle cells, mitoses and no cell atypia, which led
 to a diagnosis of cellular mesoblastic nephroma. Adjuvant chemotherapy was carr
ied out, but tumor recurrence occurred in the first year, presenting as an unres
ectable tumor that did not respond to adjuvant chemotherapy and the patient died
 at 4 years of age. DISCUSSION: The cellular variant tends to be more aggressive
, with a survival rate of 85 percent versus 100 percent for the classic variant.
 Recurrence generally occurs in the first year, particularly with the cellular v
ariant.#^ddecs^i2#^tm^len^kmesoblastic nephroma^i2#^tm^len^kkidney neoplasms^i2#
^tm^len^knephrectomy^i2#vancouv#9#20100719#07/19/2010#20101223#12/23/2010#v33n1a
14.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28
002011000100014##
00362000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704013100072002001300203#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#5#1#article#77#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DE CASO </b> CAS
E REPORT</font></p>     ^cY#v33n1a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#6#2#article#77#<p>&nbsp;</p>     ^cY#v
33n1a14.htm##
00417000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#7#3#article#77#<p><a name="enda"></a><
font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Nefroma mesobl&aac
ute;stico cong&ecirc;nito subtipo celular:  relato de caso </b></font></p>     ^
cY#v33n1a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#8#4#article#77#<p>&nbsp;</p>     ^cY#v
33n1a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#9#5#article#77#<p>&nbsp;</p>     ^cY#v
33n1a14.htm##
00496000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704026400073002001300337#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#10#6#article#77#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>Lina Gomes dos Santos<sup>I</sup>; J
uliana de Sousa Ribeiro de Carvalho<sup>II</sup>; Marcela Aguiar Reis<sup>II</su
p>; Rayli Lauro Jennyfer Brand&atilde;o Sales<sup>II</sup></b></font></p>     ^c
Y#v33n1a14.htm##
00485000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704025300073002001300326#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#11#7#article#77#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Disciplina de Patologia par
a Medicina da Universidade Federal do Piau&iacute; - UFPI; Laborat&oacute;rio de
 Anatomia Patol&oacute;gica do Hospital S&atilde;o Marcos - HSM    ^cY#v33n1a14.
htm##
00276000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704004400073002001300117#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#12#8#article#77#<br>   <sup>II</sup>UF
PI</font></p>     ^cY#v33n1a14.htm##
00356000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704012400073002001300197#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#13#9#article#77#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia</
a></font></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#14#10#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704004400074002001300118#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#15#11#article#77#<p>&nbsp;</p> <hr siz
e="1" noshade>     ^cY#v33n1a14.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009600074002001300170#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#16#12#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n1
a14.htm##
00793000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704056000074002001300634#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#17#13#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O:</b> Nefro
ma Mesobl&aacute;stico Con-g&ecirc;nito &eacute; uma rara neoplasia renal pedi&a
acute;trica. Apresenta dois subtipos histol&oacute;gicos, cl&aacute;ssico e celu
lar, sendo o &uacute;ltimo de pior progn&oacute;stico e respons&aacute;vel por a
proximadamente dois ter&ccedil;os dos casos. Esse tumor ainda &eacute; um desafi
o diagn&oacute;stico aos patologistas devido &agrave; similaridade com outras ne
oplasias pedi&aacute;tricas renais mais frequentes.    ^cY#v33n1a14.htm##
01177000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704094400074002001301018#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#18#14#article#77#<br>   <b>RELATO DO C
ASO:</b> Crian&ccedil;a do g&ecirc;nero feminino, 2 anos e 9 meses de idade, foi
 encaminhada a servi&ccedil;o m&eacute;dico com refer&ecirc;ncia em oncologia ap
resentando massa renal &agrave; esquerda. Ap&oacute;s nefrectomia, o estudo do e
sp&eacute;cime mostrou, macroscopicamente, extensa &aacute;rea tumoral granular,
 brancoacinzentada, ocupando aproximadamente todo o rim, invadindo seio renal, c
&aacute;psula e gordura perirrenal, com &aacute;reas de hemorragia e necrose. Hi
stologicamente, caracterizava-se pela presen&ccedil;a de c&eacute;lulas fusiform
es e mitoses, sem atipias celulares. O diagn&oacute;stico foi de Nefroma Mesobl&
aacute;stico Cong&ecirc;nito subtipo celular e a paciente foi submetida a quimio
terapia. Durante o primeiro ano de tratamento, houve recidiva do tumor, apresent
ando-se irressec&aacute;vel e sem resposta a nova quimioterapia. A paciente foi 
a &oacute;bito aos 4 anos de idade.    ^cY#v33n1a14.htm##
00589000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704035600074002001300430#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#19#15#article#77#<br>   <b>DISCUSS&Ati
lde;O:</b> O subtipo celular do nefroma mesobl&aacute;stico tende a ser mais agr
essivo, apresentando uma taxa de sobreviv&ecirc;ncia de 85%, comparada com 100% 
para a variante cl&aacute;ssica. Geralmente, a recorr&ecirc;ncia ocorre no prime
iro ano de tratamento, principalmente quando o subtipo &eacute; o celular. </fon
t></p>     ^cY#v33n1a14.htm##
00422000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704018900074002001300263#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#20#16#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b>nefroma mesobl&
aacute;stico, neoplasias renais, nefrectomia. </font></p> <hr size="1" noshade> 
    ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#21#17#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#22#18#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00347000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704011400074002001300188#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#23#19#article#77#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font>
</p>     ^cY#v33n1a14.htm##
01161000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704092800074002001301002#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#24#20#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A maioria das neoplasias renais da inf
&acirc;ncia &eacute; representada pelo Tumor de Wilms (TW) e ocorre, predominant
emente, na faixa et&aacute;ria de 1 a 4 anos.<sup>1 </sup>Tal fato torna esse di
agn&oacute;stico o mais prov&aacute;vel quando uma massa abdominal &eacute; dete
ctada no rim de uma crian&ccedil;a, induzindo, muitas vezes, tratamento direcion
ado a TW, mesmo sem a confirma&ccedil;&atilde;o histopatol&oacute;gica.<sup>2</s
up> Neoplasias renais em crian&ccedil;as com menos de 6 meses de vida s&atilde;o
 menos comuns. Neste grupo, o Nefroma Mesobl&aacute;stico Cong&ecirc;nito (NMC) 
&eacute; o mais frequente,<sup>1</sup> sendo 90% diagnosticados dentro do primei
ro ano de vida e, virtualmente, nunca ocorrendo ap&oacute;s 3 anos de idade.<sup
>3</sup> Esse tumor geralmente confere progn&oacute;stico favor&aacute;vel.<sup>
4</sup></font></p>     ^cY#v33n1a14.htm##
00751000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704051800074002001300592#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#25#21#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O NMC representa, aproximadamente, 3-1
0% de todas as neoplasias renais pedi&aacute;tricas e apresenta dois subtipos hi
stol&oacute;gicos, cl&aacute;ssico e celular. O subtipo celular responde por 42-
63% de todos os casos,<sup>5</sup> apresenta maiores volumes tumorais, ocorre si
gnificantemente em pacientes mais velhos,<sup>6</sup> al&eacute;m de apresentar 
maior agressividade quando comparado ao subtipo cl&aacute;ssico. <sup>7</sup></f
ont></p>     ^cY#v33n1a14.htm##
00584000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704035100074002001300425#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#26#22#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">&Eacute; ainda um desafio diagn&oacute
;stico para os patologistas em virtude da sua similaridade com outras neoplasias
 renais pedi&aacute;tricas mais comuns. A falta de familiaridade com essa rara e
ntidade pode levar a um diagn&oacute;stico err&ocirc;neo. <sup>4</sup></font></p
>     ^cY#v33n1a14.htm##
00418000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704018500074002001300259#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#27#23#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Reportamos o caso de uma crian&ccedil;
a de 2 anos de idade com agressivo NMC e sua recorr&ecirc;ncia. </font></p>     
^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#28#24#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010400074002001300178#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#29#25#article#77#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DO CASO</b></font></p>     ^
cY#v33n1a14.htm##
00845000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704061200074002001300686#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#30#26#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Crian&ccedil;a do g&ecirc;nero feminin
o, 2 anos e 9 meses de idade, foi encaminhada a servi&ccedil;o m&eacute;dico com
 refer&ecirc;ncia em oncologia, em julho de 2007, apresentando massa abdominal. 
O pai relatava epis&oacute;dio isolado de hemat&uacute;ria h&aacute; 8 meses e, 
h&aacute; aproximadamente 20 dias, observou aumento do volume abdominal da crian
&ccedil;a e um epis&oacute;dio de v&ocirc;mito. Exame ultrassonogr&aacute;fico i
ndicava a presen&ccedil;a de massa em rim esquerdo. A paciente foi submetida a n
efrectomia.</font></p>     ^cY#v33n1a14.htm##
01305000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704107200074002001301146#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#31#27#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Ao exame da pe&ccedil;a, o rim media 1
1,5 x 8,0 x 7,0 cm e pesava 266 g. Havia comprometimento perirrenal, de seio ren
al e c&aacute;psula. &Agrave; superf&iacute;cie de corte, o rim era quase que to
talmente ocupado por les&atilde;o tumoral (7,0 x 7,0 x 6,0 cm) branco-acinzentad
a e granular com extensas &aacute;reas de necrose e hemorragia (<a href="#fig1">
Figura 1</a>). N&atilde;o havia invas&atilde;o de ureter. Histologicamente, o tu
mor caracterizava-se por c&eacute;lulas ov&oacute;ides ou fusiformes, de n&uacut
e;cleos mon&oacute;tonos, sem atipias, infiltrando o par&ecirc;nquima renal circ
undante, baixa atividade mit&oacute;tica e escassa deposi&ccedil;&atilde;o de co
l&aacute;geno (<a href="#fig2">Figura 2</a>). Foram ressecados 11 linfonodos, os
 quais n&atilde;o se encontravam comprometidos. O diagn&oacute;stico foi de Nefr
oma Mesobl&aacute;stico subtipo celular. Tomografia Computadorizada (TC) de t&oa
cute;rax e abdome foram solicitadas, as quais se apresentaram normais. </font></
p>     ^cY#v33n1a14.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003500074002001300109#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#32#28#article#77#<p><a name="fig1"></a
></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#33#29#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#34#30#article#77#<p align="center"><im
g src="/img/revistas/jbn/v33n1/a14fig01.jpg"></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#35#31#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003500074002001300109#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#36#32#article#77#<p><a name="fig2"></a
></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#37#33#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#38#34#article#77#<p align="center"><im
g src="/img/revistas/jbn/v33n1/a14fig02.jpg"></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#39#35#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
01095000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704086200074002001300936#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#40#36#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Iniciou-se quimioterapia adjuvante e a
 paciente foi submetida a exames seriados de imagem. Um m&ecirc;s ap&oacute;s o 
t&eacute;rmino da quimioterapia, em mar&ccedil;o de 2008, observaram-se em ultra
ssonografia abdominal imagens nodulares retroperitoneais compat&iacute;veis com 
linfoadenomegalias com at&eacute; 2,1 cm. Foram solicitadas, ent&atilde;o, TC de
 t&oacute;rax e abdome. A TC de t&oacute;rax sugeriu pneumonia, e a TC de abdome
 apresentou les&atilde;o s&oacute;lida de 10,6 x 9,6 cm nos maiores di&acirc;met
ros em loja renal esquerda, deslocando grandes vasos abdominais e recha&ccedil;a
ndo al&ccedil;as intestinais indissoci&aacute;veis da musculatura paravertebral 
ipsilateral. Solicitou-se, ent&atilde;o, avalia&ccedil;&atilde;o cir&uacute;rgic
a pedi&aacute;trica. </font></p>     ^cY#v33n1a14.htm##
00941000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704070800074002001300782#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#41#37#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Durante a cirurgia, observou-se que o 
tumor estava aderido &agrave;s al&ccedil;as intestinais e ao p&acirc;ncreas, sen
do irressec&aacute;vel. Foi realizada apenas bi&oacute;psia da massa, a qual evi
denciou Nefroma Mesobl&aacute;stico subtipo celular (recidiva). Estudo imunohist
oqu&iacute;mico realizado apresentou positividade para vimentina. Quimioterapia 
adjuvante foi realizada, entretanto, n&atilde;o houve redu&ccedil;&atilde;o da m
assa tumoral. A paciente evoluiu com desnutri&ccedil;&atilde;o severa, febre e n
eutropenia e, em outubro de 2008, a paciente foi a &oacute;bito 15 meses ap&oacu
te;s o diagn&oacute;stico. </font></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#42#38#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010600074002001300180#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#43#39#article#77#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>    
 ^cY#v33n1a14.htm##
01127000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704089400074002001300968#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#44#40#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O NMC geralmente se apresenta como mas
sa abdominal assintom&aacute;tica, algumas vezes acompanhada de hemat&uacute;ria
. Na maioria dos casos, o diagn&oacute;stico &eacute; feito ainda no per&iacute;
odo neonatal, j&aacute; que pode levar a polidr&acirc;mnio (71% das gesta&ccedil
;&otilde;es associadas ao tumor), hidropsia e parto prematuro, al&eacute;m de hi
pertens&atilde;o (como resultado do aumento dos n&iacute;veis de renina pela inf
iltra&ccedil;&atilde;o renal) e hipercalcemia (devido &agrave; secre&ccedil;&ati
lde;o pelo tumor de subst&acirc;ncia semelhante ao paratorm&ocirc;nio). <sup>1,3
,5</sup> Exame ultrassonogr&aacute;fico revela, em geral, massa s&oacute;lida en
volvendo seio renal, com &aacute;reas c&iacute;sticas e hemorr&aacute;gicas, e i
nfiltra&ccedil;&atilde;o do tecido local.<sup>5</sup></font></p>     ^cY#v33n1a1
4.htm##
01753000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704152000074002001301594#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#45#41#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O NMC &eacute; provavelmente originado
 da prolifera&ccedil;&atilde;o do mes&ecirc;nquima nefrog&ecirc;nico. <sup>5</su
p> A variante cl&aacute;ssica &eacute; similar ao leiomioma,<sup>1,5,6</sup> des
crito predominantemente como s&oacute;lido, firme, de colora&ccedil;&atilde;o am
arelada, sem c&aacute;psula, com margens pobremente definidas,<sup>5</sup> c&eac
ute;lulas fusiformes em feixes e raras mitoses. <sup>6</sup> &Aacute;reas c&iacu
te;sticas e necrose podem eventualmente ocorrer. Em contraste, a variante celula
r &eacute; reconhecida como subtipo distinto da cl&aacute;ssica, embora ambas po
ssam coexistir (subtipo misto). <sup>5</sup> A variante celular demonstra alta c
elularidade, mitose, necrose,<sup>1</sup> hemorragia,<sup>6</sup> e &eacute; com
posta por feixes s&oacute;lidos de c&eacute;lulas ov&oacute;ides ou fusiformes c
om citoplasma reduzido. <sup>3,5</sup> Esse tipo de tumor pode invadir estrutura
s adjacentes e tende a ser mais agressivo. <sup>7</sup> Ambas as variantes s&ati
lde;o imunorreativas a marcadores fibrobl&aacute;sticos (vimentina, actina de m&
uacute;sculo liso, desmina), e negativas para marcadores epiteliais,<sup>2</sup>
 embora o diagn&oacute;stico seja baseado apenas em crit&eacute;rios morfol&oacu
te;gicos. <sup>3</sup> No caso relatado, a imuno-histoqu&iacute;mica foi positiv
a apenas para vimentina, na aus&ecirc;ncia de imunorrea&ccedil;&atilde;o para de
smina e actina do m&uacute;sculo liso. </font></p>     ^cY#v33n1a14.htm##
01258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704102500074002001301099#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#46#42#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Estudos recentes revelaram que as vari
antes cl&aacute;ssica e celular apresentam diferen&ccedil;as gen&eacute;ticas. A
penas a variante celular mostra transloca&ccedil;&atilde;o (12; 15) (p13; q25) q
ue leva a uma fus&atilde;o g&ecirc;nica ETV6-NTRK3. H&aacute; achados vari&aacut
e;veis em subtipos mistos. <sup>5,6</sup> Transloca&ccedil;&atilde;o id&ecirc;nt
ica tamb&eacute;m tem sido reportada no fibrossarcoma infantil (FSI), sugerindo 
que o NMC subtipo celular representaria FSI intrarrenal<sup>3</sup> e que n&atil
de;o estaria relacionado ao TW ou ao carcinoma de c&eacute;lulas claras renais (
CCR), como inicialmente associado. <sup>8</sup> Entretanto, quando c&eacute;lula
s fusiformes predominam no rim de uma crian&ccedil;a, o diagn&oacute;stico difer
encial deve incluir TW, CCR tipo c&eacute;lulas claras (padr&atilde;o de c&eacut
e;lulas fusiformes) e NMC, al&eacute;m de outras entidades menos comuns em crian
&ccedil;as. <sup>2</sup></font></p>     ^cY#v33n1a14.htm##
03056000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704282300074002001302897#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#47#43#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O NMC deve ser tratado com nefrectomia
 radical para reduzir os riscos de recorr&ecirc;ncia local. Esse tratamento, soz
inho, &eacute; geralmente suficiente porque o tumor tem baixo potencial de malig
nidade. Apenas 5% dos pacientes apresentam recidivas, geralmente dentro do prime
iro ano, e a maioria destes apresenta subtipo celular. Portanto, durante o prime
iro ano ap&oacute;s nefrectomia, ultrassonografias seriadas devem ser realizadas
 para detectar sinais precoces de recorr&ecirc;ncia local. <sup>1,3,9</sup> A va
riante celular &eacute; associada a pior progn&oacute;stico, com taxa de sobrevi
v&ecirc;ncia de 85%, comparada com 100% para a variante cl&aacute;ssica. <sup>9<
/sup> Doen&ccedil;a metast&aacute;tica, principalmente para pulm&otilde;es, f&ia
cute;gado, c&eacute;rebro e cora&ccedil;&atilde;o, e extensa &aacute;rea de reco
rr&ecirc;ncia local s&atilde;o raras. <sup>6,7,9</sup> Fatores de risco para rec
orr&ecirc;ncia s&atilde;o margens cir&uacute;rgicas positivas, ruptura do tumor 
durante ressec&ccedil;&atilde;o,<sup>1</sup> subtipo celular e idade do paciente
. <sup>6</sup> Pacientes com mais de 3 meses de vida apresentando variante celul
ar, com margens cir&uacute;rgicas positivas, ruptura do tumor durante ressec&cce
dil;&atilde;o ou pacientes com microinvas&otilde;es vasculares s&atilde;o candid
atos a quimioterapia adjuvante. <sup>9</sup> Quimioterapia pode ser ainda realiz
ada em casos de recorr&ecirc;ncia local, doen&ccedil;a metast&aacute;tica ou pac
ientes com tumores inoper&aacute;veis, j&aacute; que alguns NMC&acute;s s&atilde
;o quimiossens&iacute;veis. <sup>8,9</sup> As combina&ccedil;&otilde;es de vincr
istina, ciclofosfamida e doxorrubicina (VCD);<sup>9</sup> vincristina, doxorrubi
cina e actinomicina D (VDA);<sup>8</sup> ifosfamida, carboplatina e etoposide (I
CE)<sup>9</sup> podem ser usadas com sucesso. Entretanto, a combina&ccedil;&atil
de;o ICE &eacute; nefrot&oacute;xica sendo, ent&atilde;o, reservada como terapia
 de segunda linha. <sup>8,9</sup> Na literatura &eacute; aparente, entretanto, q
ue nem todos esses tumores s&atilde;o sens&iacute;veis a quimioterapia, como obs
ervado no caso relatado, ou &agrave;s combina&ccedil;&otilde;es de quimioter&aac
ute;picos. Al&eacute;m disso, o pequeno n&uacute;mero de pacientes dispon&iacute
;veis para an&aacute;lise torna dif&iacute;cil a identifica&ccedil;&atilde;o de 
fatores cl&iacute;nicos ou biol&oacute;gicos que predizem a resposta quimioter&a
acute;pica. A terapia ideal para controlar recorr&ecirc;ncia ou doen&ccedil;a me
tast&aacute;tica ainda n&atilde;o est&aacute; clara, e como os pacientes, em ger
al, recebem terapia multimodal, dificulta discernir se quimioterapia ou radioter
apia, ou ambos, s&atilde;o ativas contra o tumor. <sup>8</sup></font></p>     ^c
Y#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#48#44#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010700074002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#49#45#article#77#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>   
  ^cY#v33n1a14.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704022000076002001300296#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#50#46#article#77#1#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Glick RD, Hicks MJ, N
uchtern JG, Wesson DE, Olutoye OO, Cass DL. Renal tumors in infants less than 6 
months of age. J Pediatr Surg 2004; 39:522-5.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#51#47#article#77# </font></p>     ^cY#
v33n1a14.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704026700076002001300343#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#52#48#article#77#2#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Portugal R, Barroca H
. Clear cell sarcoma, cellular mesoblastic nephroma and metanephric adenoma: cyt
ological features and differential diagnosis with Wilms tumour. Cytopathology 20
08; 19:80-5.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#53#49#article#77# </font></p>     ^cY#
v33n1a14.htm##
00462000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704021500076002001300291#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#54#50#article#77#3#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Sebire NJ, Vujanic GM
. Paediatric renal tumours: recent developments, new entities and pathological f
eatures. Histopathology 2009; 54:516-28.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#55#51#article#77# </font></p>     ^cY#
v33n1a14.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704022200076002001300298#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#56#52#article#77#4#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Bandyopadhyay R, Chat
terjee U, Mondal SK, Banerjee S, Chatterjee US. Unusual morphology in mesoblasti
c nephroma. Pediatric Surg Int 2009; 25:109-12.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#57#53#article#77# </font></p>     ^cY#
v33n1a14.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704022500076002001300301#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#58#54#article#77#5#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Ahmed HU, Arya M, Lev
itt G, Duffy PG, Mushtaq I, Sebire NJ. Part I: Primary malignant non-Wilms' rena
l tumours in children. Lancet Oncol 2007; 8:730-7.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#59#55#article#77# </font></p>     ^cY#
v33n1a14.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704026000076002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#60#56#article#77#6#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Furtwaengler R, Reinh
ard H, Leuschner I <i>et al</i>. Mesoblastic nephroma: a report from the Gesells
chaft fur P&auml;diatrische Onkologie und H&auml;matologie. Cancer 2006; 106:227
5-83.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#61#57#article#77# </font></p>     ^cY#
v33n1a14.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704026000076002001300336#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#62#58#article#77#7#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Ramachandran C, Melni
ck SJ, Escalon E <i>et al</i>. Cytogenetic and molecular characterization of a c
ongenital mesoblastic nephroma. Pediatric and Developmental Pathology 2001; 4:40
2-11.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#63#59#article#77# </font></p>     ^cY#
v33n1a14.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704023000076002001300306#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#64#60#article#77#8#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Loeb DM, Hill DA, Dom
e JS. Complete response of recurrent cellular congenital mesoblastic nephroma to
 chemotherapy. J Pediatr Hematol Oncol 2002; 24:478-81.    ^cY#v33n1a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#65#61#article#77# </font></p>     ^cY#
v33n1a14.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704024200076002001300318#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#66#62#article#77#9#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Ahmed HU, Arya M, Lev
itt G, Duffy PG, Mushtaq I, Sebire NJ. Part II: Treatment of primary malignant n
on-Wilms' renal tumours in children. Lancet Oncology 2007; 8:842-8.    ^cY#v33n1
a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#67#63#article#77# </font></p>     ^cY#
v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#68#64#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#69#65#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00433000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704020000074002001300274#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#70#66#article#77#<p><a name="endb"></a
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda"><im
g src="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;nci
a para:</b>    ^cY#v33n1a14.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003700074002001300111#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#71#67#article#77#<br>   Lina Gomes dos
 Santos     ^cY#v33n1a14.htm##
00296000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704006300074002001300137#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#72#68#article#77#<br>   Av. Marechal C
astelo  Branco, 414/1501. Ilhotas     ^cY#v33n1a14.htm##
00285000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704005200074002001300126#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#73#69#article#77#<br>   Teresina - PI 
- Brasil CEP: 64014-058    ^cY#v33n1a14.htm##
00275000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704004200074002001300116#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#74#70#article#77#<br>   Tel/fax: 55 (8
6) 2106-8043     ^cY#v33n1a14.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010100074002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#75#71#article#77#<br>   E-mail: <a hre
f="mailto:linagsantos@uol.com.br">linagsantos@uol.com.br</a></font></p>     ^cY#
v33n1a14.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010700074002001300181#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#76#72#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 07/19/2010  
  ^cY#v33n1a14.htm##
00291000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704005800074002001300132#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#77#73#article#77#<br>   Data de aprova
&ccedil;&atilde;o: 12/23/2010    ^cY#v33n1a14.htm##
00328000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009500074002001300169#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#78#74#article#77#<br>   Os autores dec
laram a inexist&ecirc;ncia de conflitos de interesse. </font></p>     ^cY#v33n1a
14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#79#75#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#80#76#article#77#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00458000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704022500074002001300299#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a14.htm#S#p#81#77#article#77#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado no Cen
tro de Ci&ecirc;ncias da Sa&uacute;de, Departamento de Patologia, Universidade F
ederal do Piau&iacute;. </font></p>     ^cY#v33n1a14.htm##
00640000000000325000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100016000740100016000900100
01900106010001700125010001800142010001500160012005400175030001500229065000900244
06400050025303100030025801400060026186500090026700200130027603500100028980100150
0299#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#c#82#1#article#9#1#^
rND^sGlick^nRD#^rND^sHicks^nMJ#^rND^sNuchtern^nJG#^rND^sWesson^nDE#^rND^sOlutoye
^nOO#^rND^sCass^nDL#Renal tumors in infants less than 6 months of age^len#J Pedi
atr Surg#20040000#2004#39#522-5#20110300#v33n1a14.htm#0022-3468#J Pediatr Surg##
00614000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100018000740100017000920120
14500109030001400254065000900268064000500277031000300282014000500285865000900290
002001300299035001000312801001400322#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a14.htm#S#c#83#2#article#9#2#^rND^sPortugal^nR#^rND^sBarroca^nH#Clear cell sar
coma, cellular mesoblastic nephroma and metanephric adenoma: cytological feature
s and differential diagnosis with Wilms tumour^len#Cytopathology#20080000#2008#1
9#80-5#20110300#v33n1a14.htm#0956-5507#Cytopathology##
00563000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100017000740100018000910120
09000109030001500199065000900214064000500223031000300228014000700231865000900238
002001300247035001000260801001500270#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a14.htm#S#c#84#3#article#9#3#^rND^sSebire^nNJ#^rND^sVujanic^nGM#Paediatric ren
al tumours: recent developments, new entities and pathological features^len#Hist
opathology#20090000#2009#54#516-28#20110300#v33n1a14.htm#0309-0167#Histopatholog
y##
00589000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100023000740100020000970100
01700117010001800134010002100152012004700173030001900220710000200239065000900241
064000500250031000300255014000700258865000900265002001300274#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a14.htm#S#c#85#4#article#9#4#^rND^sBandyopadhyay^nR#^r
ND^sChatterjee^nU#^rND^sMondal^nSK#^rND^sBanerjee^nS#^rND^sChatterjee^nUS#Unusua
l morphology in mesoblastic nephroma^len#Pediatric Surg Int#2#20090000#2009#25#1
09-12#20110300#v33n1a14.htm##
00610000000000313000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100016000740100014000900100
01600104010001600120010001700136010001700153012006700170030001300237710000200250
065000900252064000500261031000200266014000600268865000900274002001300283#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#c#86#5#article#9#5#^rND^sAhmed^n
HU#^rND^sArya^nM#^rND^sLevitt^nG#^rND^sDuffy^nPG#^rND^sMushtaq^nI#^rND^sSebire^n
NJ#Part I: Primary malignant non-Wilms' renal tumours in children^len#Lancet Onc
ol#2#20070000#2007#8#730-7#20110300#v33n1a14.htm##
00613000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100022000740100018000960100
01900114810000600133012010000139030000700239065000900246064000500255031000400260
014000800264865000900272002001300281035001000294801000700304#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a14.htm#S#c#87#6#article#9#6#^rND^sFurtwaengler^nR#^rN
D^sReinhard^nH#^rND^sLeuschner^nI#et al#Mesoblastic nephroma: a report from the 
Gesellschaft fur Pädiatrische Onkologie und Hämatologie^len#Cancer#20060000#2006
#106#2275-83#20110300#v33n1a14.htm#0008-543X#Cancer##
00654000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100022000740100018000960100
01700114810000600131012008400137030003800221065000900259064000500268031000200273
014000700275865000900282002001300291035001000304801003800314#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a14.htm#S#c#88#7#article#9#7#^rND^sRamachandran^nC#^rN
D^sMelnick^nSJ#^rND^sEscalon^nE#et al#Cytogenetic and molecular characterization
 of a congenital mesoblastic nephroma^len#Pediatric and Developmental Pathology#
20010000#2001#4#402-11#20110300#v33n1a14.htm#1093-5266#PEDIATRIC AND DEVELOPMENT
AL PATHOLOGY##
00605000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100015000740100015000890100
01500104012009200119030002400211065000900235064000500244031000300249014000700252
865000900259002001300268035001000281801002400291#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a14.htm#S#c#89#8#article#9#8#^rND^sLoeb^nDM#^rND^sHill^nDA#^rND^sD
ome^nJS#Complete response of recurrent cellular congenital mesoblastic nephroma 
to chemotherapy^len#J Pediatr Hematol Oncol#20020000#2002#24#478-81#20110300#v33
n1a14.htm#1077-4114#J Pediatr Hematol Oncol##
00627000000000313000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080002000701180002000720100016000740100014000900100
01600104010001600120010001700136010001700153012008100170030001600251710000200267
065000900269064000500278031000200283014000600285865000900291002001300300#v33n1#V
:\SciELO\serial\jbn\v33n1\markup\v33n1a14.htm#S#c#90#9#article#9#9#^rND^sAhmed^n
HU#^rND^sArya^nM#^rND^sLevitt^nG#^rND^sDuffy^nPG#^rND^sMushtaq^nI#^rND^sSebire^n
NJ#Part II: Treatment of primary malignant non-Wilms' renal tumours in children^
len#Lancet Oncology#2#20070000#2007#8#842-8#20110300#v33n1a14.htm##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#o#1#1#text#1#201
10411#093048#v33n1a15.htm#60##
00872000000000397000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001700102
03100030011903200020012206500090012401400110013303500100014412300020015401200860
0156012009600242010003700338070007600375117000800451072000200459002001300461#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#h#2#1#text#1#le#pt#br1.1#1#4
.0#ND#15#JBN150#nd#J. Bras. Nefrol.#33#1#20110300#^f113^l114#0101-2800#1#Avaliaç
ão e manejo da doença cardiovascular em pacientes com doença renal crônica^lpt#A
ssessment and management of cardiovascular disease in patients with chronic kidn
ey disease^len#^rND^1A01^nMarcelo de Sousa^sTavares#Universidade Federal de Mina
s Gerais^iA01^1Unidade de Nefrologia Pediátrica#vancouv#6#v33n1a15.htm##
00886000000000397000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001700102
03100030011903200020012206500090012401400110013303500100014412300020015401200930
0156012010300249010003700352070007600389117000800465072000200473002001300475#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#f#3#1#text#1#le#pt#br1.1#1#4
.0#ND#15#JBN150#nd#J. Bras. Nefrol.#33#1#20110300#^f113^l114#0101-2800#1#<b>Aval
iação e manejo da doença cardiovascular em pacientes com doença renal crônica</b
>^lpt#<b>Assessment and management of cardiovascular disease in patients with ch
ronic kidney disease</b>^len#^rND^1A01^nMarcelo de Sousa^sTavares#Universidade F
ederal de Minas Gerais^iA01^1Unidade de Nefrologia Pediátrica#vancouv#6#v33n1a15
.htm##
00989000000000409000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030001600117
03100030013303200020013606500090013801400110014703500100015812300020016801200860
01700120096002560100037003520700078003891170008004670720002004750020013004770080
08900490#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#l#4#1#text#1#^mj
an./mar.^a2011#le#pt#br1.1#1#4.0#15#JBN150#nd#J. Bras. Nefrol#33#1#20110300#^f11
3^l114#0101-2800#1#Avaliação e manejo da doença cardiovascular em pacientes com 
doença renal crônica^lpt#Assessment and management of cardiovascular disease in 
patients with chronic kidney disease^len#^rND^1A01^nMarcelo de Sousa^sTavares#^i
A01^1Universidade Federal de Minas Gerais^2Unidade de Nefrologia Pediátrica#vanc
ouv#6#v33n1a15.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&
pid=S0101-28002011000100015##
00346000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704011800069002001300187#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#5#1#text#50#<p align="right"><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CARTAS</b> LETTERS</font><
/p>     ^cY#v33n1a15.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#6#2#text#50#<p>&nbsp;</p>     ^cY#v33n
1a15.htm##
00452000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704022400069002001300293#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#7#3#text#50#<p><a name="enda"></a><fon
t size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Avalia&ccedil;&atilde
;o e manejo da doen&ccedil;a cardiovascular em pacientes com doen&ccedil;a renal
 cr&ocirc;nica</b></font></p>     ^cY#v33n1a15.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#8#4#text#50#<p>&nbsp;</p>     ^cY#v33n
1a15.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#9#5#text#50#<p>&nbsp;</p>     ^cY#v33n
1a15.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704011400070002001300184#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#10#6#text#50#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><b>Marcelo de Sousa Tavares</b></font></p>
     ^cY#v33n1a15.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704016200070002001300232#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#11#7#text#50#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Unidade de Nefrologia Pedi&aacute;trica da
 Universidade Federal de Minas Gerais</font></p>     ^cY#v33n1a15.htm##
00353000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704012400070002001300194#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#12#8#text#50#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia</a><
/font></p>     ^cY#v33n1a15.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#13#9#text#50#<p>&nbsp;</p>     ^cY#v33
n1a15.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#14#10#text#50#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v33n1a15.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009600071002001300167#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#15#11#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n1a15
.htm##
00576000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704034600071002001300417#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#16#12#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A presente carta ao Editor compara as dif
iculdades de avalia&ccedil;&atilde;o e manejo da doen&ccedil;a cardiovascular em
 crian&ccedil;as e adolescentes portadores de doen&ccedil;a renal cr&ocirc;nica 
com as mesmas dificuldades encontradas em  pacientes adultos. </font></p>     ^c
Y#v33n1a15.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704024600071002001300317#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#17#13#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> insufici&ecirc;nci
a renal cr&ocirc;nica, sa&uacute;de da crian&ccedil;a, mortalidade na inf&acirc;
ncia, aterosclerose.</font></p> <hr size="1" noshade>     ^cY#v33n1a15.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#18#14#text#50#<p>&nbsp;</p>     ^cY#v3
3n1a15.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#19#15#text#50#<p>&nbsp;</p>     ^cY#v3
3n1a15.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010500071002001300176#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#20#16#text#50#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>PREZADO EDITOR,</b></font></p>     ^cY
#v33n1a15.htm##
00882000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704065200071002001300723#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#21#17#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Li com grande interesse o artigo<i> Avali
a&ccedil;&atilde;o e manejo da doen&ccedil;a cardiovascular (DCV) em pacientes c
om doen&ccedil;a renal cr&ocirc;nica</i> (DRC) dos colegas Bucharles SGE, Varela
 AM, Barberato SH e P&eacute;coits-Filho R. O artigo mostrou, com grande proprie
dade, fatores de risco, m&eacute;todos de avalia&ccedil;&atilde;o e manejo cl&ia
cute;nico da doen&ccedil;a cardiovascular na doen&ccedil;a renal cr&ocirc;nica e
m adultos. Torna-se pertinente ressaltar algumas particularidades referentes &ag
rave; popula&ccedil;&atilde;o pedi&aacute;trica.</font></p>     ^cY#v33n1a15.htm
##
00762000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704053200071002001300603#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#22#18#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">&Eacute; fato que a doen&ccedil;a cardiov
ascular tamb&eacute;m &eacute; a segunda causa de mortalidade em crian&ccedil;as
 com doen&ccedil;a renal cr&ocirc;nica terminal. <sup>1,2</sup> Dados do <i>NAPR
TCS</i> indicam que a mortalidade de crian&ccedil;as que entram em terapia renal
 substitutiva (TRS) &eacute; inversamente proporcional &agrave; idade de in&iacu
te;cio da TRS, sendo apontada como "cardiopulmonar" a causa mais frequente. <sup
>3</sup></font></p>     ^cY#v33n1a15.htm##
00405000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704017500071002001300246#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#23#19#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Diante desse quadro, como avaliar a "sa&u
acute;de cardiovascular" da crian&ccedil;a com DRC?</font></p>     ^cY#v33n1a15.
htm##
01462000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704123200071002001301303#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#24#20#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A mortalidade por etiologia cardiovascula
r na popula&ccedil;&atilde;o pedi&aacute;trica com DRC no est&aacute;gio V &eacu
te; de cerca de 40%. H&aacute; aumento da mortalidade na ordem de 700% em compar
a&ccedil;&atilde;o &agrave; popula&ccedil;&atilde;o geral (crian&ccedil;as saud&
aacute;veis da mesma faixa et&aacute;ria). A disfun&ccedil;&atilde;o endotelial 
&eacute; precoce na crian&ccedil;a com DRC e &eacute; seguida por calcifica&cced
il;&atilde;o na m&eacute;dia, com posterior hipertrofia ventricular esquerda. El
eva&ccedil;&otilde;es de PA sist&oacute;lica e PTH-intacto, c&aacute;lcio e f&oa
cute;sforo, al&eacute;m de longos per&iacute;odos em di&aacute;lise, parecem ser
 importantes fatores de risco para DCV nesta popula&ccedil;&atilde;o. <sup>4,5</
sup> A aterosclerose &eacute; um processo que se inicia na inf&acirc;ncia e de m
odo subcl&iacute;nico pode ser avaliada pela rela&ccedil;&atilde;o da espessura 
&iacute;ntima/m&eacute;dia em car&oacute;tida. Contudo, esse &eacute; um m&eacut
e;todo pouco dispon&iacute;vel no Brasil e existem dificuldades t&eacute;cnicas 
na sua realiza&ccedil;&atilde;o, dependendo da faixa et&aacute;ria. </font></p> 
    ^cY#v33n1a15.htm##
01021000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704079100071002001300862#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#25#21#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Outra dificuldade que se imp&otilde;e &ea
cute; a terapia das dislipidemias. Os n&iacute;veis de l&iacute;pides recomendad
os em crian&ccedil;as e adolescentes s&atilde;o mais baixos que os empregados pa
ra adultos. Em muitas ocasi&otilde;es a abordagem por nutricionistas n&atilde;o 
&eacute; suficiente para o adequado controle, e o uso de drogas hipolipemiantes 
torna-se necess&aacute;rio. Contudo, no pr&oacute;prio bul&aacute;rio de estatin
as dispon&iacute;veis no Brasil, a afirma&ccedil;&atilde;o "ainda n&atilde;o for
am estabelecidas a seguran&ccedil;a e a efic&aacute;cia em crian&ccedil;as" &eac
ute; a regra, causa de frequente questionamento pelos pais, impondo mais uma dif
iculdade a esta abordagem. </font></p>     ^cY#v33n1a15.htm##
00620000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704039000071002001300461#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#26#22#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Adicionando mais um fator ao d&eacute;fic
it de crescimento de crian&ccedil;as com DRC, apesar de in&uacute;meras publica&
ccedil;&otilde;es mostrando boa resposta ao uso de somatropina, as secretarias e
staduais de sa&uacute;de n&atilde;o inclu&iacute;ram a DRC no rol de indica&cced
il;&otilde;es de seu uso. </font></p>     ^cY#v33n1a15.htm##
00596000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704036600071002001300437#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#27#23#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Diante das in&uacute;meras dificuldades e
ncontradas pelos nefrologistas pedi&aacute;tricos, adicionam-se dificuldades soc
iais aos fatores supracitados como determinantes de maiores desafios no tratamen
to da crian&ccedil;a renal cr&ocirc;nica em compara&ccedil;&atilde;o aos adultos
. </font></p>     ^cY#v33n1a15.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#28#24#text#50#<p>&nbsp;</p>     ^cY#v3
3n1a15.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010700071002001300178#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#29#25#text#50#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#v33n1a15.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704027500073002001300348#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#30#26#text#50#1#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1. Mitsnefes MM. Cardiovasc
ular morbidity and mortality in children with chronic kidney disease in North Am
erica: lessons from the USRDS and NAPRTCS databases. Perit Dial Int 2005 Feb; 25
(Suppl 3):S120-2.    ^cY#v33n1a15.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#31#27#text#50# </font></p>     ^cY#v33
n1a15.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704025800073002001300331#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#32#28#text#50#2#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2. McDonald SP, Craig JC fo
r the Australian and New Zealand Paediatric Nephrology Association. Long-term su
rvival of children with End-Stage Renal Disease. N Engl J Med 2004; 350:2654-62.
    ^cY#v33n1a15.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#33#29#text#50# </font></p>     ^cY#v33
n1a15.htm##
00593000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704034900073002001300422#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#34#30#text#50#3#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">3. North American Pediatric
 Renal Trials and Collaborative Studies 2007 Annual Report. Dispon&iacute;vel em
 08 de agosto de 2010 em <a href="https://web.emmes.com/study/ped/annlrept/annlr
ept2007.pdf" target="_blank">https://web.emmes.com/study/ped/annlrept/annlrept20
07.pdf</a>.    ^cY#v33n1a15.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#35#31#text#50# </font></p>     ^cY#v33
n1a15.htm##
00427000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704018300073002001300256#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#36#32#text#50#4#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">4. Lilien MR, Groothoff JW.
 Cardiovascular disease in children with CKD or ESRD. Nat Rev Nephrol 2009; 5:22
9-35.    ^cY#v33n1a15.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#37#33#text#50# </font></p>     ^cY#v33
n1a15.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704023400073002001300307#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#38#34#text#50#5#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">5. Basiratnia M, Fazel M, L
otfi M <i>et al</i>. Sublinical atherosclerosis and related risk factors in rena
l transplant recipients. Pediatr Nephrol 2010; 25:343-8.    ^cY#v33n1a15.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#39#35#text#50# </font></p>     ^cY#v33
n1a15.htm##
00528000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704028400073002001300357#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#40#36#text#50#6#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">6. Bucharles SGE, Varela AM
, Barberato SH. P&eacute;coits Filho R. Avalia&ccedil;&atilde;o e manejo da doen
&ccedil;a cardiovascular em pacientes com doen&ccedil;a renal cr&ocirc;nica. J B
ras Nefrol 2010; 32:120-7.    ^cY#v33n1a15.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#41#37#text#50# </font></p>     ^cY#v33
n1a15.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#42#38#text#50#<p>&nbsp;</p>     ^cY#v3
3n1a15.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#43#39#text#50#<p>&nbsp;</p>     ^cY#v3
3n1a15.htm##
00430000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704020000071002001300271#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#44#40#text#50#<p><a name="endb"></a><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda"><img s
rc="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;ncia p
ara:</b>    ^cY#v33n1a15.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003900071002001300110#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#45#41#text#50#<br>   Marcelo de Sousa 
Tavares    ^cY#v33n1a15.htm##
00284000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704005400071002001300125#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#46#42#text#50#<br>   Rua Cara&ccedil;a
, 496, apto 201, Serra    ^cY#v33n1a15.htm##
00288000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704005800071002001300129#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#47#43#text#50#<br>   Belo Horizonte - 
MG - Brasil CEP: 30220-260    ^cY#v33n1a15.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010300071002001300174#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#48#44#text#50#<br>   E-mail:  <a href=
"mailto:tavares.marc@gmail.com">tavares.marc@gmail.com</a> </font></p>     ^cY#v
33n1a15.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010700071002001300178#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#49#45#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Data de submiss&atilde;o: 15/08/2010    ^
cY#v33n1a15.htm##
00288000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704005800071002001300129#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#50#46#text#50#<br>   Data de aprova&cc
edil;&atilde;o: 19/10/2010    ^cY#v33n1a15.htm##
00322000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009200071002001300163#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#51#47#text#50#<br>   O autor declara a
  inexist&ecirc;ncia de conflito  de interesse. </font></p>     ^cY#v33n1a15.htm
##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#52#48#text#50#<p>&nbsp;</p>     ^cY#v3
3n1a15.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#53#49#text#50#<p>&nbsp;</p>     ^cY#v3
3n1a15.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704020600071002001300277#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a15.htm#S#p#54#50#text#50#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O referido estudo foi realizado no Depart
amento de Pediatria, Faculdade de Medicina, Universidade Federal de Minas Gerais
. </font></p>     ^cY#v33n1a15.htm##
00605000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100020000710120146000910300
01500237065000700252064000700259031000300266032000400269014000700273865000900280
002001300289035001000302801001500312#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33
n1a15.htm#S#c#55#1#text#6#1#^rND^sMitsnefes^nMM#Cardiovascular morbidity and mor
tality in children with chronic kidney disease in North America: lessons from th
e USRDS and NAPRTCS databases^len#Perit Dial Int#200500#200502#25#^s3#S120-2#201
10300#v33n1a15.htm#0896-8608#Perit Dial Int##
00613000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100019000710100016000900110
06900106012006400175030001300239065000900252064000500261031000400266014000800270
865000900278002001300287035001000300801001300310#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a15.htm#S#c#56#2#text#6#2#^rND^sMcDonald^nSP#^rND^sCraig^nJC#for t
he Australian and New Zealand Paediatric Nephrology Association#Long-term surviv
al of children with End-Stage Renal Disease^len#N Engl J Med#20040000#2004#350#2
654-62#20110300#v33n1a15.htm#0028-4793#N Engl J Med##
00474000000000205000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690180087000710650009001580640
02100167037005800188865000900246002001300255#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a15.htm#S#c#57#3#text#6#3#North American Pediatric Renal Trials and Co
llaborative Studies 2007 Annual Report^len#20100808#08 de agosto de 2010#https:/
/web.emmes.com/study/ped/annlrept/annlrept2007.pdf#20110300#v33n1a15.htm##
00493000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100017000710100020000880120
05600108030001600164710000200180065000900182064000500191031000200196014000700198
865000900205002001300214#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a15.htm#S#
c#58#4#text#6#4#^rND^sLilien^nMR#^rND^sGroothoff^nJW#Cardiovascular disease in c
hildren with CKD or ESRD^len#Nat Rev Nephrol#2#20090000#2009#5#229-35#20110300#v
33n1a15.htm##
00603000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100020000710100015000910100
01500106810000600121012008700127030001600214065000900230064000500239031000300244
014000600247865000900253002001300262035001000275801001600285#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a15.htm#S#c#59#5#text#6#5#^rND^sBasiratnia^nM#^rND^sFa
zel^nM#^rND^sLotfi^nM#et al#Sublinical atherosclerosis and related risk factors 
in renal transplant recipients^len#Pediatr Nephrol#20100000#2010#25#343-8#201103
00#v33n1a15.htm#0097-5257#Pediatr Nephrol##
00623000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100021000710100017000920100
02000109010002300129012008600152030001400238065000900252064000500261031000300266
014000600269865000900275002001300284035001000297801001400307#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a15.htm#S#c#60#6#text#6#6#^rND^sBucharles^nSGE#^rND^sV
arela^nAM#^rND^sBarberato^nSH#^rND^sPécoits Filho^nR#Avaliação e manejo da doenç
a cardiovascular em pacientes com doença renal crônica^lpt#J Bras Nefrol#2010000
0#2010#32#120-7#20110300#v33n1a15.htm#0101-2800#J Bras Nefrol##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#o#1#1#text#1#201
10411#093051#v33n1a16.htm#62##
00983000000000445000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030001700104
03100030012103200020012406500090012601400110013503500100014612300020015601200820
01580120046002400100035002860100028003210100030003490100036003790100043004150700
05600458117000800514072000200522002001300524#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a16.htm#S#h#2#1#text#1#le#pt#br1.1#1#4.0#ILUS#16#JBN150#nd#J. Bras. Ne
frol.#33#1#20110300#^f115^l117#0101-2800#1#Buttonhole, "em casa de botão" ou "bo
toeira": uma técnica antiga redescoberta^lpt#Buttonhole: an old technique redisc
overed^len#^rND^1A01^nNelson Zocoler^sGalante#^rND^1A01^nAtsuko^sYamamoto#^rND^1
A01^nLucia Lima^sRabelo#^rND^1A01^nDenise Paulini^sMonterio#^rND^1A01^nLuiz Serg
io Fonseca de^sAzevedo#Hospital Cruz Azul^iA01^1Centro de Nefrologia e Diálise#v
ancouv#6#v33n1a16.htm##
01018000000000445000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030001700104
03100030012103200020012406500090012601400110013503500100014612300020015601201030
01580120060002610100035003210100028003560100030003840100036004140100043004500700
05600493117000800549072000200557002001300559#v33n1#V:\SciELO\serial\jbn\v33n1\ma
rkup\v33n1a16.htm#S#f#3#1#text#1#le#pt#br1.1#1#4.0#ILUS#16#JBN150#nd#J. Bras. Ne
frol.#33#1#20110300#^f115^l117#0101-2800#1#<b><i>Buttonhole</i>, "em casa de bot
ão" ou "botoeira"</b>: <b>uma técnica antiga redescoberta</b>^lpt#<b>Buttonhole<
/b>: <b>an old technique rediscovered</b>^len#^rND^1A01^nNelson Zocoler^sGalante
#^rND^1A01^nAtsuko^sYamamoto#^rND^1A01^nLucia Lima^sRabelo#^rND^1A01^nDenise Pau
lini^sMonterio#^rND^1A01^nLuiz Sergio Fonseca de^sAzevedo#Hospital Cruz Azul^iA0
1^1Centro de Nefrologia e Diálise#vancouv#6#v33n1a16.htm##
01115000000000469000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100038000500104121000300109049000700112158000300119
03000160012203100030013803200020014106500090014301400110015203500100016312300020
01730120082001750120046002570100035003030100028003380100030003660100036003960100
04300432070005800475117000800533072000200541002001300543008008900556#v33n1#V:\Sc
iELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#l#4#1#text#1#^mjan./mar.^a2011#le#pt
#br1.1#1#4.0#ilus#16#JBN150#nd#J. Bras. Nefrol#33#1#20110300#^f115^l117#0101-280
0#1#Buttonhole, "em casa de botão" ou "botoeira": uma técnica antiga redescobert
a^lpt#Buttonhole: an old technique rediscovered^len#^rND^1A01^nNelson Zocoler^sG
alante#^rND^1A01^nAtsuko^sYamamoto#^rND^1A01^nLucia Lima^sRabelo#^rND^1A01^nDeni
se Paulini^sMonterio#^rND^1A01^nLuiz Sergio Fonseca de^sAzevedo#^iA01^1Hospital 
Cruz Azul^2Centro de Nefrologia e Diálise#vancouv#6#v33n1a16.htm#Internet^ihttp:
//www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002011000100016##
00346000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704011800069002001300187#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#5#1#text#52#<p align="right"><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CARTAS</b> LETTERS</font><
/p>     ^cY#v33n1a16.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#6#2#text#52#<p>&nbsp;</p>     ^cY#v33n
1a16.htm##
00435000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704020700069002001300276#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#7#3#text#52#<p><a name="enda"></a><fon
t size="4" face="Verdana, Arial, Helvetica, sans-serif"><b><i>Buttonhole</i>, "e
m casa de bot&atilde;o" ou "botoeira". Uma t&eacute;cnica antiga redescoberta</b
></font></p>     ^cY#v33n1a16.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#8#4#text#52#<p>&nbsp;</p>     ^cY#v33n
1a16.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#9#5#text#52#<p>&nbsp;</p>     ^cY#v33n
1a16.htm##
00435000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704020600070002001300276#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#10#6#text#52#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><b>Nelson Zocoler Galante; Atsuko Yamamoto
; Lucia Lima Rabelo; Denise Paulini  Monterio; Luiz Sergio Fonseca de Azevedo</b
></font></p>     ^cY#v33n1a16.htm##
00377000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704014800070002001300218#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#11#7#text#52#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Centro de Nefrologia e Di&aacute;lise - CE
NED. Hospital Cruz Azul</font></p>     ^cY#v33n1a16.htm##
00353000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704012400070002001300194#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#12#8#text#52#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc;ncia</a><
/font></p>     ^cY#v33n1a16.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#13#9#text#52#<p>&nbsp;</p>     ^cY#v33
n1a16.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#14#10#text#52#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v33n1a16.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009600071002001300167#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#15#11#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v33n1a16
.htm##
00593000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704036300071002001300434#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#16#12#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A presente carta ao Editor aborda os arti
gos de Silva <i>et al</i>. <sup>1</sup> e de Castro <i>et al</i>. <sup>2</sup> q
ue nos levam a dois tipos de coment&aacute;rios: o primeiro de ordem lingu&iacut
e;stica, e o segundo referente a aspectos m&eacute;dicos.</font></p> <hr size="1
" noshade>     ^cY#v33n1a16.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#17#13#text#52#<p>&nbsp;</p>     ^cY#v3
3n1a16.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#18#14#text#52#<p>&nbsp;</p>     ^cY#v3
3n1a16.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010400071002001300175#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#19#15#text#52#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>PREZADO EDITOR</b></font></p>     ^cY#
v33n1a16.htm##
01625000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704139500071002001301466#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#20#16#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os artigos de Silva <i>et al</i>.<sup>1</
sup> e de Castro <i>et al</i>.<sup>2</sup> nos levam a dois tipos de coment&aacu
te;rios: o primeiro &eacute; de ordem lingu&iacute;stica: que termo usar para o 
m&eacute;todo? Buttonhole &eacute; o termo em ingl&ecirc;s e, como norma, devemo
s evitar estrangeirismos quando houver palavra equivalente em portugu&ecirc;s. A
ssim como dizemos di&aacute;lise e n&atilde;o <i>dialysis</i>, enxerto e n&atild
e;o <i>graft</i>, dialisador capilar e n&atilde;o <i>hollow fiber</i>, devemos a
bolir o termo <i>buttonhole</i>. "Casa de bot&atilde;o", embora correto, &eacute
; um termo longo e pouco euf&ocirc;nico. Sugerimos o uso de "botoeira", que sign
ifica a mesma coisa, por&eacute;m &eacute; simples, curto e sint&eacute;tico. O 
termo botoeira, segundo o dicion&aacute;rio Houaiss, foi introduzido na l&iacute
;ngua portuguesa em 1543 e significa "fenda praticada num pano ou em algo semelh
ante e, em geral, caseada &agrave; volta com linha, por onde se introduz um bot&
atilde;o para fechar uma pe&ccedil;a; casa", portanto perfeitamente adequado. Es
se termo tamb&eacute;m j&aacute; foi empregado pela comunidade m&eacute;dica por
tuguesa. Sugerimos ao JBN, e &agrave; comunidade nefrol&oacute;gica brasileira e
m geral, a normatiza&ccedil;&atilde;o deste termo em trabalhos futuros.</font></
p>     ^cY#v33n1a16.htm##
01069000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704083900071002001300910#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#21#17#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O segundo coment&aacute;rio refere-se aos
 aspectos m&eacute;dicos. Em nossa experi&ecirc;ncia, recentemente publicada (Ga
lante <i>et al</i>. <sup>3</sup>), a t&eacute;cnica da botoeira se revelou um m&
eacute;todo &uacute;til e eficiente que, em tese, poderia ser utilizado como rot
ina em todos os pacientes. Suas principais vantagens s&atilde;o a possibilidade 
de usar f&iacute;stulas de trajeto curto, a n&atilde;o forma&ccedil;&atilde;o de
 aneurismas, a redu&ccedil;&atilde;o da dor durante a pun&ccedil;&atilde;o, o pr
olongamento da vida &uacute;til da f&iacute;stula, a redu&ccedil;&atilde;o de sa
ngramentos e de hematomas e o melhor aspecto est&eacute;tico. Entretanto, alguma
s dificuldades b&aacute;sicas comprometem sua generaliza&ccedil;&atilde;o. </fon
t></p>     ^cY#v33n1a16.htm##
00640000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704041000071002001300481#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#22#18#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A primeira refere-se ao tempo de treiname
nto da equipe. &Eacute; mais f&aacute;cil e mais r&aacute;pido treinar um enferm
eiro / t&eacute;cnico novato na t&eacute;cnica cl&aacute;ssica do que na da boto
eira. Esta exige pun&ccedil;&atilde;o sempre no mesmo local, no mesmo &acirc;ngu
lo e, inicialmente, sempre pela mesma pessoa. </font></p>     ^cY#v33n1a16.htm##
01055000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704082500071002001300896#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#23#19#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A segunda &eacute; a resist&ecirc;ncia in
icial do enfermeiro / t&eacute;cnico j&aacute; treinado em hemodi&aacute;lise a 
aprender uma t&eacute;cnica nova e mais trabalhosa. Algumas vezes, al&eacute;m d
a resist&ecirc;ncia, h&aacute; dificuldade em aprender o procedimento. Al&eacute
;m das tr&ecirc;s enfermeiras que implantaram o m&eacute;todo, estamos procedend
o, progressivamente, ao treinamento do restante da equipe. Dos dezoito t&eacute;
cnicos em enfermagem, nove j&aacute; foram treinados, por&eacute;m dois n&atilde
;o se adaptaram &agrave; t&eacute;cnica. Os restantes ainda dever&atilde;o inici
ar o treinamento. &Eacute; poss&iacute;vel que um pequeno n&uacute;mero de enfer
meiros ou t&eacute;cnicos nunca se adaptem ao m&eacute;todo. </font></p>     ^cY
#v33n1a16.htm##
01447000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704121700071002001301288#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#24#20#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A terceira vem do tempo maior que a t&eac
ute;cnica da botoeira requer na pun&ccedil;&atilde;o em rela&ccedil;&atilde;o &a
grave; t&eacute;cnica cl&aacute;ssica, refletindo no tempo total de cada turno d
e di&aacute;lise. Isso ocorre essencialmente na fase inicial de cria&ccedil;&ati
lde;o do t&uacute;nel e de treinamento da equipe. Alguns pacientes, impacientes,
 preferem a t&eacute;cnica cl&aacute;ssica para economizar tempo e sair mais ced
o da unidade de di&aacute;lise. No longo prazo, o tempo total pode acabar sendo 
mais curto. O local da pun&ccedil;&atilde;o j&aacute; &eacute; conhecido, o seu 
trajeto est&aacute; pronto e, n&atilde;o havendo forma&ccedil;&atilde;o de aneur
ismas nem de hematomas, n&atilde;o h&aacute; necessidade de procurar novos ponto
s de pun&ccedil;&atilde;o. Alguns pacientes podem ser treinados para a autopun&c
cedil;&atilde;o. Tr&ecirc;s dos nossos pacientes j&aacute; se utilizam disso. A 
grande vantagem &eacute; que o paciente fica conhecendo bem o trajeto do seu t&u
acute;nel, reduzindo muito a possibilidade de falsos trajetos. Isso tamb&eacute;
m reduz o tempo consumido por cada membro da equipe. </font></p>     ^cY#v33n1a1
6.htm##
00759000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704052900071002001300600#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#25#21#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Introduzimos uma modifica&ccedil;&atilde;
o na forma de segurar a agulha, pelo tubo flex&iacute;vel da mesma e n&atilde;o 
pela "borboleta" pl&aacute;stica (pun&ccedil;&atilde;o t&aacute;til),<sup>4</sup
> aumentando, assim, a sensibilidade t&aacute;til e reduzindo a possibilidade de
 falso trajeto, pois quando a agulha est&aacute; bem posicionada, ela penetra co
m facilidade sem o emprego de for&ccedil;a excessiva (<a href="#fig1">Figura 1</
a>). </font></p>     ^cY#v33n1a16.htm##
00265000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003500071002001300106#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#26#22#text#52#<p><a name="fig1"></a></
p>     ^cY#v33n1a16.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#27#23#text#52#<p>&nbsp;</p>     ^cY#v3
3n1a16.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#28#24#text#52#<p align="center"><img s
rc="/img/revistas/jbn/v33n1/a16fig01.jpg"></p>     ^cY#v33n1a16.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#29#25#text#52#<p>&nbsp;</p>     ^cY#v3
3n1a16.htm##
03183000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704295300071002001303024#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#30#26#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Em quarto h&aacute; a remo&ccedil;&atilde
;o da crosta que se forma no local da pun&ccedil;&atilde;o e que, dois a tr&ecir
c;s dias depois desta, pode estar bastante aderida. Essa remo&ccedil;&atilde;o &
eacute; essencial para evitar que a crosta, ou fragmentos dela, estando contamin
ados levem infec&ccedil;&atilde;o para o paciente. A sua remo&ccedil;&atilde;o e
xige tempo para evitar lesar a pele do paciente ou causar dor. Em nosso servi&cc
edil;o adotamos a seguinte rotina: quando o paciente chega &agrave; unidade, ele
 faz a higieniza&ccedil;&atilde;o habitual do membro da FAV e a seguir coloca, s
obre o local da pun&ccedil;&atilde;o, uma gaze umedecida com o sab&atilde;o l&ia
cute;quido antiss&eacute;ptico; ap&oacute;s 5 a 15 minutos retiramos o res&iacut
e;duo do sab&atilde;o com gaze umedecida com &aacute;lcool 70% e a seguir, com a
 ponta de outra gaze enrolada em forma c&ocirc;nica e tamb&eacute;m umedecida co
m &aacute;lcool 70%, procedemos a remo&ccedil;&atilde;o da crosta, efetuando a p
un&ccedil;&atilde;o a seguir. Temos utilizado, al&eacute;m disso, &oacute;leo de
 am&ecirc;ndoas aplicado diariamente, preferencialmente duas vezes ao dia, pelo 
pr&oacute;prio paciente sobre o local da crosta em seu domic&iacute;lio. Tem bai
xo custo, &eacute; de f&aacute;cil aplica&ccedil;&atilde;o e mant&eacute;m a cro
sta mais amolecida e consideravelmente mais f&aacute;cil de ser removida. Um &oa
cute;bice &eacute; a n&atilde;o ades&atilde;o do paciente que, por esquecimento,
 ou voluntariamente deixa de fazer o procedimento. Um risco, ao menos te&oacute;
rico, &eacute; o uso de subst&acirc;ncia n&atilde;o est&eacute;ril em ferida rec
ente, mesmo que puntiforme. Entretanto, a pele em si e a crosta j&aacute; s&atil
de;o contaminadas. O uso de pin&ccedil;as &eacute; problem&aacute;tico e oneroso
, j&aacute; que precisam ser esterilizadas ap&oacute;s o uso para evitar contami
na&ccedil;&atilde;o cruzada entre os pacientes, o que significa a compra e a est
eriliza&ccedil;&atilde;o de dezenas delas. O uso de pin&ccedil;a favorece tamb&e
acute;m o trauma mec&acirc;nico da pele. O mesmo se pode falar quando se usa agu
lhas para isto. Quando se utiliza a mesma agulha para a remo&ccedil;&atilde;o da
 crosta e para a pun&ccedil;&atilde;o, ela pode ficar contaminada, mesmo ap&oacu
te;s antissepsia rigorosa, causando infec&ccedil;&atilde;o no paciente. Esse pro
cedimento j&aacute; foi contraindicado na literatura. <sup>5</sup> H&aacute; no 
mercado internacional agulhas rombas que j&aacute; v&ecirc;m com dispositivo pl&
aacute;stico descart&aacute;vel em forma de miniesp&aacute;tula para remo&ccedil
;&atilde;o da crosta (<i>Capick</i><sup><i>&#169;</i></sup><i> scab remover, Nip
ro Corporation</i>). Cabe a todas as equipes que utilizam o m&eacute;todo da bot
oeira solicitar &agrave;s ind&uacute;strias produtoras das agulhas que introduza
m tal dispositivo no Brasil. </font></p>     ^cY#v33n1a16.htm##
01085000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704085500071002001300926#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#31#27#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Por fim, h&aacute; um problema que vem a 
ser a troca do puncionista. Idealmente a pun&ccedil;&atilde;o deve ser feita pel
a mesma pessoa que j&aacute; "conhece" os t&uacute;neis do paciente e, assim, te
m maior facilidade na pun&ccedil;&atilde;o e comete menos erros. Entretanto, emb
ora isso seja essencial na fase de cria&ccedil;&atilde;o do t&uacute;nel, n&atil
de;o &eacute; vi&aacute;vel na pr&aacute;tica no longo prazo. F&eacute;rias, fol
gas, aus&ecirc;ncias ou troca de turno, seja do puncionista, seja do paciente, o
brigam a pun&ccedil;&atilde;o a ser feita por outra pessoa, aumentando os riscos
 de erro e de cria&ccedil;&atilde;o de falso trajeto. Acreditamos que isso tende
 a se reduzir com o treinamento prolongado e o uso intensivo do m&eacute;todo pe
la equipe. </font></p>     ^cY#v33n1a16.htm##
01409000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704117900071002001301250#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#32#28#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">J&aacute; empregamos a t&eacute;cnica da 
botoeira em 62 pacientes. Oito deixaram o procedimento por raz&otilde;es n&atild
e;o relacionadas ao m&eacute;todo: transfer&ecirc;ncia (5), &oacute;bito (2), tr
ansplante (1). Quinze por problemas relacionados &agrave; FAV propriamente dita 
e n&atilde;o ao m&eacute;todo: trombose da FAV (8), desenvolvimento inadequado d
a veia (6) e trombose venosa profunda da veia subcl&aacute;via (1). Por fim, 13 
deixaram o procedimento por falha t&eacute;cnica, que ocorreu principalmente na 
fase de implanta&ccedil;&atilde;o do m&eacute;todo no nosso servi&ccedil;o (per&
iacute;odo de aprendizado): dificuldade na forma&ccedil;&atilde;o do t&uacute;ne
l (7), desist&ecirc;ncia do paciente (4), dor (1) e infec&ccedil;&atilde;o (1). 
No momento, estamos com 26 pacientes (28,5% do total com FAV) usando a t&eacute;
cnica da botoeira, contra 65 que se utilizam da t&eacute;cnica cl&aacute;ssica. 
Somos concordes com Castro <i>et al</i>. que a t&eacute;cnica deve ser empregada
 de in&iacute;cio em f&iacute;stulas novas quando j&aacute; maduras para pun&cce
dil;&atilde;o. </font></p>     ^cY#v33n1a16.htm##
00830000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704060000071002001300671#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#33#29#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Essas dificuldades n&atilde;o devem desan
imar a equipe, pois, uma vez dominada a t&eacute;cnica, a aceita&ccedil;&atilde;
o &eacute; excelente. Consideramos que a perseveran&ccedil;a na fase inicial do 
treinamento compensa no benef&iacute;cio final ao paciente. Recente publica&cced
il;&atilde;o<sup>6</sup> mostrou que pacientes (19 de 23 - 86%) que dialisavam p
ela t&eacute;cnica de pun&ccedil;&otilde;es m&uacute;ltiplas e foram transferido
s para a da botoeira estavam satisfeitos e preferiam a nova t&eacute;cnica. </fo
nt></p>     ^cY#v33n1a16.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#34#30#text#52#<p>&nbsp;</p>     ^cY#v3
3n1a16.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010700071002001300178#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#35#31#text#52#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#v33n1a16.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704026600073002001300339#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#36#32#text#52#1#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1. Silva GST, Silva RA, Nic
olino AM <i>et al</i>. Experi&ecirc;ncia inicial com a t&eacute;cnica de <i>butt
onhole</i> em um centro de hemodi&aacute;lise brasileiro. J Bras Nefrol 2010; 32
:257-62.    ^cY#v33n1a16.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#37#33#text#52# </font></p>     ^cY#v33
n1a16.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704026500073002001300338#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#38#34#text#52#2#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2. Castro MCM, Silva CF, So
uza JMR <i>et al</i>. Pun&ccedil;&atilde;o da f&iacute;stula arteriovenosa com a
 t&eacute;cnica em casa de bot&atilde;o com agulha romba. J Bras Nefrol 2010; 32
:281-5.    ^cY#v33n1a16.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#39#35#text#52# </font></p>     ^cY#v33
n1a16.htm##
00518000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704027400073002001300347#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#40#36#text#52#3#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">3. Galante NZ, Rabelo LL, Y
amamoto A, Bonato R, Azevedo LS. One unit experiences when establishing buttonho
le technique, analysis of reasons for failure of procedure: a report. J Ren Care
 2010; 36:73-80.    ^cY#v33n1a16.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#41#37#text#52# </font></p>     ^cY#v33
n1a16.htm##
00419000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704017500073002001300248#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#42#38#text#52#4#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">4. Mott S, Prowant BF. The 
"touch cannulation" technique for hemodialysis. Nephrol Nurs J 2008; 35:65-6.   
 ^cY#v33n1a16.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#43#39#text#52# </font></p>     ^cY#v33
n1a16.htm##
00423000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704017900073002001300252#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#44#40#text#52#5#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">5. Ball LK. The buttonhole 
technique for arteriovenous fistula cannulation. Nephrol Nurs J 2006; 33:299-304
.    ^cY#v33n1a16.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#45#41#text#52# </font></p>     ^cY#v33
n1a16.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704025700073002001300330#v33
n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#46#42#text#52#6#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">6. Hashimi A, Cheema MQ, Mo
ss AH. Hemodialysis patient's experience with and attitudes toward the buttonhol
e techique for arteriovenous fistula cannulation. Clin Nephrol 2010; 74:346-50. 
   ^cY#v33n1a16.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#47#43#text#52# </font></p>     ^cY#v33
n1a16.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#48#44#text#52#<p>&nbsp;</p>     ^cY#v3
3n1a16.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#49#45#text#52#<p>&nbsp;</p>     ^cY#v3
3n1a16.htm##
00430000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704020000071002001300271#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#50#46#text#52#<p><a name="endb"></a><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#enda"><img s
rc="/img/revistas/jbn/v33n1/seta.jpg" border="0"></a><b> Correspond&ecirc;ncia p
ara:</b>    ^cY#v33n1a16.htm##
00276000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004600071002001300117#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#51#47#text#52#<br>   Luiz Sergio Fonse
ca de Azevedo     ^cY#v33n1a16.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007400071002001300145#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#52#48#text#52#<br>   Centro de Nefrolo
gia e Di&aacute;lise do Hospital Cruz Azul    ^cY#v33n1a16.htm##
00299000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704006900071002001300140#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#53#49#text#52#<br>   Av. Lins de Vasco
ncelos, 356, bl C 7º andar,  Cambuci     ^cY#v33n1a16.htm##
00290000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704006000071002001300131#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#54#50#text#52#<br>   S&atilde;o Paulo 
- SP - Brasil CEP: 01537-000    ^cY#v33n1a16.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010300071002001300174#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#55#51#text#52#<br>   E-mail: <a href="
mailto:ls.azevedo@terra.com.br">ls.azevedo@terra.com.br</a></font></p>     ^cY#v
33n1a16.htm##
00381000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704015100071002001300222#v33n1#V:\SciELO
\serial\jbn\v33n1\markup\v33n1a16.htm#S#p#56#52#text#52#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os autores declaram a inexist&ecirc;ncia 
de conflitos de interesse. </font></p>     ^cY#v33n1a16.htm##
00606000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100017000710100016000880100
01900104810000600123012009100129030001400220065000900234064000500243031000300248
014000700251865000900258002001300267035001000280801001400290#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a16.htm#S#c#57#1#text#6#1#^rND^sSilva^nGST#^rND^sSilva
^nRA#^rND^sNicolino^nAM#et al#Experiência inicial com a técnica de buttonhole em
 um centro de hemodiálise brasileiro^lpt#J Bras Nefrol#20100000#2010#32#257-62#2
0110300#v33n1a16.htm#0101-2800#J Bras Nefrol##
00597000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100018000710100016000890100
01700105810000600122012008400128030001400212065000900226064000500235031000300240
014000600243865000900249002001300258035001000271801001400281#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a16.htm#S#c#58#2#text#6#2#^rND^sCastro^nMCM#^rND^sSilv
a^nCF#^rND^sSouza^nJMR#et al#Punção da fístula arteriovenosa com a técnica em ca
sa de botão com agulha romba^lpt#J Bras Nefrol#20100000#2010#32#281-5#20110300#v
33n1a16.htm#0101-2800#J Bras Nefrol##
00638000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100018000710100017000890100
01800106010001600124010001800140012012000158030001100278710000200289065000900291
064000500300031000300305014000600308865000900314002001300323#v33n1#V:\SciELO\ser
ial\jbn\v33n1\markup\v33n1a16.htm#S#c#59#3#text#6#3#^rND^sGalante^nNZ#^rND^sRabe
lo^nLL#^rND^sYamamoto^nA#^rND^sBonato^nR#^rND^sAzevedo^nLS#One unit experiences 
when establishing buttonhole technique, analysis of reasons for failure of proce
dure: a report^len#J Ren Care#2#20100000#2010#36#73-80#20110300#v33n1a16.htm##
00485000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100014000710100018000850120
05500103030001500158710000200173065000900175064000500184031000300189014000500192
865000900197002001300206#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#
c#60#4#text#6#4#^rND^sMott^nS#^rND^sProwant^nBF#The "touch cannulation" techniqu
e for hemodialysis^len#Nephrol Nurs J#2#20080000#2008#35#65-6#20110300#v33n1a16.
htm##
00471000000000253000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100015000710120067000860300
01500153710000200168065000900170064000500179031000300184014000800187865000900195
002001300204#v33n1#V:\SciELO\serial\jbn\v33n1\markup\v33n1a16.htm#S#c#61#5#text#
6#5#^rND^sBall^nLK#The buttonhole technique for arteriovenous fistula cannulatio
n^len#Nephrol Nurs J#2#20060000#2006#33#299-304#20110300#v33n1a16.htm##
00618000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100017000710100017000880100
01500105012012600120030001300246065000900259064000500268031000300273014000700276
865000900283002001300292035001000305801001300315#v33n1#V:\SciELO\serial\jbn\v33n
1\markup\v33n1a16.htm#S#c#62#6#text#6#6#^rND^sHashimi^nA#^rND^sCheema^nMQ#^rND^s
Moss^nAH#Hemodialysis patient's experience with and attitudes toward the buttonh
ole techique for arteriovenous fistula cannulation^len#Clin Nephrol#20100000#201
0#74#346-50#20110300#v33n1a16.htm#0301-0430#Clin Nephrol##
